drugbank_id,ref_id,title,url
DB00001,,Google books,http://books.google.com/books?id=iadLoXoQkWEC&pg=PA440
DB00001,,Health Canada Approved Drug Products: Refludan (lepirudin) lyophilized powder for intravenous injection,https://pdf.hres.ca/dpd_pm/00004023.PDF
DB00001,,FDA Clinical Pharmacology and Biopharmaceutics Review: Refludan (lepirudin) lyophilized powder for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20807_Refludan_biopharmr.pdf
DB00001,,EMA Summary of Product Characteristics: Refludan (lepirudin) powder for intravenous injection or infusion,https://www.ema.europa.eu/en/documents/product-information/refludan-epar-product-information_en.pdf
DB00001,,Bayer HealthCare: Discontinuation of Refludan [lepirudin (rDNA) for injection],https://www.hrsa.gov/sites/default/files/opa/programrequirements/manufacturerletters/2012/refludan05312012.pdf
DB00002,,Bristol-Myers Squibb Company: Cetuximab Safety Data Sheet,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9BRMY_ERBITUX.pdf
DB00002,,"FDA Approved Drug Products: ERBITUX (cetuximab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125084s275lbl.pdf
DB00002,,StatPearls: Cetuximab,https://www.ncbi.nlm.nih.gov/books/NBK459293/
DB00002,,"FDA Approved Drug Products: ERBITUX (cetuximab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf
DB00004,,"FDA Approved Drug Products: LYMPHIR (denileukin diftitox-cxdl) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761312s000lbl.pdf
DB00004,,"FDA Approved Products: ONTAK (denileukin diftitox) injection, for intravenous use (February 2020)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103767s5144lbl.pdf
DB00004,,Targeted Oncology: FDA Approves Improved Denileukin Diftitox in Cutaneous T-Cell Lymphoma,https://www.targetedonc.com/view/fda-approves-improved-denileukin-diftitox-in-cutaneous-t-cell-lymphoma
DB00005,,FDA Approved Drug Products: Enbrel (etanercept) injection solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103795s5574s5577lbl.pdf
DB00005,,Health Canada Approved Drug Products: RYMTI (etanercept) solution for injection (August 2022),https://pdf.hres.ca/dpd_pm/00068678.PDF
DB00005,,"FDA Approved Drug Products: ENBREL® (etanercept) injection, for subcutaneous use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103795s5595lbl.pdf
DB00005,,FDA Approved Drug Products: Erelzi (etanercept) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761042s010lbl.pdf
DB00007,,FDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203696s001lbl.pdf
DB00007,,"FDA Approved Drug Products: Lupron Depot (leuprolide acetate) depot suspension, for intramuscular injection","https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019732s045,020517s043lbl.pdf"
DB00007,,FDA Approved Drug Products: Lupron Depot-Ped (leuprolide acetate) depot suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020263s046lbl.pdf
DB00007,,FDA Approved Drug Products: Fensolvi (leuprolide acetate) suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213150s000lbl.pdf
DB00007,,"FDA Approved Drug Products: ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021343s039,021379s041,021488s036,021731s037lbl.pdf"
DB00007,,FDA Approved Drug Products: Lupron Depot 3.75mg (leuprolide acetate) depot suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019943s034lbl.pdf
DB00007,,FDA Approved Drug Products: Lupron (leuprolide) injection; discontinued,https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019010Orig1s000rev.pdf
DB00007,,"FDA Approved Drug Products: CAMCEVI (leuprolide) injectable emulsion, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211488s000lbl.pdf
DB00007,,FDA Approved Drug Products: LUPRON DEPOT (leuprolide acetate for depot suspension) (Dec 2023),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020517s045,019732s048lbl.pdf"
DB00008,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB00009,,FDA Approved Drug Products: ACTIVASE (alteplase) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103172s5268lbl.pdf
DB00009,,Genentech: ACTIVASE (alteplase) SDS,https://www.gene.com/download/pdf/ACTIVASEVials50mgSAPSDS.pdf
DB00009,,FDA Approved Drug Products: Cathflo Activase (alteplase) powder for reconstitution for use in central venous access devices,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103172s5260lbl.pdf
DB00013,,FDA Approved Drug Products: Kinlytic Urokinase Injection (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021846s101lbl.pdf
DB00013,,Health Canada Approved Drug Products: Urokinase Injection,https://pdf.hres.ca/dpd_pm/00009157.PDF
DB00016,,FDA News Release: FDA approves first epoetin alfa biosimilar for the treatment of anemia,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607703.htm
DB00016,,Linus Pauling Institute Micronutrient Information Center: Vitamin E,http://lpi.oregonstate.edu/infocenter/vitamins/vitaminE/
DB00019,,"FDA Approved Drug Products: NEULASTA (pegfilgrastim) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125031s189s191lbl.pdf
DB00019,,Amgen: Neulasta (pegfilgrastim) MSDS,https://www.msds.amgen.com/~/media/amgen/repositorysites/msds-amgen-com/neulasta_sds.ashx
DB00019,,GENERICS AND BIOSIMILARS INITIATIVE: Biosimilars of pegfilgrastim,http://gabionline.net/Biosimilars/General/Biosimilars-of-pegfilgrastim
DB00019,,GENERICS AND BIOSIMILARS INITIATIVE: EMA approval for pegfilgrastim biosimilar Grasustek,http://gabionline.net/Biosimilars/News/EMA-approval-for-pegfilgrastim-biosimilar-Grasustek
DB00019,,FDA: Biosimilar and Interchangeable Products,https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products
DB00019,,Cancer Care Ontario Drug Information: Pegfilgrastim,https://www.cancercareontario.ca/en/node/43921
DB00019,,"FDA Approved Drug Products: STIMUFEND (pegfilgrastim-fpgk) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761173s000lbl.pdf
DB00019,,"FDA Approved Drug Products: UDENYCA (pegfilgrastim-cbqv) injection, for subcutaneous use (November 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761039s014lbl.pdf
DB00022,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB00022,,"FDA Approved Drug Products: SYLATRON (peginterferon alfa-2b) for injection, for subcutaneous use (December 2018)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103949s5312lbl.pdf
DB00023,,"UniProtKB - V6FYV8 (V6FYV8_ECOLX): E. coli L-asparaginase, type II FASTA sequence",http://www.uniprot.org/uniprot/V6FYV8
DB00023,,FDA Approved Drug Products: Elspar (asparaginase) for intravenous or intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/101063s5169lbl.pdf
DB00025,,"FDA Approved Drug Products: KOGENATE FS (Antihemophilic Factor [Recombinant], Formulated with Sucrose) For Intravenous Use, Lyophilized Powder for Reconstitution",https://www.fda.gov/media/70484/download
DB00025,,"DailyMed Label: ADVATE [antihemophilic factor (recombinant)] lyophilized powder for reconstitution, for intravenous injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da
DB00026,,FDA Approved Drug Products: KINERET (anakinra) subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103950s5189lbl.pdf
DB00026,,FDA Clinical Pharmacology and Biopharmaceutics Review: Kineret (anakinra) subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/103950-0_Kineret_Biopharmr.PDF
DB00026,,FDA Clinical Pharmacology Review: Kineret (anakinra) subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/103950-0_Kineret_Pharmr.PDF
DB00026,,"FDA Emergency Use Authorization (EUA) Drug Products: KINERET (anakinra) injection, for subcutaneous use",https://www.kineretrxhcp.com/pdf/Fact%20Sheet%20for%20Healthcare%20Providers.pdf
DB00026,,FDA Letter of Authorization (LOA): Kineret LOA 11082022,https://www.fda.gov/media/163081/download
DB00028,,FDA Approved Drug Products: Cutaquig (human immunoglobulin G-hipp) solution for subcutaneous infusion,https://www.fda.gov/media/119234/download
DB00028,,FDA Approved Drug Products: Asceniv (human immunoglobulin G-sira) for intravenous injection,https://www.fda.gov/media/122525/download
DB00028,,FDA Approved Drug Products: Bivigam (human immunoglobulin G) for intravenous injection,https://www.fda.gov/media/84782/download
DB00028,,FDA Approved Drug Products: Carimune NF (human immunoglobulin G) for intravenous injection,https://www.fda.gov/media/76582/download
DB00028,,FDA Approved Drug Products: Flebogamma 5% (human immunoglobulin G) solution for intravenous administration,https://www.fda.gov/media/76962/download
DB00028,,FDA Approved Drug Products: Flebogamma 10% (human immunoglobulin G) for intravenous administration,https://www.fda.gov/media/83042/download
DB00028,,FDA Approved Drug Products: Gammagard Liquid (human immunoglobulin G) for subcutaneous and intravenous administration,https://www.fda.gov/media/70812/download
DB00028,,"FDA Approved Drug Products: Gammagard S/D (human immunoglobulin G, solvent detergent treated) for intravenous administration",https://www.fda.gov/media/78185/download
DB00028,,"FDA Approved Drug Products: Gamunex-C (human immunoglobulin G, purified) for intravenous injection",https://www.fda.gov/media/70738/download
DB00028,,FDA Approved Drug Products: Octagam (human immunoglobulin G) solution for intravenous administration,https://www.fda.gov/media/70911/download
DB00028,,FDA Approved Drug Products: Panzyga (human immunoglobulin G-ifas) liquid for intravenous administration,https://www.fda.gov/media/115397/download
DB00028,,FDA Approved Drug Products: Privigen (human immunoglobulin G) liquid for intravenous administration,https://www.fda.gov/media/83304/download
DB00028,,FDA Approved Drug Products: Cuvitru (human immunoglobulin G) solution for subcutaneous injection,https://www.fda.gov/media/100531/download
DB00028,,FDA Approved Drug Products: Hizentra (human immunoglobulin G) liquid for subcutaneous injection,https://www.fda.gov/media/78466/download
DB00028,,FDA Approved Drug Products: Hyqvia (human immunoglobulin G/human recombinant hyaluronidase) solution for subcutaneous injection,https://www.fda.gov/media/89844/download
DB00028,,FDA Approved Drug Products: Xembify (human immunoglobulin G-klhw) solution for subcutaneous injection,https://www.fda.gov/media/128601/download
DB00028,,FDA Approved Drug Products: Hyqvia (human immunoglobulin G/human recombinant hyaluronidase) solution for subcutaneous injection,https://www.shirecontent.com/PI/PDFs/HYQVIA_USA_ENG.pdf
DB00030,,FDA Approved Drug Products: Humulin R (insulin human),https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018780s126s134lbl.pdf
DB00030,,"FDA Approved Drug Products: AFREZZA® (insulin human) inhalation powder, for oral inhalation use (February 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022472s023lbl.pdf
DB00030,,FDA Approved Drug Products: AFREZZA (insulin human) Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdf
DB00034,,IlacaBak: Interferon alfa 2a ATC Sınıflaması,https://www.ilacabak.com/etkengoster.php?Id=334
DB00035,,DDVAP Nasal Spray FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017922s038,018938s027,019955s013lbl.pdf"
DB00035,,Stimate (desmopressin acetate) nasal spray FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020355s020lbl.pdf
DB00035,,UKPAR for Desmopressin acetate 100mcg and 200mcg Tablets,http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2033807.pdf
DB00036,,"FDA Approved Drug Products: SEVENFACT [coagulation factor VIIa (recombinant)-jncw] Lyophilized Powder for Solution, for Intravenous Use",https://www.fda.gov/media/136610/download
DB00036,,Health Canada Product Monograph: NiaStase RT (eptacog alfa (activated) ) powder for injection,https://pdf.hres.ca/dpd_pm/00042076.PDF
DB00039,,FDA Approved Drug Product: Kepivance (Palifermin) Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125103s176lbl.pdf
DB00040,,FDA Approved Drug Products: Glucagon Hydrochloride Injection (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012122
DB00040,,FDA Approved Drug Products: Glucagon Intravenous or Intramuscular Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201849s002lbl.pdf
DB00040,,FDA Approved Drug Products: Glucagon for Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020928s056lbl.pdf
DB00040,,"FDA Approved Drug Products: Glucagon Subcutaneous, Intramuscular, or Intravenous Injection",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020918s052lbl.pdf
DB00040,,FDA Approved Drug Products: Glucagon Nasal Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf
DB00040,,Medsafe New Zealand: Glucagon Data Sheet,https://www.medsafe.govt.nz/profs/Datasheet/g/GlucaGeninj.pdf
DB00040,,FDA Approved Drug Products: Glucagon Subcutaneous Auto-Injector and Pre-Filled Syringe,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212097s000lbl.pdf
DB00041,,PROLEUKIN® (aldesleukin) FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf
DB00043,,"FDA Approved Drug Products: XOLAIR (omalizumab) injection, for subcutaneous use (February 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf
DB00043,,EMA Approved Drug Products: Xolair (omalizumab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf
DB00043,,Genentech: XOLAIR (omalizumab) MSDS,https://www.gene.com/download/pdf/XOLAIRPFS150mgSAPSDS2.pdf
DB00046,,HUMALOG FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020563s196s198s199,205747s022s025s026lbl.pdf"
DB00046,,"FDA Approved Drug Products: HUMALOG (insulin lispro) injection, for subcutaneous or intravenous use (July 2023)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020563s202,021017s146,021018s132,205747s028lbl.pdf"
DB00046,,FDA Approved Drug Products: HUMALOG® Mix50/50TM (50% INSULIN LISPRO PROTAMINE AND 50% INSULIN LISPRO) INJECTION,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021018s067lbl.pdf
DB00046,,FDA Approved Drug Products: HUMALOG® Mix75/25TM (75% INSULIN LISPRO PROTAMINE SUSPENSION AND 25% INSULIN LISPRO) INJECTION,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021017s074lbl.pdf
DB00047,,FDA Approved Drug Products: Lantus (Insulin glargine) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021081s073s074lbl.pdf
DB00047,,FDA Approved Drug Products: Semglee (insulin glargine-yfgn) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210605s000lbl.pdf
DB00047,,FDA Press Announcement: FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes,https://www.fda.gov/news-events/press-announcements/fda-approves-first-interchangeable-biosimilar-insulin-product-treatment-diabetes
DB00047,,"Health Canada Approved Drug Products: LANTUS (insulin glargine, rDNA origin) solution for injection",https://pdf.hres.ca/dpd_pm/00063800.PDF
DB00047,,Health Canada Approved Drug Products: Semglee (insulin glargine-yfgn) solution for subcutaneous injection,https://pdf.hres.ca/dpd_pm/00065501.PDF
DB00048,,FDA Approved Products: Qwo (collagenase clostridium histolyticum-aaes) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761146s000lbl.pdf
DB00048,,FDA Approved Products: Ziaflex (collagenase clostridium histolyticum) for intralesional use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125338s109lbl.pdf
DB00048,,"Thermo Fisher SDS: Collagenase, Type II Powder",https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FLSG%2FSDS%2F17101015_MTR-NALT_EN.pdf&title=MTcxMDEwMTU=
DB00048,,Endo International website,https://www.endo.com
DB00048,,FDA Approved Products: Santyl (collagenase) ointment,https://santyl.com/sites/default/files/2019-12/SANTYL-PI.pdf
DB00048,,Product monograph: Santyl (collagenase),https://pdf.hres.ca/dpd_pm/00028617.PDF
DB00051,,Patent: Methods related to adalimumab,https://patents.google.com/patent/US20150158943
DB00051,,"Sandoz received US FDA approval for bio similar, Hyrimoz",https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoztm-adalimumab-adaz
DB00051,,HUMIRA website,https://www.humira.com/hidradenitis-suppurativa
DB00051,,Abbvie Website,https://www.abbvie.com/our-science/pipeline/humira.html
DB00051,,FDA Approved Drug Products: HUMIRA (adalimumab) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf
DB00051,,FDA Approved Drug Products: HUMIRA (adalimumab) injection 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761059s004lbl.pdf
DB00051,,"FDA Approved Drug Products: HULIO (adalimumab-fkjp) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761154s002lbl.pdf
DB00051,,"FDA Approved Drug Products: HADLIMA (adalimumab-bwwd) injection, for subcutaneous use",https://www.organon.com/wp-content/uploads/sites/2/2022/08/FDA_b761059_S005_Hadlima_8.15.22_letterlabeling_002_clean.pdf
DB00051,,"FDA Approved Drug Products: AMJEVITA (adalimumab-atto) injection, for subcutaneous use (November 2022)",https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Amjevita/amjevita_pi_hcp_english.pdf
DB00051,,"FDA Approved Drug Products: HYRIMOZ (adalimumab-adaz) injection, for subcutaneous use",https://www.us.sandoz.com/sites/www.us.sandoz.com/files/Hyrimoz_Highlights_Prescribing_Information.pdf
DB00051,,EMA Approved Drug Products: Hyrimoz (adalimumab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/hyrimoz-epar-product-information_en.pdf
DB00051,,"FDA Approved Drug Products: YUFLYMA (adalimumab-aaty) injection, for subcutaneous use",https://www.celltrionhealthcare.com/en-us/products/yuflyma/CT-P17-BLA-USPI.pdf
DB00051,,"FDA Approved Drug Products: HADLIMA (adalimumab-bwwd) injection, for subcutaneous use (June 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761059s006lbl.pdf
DB00051,,"FDA Approved Drug Products: CYLTEZO® (adalimumab-adbm) injection, for subcutaneous use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761058s018lbl.pdf
DB00051,,"FDA Approved Drug Products: AMJEVITA (adalimumab-atto) injection, for subcutaneous use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761024s017lbl.pdf
DB00051,,"FDA Approved Drug Products: HADLIMA (adalimumab-bwwd) injection, for subcutaneous use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761059s008lbl.pdf
DB00051,,"FDA Approved Drug Products: HULIO (adalimumab-fkjp) injection, for subcutaneous use (September 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761154s005lbl.pdf
DB00051,,"FDA Approved Drug Products: HYRIMOZ (adalimumab-adaz) injection, for subcutaneous use (September 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761071s016lbl.pdf
DB00051,,"FDA Approved Drug Products: ABRILADA(adalimumab-afzb) injection, for subcutaneous use (October2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761118s007lbl.pdf
DB00051,,"FDA Approved Drug Products: HYRIMOZ (adalimumab-aaty) injection, for subcutaneous use (October2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761219s001lbl.pdf
DB00051,,"FDA Approved Drug Products: IDACIO (adalimumab-aacf) injection, for subcutaneous use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761255s002lbl.pdf
DB00052,,"FDA Approved Drug Products: Norditropin (somatropin) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021148s049lbl.pdf
DB00052,,"FDA Approved Drug Products: ZORBTIVE (somatropin) for injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020604s074lbl.pdf
DB00052,,"FDA Approved Drug Products: SEROSTIM (somatropin) for injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020604s093lbl.pdf
DB00052,,"StatPearls: Physiology, Growth Hormone",https://www.ncbi.nlm.nih.gov/books/NBK482141/
DB00052,,"FDA Approved Drug Products: ZOMACTON (somatropin) for injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/180717s048s049s050s051lbl.pdf
DB00052,,"FDA Approved Drug Products: GENOTROPIN (somatropin) for injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020280s090lbl.pdf
DB00052,,"FDA Approved Drug Products: Nutropin (somatropin) injection, for subcutaneous use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019676s044,020168s024lbl.pdf"
DB00052,,Pfizer: Genotropin (Somatropin) Safety Data Sheet,https://pfe-pfizercom-prod.s3.amazonaws.com/products/material_safety_data/Somatropin_for_inj_06-2mg_15-March-2018.pdf
DB00056,,FDA Press Announcements: FDA approves Mylotarg for treatment of acute myeloid leukemia,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574507.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
DB00058,,FDA Approved Products: PROLASTIN® 5 -C LIQUID (Alpha1-Proteinase Inhibitor [Human]) Solution for Intravenous Injection,https://www.fda.gov/media/78388/download
DB00059,,FDA Approved Drug Products: ONCASPAR (pegaspargase) injection for intramuscular or intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103411s5205lbl.pdf
DB00059,,EMA Summary of Product Characteristics: Oncaspar (pegaspargase) powder for solution for injection/infusion,https://www.ema.europa.eu/en/documents/product-information/oncaspar-epar-product-information_en.pdf
DB00062,,BLA APPROVAL,https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM611260.pdf
DB00062,,ALBUMIN (HUMAN)- albumin human solution DailyMed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ddaae99-05e1-e05c-e63c-0c58965d157d
DB00062,,PDR-Human Albumin,http://www.pdr.net/drug-summary/Human-Albumin-Grifols-25--albumin--human--1765
DB00062,,Alburx,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad74b7f5-b380-47ab-b19d-eef92c8eb7a4
DB00062,,Human Albumin,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90f0c351-3977-2b84-0a6a-e9cb091430ca
DB00062,,Plasbumin,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ead60f3e-9dcc-7afe-2220-4f2381f3c140
DB00063,,FDA Approved Drug Products: INTEGRILIN (eptifibatide) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020718s039lbl.pdf
DB00065,,Health Canada Approved Drug Products: REMSIMA (infliximab) Subcutaneous Injection,https://pdf.hres.ca/dpd_pm/00074581.PDF
DB00065,,"EMA Approved Drug Products: Remsima (infliximab) Solution, for Intravenous Infusion",https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf
DB00065,,"FDA Approved Drug Products: ZYMFENTRA (infliximab-dyyb) injection, for subcutaneous use (February 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761358Orig1s001lbl.pdf
DB00067,,FDA Approved Drug Products: VASOSTRICT (vasopressin) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204485Orig1s013lbl.pdf
DB00068,,Link,http://www.kegg.jp/entry/D00746
DB00069,,Link,http://www.google.com/patents/EP0422697A1?cl=en
DB00072,,US Patent US6870034B2 (includes Trastuzumab heavy chain sequence),https://patents.google.com/patent/US6870034
DB00072,,Health Canada Product Monograph: Ogivri (trastuzumab) powder for intravenous infusion,https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96453
DB00072,,FDA Approved Drug Products: Herceptin (trastuzumab) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf
DB00072,,FDA Approved Drug Products: Ogivri (trastuzumab-dkst) for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761074s004lbl.pdf
DB00072,,FDA Approved Drug Products: Herzuma (trastuzumab-pkrb) for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761091s001s002lbl.pdf
DB00072,,FDA Approved Drug Products: Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106Orig1s000lbl.pdf
DB00072,,FDA Approved Drug Products: Kanjinti (trastuzumab-anns) for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761073Orig1s000lbl.pdf
DB00072,,FDA Approved Drug Products: Ontruzant (trastuzumab-dttb) for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761100s000lbl.pdf
DB00072,,FDA Approved Drug Products: Trazimera (trastuzumab-qyyp) for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761081s000lbl.pdf
DB00072,,Genentech: Herceptin(R) MSDS,https://www.gene.com/download/pdf/MSDS_herceptin_vials440mg.pdf
DB00072,,FDA News Release: FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional,https://www.fda.gov/news-events/press-announcements/fda-approves-breast-cancer-treatment-can-be-administered-home-health-care-professional
DB00072,,FDA Approved Drug Products: Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf
DB00072,,Health Canada Product Monograph: ONTRUZANT (trastuzumab) intravenous infusion,https://pdf.hres.ca/dpd_pm/00064538.PDF
DB00072,,"GlobeNewsWire: Samsung Bioepis Announces Health Canada Approval of 150mg Single-use Vial and 440mg Multi-dose Vial of ONTRUZANT® (SB3), Trastuzumab Biosimilar for the Treatment of Adults with Early Breast Cancer, Metastatic Breast Cancer, and Metastatic Gastric Cancer",https://www.globenewswire.com/news-release/2022/02/02/2377477/0/en/Samsung-Bioepis-Announces-Health-Canada-Approval-of-150mg-Single-use-Vial-and-440mg-Multi-dose-Vial-of-ONTRUZANT-SB3-Trastuzumab-Biosimilar-for-the-Treatment-of-Adults-with-Early-B.html
DB00072,,EMA Product Information: HERWENDA (trastuzumab) Powder for concentrate for solution for infusion (December 2023),https://www.ema.europa.eu/en/documents/product-information/herwenda-epar-product-information_en.pdf
DB00072,,An overview of Herwenda and why it is authorised in the EU,https://www.ema.europa.eu/en/documents/overview/herwenda-epar-medicine-overview_en.pdf
DB00073,,FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm627009.htm
DB00073,,FDA Approves Two New Indications for Rituxan in Patients With Non-Hodgkin's Lymphoma,https://www.gene.com/media/press-releases/10047/2006-09-29/fda-approves-two-new-indications-for-rit
DB00073,,FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-rare-diseases-cause-inflammation-small-blood-vessels
DB00073,,FDA Approved Drug Products: Rituxan (rituximab) for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf
DB00073,,"FDA Approved Drug Products: TRUXIMA (rituximab-abbs) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf
DB00073,,"FDA Approved Drug Products: RUXIENCE (rituximab-pvvr) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761103s005lbl.pdf
DB00073,,"FDA Approved Drug Products: RIABNI (rituximab-arrx) injection, for intravenous use",https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Riabni/riabni_pi_english.pdf
DB00073,,"FDA Approved Drug Products: RITUXAN HYCELA (rituximab and hyaluronidase human) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761064s013lbl.pdf
DB00073,,Genentech: RITUXAN (rituximab) SDS,https://www.gene.com/download/pdf/RITUXANVials500mgper50mlSAPSDS.pdf
DB00073,,"FDA Approved Drug Products: RUXIENCE® (rituximab-pvvr) injection, for intravenous use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761103s011lbl.pdf
DB00078,,Link,http://web.b.ebscohost.com/dynamed/detail?vid=6&sid=48a6db20-234e-4280-b18e-dcd0e2fed388%40sessionmgr198&hid=102&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232878
DB00080,,FDA Approved Drug Products: CUBICIN (daptomycin) injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021572s063,064lbl.pdf"
DB00080,,"FDA Approved Drug Products: DAPTOMYCIN for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210282s001lbl.pdf
DB00082,,FDA Approved Drug Products: Somavert (pegvisomant) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021106s067s068lbl.pdf
DB00083,,FDA Approved Products: Botox (onabotulinumtoxinA) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103000s5318lbl.pdf
DB00083,,World Health Organization: Botulism,https://www.who.int/news-room/fact-sheets/detail/botulism
DB00083,,Allergan MSDS: Botox,https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/safety-data-sheets/Botox%20Drug%20product.PDF
DB00083,,DermNet NZ: Botulinum toxin,https://dermnetnz.org/topics/botulinum-toxin/
DB00083,,Product monograph: Botox Cosmetic (botulinum toxin A) for injection,https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/2020-06-29-botox-cosmetic-product-monograph.pdf
DB00083,,Product Monograph: Botox (Clostridium botulinum type A neurotoxin complex ) powder for injectable solution,https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/botox-pm-2014-07-07_e.pdf
DB00083,,"FDA Approved Drug Products: XEOMIN (incobotulinumtoxinA) for injection, for intramuscular or intraglandular use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125360s073lbl.pdf
DB00083,,Allergan MSDS: OnabotulinumtoxinA,https://allergan-web-cdn-prod.azureedge.net/allerganaustralia/allerganaustralia/media/allergan-australia/products/pdfs/msds/ehs-botox.pdf
DB00085,,Creon monograph,http://www.rxabbvie.com/pdf/creon_PI.pdf
DB00085,,FDA approval,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022523_pancreaze_toc.cfm
DB00085,,FDA reports,https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM308286.pdf
DB00085,,CENTER FOR DRUG EVALUATION AND RESEARCH- 20755,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020725s000PharmR.pdf
DB00085,,EMA reports,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002070/WC500210680.pdf
DB00087,,FDA Approved Drug Products: LEMTRADA (alemtuzumab) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103948s5183lbl.pdf
DB00087,,FDA Approved Drug Products: LEMTRADA (alemtuzumab) injection 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103948s5187lbl.pdf
DB00087,,FDA Approved Products: CAMPATH (alemtuzumab) intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103948s5181lbl.pdf
DB00087,,Assessment report: Lemtrada (International non-proprietary name ALEMTUZUMAB),https://www.ema.europa.eu/en/documents/assessment-report/lemtrada-epar-public-assessment-report_en.pdf
DB00088,,FDA Approved Drug Products: Ceredase (alglucerase) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020057s034lbl.pdf
DB00089,,Link,http://www.google.com/patents/WO2013006706A1?cl=en
DB00089,,Link,http://www.google.ca/patents/US4741900
DB00089,,Link,http://www.google.com/patents/US5162504
DB00090,,FDA Approved Drug Products: ALDURAZYME (laronidase) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125058s244lbl.pdf
DB00090,,FDA Approved Drug Products: Aldurazyme (laronidase) for intravenous injection (December 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125058s246lbl.pdf
DB00091,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065004
DB00091,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48c3d8a3-4289-4b52-9189-58b48596095c
DB00091,,Cyclosporine Product Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050573s039,050574s047,050625s053lbl.pdf"
DB00091,,Cayman Chem: Cyclosporine MSDS,https://www.caymanchem.com/msdss/12088m.pdf
DB00091,,NIH Stat Pearls: Cyclosporine,https://www.ncbi.nlm.nih.gov/books/NBK482450/
DB00091,,Novartis Monograph: Apo-Cyclosporine,https://pdf.hres.ca/dpd_pm/00014004.PDF
DB00091,,Neoral (Cyclosporine) FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf"
DB00091,,NY times: Drug that reduces risk in transplants gets early approval,https://www.nytimes.com/1983/09/03/us/drug-that-reduces-risk-in-transplants-gets-early-approval.html
DB00091,,FDA Approved Products: Restasis (cyclosporine ophthalmic emulsion),https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf
DB00091,,FDA Approved Drug Products: Verkazia (Cyclosporine) Ophthalmic Emulsion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214965s000lbl.pdf
DB00091,,"FDA Approved Drug Products: VEVYE (cyclosporine ophthalmic solution) 0.1%, for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217469s000lbl.pdf
DB00091,,Health Canada Product Monograph: Neoral (cyclosporine for oral use) and Sandimmune (cyclosporine for intravenous injection),http://www.ask.novartispharma.ca/download.htm?res=neoral_scrip_e.pdf&resTitleId=691
DB00091,,Health Canada Product Monograph: CEQUA (Cyclosporine Ophthalmic Solution) for topical opthalmic injection),https://pdf.hres.ca/dpd_pm/00064273.PDF
DB00091,,FDA Approved Drug Products: Neoral (Cyclosporine) oral capule and solution (October 2023),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf"
DB00095,,FDA Approved Drug Products: Raptiva (efalizumab) for subcutaneous injection,https://www.fda.gov/media/75713/download
DB00095,,US Food & Drug Administration: FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market,https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-statement-voluntary-withdrawal-raptiva-us-market
DB00098,,FDA Approved Drug Products: THYMOGLOBULIN (anti-thymocyte globulin [rabbit]) for intravenous use,https://www.fda.gov/media/74641/download
DB00099,,"DailyMed Label: NEUPOGEN (filgrastim) injection, for subcutaneous or intravenous use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193
DB00099,,"DailyMed Label; GRANIX (tbo-filgrastim) injection, for subcutaneous use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df918ec2-0907-443f-a52a-b72866959644
DB00099,,EMA Summary of Product Characteristics: HEXAL (filgrastim) subcutaneous or intravenous injection,https://www.ema.europa.eu/en/documents/product-information/filgrastim-hexal-epar-product-information_en.pdf
DB00099,,Hospira Safety Data Sheet: NIVESTYM (Filgrastim-aafi),https://www.obaid.info/pdf/MSDS/N/Nivestim.pdf
DB00099,,Drugs@FDA: Zarxio (filgrastim-sndz),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553orig1s000toc.cfm
DB00099,,Business Wire News: Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow),https://www.businesswire.com/news/home/20220302005951/en/Kashiv-Biosciences-Receives-Approval-for-Its-First-Biosimilar-RELEUKOTM-filgrastim-ayow
DB00099,,"FDA Approved Drug Products: NEUPOGEN® (filgrastim) injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103353s5198lbl.pdf
DB00099,,"FDA Approved Drug Products: NIVESTYM™ (filgrastim-aafi) injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761080s011lbl.pdf
DB00100,,"FDA Approved Drug Products: BeneFIX [coagulation factor IX (recombinant)] lyophilized powder for solution, for intravenous use",https://www.fda.gov/media/73556/download
DB00100,,DailyMed Label: IXINITY [coagulation factor IX (recombinant)] Lyophilized Powder for Solution for Intravenous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9521898c-61aa-44ab-8ab8-84274ca19943
DB00102,,Link,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000212/WC500050140.pdf
DB00103,,FDA Approved Drug Products: Fabrazyme Agalsidase Beta Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103979s5303lbl.pdf
DB00103,,EMA Summary of Product Characteristics: Replagal Agalsidase Alfa Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/replagal-epar-product-information_en.pdf
DB00103,,"FDA Approved Drug Products: FABRAZYME (agalsidase beta) for injection, for intravenous use (February 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103979s5312lbl.pdf
DB00104,,"Bioworld: Chiasma carries new oral acromegaly treatment, Mycapssa, to FDA approval",https://www.bioworld.com/articles/436089-chiasma-carries-new-oral-acromegaly-treatment-mycapssa-to-fda-approval?v=preview
DB00104,,NIH StatPearls: Acromegaly,https://www.ncbi.nlm.nih.gov/books/NBK431086/
DB00104,,FDA approval letter: Mycapssa,https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208232Orig1s000ltr.pdf
DB00104,,Product monograph: Sandostatin (octreotide acetate) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19667scm044_Sandostatin_lbl.pdf
DB00104,,NIH StatPearls: Octreotide,https://www.ncbi.nlm.nih.gov/books/NBK544333/
DB00104,,FDA Approved Drug Products: Mycapssa (octreotide) delayed-release capsules for oral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208232s000lbl.pdf
DB00104,,Cayman Chem MSDS: Octreotide acetate,https://www.caymanchem.com/msdss/23757m.pdf
DB00104,,Product monograph: Octreotide injection (octreotide acetate),https://pdf.hres.ca/dpd_pm/00024797.PDF
DB00104,,EMA Summary of Product Characteristics: Mycapssa (octreotide) gastro-resistant hard capsules for oral use (December 2022),https://www.ema.europa.eu/en/documents/product-information/mycapssa-epar-product-information_en.pdf
DB00104,,FDA Approved Drug Products: Sandostatin (octreotide acetate) for subcutaneous or intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019667s076lbl.pdf
DB00105,,FDA Approved Drug Products: INTRON (Interferon alfa-2b) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103132Orig1s5199lbl.pdf
DB00107,,FDA Approved Drug Products: Pitocin (oxytocin) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018261s031lbl.pdf
DB00107,,Prescribers Digital Reference (PDR): Oxytocin - Drug Summary,"https://www.pdr.net/drug-summary/Pitocin-oxytocin-1666%23:~:text=Oxytocin%20administered%20effectively%20by%20parenteral,between%201%20and%206%20minutes."
DB00108,,"FDA Approved Drug Products: TYSABRI (natalizumab) injection, for intravenous use (April 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125104s976s979lbl.pdf
DB00108,,"FDA Approved Drug Products: TYRUKO (natalizumab-sztn) injection, for intravenous use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761322s000lblcorrection.pdf
DB00108,,FDA News Release: FDA Approves First Biosimilar to Treat Multiple Sclerosis,https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-multiple-sclerosis
DB00108,,EMA Approved Drug Products: Tyruko (natalizumab) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/tyruko-epar-product-information_en.pdf
DB00111,,U.S. Food & Drug Administration: FDA working with manufacturers to withdraw Zinbryta from the market in the United States,https://www.fda.gov/Drugs/DrugSafety/ucm600999.htm
DB00111,,"European Medicines Agency: Public state on Zenapax (daclizumab), Withdrawal of the marketing authorization in the European Union",http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500011995.pdf
DB00111,,U.S. FDA Zinbryta (daclizumab) Prescribing Information,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761029s000lbl.pdf
DB00112,,"FDA Approved Drug Products: AVASTIN (bevacizumab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125085s331lbl.pdf
DB00112,,ClinicalTrials.gov: Bevacizumab in Severe or Critical Patients with COVID-19 Pneumonia (BEST-CP),https://clinicaltrials.gov/ct2/show/NCT04275414
DB00112,,"FDA Approved Drug Products: MVASI (bevacizumab-awwb) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761028s008lbl.pdf
DB00112,,"FDA Approved Drug Products: ALYMSYS (bevacizumab-maly) injection, for intravenous use",https://amneal.com/wp-content/uploads/2022/04/Bevacizumab-Injection-PI-Rev-04-2022-00.pdf
DB00112,,EMA Approved Drug Products: Abevmy (bevacizumab) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/abevmy-epar-product-information_en.pdf
DB00112,,"FDA Approved Drug Products: VEGZELMA (bevacizumab-adcd) injection, for intravenous use",https://www.celltrionhealthcare.com/en-us/draft-labeling-text.pdf
DB00112,,"Health Canada Approved Drug Product: VEGZELMA (bevacizumab) injection, for intravenous use",https://pdf.hres.ca/dpd_pm/00068966.PDF
DB00112,,Health Canada approves AVASTIN(R) for treatment of most aggressive form of brain cancer,https://www.newswire.ca/news-releases/health-canada-approves-avastinr-for-treatment-of-most-aggressive-form-ofbrain-cancer-539649801.html
DB00112,,"FDA Approved Drug Products: Avzivi (bevacizumab-tnjn) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761198s000lbl.pdf
DB00113,,Link,http://www.google.ca/patents/US8420081
DB00113,,Link,http://www.google.ca/patents/US7790142
DB00113,,Link,http://www.google.ca/patents/US8226949
DB00115,,Methylcobalamin vs cyanocobalamin,https://thetastyorange.wordpress.com/2013/04/02/methylcobalamin-versus-cyanocobalamin/
DB00115,,"B12, cyanocobalamin tablets, DailyMed",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed824d40-79f8-4a76-a102-813ab85f7c6a&audience=consumer
DB00115,,"Cyanocobalamin injection, DailyMed",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fb653d6-e2b2-4969-831b-c0dc37b9c0cc
DB00115,,Vitamin B12,https://ods.od.nih.gov/factsheets/VitaminB12-Consumer/
DB00115,,The metabolic processes of folic acid and Vitamin B12 deficiency,http://www.jhrr.org/article.asp?issn=2394-2010;year=2014;volume=1;issue=1;spage=5;epage=9;aulast=Mahmood
DB00115,,University of Virginia: Megaloblastic anemia,https://www.med-ed.virginia.edu/courses/path/innes/rcd/mega.cfm
DB00115,,Vitamin B 12 Health Professional Fact Sheet,https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
DB00126,,FDA Approved Drug Products: Ascor Ascorbic Acid Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209112s000lbl.pdf
DB00129,,ilacaBak: Hepa-Ornitat (l-ornithine-l-aspartate) oral granules,https://www.ilacabak.com/hepa-ornitat-3-gr-granul-30-poset-20644/kisa-urun-bilgisi
DB00129,,ilacaBak: Hepalornitin (l-ornithine-l-aspartate) solution for intravenous injection,https://www.ilacabak.com/hepalornitin-5-mg-10-ml-i-v-infuzyonluk-cozelti-hazirlamak-icin-konsantre-10-ampul-24520/kisa-urun-bilgisi
DB00130,,Endari Approval Article,https://www.drugs.com/newdrugs/fda-approves-endari-l-glutamine-oral-powder-sickle-cell-4555.html?utm_source=ddc&utm_medium=email&utm_campaign=Today%27s+news+summary+-+July+8%2C+2017&utm_content=FDA+Approves+Endari+%28L-glutamine+oral+powder%29+for+Sickle+Cell+Disease
DB00130,,FDA Approved Drug Products: Endari L-Glutamine Oral Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208587s001lbl.pdf
DB00131,,"FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting February 23-24, 2015",https://downloads.regulations.gov/FDA-1999-N-0194-0010/content.pdf
DB00136,,"1,25-DIHYDROXYCHOLECALCIFEROL - National Library of Medicine HSDB Database - ToxNet - NIH",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3482
DB00136,,DailyMed Label: Rocaltrol (calcitriol) Oral Capsule or Solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc293a1c-995d-40fa-ac99-68df12eb6d9e
DB00145,,FDA Approved Drug Products: Glycine Irrigation Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016784s035lbl.pdf
DB00146,,FDA Approved Drug Products: RAYALDEE (calcifediol) extended-release capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208010s005lbl.pdf
DB00153,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=003444
DB00153,,Endocrine Web,https://www.endocrineweb.com/conditions/hypoparathyroidism/hypoparathyroidism
DB00153,,NORD,https://rarediseases.org/rare-diseases/familial-hypophosphatemia/
DB00153,,Pediatric Pharmacotherapy,https://med.virginia.edu/pediatrics/wp-content/uploads/sites/237/2015/12/200906.pdf
DB00153,,Pubmed books,https://www.ncbi.nlm.nih.gov/books/NBK56061/
DB00153,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87e80b1f-e376-45ba-825b-a6fda4b82325
DB00158,,Health Canada Prenatal Nutrition Guidelines for Health Professionals - Folate Contributes to a Healthy Pregnancy,https://www.canada.ca/en/health-canada/services/publications/food-nutrition/prenatal-nutrition-guidelines-health-professionals-folate-contributes-healthy-pregnancy-2009.html
DB00162,,Health Canada: Dietary Reference Intakes,https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/hpfb-dgpsa/pdf/nutrition/dri_tables-eng.pdf
DB00163,,NIH ODS Vitamin E Fact Sheet for Health Professionals,https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/
DB00163,,Vitamin E | Linus Pauling Institute | Oregon State University,https://lpi.oregonstate.edu/mic/vitamins/vitamin-E
DB00165,,DailyMed: Pyridoxine hydrochloride tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cca3c335-f43c-4053-b757-5ec48cf103c5
DB00165,,FDA Approved Products: Diclegis (doxylamine succinate and pyridoxine hydrochloride),https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s002lbl.pdf
DB00165,,Vitamin B6: Health professionals fact sheet,https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/
DB00165,,"Pyridoxine, DailyMed",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a56d11c0-b033-4201-85ff-fc710506481a
DB00166,,MS Society Canada: Lipoic Acid,https://mssociety.ca/research-news/treatments-in-development/lipoic-acid
DB00169,,"Cholecalciferol (Vitamin D3) – Pharmacological Properties, Therapeutic Utility and Potential New Fields of Clinical Application by Yulian Voynikov, Georgi Momekov, Plamen Peikov",https://www.researchgate.net/publication/312164408_Cholecalciferol_Vitamin_D3_-_Pharmacological_Properties_Therapeutic_Utility_and_Potential_New_Fields_of_Clinical_Application
DB00169,,Vitamin D Supplementation: An Update,https://www.uspharmacist.com/article/vitamin-d-supplementation-an-update
DB00169,,NIH Vitamin D Fact Sheet for Health Professionals,https://ods.od.nih.gov/factsheets/Vitamind-HealthProfessional/
DB00175,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019898
DB00175,,Chemocare,http://chemocare.com/chemotherapy/side-effects/cardiovascular-events.aspx
DB00175,,Merck Manuals,https://www.merckmanuals.com/en-ca/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia
DB00177,,FDA Approved Drug Products: Diovan (valsartan) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021283s053lbl.pdf
DB00177,,FDA Approved Drug Products: EXFORGE (amlodipine and valsartan) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021990s033lbl.pdf
DB00177,,FDA Approved Drug Products: DIOVAN HCT (valsartan and hydrochlorothiazide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020818s080lbl.pdf
DB00177,,FDA Approved Drug Products: ENTRESTO (sacubitril and valsartan) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf
DB00177,,"FDA Approved Drug Products: EXFORGE HCT (amlodipine, valsartan, and hydrochlorothiazide) tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022314Orig1s036lbl.pdf
DB00177,,FDA Approved Drug Products: Valturna (aliskiren and valsartan) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022217s020lbl.pdf
DB00177,,Health Canada Product Monograph: Valsartan-HCTZ (valsartan/hydrochlorothiazide) tablets for oral use,https://pdf.hres.ca/dpd_pm/00064299.PDF
DB00178,,FDA Approved Products: Altace (ramipril) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019901s060lbl.pdf
DB00181,,FDA Approved Drug Products: Gablofen (baclofen) for intrathecal injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022462s011lbl.pdf
DB00181,,FDA Approved Drug Products: Lyvispah (baclofen) oral granules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215422lbl.pdf
DB00181,,FDA Approved Drug Products: FLEQSUVY (baclofen) oral suspension,https://azurity.com/wp-content/uploads/2022/02/FLEQSUVY-PI-02-04-2022.pdf
DB00181,,Cayman Chemical: Baclofen MSDS,https://cdn.caymanchem.com/cdn/msds/18600m.pdf
DB00181,,EMC Summary of Product Characteristics: Baclofen Oral Tablets,https://www.medicines.org.uk/emc/medicine/23850#gref
DB00182,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=083900
DB00182,,JAMA network,https://jamanetwork.com/journals/jama/article-abstract/659694
DB00182,,Australian Health Department,http://www.health.gov.au/internet/publications/publishing.nsf/Content/drugtreat-pubs-modpsy-toc~drugtreat-pubs-modpsy-2~drugtreat-pubs-modpsy-2-3~drugtreat-pubs-modpsy-2-3-pamp
DB00182,,Inchem,http://www.inchem.org/documents/pims/pharm/pimg009.htm#PartTitle:6.%20%20KINETICS
DB00182,,D-amphetamine sulfate information,http://www.acutetox.eu/pdf_human_short/35-Amphetamine%20revised.pdf
DB00182,,FDA Approved Drug Products: DYANAVEL XR (amphetamine) extended-release suspension and tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210526s000lbl.pdf
DB00185,,FDA Approved Drug Products: EVOXAC (cevimeline) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020989s008lbl.pdf
DB00186,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=070472
DB00186,,Lorazepam monograph,https://pdf.hres.ca/dpd_pm/00026294.PDF
DB00186,,FDA Approved Drug Products: Ativan (lorazepam) for intravenous or intramuscular injection [Updated 01/2023],https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018140s051lbl.pdf
DB00186,,FDA Approved Drug Products: Ativan (lorazepam) tablets for oral administration [Updated 01/2023],https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017794s049lbl.pdf
DB00187,,FDA Approved Drug Products: BREVIBLOC (esmolol hydrochloride) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019386s043lbl.pdf
DB00187,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00188,,"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf
DB00188,,Thermo Fisher Scientific: Bortezomib Safety Data Sheet,https://www.fishersci.com/store/msds?partNumber=AAJ60378LB0&productDescription=BORTEZOMIB%2C+99%25+5MG&vendorId=VN00024248&countryCode=US&language=en
DB00188,,Cayman Chemical: Bortezomib Safety Data Sheet,https://www.caymanchem.com/msdss/10008822m.pdf
DB00188,,BC Cancer: Bortezomib Monograph,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Bortezomib_monograph.pdf
DB00188,,"FDA Approved Drug Products: BORTEZOMIB for injection, for subcutaneous or intravenous use (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209191s003lbl.pdf
DB00190,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203261
DB00190,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=073589
DB00190,,Glown,https://www.glowm.com/resources/glowm/cd/pages/drugs/kl021.html
DB00191,,EmpowerPharmacy,https://www.empowerpharmacy.com/drugs/phentermine-hcl-capsules
DB00191,,Inchem,http://www.inchem.org/documents/pims/pharm/pim415.htm#SectionTitle:6.5%20%20Elimination%20and%20excretion
DB00191,,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202088Orig1s000PharmR.pdf
DB00191,,"FDA Approved Drug Products: Qsymia (phentermine and topiramate), extended-release capsules for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf
DB00193,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075960
DB00193,,WHO reports,https://www.who.int/medicines/areas/quality_safety/6_1_Update.pdf
DB00193,,FDA Approved Drug Products: Ultram (tramadol hydrochloride) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020281s045lbl.pdf
DB00193,,FDA Approved Drug Products: QDOLO (tramadol hydrochloride) oral solution C-IV,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214044s002lbl.pdf
DB00193,,"FDA Approved Drug Products: SEGLENTIS (celecoxib and tramadol hydrochloride) tablets, for oral use, C-IV",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213426s002lbl.pdf
DB00193,,DailyMed: Tramadol and Acetaminophen Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b9cc0f1-f73b-4d00-820c-b7066c96f7bf
DB00193,,"DailyMed: Tramadol Oral Capsule, Extended Release",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49128bac-1164-204b-e054-00144ff8d46c
DB00193,,"DailyMed: Tramadol Oral Tablet, Extended Release",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=036dddf3-9b80-4651-be57-e3cac0fe3bf8
DB00193,,Health Canada Approved Drug Proucts: APO-TRAMADOL (Tramadol) tablet for oral use,https://pdf.hres.ca/dpd_pm/00067035.PDF
DB00196,,"Fluconazole, Medsafe NZ data sheet",https://www.medsafe.govt.nz/profs/Datasheet/f/fluconazolecapmylan.pdf
DB00196,,EMA Summary of Product Characteristics: Diflucan (fluconazole) oral capsules,https://www.ema.europa.eu/en/documents/referral/diflucan-article-30-referral-annex-iii_en.pdf
DB00196,,FDA Approved Drug Products: Diflucan (fluconazole),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019949s065,020090s047lbl.pdf"
DB00198,,Electronic Medicines Compendium: Tamiflu (oseltamivir phosphate) 30 mg Hard Capsules Monograph,https://www.medicines.org.uk/emc/product/8050/smpc
DB00198,,Lupin launches US Tamiflu generic amid worst flu season in recent memory: Press Release,https://www.pharmaceutical-technology.com/comment/lupin-launches-us-tamiflu-generic-amid-worst-flu-season-recent-memory/
DB00198,,Dailymed - Oseltamivir (FDA),https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d306e22c-0cb8-46cb-9a40-8194a2bc9e85
DB00198,,CDC Influenza Antiviral Medications: Summary for Clinicians,https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
DB00198,,Canadian Paediatric Society - The use of antiviral drugs for influenza: Guidance for practitioners,https://www.cps.ca/en/documents/position/antiviral-drugs-for-influenza
DB00199,,NIH StatPearls: Erythromycin,https://www.ncbi.nlm.nih.gov/books/NBK532249/
DB00199,,FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf"
DB00199,,MedSafe NZ: ERA (erythromycin stearate) oral filmtabs,https://www.medsafe.govt.nz/Profs/Datasheet/e/ERAcaptab.pdf
DB00199,,Pfizer: Erythromycin MSDS,https://www.pfizer.com/system/files/products/material_safety_data/PZ00645.pdf
DB00199,,DailyMed Label: Erythromycin Ethylsuccinate for Oral Suspension,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596fa019-b0eb-4e57-93ff-195a765a2e91
DB00199,,"FDA Approved Drug Products: ERYTHROMYCIN - erythromycin tablet, film coated for oral use",https://www.accessdata.fda.gov/spl/data/fcbb9cc7-8572-4096-944c-b62bddfd1d21/fcbb9cc7-8572-4096-944c-b62bddfd1d21.xml
DB00201,,Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry,https://www.fda.gov/media/112363/download
DB00201,,Caffeine citrate injection FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20793s1lbl.pdf
DB00201,,DailyMed Search: Caffeine,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=caffeine&audience=consumer
DB00201,,PDB reference,https://www.rcsb.org/ligand/CFF
DB00201,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020793
DB00201,,"Alcohol and Drug Foundation, Australia",https://adf.org.au/drug-facts/caffeine/
DB00201,,"Migergot, DailyMed",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a31ad0c-7bdd-544b-f5df-a99d04cf541c
DB00201,,Caffeine pathway: Pharm GKB,https://www.pharmgkb.org/pathway/PA165884757
DB00201,,Caffeine and sodium benzoate injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2c6b352-f837-4903-8e4c-fb0a2b20bb60
DB00201,,"FDA Approved Drug Products: SYNALGOS®-DC (aspirin, caffeine, and dihydrocodeine bitartrate) capsules, for oral use, CIII (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/011483s035lbl.pdf
DB00202,,Health Canada Product Monograph: Quelicin (succinylcholine chloride) for injection,https://pdf.hres.ca/dpd_pm/00058027.PDF
DB00202,,FDA Approved Drug Products: Anectine (succinylcholine chloride) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/008453s036lbl.pdf
DB00202,,Pfizer SDS: Succinylcholine Chloride injection,https://cdn.pfizer.com/pfizercom/products/material_safety_data/QUELICIN(Succinylcholine_Cl)Inj_(Hosira)8-Dec-2016.pdf
DB00203,,"Electronic Medicines Compendium: Sildenafil 25mg, 50mg, 100mg film-coated tablets Monograph",https://www.medicines.org.uk/emc/product/3172/smpc
DB00203,,Electronic Medicines Compendium: Revatio (sildenafil citrate) 20 mg film-coated tablets Monograph,https://www.medicines.org.uk/emc/product/181/smpc
DB00203,,"Forbes: With Viagra Now Available Over-The-Counter In The U.K., Will The U.S. Follow Suit?",https://www.forbes.com/sites/johnlamattina/2018/05/01/with-viagra-now-available-over-the-counter-in-the-uk-will-the-us-follow-suit/#9f64aee75b65
DB00205,,FDA Approved Drug Products: DARAPRIM (pyrimethamine) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/008578s020lbl.pdf
DB00206,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00208,,FDA Approved Drug Products: TICLID (ticlopidine hydrochloride) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/19-979S018_Ticlid_prntlbl.pdf
DB00209,,Trospium,https://medlineplus.gov/druginfo/meds/a604037.html
DB00209,,FDA drug approval: Trospium,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022103s000TOC.cfm
DB00209,,FDA Approved Drug Products: Cobenfy (xanomeline tartrate/trospium chloride) capsules for oral use (September 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216158s000lbl.pdf
DB00209,,"DailyMed Label: TROSPIUM CHLORIDE oral capsule, extended release",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b8d434c-daa2-4bf2-bde6-3e59f81bd88b
DB00210,,FDA Approved Drug Products: Differin (adapalene) gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021753s004lbl.pdf
DB00210,,FDA: Pharmacology/Toxicology Review and Evaluation (adapalene),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022502s000PharmR.pdf
DB00210,,DPD Monograph: Differin (adapalene) topical cream/gel/lotion,https://pdf.hres.ca/dpd_pm/00048625.PDF
DB00210,,"FDA Approved Drug Products: Epiduo (adapalene and benzoyl peroxide), gel",https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207917Orig1s000lbl.pdf
DB00210,,INVIMA Product Authorization: Clinacyin (adapalene/clindamycin phosphate) topical gel,http://web.sivicos.gov.co/registros/pdf/1278604_2015007791.pdf
DB00210,,"FDA Approved Drug Products: Cabtreo (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel",https://pi.bauschhealth.com/globalassets/BHC/PI/Cabtreo-PI.pdf
DB00214,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076110
DB00214,,Cleveland Clinic,https://my.clevelandclinic.org/health/diseases/12564-edema
DB00214,,Hypertension Canada,https://hypertension.ca/
DB00214,,Indian Journal of Clinical Practice,http://medind.nic.in/iaa/t13/i9/iaat13i9p385.pdf
DB00214,,EMC,https://www.medicines.org.uk/emc/product/6665/smpc
DB00214,,FDA Approved Drug Products: Soaanz (torsemide) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213218s000lbl.pdf
DB00214,,Demadex (Torsemide) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020136s027lbl.pdf
DB00215,,MSDS citalopram,https://s3-us-west-2.amazonaws.com/drugbank/msds/DB00215.pdf?1549040558
DB00215,,NIH Stat Pearls: Citalopram,https://www.ncbi.nlm.nih.gov/books/NBK482222/
DB00215,,AAFP: Off-label Applications for SSRIs,https://www.aafp.org/afp/2003/0801/p498.html
DB00215,,"Celexa Information, FDA",https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm
DB00215,,"FDA Approved Drug Products: CELEXA (citalopram) tablets, for oral use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020822s054lbl.pdf
DB00215,,"DailyMed Label: SENTRALOPRAM AM-10 (citalopram hydrobromide, choline) oral kit",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0e39608-a7ed-464a-91c9-867ad7cd293c
DB00215,,Citalopram FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020822s042,021046s019lbl.pdf"
DB00215,,"Health Canada Approved Drug Proucts: ACT CITALOPRAM (Citalopram) tablets, for oral use",https://pdf.hres.ca/dpd_pm/00067722.PDF
DB00216,,FDA Approved Drug Products: RELPAX (eletriptan hydrobromide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/21016s029lbl.pdf
DB00220,,Nelfinavir FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021503s006lbl.pdf
DB00220,,FDA Approved Drug Products: VIRACEPT (nelfinavir mesylate) tablets and powder,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020778s042,020779s063,021503s025lbl.pdf"
DB00220,,Health Canada Approved Drug Products: VIRACEPT (nelfinavir mesylate) tablets and powder,https://pdf.hres.ca/dpd_pm/00037024.PDF
DB00220,,Cayman Chemical: Nelfinavir MSDS,https://cdn.caymanchem.com/cdn/msds/15144m.pdf
DB00222,,AMARYL (glimepiride) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020496s027lbl.pdf
DB00222,,Health Canada Product Monograph: Sandoz Glimepiride tablets for oral use,https://pdf.hres.ca/dpd_pm/00059900.PDF
DB00223,,FDA Approved Drug Products: PSORCON (diflorasone diacetate) ointment,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019260s009lbl.pdf
DB00225,,FDA Approved Drug Products: OMNISCANTM (gadodiamide) Injection for Intravenous Use (Feb 2024),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020123s050,022066s013lbl.pdf"
DB00225,,Product Monograph: OMNISCAN (Gadodiamide) Intravenous Injection,https://pdf.hres.ca/dpd_pm/00044089.PDF
DB00227,,FDA Approved Drug Products: Altoprev (lovastatin extended-release) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021316s036lbl.pdf
DB00227,,FDA Approved Drug Products: Mevacor (lovastatin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019643s088lbl.pdf
DB00228,,NIH StatPearls: Enflurane,https://www.ncbi.nlm.nih.gov/books/NBK554595/
DB00228,,FDA Approved Products: Efrane (enflurane) liquid for inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017087s048lbl.pdf
DB00228,,"FDA approval status, Enflurane",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017087
DB00228,,Matheson Gas MSDS: Enflurane,https://www.mathesongas.com/pdfs/msds/MAT08601.pdf
DB00230,,Pfizer,http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_lyrica_cr_pregabalin_extended_release_tablets_cv
DB00230,,FDA Label Pregabalin,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021446s036,022488s014lbl.pdf"
DB00230,,Pfizer Medical Information - Lyrica,https://www.pfizermedicalinformation.ca/en-ca/lyrica/overdosage#
DB00230,,TITCK Product Information: Pagamax Plus (pregabalin/cyanocobalamin) for oral administration,https://titck.gov.tr/storage/kubKtAttachments/G6ELRpdcScRWP.pdf
DB00230,,"FDA Approved Drug Products: LYRICA (pregabalin) Capsule/solution, for oral use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021446s041,022488s018,209501s005lbl.pdf"
DB00230,,"DailyMed Label: LYRICA CR (pregabalin) extended-release tablets, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d832165-3d98-497c-84b0-2d9ae3f838f9
DB00231,,Electronic Medicines Compendium: Temazepam 10mg Tablets Monograph,https://www.medicines.org.uk/emc/product/8792/smpc
DB00235,,FDA Approved Drug Products: PRIMACOR (milrinone) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019436s021s022lbl.pdf
DB00235,,MSDS: milrinone,https://www.caymanchem.com/msdss/13357m.pdf
DB00236,,AIFA Approved Drug Proucts: vercite (pipobroman) tablet for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004157_021992_RCP.pdf&retry=0&sys=m0b1l3
DB00237,,FDA Approved Drug Products: Butabarbital Oral Tablets and Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/000793s026lbl.pdf
DB00239,,FDA Approved Drug Products: OXISTAT (oxiconazole nitrate) topical,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19828slr009,20209slr005_oxistat_lbl.pdf"
DB00241,,Butalbital - National Library of Medicine HSDB Database,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7853
DB00241,,"Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules - FDA Label",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020232s041lbl.pdf
DB00242,,"FDA Approved Drug Products: MAVENCLAD (cladribine) tablets, for oral use (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022561s007lbl.pdf
DB00242,,DailyMed Label: Cladribine Intravenous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe
DB00242,,Cayman Chemical: Cladribine MSDS,https://cdn.caymanchem.com/cdn/msds/12085m.pdf
DB00242,,EMA Approved Drug Products: Mavenclad (cladribine) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf
DB00243,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201046
DB00243,,FDA approvals,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021526_s000_Ranexa.cfm
DB00243,,Australian Assessment Report,https://www.tga.gov.au/sites/default/files/auspar-ranolazine-180220.pdf
DB00243,,FDA Approved Drug Products: Ranexa (ranolazine) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021526s035lbl.pdf
DB00243,,Angina: Mayo clinic,https://www.mayoclinic.org/diseases-conditions/angina/symptoms-causes/syc-20369373
DB00244,,Electronic Medicines Compendium: Asacol (mesalazine) 400mg MR Tablets Monograph,https://www.medicines.org.uk/emc/product/2217/smpc
DB00244,,Electronic Medicines Compendium: Pentasa (Mesalazine) Sachet 2g Monograph,https://www.medicines.org.uk/emc/product/6309/smpc
DB00244,,FDA Approved Drug Products: Asacol HD (mesalamine) delayed-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021830s019lbl.pdf
DB00244,,FDA Approved Drug Products: Delzicol (mesalamine) delayed-release capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204412s012lbl.pdf
DB00244,,FDA Approved Drug Products: Canasa (mesalamine) suppositories for rectal use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021252s025lbl.pdf
DB00244,,FDA Approved Drug Products: APRISO® (mesalamine) extended-release capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022301s021lbl.pdf
DB00244,,"Electronic Medicines Compendium: Mezavant XL 1200mg, gastro-resistant, prolonged release tablets",https://www.medicines.org.uk/emc/product/6154/smpc#gref
DB00244,,Clinical Pharmacology Review : Asacol HD,https://www.fda.gov/files/drugs/published/N21-830S006-Clinpharm-PREA-1.pdf
DB00244,,Mesalazine MSDS Pharmacopoeia,https://www.pharmacopoeia.com/Catalogue/Preview?uri=%2Fcontent%2Ffile%2Fproducts%2Fhealthandsafety%2FCat_1075_GB.pdf
DB00244,,Mesalazine MSDS Allergan,https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/safety-data-sheets/ASACOL-HD-(Mesalamine)-SDS.pdf
DB00244,,Mesalazine MSDS USP,https://static.cymitquimica.com/products/45/pdf/sds-1392705.pdf
DB00244,,"FDA Approved Drug Products: LIALDA (mesalamine) delayed-release tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022000s023lbl.pdf
DB00244,,FDA Approved Drug Products: ROWASA (mesalamine) Rectal Suspension Enema,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019618s029lbl.pdf
DB00244,,"Product Monograph: SALOFALK (mesalamine) delayed release tablets, for oral use",https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/salofalk-tablets-pm_eng_30dec2014.pdf
DB00244,,FDA Approved Drug Products: Apriso (mesalamine) extended-release capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022301s022lbl.pdf
DB00245,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040103
DB00245,,Parkinson,https://www.parkinson.org/sites/default/files/attachments/Parkinsons-Disease-vs-Parkinsonisms.pdf
DB00245,,FDA Approved Drug Products: Cogentin (benztropine mesylate) for intravenous/intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s027lbl.pdf
DB00246,,Ziprasidone Black Box Warning,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020825s035,020919s023lbl.pdf"
DB00246,,FDA Approved Drug Products: Geodon (ziprasidone HCl),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020825s059,020919s047lbl.pdf"
DB00246,,Zeldox Pfizer Canada Product Monograph,https://www.pfizer.ca/sites/g/files/g10050796/f/201810/ZELDOX_PM_E_217496_28Sep2018.pdf
DB00246,,FDA Approved Drug Products: Geodon (ziprasidone),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020825s058,020919s045lbl.pdf"
DB00251,,FDA Approved Drug Products: TERAZOL (terconazole) cream and suppositories,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019579s037,019641s030,019964s032lbl.pdf"
DB00252,,FDA Approved Drugs: Dilantin,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/084349s085lbl.pdf
DB00252,,CEREBYX® FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020450s039lbl.pdf
DB00252,,Dilantin® FDA Label (injectable formulation),https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010151s047s048lbl.pdf
DB00252,,Phenytoin: A Guide to Therapeutic Drug Monitoring,https://journals.sagepub.com/doi/pdf/10.1177/201010581302200307
DB00253,,FDA Approved Drug Products: Allergan Medrysone Ophthalmic Suspension (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/16624s41lbl.pdf
DB00254,,"FDA Approved Drug Products: DORYX (doxycycline hyclate) delayed-release tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050795s030lbl.pdf
DB00254,,"DailyMed Label: LYMEPAK (doxycycline hyclate) tablets, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48b46003-e585-487a-beab-533e76544538
DB00254,,"DailyMed Label: VIBRAMYCIN and VIBRA-TABS (doxycycline), for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6f98d3c-5a20-4cbf-9a9c-abef10b9e465
DB00254,,Merck: Doxycycline MSDS,https://www.merck.com/docs/product/safety-data-sheets/ah-sds/Doxycycline%20Formulation_AH_BR_EN.pdf
DB00255,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00256,,EMC: Tetralysal 300mg Hard Capsules,https://www.medicines.org.uk/emc/product/926/pil
DB00256,,New Zealand data sheet: Tetralysal (lymecycline) oral capsules,https://www.medsafe.govt.nz/Profs/Datasheet/t/Tetralysalcap.pdf
DB00256,,ClearSynth: Lymecycline MSDS,http://www.t3db.ca/system/msds/attachments/000/002/587/original/T3D3952.pdf?1414204380
DB00257,,Clotrimazole Drug Summary,https://www.pdr.net/drug-summary/Clotrimazole-Cream-clotrimazole-704
DB00257,,HMDB Database,http://www.hmdb.ca/metabolites/HMDB0001922
DB00257,,The binding of Clotrimazole to the proteins of human serum,https://www.researchgate.net/publication/225525540_The_binding_of_Clotrimazole_to_the_proteins_of_human_serum
DB00257,,"Clotrimazole Cream, DailyMed",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2664f-955d-4ae1-85ff-186e4aebba49
DB00257,,FDA Approved Drug Products: Lotrisone (clotrimazole/betamethasone dipropionate) topical cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018827s050lbl.pdf
DB00257,,Health Canada Product Monograph: Canesten (clotrimazole) for topical and/or vaginal application,https://pdf.hres.ca/dpd_pm/00052378.PDF
DB00257,,Health Canada Product Monograph: Canesten (clotrimazole 1%) topical cream,https://pdf.hres.ca/dpd_pm/00055388.PDF
DB00261,,FDA Approved Drug Products: Agrylin (anagrelide) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020333s026lbl.pdf
DB00261,,CaymanChem: Anagrelide MSDS,https://www.caymanchem.com/msdss/21411m.pdf
DB00261,,Health Canada Product Monograph: Agrylin (anagrelide hydrochloride) capsules for oral use,https://pdf.hres.ca/dpd_pm/00053558.PDF
DB00262,,FDA Approved Drug Products: BiCNU (carmustine) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf
DB00264,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017963
DB00264,,Researchgate publications,https://www.researchgate.net/publication/257614687_Chemical_stability-indicating_HPLC_study_of_fixed-dosage_combination_containing_metoprolol_tartrate_and_hydrochlorothiazide
DB00264,,Heart,https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease
DB00264,,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019962s032lbl.pdf
DB00264,,FDA Approved Drug Products: Toprol-XL (metoprolol succinate) extended-release oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019962s044lbl.pdf
DB00264,,FDA Approved Drug Products: Kapspargo Sprinkle (metoprolol succinate) extended-release oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210428s001lbl.pdf
DB00264,,FDA Approved Drug Products: Lopressor (Metoprolol Tartrate) Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017963s068lbl.pdf
DB00264,,FDA Approved Drug Products: Lopressor HCT (metoprolol tartrate/hydrochlorothiazide) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/018303s041lbl.pdf
DB00264,,DailyMed: Metoprolol tartrate for intravenous injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e89cb5ec-e11b-4ca9-b3e3-34a4f144d7fe
DB00264,,FDA Approved Drug Products: TOPROL-XL (metoprolol succinate) extended-release tablets for oral use (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019962s050s052lbl.pdf
DB00264,,"FDA Approved Drug Products: Lopressor (Metoprolol Tartrate) Tablets, for oral use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017963s074lbl.pdf
DB00265,,FDA Approved Drug Products: Eurax (crotamiton) topical,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/06927slr030,09112slr021_eurax_lbl.pdf"
DB00268,,"Drug Approval Package, FDA",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022008_requip_toc.cfm
DB00268,,FDA Approved Drug Products: Requip (ropinirole) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020658s038lbl.pdf
DB00268,,FDA Approved Drug Products: Requip XL (ropinirole) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022008s012s013lbl.pdf
DB00273,,Merck,https://www.merckmanuals.com/en-ca/professional/neurologic-disorders/seizure-disorders/seizure-disorders
DB00273,,"Topamax, manufacturer's website",https://www.topamax.com
DB00273,,FDA Approved Drug Products: Topamax (topiramate) for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf
DB00273,,"MSDS, Topiramate",https://www.caymanchem.com/msdss/13623m.pdf
DB00273,,Qsymia approval information,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000_qsymia_toc.cfm
DB00273,,"FDA Approved Drug Products: Qsymia (phentermine and topiramate), extended-release capsules for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf
DB00273,,FDA Approved Drug Products: TROKENDI XR (topiramate) extended-release capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201635s030lbl.pdf
DB00275,,Health Canada Product Monograph: Olmesartan medoxomil oral tablets,https://pdf.hres.ca/dpd_pm/00048843.PDF
DB00275,,FDA Approved Drug Products: Benicar (olmesartan medoxomil) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021286s040lbl.pdf
DB00275,,FDA Approved Drug Products: Azor (amlodipine besylate/olmesartan medoxomil) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022100s039lbl.pdf
DB00275,,FDA Approved Drug Products: Benicar HCT (olmesartan medoxomil/hydrochlorothiazide) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021532s037lbl.pdf
DB00275,,FDA Approved Drug Products: Tribenzor (olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200175s033lbl.pdf
DB00275,,FDA Clinical Pharmacology and Biopharmaceutics Review: Benicar (olmesartan medoximil),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-286_Benicar_biopharmr_P1.pdf
DB00276,,Link,http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Amsacrine.htm
DB00279,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010379
DB00279,,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202231Orig1s000ClinPharm.pdf
DB00279,,FDA Approved Drug Products: Cytomel (liothyronine sodium) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/010379s054lbl.pdf
DB00279,,FDA Approved Drug Products: Triostat (liothyronine sodium) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20105s2lbl.pdf
DB00281,,Electronic Medicines Compendium: Lidocaine 1% w/v solution for injection Monograph,https://www.medicines.org.uk/emc/product/8737/smpc
DB00281,,StatPearls Internet: Lidocaine Profile,https://www.ncbi.nlm.nih.gov/books/NBK539881/#article-24262.s2
DB00281,,World Health Organization Model Lists of Essential Medicines,https://www.who.int/medicines/publications/essentialmedicines/en/
DB00282,,FDA Approved Drug Products: Aredia Pamidronate Intravenous Injection (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
DB00282,,FDA Approved Drug Products: Aredia Pamidronate Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20927lbl.pdf
DB00282,,Pfizer Canada: Pamidronate Disodium Injection,https://www.pfizer.ca/sites/default/files/201812/Pamidronate_PM_E_220092_11Dec2018.pdf
DB00284,,DailyMed: Acarbose oral tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=656769ee-e292-4950-83df-a38e6b1a9d6e
DB00284,,Health Canada Product Monograph: Acarbose oral tablets,https://pdf.hres.ca/dpd_pm/00053879.PDF
DB00284,,CaymanChem: Acarbose MSDS,https://www.caymanchem.com/msdss/11885m.pdf
DB00284,,FDA Approved Drug Products: Precose (acarbose) oral tablets [discontinued],https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020482s027lbl.pdf
DB00285,,FDA Approved Drug Products: Effexor XR® extended-release capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s110s111lbl.pdf
DB00285,,FDA Approved Drug Products: EFFEXOR XR (venlafaxine) Extended-Release Capsules (November 2021),https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020699s113lbl.pdf
DB00285,,Pfizer: EFFEXOR (Venlafaxine Hydrochloride Modified Release) MSDS,https://cdn.pfizer.com/pfizercom/products/material_safety_data/PZ01391.pdf
DB00285,,"FDA Approved Drug Products: EFFEXOR XR (venlafaxine extended-release) capsules, for oral use (August 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020699s112lbl.pdf
DB00285,,"FDA Approved Drug Products: EFFEXOR XR (venlafaxine extended-release) capsules, for oral use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf
DB00286,,NIH,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/conjugated-estrogens
DB00286,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021396
DB00286,,Pfizer,https://www.pfizermedicalinformation.com/en-us/premarin/clinical-pharmacology
DB00287,,EMA Approved Drug Products: Travatan (travoprost) Ophthalmic Solution,https://www.ema.europa.eu/en/documents/product-information/travatan-epar-product-information_en.pdf
DB00287,,Healio: Alcon receives FDA approval for first-line use of Travatan Z,https://www.healio.com/ophthalmology/ophthalmic-business/news/online/%7B92fe9833-e3b4-4d2f-9e51-13ca6603d5a8%7D/alcon-receives-fda-approval-for-first-line-use-of-travatan-z
DB00287,,"FDA Approved Drug Products: iDose TR (travoprost) intracameral implant, for intracameral administration",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218010s000lbl.pdf
DB00287,,"DailyMed Label: TRAVOPROST ophthalmic solution (ionic buffered solution) 0.004%, for topical ophthalmic use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00dc284f-fd96-423b-bb8f-b90ee13439bf
DB00287,,Health Canada Approved Drug Products: APO-TRAVOPROST (Travoprost) Ophthalmic Solution,https://pdf.hres.ca/dpd_pm/00056298.PDF
DB00289,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021411
DB00289,,NIH,https://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-adhd-the-basics/index.shtml
DB00289,,CADDRA - Canadian ADHD Practice Guidelines,https://www.caddra.ca/pdfs/caddraGuidelines2011.pdf
DB00289,,FDA Approved Drug Products: Strattera (atomoxetine) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021411s049lbl.pdf
DB00291,,FDA Approved Drug Products: LEUKERAN (chlorambucil) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
DB00294,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021187
DB00294,,PMC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683610/
DB00294,,NIH,https://www.nichd.nih.gov/health/topics/contraception/conditioninfo/types
DB00294,,NIH,https://drugs.ncats.io/drug/304GTH6RNH
DB00295,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018565
DB00295,,NIH,https://medlineplus.gov/magazine/issues/spring11/articles/spring11pg9.html
DB00295,,FDA Approved Drug Products: Infumorph Morphine Sulfate Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018565s024lbl.pdf
DB00295,,FDA Approved Drug Products: Morphine Sulfate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022207s009lbl.pdf
DB00295,,FDA Approved Drug Products: Morphine Sulfate Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022195s020lbl.pdf
DB00295,,FDA Approved Drug Products: MS Contin (Morphine Sulfate) Oral Extended Release Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019516s057lbl.pdf
DB00295,,FDA Approved Drug Products: Kadian (Morphine Sulfate) Oral Extended Release Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020616s065lbl.pdf
DB00295,,"FDA Approved Drug Products: INFUMORPH (morphine sulfate), Preservative-free, injectable solution, for intrathecal or epidural infusion, using a continuous microinfusion device, CII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018565s028s030lbl.pdf
DB00296,,Naropin (Ropivacaine Hydrochloride) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020533s014lbl.pdf
DB00296,,FDA Approved Drug Products: Naropin (ropivacaine hydrochloride) for injection (2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020533s038lbl.pdf
DB00296,,Pfizer: Ropivacaine Hydrochloride Safety Data Sheet,https://cdn.pfizer.com/pfizercom/products/material_safety_data/Ropivacaine_HCl_injection(hospira)_15-Aug-2016_0.pdf
DB00297,,Link,http://www.emedicine.com/ent/topic20.htm
DB00297,,FDA Approved Drug Products: ZYNRELEF (bupivacaine and meloxicam) extended-release solution for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s005lbl.pdf
DB00297,,FDA Approved Drug Products: Xaracoll (bupivacaine hydrochloride) for inguinal implantation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209511s000lbl.pdf
DB00297,,"FDA Approved Drug Products: Sensorcaine (bupivacaine hydrochloride, or bupivacaine hydrochloride and epinephrine) solution for injection use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018304s050lbl.pdf
DB00297,,"FDA Approved Products: MARCAINE (bupivacaine hydrochloride) injection, for infiltration, perineural, caudal, epidural, or retrobulbar use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/016964s082lbl.pdf
DB00297,,"FDA Approved Drug Products: EXPAREL (bupivacaine liposome) injectable suspension, for local infiltration",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022496s035lbl.pdf
DB00297,,StatPearls Internet: Bupivacaine Profile,https://www.ncbi.nlm.nih.gov/books/NBK532883/
DB00297,,FDA Approved Drug Products: Zynrelef (bupivicaine and meloxicam) extended-release solution for instillation (January 2024),https://zynrelef.com/prescribing-information.pdf
DB00297,,"FDA Approved Drug Products: EXPAREL (bupivacaine liposome injectable suspension), for infiltration or perineural use (November 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022496s051lbl.pdf
DB00298,,FDA Approved Products: Dapiprazole kit,https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b0fde24-9549-11cf-e053-2a95a90a9338
DB00299,,FDA Approved Drug Products: DENAVIR (penciclovir) cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020629s019lbl.pdf
DB00300,,"FDA Approved Drug Products: Atripla (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021937s044lbl.pdf
DB00300,,FDA Approved Drug Products: Cimduo (lamivudine and tenofovir disoproxil fumarate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022141s000lbl.pdf
DB00300,,"FDA Approved Drug Products: Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202123s031lbl.pdf
DB00300,,"FDA Approved Drug Products: Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210807s008lbl.pdf
DB00300,,"FDA Approved Drug Products: Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203100s036lblet.pdf
DB00300,,"FDA Approved Drug Products: Symfi (efavirenz, lamivudine, and tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022142s037lbl.pdf
DB00300,,FDA Approved Drug Products: Truvada (emtricitabine and tenofovir disoproxil fumarate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021752s061lbl.pdf
DB00300,,FDA Approved Drug Products: Viread (tenofovir disoproxil fumarate) powder/tablets for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021356s058,022577s014lbl.pdf"
DB00302,,FDA Approved Drug Products: Cyklokapron (tranexamic acid) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019281s047lbl.pdf
DB00302,,FDA Approved Drug Products: Lysteda (tranexamic acid) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022430s009lbl.pdf
DB00302,,Health Canada Product Monograph: Cyklokapron (tranexamic acid) tablets for oral use,https://pdf.hres.ca/dpd_pm/00047325.PDF
DB00302,,CaymanChem: Tranexamic acid MSDS,https://www.caymanchem.com/msdss/19193m.pdf
DB00303,,"FDA Approved Drug Products: INVANZ (ertapenem) injection, for intravenous or intramuscular use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021337s051lbl.pdf
DB00303,,EMA Approved Drug Products: Ertapenem SUN (ertapenem) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/ertapenem-sun-epar-product-information_en.pdf
DB00303,,Merck: Ertapenem MSDS,https://www.merck.com/docs/product/safety-data-sheets/hh-sds/Ertapenem%20Formulation_HH_NO_6N.pdf
DB00304,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020071
DB00304,,NIH,https://www.nichd.nih.gov/health/topics/contraception/conditioninfo/types
DB00304,,FDA Approved Drug Products: DESOGEN Tablets (desogestrel and ethinyl estradiol tablets USP),https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf
DB00305,,FDA Approved Drug Products: Jelmyto (mitomycin) pyelocalyceal solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211728s000lbl.pdf
DB00310,,FDA Approved Drug Products: Thalitone (chlorthalidone) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019574s017lbl.pdf
DB00310,,"FDA Approved Drug Products: EDARBYCLOR (azilsartan medoxomil and chlorthalidone) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202331lbl.pdf
DB00310,,FDA Approved Drug Products: Tenoretic (atenolol and chlorthalidone) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018760s029lbl.pdf
DB00313,,Depacon FDA Label (2006),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018081s42,18082s26,18723s32,19680s19,20593s11,21168s9lbl.pdf"
DB00313,,Depakene FDA,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018081
DB00313,,Depakene FDA Label (2019),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018081s069,018082s052lbl.pdf"
DB00313,,FDA Approved Drug Products: Stavzor (valproic acid) delayed-release capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022152s009lbl.pdf
DB00315,,FDA Approved Drug Products: ZOMIG/ZOMIG-ZMT (zolmitriptan) oral tablets and nasal spray,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020768s023,021231s014,021450s010lbl.pdf"
DB00316,,"Acetaminophen tablet, DailyMed",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3b408ff-f47b-4fee-ade5-5db6e25f4ee0
DB00316,,"Acetaminophen effervescent tablets, Cleveland Clinic",https://my.clevelandclinic.org/health/drugs/18282-acetaminophen-effervescent-tablets
DB00316,,FDA safety communication: FDA has reviewed possible risks of pain medicine use during pregnancy,https://www.fda.gov/Drugs/DrugSafety/ucm429117.htm
DB00316,,U.S. National Medical Library: MedlinePlus- Acetaminophen dosing for children,https://medlineplus.gov/ency/patientinstructions/000783.htm
DB00316,,FDA consumer health information: Acetaminophen,https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm263989.htm
DB00316,,FDA : Acetaminophen Information,https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm165107.htm
DB00316,,Using Acetaminophen and Nonsteroidal Anti-inflammatory Drugs Safely,https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-CounterMedicines/SafeUseofOver-the-CounterPainRelieversandFeverReducers/ucm164977.htm
DB00316,,FDA Approved Drug Products: Acetaminophen solution for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204767s000lbl.pdf
DB00317,,Health Canada Approved Drug Products: Iressa (gefitinib) tablets for oral use,https://pdf.hres.ca/dpd_pm/00060650.PDF
DB00317,,EMA Summary of Product Characteristics: Iressa (gefitinib) tablets for oral use,https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf
DB00318,,"Codeine phosphate tablets, 30mg",https://www.medicines.org.uk/emc/product/5753/smpc
DB00318,,DailyMed: Codeine and promethazine syrup,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5215931-3385-4d8e-b121-47aa1c20420c&audience=consumer
DB00318,,"Codittusin, DailyMed",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99f53fa4-98e0-4f0c-9bb2-4c7163f841ec
DB00318,,"FDA Approved Drug Products: CODEINE SULFATE tablets, for oral use CII (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022402s015lbl.pdf
DB00318,,"FDA Approved Drug Products: Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for oral use, CIII (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020232s047lbl.pdf
DB00319,,FDA Approved Drug Products: PIPRACIL (piperacillin) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf
DB00319,,FDA Approved Drug Products: ZOSYN (piperacillin and tazobactam) injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050684s098,050750s045lbl.pdf"
DB00320,,FDA Approved Drug Products: D.H.E. 45 (dihydroergotamine mesylate) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/005929s044lbl.pdf
DB00320,,FDA Approved Drug Products: Migranal (dihydroergotamine mesylate) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020148Orig1s025lbl.pdf
DB00320,,FDA Approved Drug Products: TRUDHESA (dihydroergotamine mesylate) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213436s000lbl.pdf
DB00321,,DailyMed Label: ELAVIL (amitriptyline) Oral Tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb986e14-d618-4021-91d7-599e038d9d39
DB00324,,FDA Approved Drug Products: FML (fluorometholone) ophthalmic suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/016851s063lbl.pdf
DB00327,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019034
DB00327,,Clinical trials,https://clinicaltrials.gov/ct2/show/NCT01123486
DB00327,,"FDA Approved Drug Products: HYDROMORPHONE HYDROCHLORIDE injection, for intravenous, intramuscular, or subcutaneous use, CII (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/200403s048lbl.pdf
DB00328,,Indomethacin Capsules (25 mg) - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016059s100lbl.pdf
DB00328,,Indocin I.V. (indomethacin for injection) - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018878s027lbl.pdf
DB00328,,"FDA Approved Drug Products: INDOCIN (indomethacin) Suppositories, for rectal use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017814s041s042lbl.pdf
DB00330,,FDA Approved Drug Products: Myambutol (Ethambutol) Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/016320s066lbl.pdf
DB00330,,Public Health Agency of Canada: Canadian Tuberculosis Standards 7th Edition,https://www.canada.ca/en/public-health/services/infectious-diseases/canadian-tuberculosis-standards-7th-edition/edition-17.html
DB00330,,Health Canada Approved Drug Products: Etibi (Ethambutol) Oral Tablets,https://pdf.hres.ca/dpd_pm/00048612.PDF
DB00331,,Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program,https://www.bmj.com/content/350/bmj.h454/rr-0
DB00331,,UptoDate: Pathogenesis of type 2 diabetes mellitus,https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus
DB00331,,FDA Approved Drug Products: Trijardy XR (empagliflozin/linagliptin/metformin) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212614s000lbl.pdf
DB00331,,FDA Approved Drug Products: Glumetza (metformin hydrochloride) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021748s025lbl.pdf
DB00331,,FDA Approved Drug Products: Riomet (metformin hydrochloride) oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021591s007lbl.pdf
DB00331,,FDA Approved Drug Products: Actoplus Met (pioglitazone/metformin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021842s022lbl.pdf
DB00331,,"FDA Approved Products: INVOKAMET (canagliflozin and metformin hydrochloride tablets), for oral use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204353s039,205879s017lbl.pdf"
DB00331,,FDA Approved Drug Products: Janumet (sitagliptin and metformin hydrochloride) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022044Orig1s051lbl.pdf
DB00331,,FDA Approved Drug Products: Jentadueto (linagliptin and metformin hydrochloride) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201281s031lbl.pdf
DB00331,,FDA Approved Drug Products: Kazano (alogliptin and metformin hydrochloride) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203414s012lbl.pdf
DB00331,,FDA Approved Drug Products: Kombiglyze XR (saxagliptin and metformin hydrochloride) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200678s024lbl.pdf
DB00331,,FDA Approved Drug Products: Segluromet (ertugliflozin and metformin hydrochloride) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209806s006lbl.pdf
DB00331,,FDA Approved Drug Products: Synjardy (empagliflozin/metformin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206111s022lbl.pdf
DB00331,,FDA Approved Drug Products: Xigduo XR (metformin hydrochloride/dapagliflozin) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205649s017lbl.pdf
DB00331,,CaymanChem: Metformin hydrochloride Safety Data Sheet,https://cdn.caymanchem.com/cdn/msds/13118m.pdf
DB00331,,"DailyMed Label: GLUCOPHAGE (metformin hydrochloride) tablets, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a0166c7-7097-4e4a-9036-6c9a60d08fc6
DB00331,,Viona Pharmaceuticals: Metformin hydrochloride extended-release tablets SDS,https://vionausa.com/wp-content/uploads/2020/01/SDS-Metformin-HCl-ER-Tablets.pdf
DB00331,,Bristol-Myers Squibb Company: Glucophage (metformin hydrochloride) MSDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9BRMY_00087607005_GLUCOPHAGE_TAB.pdf
DB00332,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019085
DB00332,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020291
DB00332,,Journal of Investigational Allergology and Clinical Immunology,http://www.jiaci.org/issues/vol20s1/7.pdf
DB00332,,The differential diagnosis of rhinorrhea,https://www.jacionline.org/article/S0091-6749(95)70211-3/pdf
DB00332,,COPD Foundation,https://www.copdfoundation.org/What-is-COPD/Understanding-COPD/What-is-COPD.aspx
DB00332,,EMC,https://www.medicines.org.uk/emc/product/3213/smpc
DB00333,,"FDA Approved Drug Products: DISKETS (methadone hydrochloride) tablets, for oral suspension CII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017058s028lbl.pdf
DB00334,,Canadian Mental Health Association,https://cmha.ca/mental-health/understanding-mental-illness/schizophrenia
DB00334,,NIH,https://www.nimh.nih.gov/health/topics/bipolar-disorder/index.shtml
DB00334,,Mylan-Olanzapine. Product monograph,https://pdf.hres.ca/dpd_pm/00038283.PDF
DB00334,,FDA Approved Drug Products: Zyprexa (olanzapine),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020592s072,021086s047,021253s060lbl.pdf"
DB00334,,FDA Approved Drug Products: Zyprexa (olanzapine) tablets and powder,https://pi.lilly.com/us/zyprexa-pi.pdf
DB00334,,FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf
DB00335,,LactMed: Atenolol,http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+283
DB00335,,ChemIDplus: Atenolol,https://chem.nlm.nih.gov/chemidplus/rn/29122-68-7
DB00335,,FDA Approved Products: Tenormin (atenolol) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018240s032lbl.pdf
DB00336,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00338,,"FDA Approved Drug Products: Talicia Amoxicillin, Omeprazole, and Rifabutin Oral Delayed Release Capsules",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213004lbl.pdf
DB00338,,NIH StatPearls: Omeprazole,https://www.ncbi.nlm.nih.gov/books/NBK539786/
DB00338,,FDA Approved Products: Prilosec (omeprazole) oral delayed release capsules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019810s102,022056s019lbl.pdf"
DB00338,,FDA Approved Drug Products: KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213593s000lbl.pdf
DB00340,,Link,http://newdruginformation.com/Trest.htm
DB00343,,Diltiazem - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK532937/
DB00343,,Diltiazem Hydrochloride Injection Label - Bedford Laboratories,https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-565-10%20DLT%2050MG/5539056510
DB00343,,Cardizem (diltiazem hydrochloride) Drug Summary - PDR.net,https://www.pdr.net/drug-summary/Cardizem-diltiazem-hydrochloride-2077
DB00343,,CARDIZEM® LA (diltiazem hydrochloride) extended-release tablets - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021392s019lbl.pdf
DB00343,,CARDIZEM® CD (diltiazem HCl) Capsules - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020062s040lbl.pdf
DB00346,,FDA Approved Drug Products: Alfuzosin Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021287s021lbl.pdf
DB00346,,NIH StatPearls: Benigh Prostatic Hyperplasia,https://www.ncbi.nlm.nih.gov/books/NBK558920/
DB00346,,NIH StatPearls: Alpha adrenergic receptors,https://www.ncbi.nlm.nih.gov/books/NBK539830/
DB00346,,Medicines UK: Alfuzosin hydrochloride tablets,https://www.medicines.org.uk/emc/product/3960/smpc%23gref
DB00346,,Cayman Chem: Alfuzosin MSDS,https://www.caymanchem.com/msdss/13648m.pdf
DB00346,,Product monograph: Sandoz Alfuzosin (alfuzosin hydrochloride) prolonged-release tablets,https://www.sandoz.ca/sites/www.sandoz.ca/files/Alfuzosin%20TAB%20Monograph.pdf
DB00349,,"FDA Approved Drug Products: ONFI® (clobazam) tablets, for oral use, CIV","https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202067s007,203993s009lbl.pdf"
DB00349,,"DailyMed Label: ONFI (clobazam) oral suspension or tablets, CIV",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de03bd69-2dca-459c-93b4-541fd3e9571c
DB00349,,Clobazam MSDS LGC,https://assets.lgcstandards.com/sys-master%2Fpdfs%2Fh5c%2Fh27%2F10154298933278%2FSDS_LGCFOR0910.00_ST-WB-MSDS-2565335-1-1-1.PDF
DB00349,,Clobazam (T3D4564),http://www.t3db.ca/toxins/T3D4564
DB00349,,"Health Canada Approved Drug Proucts: APO-CLOBAZAM (Clobazam) tablets, for oral use",https://pdf.hres.ca/dpd_pm/00060946.PDF
DB00354,,FDA approval: Buclizine,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010911
DB00354,,HMDB: Buclizine,http://www.hmdb.ca/metabolites/HMDB0014498
DB00358,,FDA Approved Products: Lariam (mefloquine hydrochloride) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf
DB00358,,WHO international: 2020 World Malaria Report,https://www.who.int/publications/i/item/9789240015791
DB00358,,NIH StatPearls: Malaria,https://www.ncbi.nlm.nih.gov/books/NBK551711/
DB00358,,FDA Approved Products: Mefloquine hydrochloride tablets USP,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/076392s008lbl.pdf
DB00358,,Cayman Chem MSDS: Mefloquine,https://www.caymanchem.com/msdss/23665m.pdf
DB00358,,CDC: Malaria,https://www.cdc.gov/dpdx/malaria/index.html
DB00358,,Medical Microbiology 4th edition: Malaria,https://www.ncbi.nlm.nih.gov/books/NBK8584/
DB00360,,EMA Summary of Product Characteristics: Kuvan (sapropterin) dissolvable tablets for oral use,https://www.ema.europa.eu/en/documents/product-information/kuvan-epar-product-information_en.pdf
DB00361,,Vinorelbine Tartrate,https://www.pfizer.ca/sites/g/files/g10037206/f/201710/VINORELBINE_TARTRATE_FOR_INJECTION_PM.pdf
DB00361,,Ontario Cancer Care - Drug Formulary - vinorelbine monograph,https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43701
DB00361,,Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer,http://ascopubs.org/doi/abs/10.1200/jco.2005.02.1295
DB00361,,"Vinorelbine injection, Daily Med",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06eeaab8-a00d-4b41-b46b-40163f09ecb8
DB00361,,Metabolism pathway of vinorelbine (Navelbine®) in human: Characterisation of the metabolites by HPLC–MS/MS,https://www.sciencedirect.com/science/article/abs/pii/S0731708507007625
DB00361,,Vinca Alkaloid Pharmacokinetics,https://www.pharmgkb.org/pathway/PA150981002
DB00361,,"Vinorelbine, a clinical review",https://www.nature.com/articles/6691203.pdf?origin=ppub
DB00361,,Vinorelbine FDA pharmacology review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-388S008_Navelbine_biopharmr.pdf
DB00361,,Drug Approval Package,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-388s008_Navelbine.cfm
DB00361,,"Navelbine, PDR",http://www.pdr.net/drug-summary/Navelbine-vinorelbine-tartrate-2360
DB00363,,"FDA Approved Drug Products: CLOZARIL® (clozapine) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019758s101lbl.pdf
DB00363,,"DailyMed Label: CLOZARI (clozapine) tablets, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90876802-0e3a-44c9-9ff7-1754dfbe736a
DB00364,,"FDA approval, Sucralfate suspension",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019183
DB00364,,Sucralfate tablet FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018333
DB00367,,Levonorgestrel FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021998lbl.pdf
DB00367,,Alesse 28 FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020683s012lbl.pdf
DB00367,,FDA Approved Drug Products: Mirena (levonorgestrel) intrauterine system,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021225s042lbl.pdf
DB00367,,Kyleena IUD FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208224s000lbl.pdf
DB00367,,Jaydess monograph,https://www.bayer.ca/omr/online/jaydess-pm-pt3-en.pdf
DB00367,,Levonorgestrel MSDS,http://datasheets.scbt.com/sc-205731.pdf
DB00367,,"Medicines UK, levonorgestrel",https://www.medicines.org.uk/emc/product/7308/smpc
DB00367,,"Birth control pill overdose, Medline",https://medlineplus.gov/ency/article/002599.htm
DB00367,,Climara pro FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021885lbl.pdf
DB00367,,Cleveland clinic: hormone therapy,https://my.clevelandclinic.org/health/treatments/15245-hormone-therapy
DB00367,,Norplant FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020544s010lbl.pdf
DB00367,,FDA Approved Drug Products: Mirena (levonorgestrel) intrauterine system 2022,https://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf
DB00367,,FDA Approved Drug Products: LOSEASONIQUE® (levonorgestrel and ethinyl estradiol tablets; and ethinyl estradiol tablets) for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022262s003s004lbl.pdf
DB00367,,FDA Approved Drug Products: LILETTA (levonorgestrel-releasing intrauterine system,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206229s013lbl.pdf
DB00369,,Cidofovir FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020638
DB00370,,Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing,https://onlinelibrary.wiley.com/doi/pdf/10.1002/hup.470100803
DB00370,,"Remeron approval, 1997",https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20-415S003_Remeron_Prntlbl.pdf
DB00370,,"Mirtazapine: A Newer Antidepressant, American Family Physician (AFP)",https://www.aafp.org/afp/1999/0101/p159.html
DB00370,,Remeron (Mirtazapine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf
DB00370,,FDA Approved Drug Products: REMERON/REMERONSolTab (mirtazapine) tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020415s034s036,021208s024s026lbl.pdf"
DB00370,,Health Canada Product Monograph: REMERON RD (mirtazapine) tablets,https://www.merck.ca/static/pdf/REMERON_RD-PM_E.pdf
DB00373,,Timolol FDA Label (Ophthalmic),https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021516s005lbl.pdf
DB00373,,Timolol maleate tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95
DB00373,,"Monograph, GD-LATANOPROST/TIMOLOL",https://www.pfizer.ca/sites/g/files/g10050796/f/201710/GD-latanoprost_and_timolol_PM_E_210086_17Oct2017.pdf
DB00373,,CV Pharmacology,https://www.cvpharmacology.com/cardioinhibitory/beta-blockers
DB00373,,"Approval information, FDA",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207556
DB00373,,FDA summary review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761077Orig1s000SumR.pdf
DB00373,,Link,http://www.inchem.org/documents/pims/pharm/timolol.htm
DB00373,,"MedSafe NZ, Timolol",https://medsafe.govt.nz/Profs/Datasheet/a/ArrowTimololeyedrops.pdf
DB00374,,"FDA Approved Drug Products: TYVASO (treprostinil) inhalation solution, for oral inhalation use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022387s020lbl.pdf
DB00374,,"FDA Approved Drug Products: REMODULIN (treprostinil) injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021272Orig1s032lbl.pdf
DB00374,,"FDA Approved Drug Products: ORENITRAM (treprostinil) extended-release tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203496Orig1s013lbl.pdf
DB00374,,"FDA Pharmacology Review: REMODULIN (treprostinil) injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-272_Remodulin_pharmr_P1.pdf
DB00374,,Par Pharmaceutical: Treprostinil SDS,https://www.parpharm.com/pdfs/catalog/sterile/Treprostinil_SDS_20200609.pdf
DB00374,,"FDA Clinical Pharmacology and Biopharmaceutics Review: ORENITRAM (treprostinil) extended-release tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203496Orig1s000ClinPharmR.pdf
DB00374,,Product monograph: Remodulin (Treprostinil) Solution,https://pdf.hres.ca/dpd_pm/00039705.PDF
DB00375,,Electronic Medicines Compendium: Colestid (colestipol hydrochloride) Orange 5g Monograph,https://www.medicines.org.uk/emc/product/129/smpc
DB00375,,NCBI LactMed@NIH Drugs and Lactation Database (LactMed) [Internet]: Colestipol Profile,https://www.ncbi.nlm.nih.gov/books/NBK501393/#LM514.admin-info
DB00375,,Colestipol ScienceDirect Profile,https://www.sciencedirect.com/topics/medicine-and-dentistry/colestipol
DB00375,,Colestid® (colestipol hydrochloride for oral suspension) - FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017563s023,020222s005lbl.pdf"
DB00376,,"FDA Approved Drug Products: Artane (Trihexyphenidyl) Oral Tablet, Capsule, and Elixir (Discontinued)",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006773
DB00376,,FDA Approved Drug Products: Trihexyphenidyl Oral Elixir,https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40251_Trihexyphenidyl%20Hydrochloride_Prntlbl.pdf
DB00376,,FDA Approved Drug Products: Trihexyphenidyl Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40254_Trihexyphenidyl%20Hydrochloride_Prntlbl.pdf
DB00376,,FDA: Artane (Trihexyphenidyl) Review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/006773_S036_ARTANE.pdf
DB00376,,"WHO International Pharmacopoeia - Sixth Edition, 2016: Trihexyphenidyl Hydrochloride",https://www.who.int/medicines/publications/pharmacopoeia/Trihexyphenidyl_hydrochloride.pdf
DB00376,,"Parkinson Canada Appendix 1: Canadian Guideline for Parkinson Disease, 2nd Edition",https://www.cmaj.ca/content/cmaj/suppl/2019/09/04/191.36.E989.DC1/Parkinson-final-E-online-LR.pdf
DB00378,,Link,http://www.patient.co.uk/showdoc/30003042/
DB00381,,FDA Approved Drug Products: Amlodipine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019787s062lbl.pdf
DB00381,,FDA Approved Drug Products: Amlodipine Oral Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211340s000lbl.pdf
DB00384,,Triamterene - International Agency for Research on Cancer (IARC) Monographs,https://monographs.iarc.fr/wp-content/uploads/2018/06/mono108-10.pdf
DB00384,,DYAZIDE (hydrochlorothiazide and triamterene) - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/016042s077lbl.pdf
DB00384,,PRO-TRIAZIDE (Triamterene 50 mg and Hydrochlorothiazide 25 mg) - Product Monograph,https://pdf.hres.ca/dpd_pm/00026038.PDF
DB00384,,DailyMed Label: DYRENIUM (triamterene) oral capsules,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebb177c0-d45d-4443-a85a-e76bd9931a42
DB00388,,FDA Approved Drug Products: Phenylephrine Solution for Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf
DB00388,,FDA Approved Drug Products: Phenylephrine Ophthalmic Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207926s002lbl.pdf
DB00388,,FDA Approved Drug Products: Phenylephrine Intravenous Injection (Ready to Use),https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212909s000lbl.pdf
DB00388,,"FDA Approved Drug Products: MYDCOMBI (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%, for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215352s000lbl.pdf
DB00389,,Carbimazole 5 mg Tablets - Summary of Product Characteristics - eMC,https://www.medicines.org.uk/emc/product/4267/smpc
DB00390,,Digoxin pharmacokinetics,https://sepia2.unil.ch/pharmacology/index.php?id=84
DB00390,,MedSafe NZ: Lanoxin,https://medsafe.govt.nz/profs/Datasheet/l/Lanoxintabelixinj.pdf
DB00390,,FDA Approved Drug Products: Lanoxin (digoxin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020405s015lbl.pdf
DB00391,,Electronic Medicines Compendium: Sulpiride 200 mg Tablets Summary of Product Characteristics,https://www.medicines.org.uk/emc/product/2430/smpc%23gref
DB00391,,"AIFA: Levobren (sulpiride) solution for injection, tablet, oral solution",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003582_027210_FI.pdf&retry=0&sys=m0b1l3
DB00392,,"Health Canada Approved Drug Products: PARSITAN (ethopropazine hydrochloride) tablets, oral (October 2022)",https://pdf.hres.ca/dpd_pm/00067748.PDF
DB00392,,"FDA Approved Drug Products: PARSIDOL (ethopropazine hydrochloride) tablet, oral (Discontinued)",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
DB00393,,FDA Approved Drug Products: Nymalize (nimodipine) oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203340Orig1s013lbl.pdf
DB00394,,QVAR® (beclomethasone dipropionate HFA) for oral inhalation use - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf
DB00394,,"BECONASE AQ® (beclomethasone dipropionate, monohydrate) for intranasal use only - FDA Label",https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/019389s027lbl.pdf
DB00394,,DIPROSONE® (Betamethasone Dipropionate Cream) - Product Monograph - Merck Canada Inc.,https://pdf.hres.ca/dpd_pm/00042539.PDF
DB00394,,"DIPROLENE® (augmented betamethasone dipropionate) ointment, for topical use - FDA Label",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018741s040lbl.pdf
DB00395,,Drug Scheduling: United States Drug Enforcement Administration (DEA),https://www.dea.gov/drug-scheduling
DB00395,,"Muscle relaxants for lower back pain: What is the evidence (article, Journal of Pain Management)",https://journals.lww.com/topicsinpainmanagement/Citation/2007/07000/Muscle_Relaxants_for_Low_Back_Pain__What_Is_the.1.aspx
DB00396,,Drug approval package FDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020843_s000_PrometriumTOC.cfm
DB00396,,Merck Manuals: Abnormal Uterine Bleeding Due to Ovulatory Dysfunction (AUB-O),https://www.merckmanuals.com/en-ca/professional/gynecology-and-obstetrics/menstrual-abnormalities/abnormal-uterine-bleeding-due-to-ovulatory-dysfunction-aub-o
DB00396,,AAFP: Abnormal uterine bleeding,https://www.aafp.org/afp/1999/1001/p1371.html
DB00398,,"FDA Approved Drug Products: NEXAVAR (sorafenib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021923s024lblrpl.pdf
DB00398,,EMA Approved Drug Products: Sorafenib Accord Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/sorafenib-accord-epar-product-information_en.pdf
DB00398,,Cayman Chemical: Sorafenib MSDS,https://cdn.caymanchem.com/cdn/msds/10009644m.pdf
DB00398,,CymitQuimica: Sorafenib Tosylate MSDS,https://static.cymitquimica.com/products/45/pdf/sds-1615876.pdf
DB00399,,FDA Approved Drug Products: Zometa Zoledronic Acid Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021223s041lbl.pdf
DB00399,,FDA Approved Drug Products: Reclast Zoledronic Acid Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022080lbl.pdf
DB00399,,FDA Approved Drug Products: Reclast Zoledronic Acid Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021817s028lbl.pdf
DB00400,,FDA Approved Drug Products: Gris-Peg (ultramicrosize griseofulvin) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050475s057lbl.pdf
DB00402,,FDA Approved Drug Products: Lunesta (eszopiclone) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf
DB00402,,"FDA review, Eszopiclone",https://www.fda.gov/media/84679/download
DB00402,,"Pubchem, Eszopiclone",https://pubchem.ncbi.nlm.nih.gov/compound/Eszopiclone
DB00402,,"MSDS, Eszopiclone",https://www.chemblink.com/MSDS/MSDSFiles/138729-47-2_Clear%20Synth.pdf
DB00402,,Lunesta label 2019,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021476s037lbl.pdf
DB00402,,FDA news,https://www.fda.gov/news-events/press-announcements/fda-requires-stronger-warnings-about-rare-serious-incidents-related-certain-prescription-insomnia
DB00404,,FDA Approved Drug Products: Xanax,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018276
DB00404,,FDA Pregnancy Categories,https://chemm.nlm.nih.gov/pregnancycategories.htm
DB00404,,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx
DB00404,,FDA Approved Drug Products: XANAX (Alprazolam) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018276s052lbl.pdf
DB00404,,FDA Approved Drug Products: XANAX (alprazolam) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018276s055lbl.pdf
DB00404,,FDA Approved Drug Products: XANAX XR (alprazolam) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021434s018lbl.pdf
DB00410,,"MUPIROCIN OINTMENT USP, 2% - DailyMed",https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2eba98c3-2cc8-143f-824e-c7ec90011f0b&type=display
DB00410,,MUPIROCIN OINTMENT - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50788_Mupirocin_Prntlbl.pdf
DB00410,,"BACTROBAN (mupirocin) ointment, for topical use - FDA Label",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050591s034lbl.pdf
DB00411,,FDA Approved Drug Products: Miostat (Carbachol) Intraocular Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/016968s029lbl.pdf
DB00411,,Caymen Chemical: Carbachol MSDS,https://www.caymanchem.com/msdss/14486m.pdf
DB00411,,Fisher Scientific: Carachol MSDS,https://www.fishersci.com/store/msds?partNumber=AC108240050&productDescription=CARBAMYLCHOLINE+CHLORIDE+5GR&vendorId=VN00032119&countryCode=US&language=en
DB00413,,"FDA Approval package, Mirapex",https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020667.cfm
DB00413,,Mirapex® (pramipexole dihydrochloride) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf
DB00417,,Phenoxymethylpenicillin (Penicillin V) Monograph - Government of Western Australia Child and Adolescents Health Service,https://pch.health.wa.gov.au/~/media/Files/Hospitals/PCH/General%20documents/Health%20professionals/ChAMP%20Monographs/Phenoxymethylpenicillin.pdf
DB00417,,Phenoxymethyl Penicillin 250mg/5ml Oral Solution Sugar Free (syringe) - eMC,https://www.medicines.org.uk/emc/product/2994/smpc
DB00417,,phenoxymethylpenicillin (penicillin v) - King Edward Memorial Hospital,https://www.kemh.health.wa.gov.au/~/media/Files/Hospitals/WNHS/For%20health%20professionals/Clinical%20guidelines/Pharmacy/medications/phenoxymethylpenicillin.pdf
DB00417,,Penicillin V potassium - GLOWM,https://www.glowm.com/resources/glowm/cd/pages/drugs/p016.html
DB00419,,FDA Approved Drug Products: ZAVESCA (miglustat) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021348s016lbl.pdf
DB00421,,"FDA Approved Drug Products: ALDACTONE (spironolactone) tablets, for oral use (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/012151s079lbl.pdf
DB00421,,EMA Approved Drug Products: QAIALDO (spironolactone) Oral Suspension,https://www.ema.europa.eu/en/documents/product-information/qaialdo-epar-product-information_en.pdf
DB00422,,CADDRA - Canadian ADHD Practice Guidelines,https://www.caddra.ca/pdfs/caddraGuidelines2011.pdf
DB00422,,Concerta FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf
DB00422,,FDA Approved Drug Products: Daytrana® transdermal system,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021514s030lbl.pdf
DB00422,,FDA Approved Drug Products: Aptensio XR (methylphenidate hydrochloride) extended-release capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205831s008lbl.pdf
DB00423,,FDA Approved Drug Products: Robaxin,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011011
DB00423,,FDA Approved Drug Products: Robaxin Intramuscular Injection,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011790
DB00423,,Pfizer Canada: Robax,https://www.pfizer.ca/non-prescription-products/robax
DB00424,,Dailymed: Hyoscyamine Subcutaneous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c0a1fef-c634-4ecf-9850-d188e6496b90
DB00424,,Dailymed: Anaspaz (Hyoscyamine) Orally Disintegrating Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5fd8476-418a-4149-a688-205ea943b30c
DB00425,,FDA Drug Safety Communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR,https://www.fda.gov/Drugs/DrugSafety/ucm352085.htm
DB00425,,"NIH Stat Pearls, Internet: Zolpidem",https://www.ncbi.nlm.nih.gov/books/NBK442008/
DB00425,,"Questions and Answers: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist)",https://www.fda.gov/drugs/drugsafety/ucm334041.htm
DB00425,,FDA Approved Drug Products: Ambien (zolpidem tartrate) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019908s046lbl.pdf
DB00426,,FDA Approved Drug Products: Famvir (famciclovir) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf
DB00428,,Link,http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Streptozocin.htm
DB00429,,FDA Approved Drug Products: Hemabate (carboprost tromethamine) solution for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017989s019lbl.pdf
DB00432,,"FDA Approved Drug Products: LONSURF (trifluridine and tipiracil) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf
DB00432,,FDA Approved Drug Products: TRIFLURIDINE solution for ophthalmic use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abc1d07f-91ee-4421-bc9b-457d0ed41f4c
DB00432,,"FDA Approved Drug Products: LONSURF (trifluridine and tipiracil) tablets, for oral use (August 2023)",https://taihocorp-media-release.s3.us-west-2.amazonaws.com/documents/prescribing-information.pdf
DB00432,,"EMA Product Information: LONSURF (trifluridine and tipiracil) tablets, for oral use",https://www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_en.pdf
DB00433,,Prochlorperazine Tablets BP 5mg - Summary of Product Characteristics,https://www.medicines.org.uk/emc/product/4553/smpc
DB00433,,Prochlorperazine - FDA Approval Package,https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21019A_Compazine_appltrs_prntlbl.pdf
DB00433,,Prochlorperazine - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK537083/
DB00433,,Prochlorperazine - LiverTox - NIH,https://livertox.nih.gov/Prochlorperazine.htm
DB00433,,Prochlorperazine — the forgotten antiemetic - UF Health,http://cdn.webservices.ufhealth.org/wp-content/blogs.dir/358/files/2011/11/0609-drugs-therapy-bulletin.pdf
DB00433,,Prochlorperazine Prescribing Information - AA Pharma,https://www.aapharma.ca/downloads/en/PIL/Prochlorazine_PI.pdf
DB00433,,Prochlorperazine - National Library of Medicine HSDB Database,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3171
DB00434,,FDA Approved Drug Products: Cyproheptadine hydrochloride tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/087056s045lbl.pdf
DB00434,,TGA Approved Medications: Periactin (cyproheptadine hydrochloride) tablets for oral use,https://apps.medicines.org.au/files/mkpperia.pdf
DB00434,,Cayman Chemical: Cyproheptadine MSDS,https://www.caymanchem.com/msdss/19551m.pdf
DB00434,,Health Canada Labelling Standard: Cyproheptadine,https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/cyproheptadine-labelling-standards-non-prescription-drugs.html
DB00435,,FDA Approved Drug Products: Inomax (nitric oxide) gas for inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020845s020lbl.pdf
DB00436,,FDA Approved Drug Products: CORZIDE (nadolol and bendroflumethiazide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018647s026lbl.pdf
DB00437,,"Allopurinol approval package, FDA label",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016084
DB00437,,"Allopurinol, DailyMed",https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=allopurinol
DB00438,,FDA Approved Drug Products: FORTAZ (ceftazidime) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050578s062lbl.pdf
DB00438,,FDA Approved Drug Products: AVYCAZ (ceftazidime and avibactam) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206494s007lbl.pdf
DB00438,,Cayman Chemical: ceftazidime MSDS,https://www.caymanchem.com/msdss/14828m.pdf
DB00438,,FDA Approved Drug Products: AVYCAZ (ceftazidime and avibactam) injection for intravenous use (December 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206494s011lbl.pdf
DB00439,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00440,,Health Canada Product Monograph: Polyrimethoprim (polymyxin B/trimethoprim) ophthalmic solution,https://pdf.hres.ca/dpd_pm/00016847.PDF
DB00440,,Health Canada Product Monograph: Trimethoprim oral tablets,https://pdf.hres.ca/dpd_pm/00025165.PDF
DB00440,,FDA Approved Drug Products: Trimethoprim oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018679s044lbl.pdf
DB00440,,FDA Approved Drug Products: Primsol (trimethoprim) oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/074973s008lbl.pdf
DB00440,,FDA Approved Drug Products: Bactrim (sulfamethoxazole/trimethoprim) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf
DB00440,,Health Canada Product Monograph: Septra (sulfamethoxazole/trimethoprim) for intravenous injection,https://pdf.hres.ca/dpd_pm/00043890.PDF
DB00440,,CaymanChem: Trimethoprim MSDS,https://www.caymanchem.com/msdss/16473m.pdf
DB00440,,FDA Approved Drug Products: Sulfamethoxazole/Trimethoprim oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/077612s005lbl.pdf
DB00441,,"FDA Approved Drug Products: GEMZAR (gemcitabine) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf
DB00441,,Product Monograph: GEMCITABINE Intravenous Injection,https://www.sandoz.ca/sites/www.sandoz.ca/files/Gemcitabine_Inj_PMe_20140814.pdf
DB00441,,BC Cancer: Gemcitabine Monograph,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Gemcitabine_monograph.pdf
DB00441,,Pfizer: Gemcitabine Safety Data Sheet,https://cdn.pfizer.com/pfizercom/products/material_safety_data/Gemcitabine_Injection_(Hospira)16-Nov-2016.pdf
DB00443,,FDA Approved Drug Products: Diprosone (Betamethasone dipropionate) ointment,https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/17691s19lbl.pdf
DB00443,,FDA Approved Drug Products: Celestone Soluspan (betamethasone sodium phosphate and betamethasone acetate) injectable suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/014602s062lbl.pdf
DB00443,,"DIPROLENE® (augmented betamethasone dipropionate) ointment, for topical use - FDA Label",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018741s040lbl.pdf
DB00443,,FDA Approved Drug Products: Luxiq (betamethasone valerate) Foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20934lbl.pdf
DB00443,,FDA Approved Drug Products: Enstilar (calcipotriene and betamethasone dipropionate) foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207589s005s006s007lbl.pdf
DB00446,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00446,,"Federal Register: Determination That CHLOROMYCETIN (Chloramphenicol) Capsules, 250 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness",https://www.federalregister.gov/documents/2012/07/13/2012-17091/determination-that-chloromycetin-chloramphenicol-capsules-250-milligrams-were-withdrawn-from-sale
DB00448,,Lansoprazole - Drugs and Lactation Database,https://www.ncbi.nlm.nih.gov/books/NBK501283/
DB00448,,FDA Approved Drug Products: Prevacid (lansoprazole),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020406s087s088,021428s034s035lbl.pdf"
DB00449,,FDA Approved Drug Products: PROPINE (dipivefrin hydrochloride) solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/18239s25lbl.pdf
DB00450,,DailyMed: INAPSINE (droperidol) injection,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=f4fa5e60-5f70-46d7-8e29-dfcf8b783f2c&type=pdf
DB00450,,Health Canada Product Monograph: fentanyl citrate injection,https://pdf.hres.ca/dpd_pm/00044064.PDF
DB00451,,FDA Approved Drug Products: Synthroid® oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021402s024s028lbl.pdf
DB00451,,FDA Approved Drug Products: SYNTHROID (levothyroxine sodium) tablets for oral use (revised Aug 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021402s036lbl.pdf
DB00454,,FDA Approved Drug Products: DEMEROL (meperidine hydrochloride) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf
DB00454,,FDA Approved Drug Products: DEMEROL (meperidine hydrochloride) solution and tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf
DB00454,,FDA Approved Drug Products: MEPERGAN (meperidine HCl and promethazine HCl) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011730s031lbl.pdf
DB00454,,"FDA Approved Drug Products: DEMEROL (meperidine hydrochloride injection), for subcutaneous, intramuscular, and intravenous use, CII (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021171s053lbl.pdf
DB00455,,Health Canada Product Monograph: Claritin (loratadine),https://pdf.hres.ca/dpd_pm/00051759.PDF
DB00455,,Comparative Pharmacology of the H1 Antihistamines,http://www.jiaci.org/issues/vol16s1/2.pdf
DB00457,,"FDA approval information, Prazosin",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=071745
DB00457,,"Cardiac anesthesiology, University of Toronto",http://pie.med.utoronto.ca/CA/CA_content/CA_cardiacPhys_peripheralResistance.html
DB00457,,The pharmacology of adrenergic receptors,http://www.uky.edu/~mtp/OBI836AR.html
DB00457,,FDA Approved Drug Products: Minipress (prazosin) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017442%20s043lbl.pdf
DB00457,,DailyMed Label: MINIPRESS (prazosin hydrochloride) Oral Capsules,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc
DB00458,,AACAP: Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/ Hyperactivity Disorder,http://www.aacap.org/App_Themes/AACAP/docs/practice_parameters/jaacap_adhd_2007.pdf
DB00458,,APA: Practice Guideline for the Treatment of Patients with Panic Disorder,https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf
DB00458,,APA: Practice Guideline for the Treatment of Patients with Schizophrenia Second Edition,https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf
DB00458,,APA: Practice Guideline for the Treatment of Patients with Bipolar Disorder Second Edition,https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf
DB00458,,APA: Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder,https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd.pdf
DB00458,,TOXNET: Imipramine,http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+3100
DB00461,,Nabumetone Health Canada Monograph,https://pdf.hres.ca/dpd_pm/00042393.PDF
DB00461,,ChemIDplus: Nabumetone,https://chem.nlm.nih.gov/chemidplus/rn/42924-53-8
DB00461,,FDA: Relafen,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019583
DB00461,,FDA Approved Products: Relafen (nabumetone) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/019583s023lbl.pdf
DB00465,,Acular FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019700s028lbl.pdf
DB00465,,Ketorolac Tromethamine IV/IM,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bb3cb6eb-5f5e-4389-81df-2095198c0565&type=display
DB00465,,Ketorolac: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use In Pain Management,https://link.springer.com/article/10.2165/00003495-199753010-00012
DB00465,,Ketorolac for Pain Management: A Review of the Clinical Evidence),https://www.ncbi.nlm.nih.gov/books/NBK254117/pdf/Bookshelf_NBK254117.pdf
DB00465,,FDA Approved Drug Products: Ketorolac tromethamine oral tablets,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1191f151-ab29-1f7e-e054-00144ff88e88&type=display
DB00465,,FDA Approved Drug Products: Toradol (ketorolac tromethamine) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019645s019lbl.pdf
DB00465,,FDA Approved Drug Products: Sprix (ketorolac tromethamine) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022382s018lbl.pdf
DB00465,,FDA Approved Drug Products: ACULAR LS (ketorolac tromethamine) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021528s008lbl.pdf
DB00465,,FDA Approved Drug Products: ketorolac tromethamine injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/074802s038lbl.pdf
DB00465,,FDA Approved Drug Products: Sprix (ketorolac tromethamine) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022382s021lbl.pdf
DB00465,,FDA Approved Drug Products: OMIDRIA (phenylephrine and ketorolac) intraocular solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205388s006lbl.pdf
DB00466,,Link,http://yosemite.epa.gov/oswer/CeppoEHS.nsf/Profiles/124-87-8?OpenDocument
DB00470,,FDA Approved Drug Products: Syndros (Dronabinol) Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205525Orig1s009lbledt.pdf
DB00470,,WHO Expert Committee on Drug Dependence Pre-Review: delta-9-tetrahydrocannibinol,https://www.who.int/medicines/access/controlled-substances/Section1.THC.Chemistry.pdf?ua=1
DB00470,,FDA Approved Drug Products: Syndros (Dronabinol) Oral Solution 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205525s011lbl.pdf
DB00470,,Health Canada Approved Drug Proucts: Marinol (Dronabinol) Oral Solution,https://pdf.hres.ca/dpd_pm/00013378.PDF
DB00471,,Singulair (montelukast sodium) US FDA Label 2019,https://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf
DB00471,,Apo-Montelukast Canadian Product Monograph,https://pdf.hres.ca/dpd_pm/00049133.PDF
DB00471,,Electronic Medicines Compendium: Montelukast 10 mg Film Coated Tablets Monograph,https://www.medicines.org.uk/emc/product/1243/smpc
DB00471,,NCBI StatPearls [Internet]: Montelukast Profile,https://www.ncbi.nlm.nih.gov/books/NBK459301/
DB00471,,Electronic Medicines Compendium: Montelukast 4mg Chewable Tablets Monograph,https://www.medicines.org.uk/emc/product/6098/smpc
DB00471,,Montelukast sodium tablets and chewable tablets Canadian Product Monograph,https://pdf.hres.ca/dpd_pm/00035313.PDF
DB00471,,Electronic Medicines Compendium: Montelukast 5 mg Chewable Tablets Monograph,https://www.medicines.org.uk/emc/product/2710/smpc
DB00471,,FDA Approved Drug Products: SINGULAIR (montelukast) oral tablets and granules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020829s074,020830s076,021409s052lbl.pdf"
DB00472,,FDA Approved Drug Products: Prozac (fluoxetine) oral capsules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s103,021235s023lbl.pdf"
DB00472,,Fluoxetine: A case history of its discovery and preclinical development,https://pdfs.semanticscholar.org/b3f2/73276b41415c203b19627f2a29d70a32a5d2.pdf
DB00472,,The Distribution of Fluoxetine in Human Fluids and Tissues,https://watermark.silverchair.com/31-7-409.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAlswggJXBgkqhkiG9w0BBwagggJIMIICRAIBADCCAj0GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMxq-BdA0pD4hBv9fbAgEQgIICDi9e5SvYdtSTd4n3-ojFsd3phOj6pqFzsbalEBbPOpwULSMguJn_LLSPIgFAyvDZTzElshjv7v1lNiLqb8oVellZb22LL5Zt_sMLZsh6BITXlS-jG-MAQrwGnqi-ExPTlUm-aehAYMpw7Nx9JHGpAXKF1AkHxZ9EMNd5U24o8BBQLvPbykxmSRb0NRhxqz3lAhGzQHQNzYprgkznEu4MX5QwUYuTmxBgZusq9Actqtixc3hcxmsnygZY5CHQzC2u8lIr6GB8vDT5Pc9rDnYMHRzBlNRAYmxcL-UphitDIKgQ3GGxLDhM6kNaaZGBZpA0zTWUJuXs9YulpoviYcDHkwEae5fclzgF902nxuz7XSYli9cY-mqAnntE8jFn8NVrqVbxFzKr0IRb_MzQCD-WU1XE122FsoG0jKpvhpSOJ0VF2BzuHetWI7y1FiB1BJ8-xtNEf_d_0oIsQbmDhJjjgw7P0H_J6I-Xba3WouJx_cay7oQyTr5B6f_dO9oAoeaHaatNci2zlHoWmsNNRCmMMdwlOAs45z63wihln_w0-PlBppn63qgRMUo-7BFytjAVUl6pyf0JG2MkvtqVHfFQU3n8cYNrfGuYN_VirR4yfviv8c3QpYVHkG56bKuOCRYeGevdftSprL8MWpsOV7kiiYEJEaaJTOgg-BOwAIuXpcQUPcC3xULFqRECDCjuBA0
DB00472,,DailyMed - Fluoxetine,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59de2889-c3d3-4ebf-8826-13f30a3fa439
DB00472,,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx
DB00472,,Health Canada Product Monograph: Fluoxetine oral capsules,https://pdf.hres.ca/dpd_pm/00038615.PDF
DB00472,,FDA Approved Drug Products: Sarafem (fluoxetine hydrochloride) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021860s015lbl.pdf
DB00472,,DailyMed Label: PROZAC (fluoxetine capsules) for oral use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c88f33ed-6dfb-4c5e-bc01-d8e36dd97299
DB00475,,FDA Approved Drug Products: Librax (chlordiazepoxide hydrochloride and clidinium bromide) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/012750s068lbl.pdf
DB00475,,FDA Approved Drug Products: LIMBITROL (chlordiazepoxide and amitriptyline HCI) double strength tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/016949s042lbl.pdf
DB00475,,DailyMed Label: Chlordiazepoxide hydrochloride Oral Capsules,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ff8641-ae8a-4016-acb1-cb1b7890f5ed
DB00476,,Cymbalta Health Canada Monograph,https://pdf.hres.ca/dpd_pm/00035593.PDF
DB00476,,Yentreve EMA SmPC,https://www.ema.europa.eu/en/documents/product-information/yentreve-epar-product-information_en.pdf
DB00476,,EAU Stress Urinary Incontinence Guidelines,https://uroweb.org/guideline/urinary-incontinence/#1
DB00476,,Original FDA Label Cymbalta,https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21427lbl.pdf
DB00476,,FDA Approved Products: Cymbalta (duloxetine) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021427s049lbl.pdf
DB00476,,FDA Approved Drug Products: CYMBALTA (duloxetine) delayed-release capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021427s056lbl.pdf
DB00476,,FDA Approved Drug Products: CYMBALTA (duloxetine) delayed-release capsules (August 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212516s005lbl.pdf
DB00479,,FDA Approves Arikayce,https://www.drugs.com/newdrugs/fda-approves-arikayce-amikacin-liposome-inhalation-suspension-mycobacterium-avium-complex-mac-lung-4829.html
DB00479,,Stat Pearls: Amikacin,https://www.ncbi.nlm.nih.gov/books/NBK430908/
DB00479,,FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622048.htm
DB00479,,FDA Approved Drug Products: Arikayce (amikacin liposome suspension) for inhalation (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207356s012lbl.pdf
DB00480,,FDA Approved Products: Revlimid (Lenalidomide) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021880s057lbl.pdf
DB00480,,Celegene Corporation: Lenalidomide Safety Data Sheet,https://packageinserts.bms.com/sds/sds_revlimid.pdf
DB00480,,Cayman Chemical: Lenalidomide Safety Data Sheet,https://www.caymanchem.com/msdss/14643m.pdf
DB00480,,"FDA Approved Products: REVLIMID (lenalidomide) capsules, for oral use 2022",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021880s065lbl.pdf
DB00481,,EVISTA (raloxifene hydrochloride) Tablet for Oral Use - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022042lbl.pdf
DB00482,,"FDA drug safety, June 28 2018",https://www.fda.gov/Drugs/DrugSafety/ucm611959.htm
DB00482,,Medscape drug reference,https://www.medscape.com/viewarticle/895722
DB00482,,Pfizer Medical Information,https://www.pfizermedicalinformation.ca/en-ca/celebrex/action-and-clinical-pharmacology
DB00482,,"Medicines UK, Celebrex 200mg capsule",https://www.medicines.org.uk/emc/product/2945/smpc
DB00482,,"FDA approvals, Celebrex",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020998
DB00482,,Bpac NZ: Celecoxib,https://bpac.org.nz/2018/celecoxib.aspx
DB00482,,CaymanChem: Celecoxib MSDS,https://www.caymanchem.com/msdss/10008672m.pdf
DB00482,,US Pharmacist: Cardiovascular risk associated with NSAIDS and COX2 inhibitors,https://www.uspharmacist.com/article/cardiovascular-risk-associated-with-nsaids-and-cox2-inhibitors
DB00482,,FDA Approved Drug Products: CELEBREX (celecoxib) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020998s056lbl.pdf
DB00482,,FDA Approved Drug Products: ELYXYB (celecoxib) solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212157s002lbl.pdf
DB00482,,FDA Approved Drug Products: SEGLENTIS (celecoxib and tramadol hydrochloride) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213426s000lbl.pdf
DB00484,,MIRVASO (brimonidine) topical gel - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204708s005lbl.pdf
DB00484,,Brimonidine (brimonidine tartrate) ophthalmic solution - Product Monograph,https://www.sandoz.ca/sites/www.sandoz.ca/files/Brimonidine%20Product%20Monograph.pdf
DB00484,,Mirvaso (brimonidine) topical gel - EU Summary of Product Characteristics,https://www.ema.europa.eu/en/documents/product-information/mirvaso-epar-product-information_en.pdf
DB00484,,ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020613s031lbl.pdf
DB00484,,FDA Approved Drug Products: COMBIGAN (brimonidine tartrate/timolol maleate) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021398s007lbl.pdf
DB00484,,FDA Approved Drug Products: SIMBRINZA (brinzolamide and brimonidine tartrate) suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204251s006lbl.pdf
DB00485,,DailyMed: Teva Pharmaceuticals Dicloxacillin sodium oral capsules,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8478f242-c715-4984-ac1d-dc79dc28665e
DB00486,,FDA Approved Drug Products: Cesamet (nabilone) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf
DB00489,,FDA Approved Drug Products: Betapace (sotalol) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019865s022lbl.pdf
DB00489,,FDA Approved Drug Products: Sotalol hydrochloride for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022306s005lblrpl.pdf
DB00489,,FDA Approved Drug Products: Sotylize (sotalol hydrochloride) solution for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205108s000lbl.pdf
DB00489,,Dailymed: Sotalol Tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62a71c8c-d92d-4122-848f-9ae35f8bbe2b
DB00490,,Buspirone - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK531477/
DB00490,,Buspirone (hydrochloride) Safety Data Sheet - Cayman Chemical,https://www.caymanchem.com/msdss/22028m.pdf
DB00490,,Buspirone hydrochloride (B7148) - Sigma Aldrich Product Information Sheet,https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/b7148pis.pdf
DB00490,,BuSpar® (buspirone HCl) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/18731s39s45lbl.pdf
DB00491,,FDA Approved Drug Products: Glyset (miglitol) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf
DB00492,,DailyMed: Aurobindo Fosinopril sodium and Hydrochlorothiazide oral tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35019655-9a30-4305-a262-936ad0e73071
DB00492,,DailyMEd: Aurobindo Fosinopril sodium oral tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aee04f17-8ee9-42f5-861f-b6ba17220ca4
DB00493,,FDA Approved Drug Products: Claforan (cefotaxime) for injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050547s071,050596s042lbl.pdf"
DB00494,,FDA Approved Drug Products: Comtan (entacapone) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020796s026lbl.pdf
DB00494,,FDA Approved Drug Products: Stalevo (carbidopa/levodopa/entacapone) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021485s042lbl.pdf
DB00496,,"Enablex® (darifenacin)[package insert]. Rockaway, New Jersey: Warner Chilcott (US), LLC.; 2012.",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021513
DB00496,,FDA Approved Drug Products: Enablex (darifenacin hydrobromide) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf
DB00497,,FDA Approved Drug Products: Percodan,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007337
DB00497,,"FDA Approved Drug Products: XTAMPZA ER (oxycodone) extended-release capsules, for oral use, CII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208090s021lbl.pdf
DB00498,,Link,http://www.patient.co.uk/showdoc/30002156/
DB00499,,Link,http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Flutamide.htm
DB00499,,DailyMed: Flutamide USP oral capsules,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=328910be-4d0e-4d7b-a062-e3ce0cf793b9
DB00500,,TITCK Product Information: Tolectin (tolmetin) capsules for oral use,https://titck.gov.tr/storage/kubKtAttachments/a771745e33260.pdf
DB00501,,"DPD Approved Drug Products: Cimetidine (200, 300, 400, 600, 800 mg)",https://pdf.hres.ca/dpd_pm/00049348.PDF
DB00502,,Clinical pharmacology of atypical antipsychotics: an update,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464358/
DB00502,,"Mechanism of Action of Antipsychotics, Haloperidol and Olanzapine in vitro",https://vtechworks.lib.vt.edu/handle/10919/31133
DB00502,,Haloperidol Overview,https://www.sciencedirect.com/topics/neuroscience/haloperidol
DB00502,,Haldol Decanoate,https://www.medicines.org.uk/emc/product/968
DB00502,,FDA Approved Drug Products: Haldol (haloperidol) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/015923s095lbl.pdf
DB00503,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB00503,,"FDA Approved Drug Products: NORVIR (ritonavir) Capsules, Soft Gelatin for Oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020945s033lbl.pdf
DB00503,,FDA Approved Drug Products: Norvir (ritonavir) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020659s071,%20209512s006,%20022417s023lbl.pdf"
DB00503,,CaymanChem: Ritonavir MSDS,https://www.caymanchem.com/msdss/13872m.pdf
DB00503,,FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021251s058,021906s053lbl.pdf"
DB00503,,"DailyMed Label: Viekira Pak (dasabuvir, ombitasvir, paritaprevir, ritonavir) kit",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab74e474-9fd6-902c-9bd9-16dc9541edd0
DB00503,,INVIMA Product Registration: Viralnich (atazanavir/ritonavir) coated tablets for oral use,http://web.sivicos.gov.co/registros/pdf/15871361_2019056386.pdf
DB00503,,INVIMA Product Registration: Virontar (darunavir/ritonavir) coated tablets for oral use,http://web.sivicos.gov.co/registros/pdf/15624000_2018032994.pdf
DB00503,,"FDA Approved Drug Products: PAXLOVID (nirmatrelvir and ritonavir) tablets, co-packaged for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf
DB00503,,Summary of Product Characteristics: Paxlovid (nirmatrelvir and ritonavir) oral tablets,https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf
DB00503,,EMA News: COVID-19: EMA recommends conditional marketing authorisation for Paxlovid,https://www.ema.europa.eu/en/news/covid-19-ema-recommends-conditional-marketing-authorisation-paxlovid
DB00507,,"Nitazoxanide, Pub Chemistry",https://pubchem.ncbi.nlm.nih.gov/compound/nitazoxanide#section=Top
DB00507,,EPA Chemistry Dashboard: Nitazoxanide,https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID5033757
DB00507,,Nitazoxanide: A New Thiazolide Antiparasitic Agent,https://academic.oup.com/cid/article/40/8/1173/320667
DB00507,,"Validated and optimized high-performance liquid chromatographic determination of tizoxanide, the main active metabolite of nitazoxanide in human urine, plasma and breast milk.",https://watermark.silverchair.com/bms041.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAa8wggGrBgkqhkiG9w0BBwagggGcMIIBmAIBADCCAZEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM-kpbjlKq5U2lFyDhAgEQgIIBYtw6PzXSgZ5bAcaADgK2chDdauq8S51YHhYRw2Y7CIqmEeNFeLDH-rPr1iU638KpXjSSSF4fxBrEqou8j3cmjinfNQE6HzzUfT1TW-mw2FG6HRriDDfPiAtqmYjqfHnj1uoWLgg9akVMmPkY9wzidxGUnBnkVUSeRFt2OCyUmPnB4jgKL-rn-0xMBo-jQtYEFjbZQe4yDLXsCVGzj_gOvGh6p_jYdqHBmqiSC77yOgylIcZ_OGn_RkHOnUNM66W0MIjnQb4mWYa_hRTYffMU2OX2oYVkrmOUkkDEmxeF2J3mL-xz3SKmGZ0JtwyBc_bkblRXVNt8ci9BESlTsIvnQlFY6ZP0eF21RF3IRwxZp4T5D6yZOUR9o9FLP51YoOiXvzNra-NL7gonkbC0zM32XUNXL8d2d6IB0gcGl81HVTjSjNJJ-HJKM4eI-ZUNNFu4vIVwlNA7WetsoU8aZsrzZ6w4zg
DB00507,,"Pharmacology review, Nitazoxanide",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-497_Alinia_Pharmr_P1.pdf
DB00507,,FDA Approved Drug Products: ALINIA (nitazoxanide) oral,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021497s001,021498s004lbl.pdf"
DB00512,,CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis,https://www.drugs.com/newdrugs/cutispharma-announces-fda-approval-firvanq-vancomycin-clostridium-difficile-associated-diarrhea-4687.html?utm_source=ddc&utm_medium=email&utm_campaign=Today%27s+news+summary+-+January+30%2C+2018&utm_content=CutisPharma+Announces+FDA+Approval+of+Firvanq+%28vancomycin%29+for+Treatment+of+Clostridium+Difficile+Associated+Diarrhea+and+Staphylococcus+Aureus+Colitis
DB00512,,FDA Approved Drug Products: Vancomycin hydrochloride for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209481s016lbl.pdf
DB00512,,FDA Approved Drug Products: Firvanq (vancomycin hydrochloride) for oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208910s007lbl.pdf
DB00513,,FDA Approved Drug Products: Amicar (aminocaproic acid) oral tablets/solution,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/015197s043,015230s035lbl.pdf"
DB00514,,FDA Approved Drug Products: Nuedexta Dextromethorphan Hydrobromide and Quinidine Sulfate Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021879s014lbl.pdf
DB00514,,"Dailymed: Brompheniramine, Pseudoephedrine, and Dextromethorphan Oral Syrup",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e241d83e-996c-494d-b3fe-97f1ef4809ed
DB00514,,Dailymed: Guaifenesin and Dextromethorphan Oral Extended Release Tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70987d06-d206-445f-bd0d-5e1345b8465c
DB00514,,FDA Drug Quality Assessment: Nuedexta Dextromethorphan and Quinidine Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000ChemR.pdf
DB00514,,FDA Approved Drug Products: Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011265
DB00514,,"FDA Approved Drug Products: AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets, for oral use",https://www.auvelity.com/prescribing-information.pdf
DB00515,,FDA Approved Drug Products: Cisplatin for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018057s089lbl.pdf
DB00515,,Health Canada Product Monograph: Cisplatin for intravenous injection,https://pdf.hres.ca/dpd_pm/00036611.PDF
DB00518,,FDA Approved Drugs Products: Albendazole Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf
DB00519,,FDA Approved Drug Products: Mavik (trandolapril) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020528s025lbl.pdf
DB00519,,FDA Approved Drugs: Tarka® extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020591s030lbl.pdf
DB00526,,"FDA Approved Drug Product: ELOXATIN (oxaliplatin) injection, for intravenous use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021759s024lbl.pdf
DB00526,,"FDA Approved Drug Products: ELOXATIN (oxaliplatin) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021492s016lbl.pdf
DB00526,,Oxaliplatin MSDS,https://cdn.pfizer.com/pfizercom/products/material_safety_data/Oxaliplatin_Injection_Solution(Hospira)_19-Jul-2016.pdf
DB00526,,Sanofi-aventis receives FDA approval for new Eloxatin™ formulation,https://www.news.sanofi.us/press-releases?item=118476
DB00531,,FDA Approved Drug Products: Cyclophosphamide Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212501s000lbl.pdf
DB00531,,FDA Approved Drug Products: Cyclophosphamide for intravenous injection (November 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210735s002lbl.pdf
DB00531,,FDA Approved Drug Products: Cyclophosphamide capsules for oral use (September 2019),https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203856s003lbl.pdf
DB00535,,FDA Approved Drug Products: Omnicef (cefdinir),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf"
DB00535,,"Pfizer MSDS, Cefdinir",https://www.pfizer.com/system/files/products/material_safety_data/PD012.pdf
DB00535,,Omnicef,https://www.rxlist.com/omnicef-drug.htm
DB00535,,Appropriate prescribing of beta-lactamase antibiotics,https://www.aafp.org/afp/2000/0801/p611.html
DB00535,,DailyMed: Cefdinir oral capsules,https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38f6adf7-e26c-4764-8ec9-360813874dd4
DB00537,,FDA Approved Drug Products: Cipro,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019537
DB00537,,FDA Approved Drug Products: Cetraxal Solution/Drops;Otic,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021918
DB00537,,FDA Approved Drug Products: Ciloxan Solution/Drops; Opthmalmic,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019992
DB00537,,FDA Approved Drug Products: Ciloxan Ointment; Opthalmic,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020369
DB00537,,FDA Approved Drug Products: CIPRO IV (ciprofloxacin) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019847s062lbl.pdf
DB00537,,FDA Approved Drug Products: CIPRO (ciprofloxacin) oral tablets and suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019537s093,020780s049lbl.pdf"
DB00537,,FDA Approved Drug Products: Cipro HC Suspension/Drops; Otic,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020805
DB00537,,FDA Approved Drug Products: CIPRO XR (ciprofloxacin) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021473s043lbl.pdf
DB00537,,FDA Approved Drug Products: Ciprodex Suspension/Drops; Otic,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021537
DB00537,,FDA Approved Drug Products: Otiprio Injection,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207986
DB00537,,Pfizer: Ciprofloxacin MSDS,https://www.pfizer.com/sites/default/files/products/material_safety_data/PZ01031.pdf
DB00537,,FDA Approved Drug Products: OTOVEL (ciprofloxacin and fluocinolone acetonide) otic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208251orig1s000lbl.pdf
DB00540,,EMC Summary of product characteristics: Nortriptyline,https://www.medicines.org.uk/emc/product/4090/smpc
DB00540,,FDA Approved Products: Nortriptyline oral capsules and oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018012s27lbl.pdf
DB00540,,NIH StatPearls: Nortriptyline,https://www.ncbi.nlm.nih.gov/books/NBK482214/
DB00540,,Product monograph: Nortriptyline tablets,https://pdf.hres.ca/dpd_pm/00001266.PDF
DB00540,,MedSafe NZ data sheet: Nortriptyline tablets,https://www.medsafe.govt.nz/profs/datasheet/n/nortriptylinenrimtab.pdf
DB00540,,CaymanChem MSDS: Nortriptyline,https://www.caymanchem.com/msdss/15904m.pdf
DB00541,,FDA Approved Drug Products: Marqibo (vincristine sulfate liposome) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf
DB00542,,FDA Approved Drug Products: Lotensin Benazepril Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019851s054lbl.pdf
DB00542,,FDA Approved Drug Products: Lotensin HCT (lotensin hydrochloride/hydrochlorothiazide) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020033s063lbl.pdf
DB00542,,FDA Approved Drug Products: LOTREL (amlodipine and benazepril hydrochloride) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020364Orig1s068lbl.pdf
DB00545,,FDA Approved Drug Products: Mestinon (pyridostigmine bromide) syrup and tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/15193s18lbl.pdf
DB00545,,FDA Approved Drug Products: REGONOL (pyridostigmine bromide) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/17398s015lbl.pdf
DB00545,,NIH: pyridostigmine bromide CSWG report,https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/pyridostbromide_508.pdf
DB00545,,Cayman Chemical: pyridostigmine MSDS,https://www.caymanchem.com/msdss/23831m.pdf
DB00551,,Link,http://www.medicinenet.com/acetohydroxamic_acid-oral/article.htm
DB00555,,Lamictal FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020241s060,020764s053,022251s024lbl.pdf"
DB00555,,FDA Approved Products: Lamictal (lamotrigine) chewable dispersible tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020241s10s21s25s26s27,020764s3s14s18s19s20lbl.pdf"
DB00555,,FDA Approved Drug Products: LAMICTAL (lamotrigine) tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020241s064,020764s057,022251s028lbl.pdf"
DB00555,,FDA Approved Drug Products: LAMICTAL XR (lamotrigine) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022115s029lbl.pdf
DB00556,,FDA Approved Drug Products: Optison (perflutren protein-type A microspheres) suspension for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020899s024lbl.pdf
DB00557,,Health Canada Product Monograph: Hydroxyzine HCl oral capsules,https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf
DB00557,,CaymanChem: Hydroxyzine MSDS,https://www.caymanchem.com/msdss/24039m.pdf
DB00557,,FDA Approved Drug Products: Hydroxyzine HCl oral tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/088617Orig1s043,088618Orig1s043,088619Orig1s044lbl.pdf"
DB00557,,FDA Approved Drug Products: Vistaril (hydroxyzine pamoate),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf"
DB00557,,FDA Approved Drug Products: VISTARIL (hydroxyzine pamoate) capsules and suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011459s051_011795s028lbl.pdf
DB00557,,DailyMed: hydroxyzine hydrochloride injection,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=8af7e5ce-d9d9-44cc-9f2f-4ddbc89e758a&type=pdf
DB00559,,FDA Approved Drugs: Tracleer® oral tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021290s039,209279s005lbl.pdf"
DB00563,,FDA Approved Drug Products: Methotrexate Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208004s002lbl.pdf
DB00563,,FDA Approved Drug Products: Methotrexate Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205776s002lbl.pdf
DB00563,,FDA Approved Drug Products: Methotrexate Prefilled Syringe for Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204824s009lbl.pdf
DB00563,,FDA Approved Drug Products: Methotrexate Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011719s125lbl.pdf
DB00563,,FDA Approved Drug Products: Methotrexate Sodium Oral Tablets,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008085
DB00563,,Cayman Chemicals: Methotrexate MSDS,https://www.caymanchem.com/msdss/13960m.pdf
DB00563,,FDA Approved Drug Products: RediTrex Methotrexate Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210737s000lbl.pdf
DB00563,,"FDA Approved Drug Products: METHOTREXATE injection, for intravenous, intramuscular, subcutaneous, or intrathecal use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/011719Orig1s131lbl.pdf
DB00563,,EMA Summary of Product Characteristics: Nordimet (methotrexate) solution for injection,https://www.ema.europa.eu/en/documents/product-information/nordimet-epar-product-information_en.pdf
DB00564,,FDA Approved Drug Products: EQUETRO (carbamazepine) extended-release capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf
DB00564,,"Pharm KGB, carbamazepine pathway, pharmacokinetics",https://www.pharmgkb.org/pathway/PA165817070
DB00564,,Carbamazepine MSDS,https://www.caymanchem.com/msdss/15422m.pdf
DB00564,,"ipolar Disorders and Carbamazepine: Pharmacokinetics,Pharmacodynamics, Therapeutic Effects and Indications of Carbamazepine: Review of Articles",https://www.omicsonline.org/open-access/bipolar-disorders-and-carbamazepine-pharmacokineticspharmacodynamics-therapeutic-effects-and-indications-ofcarbamazepine-review-of-2472-095X-1000112.php?aid=79291
DB00564,,FDA Approved Drug Products: Tegretol (carbamazepine),https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s115_018281_s058_018927s055_020234_s047.pdf
DB00564,,FDA Approved Drug Products: CARNEXIV (carbamazepine) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206030s002lbl.pdf
DB00564,,FDA Approved Drug Products: Carbatrol (carbamazepine) extended-release capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020712s037lbl.pdf
DB00564,,FDA Approved Drug Products: Carbatrol (carbamazepine) extended-release capsules for oral use (April 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020712s038lbl.pdf
DB00565,,FDA Approved Drug Products: Nimbex (cisatracurium besylate) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020551s028lbl.pdf
DB00567,,Cephalexin Product Monograph,https://pdf.hres.ca/dpd_pm/00043813.PDF
DB00567,,FDA Approved Drug Products: Cephalexin Oral Capsule,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050405
DB00567,,FDA Approved Drug Products: Cephalexin Oral Suspension,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050406
DB00567,,FDA Approved Drug Products: Cephalexin Oral Tablet,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=063024
DB00571,,FDA Approved Drug Products: HEMANGEOL (propranolol hydrochloride) oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205410s006lbl.pdf
DB00571,,FDA Approved Drug Products: Propranolol Oral Tablet,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016762
DB00571,,FDA Approved Drug Products: INNOPRAN XL (propranolol hydrochloride) extended release capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021438s025lbl.pdf
DB00571,,FDA Approved Drug Products: INDERIDE (propranolol hydrochloride and hydrochlorothiazide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018031s037s038lbl.pdf
DB00572,,FDA Approved Drug Products: Atropine sulfate injection for intravenous use,https://www.americanregent.com/media/3227/ref-1511_atropine-sulfate-injection-usp-full-prescribing-information.pdf
DB00572,,FDA Approved Drug Products: ATROPEN (atropine) injection for intramuscular use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/017106s052lbl.pdf
DB00572,,FDA Approved Drug Products: ISOPTO ATROPINE (atropine sulfate) ophthalmic solution for topical ophthalmic use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208151lbl.pdf
DB00572,,"FDA Approved Drug Products: Atropine sulfate injection, for intravenous, intramuscular, subcutaneous, intraosseous or endotracheal use.",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209260s000lbl.pdf
DB00572,,FDA Approved Drug Products: MOTOFEN (difenoxin and atropine sulphate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017744s026lbl.pdf
DB00572,,Cayman chemical: Atropine SDS,https://cdn.caymanchem.com/cdn/msds/12008m.pdf
DB00572,,FDA Approved Drug Products: LOMOTIL (diphenoxylate hydrochloride and atropine sulfate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012462s048lbl.pdf
DB00574,,FDA Approved Drug Products: Fintepla (fenfluramine) oral solution,https://zogenix.com/pi/Fintepla-prescribing-information.pdf
DB00574,,PubChem: fenfluramine,https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3080
DB00574,,MSDS: fenfluramine,https://www.caymanchem.com/msdss/22491m.pdf
DB00575,,FDA Approved Drug Products: Catapres Clonidine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017407
DB00575,,FDA Approved Drug Products: Catapres Clonidine Transdermal System,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018891s028lbl.pdf
DB00575,,FDA Approved Drug Products: Duraclon Clonidine Hydrochloride Injection Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020615s003lbl.pdf
DB00575,,FDA Approved Drug Products: Kapvay (clonidine hydrochloride) Oral Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf
DB00575,,Cayman Chemicals: Clonidine MSDS,https://www.caymanchem.com/msdss/15949m.pdf
DB00577,,Valacyclovir: AAFP,https://www.aafp.org/afp/2003/0215/p757.html
DB00577,,Valacyclovir approval package,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-550S012_Valacyclovir.cfm
DB00577,,FDA Approved Drug Products: VALTREX (valacyclovir) oral,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020487s022lbl.pdf
DB00580,,FDA Approved Drug Products: Betra (valdecoxib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf
DB00581,,Lactulose Canadian Product Monograph,https://pdf.hres.ca/dpd_pm/00031381.PDF
DB00581,,NCBI StatPearls [Internet]: Lactulose,https://www.ncbi.nlm.nih.gov/books/NBK536930/#article-24004.s1
DB00581,,WHO Model List of Essential Medicines 19th List (April 2015 - Amended November 2015),https://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
DB00581,,DailyMed: lactulose solution,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=a89835c9-8ce5-4627-8d7d-70ff175b2e07&type=pdf
DB00582,,International Patent WO 98/58677: Pharmaceutical formulations containing voriconazole,https://patents.google.com/patent/WO1998058677A1/
DB00582,,VFENDⓇ FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021630s034,021266s045,021267s055lbl.pdf"
DB00582,,Health Canada Approved Products: Vfend (voriconazole) multiple forms/routes,https://pdf.hres.ca/dpd_pm/00056992.PDF
DB00582,,VFend FDA Approval Letter,https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21266ltr.pdf
DB00582,,"FDA Approved Drug Products: VORICONAZOLE for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208562s006lbl.pdf
DB00582,,EMA Approved Products: Vfend (voriconazole) oral tablets,https://www.ema.europa.eu/en/documents/product-information/vfend-epar-product-information_en.pdf
DB00582,,FDA Approved Drug Products: VFEND (voriconazole) multiple forms/routes,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021266s053,021267s063,021630s042lbl.pdf"
DB00584,,Enalapril Oral Tablets - Product Monograph,https://pdf.hres.ca/dpd_pm/00035279.PDF
DB00584,,Angiotensin Converting Enzyme Inhibitors (ACEI) - StatPearls,https://www.ncbi.nlm.nih.gov/books/NBK431051/
DB00584,,FDA Approved Drug Products: VASOTEC (enalapril maleate) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018998s083lbl.pdf
DB00584,,FDA Approved Drug Products: EPANED (enalapril maleate) solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208686s002lbl.pdf
DB00584,,FDA Approved Drug Products: LEXXEL (enalapril maleate and felodipine) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020668s005lbl.pdf
DB00584,,FDA Approved Drug Products: VASERETIC (enalapril maleate and hydrochlorothiazide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019221s050lbl.pdf
DB00586,,Drugs@FDA: Voltaren Delayed Release,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019201
DB00586,,Health Canada Product Monograph: Diclofenac oral tablets,https://pdf.hres.ca/dpd_pm/00054964.PDF
DB00588,,FDA Approved Drug Products December 1990,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process&rptName=2&reportSelectMonth=12&reportSelectYear=1990&nav
DB00588,,FDA Approved Drugs: Dymista nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202236s010lbl.pdf
DB00590,,Doxazosin FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019668s021lbl.pdf
DB00590,,"FDA approval package, Cardura",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019668
DB00590,,"MSDS, Pfizer",https://www.pfizer.com/sites/default/files/products/material_safety_data/PZ01040.pdf
DB00590,,Cardura XL label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021269s011lbl.pdf
DB00590,,Cardura monograph,https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf
DB00590,,FDA Approved Drug Products: CARDURA (doxazosin mesylate) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019668s028lbl.pdf
DB00590,,FDA Approved Drug Products: CARDURA XL (doxazosin) extended release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021269Orig1s021lbl.pdf
DB00591,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202368
DB00591,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a52763d0-7024-48a8-9cca-3127333dfb01
DB00591,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be70a464-f936-4721-8cbb-b106075bfd4d
DB00591,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4400e471-7402-11df-93f2-0800200c9a66
DB00591,,Drugs.com,https://www.drugs.com/newdrugs/fda-approves-yutiq-fluocinolone-acetonide-intravitreal-implant-chronic-non-infectious-posterior-4845.html
DB00591,,Retina today,http://retinatoday.com/pdfs/0609_12.pdf
DB00596,,FDA Approved Drug Products: Halobetasol Propionate Cream or Ointment,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019968s011lbl.pdf
DB00596,,FDA Approved Drug Products: Halobetasol Propionate Topical Lotion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208183s000lbl.pdf
DB00596,,FDA Summary Review: Halobetasol Propionate,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208183Orig1s000PharmR.pdf
DB00596,,Health Canada Approved Drug Products: Ultravate Halobetasol Propionate Topical Cream or Ointment,https://pdf.hres.ca/dpd_pm/00053569.PDF
DB00596,,FDA Approved Drug Products: LEXETTE (halobetasol propionate) topical foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210566s003lbl.pdf
DB00597,,FDA Approved Drug Products: Prohance (gadoteridol) injection for intravenous administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020131s035lbl.pdf
DB00597,,"FDA Approved Drug Products: PROHANCE (gadoteridol injection) single dose, for intravenous use (Jan 2024)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020131s040,021489s021lbl.pdf"
DB00597,,"FDA Approves Bracco Diagnostics Inc.'s ProHance® (Gadoteridol) Injection, 279.3 mg/mL, for Pediatric Patients Younger than Two Years",https://www.prnewswire.com/news-releases/fda-approves-bracco-diagnostics-incs-prohance-gadoteridol-injection-279-3-mgml-for-pediatric-patients-younger-than-two-years-301198118.html
DB00598,,FDA Approved Drug Products: Normodyne Labetalol Hydrochloride Injection (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018686
DB00598,,FDA Approved Drug Products: Labetalol Hydrochloride Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019425s021lbl.pdf
DB00598,,FDA Approved Drug Products: Labetalol Hydrochloride Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018716s026lbl.pdf
DB00599,,EMC Summary of Product Characteristics: Thiopental powder for solution for injection,https://www.medicines.org.uk/emc/product/9376/smpc
DB00600,,FDA Approved Products: Benoquin (monobenzone) cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/08173slr015_benoquin_lbl.pdf
DB00601,,FDA Approved Drug Products: Zyvox (linezolid) for intravenous or oral administration,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021130s039s040,021131s034s035,021132s038s039lbl.pdf"
DB00601,,Health Canada Product Monograph: Linezolid oral tablets,https://pdf.hres.ca/dpd_pm/00045786.PDF
DB00601,,FDA Pharmacology and Biopharmaceutics Review: Linezolid,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21130_Zyvox_biopharmr.pdf
DB00602,,FDA Approved Drug Products: Sklice (ivermectin 0.5%) topical lotion (OTC),https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202736s003lbl.pdf
DB00602,,FDA Approved Drug Products: Soolantra (ivermectin 1%) topical cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206255s004lbl.pdf
DB00602,,FDA Approved Drug Products: Stromectol (Ivermectin) Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdf
DB00602,,Nature News: Flawed ivermectin preprint highlights challenges of COVID drug studies,https://www.nature.com/articles/d41586-021-02081-w
DB00602,,CDC Health Alert Network: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19,https://emergency.cdc.gov/han/2021/han00449.asp
DB00603,,FDA Approved Drug Products: Provera Medroxyprogesterone Acetate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf
DB00603,,FDA Approved Drug Products: Conjugated Estrogens and Medroxyprogesterone Acetate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020527s065lbl.pdf
DB00603,,FDA Approved Drug Products: Medroxyprogesterone Acetate Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021583s023lbl.pdf
DB00603,,FDA Approved Drug Products: Medroxyprogesterone Acetate Intramuscular Injection 150mg/mL,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020246s058lbl.pdf
DB00603,,FDA Approved Drug Products: Medroxyprogesterone Acetate Intramuscular Injection 400mg/mL,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/012541s086lbl.pdf
DB00603,,Pfizer Canada: Depo-Provera Monograph,https://www.pfizer.ca/sites/default/files/201803/DEPO-PROVERA_PM_E_210121_13Feb2018.pdf
DB00603,,Cayman Chemicals: Medroxyprogesterone Acetate MSDS,https://www.caymanchem.com/msdss/23664m.pdf
DB00608,,FDA Approved Drug Products: Chloroquine Phosphate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/083082s050lbl.pdf
DB00608,,FDA Approved Drug Products: Aralen Chloroquine Oral Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006002
DB00608,,FDA: Emergency use Authorization for Hydroxychloroquine and Chloroquine Revoked,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and
DB00609,,FDA Approved Drugs: Trecator® oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/013026s029lbl.pdf
DB00612,,Bisoprolol monograph,https://www.sandoz.ca/sites/www.sandoz.ca/files/Bisoprolol_TAB_Monograph.pdf
DB00612,,Summary of product characteristics,https://www.medicines.org.uk/emc/product/6126/smpc
DB00612,,"Bisoprolol, health links AU",http://secure.healthlinks.net.au/content/apo/index_pi_apo.cfm?product=txpbisop
DB00612,,CaymanChem: Bisoprolol MSDS,https://www.caymanchem.com/msdss/23827m.pdf
DB00612,,"Monograph, Bisoprolol",http://www.labriva.com/monographies/02471272eng.pdf
DB00612,,DailyMed Label: Bisoprolol fumarate Oral Tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bba0bc2b-602f-4df1-a761-85bd3c80c7de
DB00612,,Health Canada Approved Drug Products: BISOPROLOL (bisoprolol fumarate) tablets for oral use (January 2020),https://pdf.hres.ca/dpd_pm/00054643.PDF
DB00615,,"FDA Approved Drug Products: Talicia Amoxicillin, Omeprazole, and Rifabutin Oral Delayed Release Capsules",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213004lbl.pdf
DB00619,,FDA Approved Drug Products: Gleevec (Imatinib) Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf
DB00619,,FDA Approved Drug Products: Gleevec (Imatinib) Oral Tablet 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s060lbl.pdf
DB00619,,Cayman Chemical: Imatinib MSDS,https://cdn.caymanchem.com/cdn/msds/13139m.pdf
DB00619,,How Imatinib Transformed Leukemia Treatment and Cancer Research,https://www.cancer.gov/research/progress/discovery/gleevec
DB00619,,Imatinib Koanaa,https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-koanaa
DB00619,,Imatinib Glivec,https://www.ema.europa.eu/en/medicines/human/EPAR/glivec
DB00620,,FDA Approved Drug Products: Aristocort Triamcinolone Oral Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011161
DB00620,,FDA Approved Drug Products: Triamcinolone Hexacetonide Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016466s046lbl.pdf
DB00620,,FDA Approved Drug Products: Triamcinolone Acetonide Topical Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/012104s032lbl.pdf
DB00620,,FDA Approved Drug Products: Triamcinolone Acetonide 10mg/mL Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012041s045lbl.pdf
DB00620,,FDA Approved Drug Products: Triamcinolone Acetonide 40mg/mL Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/014901s045lbl.pdf
DB00620,,FDA Approved Drug Products: Triamcinolone Acetonide Topical Cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/pre96/011601s036lbl.pdf
DB00620,,FDA Approved Drug Products: Triamcinolone Acetonide Intravitreal Injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022223,022048lbl.pdf"
DB00620,,FDA Approved Drug Products: Triamcinolone Acetonide Intraarticular Extended Release Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208845s000lbl.pdf
DB00620,,Cayman Chemicals: Triamcinolone Acetonide MSDS,https://www.caymanchem.com/msdss/18026m.pdf
DB00620,,FDA Approved Drug Products: Xipere (triamcinolone acetonide) suspension for suprachoroidal injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211950s000lbl.pdf
DB00620,,PR Newswire: Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis,https://www.prnewswire.com/news-releases/bausch--lomb-and-clearside-biomedical-announce-fda-approval-of-xipere-triamcinolone-acetonide-injectable-suspension-for-suprachoroidal-use-for-the-treatment-of-macular-edema-associated-with-uveitis-301407260.html
DB00624,,FDA Approved Drug Products: Vogelxo Testosterone Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204399s000lbl.pdf
DB00624,,FDA Approved Drug Products: Natesto (Testosterone) Nasal Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205488s002lbl.pdf
DB00624,,FDA Approved Drug Products: Testim (Testosterone) Topical Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021454s027lbl.pdf
DB00624,,FDA Approved Drug Products: Fortesta Testosterone Topical Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021463s020lbl.pdf
DB00624,,FDA Approved Drug Products: Androgel 1.62% Testosterone Topical Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022309s020lbl.pdf
DB00624,,FDA Approved Drug Products: Androgel 1% Testosterone Topical Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021015s045lbl.pdf
DB00624,,FDA Approved Drug Products: Androderm Testosterone Transdermal System,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020489s034lbl.pdf
DB00625,,FDA Approved Drugs: Sustiva® oral capsules/tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf"
DB00626,,FDA Approved Drug Products: Bacitracin Injection,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=060733
DB00626,,"FDA Approved Drug Products: Bacitracin, Neomycin, and Polymyxin B Ophthalmic Ointment",https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50417slr011_neosporin_lbl.pdf
DB00626,,"FDA Approved Drug Products: Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone Topical Ointment",https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
DB00626,,Pfizer: Corticosporin Safety Data Sheet,https://www.pfizer.com/sites/default/files/products/material_safety_data/Cortisporin_Ointment_1-Sep-2015.pdf
DB00626,,FDA Briefing Document: Bacitracin for Intramuscular Injection,https://www.fda.gov/media/123641/download
DB00627,,FDA Approved Drug Products: Niacin Film Coated Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020381s048lbl.pdf
DB00627,,FDA Approved Drug Products: Niacin Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/40378_Niacor_Prntlbl.pdf
DB00627,,FDA Approved Drug Products: M.V.I. Pediatric Multivitamin Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018920s038lbl.pdf
DB00627,,FDA Approved Drug Products: Infuvite Pediatric Multivitamin Intravenous Injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021265s030,021646s022lbl.pdf"
DB00627,,FDA Approved Drug Products: Infuvite Adult Multivitamin Intravenous Injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021163s032,021559s025lbl.pdf"
DB00627,,FDA Approved Drug Products: M.V.I. Adult Multivitamin Intravenous Injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021625s023,021643s019lbl.pdf"
DB00627,,Jubilant Life Sciences: Niacin MSDS,https://www.jubl.com/lsi/uploads/files/133msds_Niacin.pdf
DB00627,,"DailyMed: Niacin Oral Tablet, Extended Release",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf57262f-2314-31a3-e478-d927a91a11b9
DB00628,,FDA Approved Drug Products: Tranxene T-TAB (clorazepate dipotassium) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017105s085lbl.pdf
DB00628,,US Food & Drug Administration: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class,https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class
DB00628,,Toronto Research Chemicals: Clorazepic acid dipotassium salt SDS,https://www.trc-canada.com/prod-img/MSDS/C587365MSDS.pdf
DB00630,,FDA Approved Drugs: Alendronate,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020560s070lbl.pdf
DB00632,,DailyMed: docosanol cream,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=995e7f09-bc18-4eed-96ab-43da286f7982&type=pdf
DB00633,,FDA Approved Drug Products: Precedex (dexmedetomidine hydrochloride) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021038s035lbl.pdf
DB00633,,FDA Approved Drug Products: Igalmi (dexmedetomidine) film for sublingual or buccal administration,https://igalmihcp.com/igalmi-pi.pdf
DB00633,,UIC Drug Information Group: What evidence is available on the off-label use of dexmedetomidine for alcohol withdrawal syndrome?,https://dig.pharmacy.uic.edu/faqs/2020-2/november-2020-faqs/update-what-evidence-is-available-on-the-off-label-use-of-dexmedetomidine-for-alcohol-withdrawal-syndrome/
DB00635,,FDA Approved Drug Products: Meticorten Prednisone Oral Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009766
DB00635,,FDA Approved Drug Products: Rayos Prednisone Delayed-Release Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf
DB00635,,EMA Approved Drug Products: Lynparza (olaparib) Oral Tablets (March 2023),https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf
DB00639,,FDA Approved Drug Products: Gynazole-1 (butoconazole nitrate) vaginal cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19881slr009_gynazole_lbl.pdf
DB00640,,FDA Approved Drug Products: Adenocard (Adenosine) Intravenous Injection (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019937
DB00640,,FDA Approved Drug Products: Adenoscan (Adenosine) Intravenous Injection (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020059s017s018lbl.pdf
DB00640,,Dailymed: Adenocard (Adenosine) Intravenous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0e32589-dad9-4887-8481-bcf7f6618466
DB00640,,Cayman Chemical: Adenosine MSDS,https://www.caymanchem.com/msdss/21232m.pdf
DB00641,,FDA Approved Drug Products: Zocor (simvastatin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019766s099lbl.pdf
DB00642,,FDA Approved Drug Products: ALIMTA (pemetrexed) Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021462s053lbl.pdf
DB00642,,FDA Approved Drug Products: ALIMTA (pemetrexed) Intravenous Injection (Nov 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021462s055lbl.pdf
DB00642,,Pemetrexed MSDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9LILL_00002764001_00002762301_ALIMTA_FOR_INJECTION.pdf
DB00642,,EMA Approved Drug Products: ALIMTA (pemetrexed) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/alimta-epar-product-information_en.pdf
DB00643,,Vermox (Mebendazole) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017481s047lbl.pdf
DB00646,,FDA Approved Drug Products: Nystatin oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/64142ap_appltr_prntlbl_chemr.pdf
DB00646,,DPD Approved Drugs: Nystatin,https://pdf.hres.ca/dpd_pm/00010205.PDF
DB00646,,DPD Approved Drugs: Viaderm K.C.®,https://pdf.hres.ca/dpd_pm/00046265.PDF
DB00646,,ThermoFisher Scientific: Nystatin MSDS,https://www.fishersci.com/store/msds?partNumber=BP29495&productDescription=NYSTATIN+5+G&vendorId=VN00033897&countryCode=US&language=en
DB00646,,MedSafe NZ: Nystatin,https://www.medsafe.govt.nz/Profs/Datasheet/n/nilstatcapdrpowdtabcrointvagcr.pdf
DB00646,,DPD Approved Drugs: Flagystatin® vaginal ovules,https://pdf.hres.ca/dpd_pm/00046934.PDF
DB00647,,FDA data,http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/Darvocet-N_July2009.pdf
DB00647,,Drug Information,http://www.rxlist.com/darvon-drug.htm
DB00647,,Drugs.com,https://www.drugs.com/propoxyphene.html
DB00648,,FDA Approved Drug Products: LYSODREN (mitotane) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/016885s029lbl.pdf
DB00648,,FDA Approved Drug Products: Lysodren (mitotane) tablets for oral use (January 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/016885Orig1s032lbl.pdf
DB00648,,Cayman Chemical: Mitotane MSDS,https://cdn.caymanchem.com/cdn/msds/18651m.pdf
DB00654,,FDA Approved Drug Products: Xalatan (latanoprost) Ophthalmic Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020597s044lbl.pdf
DB00654,,Cayman Chemical: Latanoprost MSDS,https://www.caymanchem.com/msdss/16812m.pdf
DB00654,,Drugs.com: Latanoprost ophthalmic,https://www.drugs.com/mtm/latanoprost-ophthalmic.html
DB00654,,FDA Approved Drug Products: ROCKLATAN (netarsudil and latanoprost) Ophthalmic Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208259s006lbl.pdf
DB00654,,Health Canada Approved Drug Products: SANDOZ LATANOPROST (Latanoprost) Ophthalmic Solution,https://www.sandoz.ca/sites/www.sandoz.ca/files/Sandoz%20Latanoprost%20Product%20Monograph.pdf
DB00654,,"FDA Approved Drug Products: IYUZEH (latanoprost ophthalmic solution) 0.005%, for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216472s000lbl.pdf
DB00654,,Health Canada Product Monograph: ACT LATANOPROST/TIMOLOL (Latanaprost and Timolol) Ophthalmic Solution,https://pdf.hres.ca/dpd_pm/00056431.PDF
DB00656,,Trazodone,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf
DB00656,,"Monograph, Trazodone",https://pdf.hres.ca/dpd_pm/00030282.PDF
DB00656,,"Trazodone overdose, NIH Medline",https://medlineplus.gov/ency/article/002559.htm
DB00656,,"Rapid structure determination of microgram-level drug metabolites using HPLC-MS, fraction collection and NMR spectroscopy",https://pubs.rsc.org/en/content/articlelanding/2010/ay/c0ay00290a#!divAbstract
DB00656,,"FDA application review, Trazodone",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022411s000MedR.pdf
DB00657,,FDA Approved Drug Products: INVERSINE (mecamylamine hydrochloride) tablets,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=e1fc95fe-7816-47b6-b73d-b2f644f79872&type=pdf
DB00659,,FDA Approved Drug Products: CAMPRAL (acamprosate calcium) delayed-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021431s013lbl.pdf
DB00659,,AAFP: Acamprosate (Campral) for Treatment of Alcoholism,https://www.aafp.org/afp/2006/0815/p645.html
DB00659,,"NIH Online Books: Incorporating Alcohol Pharmacotherapies Into Medical Practice, Chapter 2 - Acamprosate",https://www.ncbi.nlm.nih.gov/books/NBK64035/
DB00659,,Chemical book: Acamprosate chemical properties,https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4310705.htm
DB00659,,DailyMed: Acamprosate calcium delayed release tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe6f754f-62b4-4c86-805d-221332409516
DB00660,,FDA Approved Drug Products: SKELAXIN (metaxalone) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/013217s057lbl.pdf
DB00661,,FDA Approved Drug Products: Verelan® PM extended-release capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020943s035lbl.pdf
DB00661,,FDA Approved Drug Products: Verapamil HCl for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018925s010lbl.pdf
DB00661,,Verapamil FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018817s033lbl.pdf
DB00661,,FDA Approved Drugs: Tarka® extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020591s030lbl.pdf
DB00661,,CaymanChem: Verapamil MSDS,https://www.caymanchem.com/msdss/14288m.pdf
DB00661,,FDA Approved Drug Products: Calan SR tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019152s044lbl.pdf
DB00662,,FDA Approved Drug Products: TIGAN (trimethobenzamide hydrochloride) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017531s014lbl.pdf
DB00662,,FDA Approved Drug Products: TIGAN (trimethobenzamide hydrochloride) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017530s024lbl.pdf
DB00668,,Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm617173.htm
DB00668,,"Epinephrine, by Injection: NIH",https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0010119/?report=details
DB00668,,Symjepi Approval History,https://www.drugs.com/history/symjepi.html
DB00668,,FDA approves Auvi-Q,https://www.drugs.com/newdrugs/sanofi-announces-fda-approval-auvi-q-first-voice-guided-epinephrine-auto-injector-patients-3424.html
DB00668,,Epipen.ca,https://www.epipen.ca
DB00668,,Medicines UK document,https://www.medicines.org.uk/emc/product/4289/smpc#PHARMACOKINETIC_PROPS
DB00668,,Croup: American Family Physician Document,https://www.aafp.org/afp/2011/0501/p1067.html
DB00668,,NIH STAT pearls,https://www.ncbi.nlm.nih.gov/books/NBK482160/
DB00668,,PubChem: Epinephrine,https://pubchem.ncbi.nlm.nih.gov/compound/epinephrine#section=Absorption-Distribution-and-Excretion
DB00668,,"FDA Approved Drug Products: ADRENALIN (epinephrine injection) 1 mg/mL, for intramuscular, subcutaneous, and intravenous use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204200Orig1s009,204640Orig1s009lbl.pdf"
DB00668,,FDA Approved Drug Products: NEFFY (epinephrine) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214697s000lbl.pdf
DB00669,,FDA Approved Drug Products: Sumatriptan and Naproxen Oral Tablets,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021926
DB00669,,FDA Approved Drug Products: Sumatriptan Nasal Powder,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206099
DB00669,,FDA Approved Drug Products: Sumatriptan Nasal Spray,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210884
DB00669,,FDA Approved Drug Products: Sumatriptan Subcutaneous Injection,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020080
DB00669,,FDA Approved Drug Products: Sumatriptan Subcutaneous Solution,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208223
DB00669,,FDA Approved Drug Products: Sumatriptan Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020132s029lbl.pdf
DB00669,,"Sumatriptan Tablets, USP monograph",https://pdf.hres.ca/dpd_pm/00036027.PDF
DB00671,,"FDA Approved Drug Products: SUPRAX (cefixime) for oral use, (October 2019)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202091s009lbl.pdf
DB00671,,HealthLink BC: Cefixime - Oral,https://www.healthlinkbc.ca/medications/cefixime-oral
DB00671,,Fischer Scientific: Cefixime MSDS,https://www.fishersci.com/store/msds?partNumber=AC459480010&productDescription=CEFIXIME%2C+98%25+1GR&vendorId=VN00032119&countryCode=US&language=en
DB00671,,Mescape: cefixime (Rx),https://reference.medscape.com/drug/suprax-cefixime-342503
DB00673,,FDA Approved Drug Products: Aprepitant Oral Capsules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021549s031,207865s004lbl.pdf"
DB00673,,FDA Approved Drug Products: Aprepitant Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209296s003lbl.pdf
DB00674,,"FDA Approved Drug Products: RAZADYNE (galantamine hydrobromide), for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021615s021lbl.pdf
DB00674,,"DailyMed Label: RAZADYNE - galantamine hydrobromide CAPSULE, EXTENDED RELEASE RAZADYNE - galantamine hydrobromide TABLET, FILM COATED",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec9b5a9c-8caf-4f9b-8c1b-209b2de556dc
DB00674,,Fisher Scientific: Galantamine hydrobromide MSDS,https://www.fishersci.com/store/msds?partNumber=AAJ6248203&productDescription=GALANTHAMINE+HYDROBROMIDE+1G&vendorId=VN00024248&countryCode=US&language=en
DB00675,,FDA Approved Drug Products: Tamoxifen Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf
DB00675,,FDA Approved Drug Products: Tamoxifen Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021807s006lbl.pdf
DB00678,,FDA Approved Drug Products: Losartan Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf
DB00678,,FDA Approved Drug Products: Losartan and Hydrochlorothiazide Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020387s063lbl.pdf
DB00678,,Cayman Chemicals: Losartan Potassium MSDS,https://www.caymanchem.com/msdss/10006594m.pdf
DB00678,,FDA Approved Drug Products: HYZAAR (losartan potassium and hydrochlorothiazide) tablets for oral use (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020387s071lbl.pdf
DB00682,,Warfarin DPD Monograph,https://pdf.hres.ca/dpd_pm/00047189.PDF
DB00682,,ChemIDplus: Warfarin,https://chem.nlm.nih.gov/chemidplus/rn/81-81-2
DB00682,,HSDB: Warfarin,http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+1786
DB00682,,LactMed: Warfarin,http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+279
DB00682,,FDA Approved Drug Products: COUMADIN (warfarin sodium),https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf
DB00682,,DailyMed: Warfarin sodium tablets for oral use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ad881e0-ca41-42ad-9d7d-eb85b3a30af0
DB00683,,Drug Scheduling: United States Drug Enforcement Administration (DEA),https://www.dea.gov/drug-scheduling
DB00683,,DailyMed: Midazolam,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9a443652-6aff-4e27-83fe-90c65fa0f3c1&type=display
DB00683,,NAYZILAM® (midazolam) nasal spray - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf
DB00683,,"FDA Approved Drug Products: NAYZILAM (midazolam) nasal spray, CIV Jan 2023",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211321s008lbl.pdf
DB00683,,DailyMed: Midazolam injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9532689f-bf0f-5854-98ef-543a0ae2d8c8
DB00683,,"FDA Approved Drug Products: SEIZALAM® (midazolam injection), for intramuscular use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209566s003lbl.pdf
DB00683,,EMA Approved Drug Products: BUCCOLAM oromucosal solution,https://www.ema.europa.eu/en/documents/product-information/buccolam-epar-product-information_en.pdf
DB00683,,Health Canada Approved Drug Products: Midazolam Intramuscular or Intravenous Injection (January 2023),https://pdf.hres.ca/dpd_pm/00069010.PDF
DB00683,,Midazolam Chemical Handbook,https://www.chemicalbook.com/ChemicalProductProperty_US_CB3418581.aspx
DB00683,,CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211321Orig1s000,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211321Orig1s000MedR.pdf
DB00684,,FDA Approved Drug Products: TOBI PODHALER (tobramycin) inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201688s010lbl.pdf
DB00684,,FDA Approved Drug Products: TOBREX (tobramycin) ophthalmic,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050541s030lbl.pdf
DB00684,,FDA Approved Drug Products: tobramycin for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/065122s008lbl.pdf
DB00684,,Cayman Chemical: tobramycin MSDS,https://www.caymanchem.com/msdss/14596m.pdf
DB00684,,FDA Approved Drug Products: Tobramycin for injection for intravenous use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050789s017lbl.pdf
DB00684,,FDA Approved Drug Products: TOBI (tobramycin) inhalation solution for oral inhalation use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050753s028lbl.pdf
DB00684,,FDA Approved Drug Products: TOBI (tobramycin) inhalation solution for oral inhalation use (April 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205433s008lbl.pdf
DB00685,,Dailymed: Trovan (trovafloxacin mesylate) oral tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da9b26bb-d2d7-4113-a0f9-c6c2280f4875
DB00687,,DPD Approved Drugs: Florinef,https://pdf.hres.ca/dpd_pm/00050125.PDF
DB00687,,MedSafe NZ: Florinef,https://www.medsafe.govt.nz/profs/Datasheet/f/Florineftab.pdf
DB00687,,UK Approved Drugs: Fludrocortisone,https://www.medicines.org.uk/emc/product/2266
DB00687,,CaymanChem: Fludrocortisone acetate MSDS,https://www.caymanchem.com/msdss/24032m.pdf
DB00688,,"FDA label, Mycophenolate mofetil","https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050722s021,050723s019,050758s019,050759s024lbl.pdf"
DB00688,,"MSDS, Mycophenolate mofetil",http://datasheets.scbt.com/sc-200971.pdf
DB00688,,FDA Approved Drug Products: Cellcept (mycophenolate mofetil) for oral or intravenous administration,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050722s049s051,050723s049s051,050758s047s049lbl.pdf"
DB00690,,Link,http://www.inchem.org/documents/pims/pharm/pim640.htm
DB00692,,"FDA Approved Drug Products: RYZUMVI (phentolamine ophthalmic solution) 0.75%, for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217064s000lbl.pdf
DB00692,,Oraverse: Phentolamine mesylate MSDS,http://www.oraverse.com/assets/pdf/MSDS.pdf
DB00692,,"DailyMed Label: ORAVERSE (phentolamine mesylate) submucosal injection, solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4025cf98-ea87-4531-b0fc-6283c84f63f3
DB00692,,"DailyMed Label: PHENTOLAMINE MESYLATE intravenous or intramuscular injection, powder, for solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed6c506c-5535-4b7c-ae1a-d63f09d796c9
DB00694,,"FDA Approved Drug Products: VYXEOS (daunorubicin and cytarabine) liposome for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209401s006lbl.pdf
DB00694,,Health Canada Approved Drug Products: daunorubicin solution for injection,https://pdf.hres.ca/dpd_pm/00057229.PDF
DB00694,,FDA Approved Drug Products: Daunorubicin hydrochloride injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29fe455e-f177-4b0e-99fb-60a53016db72
DB00695,,"FDA Approved Drug Products: Furosemide Injection, for intravenous or intramuscular use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018667s036lbl.pdf
DB00695,,Furosemide - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK499921/
DB00695,,Furosemide SAFETY DATA SHEET - Cayman Chemical,https://www.caymanchem.com/msdss/17273m.pdf
DB00695,,Lasix Oral (furosemide) Product Monograph,http://products.sanofi.ca/en/lasix.pdf
DB00695,,"FDA Approved Drug Products: Furoscix (furosemide injection), for subcutaneous use (October 2022)",https://www.furoscix.com/wp-content/uploads/2022/10/prescribing-information.pdf
DB00697,,Reflexes: Components of a Reflex Arc,https://courses.lumenlearning.com/boundless-ap/chapter/reflexes/
DB00698,,FDA Approved Drug Products: Macrocrystalline Nitrofurantoin Oral Capsule,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016620
DB00698,,FDA Approved Drug Products: Nitrofurantoin and Macrocrystalline Nitrofurantoin Oral Capsule,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020064
DB00698,,FDA Approved Drug Products: Nitrofurantoin Oral Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009175s046lbl.pdf
DB00698,,FDA Approved Drug Products: Nitrofurantoin Oral Tablet,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008693
DB00700,,FDA Approved Drug Products: Inspra (eplerenone) tablets for oral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021437s015lbl.pdf
DB00706,,FDA Approved Drug Products: Flomax,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020579
DB00706,,Urology Times: Urologists no longer primary initiator of tamsulosin,https://www.urologytimes.com/modern-medicine-feature-articles/urologists-no-longer-primary-initiator-tamsulosin
DB00708,,FDA approves Dsuvia,https://www.drugs.com/newdrugs/fda-approves-dsuvia-sufentanil-sublingual-severe-pain-4855.html
DB00708,,"Noting Military Potential, FDA Approves Powerful Painkiller Dsuvia",https://www.wsj.com/articles/noting-military-potential-fda-approves-powerful-painkiller-dsuvia-1541200765
DB00708,,"FDA Approved Drug Products: DSUVIA® (sufentanil) sublingual tablet, CII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209128s007lbl.pdf
DB00709,,"FDA Approved Drug Products: Triumeq/Triumeq PD (abacavir, dolutegravir, and lamivudine) for oral administration",https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG-IFU.PDF
DB00709,,FDA Approved Drug Products: Dovato (dolutegravir and lamivudine) tablets for oral use (April 2024),https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Dovato/pdf/DOVATO-PI-PIL.PDF
DB00709,,FDA Approved Drug Products: Cimduo (lamivudine and tenofovir disoproxil fumarate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022141s000lbl.pdf
DB00709,,FDA Approved Drug Products: Epivir (lamivudine) for oral administration (May 2019),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf"
DB00709,,"FDA Approved Drug Products: Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210807s008lbl.pdf
DB00709,,"FDA Approved Drug Products: Symfi (efavirenz, lamivudine, and tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022142s037lbl.pdf
DB00710,,FDA Approved Drug Products: Boniva Ibandronate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021455s021lbl.pdf
DB00710,,FDA Approved Drug Products: Boniva Ibandronate Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021858s022lbl.pdf
DB00714,,FDA Approved Drug Products: Apomorphine Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf
DB00714,,FDA Approved Drug Products: Apomorphine Sublingual Film,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210875lbl.pdf
DB00714,,Cayman Chemical: Apomorphine MSDS,https://www.caymanchem.com/msdss/16094m.pdf
DB00714,,"FDA Approved Drug Products: APOKYN® (apomorphine hydrochloride) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021264s022lbl.pdf
DB00714,,FDA Approved Drug Products: KYNMOBI® (apomorphine hydrochloride) sublingual film 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210875s006lbl.pdf
DB00715,,Paxil CR FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020936s053lbl.pdf
DB00715,,Paroxetine FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020031s067,020710s031.pdf"
DB00715,,Brisdelle FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s004lbl.pdf
DB00715,,"GSK monograph, Paxil",https://ca.gsk.com/media/530543/paxil_pm-2014-11-13.pdf
DB00715,,Paxil,https://www.drugs.com/paxil.html
DB00715,,Putting GlaxoSmithKline to the test over paroxetine,https://www.bmj.com/bmj/section-pdf/749788?path=/bmj/347/7933/Feature.full.pdf
DB00715,,Annotation of CPIC Guideline for paroxetine and CYP2D6,https://www.pharmgkb.org/guidelineAnnotation/PA166127636
DB00715,,Sandoz paroxetine tablets,https://www.sandoz.ca/sites/www.sandoz.ca/files/Sandoz%20Paroxetine%20tablets%20PMe%2020170315.pdf
DB00715,,"Paroxetine, psychopharmacology institute",https://psychopharmacologyinstitute.com/section/paroxetine-moa-indications-pharmacokinetics-and-dosing-2051-4053#%20Pharmacokinetics
DB00717,,DPD Approved Drugs: Jencycla oral tablets,https://pdf.hres.ca/dpd_pm/00051107.PDF
DB00717,,FDA Approved Drug Products: CombiPatch® transdermal system,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020870s023lbl.pdf
DB00717,,FDA Approved Drug Products: Femhrt® tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021065s024lbl.pdf
DB00717,,FDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203696s001lbl.pdf
DB00717,,FDA Approved Drug Products: Generess Fe chewable tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022573s008lbl.pdf
DB00717,,FDA Approved Drug Products: Lo Loestrin Fe oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022501s000lbl.pdf
DB00717,,CaymanChem: Norethisterone MSDS,https://www.caymanchem.com/msdss/20941m.pdf
DB00717,,The Embryo Project Encyclopedia: Progestin,https://embryo.asu.edu/pages/progestin-synthetic-progesterone
DB00720,,Health Canada Approved Drug Products: Clodronate Oral Capsules,https://pdf.hres.ca/dpd_pm/00041216.PDF
DB00721,,Clinical Trial NCT00299897,https://www.clinicaltrials.gov/ct2/show/NCT00299897
DB00721,,FDA Approved Drug Products: Novocain Procain Hydrochloride Injection,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c80c810a-60e0-49bd-139c-95aec3a286fc&type=display
DB00722,,FDA Approved Drug Products: Lisinopril Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019558s063lbl.pdf
DB00722,,FDA Approved Drug Products: Lisinopril Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208401s002lbl.pdf
DB00722,,FDA Approved Drug Products: Lisinopril and Hydrochlorothiazide Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019888s067lbl.pdf
DB00722,,Cayman Chemicals: Lisinopril MSDS,https://www.caymanchem.com/msdss/16833m.pdf
DB00727,,"FDA Approved Drug Products: Nitroglycerin in 5% Dextrose Injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019970s015lbl.pdf
DB00727,,Health Canada Approved Drug Products: NITROLINGUAL PUMPSPRAY (Nitroglycerin) Sublingual Spray,http://products.sanofi.ca/en/nitrolingual-pumpspray.pdf
DB00727,,Pfizer: Nitroglycerin MSDS,https://www.pfizer.com/sites/default/files/products/material_safety_data/Nitroglycerin_in_Dextrose_Injection_(hospira)060214.pdf
DB00727,,FDA Approved Drug Products: NITRO-DUR (nitroglycerin) Transdermal Infusion System,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf
DB00727,,FDA Approved Drug Products: NitroMist (nitroglycerin) lingual aerosol,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021780s008lbl.pdf
DB00727,,"DailyMed Label: RECTIV (nitroglycerin) Ointment 0.4%, for intra-anal use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4
DB00727,,DailyMed Label: NITROSTAT (nitroglycerin) sublingual tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79ba021e-183c-4b4d-822e-4ff5ef54ca61
DB00728,,FDA Approved Drug Products: ZEMURON (rocuronium bromide) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020214Orig1s038lbl.pdf
DB00731,,FDA Approved Drug Products: STARLIX (nateglinide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021204s023lbl.pdf
DB00734,,Pharmacokinetics of Risperidone: Clinical Summary,https://psychopharmacologyinstitute.com/antipsychotics/risperidone/pharmacokinetics-risperidone/
DB00734,,FDA Approved Drug Products: Risperdal (risperidone) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020272s085,020588s072,021444s058lbl.pdf"
DB00734,,FDA Approved Drug Products: Risperdal Consta (risperidone) long-acting intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021346s063lbl.pdf
DB00734,,FDA Approved Drug Products: Perseris (risperidone) extended-release suspension for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210655s004lbl.pdf
DB00734,,Health Canada Product Monograph: Risperdal (risperidone) oral tablets,https://pdf.hres.ca/dpd_pm/00047330.PDF
DB00734,,"FDA Approved Drug Products: RYKINDO (risperidone) for extended-release injectable suspension, for intramuscular use",https://www.luye.cn/lvye_en/rykindo.pdf
DB00734,,"FDA Approved Drug Products: UZEDY (risperidone) extended-release injectable suspension, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213586s000lbl.pdf
DB00735,,FDA Approved Drug Products: NAFTIN (naftifine hydrochloride) gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204286s004lbl.pdf
DB00735,,FDA Approved Drug Products: NAFTIN (naftifine hydrochloride) topical,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf"
DB00736,,"DailyMed Label: NEXIUM (esomeprazole magnesium) delayed-release capsules or granules, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96
DB00737,,Antivert (meclizine hydrochloride) - Drug Summary - PDR.net,https://www.pdr.net/drug-summary/Antivert-meclizine-hydrochloride-1822
DB00737,,"BONAMINE® (Meclizine Hydrochloride Tablets 25 mg, USP) - Product Monograph",https://pdf.hres.ca/dpd_pm/00013453.PDF
DB00737,,FDA Approved Drug Products: ANTIVERT (meclizine) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/010721s058lbl.pdf
DB00740,,FDA Approved Drug Products: RILUTEK (riluzole) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020599s019lbl.pdf
DB00740,,FDA Approved Drug Products: EXSERVAN (riluzole) film,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212640s001lbl.pdf
DB00740,,FDA Approved Drug Products: TIGLUTIK (riluzole) suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209080s003lbl.pdf
DB00741,,FDA Approved Drug Products: Vosol Hydrocortisone and Glacial Acetic Acid Otic Drops,https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/012770s024lbl.pdf
DB00741,,"FDA Approved Drug Products: Casporyn Neomycin Sulfate, Polymixin B Sulfate, and Hydrocortisone Otic Drops",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/060613s013lbl.pdf
DB00741,,FDA Approved Drug Products: Cortef Hydrocortisone Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/008697s036lbl.pdf
DB00741,,FDA Approved Drug Products: Cortenema Hydrocortisone Rectal Enema,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016199s035lbl.pdf
DB00741,,"FDA Approved Drug Products: Bacitracin, Neomycin, Polymyxin B, and Hydrocortisone Topical Ointment",https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
DB00741,,FDA Approved Drug Products: Xerese (Acyclovir and Hydrocortisone) Topical Cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022436s004lbl.pdf
DB00741,,FDA Approved Drug Products: Hydrocortone Hydrocortisone Oral Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008506
DB00741,,FDA Approved Drug Products: ALKINDI SPRINKLE (hydrocortisone) oral granules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213876s000lbl.pdf
DB00742,,FDA Approved Drug Products: BRONCHITOL (mannitol) oral inhalation powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202049s000lbl.pdf
DB00743,,FDA Approved Drug Products: MultiHance (gadobenate dimeglumine) for injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021357s018,021358s017lbl.pdf"
DB00743,,FDA Approved Drug Products: MultiHance (gadobenate dimeglumine) Injection (Feb 2024),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021357s025,021358s023lbledt.pdf"
DB00746,,Link,http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/203185.html
DB00747,,FDA Approved Drug Products: TRANSDERM SCOP (scopolamine) patch,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf
DB00747,,Cayman Chemical: scopolamine MSDS,https://www.caymanchem.com/msdss/14108m.pdf
DB00750,,DailyMed: Prilocaine Hydrochloride Subcutaneous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca454f96-2e2d-46ed-95af-c741726773de
DB00755,,DailyMed Label: TWYNEO (tretinoin and benzoyl peroxide) topical cream,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27208dff-e376-4c18-b56e-0a260f685a39
DB00755,,"FDA Approved Drug Products: VESANOID (tretinoin) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020438s007s008lbl.pdf
DB00755,,"DailyMed Label: CLINDAMYCIN PHOSPHATE and TRETINOIN Gel 1.2% / 0.025%, for topical use only",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79e1c8f6-59cd-4efa-9efa-0762d4b1a10c
DB00755,,DailyMed Label: Tretinoin Topical Cream or Gel,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba377a5e-e48a-4bd9-9d76-929d70793396
DB00755,,"DailyMed Label: TRIDERMA (hydroquinone, tretinoin, fluocinolone acetonide) topical cream",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0be231f-2572-3b39-e053-2a95a90ac948
DB00755,,"Medisca: TRETINOIN, USP (Retinoic Acid) MSDS",https://www.medisca.com/NDC_SPECS/MUS/0001/MSDS/0001.pdf
DB00755,,Cancer Care Ontario Tretinoin Monograph,https://www.cancercareontario.ca/sites/ccocancercare/files/tretinoin.pdf
DB00757,,FDA Approved Drug Products: ANZEMET (dolasetron mesylate) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020624s025lbl.pdf
DB00757,,FDA Approved Drug Products: ANZEMET (dolasetron mesylate) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020623s012lbl.pdf
DB00758,,FDA Approved Drug Products: Clopidogrel Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020839s072lbl.pdf
DB00759,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00761,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00762,,"FDA Approved Drug Products: CAMPTOSAR (irinotecan hydrochloride) injection, for intravenous use (January 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020571Orig1s053lbl.pdf
DB00762,,"FDA Approved Drug Products: ONIVYDE (irinotecan liposome injection), for intravenous use (February 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/207793s016lbl.pdf
DB00762,,Cayman Chemical: Irinotecan (hydrochloride hydrate) MSDS,https://cdn.caymanchem.com/cdn/msds/14180m.pdf
DB00762,,Health Canada Approved Drug Products: Irinotecan Hydrochloride Intravenous Injection,https://pdf.hres.ca/dpd_pm/00056704.PDF
DB00763,,CaymenChem: Methimazole MSDS,https://www.caymanchem.com/msdss/23718m.pdf
DB00763,,FDA Approved Drug Products: TAPAZOLE (methimazole) oral tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040320s005lbl.pdf
DB00763,,DPD Approved Drugs: Methimazole,http://www.paladin-labs.com/our_products/tapazole_en.pdf?ver=4.0
DB00766,,Augmentin drug summary,https://www.pdr.net/drug-summary/Augmentin-XR-amoxicillin-clavulanate-potassium-2206
DB00766,,FDA Approved Drug Products: Augmentin Amoxicillin and Clavulanate Oral Tablets and Suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf"
DB00766,,Public assessment report: CO-AMOXCOO,http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con059922.pdf
DB00766,,"EMA, Clavulanic acid summary report",https://www.ema.europa.eu/en/documents/mrl-report/clavulanic-acid-summary-report-1-committee-veterinary-medicinal-products_en.pdf
DB00766,,"Augmentin IV, Medicines UK",https://www.medicines.org.uk/emc/medicine/2025
DB00766,,Timentin FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050658s022lbl.pdf
DB00766,,Product monograph: Clavulin (amoxicillin and clavulanate potassium) oral tablets and suspension,https://ca.gsk.com/media/590864/clavulin.pdf
DB00768,,FDA Approved Drug Products: PAZEO (olopatadine hydrochloride) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206276s000lbl.pdf
DB00768,,FDA Approved Drug Products: PATANASE (olopatadine hydrochloride) Nasal Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021861lbl.pdf
DB00768,,"Opatanol, INN-olopatadine - European Medicines Agency - Europa EU",https://www.ema.europa.eu/en/documents/product-information/opatanol-epar-product-information_en.pdf
DB00768,,OLOPATADINE - Product Monograph - Sandoz Canada Inc.,https://www.sandoz.ca/sites/www.sandoz.ca/files/Olopatadine%200_2%25%20Product%20Monograph.pdf
DB00768,,Patanol (olopatadine hydrochloride ophthalmic solution) 0.1% - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20688slr016_patanol_lbl.pdf
DB00768,,FDA Approved Drug Products: Ryaltris (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211746s000lbl.pdf
DB00768,,Health Canada Approved Drug Proucts: Ryaltris (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray,https://pdf.hres.ca/dpd_pm/00067564.PDF
DB00770,,FDA Approved Drug Products: CAVERJECT (alprostadil) injection for intracavernosal use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020379s038lbl.pdf
DB00770,,FDA Approved Drug Products: Edex (alprostadil) injection for intracavernous use only,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020649s023lbl.pdf
DB00770,,DailyMed label: PROSTIN VR PEDIATRIC (alprostadil) injection solution for intravenous use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=930f8c02-46a8-4cff-a484-660468ab23c3&audience=consumer
DB00770,,Pfizer: Alprostadil SDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9PFIZ_CAVERJECT_PDS_STR_MCG_PDR.pdf
DB00770,,Health Canada Approved Drug Products: PROSTIN VR STERILE (alprostadil) solution for injection,https://pdf.hres.ca/dpd_pm/00050589.PDF
DB00770,,DailyMed Label: MUSE (alprostadil) suppository,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55f3f9-c4cf-11df-851a-0800200c9a66&audience=consumer
DB00770,,Medisca: Alprostadil SDS,https://www.medisca.com.au/NDC_SPECS/MAU/0944/MSDS/0944.pdf
DB00771,,FDA Approved Drug Products: Librax (chlordiazepoxide hydrochloride and clidinium bromide) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/012750s068lbl.pdf
DB00774,,FDA Approved Drug Products: Saluron Hydroflumethiazide Oral Tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6153ef9e-77f0-4233-a5bc-3e3d1f732323
DB00776,,"DailyMed Label: TRILEPTAL (oxcarbazepine) film-coated tablets or suspension, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b
DB00776,,DPD Approved Drugs: Oxcarbazepine,https://pdf.hres.ca/dpd_pm/00048247.PDF
DB00776,,MedSafe NZ: Oxcarbazepine,https://www.medsafe.govt.nz/profs/Datasheet/t/Trileptaltab.pdf
DB00776,,CaymenChem: Oxcarbazepine MSDS,https://www.caymanchem.com/msdss/17340m.pdf
DB00776,,"DailyMed Label: OXTELLAR XR (oxcarbazepine) extended-release tablets, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa610e56-1d1d-11e1-8bc2-0800200c9a66
DB00778,,Link,http://home.intekom.com/pharm/hmr/rulide.html
DB00780,,Nardil monograph,https://davisplus.fadavis.com/3976/meddeck/pdf/phenelzine.pdf
DB00780,,New Zealand report,http://www.medsafe.govt.nz/profs/Datasheet/n/nardiltab.pdf
DB00783,,FDA Approved Products: Estrace (Estradiol) oral tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf"
DB00783,,FDA Approved Products: Evamist (Estradiol) transdermal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022014s001lbl.pdf
DB00783,,FDA Approved Products: Depo-Estradiol (estradiol cypionate) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/085470s015lbl.pdf
DB00783,,FDA Approved Products: Estring (Estradiol vaginal ring),https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020472s007lbl.pdf
DB00783,,FDA Approved Products: Climara (estradiol) transdermal system,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020375s026lbl.pdf
DB00783,,FDA approved products: Estrace (estradiol vaginal cream),https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/86069s018lbl.pdf
DB00783,,Estra-50 (Estradiol pellet) implantable,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca
DB00783,,FDA Approved Products: Esclim (Estradiol) transdermal system,https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20847lblpt.pdf
DB00783,,NIH StatPearls: Estradiol,https://www.ncbi.nlm.nih.gov/books/NBK549797/
DB00783,,Pfizer MSDS: Estradiol tablets MSDS,https://www.pfizer.com/sites/default/files/products/material_safety_data/PZ00638.pdf
DB00783,,CaymanChem: Ethinyl estradiol safety data sheet,https://www.caymanchem.com/msdss/10006486m.pdf
DB00783,,FDA Approved Products: Premarin (conjugated estrogens) vaginal cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020216s073s074s075lbl.pdf
DB00783,,FDA Approved Drug Products: Vagifem® (estradiol vaginal inserts),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020908s027lbl.pdf
DB00783,,FDA Approved Drug Products: Angeliq (drospirenone and estradiol) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021355s009s010lbl.pdf
DB00787,,FDA Approved Drug Products: Zovirax Topical Cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021478s007lbl.pdf
DB00787,,"FDA Drug Approval Package: Zovirax Oral Capsules, Oral Tablets, Oral Suspension",https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018828s031lbl.pdf
DB00787,,FDA Approved Drug Products: Zovirax Topical Ointment,https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/018604s018lbl.pdf
DB00787,,FDA Approved Drug Products: Xerese (Acyclovir and Hydrocortisone) Topical Cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022436s004lbl.pdf
DB00787,,FDA Approved Drug Products: Sitavig Buccal Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203791s000lbl.pdf
DB00787,,FDA Approved Drug Products: Avaclyr Ophthalmic Ointment (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0202408s000lbl.pdf
DB00787,,FDA Approved Drug Products: Zovirax Acyclovir Intravenous Infusion (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018603s030lbl.pdf
DB00788,,Naprelan FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf
DB00788,,Naprosyn FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf"
DB00788,,Over-the-counter Medications in Pregnancy,https://www.aafp.org/afp/2003/0615/p2517.html
DB00788,,Treximet FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021926s013lbl.pdf
DB00788,,Vimovo FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022511s023lbl.pdf
DB00794,,Electronic Medicines Compendium: Primidone 50 mg Tablet Monograph,https://www.medicines.org.uk/emc/product/2941/smpc
DB00794,,FDA Approved Drug Products: Mysoline Primidone Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009170s035lbl.pdf
DB00794,,Cayman Chemical: Primidone MSDS,https://www.caymanchem.com/msdss/19277m.pdf
DB00795,,FDA Approved Drug Products: Azulfidine (sulfasalazine) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/007073s130lbl.pdf
DB00795,,Health Canada Approved Drug Proucts: SALAZOPYRIN (Sulfasalazine) and SALAZOPYRIN EN (Sulfasalazine) tablet for oral use,https://pdf.hres.ca/dpd_pm/00058401.PDF
DB00795,,Sulfasalazine MSDS,https://cdn.caymanchem.com/cdn/msds/15025m.pdf
DB00795,,Sulfasalazine,https://www.ncbi.nlm.nih.gov/books/NBK557809/
DB00795,,Sulfasalazine,https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3395#section=Toxicity-Summary
DB00795,,FDA Approved Drug Products: Azulfidine (sulfasalazine) tablets for oral use 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/007073s133lbl.pdf
DB00796,,FDA Approved Drug Products: Atacand (candesartan cilexetil) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020838s041lbl.pdf
DB00796,,FDA Approved Drug Products: ATACAND HCT (candesartan cilexetil and hydrochlorothiazide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021093s021lbl.pdf
DB00798,,FDA Approved Drug Products: Gentamicin solution for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/062366s033lbl.pdf
DB00798,,FDA Approved Drug Products: PRED-G (gentamicin and prednisolone acetate) ophthalmic suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050586s032lbl.pdf
DB00798,,FDA Approved Drug Products: PRED-G (gentamicin and prednisolone acetate) ophthalmic ointment,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050612s021lbl.pdf
DB00798,,DailyMed Drug Label Information: Gentamicin sulfate injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cce2238-28d3-4280-b520-ffc3067a2ffa
DB00798,,DailyMed Drug Label Information: Gentamicin ophthalmic solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32d5af97-70bd-4ee4-81d4-67578dc677a0
DB00798,,DailyMed Drug Label Information: Gentamicin topical cream,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e673c84f-d3cc-4e61-bdc7-5679cde9f359
DB00798,,DPD Approved Drug Products: Gentamicin solution for injection,https://pdf.hres.ca/dpd_pm/00041017.PDF
DB00799,,FDA Approved Drug Products: ARAZLO (tazarotene) lotion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211882s000lbl.pdf
DB00799,,FDA Approved Drug Products: AVAGE (tazarotene) cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021184s009lbl.pdf
DB00799,,FDA Approved Drug Products: FABIOR (tazarotene) foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202428lbl.pdf
DB00799,,FDA Approved Drug Products: TAZORAC (tazarotene) gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
DB00801,,"Paxipam approval, FDA",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017736
DB00801,,"Federal drug register, FDA",https://www.federalregister.gov/documents/2004/05/05/04-10194/schering-corp-et-al-withdrawal-of-approval-of-92-new-drug-applications-and-49-abbreviated-new-drug
DB00802,,FDA Approved Drug Products: Alfentanil Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019353s023lbl.pdf
DB00802,,"FDA Approved Drug Products: ALFENTANIL HCl Injection, for Intravenous use, CII (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019353s029lbl.pdf
DB00804,,"FDA Approved Drug Products: Dicyclomine Oral Capsules, Oral Tablets, and Intramuscular Injections","https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/007409s042,008370s033lbl.pdf"
DB00804,,"Canadian Agency for Drugs and Technologies in Health: Dicyclomine for Gastrointestinal Conditions: A Review of the Clinical Effectiveness, Safety, and Guidelines",https://www.ncbi.nlm.nih.gov/books/NBK350056/pdf/Bookshelf_NBK350056.pdf
DB00806,,FDA Approved Drug Products: TRENTAL (pentoxifylline) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018631s041lbl.pdf
DB00806,,MSDS: pentoxifylline,https://www.caymanchem.com/msdss/18720m.pdf
DB00808,,Thiazide Diruetics in Hypertension- European Journal of Cardiology,https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-8/Thiazide-diuretics-in-hypertension
DB00808,,Significant Drug–Drug Interactions with Antineoplastics,https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL1876
DB00808,,FDA Approved Drug Products: Lozol (Indapamide),https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018538s028lbl.pdf
DB00809,,DailyMed Label: Tropicamide Ophthalmic Solution/Drops,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=521592d1-53a1-4314-8b3f-d808f3bccfcd
DB00809,,DailyMed Label: PAREMYD (hydroxyamphetamine and tropicamide) ophthalmic solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da8a8a19-ac1b-4160-aac4-c4c57598eb5d
DB00809,,Cayman Chemical: Tropicamide Safety Data Sheet,https://www.caymanchem.com/msdss/16606m.pdf
DB00809,,"FDA Approved Drug Products: MYDCOMBI (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%, for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215352s000lbl.pdf
DB00811,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB00811,,FDA Approved Drug Products: Rebetol (ribavirin) oral capsules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020903s057,021546s013lbl.pdf"
DB00813,,FDA Approved Drug Products: Abstral Sublingual Tablet,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022510
DB00813,,FDA Approved Drug Products: Actiq Transmucosal Lozenge,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020747
DB00813,,FDA Approved Drug Products: Fentora Buccal Tablet,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021947
DB00813,,FDA Approved Drug Products: Subsys Sublingual Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202788s016lbl.pdf
DB00813,,FDA Approved Drug Products: Duragesic Transdermal System,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019813
DB00813,,FDA Approved Drug Products: Lazanda Metered Nasal Spray,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022569
DB00813,,FDA Approved Drug Products: Sublimaze Preservative Free Intramuscular and Intravenous Injection,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016619
DB00813,,CDC Drug Overdose Deaths 2017,https://www.cdc.gov/drugoverdose/data/statedeaths.html
DB00813,,Government of Canada: Canada's opioid crisis,https://www.canada.ca/en/services/health/campaigns/drug-prevention.html
DB00813,,"FDA Approved Drug Products: ACTIQ® (fentanyl citrate) oral transmucosal lozenge, CII (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020747s062lbl.pdf
DB00814,,FDA approved products: Mobic (meloxicam) oral tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s024s025,021530s014s015lbl.pdf"
DB00814,,Medsafe NZ: Mobictab (meloxicam) oral tablets,https://www.medsafe.govt.nz/profs/Datasheet/m/Mobictab.pdf
DB00814,,American College of Cardiology: Meloxicam,https://www.cardiosmart.org/Healthwise/d045/32/d04532
DB00814,,FDA Approved Drug Products: ZYNRELEF (bupivacaine and meloxicam) extended-release solution for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s005lbl.pdf
DB00814,,FDA Approved Drug Products: Zynrelef (bupivicaine and meloxicam) extended-release solution for instillation (January 2024),https://zynrelef.com/prescribing-information.pdf
DB00818,,FDA Approved Drug Products: DIPRIVAN (propofol) injectable emulsion for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019627s069lbl.pdf
DB00819,,FDA Approved Drug Products: DIAMOX SEQUELS (acetazolamide extended release) oral capsules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/12945s037,038lbl.pdf"
DB00819,,AA Pharma Inc.: ACETAZOLAMIDE Product Monograph,https://pdf.hres.ca/dpd_pm/00045130.PDF
DB00819,,FDA Approved Drug Products: Acetazolamide (for injection),https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205358Orig1s000lbl.pdf
DB00820,,FDA Approved Drug Products: Cialis (tadalafil) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021368s030lbl.pdf
DB00820,,FDA Approved Drug Products: Adcirca (tadalafil) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022332Orig1s011lbl.pdf
DB00820,,DPD Approved Drug Products: Opsynvi (tadalafil/macitentan) combination tablets,https://pdf.hres.ca/dpd_pm/00063187.PDF
DB00820,,Medisca: Tadalafil MSDS,https://www.medisca.com.au/NDC_SPECS/MAU/3062/MSDS/3062.pdf
DB00820,,FDA Approved Drug Products: Entadfi (finasteride/tadalafil) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215423s000lbl.pdf
DB00820,,FDA Approved Drug Products: Opsynvi (macitentan and tadalafil) tablets for oral use,https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/OPSYNVI-pi.pdf
DB00822,,DailyMed: disulfiram tablets,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=b90f8ff4-4fb3-46ab-8149-cb55f24a4044&type=pdf
DB00826,,FDA Approved Drug Products: Natacyn (natamycin) suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050514s009lbl.pdf
DB00828,,FDA Approved Drug Products: Monurol (fosfomycin tromethamine),https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050717s009lbl.pdf
DB00829,,Electronic Medicines Compendium: Diazepam Tablets BP 2mg Monograph,https://www.medicines.org.uk/emc/product/4523/smpc
DB00829,,"Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance a Stable, Non-Aqueous Diazepam, Subcutaneous Injection for Treatment of Acute Repetitive Seizures in Patients with Epilepsy: Press Release",https://globenewswire.com/news-release/2015/10/01/772768/0/en/Xeris-Pharmaceuticals-Awarded-Phase-I-II-NIH-SBIR-Fast-Track-Grant-to-Advance-a-Stable-Non-Aqueous-Diazepam-Subcutaneous-Injection-for-Treatment-of-Acute-Repetitive-Seizures-in-Pat.html
DB00829,,FDA Approved Drug Products Valtoco Diazepam Nasal Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211635s000lbl.pdf
DB00829,,"FDA Approved Drug Products: VALTOCO® (diazepam nasal spray), CIV Jan 2023",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211635s008lbl.pdf
DB00829,,FDA Approved Drug Products: Diastat® AcuDial™ Rectal Delivery System (diazepam rectal gel),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020648s023lbl.pdf
DB00829,,"FDA Approved Drug Products: VALIUM (diazepam) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/013263s097lbl.pdf
DB00829,,FDA Approved Drug Products: DIAZEPAM AUTOINJECTOR,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020124s034lbl.pdf
DB00829,,"FDA Approved Drug Products: DIAZEPAM- diazepam injection, solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b8dc373-fa01-42c9-89af-4e00bf00180a
DB00829,,FDA Approved Drug Products: DIAZEPAM- diazepam oral solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdb839fb-27e5-4a11-aed6-da0a7ab6e996
DB00836,,Thermo Fisher Scientific: Loperamide hydrochloride MSDS,https://www.fishersci.com/store/msds?partNumber=AAJ6016814&productDescription=LOPERAMIDE+HYDROCLRIDE+98%2B+25G&vendorId=VN00024248&countryCode=US&language=en
DB00836,,DailyMed Label: ANTI-DIARRHEAL (loperamide hcl) Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e34f5bbc-e43c-a69e-e94d-ebc319518204
DB00836,,FDA Discontinued Drug Products: IMODIUM (loperamide) Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017690s005lbl.pdf
DB00839,,DailyMed: TOLINASE (tolazamide) tablets,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=aae8b7a4-742a-4bec-a283-31b9408ee1aa&type=pdf
DB00842,,FDA Approved Drug Products: Oxazepam oral capsules,https://genesight.com/wp-content/uploads/2017/05/Serax-FDA-Label.pdf
DB00842,,Health Canada Product Monograph: Oxazepam oral tablets,https://pdf.hres.ca/dpd_pm/00038954.PDF
DB00842,,CaymanChem: Oxazepam MSDS,https://www.caymanchem.com/msdss/15909m.pdf
DB00843,,FDA Approved Drug Products: Aricept/Aricept ODT (donepezil hydrochloride) tablets for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020690s042,021720s014,022568s011lbl.pdf"
DB00843,,"Australian monograph, Donepezil",https://www.sunpharma.com/australia-pi-download/50508/Donepezil
DB00843,,"Pfizer MSDS, Donepezil hydrochloride",https://www.pfizer.com/sites/default/files/products/material_safety_data/PZ00471.pdf
DB00843,,FDA Approved Drug Products: Namzaric (memantine hydrochloride and donepezil hydrochloride) extended-release capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206439s003lbl.pdf
DB00843,,"Pfizer monograph, donepezil",https://www.pfizer.ca/sites/default/files/201612/ARICEPT_PM_E_177353_18Dec2014_R.pdf
DB00843,,FDA Approved Drug Products: Adlarity (donepezil) transdermal system,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212304s000lbl.pdf
DB00844,,"FDA Approved Drug Products: NUBAIN (nalbuphine) injection, for intramuscular, subcutaneous, or intravenous use (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018024s043lbl.pdf
DB00845,,FDA Approved Drug Products: Lamprene (clofazimine) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
DB00845,,CaymanChem: Clofazimine MSDS,https://www.caymanchem.com/msdss/23301m.pdf
DB00847,,"PRN News Wire: U.S. FDA Approves CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystinosis",https://www.prnewswire.com/news-releases/us-fda-approves-cystadrops-cysteamine-ophthalmic-solution-0-37-a-new-practical-treatment-option-for-the-ocular-manifestations-of-cystinosis-301118026.html
DB00847,,FDA Approved Products: Cystadrops (cysteamine solution 0.37%) for ophthalmic use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211302s000lbl.pdf
DB00847,,FDA approved products: CYSTARAN (cysteamine 0.44%) for ophthalmic use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200740s000lbl.pdf
DB00847,,FDA approved products: PROCYSBI (cysteamine bitartrate) delayed-release oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203389s000lbl.pdf
DB00847,,FDA Approved Products: CYSTAGON® (cysteamine bitartrate) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020392s010lbl.pdf
DB00848,,FDA approval: Levamisole,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020035
DB00852,,FDA Approved Drug Products: Zyrtec Cetirizine and Pseudoephedrine Oral Tablets (OTC),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19835slr016,21150slr005,30346slr011_zyrtec_lbl.pdf"
DB00852,,FDA Approved Drug Products: Motrin Cold and Sinus Ibuprofen and Pseudoephedrine Oral Caplets (OTC),https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019899Orig1s019lbl.pdf
DB00852,,FDA Approved Drug Products: Semprex Avacristine and Pseudoephedrine Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019806s013lbl.pdf
DB00852,,FDA Approved Drug Products: Mucinex Guaifenesin and Pseudoephedrine Oral Extended Release Tablets (OTC),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021620Orig1s038,021585Orig1s033lbl.pdf"
DB00852,,FDA Approved Drug Products: Loratadine and Pseudoephedrine Oral Extended Release Tablets (OTC),https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/75706_Loratadine%20And%20Pseudoephedrine%20Sulfate_Prntlbl.pdf
DB00852,,FDA Approved Drug Products: Clarinex 12 Hour Desloratadine and Pseudoephedrine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021313s012lbl.pdf
DB00852,,FDA Approved Drug Products: Clarinex 24 Hour Desloratadine and Pseudoephedrine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021605s017lbl.pdf
DB00853,,FDA Approved Drug Products: TEMODAR (temozolomide) capsules and injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022277s013lbl.pdf
DB00853,,Cayman Chemical: temozolomide MSDS,https://www.caymanchem.com/msdss/14163m.pdf
DB00853,,FDA Approved Drug Products: TEMODAR (temozolomide) capsules and injection (September 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021029s036_037_038lbl.pdf
DB00855,,"FDA Approved Drug Products: AMELUZ (aminolevulinic acid hydrochloride) topical gel, 10% (October 2023)",https://www.accessdata.fda.gov/spl/data/48fe5174-9f24-4a2a-996c-0e90bf58f9fc/48fe5174-9f24-4a2a-996c-0e90bf58f9fc.xml
DB00855,,"FDA Approved Drug Products: AMELUZ (aminolevulinic acid hydrochloride) gel, 10%, for topical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208081s011lbl.pdf
DB00855,,"FDA Approved Drug Products: LEVULAN KERASTICK (aminolevulinic acid HCl) for topical solution, 20%",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020965s016lbl.pdf
DB00855,,FDA Approved Drug Products: GLEOLAN [aminolevulinic acid hydrochloride (ALA HCl)] for oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208630s003lbl.pdf
DB00855,,"FDA Approved Drug Products: LEVULAN®KERASTICK™ (aminolevulinic acid HCl) for Topical Solution, 20%",https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20965lbl.pdf
DB00857,,FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Topical Cream (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020192
DB00857,,FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf
DB00857,,"Health Canada Approved Drug Products: Lamisil Terbinafine Oral Tablets, Topical Cream, and Topical Spray",https://pdf.hres.ca/dpd_pm/00035035.PDF
DB00857,,Cayman Chemicals: Terbinafine MSDS,https://www.caymanchem.com/msdss/10011619m.pdf
DB00860,,FDA Approved Drug Products: Delta-Cortef Prednisolone Oral Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009987
DB00860,,FDA Approved Drug Products: Prednisolone Oral Syrup,https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40287_Prednisolone_Prntlbl.pdf
DB00860,,Cayman Chemicals: Prednisolone MSDS,https://www.caymanchem.com/msdss/20866m.pdf
DB00860,,FDA Approved Drug Products: Prednisolone Acetate Oral Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022067s007lbl.pdf
DB00860,,FDA Approved Drug Products: Prednisolone Acetate Ophthalmic Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017100s045lbl.pdf
DB00860,,FDA Approved Drug Products: Orapred Prednisolone Sodium Phosphate Orally Disintegrating Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf
DB00860,,FDA Approved Drug Products: Pediapred Prednisolons Sodium Phosphate Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019157s021lbl.pdf
DB00860,,EMA Approved Drug Products: Lynparza (olaparib) Oral Tablets (March 2023),https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf
DB00862,,FDA Approved Drug Products: LEVITRA (vardenafil hydrochloride) tablets for oral use (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021400s023lbl.pdf
DB00862,,FDA Approved Drug Products: STAXYN (vardenafil hydrochloride) orally disintegrating tablets (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/200179s005lbl.pdf
DB00862,,Health Canada Approved Drug Products: STAXYN (vardenafil) orally disintegrating tablets (February 2020),https://pdf.hres.ca/dpd_pm/00055198.PDF
DB00863,,FDA drug approval package: Zantac,https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/18703S56_zantac.cfm
DB00863,,FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019090s053,019593s042lbl.pdf"
DB00863,,GlaxoSmithKline Canada Inc. Product Monograph: Zantac (ranitidine),https://ca.gsk.com/media/592906/zantac.pdf
DB00863,,Ranitidine product monograph,https://pdf.hres.ca/dpd_pm/00043712.PDF
DB00864,,FDA Approved Drug Products: Prograf (tacrolimus) capsules/granules for oral use and injection for intravenous administration,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050708s050,050709s042,210115s002lbl.pdf"
DB00864,,FDA Approved Drug Products: Astagraf XL (tacrolimus) extended-release capsules for oral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204096s009lbl.pdf
DB00864,,FDA Approved Drug Products: Envarsus XR (tacrolimus) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206406s008lbl.pdf
DB00864,,FDA Approved Drug Products: Protopic (tacrolimus) topical ointment,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf
DB00868,,DailyMed Label: Benzonatate Oral Capsules,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6de49806-eceb-4fc5-a90c-5d00c9025ae0
DB00868,,Cayman Chemical: Benzonatate MSDS,https://www.caymanchem.com/msdss/23936m.pdf
DB00869,,FDA Approved Drug Products: TRUSOPT (dorzolamide hydrochloride) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020408s050lbl.pdf
DB00869,,"FDA Approved Drug Products: COSOPT PF (dorzolamide hydrochloride, timolol maleate) ophthalmic solution",https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202667s000lbl.pdf
DB00869,,Cayman Chemical Safety Data Sheet: Dorzolamide (hydrochloride),https://www.caymanchem.com/msdss/14616m.pdf
DB00870,,NIH DailyMed: Suprofen,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8de2c303-5d99-46b6-ad6d-a4caadea3604
DB00871,,FDA Approved Drug Products: Bricanyl (Terbutaline Sulfate) Injection,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017466
DB00871,,Dailymed: Terbutaline Sulfate Subcutaneous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ae8fb3d-9df3-4948-bb07-6e4169521f15
DB00871,,Dailymed: Terbutaline Sulfate Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=382dcebb-6e41-4335-818d-b5822e3fb884
DB14596,,Electronic Medicines Compendium: Loteprednol etabonate Monograph,https://www.medicines.org.uk/emc/product/6212
DB14596,,Inveltys FDA Approval Press Release,https://www.drugs.com/newdrugs/fda-approves-inveltys-loteprednol-etabonate-post-operative-inflammation-pain-following-ocular-4808.html?utm_source=ddc&utm_medium=email&utm_campaign=Today%27s+news+summary+-+August+24%2C+2018&utm_content=FDA+Approves+Inveltys+%28loteprednol+etabonate%29+for+Post-Operative+Inflammation+and+Pain+Following+Ocular+Surgery
DB14596,,FDA Approved Drug Products: Eysuvis (loteprednol etabonate) ophthalmic suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210933s000lbl.pdf
DB00874,,MyHealth.Alberta.ca Network: Guaifenesin - Oral Profile,https://myhealth.alberta.ca/Health/medications/Pages/conditions.aspx?hwid=fdb0118&
DB00874,,Electronic Medicines Compendium: Robitussin Chesty Cough Medicine Monograph,https://www.medicines.org.uk/emc/product/3879/smpc
DB00875,,"Lundbeck Canada Inc. Product Monograph: FLUANXOL (Flupentixol), as oral tablets or intramuscular injection",https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Fluanxol%20PM%20EN%2012Dec%202017.pdf
DB00875,,MP Biomedicals Australasia Pty Limited: cis(Z)-FLUPENTHIXOL Material Safety Data Sheet,http://www.t3db.ca/system/msds/attachments/000/002/311/original/T3D2920.pdf?1414204320
DB00875,,Summary of Product Characteristics: Deanxit (flupentixol and melitracen) oral tablets,https://www.papaloizou.com/PublicDocsPDF/SPCs/Deanxit_SPC.pdf
DB00875,,Package Leaflet: Fluanxol (flupentixol) oral tablets,https://www.medicines.org.uk/emc/files/pil.998.pdf
DB00875,,British Pharmacopoeia: Flupentixol Hydrochloride Safety data sheet,https://www.pharmacopoeia.com/Catalogue/Preview?uri=/content/file/products/healthandsafety/Cat-1132_GB.pdf
DB00876,,FDA Approved Drug Products: Teveten HCT (eprosartan mesylate/hydrochlorothiazide) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021268s019lbl.pdf
DB00877,,FDA Approved Drug Products: RAPAMUNE (sirolimus) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021083s069s070,021110s087s088lbl.pdf"
DB00877,,"FDA Approved Drug Products: FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213312lbl.pdf
DB00877,,"Pfizer News: PFIZER’S RAPAMUNE® (SIROLIMUS) BECOMES FIRST FDA-APPROVED TREATMENT FOR LYMPHANGIOLEIOMYOMATOSIS (LAM), A RARE PROGRESSIVE LUNG DISEASE","https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_rapamune_sirolimus_becomes_first_fda_approved_treatment_for_lymphangioleiomyomatosis_lam_a_rare_progressive_lung_disease#:~:text=Pfizer%20Inc.,kidneys%20and%20the%20lymphatic%20system."
DB00877,,ThermoFischer Scientific: Rapamycin MSDS,https://www.fishersci.com/store/msds?partNumber=BP29631&productDescription=RAPAMYCIN&vendorId=VN00033897&countryCode=US&language=en
DB00877,,Pfizer: RAPAMUNE MSDS,https://pfe-pfizercom-prod.s3.amazonaws.com/products/material_safety_data/sirolimus_tablets_21-march-2018.pdf
DB00877,,EMA Summary of Product Characteristics: Rapamune (sirolimus) Oral Solution,https://www.ema.europa.eu/en/documents/product-information/rapamune-epar-product-information_en.pdf
DB00877,,FDA Approved Drug Products: HYFTOR (sirolimus topical gel),https://hyftorpi.com/wp-content/uploads/2022/04/HYFTOR_Approved-PI-PPI_3.22-1-2.pdf
DB00877,,BioSpace News: FDA approves Nobelpharma's HYFTOR™ (sirolimus topical gel) 0.2%,https://www.biospace.com/article/releases/fda-approves-nobelpharma-s-hyftor-sirolimus-topical-gel-0-2-percent-/?s=74
DB00878,,Health Canada Product Monograph: Peridex (chlorhexidine gluconate) oral rinse,https://pdf.hres.ca/dpd_pm/00004798.PDF
DB00878,,FDA Approved Drug Products: Peridex (chlorhexidine gluconate) oral rinse,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s020lbl.pdf
DB00878,,FDA Approved Drug Products: Avagard (chlorhexidine/ethyl alcohol) topical solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021074Orig1s012lbl.pdf
DB00878,,FDA Approved Drug Products: Pre-Scrub (chlorhexidine gluconate) topical scrub,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019822Orig1s008lbl.pdf
DB00878,,FDA Approved Drug Products: ChloraPrep One-Step (chlorhexidine/isopropyl alcohol) topical swab,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/21555Orig1s024lbl.pdf
DB00878,,FDA Approved Drug Products: Chlorhexidine gluconate topical cloth,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021669Orig1s023lbl.pdf
DB00878,,FDA Approved Drug Products: PerioChip (chlorhexidine gluconate) chip for oral insertion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020774s012lbl.pdf
DB00878,,CaymanChem: Chlorhexidine MSDS,https://www.caymanchem.com/msdss/17343m.pdf
DB00878,,WHO Guidelines on Hand Hygiene in Health Care (2009),https://apps.who.int/iris/bitstream/handle/10665/44102/9789241597906_eng.pdf;jsessionid=E945C08B4281AF2C17706CBFAA43FD18?sequence=1
DB00878,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00878,,Federal Register: Determination that Chlorhexidine Gluconate Topical Tincture 0.5% Was Withdrawn From Sale for Reasons of Safety,https://www.govinfo.gov/content/pkg/FR-1997-10-06/pdf/97-26353.pdf
DB00879,,FDA Press Announcements: FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic,https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic
DB00879,,FDA Approved Drug Products: Emtriva (Emtricitabine) Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021500s029lbl.pdf
DB00879,,FDA Approved Drug Products: Descovy (Emtricitabine and Tenofovir Alafenamide) Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208215s012lbl.pdf
DB00879,,Cayman Chemicals: Emtricitabine MSDS,https://www.caymanchem.com/msdss/16879m.pdf
DB00879,,FDA Approved Drug Products: Truvada (emtricitabine and tenofovir disoproxil fumarate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021752s061lbl.pdf
DB00879,,"FDA Approved Drug Products: Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210455s004lbl.pdf
DB00879,,"FDA Approved Drug Products: Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203100s036lblet.pdf
DB00879,,"FDA Approved Drug Products: Odefsey (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208351s006lbl.pdf
DB00879,,"FDA Approved Drug Products: Genvoya (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207561s023lbl.pdf
DB00879,,"FDA Approved Drug Products: Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202123s031lbl.pdf
DB00879,,"FDA Approved Drug Products: Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide) Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210251s006lbl.pdf
DB00879,,"FDA Approved Drug Products: Atripla (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021937s044lbl.pdf
DB00879,,"EMA Approved Drug Products: Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) Oral Tablets",https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_en.pdf
DB00881,,FDA Approved Drug Products: Quinapril Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019885s043lbl.pdf
DB00881,,FDA Approved Drug Products: Quinapril and Hydrochlorothiazide Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020125s022lbl.pdf
DB00881,,Cayman Chemicals: Quinapril MSDS,https://www.caymanchem.com/msdss/21439m.pdf
DB00881,,Pfizer Canada: Quinapril Oral Tablets,https://pdf.hres.ca/dpd_pm/00038674.PDF
DB00883,,FDA Approved Products: Bidil (isosorbide dinitrate and hydralazine hydrochloride) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020727lbl.pdf
DB00884,,Risedronate Sodium Tablet MSDS,https://www.greenstonellc.com/sites/default/files/pdfs/MSDS/RISEDRONATE%20SODIUM%20TABLETS%20MSDS_0.pdf
DB00884,,FDA Approved Drugs: Risedronic Acid Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020835s048lbl.pdf
DB00884,,FDA Approved Drug Products: Risedronic Acid Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022560s007lbl.pdf
DB00893,,Iron dextran FDA LABEL,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017441s171lbl.pdf
DB00899,,"FDA Approved Drug Products: ULTIVA® (remifentanil hydrochloride), for injection, for intravenous use, CII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020630s030lbl.pdf
DB00904,,Electronic Medicines Compendium: Zofran (ondansetron hydrochloride dihydrate) Tablets 4mg and 8mg Monograph,https://www.medicines.org.uk/emc/product/195/smpc
DB00904,,"Midatech’s Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in US: Press Release",https://www.cnbc.com/2016/04/11/globe-newswire-midatechas-commercial-launch-of-zuplenza-ondansetron-oral-soluble-film-to-prevent-post-operative-chemotherapy-and-radiation.html
DB00904,,"Federal Register: Determination That Ondansetron (Ondansetron Hydrochloride) Injection, USP in PL 2408 Plastic Container, 32 Milligrams in 50 Milliliters, Was Withdrawn From Sale for Reasons of Safety or Effectiveness",https://www.federalregister.gov/documents/2015/06/10/2015-14145/determination-that-ondansetron-ondansetron-hydrochloride-injection-usp-in-pl-2408-plastic-container
DB00904,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00905,,FDA Approved Drug Products: Lumigan (bimatoprost) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022184s006lbl.pdf
DB00905,,"Allergen monograph, Bimatoprost",https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf
DB00905,,Bitamaprost MedSafe NZ,https://medsafe.govt.nz/Profs/Datasheet/b/BimatoprostMultichemeyedrops.pdf
DB00905,,Latisse FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022369s005lbl.pdf
DB00905,,FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s002s003lbl.pdf
DB00905,,"Bimataprost metabolism, MDPI",https://www.mdpi.com/1420-3049/12/3/373/htm
DB00905,,CaymanChem: Bimatoprost MSDS,https://www.caymanchem.com/msdss/10008027m.pdf
DB00905,,FDA Approved Products: Durysta (bimatoprost) implant for intracameral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211911s000lbl.pdf
DB00907,,FDA Approved Products: Numbrino (cocaine hydrochloride) nasal solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209575s000lbl.pdf
DB00907,,FDA Approved Products: Goprelto (cocaine hydrochloride) nasal solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf
DB00907,,DailyMed: Cocaine hydrochloride solution,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=24faa247-fe12-4574-881d-445b078b3e87&type=display
DB00908,,FDA Approved Drug Products: Quinidex Extentabs (quinidine sulfate) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/12796s49lbl.pdf
DB00908,,FDA Approved Drug Products: Quinidine gluconate extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/089338s036lbl.pdf
DB00909,,FDA Approved Drug Products: ZONEGRAN (zonisamide) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020789s036lbl.pdf
DB00909,,FDA Approved Drug Products: ZONISADE (zonisamide) suspension for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214273s000lbl.pdf
DB00911,,FDA Approved Drug Products: Tindamax (tinidazole) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021618s008lbl.pdf
DB00912,,FDA Approved Drug Products: PRANDIN (repaglinide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020741s044lbl.pdf
DB00916,,FDA Approved Drug Products: Flagyl (metronidazole) capsules for oral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020334s008lbl.pdf
DB00916,,"FDA approvals, Metronidazole",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012623
DB00916,,"Canadian monograph, Flagyl",http://products.sanofi.ca/en/flagyl.pdf
DB00916,,Flagyl,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012623s061lbl.pdf
DB00916,,DailyMed: Flagyl (metronidazole) oral tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b39cc0e4-57ad-4d70-a105-44ebccf201f8
DB00916,,FDA Approved Drug Products: Metronidazole gel (January 2023),https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0d7d4e8-28c0-4211-8d76-73a173b48d9a
DB00916,,"FDA Approved Drug Products: FLAGYL (metronidazole) tablets, for oral use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/012623s070lbl.pdf
DB00916,,DailyMed: Metronidazole Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d99119c9-eab3-4126-9e6e-4d6a9cdf4002
DB00916,,DailyMed: Metronidazole Oral Capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9b4c86c-932b-4b43-ab1a-6d9e07958044
DB00916,,FDA Approved Drug Products: LIKMEZ (metronidazole) oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216755s000lbl.pdf
DB00918,,FDA Approved Drug Products: Almotriptan Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf
DB00920,,FDA Approved Drug Products: Zaditor (ketotifen fumarate) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21066lbl.pdf
DB00920,,Health Canada Product Monograph: Zaditen (ketotifen fumarate) for oral administration,https://pdf.hres.ca/dpd_pm/00017437.PDF
DB00921,,"FDA Approved Drug Products: Bunavail (buprenorphine and naloxone) Sublingual, Buccal Film",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205637s023s024lbl.pdf
DB00921,,FDA Approved Drug Products: BRIXADI (buprenorphine) extended-release injection for subcutaneous use CIII (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210136Orig1s000lbl.pdf
DB00921,,"FDA Approved Drug Products: BUPRENEX (buprenorphine hydrochloride) injection, for intravenous or intramuscular administration, CIII (June 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018401s026lbl.pdf
DB00921,,"FDA Approved Drug Products: SUBOXONE (buprenorphine and naloxone) sublingual tablets, CIII (June 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020733s031s032lbl.pdf
DB00921,,"FDA Approved Drug Products: BELBUCA (buprenorphine buccal film), CIII (June 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207932s019s020lbl.pdf
DB00921,,"FDA Approved Drug Products: BUTRANS (buprenorphine) transdermal system, CIII (June 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021306s039lbl.pdf
DB00921,,"FDA Approved Drug Products: SUBLOCADE (buprenorphine extended‐release) injection, for subcutaneous use, CIII (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209819s028lbl.pdf
DB00924,,CaymenChem: Cyclobenzaprine hydrochloride MSDS,https://www.caymanchem.com/msdss/15885m.pdf
DB00924,,FDA Approved Drugs: Cyclobenzaprine,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017821s051lbl.pdf
DB00924,,DPD Approved Drugs: Cyclobenzaprine,https://pdf.hres.ca/dpd_pm/00038944.PDF
DB00927,,"FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
DB00927,,"Mylan Pharmaceuticals Product Monograph: Famotidine, for intravenous injection",https://pdf.hres.ca/dpd_pm/00025674.PDF
DB00927,,Cayman Chemical: Famotidine MSDS,https://www.caymanchem.com/msdss/23828m.pdf
DB00927,,Famotidine - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK534778/
DB00927,,Prophylaxis and management of stress ulceration - NCBI,https://www.ncbi.nlm.nih.gov/books/NBK6992/
DB00928,,FDA Approved Drug Products: ONUREG (azacitidine) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214120s000lbl.pdf
DB00928,,Health Canada Product Monograph: VIDAZA (azacitidine) injection,http://media.celgene.com/content/uploads/sites/23/Vidaza-Product_Monograph_-_English_Version.pdf
DB00928,,"FDA Approved Drug Products: VIDAZA (azacitidine) injection, subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050974s034lbl.pdf
DB00928,,"FDA Approved Drug Products: VIDAZA (azacitidine) injection, subcutaneous or intravenous use (September 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050794s035lbl.pdf
DB00928,,Celgene: Azacitidine SDS,https://packageinserts.bms.com/sds/sds_vidaza.pdf
DB00929,,Cayman Chemicals: Misoprostol MSDS,https://www.caymanchem.com/msdss/13820m.pdf
DB00929,,FDA Approved Drug Products: Misoprostol Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019268s051lbl.pdf
DB00929,,FDA Approved Drug Products: Misoprostol and Diclofenac Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020607s031lbl.pdf
DB00935,,Drugs.com: FDA Approves Upneeq,https://www.drugs.com/newdrugs/fda-approves-upneeq-oxymetazoline-hydrochloride-ophthalmic-solution-acquired-blepharoptosis-droopy-5297.html
DB00935,,FDA Approved Drug Products: KOVANAZE (tetracaine HCl and oxymetazoline HCl) Nasal Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208032s000lbl.pdf
DB00935,,"FDA Approved Drug Products: RHOFADE (oxymetazoline hydrochloride) cream, for topical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf
DB00935,,"FDA Approved Drug Products: UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/0212520s000lbl.pdf
DB00935,,Cayman Chemical: Oxymetazoline Safety Data Sheet,https://www.caymanchem.com/msdss/23826m.pdf
DB00935,,"DailyMed Label: AFRIN NO DRIP ORIGINAL PUMP MIST- oxymetazoline hydrochloride spray, metered",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=530b2d27-5883-489e-87fa-90b45eb93b3c
DB00935,,StatPearls: Alpha 1 Receptor Agonists,https://www.ncbi.nlm.nih.gov/books/NBK551698/
DB00936,,"FDA Approved Drug Products: HELIDAC Therapy (bismuth subsalicylate, metronidazole, and tetracycline)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050719s017s020lbl.pdf
DB00938,,FDA Approved Drug Products: Serevent Salmeterol Xinafoate Inhaled Metered Aerosol (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020236
DB00938,,FDA Approved Drug Products: Wixela Inhub Fluticasone and Salmeterol Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208891Orig1s000lbl.pdf
DB00938,,FDA Approved Drug Products: Serevent Diskus Salmeterol Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf
DB00938,,FDA Approved Drug Products: Airduo Respiclick Fluticasone and Salmeterol Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208799s001lbl.pdf
DB00938,,FDA Approved Drug Products: Advair HFA Fluticasone and Salmeterol Inhalation Aerosol,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021254s028lbl.pdf
DB00938,,FDA Approved Drug Products: Advair Diskus Fluticasone and Salmeterol Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021077s061lbl.pdf
DB00938,,Cayman Chemical: Salmeterol MSDS,https://www.caymanchem.com/msdss/16009m.pdf
DB00945,,Mayo Clinic website: Salicylate,https://www.mayoclinic.org/drugs-supplements/salicylate-oral-route-rectal-route/proper-use/drg-20070551
DB00945,,Health Canada Product Monograph: Aspirin (acetylsalicylic acid) for oral administration,https://pdf.hres.ca/dpd_pm/00000653.PDF
DB00945,,"FDA Approved Drug Products: SYNALGOS®-DC (aspirin, caffeine, and dihydrocodeine bitartrate) capsules, for oral use, CIII (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/011483s035lbl.pdf
DB00950,,DPD Approved Drugs: Allegra® oral tablets,https://pdf.hres.ca/dpd_pm/00053954.PDF
DB00950,,Allegra (Fexofenadine Hydrochloride) FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020872s018,021963s002lbl.pdf"
DB00950,,FDA Approved Drug Products: Allegra-D® extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020786s026lbl.pdf
DB00951,,"FDA Approved Drug Products: RIFATER (rifampin, isoniazid and pyrazinamide USP) tablets (February 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050705s022lbl.pdf
DB00953,,"FDA Approved Drug Products: MAXALT (rizatriptan benzoate) tablets, for oral use and MAXALT-MLT (rizatriptan benzoate) orally disintegrating tablets (October 2019)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020864s023,020865s024lbl.pdf"
DB00953,,FDA Approved Drug Products: RizaFilm (rizatriptan) oral film,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205394s000lbl.pdf
DB00953,,Organon: Rizatriptan MSDS,https://www.organon.com/docs/product/safety-data-sheets/Rizatriptan%20Formulation_HH_US_EN.pdf
DB00953,,Health Canada Approved Drug Products: ACT RIZATRIPTAN (Rizatriptan) Oral Tablets,https://pdf.hres.ca/dpd_pm/00056193.PDF
DB00953,,Health Canada Approved Drug Products: ACCEL-RIZATRIPTAN ODT (Rizatriptan) Orally Disintegrating Tablets,https://pdf.hres.ca/dpd_pm/00048445.PDF
DB00956,,FDA Label: Hydrocodone Tab ER,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf
DB00956,,DPD Monograph: Dimetane Syrup,https://pdf.hres.ca/dpd_pm/00045954.PDF
DB00956,,Drugs@FDA: Hycodan,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005213
DB00956,,"FDA Approved Drug Products: HYSINGLA® ER (hydrocodone bitartrate) extended-release tablets, for oral use, CII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206627s015lbl.pdf
DB00957,,FDA Approved Drug Products: Ortho Cyclen Norgestimate and Ethinyl Estradiol Oral Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019653
DB00957,,FDA Approved Drug Products: Ortho Tri-Cyclen Norgestimate and Ethinyl Estradiol Oral Tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019653s058,019697s054lbl.pdf"
DB00957,,FDA Approved Drug Products: Ortho Tri-Cyclen Lo Norgestimate and Ethinyl Estradiol Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021241s027lbl.pdf
DB00958,,FDA Approved Drug Products: Paraplatin (Carboplatin) Intravenous Injection (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019880
DB00958,,Dailymed: Carboplatin Intravenous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6
DB00959,,FDA Approved Drug Products: Medrol Methylprednisolone Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011153s075lbl.pdf
DB00959,,FDA Approved Drug Products: Depo-Medrol Methylprednisolone Acetate Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011757s114lbl.pdf
DB00959,,Cayman Chemicals: Methylprednisolone MSDS,https://www.caymanchem.com/msdss/15013m.pdf
DB00959,,Efficacy and Safety of Corticosteroids in COVID-19,https://clinicaltrials.gov/ct2/show/NCT04273321
DB00960,,FDA Approved Drug Products: Visken (Pindolol) Oral Tablets,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018285
DB00960,,Dailymed: Pindolol Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=611be921-e9b6-4800-80b2-c2d4f677cdb2
DB00960,,Health Canada Approved Drug Products: Apo-Pindolol (Pindolol) Oral Tablet,https://pdf.hres.ca/dpd_pm/00047827.PDF
DB00963,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB00965,,Link,http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=355795
DB00966,,FDA Approved Drug Products: MICARDIS (telmisartan) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020850s045lbl.pdf
DB00966,,McKesson: Telmisartan SDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/MSDS_9BEHGI_MICARDIS_HCT.pdf
DB00968,,"DailyMed Label: METHYLDOPA oral tablet, film coated",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00206aae-7db1-4ae9-8500-b03fd6788d74
DB00968,,DailyMed Label: METHYLDOPA AND HYDROCHLOROTHIAZIDE oral tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bf74178-66b8-44d4-a87d-1fd760b94ad3
DB00968,,DailyMed Label: Methyldopate Intravenous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd
DB00968,,Cayman Chemical: Methyldopa Safety Data Sheet,https://www.caymanchem.com/msdss/21814m.pdf
DB00972,,FDA Approved Drug Product: Azelastine nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020114s028lbl.pdf
DB00972,,FDA Approved Drugs: Azelastine ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021127s013lbl.pdf
DB00972,,CaymenChem: Azelastine MSDS,https://www.caymanchem.com/msdss/20873m.pdf
DB00972,,FDA Approved Drugs: Dymista nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202236s010lbl.pdf
DB00972,,FDA News Release: Astepro OTC Approval,https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-antihistamine-nonprescription-use?utm_medium=email&utm_source=govdelivery
DB00973,,FDA Approved Drug Products: Zetia (ezetimibe) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021445s033lbl.pdf
DB00973,,FDA Approved Drug Products: Liptruzet (ezetimibe/atorvastatin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/200153s005lbl.pdf
DB00973,,FDA Approved Drug Products: Vytorin (ezetimibe/simvastatin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021687s062lbl.pdf
DB00973,,CaymanChem: Ezetimibe MSDS,https://www.caymanchem.com/msdss/16331m.pdf
DB00973,,Health Canada Product Monograph: Ezetimibe oral tablets,https://pdf.hres.ca/dpd_pm/00028732.PDF
DB00973,,FDA Approved Products: Nexlizet (bempedoic acid and ezetimibe) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211617s000lbl.pdf
DB00977,,FDA Approved Drug Products: Estinyl Ethinylestradiol Oral Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005292
DB00977,,FDA Approved Drug Products: Yaz Ethinylestradiol and Drospirenone Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021676s019lbl.pdf
DB00977,,FDA Approved Drug Products: Taytulla Ethinylestradiol and Norethindrone Acetate Oral Capsules and Ferrous Fumarate Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204426s007lbl.pdf
DB00977,,"FDA Approved Drug Products: Safyral Ethinylestradiol, Drospirenons, and Levomefolate Calcium Oral Tablets and Levomefolate Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022574s009lbl.pdf
DB00977,,FDA Approved Drugs: Nuvaring® vaginal ring,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021187s037lbl.pdf
DB00977,,FDA Approved Drug Products: Lo Ovral 28 Ethinylestradiol and Norgestrel Oral Tablets and Ferrous Fumarate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018206s020lbl.pdf
DB00977,,FDA Approved Drug Products: Femhrt® tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021065s024lbl.pdf
DB00977,,FDA Approved Drug Products: Estrostep Fe Ethinylestradiol and Norethindrone Oral Tablets and Ferrous Fumarate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020130s018lbl.pdf
DB00977,,FDA Approved Drug Products: Cyclessa Ethinylestradiol and Desogestrel Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021090s008lbl.pdf
DB00977,,FDA Approved Drug Products: Annovera Ethinylestradiol and Segesterone Acetate Vaginal System,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
DB00977,,FDA Approved Drug Products: Ortho Tri-Cyclen Norgestimate and Ethinyl Estradiol Oral Tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019653s058,019697s054lbl.pdf"
DB00977,,FDA Approved Drug Products: Seasonale Ethinylestradiol and Levonorgestrel Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021544s013lbl.pdf
DB00977,,FDA Approved Drug Products: LOSEASONIQUE® (levonorgestrel and ethinyl estradiol tablets; and ethinyl estradiol tablets) for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022262s003s004lbl.pdf
DB00978,,FDA Approved Products: Maxaquin (lomeafloxacin hydrochloride) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20013s015lbl.pdf
DB00979,,Link,http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202173.html
DB00982,,FDA Approved Drug Products: Accutane Oral Capsule,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018662
DB00982,,FDA Approved Drug Products: Absorica,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021951
DB00982,,iPLEDGE Program Home Page,https://www.ipledgeprogram.com/iPledgeUI/home.u
DB00982,,New Zealand Drug Data Sheet: Oratane,https://medsafe.govt.nz/profs/Datasheet/o/oratanecap.pdf
DB00982,,Isotretinoin MSDS,https://www.caymanchem.com/msdss/21648m.pdf
DB00982,,Health Canada Product Monograph: Accutane Roche (isotretinoin) capsules for oral administration,https://pdf.hres.ca/dpd_pm/00052764.PDF
DB00983,,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf
DB00983,,FDA Approved Drug Products: Bevespi Aerosphere inhalation aerosol,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208294s005lbl.pdf
DB00983,,FDA Approved Drug Products: Duaklir® Pressair® inhalation powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210595lbl.pdf
DB00983,,FDA Approved Drug Products: Dulera® inhalation aerosol,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022518s026lbl.pdf
DB00983,,FDA Approved Drug Products: Foradil® Aerolizer inhalation powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20831s2lbl.pdf
DB00983,,FDA Approved Drug Products: Symbicort (budesonide/formoterol fumarate) inhalation aerosol,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s042lbl.pdf
DB00983,,Health Canada Product Monograph: Oxeze (formoterol) dry powder inhaler,https://pdf.hres.ca/dpd_pm/00044980.PDF
DB00983,,CaymanChem: Formoterol MSDS,https://www.caymanchem.com/msdss/15584m.pdf
DB00983,,Global Initiative for Asthma: 2019 Guidelines Pocket Guide,https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf
DB00984,,InChem Data Sheet,http://www.inchem.org/documents/pims/pharm/pim909.htm
DB00985,,FDA Approved Drug Products: Dimenhydrinate Oral Liquid (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=080715
DB00985,,Dailymed: Dimenhydrinate Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b32c52a-f2b0-4acc-e053-2a91aa0a5bcc
DB00985,,Dailymed: Dimenhydrinate Intramuscular and Intravenous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc71539e-1a33-4709-8a24-c2894e8dbc1c
DB00985,,US Patent: US2499058A,https://patents.google.com/patent/US2499058
DB00985,,Sandoz Canada: Dimenhydrinate Intramuscular and Intravenous Injection,https://www.sandoz.ca/sites/www.sandoz.ca/files/Dimenhydrinate%20Product%20Monograph.pdf
DB00985,,Heads of Medicines Agencies Public Assessment Report: Dimenhydrinate Oral Lozenge,https://mri.cts-mrp.eu/human/downloads/DK_H_2835_001_PAR.pdf
DB00986,,FDA Approved Drug Products: Robinul (Glycopyrrolate) Oral Tablet (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012827
DB00986,,US Patent: US2956062A,https://patentimages.storage.googleapis.com/d5/d2/d7/3faf3716058474/US2956062.pdf
DB00986,,FDA Approved Drug Products: Qbrexza (Glycopyrronium Tosylate) Topical Cloth,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf
DB00986,,FDA Approved Drug Products: Lonhala Magnair (Glycopyrronium) Inhalation Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208437s003lbl.pdf
DB00986,,Cayman Chemical: Glycopyrrolate MSDS,https://www.caymanchem.com/msdss/16498m.pdf
DB00986,,FDA Assessment Report: Seebri Neohaler (Glycopyrronium) Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207923Orig1s000ClinPharmR.pdf
DB00986,,EMA Assessment Report: Seebri Breezhaler (Glycopyrronium) Inhalation Powder,https://www.ema.europa.eu/en/documents/assessment-report/seebri-breezhaler-epar-public-assessment-report_en.pdf
DB00986,,FDA Approved Drug Products: Glyrx-PF (Glycopyrronium) Intravenous or Intramuscular Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210997s000lbl.pdf
DB00986,,FDA Approved Drug Products: Cuvposa (Glycopyrronium) Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022571s008lbl.pdf
DB00986,,"FDA Approved Drug Products: Breztri Aerosphere (Budesonide, Glycopyrronium, and Formoterol Fumarate) Inhalation Aerosol",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212122s000lbl.pdf
DB00986,,FDA Approved Drug Products: Bevespi Aerosphere (Glycopyrronium and Formoterol Fumarate) Inhalation Aerosol,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208294s009lbl.pdf
DB00986,,FDA Approved Drug Products: Dartisla ODT (glycopyrrolate) orally-disintegrating tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215019s000lbl.pdf
DB00987,,Health Canada Product Monograph: Cytarabine injection,https://pdf.hres.ca/dpd_pm/00041024.PDF
DB00987,,"FDA Approved Drug Products: VYXEOS (daunorubicin and cytarabine) liposome for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209401s006lbl.pdf
DB00993,,FDA Approved Drug Products: Imuran Azathioprine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016324s039lbl.pdf
DB00994,,FDA Approved Drug Products: Neo-Fradin (Neomycin Sulfate) Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/065010s002lbl.pdf
DB00994,,"FDA Approved Drug Products: Casporyn Neomycin Sulfate, Polymixin B Sulfate, and Hydrocortisone Otic Drops",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/060613s013lbl.pdf
DB00994,,"FDA Approved Drug Products: Maxitrol Neomycin, Polymyxin B, and Dexamethasone Ophthalmic Suspension",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050023s036lbl.pdf
DB00994,,Cayman Chemical: Neomycin sulfate Safety Data Sheet,https://www.caymanchem.com/msdss/14287m.pdf
DB00994,,Neomycin - LiverTox - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK547874/
DB00995,,NIH StatPearls: Inflammatory arthritis,https://www.ncbi.nlm.nih.gov/books/NBK507704/
DB00996,,FDA Approved Drug Products: Neurontin (gabapentin) for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
DB00996,,DPD Approved Drugs: Gabapentin,https://pdf.hres.ca/dpd_pm/00044022.PDF
DB00996,,MedSafe NZ: Gabapentin,https://www.medsafe.govt.nz/profs/Datasheet/a/arrowgabapentincap.pdf
DB00996,,EMA Approved Drugs: Gabapentin,https://www.ema.europa.eu/en/documents/referral/neurontin-article-30-referral-annex-i-ii-iii_en.pdf
DB00996,,FDA Approved Drugs: Gabapentin XR,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022399s008lbl.pdf
DB00996,,CaymenChem: Gabapentin MSDS,https://www.caymanchem.com/msdss/10008346m.pdf
DB00997,,"FDA Approved Drug Products: DOXIL (doxorubicin hydrochloride) liposome injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050718Orig1s060lbl.pdf
DB00997,,"FDA Approved Drug Products: DOXORUBICIN HYDROCHLORIDE injection, for intravenous use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf"
DB00997,,EMA Approved Drug Products: Celdoxome (Doxorubicin hydrochloride) pegylated liposomal for intravenous use,https://www.ema.europa.eu/en/documents/product-information/celdoxome-pegylated-liposomal-epar-product-information_en.pdf
DB00997,,Doxorubicin Hydrochloride Pfizer MSDS,https://pfe-pfizercom-prod.s3.amazonaws.com/products/material_safety_data/doxorubicin_HCl_soln_inj_25-Jan-2018.pdf
DB00997,,Doxorubicin Hydrochloride Cayman Chemical MSDS,https://cdn.caymanchem.com/cdn/msds/15007m.pdf
DB00997,,"FDA Approved Drug Products: DOXORUBICIN HYDROCHLORIDE injection, powder, lyophilized, for solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f62aa88d-1e25-4049-87ec-99d42edd1d31
DB00997,,"FDA Approved Drug Products: DOXORUBICIN HYDROCHLORIDE injection, suspension, liposomal",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54e2a32f-7f41-4ed7-926d-f6c9b0b225c6
DB00999,,FDA Approved Drug Products: Esidrix Hydrochlorothiazide Oral Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011793
DB00999,,FDA Approved Drug Products: Hydrochlorothiazide Oral Tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf"
DB00999,,FDA Approved Drug Products: Hydrochlorothiazide Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020504s018lbl.pdf
DB00999,,FDA Approved Drug Products: Losartan and Hydrochlorothiazide Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020387s063lbl.pdf
DB00999,,FDA Approved Drug Products: Irbesartan and Hydrochlorothiazide Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020758s073lbl.pdf
DB00999,,FDA Approved Drug Products: Lisinopril and Hydrochlorothiazide Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019888s067lbl.pdf
DB00999,,FDA Approved Drug Products: Quinapril and Hydrochlorothiazide Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020125s022lbl.pdf
DB00999,,FDA Approved Drug Products: HYZAAR (losartan potassium and hydrochlorothiazide) tablets for oral use (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020387s071lbl.pdf
DB01001,,"FDA Approved Drug Products: AIRSUPRA (albuterol and budesonide) inhalation aerosol, for oral inhalation use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214070s000lbl.pdf
DB01002,,EMC Summary of Product Characteristics: Chirocaine (levobupivacaine hydrochloride) solution for injection,https://www.medicines.org.uk/emc/product/1555/smpc
DB01003,,Health Canada Product Monograph: Nalcrom (sodium cromoglycate) oral capsules,https://pdf.hres.ca/dpd_pm/00015168.PDF
DB01005,,"DailyMed Label: SIKLOS (hydroxyurea) tablets, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76957c0d-0f98-4376-bb06-eee651adc09d
DB01005,,"FDA Approved Drug Products: DROXIA (hydroxyurea) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/016295s057lbl.pdf
DB01005,,"FDA Approved Drug Products: SIKLOS (hydroxyurea) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208843s003lbl.pdf
DB01005,,EMA Approved Drug Products: Xromi (hydroxycarbamide) solution for oral use,https://www.ema.europa.eu/en/documents/product-information/xromi-epar-product-information_en.pdf
DB01005,,Health Canada Approved Drug Proucts: APO-HYDROXYUREA (Hydroxyurea) capsules for oral use,https://pdf.hres.ca/dpd_pm/00071362.PDF
DB01005,,EMA Approved Drug Products: Siklos (hydroxycarbamide) solution for oral use,https://www.ema.europa.eu/en/documents/product-information/siklos-epar-product-information_en.pdf
DB01005,,"Dailymed Label: HYDREA (hydroxyurea) capsule, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6053c775-68de-45e4-9af9-33b18fd0e140
DB01005,,Hydroxyurea MSDS,https://safety365.sevron.co.uk/substances/accessSDS/SDS-46969-571e018e547121.20013502
DB01005,,"FDA Approved Drug Products: SIKLOS (hydroxyurea) tablets, for oral use (Dec 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208843s004lbl.pdf
DB01005,,"FDA Approved Drug Products: DROXIA (hydroxyurea) capsules, for oral use (Dec 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/016295s058lbl.pdf
DB01006,,FDA Approved Drug Products: Femara Letrozole Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf
DB01006,,FDA Approved Drug Products: Kisquali Femara Co-Pack Letrozole and Ribociclib Succinate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209935s006lbl.pdf
DB01007,,Electronic Medicines Compendium: Tioconazole 283 mg/ml medicated nail lacquer,https://www.medicines.org.uk/emc/product/12790/smpc#gref
DB01012,,FDA Approved Drug Products: SENSIPAR (cinacalcet) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021688s027lbl.pdf
DB01013,,FDA Approved Drug Products: Temovate Clobetasol Propionate Topical Cream (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019322
DB01013,,FDA Approved Drug Products: Olux-E Clobetasol Propionate Topical Aerosol Foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022013s013lbl.pdf
DB01013,,FDA Approved Drug Products: Olux Clobetasol Propionate Topical Aerosol Foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021142s022lbl.pdf
DB01013,,FDA Approved Drug Products: Impoyz Clobetasol Propionate Topical Cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209483s000lbl.pdf
DB01013,,FDA Approved Drug Products: Clobex Clobetasol Propionate Topical Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021835s015lbl.pdf
DB01013,,FDA Approved Drug Products: Clobex Clobetasol Propionate Topical Lotion,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021535Orig1s003,%20021644Orig1s003lbl.pdf"
DB01013,,Health Canada Approved Drug Products: Clobetasol Propionate Topical Spray,https://pdf.hres.ca/dpd_pm/00044987.PDF
DB01013,,"FDA Approved Drug Products: CLOBETASOL PROPIONATE OPHTHALMIC SUSPENSION 0.05%, for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218158s000lbl.pdf
DB01014,,FDA Approved Drug Products: Colazal (basalazide disodium) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020610s025lbl.pdf
DB01015,,FDA Approved Drug Products: Bactrim (sulfamethoxazole/trimethoprim) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf
DB01015,,Health Canada Product Monograph: Septra (sulfamethoxazole/trimethoprim) for intravenous injection,https://pdf.hres.ca/dpd_pm/00043890.PDF
DB01015,,FDA Approved Drug Products: Sulfamethoxazole/Trimethoprim oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/077612s005lbl.pdf
DB01015,,CaymanChem: Sulfamethoxazole MSDS,https://www.caymanchem.com/msdss/23613m.pdf
DB01016,,FDA Approved Drug Products: Micronase (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017498
DB01016,,FDA Approved Drug Products: Glucovance (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021178s018lbl.pdf
DB01016,,FDA Approved Drug Products: Glynase (Glyburide) Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020051s022lbl.pdf
DB01016,,Pfizer: Glyburide Tablets MSDS,https://www.pfizer.com/system/files/products/material_safety_data/MICRONASE.pdf
DB01017,,FDA Approved Drug Products: Minocin Minocycline Oral Capsules (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050315
DB01017,,FDA Approved Drug Products: Ximino Minocycline Oral Extended Release Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201922s002lbl.pdf
DB01017,,FDA Approved Drug Products: Solodyn Minocycline Oral Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050808s023lbl.pdf
DB01017,,FDA Approved Drug Products: Minocycline Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/65-005_Minocycline%20Hydrochloride_prntlbl.pdf
DB01017,,FDA Approved Drug Products: Minocin Minocycline Oral Pellet-Filled Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050649s027lbl.pdf
DB01017,,FDA Approved Drug Products: Minocin Minocycline Powder for Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050444s049lbl.pdf
DB01017,,FDA Approved Drug Products: Arestin Minocycline Subgingival Microspheres,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050781s020lbl.pdf
DB01017,,FDA Approved Drug Products: Amzeeq Minocycline Topical Foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212379s000lbl.pdf
DB01017,,Cayman Chemical: Minocycline MSDS,https://www.caymanchem.com/msdss/14454m.pdf
DB01018,,FDA Approved Drug Products: Tenex Guanfacine Hydrochloride Oral Tablets (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019032s021lbl.pdf
DB01018,,FDA Approved Drug Products: Intuniv Guanfacine Hydrochloride Extended Release Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s019lbl.pdf
DB01018,,Cayman Chemical: Guanfacine MSDS,https://www.caymanchem.com/msdss/22907m.pdf
DB01019,,DailyMed Drug Label Information: Bethanechol chloride oral tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8693204e-3bb5-4ada-93a4-eda563615db9
DB01020,,FDA Approved Drug Products: Monoket (isosorbide mononitrate) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdf
DB01020,,Spectrum Chemical: 5-Isosorbide Mononitrate MSDS,https://www.spectrumchemical.com/MSDS/TCI-I0403.pdf
DB01020,,DailyMed Label: Isosorbide Mononitrate (ISMN) extended-release tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=897a0327-25d4-4769-bd6a-0e674264017f
DB01020,,Organic Nitrates - LiverTox - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK547928/
DB01022,,"FDA Review: Vitamin K1 Subcutaneous, Intramuscular, and Intravenous Injection",https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/087955.PDF
DB01022,,Dailymed: Phytonadione Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429b58b-ec2b-4a18-95d9-a9d804321192
DB01022,,FDA Approved Drug Products: Mephyton (Phylloquinone) Oral Tablet,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010104
DB01024,,FDA Approved Drug Products: Myfortic (mycophenolic acid) delayed-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050791s030lbl.pdf
DB01024,,FDA Approved Drug Products: MYFORTIC (mycophenolic acid) delayed-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050791s035lbl.pdf
DB01024,,FDA Approved Drug Products: Cellcept (mycophenolate mofetil) for oral or intravenous administration,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050722s049s051,050723s049s051,050758s047s049lbl.pdf"
DB01024,,Santa Cruz Biotechnology: Mycophenolic acid SDS,https://datasheets.scbt.com/sc-200110.pdf
DB01026,,EMA SmPC: Ketoconazole,https://www.ema.europa.eu/en/documents/product-information/ketoconazole-hra-epar-product-information_en.pdf
DB01026,,FDA Label: Ketoconazole Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018533s041lbl.pdf
DB01026,,HSDB: Ketoconazole,http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+7447
DB01026,,Ketoconazole FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018533s040lbl.pdf
DB01026,,CPHI Online: Front-2 Ovules (clindamycin/ketoconazole) for vaginal use,https://www.cphi-online.com/front-2-ovules-clindamycin-ketoconazole-prod1239202.html
DB01028,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB01029,,FDA Approved Drug Products: Irbesartan Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020757s069lbl.pdf
DB01029,,FDA Approved Drug Products: Irbesartan and Hydrochlorothiazide Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020758s073lbl.pdf
DB01029,,Cayman Chemicals: Irbesartan MSDS,https://www.caymanchem.com/msdss/11952m.pdf
DB01029,,Sandoz Canada: Irbesartan Product Monograph,https://www.sandoz.ca/sites/www.sandoz.ca/files/Irbesartan%20Product%20Monograph.pdf
DB01033,,FDA Approved Drug Products: PURINETHOL (mercaptopurine) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/009053s040lbl.pdf
DB01033,,FDA Approved Drug Products: PURIXAN (mercaptopurine) suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205919s004lbl.pdf
DB01039,,FDA Approved Drug Products: Lipidil Fenofibrate Oral Capsules (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019304
DB01039,,FDA Approved Drug Products: Fenofibrate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf
DB01039,,FDA Approved Drug Products: Fenofibrate Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf
DB01039,,Cayman Chemicals: Fenofibrate MSDS,https://www.caymanchem.com/msdss/10005368m.pdf
DB01039,,"FDA Approved Drug Products: ANTARA (fenofibrate) capsules, for oral use (July 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021695s028lbl.pdf
DB01041,,FDA Approved Drug Products: Thalidomid (thalidomide) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020785s069lbl.pdf
DB01041,,Cayman Chemical: Thalidomide MSDS,https://cdn.caymanchem.com/cdn/msds/14610m.pdf
DB01041,,Health Canada Approved Drug Proucts: Thalidomid (thalidomide) capsules for oral use,https://pdf.hres.ca/dpd_pm/00060578.PDF
DB01042,,DailyMed: Melphalan USP tablets for oral use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bc0a79d-eb07-9685-8e98-4f1979b84a48
DB01042,,"FDA Approved Drug Products: EVOMELA (melphalan) for injection, for intravenous use (April 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207155Orig1s005lbl.pdf
DB01042,,FDA Approved Drug Products: HEPZATO (melphalan) KIT Hepatic Delivery System (HDS) for intra-arterial use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf
DB01042,,Cayman Chemical: Melphalan MSDS,https://cdn.caymanchem.com/cdn/msds/16665m.pdf
DB01043,,135 million people will live with dementia worldwide by 2050,https://www.alzheimersresearchuk.org/135-million-people-will-live-with-dementia-worldwide-by-2050/
DB01043,,Sandoz Monograph: Memantine hydrochloride oral tablets,https://www.sandoz.ca/sites/www.sandoz.ca/files/Memantine_FCT_PM_English20150916.pdf
DB01043,,"FDA Approved Drug Products: NAMENDA (memantine hydrochloride) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021487s025lbl.pdf
DB01044,,MedEx: Gatidex (gatifloxacin/dexamethasone) ophthalmic solution,https://medex.com.bd/brands/15835/gatidex-0301
DB01044,,Vademecum: Zypred (gatifloxacin/prednisolone acetate) ophthalmic suspension,https://www.vademecum.es/equivalencia-lista-zypred+suspension+oftalmica-chile-s01ca02+p5-cl_1
DB01044,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB01044,,Federal Register: Determination That TEQUIN (Gatifloxacin) Was Withdrawn From Sale for Reasons of Safety or Effectiveness,"https://www.federalregister.gov/documents/2008/09/09/E8-20938/determination-that-tequin-gatifloxacin-was-withdrawn-from-sale-for-reasons-of-safety-or#:~:text=The%20Food%20and%20Drug%20Administration%20(FDA)%20has%20determined%20that%20TEQUIN,reasons%20of%20safety%20or%20effectiveness."
DB01045,,"FDA Approved Drug Products: RIFATER (rifampin, isoniazid and pyrazinamide USP) tablets (February 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050705s022lbl.pdf
DB01045,,FDA Approved Drug Products: RIFADIN (rifampin capsules) and RIFADIN IV (rifampin for injection) (February 2023),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s088,050627s033lbl.pdf"
DB01045,,Thermo Fisher Scientific: Rifampin MSDS,https://www.fishersci.se/chemicalProductData_uk/wercs?itemCode=10103443&lang=EN
DB01045,,FDA Approved Drug Products: RIFADIN (rifampin capsules) and RIFADIN IV (rifampin for injection) (December 2023),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s091,050627s036lbl.pdf"
DB01046,,FDA Approved Drug Products: Amitiza (lubiprostone) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021908s018lbl.pdf
DB01048,,Link,http://pharmgkb.org/pathway/PA166104634#
DB01048,,"FDA Approved Drug Products: Triumeq/Triumeq PD (abacavir, dolutegravir, and lamivudine) for oral administration",https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG-IFU.PDF
DB01048,,"FDA Approved Drug Products: ZIAGEN (abacavir) solution or tablets, for oral use (November 2020)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020977s035,020978s038lbl.pdf"
DB01049,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009087
DB01049,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=081113
DB01049,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf973160-d467-4192-a432-04c8c2140369
DB01049,,Kegg,http://www.genome.jp/dbget-bin/www_bget?dr:D02268
DB01050,,Current issues in pharmacy and medical sciences,https://www.degruyter.com/downloadpdf/j/cipms.2014.27.issue-1/cipms-2014-0003/cipms-2014-0003.pdf
DB01050,,FDA Approved Drug Products: Caldolor (ibuprofen) solution for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022348s021lbl.pdf
DB01051,,"Federal Register: Determination That ALBAMYCIN (Novobiocin Sodium) Capsule, 250 Milligrams, Was Withdrawn From Sale for Reasons of Safety or Effectiveness",https://www.federalregister.gov/documents/2011/01/19/2011-1000/determination-that-albamycin-novobiocin-sodium-capsule-250-milligrams-was-withdrawn-from-sale-for
DB01051,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB01053,,article,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC444435/pdf/aac00346-0019.pdf
DB01053,,Webmd,http://www.webmd.com/drugs/2/drug-3781/penicillin-g-benzathine-intramuscular/details
DB01053,,monograph,https://www.drugs.com/cdi/penicillin-g-benzathine-suspension.html
DB01053,,FDA Approved Drug Products: Penicillin G Potassium Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050638s020lbl.pdf
DB01053,,FDA Approved Drug Products: Penicillin G Sodium Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/065068s013lbl.pdf
DB01054,,Bayer Austria: Baypress (nitrendipine) oral tablets,https://www.bayer.at/static/documents/produkte/gi/Baypress20mg_gi.pdf
DB01054,,TITCK Product Information: Eneas (enalapril/nitrendipine) oral tablets,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/KUB_temiz.pdf_8a19f4b2-53d2-4caa-919b-3fb2c1946fc0.pdf
DB01058,,FDA Approved Drug Products: Biltricide (praziquantel) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018714s018lbl.pdf
DB01058,,Health Canada Product Monograph: Biltricide (praziquantel) tablets for oral use,https://pdf.hres.ca/dpd_pm/00039232.PDF
DB01058,,"FDA Approved Drug Products: BILTRICIDE (praziquantel) tablets, for oral use (Feb 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018714s020lbl.pdf
DB01060,,"FDA Approved Drug Products: Talicia Amoxicillin, Omeprazole, and Rifabutin Oral Delayed Release Capsules",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213004lbl.pdf
DB01060,,FDA Approved Drug Products: Amoxil Amoxicillin Oral Capsules (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050459
DB01060,,FDA Approved Drug Products: Omeclamox-Pak Oral Capsules and Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050824s007lbl.pdf
DB01060,,FDA Approved Drug Products: Augmentin XR Amoxicillin and Clavulanate Oral Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050785s015lbl.pdf
DB01060,,FDA Approved Drug Products: Augmentin Amoxicillin and Clavulanate Oral Tablets and Suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf"
DB01060,,FDA Approved Drug Products: Amoxicillin and Clavulanate Oral Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/065162s021lbl.pdf
DB01060,,FDA Approved Drug Products: Amoxicillin Oral Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/065119s020lbl.pdf
DB01060,,FDA Approved Drug Products: Amoxicillin Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/065056s017lbl.pdf
DB01060,,"FDA Approved Drug Products: VOQUEZNA TRIPLE PAK (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets), co-packaged for oral use and VOQUEZNA DUAL PAK (vonoprazan tablets; amoxicillin capsules) co-packaged for oral use",http://www.phathompharma.com/wp-content/uploads/VOQUEZNA-TRIPLE-PAK-and-VOQUEZNA-DUAL-PAK-FDA-Final-Label-3.pdf
DB01062,,"HMDB MSDS, Oxybutinin",http://www.hmdb.ca/system/metabolites/msds/000/013/858/original/HMDB15195.pdf?1358895165
DB01062,,Ditropan XL FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020897s037lbl.pdf
DB01064,,FDA Approved Drugs Products: Isuprel (Isoprenaline) Sublingual and Rectal Tablets (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006328
DB01064,,"FDA Approved Drug Products: Isuprel (Isoprenaline) Intravenous, Intramuscular, Subcutaneous, and Intracardiac Injection",https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/010515s031lbl.pdf
DB01064,,Cayman Chemical: Isoproterenol MSDS,https://www.caymanchem.com/msdss/15592m.pdf
DB01064,,US Patent: US2308232A,https://patentimages.storage.googleapis.com/65/ae/7d/7121f1101eb358/US2308232.pdf
DB01067,,Clinical Practice Guidelines - 2018 Full Guidelines - Diabetes Canada - Chapter 13: Pharmacologic Glycemic Management of Type 2 Diabetes in Adults,http://guidelines.diabetes.ca/cpg/chapter13
DB01067,,Glipizide - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK459177/
DB01067,,Glipizide 5 mg Tablets - Summary of Product Characteristics (SmPC) - European Medicines Agency,https://www.medicines.org.uk/emc/product/8543/smpc
DB01067,,Glucotrol (Glipizide) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf
DB01067,,GLUCOTROL XL® (glipizide) extended release tablets - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020329s029lbl.pdf
DB01067,,METAGLIP (glipizide and metformin HCl) Tablets - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021460s010lbl.pdf
DB01068,,Electronic Medicines Compendium: Clonazepam Rosemont 2mg/5ml Oral Solution,https://www.medicines.org.uk/emc/product/6022/smpc
DB01068,,DailyMed Label: KLONOPIN (clonazepam) Oral Tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=542f22e8-dad2-47a8-93b6-30936715d73b
DB01068,,"FDA Approved Drug Products: KLONOPIN (clonazepam) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017533s062lbl.pdf
DB01068,,"Health Canada Approved Drug Proucts: Rivotril (Clonazepam) 0.5 mg and 2 mg Tablets, for oral use",https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/763/original/Rivotril_PM_E.pdf?1551482154
DB01069,,FDA Approved Drug Products: Phenergran Promethazine Oral Tablets (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/07935s030lbl.pdf
DB01069,,FDA Approved Drug Products: Promethazine with Phenylephrine and Codeine Oral Syrup,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/088764Orig1s084lbl.pdf
DB01069,,Cayman Chemical: Promethazine MSDS,https://www.caymanchem.com/msdss/16478m.pdf
DB01070,,Codifa: Atiten (dihydrotachisterol) oral drops,https://www.codifa.it/farmaci/a/atiten-diidrotachisterolo-vitamine-d
DB01072,,FDA Approved Drug Products: Evotaz (atazanavir and cobicistat) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206353s007lbl.pdf
DB01072,,FDA Approved Drug Products: Reyataz (atazanavir) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021567s044,206352s008lbl.pdf"
DB01072,,"FDA Approved Drug Products: REYATAZ (atazanavir) capsules/oral powder, for oral use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021567s048,206352s010lbl.pdf"
DB01075,,StatPearls [Internet]: Diphenhydramine,https://www.ncbi.nlm.nih.gov/books/NBK526010/#article-20535.s1
DB01075,,Electronic Medicines Compendium: Histergan (diphenhydramine hydrochloride) Tablets Patient Information,https://www.medicines.org.uk/emc/product/8071/pil
DB01075,,Electronic Medicines Compendium: Histergan (diphenhydramine hydrochloride) Cream Monograph,https://www.medicines.org.uk/emc/product/2303/smpc
DB01075,,Electronic Medicines Compendium: Boots Sleepeaze (diphenhydramine hydrochloride) 50mg Tablets Monograph,https://www.medicines.org.uk/emc/product/6568/smpc
DB01075,,Electronic Medicines Compendium: Nytol One-A-Night (diphenhydramine hydrochloride) Monograph,https://www.medicines.org.uk/emc/product/340/smpc
DB01075,,DailyMed: Ibuprofen PM (ibuprofen/diphenhydramine) product information,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c5c1f48-d285-4faa-96d0-b04f435c9c5c
DB01075,,BASG Product Information: Multodrin (dexamethasone/diphenhydramine hydrochloride) topical ointment,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=13232&type=DOTC_FACH_INFO
DB01076,,Merck Manuals,https://www.merckmanuals.com/en-ca/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia
DB01076,,Chemocare,http://chemocare.com/chemotherapy/side-effects/cardiovascular-events.aspx
DB01076,,Laguna Treatment,https://lagunatreatment.com/lipitor/
DB01076,,FDA Approved Drug Products: Lipitor (atorvastatin calcium) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020702s074lbl.pdf
DB01076,,INVIMA Product Authorization: Lipomega (atorvastatin calcium/omega-3 ethyl esters) oral capsule,http://web.sivicos.gov.co/registros/pdf/1323473_2015026114.pdf
DB01077,,FDA Approved Drug Products: Didronel Etidronate Oral Tablet (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf
DB01079,,FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65,https://www.erienewsnow.com/story/40228826/fda-approves-the-reintroduction-of-zelnorm-tegaserod-for-irritable-bowel-syndrome-with-constipation-ibs-c-in-women-under-65
DB01080,,FDA Approved Drug Products: Sabril (vigabatrin) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020427s021,022006s023lbl.pdf"
DB01080,,Health Canada Product Monograph: Sabril (vigabatrin) for oral use,https://pdf.hres.ca/dpd_pm/00051654.PDF
DB01080,,Vigabatrin REMS Program,https://vigabatrinrems.com/#Main
DB01082,,Streptomycin FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf
DB01082,,DailyMed Drug Label Information: Streptomycin injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e
DB01083,,FDA Approved Drug Products: Xenical (orlistat) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020766s035lbl.pdf
DB01083,,FDA Approved Drug Products: ALLI (orlistat) oral capsules OTC,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021887lbl.pdf
DB01083,,FDA: Orlistat (marketed as Alli and Xenical) Information,https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/orlistat-marketed-alli-and-xenical-information
DB01083,,NIH StatPearls: Orlistat,https://www.ncbi.nlm.nih.gov/books/NBK542202/
DB01083,,DailyMed: Alli (orlistat) oral capsule,https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2d3bd73-f3af-4ea5-a57c-66b0004cfe4f
DB01083,,Product monograph: Xenical (orlistat) oral capsules,https://www.rochecanada.com/PMs/Xenical/Xenical_PM_E.pdf
DB01083,,Fagron MSDS: Orlistat,https://fagron.com/sites/default/files/document/msds_coa/96829-58-2_(USA).pdf
DB01083,,FDA Approved Drug Products: Xenical (orlistat) capsules for oral use (Updated 11/2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020766s038lbl.pdf
DB01085,,"FDA Approved Drug Products: QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217836s000lbl.pdf
DB01085,,"FDA Approved Drug Products: Isopto Carpine (pilocarpine hydrochloride) ophthalmic solution 1%, 2% and 4% (June 2010)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf
DB01085,,"DailyMed Label: SALAGEN (pilocarpine hydrochloride) Oral Tablets, film coated",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b
DB01085,,FDA Approved Drug Products: VUITY (pilocarpine hydrochloride) 1.25% ophthalmic solution (April 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214028Orig1s003lbl.pdf
DB01085,,Cayman Chemical: (+)-Pilocarpine hydrochloride MSDS,https://cdn.caymanchem.com/cdn/msds/14487m.pdf
DB01086,,INVIMA Product Authorization: Aldrifress (benzocaine/cetylpyridinium chloride) chewable tablets,http://web.sivicos.gov.co/registros/pdf/1374183_2015045084.pdf
DB01086,,BASG Product Information: Herposicc (benzocaine/zinc oxide) lip ointment,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=6309&type=DOTC_FACH_INFO
DB01086,,Dailymed: Dermoplast First Aid (Benzocaine and Benzethonium) Topical Spray,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec93011d-7069-4021-8dd2-3d51eb6026e1
DB01086,,Dailymed: Rite Aid Maximum Toothache Reliever (Benzocaine and Menthol) Oral Gel,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8347cb51-4d51-0b83-e053-2991aa0ad9e2
DB01086,,Dailymed: Americaine (Benzocaine) Topical Ointment,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d13c022f-2f91-40b4-bd66-0cfc0e147a5f&type=display
DB01088,,"FDA Approved Drug Products: VENTAVIS (iloprost) inhalation solution, for oral inhalation use (March 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021779s021lbl.pdf
DB01088,,"FDA Approved Drug Products: AURLUMYN (iloprost) injection, for intravenous use (February 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217933s000lbl.pdf
DB01088,,Cayman Chemical: Iloprost MSDS,https://cdn.caymanchem.com/cdn/msds/18215m.pdf
DB01095,,FDA Approved Drug Products: Lescol XL (fluvastatin sodium) extended-release oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021192s031lbl.pdf
DB01098,,Crestor (Rosuvastatin Calcium) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021366s016lbl.pdf
DB01098,,FDA Approved Drug Products: Crestor (rosuvastatin) tablets for oral use (July 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021366s045lbl.pdf
DB01098,,FDA Approved Drug Products: Ezallor Sprinkle (rosuvastatin) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208647s006s007s008s009s010s011lbl.pdf
DB01101,,"FDA Approved Drug Products: XELODA® (capecitabine) tablets, for oral use Jan 2023",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf
DB01101,,"Health Canada Approved Drug Proucts: APO-CAPECITABINE, tablets for oral use",https://pdf.hres.ca/dpd_pm/00064793.PDF
DB01104,,EMA Label: Zoloft; INN: sertraline,http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Zoloft_30/WC500007023.pdf
DB01104,,FDA Approved Drug Products: Zoloft (sertraline hydrochloride) for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019839S74S86S87_20990S35S44S45lbl.pdf
DB01104,,"Zoloft, PDR",https://www.pdr.net/drug-summary/Zoloft-sertraline-hydrochloride-474.3608
DB01104,,AAFP: Off-label Applications for SSRIs,https://www.aafp.org/afp/2003/0801/p498.html
DB01104,,"Sertraline, pubchem",https://pubchem.ncbi.nlm.nih.gov/compound/sertraline
DB01104,,"Sertraline, Pfizer SDS",https://pfe-pfizercom-prod.s3.amazonaws.com/products/material_safety_data/sertraline_hydrochloride_capsules_2-June-2016.pdf
DB01104,,Sertraline pathway,https://www.pharmgkb.org/pathway/PA166181117
DB01104,,Psychology Today article,https://www.psychologytoday.com/ca/blog/the-superhuman-mind/201702/number-one-reason-ssris-take-four-six-weeks-work
DB01109,,"FDA Approved Drug Products: HEPARIN SODIUM IN 5% DEXTROSE INJECTION, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019952s048lbl.pdf
DB01109,,BASG Product Information: Sensicutan (bisabolol/heparin sodium) topical ointment,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-24304&type=DOTC_FACH_INFO
DB01109,,"AIFA Package Leaflet: PROCTOSOLL (benzocaine, heparin, hydrocortisone) rectal cream",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004375_027377_RCP.pdf&retry=0&sys=m0b1l3
DB01109,,FDA approved drug product: HEPARIN SODIUM IN SODIUM CHLORIDE injection for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018609s058lbl.pdf
DB01109,,"FDA approved drug product: HEPARIN SODIUM INJECTION, for intravenous or subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/017029s159lbl.pdf
DB01110,,FDA Approved Drug Products: Oravig (miconazole) buccal tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022404s005lbl.pdf
DB01110,,"FDA Approved Drug Products: Vusion (miconazole nitrate, zinc oxide, white petrolatum) topical ointment",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021026s013lbl.pdf
DB01110,,FDA Approved Drug Products: miconazole nitrate suppositories and cream,https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/75-329_Miconazole%20Nitrate_prntlbl.pdf
DB01110,,DailyMed miconazole nitrate,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=745242b5-c10f-4c59-8037-e7e0e4c948d6
DB01110,,FDA Approved Drug Products: Monistat (miconazole nitrate) suppositories and cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017450Orig1s056lbl.pdf
DB01110,,AIFA Product Information: Nizacol (miconazole) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000873_025999_FI.pdf&retry=0&sys=m0b1l3
DB01111,,FDA Approved Drug Products: Coly-Mycin (colistimethate) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050108s033lbl.pdf
DB01114,,MSDS,http://msds.orica.com/pdf/shess-en-cds-010-000000033835.pdf
DB01114,,Berko Ilac: Iburamin (ibuprofen/chlorpheniramine) cold syrup,http://berkoilac.com.tr/wp-content/uploads/2017/05/iburamin-cold-syrup-en.pdf
DB01114,,ilacaBak: Pulmotus (levodropropizine/chlorpheniramine maleate) oral syrup,https://www.ilacabak.com/pulmotus-30-mg-2-mg-5-ml-surup-24674/kisa-urun-bilgisi
DB01115,,FDA Approved Drug Products: Procardia Nifedipine Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018482s052lbl.pdf
DB01115,,FDA Approved Drug Products: Procardia XL Nifedipine Oral Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019684s029lbl.pdf
DB01115,,FDA Approved Drug Products: Adalat CC Nifedipine Oral Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020198s023lbl.pdf
DB01115,,Cayman Chemical: Nifedipine MSDS,https://www.caymanchem.com/msdss/11106m.pdf
DB01118,,Electronic Medicines Compendium Amiodarone 100mg Tablets,https://www.medicines.org.uk/emc/product/6019/smpc
DB01118,,Nexterone FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022325lbl.pdf
DB01118,,FDA Approved Drug Products: CORDARONE (amiodarone HCl) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018972s054lbl.pdf
DB01118,,NIH StatPearls: Amiodarone,https://www.ncbi.nlm.nih.gov/books/NBK482154/
DB01118,,AAFP: Medication Guide for Amiodarone,https://www.aafp.org/afp/2005/0401/p1434.html
DB01118,,FDA Approved Drug Products: NEXTERONE (amiodarone HCl) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022325s013lbl.pdf
DB01119,,"FDA Approved Drug Products: Proglycem (diazoxide) oral capsules, suspension","https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/017425s017,017453s023lbl.pdf"
DB01119,,MSD: Diazoxide (<15%) formulation SDS,https://www.msd.com/docs/product/safety-data-sheets/hh-sds/Diazoxide%20(LT15_pct)%20Formulation_HH_ID_6N.pdf
DB01119,,New Zealand Drug Data Sheet: DBL (diazoxide) injection for intravenous use,https://www.medsafe.govt.nz/profs/datasheet/d/DBLDiazoxideinj.pdf
DB01124,,DailyMed: tolbutamide tablets,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=3995eed8-39ec-ce5e-8cc2-062f93445c8d&type=pdf
DB01126,,Avodart (dutasteride capsules) - Product Monograph,https://ca.gsk.com/media/588688/avodart.pdf
DB01126,,FDA Approved Drug Products: AVODART (dutasteride) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdf
DB01126,,FDA Approved Drug Products: JALYN (dutasteride and tamsulosin hydrochloride) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022460Orig1s011lbl.pdf
DB01127,,AIFA Product Information: Pevaryl (econazole) for vaginal use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001445_023603_RCP.pdf&retry=0&sys=m0b1l3
DB01128,,FDA Approved Drug Products: Casodex (bicalutamide) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
DB01132,,FDA Approved Drug Products: Actos (pioglitazone) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf
DB01132,,FDA Approved Drug Products: Actoplus Met (pioglitazone/metformin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021842s022lbl.pdf
DB01132,,FDA Approved Drug Products: Duetact (pioglitazone/glimepiride) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021925s017lbl.pdf
DB01132,,FDA Approved Drug Products: Oseni (pioglitazone/alogliptin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022426s012lbl.pdf
DB01132,,CaymanChem: Pioglitazone MSDS,https://www.caymanchem.com/msdss/22263m.pdf
DB01132,,Diabetes Canada: Clinical Practice Guidelines for Diabetes 2018,http://guidelines.diabetes.ca/docs/CPG-2018-full-EN.pdf
DB01133,,FDA Approved Drug Products: Skelid Tiludronate Disodium Oral Tablets (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020707s006lbl.pdf
DB01136,,FDA Approved Drug Products: Carvedilol Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf
DB01136,,FDA Approved Drug Products: Carvedilol Oral Extended Release Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022012s022lbl.pdf
DB01137,,FDA Approved Drug Products: Levaquin (levofloxacin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020634s071lbl.pdf
DB01137,,FDA Approved Drug Products: Quixin (levofloxacin) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021199s014lbl.pdf
DB01137,,Health Canada Product Monograph: Levofloxacin oral tablets,https://pdf.hres.ca/dpd_pm/00050865.PDF
DB01137,,Health Canada Product Monograph: Quinsair (levofloxacin hemihydrate) solution for inhalation,https://pdf.hres.ca/dpd_pm/00051502.PDF
DB01137,,Health Canada Product Monograph: Levofloxacin in 5% dextrose for injection,https://pdf.hres.ca/dpd_pm/00053176.PDF
DB01137,,CaymanChem: Levofloxacin MSDS,https://www.caymanchem.com/msdss/20382m.pdf
DB01142,,FDA Label: SilenorTM (doxepin) tablets for oral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022036lbl.pdf
DB01142,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016798
DB01142,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022036
DB01142,,Encyclopedia,https://www.encyclopedia.com/medicine/drugs/pharmacology/doxepin
DB01142,,American Psychiatric Association,https://www.psychiatry.org/patients-families/depression/what-is-depression
DB01142,,Canadian Mental Health Association,https://cmha.ca/documents/anxiety-disorders
DB01142,,HealthLink BC,https://www.healthlinkbc.ca/health-topics/uh1001
DB01142,,Cleveland Clinic,http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/dermatology/pruritus-itch/
DB01142,,Merck Manuals,https://www.merckmanuals.com/en-ca/professional/neurologic-disorders/pain/neuropathic-pain
DB01142,,Dehli Psychiatry Journal paper,http://medind.nic.in/daa/t12/i2/daat12i2p402.pdf
DB01142,,Novo-doxepin product monograph,https://pdf.hres.ca/dpd_pm/00024530.PDF
DB01147,,Health Canada Product Monograph: Cloxacillin sodium for oral use,https://pdf.hres.ca/dpd_pm/00055444.PDF
DB01147,,Health Canada Product Monograph: Cloxacillin sodium powder for solution for injection,https://pdf.hres.ca/dpd_pm/00049752.PDF
DB01153,,TITCK Product Information: Zalain (sertaconazole nitrate) vaginal tablet,https://titck.gov.tr/storage/kubKtAttachments/170d12d279741.pdf
DB01153,,DailyMed: Ertaczo (sertaconazole) topical cream,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e11cbfd-47c8-4d0f-ac7d-0beca0ea58aa
DB01153,,TITCK Product Information: Zalain (sertaconazole nitrate) topical solution,https://titck.gov.tr/storage/kubKtAttachments/8958714063085.pdf
DB01156,,Dailymed: Contrave (bupropion + naltrexone),https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed2da3a6-0614-4bea-8e82-962cbaae6428
DB01156,,FDA Approved Drug Products: Wellbutrin XL® extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021515s040lbl.pdf
DB01156,,FDA Approved Drug Products: Wellbutrin immediate-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018644s054lbl.pdf
DB01156,,"FDA Approved Drug Products: AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets, for oral use",https://www.auvelity.com/prescribing-information.pdf
DB01157,,FDA Approved Products: Neutrexin (trimetrexate glucuronate) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020326s015lbl.pdf
DB01161,,FDA Approved Drug Products: CLOROTEKAL (chloroprocaine hydrochloride) injection for intrathecal use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208791s000lbl.pdf
DB01161,,"FDA Approved Drug Products: Nesacaine and Nesacaine-MPF (chloroprocaine HCl) injection, USP",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/009435s044lbl.pdf
DB01161,,FDA Approved Drug Products: IHEEZOTM (chloroprocaine hydrochloride) gel for topical ophthalmic use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216227s000lbl.pdf
DB01161,,NIH StatPearls: Chloroprocaine,https://www.ncbi.nlm.nih.gov/books/NBK532901/
DB01162,,FDA Approved Drug Products: Terazosin Oral Capsules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf"
DB01162,,FDA Approved Drug Products: HYTRIN (terazosin) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019057s022lbl.pdf
DB01167,,FDA Approved Drug Products: SPORANOX (itraconazole) Oral Capsules (February 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020083s068lbl.pdf
DB01167,,"FDA Approved Drug Products: TOLSURA (itraconazole) capsules, for oral use (December 2018)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208901s000lbl.pdf
DB01167,,FDA Approved Drug Products: SPORANOX (itraconazole) Oral Solution (February 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020657s040lbl.pdf
DB01167,,Cayman Chemical: Itraconazole MSDS,https://cdn.caymanchem.com/cdn/msds/13288m.pdf
DB01169,,European Public Assessment Report: Trisenox,https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf
DB01171,,Monamine Oxidase Inhibitors,https://books.google.ca/books?id=iUi5ErxyhVYC&pg=PA191&lpg=PA191&dq=moclobemide+clearance&source=bl&ots=9-XcLmfB1Y&sig=jKPdSO_2hzyh2adnG3Ap73GqEZQ&hl=en&sa=X&ved=0ahUKEwiPxOSHgrXZAhUY5WMKHeVgCk44ChDoAQgoMAA#v=onepage&q=moclobemide%20clearance&f=false
DB01171,,Citalopram,https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID8022826
DB01175,,FDA Approved Drug Products: Lexapro (escitalopram) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021323s051,021365s036lbl.pdf"
DB01175,,DPD Approved Drugs: Escitalopram,https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Cipralex%20JUN2018_PM_E_clean.pdf
DB01175,,Medsafe NZ: Escitalopram,https://www.medsafe.govt.nz/profs/Datasheet/l/loxalatetab.pdf
DB01175,,CaymenChem: Escitalopram MSDS,https://www.caymanchem.com/msdss/22405m.pdf
DB01175,,"FDA Approved Drug Products: Lexapro® (escitalopram) tablets, for oral use (May 2023)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021323s055,021365s039lbl.pdf"
DB01175,,"FDA Approved Drug Products: Lexapro® (escitalopram) tablets, for oral use (August 2023)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021323s057,021365s040lbl.pdf"
DB01183,,Link,http://www.medscape.com/viewarticle/441915_3
DB01183,,FDA Approved Drug Products: Kloxxado (Naloxone) Nasal Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212045s000lbl.pdf
DB01183,,Caymen Chemical: Naloxone MSDS,https://www.caymanchem.com/msdss/15594m.pdf
DB01183,,International Pharmacopoeia: Naloxone Hydrochloride,https://apps.who.int/phint/pdf/b/6.1.245.Naloxone-hydrochloride-(Naloxoni-hydrochloridum).pdf
DB01183,,FDA Approved Drug Products: Narcan (Naloxone) Injection (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016636
DB01183,,"FDA Approved Drug Products: Suboxone (Buprenorphine, Naloxone) Sublingual, Buccal Film",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022410s042lbl.pdf
DB01183,,"FDA Approved Drug Products: Zubsolv (Buprenorphine, Naloxone) Sublingual Tablet",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204242s019lbl.pdf
DB01183,,British Columbia CDC: Administration of Naloxone,http://www.bccdc.ca/resource-gallery/Documents/Educational%20Materials/Epid/Other/NaloxoneDSTUseforRN.pdf
DB01183,,FDA Approved Drug Products: Narcan (Naloxone) Nasal Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208411Orig1s004lbl.pdf
DB01183,,DailyMed: Lifems (Naloxone Hydrochloride) Kit,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0e1f14d-18db-42e6-a74c-aecbe03c6f66
DB01183,,"Dailymed: Naloxone Hydrochloride Subcutaneous, Intramuscular, Intravenous Injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1303f15-c48b-a44d-b28a-72f370094e02#L3771a8f1-c2b1-4874-8c0d-dcdefc051a04
DB01183,,DailyMed: Naloxone and Pentazocine Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a28450a0-ac93-4235-b9a6-58cdf24773cb
DB01183,,FDA Approved Drug Products: Naloxone Hydrochloride Injection Auto-Injector (referred throughout as NALOXONE AUTO-INJECTOR) for intramuscular or subcutaneous use,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d2d67261-1f34-4ac4-a29c-ebca7ba28f0d&type=display
DB01183,,Kaléo News: FDA Approves Kaléo’s Naloxone Auto-Injector 10 mg for the Treatment of Known or Potential Exposure to Ultra-Potent Weaponized Opioids,https://kaleo.com/press-release/fda-approves-kaleos-naloxone-auto-injector-10-mg-for-the-treatment-of-known-or-potential-exposure-to-ultra-potent-weaponized-opioids/
DB01183,,FDA Approved Drug Products: Naloxone Hydrochloride Nasal Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208969s000lbl.pdf
DB01183,,FDA Approved Drug Products: NARCAN® (naloxone hydrochloride) Nasal Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208411s007lbl.pdf
DB01184,,TITCK Product Information: Duedom (dexlansoprazole/domperidone) oral capsules,https://titck.gov.tr/storage/kubKtAttachments/7993bbe835985.pdf
DB01186,,FDA Approved Products: Permax (pergolide),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf"
DB01188,,"FDA Approved Drug Products: LOPROX (ciclopirox) cream, gel, and suspension","https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018748s024,019824s023,020519s016lbl.pdf"
DB01188,,FDA Approved Drug Products: LOPROX (ciclopirox) shampoo,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021159s020lbl.pdf
DB01188,,FDA Approved Drug Products: Penlac (ciclopirox) solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf
DB01189,,FDA Approved Drug Products: Suprane (Desflurane) Inhalational Liquid,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020118s026lbl.pdf
DB01190,,FDA Approved Drug Products: Onexton (clindamycin phosphate/benzoyl peroxide) topical gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050819s012lbl.pdf
DB01190,,FDA Approved Drug Products: Ziana (clindamycin phosphate/tretinoin) topical gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050802lbl.pdf
DB01190,,FDA Approved Drug Products: Evoclin (clindamycin phosphate) topical foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050801s018lbl.pdf
DB01190,,FDA Approved Drug Products: Clindesse (clindamycin phosphate) vaginal cream,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050793s015lbl.pdf
DB01190,,FDA Approved Drug Products: Clindamycin in 0.9% NaCl for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208083s003lbl.pdf
DB01190,,FDA Approved Drug Products: Cleocin (clindamycin hydrochloride) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050162s101lbl.pdf
DB01190,,FDA Approved Drug Products: Cleocin T (clindamycin phosphate) topical gel/solution/lotion,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050537s041,050600s018,050615s019lbl.pdf"
DB01190,,FDA Approved Drug Products: Cleocin (clindamycin phosphate) vaginal suppositories,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050767s016lbl.pdf
DB01190,,Health Canada Product Monograph: Clindets (clindamycin phosphate) topical swabs,https://pdf.hres.ca/dpd_pm/00036879.PDF
DB01190,,CaymanChem: Clindamycin MSDS,https://www.caymanchem.com/msdss/15006m.pdf
DB01190,,Health Canada Product Monograph: Clindamycin oral capsules,https://pdf.hres.ca/dpd_pm/00054159.PDF
DB01190,,INVIMA Product Characteristics: Tensonorm (miconazole/clindamycin) vaginal ovules,http://consultaregistro.invima.gov.co:8082//Consultas/GenerarPdf?filename=c:%5Cupload%5CDocumentos%5CPDF%5Cp_346310.pdf
DB01190,,FDA Approved Drug Products: Xaciato (clindamycin phosphate) vaginal gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215650s000lbl.pdf
DB01190,,"FDA Approved Drug Products: Cabtreo (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel",https://pi.bauschhealth.com/globalassets/BHC/PI/Cabtreo-PI.pdf
DB01192,,"FDA Approved Drug Products: OPANA® ER (oxymorphone hydrochloride) extended-release tablets, for oral use, CII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021610s031lbl.pdf
DB01194,,FDA Approved Drug Products: AZOPT (brinzolamide) suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020816s023lbl.pdf
DB01194,,FDA Approved Drug Products: SIMBRINZA (brinzolamide and brimonidine tartrate) suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204251s006lbl.pdf
DB01194,,EMA Product Information: AZARGA (brinzolamide and timolol maleate) suspension,https://www.ema.europa.eu/en/documents/product-information/azarga-epar-product-information_en.pdf
DB01194,,"FDA Approved Drug Products: SIMBRINZA (brinzolamide and brimonidine tartrate ophthalmic suspension) 1%/0.2%, for topical ophthalmic use (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204251s012lbl.pdf
DB01194,,Brinzolamide MSDS,https://static.cymitquimica.com/products/45/pdf/sds-1076363.pdf
DB01194,,EMA Approved Drug Products: SIMBRINZA (brinzolamide and brimonidine tartrate ophthalmic suspension) 1%/0.2@ for topical opththalmic use (May 2023),https://ec.europa.eu/health/documents/community-register/2014/20140718129060/anx_129060_en.pdf
DB01194,,EMA Approved Drug Products: AZOPT (brinzolamide) suspension,https://www.ema.europa.eu/en/documents/product-information/azopt-epar-product-information_en.pdf
DB01195,,FDA Approved Drug Products: Tambocor Flecainide Acetate Oral Tablets,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018830
DB01195,,Medsafe New Zealand Approved Drug Products: Tambocor Oral Tablets and Capsules,https://www.medsafe.govt.nz/profs/datasheet/t/tambocortabcap.pdf
DB01195,,Flecainide Acetate,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6b78d4-8ac8-464b-bb78-ee70cbc97898
DB01195,,Cayman Chemicals: Flecainide MSDS,https://www.caymanchem.com/msdss/20388m.pdf
DB01200,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB01200,,GovInfo: 60 FR 3404 - Sandoz Pharmaceuticals Corp.; Bromocriptine Mesylate (Parlodel); Withdrawal of Approval of the Indication for the Prevention of Physiological Lactation,https://www.govinfo.gov/app/details/FR-1995-01-17/95-1074
DB01202,,FDA Approved Drugs: Levetiracetam Tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021035s100,021505s040lbl.pdf"
DB01202,,FDA Approved Drugs: Levetiracetam ODT,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207958s008lbl.pdf
DB01202,,DPD Approved Drugs: Levetiracetam,https://pdf.hres.ca/dpd_pm/00047496.PDF
DB01202,,CaymenChem: Levetiracetam MSDS,https://www.caymanchem.com/msdss/9001820m.pdf
DB01202,,MedSafe NZ: Levetiracetam,https://www.medsafe.govt.nz/profs/Datasheet/k/Keppratab.pdf
DB01203,,FDA Approved Drug Products: Nadolol Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018063s063lbl.pdf
DB01203,,FDA Approved Drug Products: CORZIDE (nadolol and bendroflumethiazide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018647s026lbl.pdf
DB01203,,The Human Metabolome Database: Nadolol MSDS,http://www.hmdb.ca/system/metabolites/msds/000/013/997/original/HMDB15334.pdf?1358895036
DB01206,,FDA Approved Drug Products: GLEOSTINE (lomustine) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017588s043lbl.pdf
DB01211,,"FDA Approved Drug Products: VOQUEZNA TRIPLE PAK (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets), co-packaged for oral use and VOQUEZNA DUAL PAK (vonoprazan tablets; amoxicillin capsules) co-packaged for oral use",http://www.phathompharma.com/wp-content/uploads/VOQUEZNA-TRIPLE-PAK-and-VOQUEZNA-DUAL-PAK-FDA-Final-Label-3.pdf
DB01212,,"DailyMed Label: ceftriaxone sodium injection, powder for solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d1ad77f-2c6b-4250-82e5-ab3574444e08
DB01212,,FDA: Ceftriaxone - Injection products,https://www.fda.gov/drugs/development-resources/ceftriaxone-injection-products
DB01216,,FDA Approved Drug Products: PROPECIA (finasteride) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020788s028lbl.pdf
DB01216,,Finasteride - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK513329/
DB01216,,FDA Approved Drug Products: PROSCAR (finasteride) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020180s047lbl.pdf
DB01216,,FDA Approved Drug Products: Entadfi (finasteride/tadalafil) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215423s000lbl.pdf
DB01217,,FDA Approved Drug Products: Arimidex (anastrozole) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf
DB01217,,EMA Approved Drugs: Anastrozole,https://www.ema.europa.eu/en/documents/referral/arimidex-article-30-referral-annex-iii_en.pdf
DB01217,,DPD Approved Drugs: Anastrozole,https://pdf.hres.ca/dpd_pm/00037304.PDF
DB01217,,Medsafe NZ: Anastrozole,https://www.medsafe.govt.nz/profs/Datasheet/r/rolintab.pdf
DB01217,,CaymenChem: Anastrozole MSDS,https://www.caymanchem.com/msdss/11987m.pdf
DB01221,,Ketamine,http://ketamine.com/history-of-ketamine/
DB01221,,Ketamine monograph,https://www.sandoz.ca/sites/www.sandoz.ca/files/Ketamine_HCl_PMe_20150506.pdf
DB01221,,Time magazine,http://time.com/4876098/new-hope-for-depression/
DB01222,,FDA Approved Drug Products: Rhinocort Budesonide Nasal Metered Aerosol (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020233
DB01222,,FDA Approved Drug Products: Entocort Budesonide Oral Extended Release Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021324s018lbl.pdf
DB01222,,FDA Approved Drug Products: Ortikos Budesonide Oral Extended Release Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211929s000lbl.pdf
DB01222,,FDA Approved Drug Products: Pulmicort Budesonide Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021949s013lbl.pdf
DB01222,,FDA Approved Drug Products: Pulmicort Budesonide Inhalation Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020929s052lbl.pdf
DB01222,,FDA Approved Drug Products: Rhinocort Budesonide Nasal Metered Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020746Orig1s037lbl.pdf
DB01222,,FDA Approved Drug Products: Symbicort (budesonide/formoterol fumarate) inhalation aerosol,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s042lbl.pdf
DB01222,,FDA Approved Drug Products: Uceris Budesonide Oral Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203634s000lbl.pdf
DB01222,,FDA Approved Drug Products: Uceris Budesonide Rectal Aerosol Foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205613s000lbl.pdf
DB01222,,"BioSpace News: Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva",https://www.biospace.com/article/releases/viatris-inc-announces-receipt-of-the-first-fda-approval-for-generic-version-of-symbicort-inhalation-aerosol-breyna-budesonide-and-formoterol-fumarate-dihydrate-inhalation-aerosol-in-partnership-with-kindeva/?s=74
DB01222,,EMA Approved Drug Products: Kinpeygo (budesonide) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/kinpeygo-epar-product-information_en.pdf
DB01222,,EMA Approved Drug Products: Jorveza (budesonide) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/jorveza-epar-product-information_en.pdf
DB01222,,"FDA Approved Drug Products: AIRSUPRA (albuterol and budesonide) inhalation aerosol, for oral inhalation use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214070s000lbl.pdf
DB01222,,"FDA Approved Drug Products: TARPEYO (budesonide) delayed release capsules, for oral use (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215935s003lbl.pdf
DB01222,,FDA Approved Drug Products: EOHILIA (budesonide) oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213976s000lbl.pdf
DB01223,,AIFA Product Information: Aminomal (aminophylline) for injection or rectal administration,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000550_011226_RCP.pdf&retry=0&sys=m0b1l3
DB01224,,Quetiapine fumarate fda label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022047s033s037lbl.pdf
DB01224,,AstraZeneca SDS: Quetiapine,https://www.astrazeneca.com.au/content/dam/az-au/Material%20Safety%20Data/2018/MSDS_Seroquel%20Tablets_SDS1010_12.17_v3.0.pdf
DB01224,,"FDA Approved Drug Products: SEROQUEL (quetiapine) tablets, for oral use (January 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020639s072lbl.pdf
DB01225,,"FDA Approved Drug Products: Lovenox (enoxaparin sodium injection), for subcutaneous and intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020164s116lbl.pdf
DB01225,,NIH StatPearls: Enoxaparin,https://www.ncbi.nlm.nih.gov/books/NBK539865/
DB01225,,Medsafe NZ Datasheet: CLEXANE AND CLEXANE FORTE (enoxaparin sodium) for injection,https://www.medsafe.govt.nz/Profs/Datasheet/c/Clexaneinj.pdf
DB01225,,Pfizer: Enoxaparin sodium MSDS,https://pfe-pfizercom-d8-prod.s3.amazonaws.com/products/material_safety_data/PZ01437.pdf
DB01227,,EMA: Public statement on the recommendation to suspend the marketing authorisation for Orlaam (levacetylmethadol) in the European Union,https://www.ema.europa.eu/en/documents/public-statement/public-statement-recommendation-suspend-marketing-authorisation-orlaam-levacetylmethadol-european_en.pdf
DB01231,,Link,http://www.medicinenet.com/diphenidol_hcl-oral/article.htm
DB01232,,FDA Approved Drug Products: Invirase (saquinavir mesylate) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021785s024lbl.pdf
DB01232,,Health Canada Product Monograph: Invirase (saquinavir mesylate) for oral administration,https://pdf.hres.ca/dpd_pm/00055570.PDF
DB01232,,CaymanChem: Saquinavir MSDS,https://www.caymanchem.com/msdss/9001893m.pdf
DB01233,,Metoclopramide FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017854s062lbl.pdf
DB01233,,Reglan injection FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017862s063lbl.pdf
DB01233,,Metoclopramide MSDS,https://pfe-pfizercom-prod.s3.amazonaws.com/products/material_safety_data/Metoclopramide_Inj(Hospira)_4-jan-2017.pdf
DB01233,,FDA Approved Drug Products: Gimoti Metoclopramide Nasal Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209388s000lbl.pdf
DB01233,,INVIMA Product Authorization: Clifar (metoclopramide hydrochloride/simethicone) oral suspension,http://web.sivicos.gov.co/registros/pdf/1388632_2015050647.pdf
DB01234,,FDA Approved Drug Products: Decadron Dexamethasone Oral Tablet (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011664
DB01234,,FDA Approved Drug Products: Ciprodex Dexamethasone and Ciprofloxacin Otic Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021537s017lbl.pdf
DB01234,,FDA Approved Drug Products: Dexamethasone Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/40572s002lbledt.pdf
DB01234,,FDA Approved Drug Products: Dextenza Dexamethasone Ophthalmic Insert,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208742s007lbl.pdf
DB01234,,FDA Approved Drug Products: Dexycu Dexamethasone Intraocular Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208912s000lbl.pdf
DB01234,,FDA Approved Drug Products: Hemady Dexamethasone Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf
DB01234,,FDA Approved Drug Products: Maxidex Dexamethasone Ophthalmic Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/013422s045lbl.pdf
DB01234,,"FDA Approved Drug Products: Maxitrol Neomycin, Polymyxin B, and Dexamethasone Ophthalmic Suspension",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050023s036lbl.pdf
DB01234,,FDA Approved Drug Products: Ozurdex Dexamethasone Intravitreal Implant,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022315s012lbl.pdf
DB01234,,"FDA Approved Drug Products: Maxitrol Neomycin, Polymyxin B, and Dexamethasone Ophthalmic Ointment",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050065s064lbl.pdf
DB01234,,FDA Approved Drug Products: Tobradex Tobramycin and Dexamethasone Ophthlamic Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050818s001lbl.pdf
DB01234,,RECOVERY trial news release: dexamethasone,https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf
DB01235,,FDA Approved Drug Products: Sinemet,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017555
DB01236,,"FDA Approved Drug Products: Ultane (sevoflurane), volatile liquid for inhalation",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020478s032lbl.pdf
DB01236,,Cayman chemical: Sevoflurane SDS,https://cdn.caymanchem.com/cdn/msds/23996m.pdf
DB01238,,FDA Drug Approval Package: Aripiprazole,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-436_Abilify.cfm
DB01238,,Clinicaltrails.gov: National Pregnancy Registry for Atypical Antipsychotics,https://clinicaltrials.gov/ct2/show/NCT01246765
DB01238,,"FDA Approved Drug Products: ABILIFY (aripiprazole) tablets for oral use, orally disintegrating tablets, oral solution, injection for intramuscular use only (November 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021436s048lbledit.pdf
DB01238,,"FDA Approved Drug Products: ABILIFY ASIMTUFII® (aripiprazole) extended-release injectable suspension, for intramuscular use",https://www.otsuka-us.com/sites/g/files/qhldwo7066/files/media/static/Abilify-Asimtufii-PI.pdf
DB01241,,FDA Approved Drug Products: Gemfibrozil Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018422s058lbl.pdf
DB01241,,Cayman Chemicals: Gemfibrozil MSDS,https://www.caymanchem.com/msdss/14835m.pdf
DB01247,,Validus pharma news,http://validuspharma.com/blog/marplan-acquisition/
DB01247,,National Institute of Mental Health,https://www.nimh.nih.gov/health/topics/depression/index.shtml
DB01248,,FDA Approved Drug Products: DOCETAXEL injection for intravenous use (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022234s022lbl.pdf
DB01248,,Pfizer: Docetaxel Injection SDS,https://cdn.pfizer.com/pfizercom/products/material_safety_data/PZ00906.pdf
DB01248,,FDA Approved Drug Products: TAXOTERE (docetaxel) for injection concentrate (December 1999),https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20449S11LBL.PDF
DB01250,,FDA Approved Drug Products: DIPENTUM (olsalazine) Oral Capsules (November 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019715s032lbl.pdf
DB01250,,Health Canada Approved Drug Products: DIPENTUM (olsalazine sodium) Oral Capsules,https://pdf.hres.ca/dpd_pm/00029931.PDF
DB01250,,FDA Approved Drug Products: Dipentum (olsalazine) oral capsules (October 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019715s033lbl.pdf
DB01254,,FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf
DB01254,,Bristol Myers Squibb: Dasatinib SDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9BRMY_SPRYCEL_TAB_50MG_60BT.pdf
DB01254,,FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006),https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/022072lbl.pdf
DB01255,,"FDA Approved Drug Products: VYVANSE (lisdexamfetamine dimesylate) capsules and chewable tablets, for oral use, CII (January 2022)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021977s048,208510s005lbl.pdf"
DB01255,,Health Canada Approved Drug Products: VYVANSE (lisdexamfetamine dimesylate) Oral Capsules,https://pdf.hres.ca/dpd_pm/00070353.PDF
DB01256,,Link,http://www.centerwatch.com/patient/drugs/dru946.html
DB01256,,FDA Approved Drug Products: ALTABAX (retapamulin) ointment,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022055s007lbl.pdf
DB01257,,FDA: Eculizumab New Indication,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-neuromyelitis-optica-spectrum-disorder-rare-autoimmune-disease-central
DB01257,,FDA Approved Drug Products: Eculizumab Intravenous Infusion,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166
DB01257,,Alexion Pharma: Soliris Product Monograph,https://alexion.com/Documents/Canada/Product-Monograph-Soliris-English.aspx
DB01257,,CHMP Summary of Positive Opinion: Bekemv (eculizumab),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/bekemv
DB01257,,CHMP Summary of Positive Opinion: Epysqli (eculizumab),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/epysqli
DB01257,,EMA Approved Drug Products: Epysqli (Eculizumab) solution for infusion,https://www.ema.europa.eu/en/documents/product-information/epysqli-epar-product-information_en.pdf
DB01257,,"FDA Approved Drug Products: SOLIRIS (eculizumab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125166s434lbl.pdf
DB01261,,FDA Drug Approval Package: Sitagliptin,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000TOC.cfm
DB01261,,Merck Pregnancy Registry: Sitagliptin,http://www.merckpregnancyregistries.com/januvia.html
DB01261,,"FDA Approved Drug Products: JANUMET (sitagliptin and metformin hydrochloride) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022044s048lbl.pdf
DB01261,,"FDA Approved Drug Products: JANUVIA (sitagliptin) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021995s047lbl.pdf
DB01261,,"FDA Approved Drug Products: STEGLUJAN (ertugliflozin and sitagliptin) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209805s010lbl.pdf
DB01261,,"FDA Approved Drug Products: JANUVIA (sitagliptin) tablets, for oral use, 2022",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021995s050lbl.pdf
DB01262,,FDA Approved Drug Products: decitabine for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205582s000lbl.pdf
DB01262,,Cayman Chemical: decitabine MSDS,https://www.caymanchem.com/msdss/11166m.pdf
DB01262,,SignalChem decitabine product sheet,https://www.signalchem.com/shared_product_sheets/P3320-15.pdf
DB01263,,"FDA Approved Drug Products: NOXAFIL (posaconazole) injection, suspension, and tablets","https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022003s028,205053s014,205596s015,214770s002lbl.pdf"
DB01264,,Link,http://www.medilexicon.com/drugs/prezista.php
DB01264,,FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf"
DB01264,,Medicines UK: Zentiva 800mg film coated tablets,https://www.medicines.org.uk/emc/product/10124/smpc
DB01264,,Clinicaltrials.gov: Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV (DACO-nCoV),https://clinicaltrials.gov/ct2/show/NCT04252274
DB01267,,FDA Approved Drug Products: Invega (paliperidone) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf
DB01267,,FDA Approved Drug Products: Invega Trinza (paliperidone palmitate) extended-release suspension for intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207946s008lbl.pdf
DB01267,,FDA Approved Drug Products: Invega Sustenna (paliperidone palmitate) extended-release suspension for intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022264Orig1s033lbl.pdf
DB01267,,FDA Approved Drug Products: Invega Hafyera (paliperidone palmitate) extended-release suspension for gluteal intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207946s010lbl.pdf
DB01268,,FDA Approved Drug Products: Sutent (sunitinib malate) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021938s039lbledt.pdf
DB01269,,FDA Approved Drug Products: VECTIBIX (panitumumab) Injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125147s207lbl.pdf
DB01270,,FDA Approved Drug Products: Lucentis (ranibizumab) for intravitreal injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf
DB01270,,FDA Approved Drug Products: Susvimo (ranibizumab) for intravitreal use via ocular implantation,https://www.gene.com/download/pdf/susvimo_prescribing.pdf
DB01270,,"GlobeNewswire News Release: Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)",https://www.globenewswire.com/news-release/2022/03/10/2400731/0/en/Health-Canada-Approves-Samsung-Bioepis-and-Biogen-s-BYOOVIZ-SB11-LUCENTIS-Biosimilar-ranibizumab.html
DB01270,,EMA Medicines: Lucentis,https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis
DB01270,,EMA Approved Drug Products: Lucentis (ranibizumab) intravitreal injection,https://www.ema.europa.eu/en/documents/product-information/lucentis-epar-product-information_en.pdf
DB01270,,"FDA Approved Drug Products: CIMERLI (ranibizumab-eqrn) injection, for intravitreal use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761165s000lbl.pdf
DB01270,,EMA Approved Drug Products: Ranivisio (ranibizumab) Intravitreal Injection,https://www.ema.europa.eu/en/documents/product-information/ranivisio-epar-product-information_en.pdf
DB01270,,Health Canada Approved Drug Proucts: RANOPTO (Ranibizumab) injection for intravitreal use,https://pdf.hres.ca/dpd_pm/00072813.PDF
DB01270,,"Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®","https://www.eqs-news.com/news/corporate/health-canada-approves-fyb201-ranopto-ranibizumab-a-biosimilar-to-lucentis/1954825#:~:text=Munich%2C%20Amsterdam%2C%20Zug%2C%20Toronto,serious%20retinal%20diseases%20in%20Canada."
DB01273,,FDA Approved Drug Products: TYRVAYA (varenicline) nasal spray,https://www.tyrvaya-pro.com/files/prescribing-information.pdf
DB01274,,TITCK Product Information: Airbir (arformoterol tartrate/budesonide) capsule with powder for inhalation,https://titck.gov.tr/storage/kubKtAttachments/8b65920873041.pdf
DB01274,,FDA Approved Drug Products: Brovana (arformoterol tartrate) solution for inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021912Orig1s032lblrpl.pdf
DB01275,,FDA Approved Drug Products: Apresoline Hydralazine Hydrochloride Tablets and Injections (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008303
DB01275,,FDA Approved Drug Products: Hydralazine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf
DB01275,,FDA Approved Drug Products: Hydralazine and Isosorbide Dinitrate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020727s010lbl.pdf
DB01276,,FDA Drug Approval Package: Exenatide,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_byettatoc.cfm
DB01276,,FDA Pharmacology Review: Exenatide,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021919s000pharmr.pdf
DB01276,,FDA Approved Drug Products: Bydureon (exenatide extended-release) suspension for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022200s031lbl.pdf
DB01276,,FDA Approved Drug Products: Bydureon BCise (exenatide extended-release) suspension for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209210s019lbl.pdf
DB01276,,FDA Approved Drug Products: Byetta (exenatide) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021773s046s047lbl.pdf
DB01276,,OptumRx: Bydureon (exenatide) Pen – Product discontinuation,https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-recalls-shortages/drugwithdrawal_bydurenpen_2020-1104.pdf
DB01276,,FDA Approved Drug Products: BYDUREON (exenatide) extended-release injectable suspension for subcutaneous use (December 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022200s034lbl.pdf
DB01277,,FDA Approved Drug Products: Increlex Mecasermin Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021839s024lbl.pdf
DB01280,,FDA Approved Drug Products: NELARABINE- nelarabine injection,https://www.accessdata.fda.gov/spl/data/8f294d33-293a-4696-808f-2dbdf94d729d/8f294d33-293a-4696-808f-2dbdf94d729d.xml
DB01280,,"FDA Approved Drug Products: ARRANON (nelarabine) injection, for intravenous use 2",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021877s010lbl.pdf
DB01280,,"Health Canada Approved Drug Proucts: ATRIANCE (Nelarabine) injection, for intravenous use",https://pdf.hres.ca/dpd_pm/00068601.PDF
DB01280,,FDA Approved Drug Products: ARRANON® (nelarabine) Injection FOR INTRAVENOUS USE,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf
DB01280,,Fact sheet - Atriance (nelarabine),https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/fact-sheet-atriance-nelarabine.html
DB01280,,Atriance,https://www.ema.europa.eu/en/medicines/human/EPAR/atriance
DB01281,,FDA Approved Drug Products: Orencia (abatacept) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125118s240lbl.pdf
DB01281,,Health Canada Approved Drug Products: Orencia (abatacept) for injection,https://pdf.hres.ca/dpd_pm/00066773.PDF
DB01281,,FDA Approved Drug Products: Orencia (abatacept) for intravenous or subcutaneous injection (October 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125118s250lbl.pdf
DB01285,,FDA Approved Drug Products: CORTROPHIN (corticotropin) gel for injection,https://www.cortrophin.com/pdfs/purified-cortrophin-gel-prescribing-information.pdf
DB01288,,AIFA Product Information: Dosberotec (fenoterol hydrobromide) for inhalation,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001436_023457_RCP.pdf&retry=0&sys=m0b1l3
DB01294,,"DailyMed Label: PEPTO-BISMOL (bismuth subsalicylate) kit, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33baaf04-498d-44f2-9288-02b8f874f914
DB01294,,Santa Cruz Biotechnology: Bismuth(III) subsalicylate Safety Data Sheet,https://datasheets.scbt.com/sc-227416.pdf
DB01294,,Spectrum Chemical: Bismuth salicylate Safety Data Sheet,https://www.spectrumchemical.com/MSDS/BI152_AGHS.pdf
DB01294,,"FDA Approved Drug Products: HELIDAC Therapy (bismuth subsalicylate, metronidazole, and tetracycline)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050719s017s020lbl.pdf
DB01296,,TITCK Product Information: Dona (crystalline glucosamine sulfate) for intramuscular injection,https://titck.gov.tr/storage/kubKtAttachments/13353d0c28269.pdf
DB01296,,TITCK Product Information: Dona Plus (chondroitin sulfate/glucosamine sulfate) powder for oral use,https://titck.gov.tr/storage/kubKtAttachments/UVnN4UbiHGM70.pdf
DB01296,,Zoetisus Safety Data Sheet: Glucosamine sulfate,https://www.zoetisus.com/contact/pages/product_information/msds_pi/msds/restor-a-flex.pdf
DB01296,,AAFP (American Family Physician): Glucosamine,https://www.aafp.org/afp/2008/0815/p471.html
DB01296,,NIH MedlinePlus: Glucosamine,https://medlineplus.gov/druginfo/natural/747.html
DB01296,,"DailyMed: Theraflex advance (ibuprofen, glucosamine sulfate, Chondroitin sulfate) oral tablet",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fbde87b-d0d9-4a62-b8a3-9320cbb727a5
DB01296,,National Capital Poison Center: What you need to know about glucosamine,https://www.poison.org/articles/2016-sep/glucosamine
DB01299,,FDA Approved Drug Products: FANSIDAR (sulfadoxine and pyrimethamine) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf
DB01306,,FDA Approved Drug Products: Novolog (insulin aspart) for SC/IV injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020986s090s091lbl.pdf
DB01306,,"EMA Approved Drug Products: Truvelog Mix 30 (insulin aspart and protamine-crystallised insulin aspart, 30:70) subcutaneous injection",https://www.ema.europa.eu/en/documents/product-information/truvelog-mix-30-epar-product-information_en.pdf
DB01306,,FDA Approved Drug Products: Fiasp (insulin aspart) injection for subcutaneous or intravenous administration (June 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208751s020lbl.pdf
DB01307,,FDA Approved Drug Products: Levemir (insulin detemir) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021536s057s058lbl.pdf
DB01307,,FDA Approved Drug Products: Levemir (insulin detemir) for subcutaneous injection 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021536s060lbl.pdf
DB01307,,"Health Canada Approved Drug Proucts: LEVEMIR® (insulin detemir) injection, for subcutaneous use",https://pdf.hres.ca/dpd_pm/00062477.PDF
DB01309,,FDA Approved Drug Products: Apidra (insulin glulisine),https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021629s030lbl.pdf
DB01320,,FDA Approved Drug Products: SESQUIENT (fosphenytoin) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210864s000lbl.pdf
DB01329,,TITCK Product Information: Cefobid (cefoperazone sodium) for intramuscular/intravenous injection,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK%20UYGUN%20K%C3%9CB%20CEFOB%C4%B0D%201%20G%20FLAKON.pdf_fb7aad55-86fd-4e8c-8e90-104b4e8a990c.pdf
DB01339,,FDA Approved Drug Products: vecuronium bromide injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/075549s013lbl.pdf
DB01356,,ILO: Lithium,http://www.ilo.org/dyn/icsc/showcard.display?p_card_id=0710
DB01362,,FDA Approved Drug Products: OMNIPAQUE (iohexol) injection and oral solution.,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018956s101lbl.pdf
DB01364,,FDA Approved Drug Products: Emerphed Ephedrine Sulfate Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213407s000lbl.pdf
DB01364,,FDA Approved Drug Products: Akovaz Ephedrine Sulfare Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208289s005lbl.pdf
DB01364,,Cayman Chemical: Ephedrine MSDS,https://www.caymanchem.com/msdss/14143m.pdf
DB01364,,Dailymed: Ephedrine Nasal Spray,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bf3e120-ac51-4b14-8584-ab561f6ed446
DB01364,,"Dailymed: Ephedrine Intravenous, Intramuscular, and Subcutaneous Injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4a4021c-c092-41bf-91ed-ef483fd52732
DB01364,,FDA Approved Drug Products: Rezipres (Ephedrine Hydrochloride) Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213536s000lbl.pdf
DB01377,,"FDA Approved Drug Products: CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209589s014lbl.pdf
DB01380,,FDA Approved Drug Products: Cortone Cortisone Acetate Injection (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007110
DB01380,,DailyMed Label: Cortisone acetate tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85cfed58-e5f1-4170-8d83-60e6bebd3610
DB01381,,National Toxicology Program: Ginkgo Biloba Extract Nomination Background,https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/ginkgo_gbe_508.pdf
DB01381,,"European Medicines Agency: Ginkgo biloba L., folium Monograph",https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ginkgo-biloba-l-folium_en.pdf
DB01381,,International Agency for Research on Cancer (IARC): Ginkgo biloba Monograph,https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono108-03.pdf
DB01381,,"European Medicines Agency: Assessment report on Ginkgo biloba L., folium",https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ginkgo-biloba-l-folium_en.pdf
DB01381,,Natural Medicines: Ginkgo,https://naturalmedicines.therapeuticresearch.com/media/25766873/Natural-Medicines-Sample-Monograph.pdf
DB01390,,TITCK Product Information: ENHOŞ MEYVE TUZU (tartaric acid/sodium bicarbonate) effervescent powder,https://titck.gov.tr/storage/kubKtAttachments/fd01d4b758283.pdf
DB01390,,INVIMA Product Authorization: Lua Plus Fruit Salt (simeticone/sodium bicarbonate) oral granules,http://web.sivicos.gov.co/registros/pdf/15576037_2018016823.pdf
DB01390,,AIFA Package Leaflet: TETROFOSMINA ROTOP (sodium bicarbonate and tetrofosmin) intravenous kit,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004345_046081_RCP.pdf&retry=0&sys=m0b1l3
DB01390,,FDA Approved Drug Products: KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213593s000lbl.pdf
DB01394,,FDA Approved Drug Products: Colcrys (colchicine) tablets for oral use (May 2020),https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022352s026lbl.pdf
DB01394,,Cayman Chemical: Colchicine MSDS,https://www.caymanchem.com/msdss/9000760m.pdf
DB01394,,FDA Pharmacology Review: Mitigare (colchicine) Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000PharmR.pdf
DB01394,,"FDA Approved Drug Products: LODOCO (colchicine) tablets, for oral use (June 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215727s000lbl.pdf
DB01395,,YAZ fda label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021676s009lbl.pdf
DB01395,,Yaz Bayer monograph,https://www.bayer.ca/omr/online/yaz-pm-en.pdf
DB01395,,"2012 FDA safety statement, YAZ",https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-information-about-risk-blood-clots-women-taking-birth-control
DB01395,,"FDA pharmacology review, Drospirenone",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022532Orig1s000PharmR.pdf
DB01395,,Angeliq EU label,http://mri.cts-mrp.eu/download/NL_H_0380_001_FinalSPC.pdf
DB01395,,drospirenone/ethinyl estradiol - Drug Summary,https://www.pdr.net/drug-summary/Yaz-drospirenone-ethinyl-estradiol-98
DB01395,,Angeliq FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021355s003lbl.pdf
DB01395,,Safyral FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022574s001lbl.pdf
DB01395,,Product monograph: Nexstellis (estetrol and drospirenone) oral tablets,http://searchlightpharma.com/app/uploads/2021/03/Nextstellis-product-monograph-en-05mar21.pdf
DB01395,,FDA Approved Drug Products: NEXTSTELLIS (drospirenone and estetrol) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf
DB01395,,"FDA Approved Drug Products: YASMIN (drospirenone/ethinyl estradiol) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021098s029lbl.pdf
DB01403,,Link,http://www.doctissimo.fr/medicament-NOZINAN.htm
DB01409,,FDA Drug Approval Package: Tiotropium Bromide Powder for Inhalation,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021395
DB01409,,FDA Approved Drug Products: Tiotropium and Olodaterol Metered Inhalation Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206756s011lbl.pdf
DB01409,,FDA Approved Drug Products: Tiotropium Inhalation Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207070s000lbl.pdf
DB01409,,FDA Approved Drug Products: Tiotropium Metered Inhalation Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021936s012lbl.pdf
DB01410,,TITCK Product Information: Tivenos (ciclesonide/tiotropium bromide) powder for inhalation,https://titck.gov.tr/storage/kubKtAttachments/1630c32886718.pdf
DB01411,,ilacaBak: Pranlux (pranlukast) oral capsules,https://www.ilacabak.com/pranlux-112-5-mg-30-kapsul-16969/kisa-urun-bilgisi
DB01413,,FDA Approved Drug Products: MAXIPIME (cefepime hydrochloride) injection for intravenous or intramuscular use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050679s046lbl.pdf
DB01413,,"FDA Approved Drug Products: Cefepime and dextrose injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050821s006lbl.pdf
DB01413,,Hospira: Cefepime hydrochloride SDS,https://safetydatasheets.pfizer.com/DirectDocumentDownloader/Document?prd=PZ03078~~PDF~~MTR~~HSP~~EN~~PFIZER&DocType=DOC
DB01413,,"FDA Approved Drug Products: EXBLIFEP (cefepime and enmetazobactam) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216165s000lbl.pdf
DB01420,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cdef530-023e-4d34-8e97-77f143b0068f
DB01420,,Empowerpharmacy,https://www.empowerpharmacy.com/drugs/testosterone-propionate-injection
DB01420,,Fittness uncovered,http://www.fitnessuncovered.co.uk/performance-drugs/profiles/testosterone-propionate
DB01424,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB01435,,INVIMA Product Authorization: Calzas (antipyrine/benzocaine) oral solution,http://web.sivicos.gov.co/registros/pdf/15608084_2018025517.pdf
DB01436,,"LEO Pharma Inc. Product Monograph: ONE-ALPHA (alfacalcidol), for oral and intravenous use",https://pdf.hres.ca/dpd_pm/00040724.PDF
DB01436,,Biosynth Carbosynth: Alfacalcidol Safety Data Sheet,https://static.cymitquimica.com/products/3D/pdf/sds-FA17275.pdf
DB01436,,AIFA Package Leaflet: DEDIOL (Alfacalcidol) for oral and intravenous use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000819_025487_RCP.pdf&retry=0&sys=m0b1l3
DB01436,,Summary of Product Characteristics: Alfacalcidol Aristo oral capsules,https://file.wuxuwang.com/hma/DK_H_2674_001_FinalSPC.pdf
DB01438,,Phenazopyridine Hydrochloride,https://pdf.hres.ca/dpd_pm/00011122.PDF
DB01438,,Drug summary: phenazopyridine,https://www.pdr.net/drug-summary/Pyridium-phenazopyridine-hydrochloride-3457.101
DB01438,,FDA information Phenazopyridine,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019358
DB01438,,"HMDB, phenazopyridine",http://www.hmdb.ca/metabolites/HMDB0015506
DB01438,,Phenazopyridine DailyMed,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=da0a825f-329d-ae56-b834-eeaf65ff596c&type=display
DB01438,,"MSDS, Phenazopyridine",https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_FSHSCI_REAGENT_PHENAZOPYRIDINE_HCL_50MG.pdf
DB01438,,UPMC: Final Diagnosis -- Suicide Attempt with Ingestion of Pyridium Tablets,https://path.upmc.edu/cases/case311/dx.html
DB01438,,Intracellular Drug Bioavailability: Effect of Neutral Lipids and Phospholipids,https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.8b00064
DB01438,,O Factors Affecting Drug Metabolism,https://www.pharmacologicalsciences.us/pharmaceutical-chemistry/o-factors-affecting-drug-metabolism.html
DB01438,,Phenazopyridine hydrochloride,https://ntp.niehs.nih.gov/ntp/roc/content/profiles/phenazopyridinehydrochloride.pdf
DB01452,,"Huecker MR, Marraffa J. Heroin. [Updated 2018 Oct 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan.",https://www.ncbi.nlm.nih.gov/books/NBK441876/
DB01452,,Electronic Medicines Compendium: Diamorphine Hydrochloride BP 100 mg Lyophilisate for Solution for Injection Monograph,https://www.medicines.org.uk/emc/product/2040/smpc
DB01452,,"Murphy PB, Barrett MJ. Morphine. [Updated 2018 Oct 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan",https://www.ncbi.nlm.nih.gov/books/NBK526115/
DB01463,,Link,http://home.intekom.com/pharm/merckp/reactivn.html
DB01546,,Link,http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=11
DB01551,,"FDA Approved Drug Products: SYNALGOS®-DC (aspirin, caffeine, and dihydrocodeine bitartrate) capsules, for oral use, CIII (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/011483s035lbl.pdf
DB01576,,FDA Drug Approval Package for Dextroamphetamine,https://www.accessdata.fda.gov/drugsatfda_docs/anda/2001/040361_dextroamphetamine_toc.cfm
DB01576,,FDA Approved Drug Products: Adderall (dextroamphetamine) capsule,https://pi.shirecontent.com/PI/PDFs/AdderallXR_USA_ENG.PDF
DB01577,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB01586,,"FDA Approved Drug Products: URSO 250 and URSO FORTE (ursodiol) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020675s028lbl.pdf
DB01586,,Medisca: Ursodiol MSDS,https://www.medisca.com/NDC_SPECS/MUS/1987/MSDS/1987.pdf
DB01586,,DailyMed Label: URSODIOL Oral Capsules,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a061bb07-a85d-4b08-877f-ce02156f0de7
DB01589,,FDA Approved Drug Products: Doral (quazepam) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018708s029lbl.pdf
DB01591,,FDA Approved Drug Products: Solifenacin Succinate Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021518s017lbl.pdf
DB01591,,Cayman Chemicals: Solifenacin MSDS,https://www.caymanchem.com/msdss/17320m.pdf
DB01593,,Zinc and its importance for human health: An integrative review,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724376/
DB01593,,The Essential Toxin: Impact of Zinc on Human Health,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872358/
DB01593,,Dietary factors affecting Zinc bioavailability,http://journals.sagepub.com/doi/pdf/10.1177/156482650102200204
DB01593,,Zinc,https://www.mayoclinic.org/drugs-supplements-zinc/art-20366112
DB01593,,"Zinc Transporters, Mechanisms of Action and Therapeutic Utility: Implications for Type 2 Diabetes Mellitus",https://www.hindawi.com/journals/jnme/2012/173712/
DB01593,,"Zinc, future mono/adjunctive therapy for depression: Mechanisms of antidepressant action",https://www.sciencedirect.com/science/article/abs/pii/S1734114015000274
DB01593,,MeSH Zinc,https://www.ncbi.nlm.nih.gov/mesh?Db=mesh&Cmd=DetailsSearch&Term=%22Zinc%22%5BMeSH+Terms%5D
DB01593,,Agency for Toxic Substances and Disease Registry: Toxicological Profile for Zinc,https://www.atsdr.cdc.gov/toxprofiles/tp60-c3.pdf
DB01593,,ZINC COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6912
DB01593,,"Pharmacokinetics, tissue distribution, and excretion of zinc oxide nanoparticles",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394467/
DB01593,,Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia,https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.2830310203
DB01593,,Zinc Therapy in Dermatology: A review,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120804/
DB01593,,Treatment of Wilson’s Disease with Zinc. I. Oral Zinc Therapy Regimens,https://pdfs.semanticscholar.org/896f/03dae9396d9463c552aff6e9ab78dcd44f06.pdf
DB01593,,Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394849/
DB01593,,Zinc Supplementation in treating diarrhea in children,http://www.cochrane.org/CD005436/INFECTN_oral-zinc-supplementation-treating-diarrhoea-children
DB01593,,Zinc homeostasis in humans,https://academic.oup.com/jn/article/130/5/1360S/4686372
DB01593,,"ZINC: Uses, Side Effects, Interactions and Warnings - WebMD",https://www.webmd.com/vitamins.../ingredientmono-982-zinc.aspx?...982...zinc
DB01593,,Zinc Toxicity in Humans,https://pdfs.semanticscholar.org/a9e2/8321ae506e646f32ce59d87b7589851aa7e4.pdf
DB01593,,Chapter 16. Zinc,http://www.fao.org/docrep/004/y2809e/y2809e0m.htm
DB01593,,Zinc metabolism,http://flipper.diff.org/app/pathways/3503
DB01593,,"Copper and Zinc, Biological Role and Significance of Copper/Zinc Imbalance",https://www.omicsonline.org/copper-and-zinc-biological-role-and-significance-of-copper-zincimbalance-2161-0495.S3-001.php?aid=3055
DB01593,,The emerging role of zinc transporters,https://www.nature.com/articles/sigtrans201729
DB01597,,"FDA Approved Drug Products: Recarbrio (imipenem, cilastatin, and relebactam) for intravenous injection",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212819s002lbl.pdf
DB01597,,FDA: Primaxin Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050587s081lbl.pdf
DB01597,,ChemSpider: Cilastatin,http://www.chemspider.com/Chemical-Structure.4940183.html?rid=95b4e0e3-45f3-40b1-ab49-455b5e0f4b98
DB01597,,FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s002s003lbl.pdf
DB01597,,Drugs@FDA: Primaxin,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050587
DB01598,,FDA: Primaxin Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050587s081lbl.pdf
DB01598,,"FDA Approved Drug Products: Recarbrio (imipenem, cilastatin, and relebactam) for intravenous injection",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212819s002lbl.pdf
DB01598,,Drugs@FDA: Primaxin,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050587
DB01601,,FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021251s058,021906s053lbl.pdf"
DB01601,,Nature Biotechnology: Coronavirus puts drug repurposing on the fast track,https://www.nature.com/articles/d41587-020-00003-1
DB01601,,CaymanChem: Lopinavir MSDS,https://www.caymanchem.com/msdss/13854m.pdf
DB01601,,Health Canada Product Monograph: Kaletra (lopinavir/ritonavir) for oral use,https://pdf.hres.ca/dpd_pm/00053305.PDF
DB01606,,FDA Approved Drug Products: ZOSYN (piperacillin and tazobactam) injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050684s098,050750s045lbl.pdf"
DB01606,,Medsafe NZ: Tazocin,https://medsafe.govt.nz/profs/Datasheet/t/Tazocininj.pdf
DB01606,,Pfizer medical information,https://www.pfizermedicalinformation.com/en-us/zosyn/warnings
DB01606,,"FDA Approved Drug Products: ZERBAXA (ceftolozane and tazobactam) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206829s011s012lbl.pdf
DB01606,,FDA Approved Drug Products: ZERBAXA (ceftolozane and tazobactam) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206829s009lbl.pdf
DB01607,,FDA Approved Drug Products: TIMENTIN (sterile ticarcillin disodium and clavulanate potassium) for Intravenous Administration,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf"
DB01611,,FDA Approved Drug Products: Hydroxychloroquine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf
DB01611,,FDA: Emergency use Authorization for Hydroxychloroquine and Chloroquine Revoked,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and
DB01611,,"FDA Approved Drug Products: PLAQUENIL (hydroxychloroquine sulfate) tablets, for oral use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/009768s060lbl.pdf
DB01616,,Spasmonal Package Insert,http://www.medicines.org.uk/EMC/medicine/24562/SPC/
DB01620,,Pheniramine/Naphazoline Eye Drop Monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5649c6e2-966f-44d9-b57e-5bb988eb373d
DB01620,,Acetaminophen/Pheniramine/Phenylephrine Solution Monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49ada090-e70e-476f-89ce-9647c064e1e6
DB01620,,Cameo Chemicals: Pheniramine maleate,https://cameochemicals.noaa.gov/chemical/20879
DB01621,,Product Monograph: PIPORTIL (pipotiazine palmitate) intramuscular injection,https://products.sanofi.ca/en/piportil-l4.pdf
DB01624,,Link,http://medicaid.alabama.gov/documents/2.0_Newsroom/2.4_Procurement/2.4.3_Pharm_Support_ITB/2.4.3_Antipsychotic_Agents_Class_Review_8-10-11.pdf
DB01624,,Link,http://www.mentalhealth.com/drug/p30-z03.html
DB01627,,FDA Approved Drug Products: Lincocin (lincomycin) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050317s183lbl.pdf
DB01627,,EMA Committee Report Lincomycin Sep 1998,https://www.ema.europa.eu/en/documents/mrl-report/lincomycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf
DB01627,,Cayman Chemical: lincomycin MSDS,https://www.caymanchem.com/msdss/21526m.pdf
DB01656,,FDA Approved Drug Products: Daliresp (roflumilast) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022522s009lbl.pdf
DB01656,,FDA Approved Drug Products: Zoryve (roflumilast) cream for topical use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215985s000lbl.pdf
DB01656,,Arcutis Biotherapeutics: FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older,https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/
DB01656,,Health Canada Approved Drug Products: ZORYVE (Roflumilast) Topical Cream,https://pdf.hres.ca/dpd_pm/00070453.PDF
DB01656,,EMA Approved Drug Products: DAXAS (roflumilast) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/daxas-epar-product-information_en.pdf
DB01656,,"FDA Approved Drug Products: ZORYVE (roflumilast) topical foam, 0.3% (December 2023)",https://www.arcutis.com/wp-content/uploads/zoryve-foam-pi-hcp.pdf
DB01656,,"FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older",https://www.biospace.com/article/releases/fda-approves-arcutis-zoryve-roflumilast-topical-foam-0-3-percent-for-the-treatment-of-seborrheic-dermatitis-in-individuals-aged-9-years-and-older/?s=74
DB01656,,"FDA Approved Drug Products: ZORYVE (roflumilast) cream 0.3% and 0.15%, for topical use (July 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215985s007lbl.pdf
DB01669,,US Biological,http://www.usbio.net/item/O8070-50
DB01685,,Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review,https://www.pmda.go.jp/files/000153624.pdf
DB01708,,The NIH National Library of Medicine,http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-dhea.html
DB01708,,INTRAROSA™ FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208470s001lbl.pdf
DB01744,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB01914,,Baxter Health GLUCOSE INTRAVENOUS INFUSION BP Product information,http://www.baxterhealthcare.com.au/downloads/healthcare_professionals/cmi_pi/glucose%20IVI_pi.pdf
DB01914,,Glucose injection (Viaflex bag) Product information,http://www.medsafe.govt.nz/profs/Datasheet/g/glucoseinjviaflex.pdf
DB01956,,FDA GRAS,https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm465256.pdf
DB01956,,KEGG metabolism,http://www.genome.jp/kegg-bin/show_pathway?hsa00430
DB02546,,Vorinostat FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021991s009lbl.pdf
DB02638,,"FDA Approved Drug Products: TERLIVAZ (terlipressin) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf
DB02703,,Health Canada Product Monograph: Fucidin (fucidic acid) for topical use,https://pdf.hres.ca/dpd_pm/00040056.PDF
DB03088,,HMDB: Pyroglutamic Acid Metabocard,http://www.hmdb.ca/metabolites/HMDB0000267
DB03088,,Pyroglutamic acid: throwing light on a lightly studied metabolite,https://pdfs.semanticscholar.org/c50e/3ad15345b8901709d52d89f38c1c0fb6080c.pdf
DB03166,,eMedicine,http://www.emedicinehealth.com/drug-acetic_acid_otic/article_em.htm
DB03209,,European Medicines Agency (EMA): TEYSUNO (tegafur/gimeracil/oteracil) Summary of Product Characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001242/WC500104415.pdf
DB03404,,FDA Approved Drug Products: PANHEMATIN® (hemin for injection),https://www.panhematin.com/pdf/panhematin-marketing-PI.pdf
DB03615,,WHO: Critically Important Antimicrobials for Human Medicine 6th Revision,https://apps.who.int/iris/bitstream/handle/10665/312266/9789241515528-eng.pdf?ua=1
DB03619,,FDA Approved Drug Products: KYBELLA (deoxycholic acid) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206333s002s003lbl.pdf
DB03701,,"Brown, AM., et al. (2016). Vanoxerine for self-administration for terminating acute episodes of cardiac arrhythmia in mammals (U.S. Patent No. 2016/0038482 A1). U.S. Patent and Trademark Office.",https://patents.google.com/patent/US20160038482A1/en
DB03701,,Tocris: Vanoxerine SDS,https://documents.tocris.com/pdfs/tocris_msds/0421_sds.pdf?1652979250&_ga=2.95035294.341160112.1652998395-1186418058.1652998395&_gac=1.120108154.1652998395.Cj0KCQjw1ZeUBhDyARIsAOzAqQI3t8tYeMWXB62y98EMvVb_N3btJDrKk2XAph0Vwu8cXt0lwX9C4wsaAv_bEALw_wcB
DB03766,,RXmed.com: AMINO-CERV Monograph,https://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/cps-_monographs/CPS-_(General_Monographs-_A)/AMINO.html
DB03766,,FDA Listing of Propionic Acid,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1081
DB03766,,EFSA Journal: Safety of the extension of use of sodium propionate (E 281) as a food additive,https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2016.4546
DB03766,,"INCHEM Propionic Acid and its Calcium, Potassium, and Sodium Salts (WHO Food Additive Series 5)",http://www.inchem.org/documents/jecfa/jecmono/v05je16.htm
DB03766,,PROPIONIC ACID IS AN ALTERNATIVE TO ANTIBIOTICS IN POULTRY DIET,https://pdfs.semanticscholar.org/0f06/ef56b8d936245c4c0d4e124f0c4dc3c6bfda.pdf
DB03766,,PubChem Propionic Acid Profile,https://pubchem.ncbi.nlm.nih.gov/compound/propionic_acid#section=Pharmacology-and-Biochemistry
DB03766,,NIH Toxnet: Propionic Acid Profile,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1192
DB03904,,DailyMed Label: CEM-UREA- urea topical solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=697b1730-b716-444f-8671-934f47ae21bd
DB04209,,Health Canada Approved Drug Products: VABLYS (Dequalinium) Vaginal Tablets,https://files.duchesnay.com/duchesnay/vablys/vablys-monograph.pdf
DB04209,,Cayman Chemical: Dequalinium MSDS,https://www.chemblink.com/MSDS/MSDSFiles/522-51-0_Cayman.pdf
DB04224,,OLEIC ACID - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1240
DB04272,,Drugs.com: Phexxi Approval History,https://www.drugs.com/history/phexxi.html
DB04272,,"FDA Approved Drug Products: PHEXXI (lactic acid, citric acid, and potassium bitartrate) vaginal gel",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208352s000lbl.pdf
DB04272,,"FDA Approved Drug Products: CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209589s014lbl.pdf
DB04339,,NPRA Product Information: Mucoprom (carbocisteine/promethazine hydrochloride) oral syrup,http://quest3plus.bpfk.gov.my/front-end/attachment/599/pharma/242472/V_19694_20200409_151612_D4.pdf
DB04339,,Medicines UK: Carbocisteine 250 mg/ 5 ml syrup,https://www.medicines.org.uk/emc/product/8602/smpc%23gref
DB04339,,Toronto Research Chemical MSDS: Carbocisteine,https://www.trc-canada.com/prod-img/MSDS/C178760MSDS.pdf
DB04339,,NIH StatPearls: Mucolytic Medications,https://www.ncbi.nlm.nih.gov/books/NBK559163/
DB04339,,NHS UK: Carbocisteine,https://www.nhs.uk/medicines/carbocisteine/
DB04339,,NIH Stat Pearls: Chronic Obstructive Pulmonary Disease (COPD),https://www.ncbi.nlm.nih.gov/books/NBK559281/
DB04339,,FDA Thailand: LOVISCOL INFANT (Carbocisteine) oral drops,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022460027511C
DB04339,,INVIMA information: PEDIALAB® 50 mg/ 1 mL (carbocisteine) oral solution,http://web.sivicos.gov.co/registros/pdf/15805942_2019038907.pdf
DB04339,,FDA Thailand: CARBOCTER (carbocisteine) oral tablet,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022390005211C
DB04398,,Drugs.com: Phexxi Approval History,https://www.drugs.com/history/phexxi.html
DB04398,,"FDA Approved Drug Products: PHEXXI (lactic acid, citric acid, and potassium bitartrate) vaginal gel",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208352s000lbl.pdf
DB04573,,Trimesta,http://www.syntheticbiologics.com/trimesta
DB04796,,Link,http://www.hybrigenics.com/Pharma/Pharma-Content/Inecalcitol-Development.html
DB04815,,TITCK Product Information: Precort-A (desonide/clioquinol) topical ointment,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/TITCK-PRECORT%20A%20MERHEM-UYGUN%20KUB.pdf_c5a0f05b-095a-43a3-9cf1-c45f707f9032.pdf
DB04817,,FDA Federal Register: List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,https://www.govinfo.gov/content/pkg/FR-1998-10-08/html/98-26923.htm
DB04835,,FDA Approved Drug Products: Selzentry (maraviroc) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022128Orig1s019,208984Orig1s002lbl.pdf"
DB04844,,"FDA Approved Drug Products: XENAZINE (tetrabenazine) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf
DB04845,,FDA Approved Drug Products: Ixempra (ixabepilone) kit for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf
DB04847,,EMA Approved Drug Products: Evrenzo (roxadustat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/evrenzo-epar-product-information_en.pdf
DB04847,,European Medicines Agency: Evrenzo (roxadustat),https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo
DB04850,,Link,https://clinicaltrials.gov/ct2/show/NCT01516203
DB04854,,Takeda: Important Safety Information on ULORIC (febuxostat) – Increased Risk of Cardiovascular Fatal Outcomes,https://www.takeda.com/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/uloric/uloric-dhcpl-04nov2019--en.pdf
DB04854,,"FDA Approved Products: ULORIC (febuxostat) tablets, for oral use (February 2019)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021856s013lbl.pdf
DB04854,,Selleck Chemicals: Febuxostat Safety Data Sheet,https://www.selleck.cn/msds/MSDS_S1547.pdf
DB04854,,Clearsynth Labs: Febuxostat D9 Safety Data Sheet,https://www.clearsynth.com/en/msds_sample?catnumber=CS-O-06611&compound=Febuxostat%20D9
DB04854,,"FDA Approved Drug Products: ULORIC (febuxostat) tablets, for oral use (April 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021856s015lbl.pdf
DB04855,,MULTAQ® (dronedarone hydrochloride) Product Monograph,http://products.sanofi.ca/en/multaq.pdf
DB04855,,MULTAQ® (dronedarone) Safety Data Sheet - Van Wert Health,https://www.vanwerthospital.org/docs/default-source/SDS/dronedarone-sds.pdf?sfvrsn=2
DB04855,,Health Canada Endorsed Important Safety Information on Multaq,http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/14651a-eng.php
DB04855,,Atrial Fibrillation (A Fib) - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK526072/
DB04855,,FDA Approved Drug Products: Multaq (dronedarone) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022425s025lbl.pdf
DB04855,,FDA Approved Drug Products: Multaq (dronedarone) tablets for oral use (October 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022425s028s030lbl.pdf
DB04861,,FDA Approved Drug Products: Nebivolol Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
DB04861,,FDA Approved Drug Products: Nebivolol and Valsartan Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf
DB04871,,"Federal Register: Determination That BELVIQ (Lorcaserin Hydrochloride) Tablets, 10 Milligrams, and BELVIQ XR (Lorcaserin Hydrochloride) Extended-Release Tablets, 20 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness",https://www.federalregister.gov/documents/2021/03/04/2021-04449/determination-that-belviq-lorcaserin-hydrochloride-tablets-10-milligrams-and-belviq-xr-lorcaserin
DB04871,,US Food & Drug Administration: FDA Requests Voluntary Withdrawal of Weight-Loss Medication After Clinical Trial Shows an Increased Occurrence of Cancer,https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requests-voluntary-withdrawal-weight-loss-medication-after-clinical-trial-shows
DB04876,,Summary of Product Characteristics: Galvus (vildagliptin) oral tablets,https://www.ema.europa.eu/en/documents/product-information/galvus-epar-product-information_en.pdf
DB04876,,Cayman Chemical: Vildagliptin Safety Data Sheet,https://www.caymanchem.com/msdss/14705m.pdf
DB04876,,Summary of Product Characteristics: Eucreas (vildagliptin and metformin) oral tablets,https://www.ema.europa.eu/en/documents/product-information/eucreas-epar-product-information_et.pdf
DB04876,,Australian Public Assessment Report: Vildagliptin,https://www.tga.gov.au/file/1106/download
DB04890,,FDA Approved Drug Products: Bepreve (bepotastine besilat) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022288s008lbl.pdf
DB04895,,FDA Approved Drug Products: Macugen (Pegaptanib) Intravitreous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf
DB04896,,Brain Uses Serotonin To Perpetuate Chronic Pain Signals In Local Nerves,https://www.hopkinsmedicine.org/news/media/releases/brain_uses_serotonin_to_perpetuate_chronic_pain_signals_in_local_nerves
DB04901,,Link,http://www.freshpatents.com/Anti-cd80-antibody-having-adcc-activity-for-adcc-mediated-killing-of-b-cell-lymphoma-cells-alone-or-in-combination-with-other-therapies-dt20070322ptan20070065436.php?type=description
DB04908,,FDA Approved Drug Products: ADDYI (flibanserin) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022526s009lbl.pdf
DB04911,,FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206334s005lbl.pdf
DB04911,,"Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran",https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-medicines-company-adding-potentially-first-class-investigational-cholesterol-lowering-therapy-inclisiran
DB04911,,DailyMed: Orbactiv (oritavancin) powder for injection,https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=085d6d1a-21c2-11e4-8c21-0800200c9a66
DB04911,,Mckesson: Oritavancin diphosphate MSDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9ICS_ORBACTIV_VL_400MG_3ML_3CT.pdf
DB04911,,Orbactiv website,http://www.orbactiv.com/dosing-and-administration.html
DB04911,,Press release: Melinta therapeutics announces FDA approval of KIMYRSA™ (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections,https://melinta.com/melinta-therapeutics-announces-fda-approval-of-kimyrsa-oritavancin-for-the-treatment-of-adult-patients-with-acute-bacterial-skin-and-skin-structure-infections-absssi/
DB04911,,FDA Approved Drug Products: KIMYRSA (oritavancin) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214155s000lbl.pdf
DB04918,,Health Canada Product Monograph: Zevtera (ceftobiprole medocaril sodium) for intravenous injection,https://pdf.hres.ca/dpd_pm/00060684.PDF
DB04918,,FDA Approved Drug Products: Zevtera (ceftobiprole medocaril sodium) injection for intravenous use,https://www.basilea.com/fileadmin/basilea.com/redaktion/documents/ZEVTERA_US_prescribing_information.pdf?v=1712131286
DB04918,,EMA Refusal Assessment Report: Zeftera,https://www.ema.europa.eu/en/documents/assessment-report/zeftera-epar-public-assessment-report_en.pdf
DB04918,,FDA Press Announcement: FDA Approves New Antibiotic for Three Different Uses,https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses
DB04920,,FDA Approved Drug Products: Cleviprex (clevidipine) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022156s007lbl.pdf
DB04931,,EMA Approved Drugs: Afamelanotide,https://www.ema.europa.eu/en/documents/product-information/scenesse-epar-product-information_en.pdf
DB04931,,FDA News Release: Scenesse,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder
DB04931,,CaymanChem: Afamelanotide MSDS,https://www.chemblink.com/MSDS/MSDSFiles/75921-69-6_Cayman.pdf
DB04931,,EMA Summary for the Public: Afamelanotide,https://www.ema.europa.eu/en/documents/overview/scenesse-epar-summary-public_en.pdf
DB04931,,FDA Orphan Drugs: Afamelanotide,https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
DB04931,,EMA Orphan Drugs: Afamelanotide,https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/08/541-public-summary-positive-opinion-orphan-designation-nle4-d-phe7-alpha-melanocyte-stimulating_en.pdf
DB04931,,FDA Approved Drugs: Afamelanotide,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf
DB04938,,FDA Approved Drug Products: Osphena (ospemifene) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203505s015lbl.pdf
DB04946,,"FDA Approved Drug Products: FANAPT (iloperidone) tablets, for oral use (April 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022192s023lbl.pdf
DB04946,,Cayman Chemical: Iloperidone MSDS,https://cdn.caymanchem.com/cdn/msds/22957m.pdf
DB04948,,FDA News,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm
DB04948,,FDA reports,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM602419.pdf
DB04950,,Link,http://www.wipo.int/pctdb/en/wo.jsp?WO=2004061120&IA=WO2004061120&DISPLAY=DESC
DB04951,,FDA Approved Drug Products: Esbriet (pirfenidone) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022535s012,208780s002lbl.pdf"
DB04951,,Health Canada Product Monograph: Esbriet (pirfenidone) for oral use,https://pdf.hres.ca/dpd_pm/00056805.PDF
DB04951,,CaymanChem: Pirfenidone MSDS,https://www.caymanchem.com/msdss/13986m.pdf
DB04951,,EMA Approved Drug Products: Pirfenidone AET (pirfenidone) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/pirfenidone-aet-epar-product-information_en.pdf
DB04974,,Definition of rimiducid - NCI Drug Dictionary - National Cancer Institute,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rimiducid
DB04974,,"Technology - Bellicum Pharmaceuticals, Inc.",https://www.bellicum.com/technology/
DB04979,,Link,http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=453546
DB05016,,EMA Product Label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002720/WC500171813.pdf
DB05018,,"Migalastat for the treatment of Fabry Disease: Sunder-Plassmann G., Schiffmann R., and Nicholls K.",https://www.tandfonline.com/doi/abs/10.1080/21678707.2018.1469978?journalCode=ieod20
DB05018,,Amicus Therapeutics News Release: FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease,http://ir.amicusrx.com/news-releases/news-release-details/fda-approves-galafoldtm-migalastat-treatment-certain-adult
DB05018,,Drugs.com: FDA Approves Galafold (migalastat) for the Treatment of Fabry Disease,https://www.drugs.com/newdrugs/fda-approves-galafold-migalastat-fabry-4797.html
DB05018,,"FDA approved drug product: GALAFOLD® (migalastat) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208623s006s007lbl.pdf
DB05018,,EMA Approved Drug Products: GALAFOLD (Migalastat) capsules for oral use,https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/107/original/WC500208434.pdf?1534267664
DB05018,,Health Canada Approved Drug Proucts: GALAFOLD (Migalastat) capsules for oral use,https://pdf.hres.ca/dpd_pm/00041104.PDF
DB05025,,"FDA Approved Drug Products: MIPLYFFA (arimoclomol) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf
DB05025,,"FDA News Release: FDA Approves First Treatment for Niemann-Pick Disease, Type C",https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c
DB05084,,FDA Approved Drug Products: Tymlos (abaloparatide) for subcutaneous injection,https://radiuspharm.com/wp-content/uploads/tymlos/tymlos-prescribing-information.pdf
DB05084,,EMA Summary of Opinion: Eladynos (abaloparatide),https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-eladynos_en.pdf
DB05084,,EMA Approved Drug Products: Eladynos (abaloparatide) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/eladynos-epar-product-information_en.pdf
DB05084,,Radius Health: European Commission Approves ELADYNOS (Abaloparatide) for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture,"https://radiuspharm.com/european-commission-approves-eladynos-abaloparatide-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-increased-risk-of-fracture/#:~:text=European%20Commission%20Approves%20ELADYNOS%20(Abaloparatide,2022%20%E2%80%93%20Radius%20Health%2C%20Inc."
DB05084,,The Center for Drug Evaluation and Research: Abaloparatide Pharmacology Review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000PharmR.pdf
DB05087,,FDA Approved Drug Products: Ztalmy (ganaxolone) suspension for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf
DB05087,,BioSpace: Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder,https://www.biospace.com/article/releases/marinus-pharmaceuticals-announces-fda-approval-of-ztalmy-ganaxolone-for-cdkl5-deficiency-disorder/?s=74
DB05087,,EMA Approved Drug Products: Ztalmy (ganaxolone) suspension for oral use,https://www.ema.europa.eu/en/documents/product-information/ztalmy-epar-product-information_en.pdf
DB05087,,Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder,https://ir.marinuspharma.com/news/news-details/2023/Marinus-Pharmaceuticals-Announces-European-Commission-Approval-of-ZTALMY-ganaxolone-for-the-Adjunctive-Treatment-of-Epileptic-Seizures-Associated-with-CDKL5-Deficiency-Disorder/default.aspx
DB05154,,"Pretomanid FDA label, August 2019",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf
DB05154,,"MSDS, Pretomanid",https://www.sigmaaldrich.com/catalog/product/sigma/sml1290?lang=en&region=US
DB05154,,"Pretomanid briefing document, FDA",https://www.fda.gov/media/127592/download
DB05154,,TB Alliance,https://www.tballiance.org/news/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis
DB05154,,TB Alliance presentation slides,https://www.fda.gov/media/128001/download
DB05154,,"FDA Approved Drug Products: Pretomanid tablets, for oral use (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212862s004lbl.pdf
DB05187,,"FDA Approved Drug Products: IQIRVO (elafibranor) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218860s000lbl.pdf
DB05187,,Ipsen: Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis,https://www.ipsen.com/press-releases/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis/
DB05187,,EMA Approved Drug Products: Iqirvo (elafibranor) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/iqirvo-epar-product-information_en.pdf
DB05187,,GlobeNewswire: GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval,https://www.globenewswire.com/news-release/2024/09/23/2951030/0/en/GENFIT-Ipsen-s-Iqirvo-Elafibranor-Receives-EU-Approval-as-a-First-in-Class-Treatment-for-Primary-Biliary-Cholangitis-following-U-S-FDA-Accelerated-Approval.html
DB05217,,Link,http://www.geminx.com/en/research/gmx1777.php
DB05218,,Link,http://www.medicalnewstoday.com/articles/71766.php
DB05239,,FDA Approved Drug Products: COTELLIC (cobimetinib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206192s005lbl.pdf
DB05239,,EPAR Assessment report: Cotellic (International non-proprietary name cobimetinib),https://www.ema.europa.eu/en/documents/assessment-report/cotellic-epar-public-assessment-report_en.pdf
DB05239,,LA ROCHE PRODUCT MONOGRAPH COTELLIC®(COBIMETINIB),https://pdf.hres.ca/dpd_pm/00043025.PDF
DB05241,,Link,http://www.exelixis.com/eortc/posters/AACR_NCI_EORTC2007_XL765_preclin.pdf
DB05257,,Link,http://www.freepatentsonline.com/6235316.html
DB05259,,"FDA Approved Drug Products: COPAXONE (glatiramer acetate), injection for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020622s114lbl.pdf
DB05259,,"FDA Approval Package: COPAXONE (glatiramer acetate), injection for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020622_S015_COPAXONE_INJECTION_AP.pdf
DB05259,,Teva Pharmaceuticals: Glatiramer acetate SDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9TEVA_COPAXONE_SYR_40MG_12CT.pdf
DB05260,,Santa Cruz Biotechnology: Gallium(III) nitrate hydrate MSDS,https://datasheets.scbt.com/sc-250047.pdf
DB05260,,DailyMed Label: GANITE (gallium nitrate) Intravenous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bc2ddf8-d695-46b3-bf76-9f85ce6027e3
DB05260,,The Federal Register: Determination That GANITE (Gallium Nitrate) Injectable and Five Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,https://www.federalregister.gov/documents/2014/02/18/2014-03458/determination-that-ganite-gallium-nitrate-injectable-and-five-other-drug-products-were-not-withdrawn
DB05294,,FDA Approved Drug Products: Caprelsa (vandetanib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022405s019lbl.pdf
DB05311,,"Kalbitor, INN-ecallantide - European Medicines Agency - Europa EU",http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/002200/WC500122745.pdf
DB05311,,FDA Approved Drug Products: KALBITOR (ecallantide) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf
DB05316,,Acadia pharmaceuticals pipeline,https://www.acadia-pharm.com/pipeline/
DB05316,,FDA Approved Drug Product: NUPLAZID (pimavanserin) for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207318s010lbl.pdf
DB05316,,Acadia Pharmaceuticals: Pimavanserin – Dementia-Related Psychosis,https://www.acadia-pharm.com/pipeline/pimavanserin-drp/
DB05316,,Spectrum Chemical: Pimavanserin MSDS,https://www.spectrumchemical.com/MSDS/P3716_AGHS.pdf
DB05316,,DailyMed Label: Nuplazid (pimavanserin tartrate) capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b
DB05316,,BusinessWire: Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis,https://www.businesswire.com/news/home/20210405005229/en/Acadia-Pharmaceuticals-Receives-Complete-Response-Letter-from-U.S.-FDA-for-Supplemental-New-Drug-Application-for-Pimavanserin-for-the-Treatment-of-Hallucinations-and-Delusions-Associated-with-Dementia-Related-Psychosis
DB05316,,"FDA Approved Drug Products: NUPLAZID® (pimavanserin) capsules/tablets, for oral use (September 2023)",https://www.nuplazid.com/pdf/nuplazid-prescribing-information.pdf?_gl=1*mebd6r*_up*MQ..&gclid=CjwKCAjwjaWoBhAmEiwAXz8DBZ04xBz6PBVIgYU1lVbkdeW9-4zdy1p3RTV1TR9XO_PlFQ2Ya6jZeRoCRYkQAvD_BwE&gclsrc=aw.ds
DB05316,,Acadia Pharmaceuticals Announces Label Update for NUPLAZID® (pimavanserin),"https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-label-update-for-nuplazid-pimavanserin/#:~:text=Pimavanserin%20was%20approved%20for%20the,pimavanserin%20in%20other%20neuropsychiatric%20conditions."
DB05332,,Link,http://www.google.com/patents/US6835809
DB05344,,BioSpace: Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors,https://www.biospace.com/article/releases/results-from-neurotech-s-nt-501-phase-2-retinitis-pigmentosa-studies-demonstrate-consistent-biological-effect-on-photoreceptors-/
DB05351,,"DailyMed Label: DEXILANT (dexlansoprazole) delayed-release capsules, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9819f033-3bbe-442e-8e92-45fec77b237d
DB05351,,FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016),https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022287s025_0208056s003lbl.pdf
DB05351,,TWi Pharmaceuticals: Dexlansoprazole MSDS,https://www.twipharma.com/usa/upload/SDS_Dexlansoprazole.pdf
DB05381,,DailyMed: Histamine positive test control injection,https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c20f3f4-65f8-4cdb-bdd1-5774da1c551b
DB05381,,BASG: ALK Prick Positiv Kontrolle (Histamine) Intradermal Solution,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-26859&type=DOTC_FACH_INFO
DB05382,,DailyMed: CVS Iodine,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b11db4e5-6a6d-4d4a-b980-600692b54176
DB05382,,Drugs.com: Iodine tincture information,https://www.drugs.com/otc/590514/iodine-tincture-rojo.html
DB05382,,Mayo Clinic: Topical iodine side effects,https://www.mayoclinic.org/drugs-supplements/iodine-topical-route/side-effects/drg-20064375?p=1
DB05382,,"NIH Statpearls: Physiology, thyroid hormone",https://www.ncbi.nlm.nih.gov/books/NBK500006/
DB05382,,NIH StatPearls: Skin (integument) antiseptics,https://www.ncbi.nlm.nih.gov/books/NBK507853/
DB05467,,Health Canada Product Monograph: Sohonos (palovarotene) capsules for oral use,https://pdf.hres.ca/dpd_pm/00064435.PDF
DB05467,,"Ipsen: Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses",https://www.ipsen.com/press-releases/ipsen-announces-withdrawal-of-palovarotene-nda-confirming-intention-to-re-submit-following-additional-data-analyses/
DB05467,,Ipsen Press Release: Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for fibrodysplasia ossificans progressiva,https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2022/01/23202852/Ipsen-Health-Canada-approves-Ipsens-Sohonos-palovarotene-capsules-24-January-2022.pdf
DB05467,,"FDA Approved Drug Products: SOHONOS (palovarotene) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215559s000lbl.pdf
DB05467,,PALOVAROTENE FOR THE PREVENTION OF HETEROTOPIC OSSIFICATION IN ADULTS AND CHILDREN (≥ 8 YEARS OF AGE FOR FEMALES AND ≥ 10 YEARS OF AGE FOR MALES) WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP),https://www.fda.gov/media/169788/download
DB05467,,"US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva",https://www.globenewswire.com/news-release/2023/08/16/2726780/0/en/US-FDA-approves-Ipsen-s-SohonosTM-palovarotene-capsules-the-first-and-only-treatment-for-people-with-fibrodysplasia-ossificans-progressiva.html
DB05501,,"FDA Approved Drug Products: XOLREMDI (mavorixafor) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218709s000lbl.pdf
DB05501,,"FDA: FDA approves first drug for WHIM syndrome, a rare disorder that can lead to recurrent, life-threatening infections",https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections
DB05521,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB05521,,FDA Approved Drug Products: Incivek (telaprevir) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201917s012lbl.pdf
DB05541,,Briviact FDA Approval,http://www.ucb.com/stories-media/press-releases/article/U-S-FDA-approves-UCB-s-new-epilepsy-treatment-BRIVIACT-for-patients-with-partial-onset-seizures
DB05578,,FDA Approved Drug Products: Cyramza (ramucirumab) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf
DB05597,,Biospace: Valentis ends lead drug development after mid stage study failure,https://www.biospace.com/valentis-inc-ends-lead-drug-development-after-mid-stage-study-failure
DB05619,,"Biospace: Neose Technologies, Inc. Provides Update On NE-180 Program",https://www.biospace.com/article/releases/neose-technologies-inc-provides-update-on-ne-180-program-/
DB05620,,Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid,https://clinicaltrials.gov/ct2/show/NCT00381433
DB05631,,Link,http://clinicaltrials.gov/show/NCT00320502
DB05646,,US Patent: Serp-1,https://patentimages.storage.googleapis.com/a4/4f/34/f349b378a3f746/US7514405.pdf
DB05646,,Newswire: Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates,https://www.newswire.ca/news-releases/viron-phase-2a-data-published-in-leading-cardiovascular-journal-circulation-cardiovascular-interventions-507194481.html
DB05667,,FDA Approved Drug Products: RECORLEV (levoketoconazole) tablets,https://www.recorlev.com/full-prescribing-information.pdf
DB05667,,"University of Michigan: 2S,4R-Ketoconazole is the Relevant Enantiomer of Ketoconazole for Cortisol Synthesis Inhibition: Steroidogenic P450s Inhibition Involves Multiple Mechanisms",https://strongbridgebio.com/wp-content/uploads/strongbridge-poster-steroidogenic-p450s-inhibition-involves-multiple-mechanisms.pdf
DB05676,,"FDA approvals, Otezla",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205437
DB05676,,Otezla product information,http://www.guildlink.com.au/gc/ws/celgene/pi.cfm?product=cjpaprem
DB05676,,FDA Approved Drug Products: Otezla (apremilast) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205437s011lbl.pdf
DB05676,,Medsafe NZ,https://medsafe.govt.nz/profs/Datasheet/o/otezlatab.pdf
DB05676,,"EMA label, Otezla",https://www.ema.europa.eu/en/documents/assessment-report/otezla-epar-public-assessment-report_en.pdf
DB05679,,FDA Approved Drug Products: Stelara (ustekinumab) injection for subcutaneous or intravenous use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125261s154,761044s006lbl.pdf"
DB05679,,Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis,https://www.drugs.com/newdrugs/janssen-announces-fda-approval-stelara-ustekinumab-adults-moderately-severely-active-ulcerative-5084.html
DB05679,,Health Canada Approved Drug Products: STELARA (ustekinumab) subcutaneous or intravenous injection,https://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/stelara_cpm.pdf
DB05679,,"FDA Approved Drug Products: STELARA (ustekinumab) injection, for subcutaneous or intravenous use (July 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761044s010lbl.pdf
DB05679,,"FDA Approved Drug Products: STELARA (ustekinumab) injection, for subcutaneous or intravenous use (March 2023)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125261s158,761044s009lbl.pdf"
DB05679,,FDA Approved Drug Products: Wezlana (ustekinumab-auub) injection for subcutaneous or intravenous administration,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761285s000,761331s000lbl.pdf"
DB05679,,"BioSpace: Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)",https://www.biospace.com/article/releases/alvotech-and-jamp-pharma-announce-receipt-of-marketing-authorization-for-jamteki-avt04-the-first-biosimilar-of-stelara-ustekinumab-/?keywords=Health+canada
DB05698,,Link,http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=486259
DB05716,,EU Clinical Trials Register: A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa,https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023121-38/GB
DB05723,,Link,http://www.alkermes.com/newsroom/showArticle.aspx?id=407
DB05725,,Biospace: Sosei Inc. Announces Start Of Phase II Trial Of AD 337 In Fibromyalgia Syndrome,https://www.biospace.com/article/releases/sosei-inc-announces-start-of-phase-ii-trial-of-ad-337-in-fibromyalgia-syndrome-/
DB05725,,Fierce Biotech: Sosei Drug Misses Goal in Fibromyalgia Trial,https://www.fiercebiotech.com/biotech/press-release-sosei-drug-misses-goal-fibromyalgia-trial
DB05726,,Sarepta Therapeutics: AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting,https://investorrelations.sarepta.com/news-releases/news-release-details/avi-biopharma-initiates-neugene-antisense-clinical-program
DB05726,,Sarepta Therapeutics: AVI BioPharma Reports Third Quarter Financial Results,https://investorrelations.sarepta.com/news-releases/news-release-details/avi-biopharma-reports-third-quarter-financial-results
DB05777,,TOXNET,https://chem.nlm.nih.gov/chemidplus/rn/120313-91-9
DB05777,,Bloodjournal,http://www.bloodjournal.org/content/bloodjournal/80/5/1254.full.pdf?sso-checked=1
DB05812,,FDA Approved Drug Products: YONSA (abiraterone acetate) tablets for oral use (March 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210308s003lbl.pdf
DB05812,,FDA Approved Drug Products: ZYTIGA (abiraterone acetate) tablets for oral use (August 2021),https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202379s035lbl.pdf
DB05812,,Health Canada Approved Drug Proucts: AKEEGA (Niraparib and abiraterone acetate) tablets for oral use,https://pdf.hres.ca/dpd_pm/00071216.PDF
DB05812,,Janssen: Abiraterone acetate MSDS,https://www.obaid.info/pdf/MSDS/Z/Zytiga.pdf
DB05812,,EMA Approved Drug Products: ZYTIGA (abiraterone acetate) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf
DB05812,,Health Canada Approved Drug Products: ZYTIGA (Abiraterone) Oral Tablets,https://pdf.hres.ca/dpd_pm/00063577.PDF
DB05812,,"FDA Approved Drug Products: AKEEGA (niraparib and abiraterone acetate) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf
DB05851,,Link,http://clinicaltrials.gov/ct2/show/NCT00004890?term=AIDS&lup_s=03%2F06%2F2013&lup_d=30
DB05875,,Link,http://www.abcam.com/Substance-P-protein-ab9608.html
DB05889,,EMA Approved Drug Products: BESPONSA (inotuzumab ozogamicin) Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf
DB05889,,"FDA Approved Drug Products: BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf
DB05941,,CytoDyn: Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients,https://www.cytodyn.com/newsroom/press-releases/detail/405/treatment-with-cytodyns-leronlimab-indicates-significant
DB05958,,"BMJ: SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo",https://jitc.bmj.com/content/10/Suppl_2/A1228
DB05990,,MSDS,http://www.selleckchem.com/msds/MSDS_S7660.pdf
DB05990,,FDA Approved Products: Ocaliva (obeticholic acid) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207999s007lbl.pdf
DB05990,,FDA Accepts Intercept’s NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review,http://ir.interceptpharma.com/news-releases/news-release-details/fda-accepts-intercepts-nda-oca-treatment-liver-fibrosis-due-nash
DB05990,,"EMA Summary of product characteristics, Ocaliva (obeticholic acid) 5 and 10 mg oral tablets",https://www.ema.europa.eu/en/documents/product-information/ocaliva-epar-product-information_en.pdf
DB05990,,Product Monograph: Ocaliva (obeticholic acid) oral tablets,https://pdf.hres.ca/dpd_pm/00045776.PDF
DB05990,,NIH InXight Drugs: Obeticholic acid,https://drugs.ncats.io/substance/0462Z4S4OZ
DB05990,,"FDA Drug Safety Communication: Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis",https://www.fda.gov/drugs/drug-safety-and-availability/due-risk-serious-liver-injury-fda-restricts-use-ocaliva-obeticholic-acid-primary-biliary-cholangitis
DB06014,,"FDA Approved Drug Products: EXONDYS 51 (eteplirsen) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206488s027s028s029lbl.pdf
DB06016,,"FDA Approved Drug Products: VRAYLAR (cariprazine) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204370s006lbl.pdf
DB06016,,Cision PR Newswire: Health Canada Approves VRAYLAR® (cariprazine) for the Treatment of Bipolar l Disorder and Schizophrenia in Adults,https://www.newswire.ca/news-releases/health-canada-approves-vraylar-r-cariprazine-for-the-treatment-of-bipolar-l-disorder-and-schizophrenia-in-adults-867345766.html
DB06016,,Health Canada Approved Drug Products: VRAYLAR (Cariprazine) Oral Capsules (September 2022),https://pdf.hres.ca/dpd_pm/00067467.PDF
DB06045,,FDA Approved Drug Products: DAYBUE (trofinetide) Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217026s000lbl.pdf
DB06045,,FDA News: FDA approves first treatment for Rett Syndrome,https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-rett-syndrome
DB06045,,Acadia Pharmaceuticals: Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older,https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-u-s-fda-approval-of-daybue-trofinetide-for-the-treatment-of-rett-syndrome-in-adult-and-pediatric-patients-two-years-of-age-and-older/
DB06048,,PR Newswire: In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months,https://www.prnewswire.com/news-releases/in-a-phase-2-study-pf-04523655-rtp801i-14-showed-improved-vision-over-standard-of-care-in-patients-with-diabetic-macular-edema-at-12-months-118269674.html
DB06056,,Nature: Alcon licenses complement pathway inhibitor for macular degeneration,https://www.nature.com/articles/nrd3063
DB06077,,FDA Approved Drug Products: Caplyta (lumateperone) capsules for oral use,https://www.intracellulartherapies.com/docs/caplyta_pi.pdf
DB06077,,24. The Clinical Development of Lumateperone (ITI-007) for the Treatment of Schizophrenia,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5475480/
DB06077,,S44. Lumateperone (ITI-007) for the Treatment of Schizophrenia: Placebo-Controlled Clinical Trials and an Open-Label Safety Switching Study,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888500/
DB06077,,FDA Approved Drug Products: Caplyta (lumateperone) capsules for oral use (June 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209500s011lbl.pdf
DB06081,,FDA news,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm630866.htm
DB06081,,Guide to Pharmacology,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=9123
DB06081,,Clinical trials,https://clinicaltrials.gov/ct2/show/NCT03172208
DB06081,,FDA Approved Drug Products: CABLIVI (caplacizumab-yhdp) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761112s007lbl.pdf
DB06083,,"FDA Approved Drug Proucts: VTAMA (tapinarof) cream, for topical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf
DB06119,,"FDA Approved Drug Products: XCOPRI (cenobamate tablets), for oral use (November 2019)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf
DB06119,,"FDA Approved Drug Products: XCOPRI (cenobamate tablets), for oral use, CV (April 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212839s009s010lbl.pdf
DB06127,,Link,http://clinicaltrials.gov/show/NCT00525330
DB06137,,"FDA Approved Drug Products: KLISYRI (tirbanibulin) ointment, for topical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf
DB06137,,Drugs.com: Klisyri FDA Approval History,https://www.drugs.com/history/klisyri.html
DB06137,,Cayman Chemical: KX2-391 Safety Data Sheet,https://www.caymanchem.com/msdss/21429m.pdf
DB06145,,article,http://jac.oxfordjournals.org/content/22/Supplement_B/13.abstract
DB06145,,article,https://www.ncbi.nlm.nih.gov/pubmed/9571302
DB06145,,article,http://www.medicinenet.com/spiramycin-oral_capsule/article.htm
DB06145,,product info,https://www.drugs.com/mmx/spiramycin.html
DB06147,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB06150,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB06151,,Dailymed: Acetylcysteine Respiratory Inhalant,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81
DB06151,,"Dailymed: Acetylcysteine Intravenous Injection, Solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c35cd2d4-6a28-4ba9-8cca-d6557fe50438
DB06151,,"Health Canada Approved Drug Products: Acetylcysteine USP Solution for Intravenous Injection, Respiratory Inhalation, or Oral Administration",https://pdf.hres.ca/dpd_pm/00057334.PDF
DB06151,,FDA Approved Drug Products: Cetylev (Acetylcysteine) Oral Effervescent Tablets for Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207916s003lbl.pdf
DB06151,,FDA Approved Drug Products: Mucomyst (Acetylcysteine) Oral and Respiratory Solution (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013601
DB06152,,"PubChem, Nylidrin",https://pubchem.ncbi.nlm.nih.gov/compound/nylidrin
DB06152,,Nylidrin (Oral),https://www.drugs.com/cons/nylidrin.html
DB06152,,Nylidrin - Oral,https://myhealth.alberta.ca/Health/medications/Pages/conditions.aspx?hwid=fdb0207
DB06152,,Nylidrin,https://reference.medscape.com/drug/nylidrin-342462#10
DB06152,,Drug monograph,http://www.druginfosys.com/drug.aspx?drugcode=2016&type=1
DB06152,,ToxNet Nylidrin,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3137
DB06152,,Central cardiovascular effects of nylidrin (buphenine),https://www.sciencedirect.com/science/article/pii/0014299980903362
DB06152,,"Buphenine, MIMS",http://www.mims.com/india/drug/info/buphenine?type=full&mtype=generic
DB06152,,Central cardiovascular effects of nylidrin (buphenine).,https://www.ncbi.nlm.nih.gov/m/pubmed/6105964/
DB06152,,Nylidrin,http://decs.bvs.br/cgi-bin/wxis1660.exe/decsserver/?IsisScript=../cgi-bin/decsserver/decsserver.xis&task=exact_term&previous_page=homepage&interface_language=i&search_language=i&search_exp=nylidrin
DB06152,,Beta-Adrenergic Agonists,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034018/
DB06152,,Local and systemic hemodynamic effects of nylidrin,https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt196455569
DB06152,,Nylidrin Hydrochloride,https://drugs.ncats.io/ginas/app/substance/EC69E3PW7E
DB06152,,Specific blockade of spasmogens by β‐receptor stimulation with nylidrin and isoprenaline,https://www.researchgate.net/publication/18774229_Specific_blockade_of_spasmogens_by_b-receptor_stimulation_with_nylidrin_and_isoprenaline
DB06152,,NyIidrin HCL: A BETA-SYMPATHETIC STIMULANT IN THE MANAGEMENT OF HAEMORRHAGIC SHOCK,https://pdfs.semanticscholar.org/1a78/f56fd773ac5e0c0a624812090e41ca12a7cd.pdf
DB06153,,Paladin Labs - Product Monograph: SANDOMIGRAN (Pizotifen hydrogen malate 0.5 mg and 1 mg tablets),http://www.paladin-labs.com/our_products/Sandomigran_en.pdf
DB06154,,Pentaerythritol tetranitrate,https://pubchem.ncbi.nlm.nih.gov/compound/pentaerythritol_tetranitrate
DB06154,,CheBi - Pentaerythritol,https://www.ebi.ac.uk/chebi/searchId.do?chebiId=25879
DB06154,,PETN,https://www.britannica.com/science/PETN
DB06154,,OSHA document,https://www.osha.gov/dts/chemicalsampling/data/CH_260110.html
DB06154,,Pentaerythritol tetra nitrate,https://www.drugs.com/international/pentaerythritol-tetranitrate.html
DB06154,,Determination of Pentaerythritol Tetranitrate in Pharmaceuticals by High Performance Liquid Chromatography,https://www.tandfonline.com/doi/abs/10.1080/01483918808076749
DB06154,,Pentaerythrityl tetranitrate (PETN): a better nitrate?,https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/eht403/3056872
DB06154,,Pentaerythritol tetranitrate,http://www.genome.jp/dbget-bin/www_bget?dr:D01721
DB06154,,Pentaerythritol tetranitrate,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6313
DB06154,,Medscape- Pentaerythritol tetra nitrate,https://reference.medscape.com/drug/duotrate-pentylan-pentaerythritol-tetranitrate-342279#10
DB06154,,Characterization of the Antioxidant Properties of Pentaerithrityl Tetranitrate (PETN)-Induction of the Intrinsic Antioxidative System Heme Oxygenase-1 (HO-1),http://www.springerprotocols.com/Abstract/doi/10.1007/978-1-60761-411-1_22?verPrint=print
DB06154,,Pentaerythritol tetranitrate,http://www.t3db.ca/toxins/T3D0265
DB06154,,Pentaerythritoltetranitrate (PETN) EPA document,https://cfpub.epa.gov/ncea/pprtv/documents/PentaerythritoltetranitratePETN.pdf
DB06154,,PENTAERYTHRITE TETRANITRATE,http://nj.gov/health/eoh/rtkweb/documents/fs/1474.pdf
DB06154,,Pentaerithrityl tetranitrate improves angiotensin II induced vascular dysfunction via induction of heme oxygenase-1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080599/
DB06168,,FDA Approved Drug Products: Ilaris (canakinumab) injection for subcutaneous administration (August 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125319s107lbl.pdf
DB06168,,Health Canada Product Monograph: Ilaris (canakinumab) solution for subcutaneous injection,https://pdf.hres.ca/dpd_pm/00068195.PDF
DB06176,,FDA Approved Drug Products: ISTODAX (romidepsin) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022393s017lbl.pdf
DB06186,,FDA Approved Drug Products: Yervoy (ipilimumab) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125377s121lbl.pdf
DB06186,,BC Cancer Agency: Yervoy Monograph,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Ipilimumab_monograph.pdf
DB06186,,FDA Approved Drug Products: Yervoy (ipilimumab) for intravenous injection (May 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125377s122lbl.pdf
DB06196,,FDA Approved Drug Products: FIRAZYR (icatibant) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022150s012s013lbl.pdf
DB06196,,"FDA Approved Drug Products:FIRAZYR (icatibant) Injection, for subcutaneous use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf
DB06196,,FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE),https://www.fiercepharma.com/pharma/fda-approves-shire-s-firazyr%C2%AE-icatibant-injection-for-acute-attacks-of-hereditary-angioedema
DB06196,,Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients,https://www.globenewswire.com/news-release/2017/10/26/1153776/0/en/Shire-Receives-European-Approval-for-Label-Extension-of-FIRAZYR-icatibant-injection-for-the-Symptomatic-Treatment-of-Acute-HAE-Attacks-in-Paediatric-Patients.html
DB06202,,Link,http://www.lasofoxifene.com/
DB06202,,Fablyn development history,http://www.drugdevelopment-technology.com/projects/lasofoxifene/
DB06202,,FDA Reproductive Health Drugs Advisory Committee Briefing Document,https://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4381b1-02-Pfizer.pdf
DB06202,,EMA Summary of product characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000977/WC500020092.pdf
DB06204,,FDA Approved Drug Products: NUCYNTA (tapentadol) tablets for oral use C-II Initial U.S. (July 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022304s024lbl.pdf
DB06204,,Johnson & Johnson: NUCYNTA® ER (Tapentadol Extended-Release Tablets) Receives FDA Approval For The Management Of Moderate To Severe Chronic Pain,https://www.jnj.com/media-center/press-releases/nucynta-er-tapentadol-extended-release-tablets-receives-fda-approval-for-the-management-of-moderate-to-severe-chronic-pain
DB06204,,FDA Approved Drug Products: NUCYNTA ER (tapentadol) extended-release tablets for oral use C-II (March 2021),https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200533s023lbl.pdf
DB06204,,FDA Approved Drug Products: NUCYNTA (tapentadol) oral solution C-II (July 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203794s010lbl.pdf
DB06204,,Cayman Chemical: Tapentadol (hydrochloride) MSDS,https://cdn.caymanchem.com/cdn/msds/18660m.pdf
DB06204,,FDA Approved Drug Products: NUCYNTA® (tapentadol) oral solution C-II,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203794s011lbl.pdf
DB06205,,FDA Approved Drug Products: Vitrase Hyaluronidase Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021640s025lbl.pdf
DB06206,,FDA Approved Products: Bridion (sugammadex) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022225s008lbl.pdf
DB06207,,FDA Approved Drug Products: RAPAFLO (silodosin) Capsule for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf
DB06207,,Biosynth Carbosynth: Silodosin Safety Data Sheet,https://static.cymitquimica.com/products/3D/pdf/sds-FS27830.pdf
DB06207,,Selleck Chemicals: Silodosin Safety Data Sheet,https://www.selleckchem.com/msds/MSDS_S1613.pdf
DB06215,,Feraheme Product Info,http://www.feraheme.com
DB06215,,FDA Orders Stricter Warnings for Ferumoxytol (Feraheme ),https://www.medscape.com/viewarticle/842309
DB06215,,EMA label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002215/WC500129751.pdf
DB06215,,Ferumoxytol,https://link.springer.com/article/10.2165%2F11209880-000000000-00000
DB06215,,Ferumoxytol pubChem,https://pubchem.ncbi.nlm.nih.gov/compound/49868115#section=Top
DB06215,,Plasma Pharmacokinetics of Two Consecutive Doses of Ferumoxytol in Healthy Subjects,https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1038/clpt.2010.80
DB06215,,Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412424/
DB06215,,"Ferumoxytol, Davisplus",https://davisplus.fadavis.com/3976/meddeck/pdf/ferumoxytol.pdf
DB06215,,Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD,https://www.researchgate.net/publication/290788673_Ferumoxytol-Enhanced_Magnetic_Resonance_Imaging_in_Late-Stage_CKD
DB06215,,Feraheme-ferumoxytol,https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1035/feraheme-ferumoxytol
DB06215,,Cardiovascular magnetic resonance T2* for tissue iron assessment in the heart,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213428/
DB06215,,"T1 and T2 images, Radiology Masterclass",https://www.radiologymasterclass.co.uk/tutorials/mri/t1_and_t2_images
DB06215,,Feraheme PDR,http://www.pdr.net/drug-summary/Feraheme-ferumoxytol-1201
DB06217,,European Medicines Agency Summary of product characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001215/WC500097154.pdf
DB06218,,European Directorate for the Quality of Medicines & HealthCare: Lacosamide MSDS,https://sds.edqm.eu/pdf/SDS/EDQM_201700391_1.0_SDS_EN.pdf
DB06218,,FDA Approved Drug Products: VIMPAT (lacosamide) intravenous injection or oral solution or tablets (October 2023),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022253s057,022254s047,022255s039lbl.pdf"
DB06218,,"FDA Approved Drug Products: MOTPOLY XR (lacosamide) extended-release capsules, for oral use, CV (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216185s000lbl.pdf
DB06218,,EMA Approved Drug Products: Vimpat (lacosamide) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/vimpat-epar-product-information_en.pdf
DB06218,,Health Canada Approved Drug Products: VIMPAT (lacosamide) Oral Tablets or Intavenous Injection,https://pdf.hres.ca/dpd_pm/00068756.PDF
DB06219,,"FDA Approved Drug Products: DALVANCE (dalbavancin) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021883s010lbl.pdf
DB06224,,Link,http://www.isispharm.com/product_pipeline.html
DB06228,,"FDA Approved Products: XARELTO (rivaroxaban) tablets or suspension, for oral use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022406s039,202439s038lbl.pdf"
DB06228,,FDA Approved Drug Products: Xarelto (rivaroxaban) tablets/suspension for oral administration (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022406s041lbl.pdf
DB06230,,European Medicines Agency (EMA) Summary of product characteristics: Selincro (nalmefene) oral tablets,https://www.ema.europa.eu/en/documents/product-information/selincro-epar-product-information_en.pdf
DB06230,,"DailyMed Label: NALMEFENE HYDROCHLORIDE injection, solution for intravenous, intramuscular, or subcutaneous use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3abfbffc-9e52-4fc6-ae92-6e0a97f4afe7
DB06230,,EMA Assessment Report: Selincro (nalmafene) oral tablets,https://www.ema.europa.eu/en/documents/assessment-report/selincro-epar-public-assessment-report_en.pdf
DB06230,,Australian Public Assessment Report: Nalmefene (as hydrochloride dihydrate),https://www.tga.gov.au/sites/default/files/auspar-nalmefene-as-hydrochloride-dihydrate-160809.pdf
DB06230,,FDA Approved Drug Products: OPVEE (nalmefene) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217470Orig1s000.pdf
DB06234,,FDA Approved Drug Products: Livtencity (maribavir) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215596lbl.pdf
DB06234,,FDA News Release: FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-common-type-post-transplant-infection-resistant-other-drugs
DB06234,,Health Canada Approved Drug Products: LIVTENCITY (maribavir) Oral Tablets,https://pdf.hres.ca/dpd_pm/00067349.PDF
DB06234,,EMA Approved Drug Products: LIVTENCITY (maribavir) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/livtencity-epar-product-information_en.pdf
DB06234,,Takeda: European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies,"https://www.takeda.com/newsroom/newsreleases/2022/european-commission-ec-approves-livtencitytm-maribavir/#:~:text=European%20Commission%20(EC)%20Approves%20LIVTENCITY,One%20or%20More%20Prior%20Therapies"
DB06235,,Link,http://www.antisoma.com/asm/media/press/pr2007/2007-08-22/
DB06237,,FDA Approved Drug Products: Stendra (avanafil) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202276s018lbl.pdf
DB06237,,EMA CHMP Assessment Report: Avanafil (INN),https://www.ema.europa.eu/en/documents/assessment-report/spedra-epar-public-assessment-report_en.pdf
DB06237,,CaymanChem: Avanafil M4 metabolite,https://www.caymanchem.com/pdfs/27843.pdf
DB06237,,CaymanChem: Avanafil M16 metabolite,https://www.caymanchem.com/pdfs/27844.pdf
DB06237,,EMA Summary of Product Characteristics: Spedra (avanafil) oral tablets,https://www.ema.europa.eu/en/documents/product-information/spedra-epar-product-information_en.pdf
DB06237,,FDA Approved Drug Products: Stendra (avanafil) tablets for oral use 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202276s020lbl.pdf
DB06243,,"FDA Approved Drug Products: IWILFIN™ (eflornithine) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215500s000lbl.pdf
DB06243,,"FDA Approved Drug Products: VANIQA™ (eflornithine hydrochloride) Cream 13.9%, for topical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21145lbl.pdf
DB06243,,Eflornithine MSDS,https://s3-us-west-2.amazonaws.com/drugbank/msds/DB06243.pdf?1445271619
DB06243,,US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer,https://www.biospace.com/article/releases/us-worldmeds-announces-fda-approval-of-iwilfin-eflornithine-to-strengthen-fight-against-aggressive-childhood-cancer/?s=74
DB06243,,Iwilfin FDA Approval History,https://www.drugs.com/history/iwilfin.html
DB06261,,"FDA Approved Drug Products: Cysview (hexaminolevulinate hydrochloride), for Intravesical Solution For bladder instillation only",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022555s005lbl.pdf
DB06263,,Amrubicin,http://www.lookchem.com/Amrubicin/
DB06263,,Amrubicin for the Treatment of Small Cell Lung Cancer: Does Effectiveness Cross the Pacific?,https://www.sciencedirect.com/science/article/pii/S1556086415300460
DB06263,,Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function,https://www.sciencedirect.com/science/article/pii/S2213089616300603
DB06263,,Amrubicin® Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer,https://www.businesswire.com/news/home/20080325005495/en/Amrubicin-Receives-FDA-Orphan-Drug-Designation-Treatment
DB06263,,Phase I–II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer,https://academic.oup.com/annonc/article/16/3/430/159840
DB06263,,"randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer",https://academic.oup.com/annonc/article/28/2/285/2676905
DB06273,,"FDA Approved Drug Products: ACTEMRA (tocilizumab) injection, for intravenous or subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125276s131lbl.pdf
DB06273,,Clinical Trials: TOCIVID-19,https://clinicaltrials.gov/ct2/show/study/NCT04317092
DB06273,,Clinical Trials: COVACTA,https://clinicaltrials.gov/ct2/show/NCT04320615
DB06273,,GlobeNewsWire News Release: Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19,https://www.globenewswire.com/news-release/2021/12/07/2347122/0/en/Actemra-RoActemra-approved-by-the-European-Commission-to-treat-patients-with-severe-COVID-19.html
DB06273,,Summary of Product Characteristics: RoActemra (tocilizumab) intravenous injection,https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf
DB06273,,Health Canada Approved Drug Products: ACTEMRA (tocilizumab) Intravenous or Subcutaneous Injection,https://pdf.hres.ca/dpd_pm/00067693.PDF
DB06273,,"FDA Approved Drug Products: ACTEMRA (tocilizumab) injection, for intravenous or subcutaneous use (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125276s138lbl.pdf
DB06273,,"FDA Approved Drug Products: TOFIDENCE (tocilizumab-bavi) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761354s000lbl.pdf
DB06274,,Link,http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm194328.htm
DB06274,,FDA Approved Drug Products: Entereg (alvimopan) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021775s018lbl.pdf
DB06282,,FDA Approved Drug Products: Levocetirizine Dihydrochloride Tablets and Oral Solution,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022064s038,022157s020lbl.pdf"
DB06283,,FDA Approved Drug Products: Prialt (ziconotide) solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021060s006lbl.pdf
DB06285,,"FDA Approved Drug Products: FORTEO (teriparatide) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021318Orig1s056lbl.pdf
DB06285,,EMA Approved Drug Products: Sondelbay (teriparatide) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/sondelbay-epar-product-information_en.pdf
DB06285,,Eli Lilly and Company: Forteo (Teriparatide) MSDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9LILL_00002897101_00002840001_FORTEO_INJECTION.pdf
DB06285,,EMA Approved Drug Products: Kauliv (teriparatide) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/kauliv-epar-product-information_en.pdf
DB06285,,Health Canada Approved Drug Products: FORTEO (teriparatide) Subcutaneous Injection,https://pdf.hres.ca/dpd_pm/00062481.PDF
DB06288,,"FDA Approved Drug Products: BARHEMSYS (amisulpride) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510Orig1s002Lbl.pdf
DB06288,,Summary of Product Characteristics: Amisulpride Oral Tablets,https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0577-125-003_23022017121045.pdf
DB06288,,Cayman Chemical: Amisulpride Safety Data Sheet,https://www.caymanchem.com/msdss/14619m.pdf
DB06290,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB06290,,FDA Approved Drug Products: OLYSIO (simeprevir) capsules for oral use (November 2017),https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205123s014lbl.pdf
DB06292,,FDA Drug Approval Package: Dapagliflozin,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000TOC.cfm
DB06292,,FDA Approved Drug Products: Farxiga Dapagliflozin Oral Tablets,https://drugbank.s3.us-west-2.amazonaws.com/cite_this/external_links/attachments/000/012/024/original/202293s022lbl.pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAJTZC3DSCEEG75A6Q%2F20230509%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20230509T204548Z&X-Amz-Expires=10&X-Amz-SignedHeaders=host&X-Amz-Signature=92a7b23473af8cc5067f3c3f54dee76d391e4f60b76ad3f86c88d7aebbdbe84e
DB06292,,FDA Approved Drug Products: Qtern (dapagliflozin/saxagliptin) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209091s005lbl.pdf
DB06292,,FDA Approved Drug Products: Xigduo XR (metformin hydrochloride/dapagliflozin) extended-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205649s017lbl.pdf
DB06292,,"FDA Approved Drug Products: FARXIGA® (dapagliflozin) tablets, for oral use (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s026lbl.pdf
DB06292,,"FDA Approved Drug Products: FARXIGA® (dapagliflozin) tablets, for oral use (September 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s030lbl.pdf
DB06292,,"FDA Approved Drug Products: FARXIGA (dapagliflozin) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202293s024lbl.pdf
DB06292,,FDA Approves Treatment for Chronic Kidney Disease,https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease
DB06292,,FDA Approved Drug Products: Farxiga (dapagliflozin) tablets for oral use (June 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202293s031lbl.pdf
DB06307,,Link,http://www.medicalnewstoday.com/articles/104218.php
DB06309,,Link,http://www.medicalnewstoday.com/articles/84205.php
DB06313,,Link,http://www.bionomics.com.au/page.php?page=188&section=103
DB06316,,Link,http://www.rigel.com/rigel/pr_1147824317
DB06318,,Link,http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=575732
DB06323,,Link,http://www.orthologic.com/research-development/AZX100modeofaction.php
DB06329,,Link,http://ir.anadyspharma.com/phoenix.zhtml?c=148908&p=irol-newsArticle&ID=986017&highlight=
DB06342,,Link,http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=574048
DB06343,,FDA News Release: Teprotumumab approval,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease
DB06343,,FDA Approved Drug Products: Tepezza (teprotumumab-trbw) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf
DB06343,,FDA Approved Drug Products: Tepezza (teprotumumab-trbw) for intravenous injection (December 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761143s021lbl.pdf
DB06343,,FDA Approved Drug Products: TEPEZZA (teprotumumab-trbw) for intravenous injection (April 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761143s024lbl.pdf
DB06347,,Link,http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=1077812&highlight=
DB06352,,Link,http://www.turkjbiochem.com/2003/054_061.pdf
DB06356,,Link,http://www.micromet.de/index.php?id=117
DB06361,,Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine,http://ascopubs.org/doi/10.1200/jco.2004.22.14_suppl.2584
DB06366,,Pertuzumab protein sequence,http://www.freepatentsonline.com/20110117097.pdf
DB06366,,FDA News Release: FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional,https://www.fda.gov/news-events/press-announcements/fda-approves-breast-cancer-treatment-can-be-administered-home-health-care-professional
DB06366,,FDA Approved Drug Products: Perjeta (pertuzumab) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf
DB06366,,Health Canada Product Monograph: Perjeta (pertuzumab) for intravenous injection,https://pdf.hres.ca/dpd_pm/00056094.PDF
DB06366,,FDA Approved Drug Products: Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf
DB06366,,FDA Drug Approvals: FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pertuzumab-adjuvant-treatment-her2-positive-breast-cancer
DB06372,,FDA Approved Drug Products: ARCALYST (rilonacept) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125249s049lbl.pdf
DB06374,,FDA Approved Drug Products: ORSERDU (elacestrant) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf
DB06374,,"BioSpace: Stemline Therapeutics Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer",https://www.biospace.com/article/releases/stemline-therapeutics-a-subsidiary-of-menarini-group-receives-u-s-fda-approval-for-orserdutm-elacestrant-as-the-first-and-only-treatment-specifically-indicated-for-patients-with-esr1-mutations-in-er-her2-advanced-or-metastatic-breast-cancer/
DB06374,,EMA Summary of Product Characteristics: Orserdu (elacestrant) film-coated tablets for oral administration,https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf
DB06374,,"NewsWire: European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation",https://www.newswire.ca/news-releases/european-commission-approves-menarini-group-s-orserdu-r-elacestrant-for-the-treatment-of-patients-with-er-her2-locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation-893901255.html
DB06402,,FDA Approved Drug Products: Vibativ (telavancin) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022110s016lbl.pdf
DB06404,,FDA Approved Blood Products: Cinryze C1 Esterase Inhibitor Intravenous Injection,https://www.fda.gov/media/75907/download
DB06404,,FDA: Supplemental Approval of C1 Esterase Inhibitors,https://www.fda.gov/media/142719/download?utm_medium=email&utm_source=govdelivery
DB06404,,FDA Approved Blood Products: Haegarda C1 Esterase Inhibitor Subcutaneous Injection,https://www.fda.gov/media/105611/download
DB06404,,FDA Approved Drug Products: BERINERT [C1 Esterase Inhibitor (Human)] Intravenous Injection,https://www.fda.gov/media/77803/download
DB06410,,FDA Approved Drug Products: HECTOROL (doxercalciferol) capsules and injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020862s031,021027s034lbl.pdf"
DB06412,,"Report on Carcinogens, Thirteenth Edition",http://ntp.niehs.nih.gov/ntp/roc/content/profiles/oxymetholone.pdf
DB06413,,Link,http://www.medilexicon.com/drugs/nuvigil.php
DB06414,,FDA Approved Drug Products: Intelence (etravirine) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022187s025lbl.pdf
DB06419,,FDA Orphan Drug Designations and Approvals,https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
DB06419,,Human Disposition and Metabolism of Orally Administered (14C)ABT-773,http://www.digitalconference.net/ICAAC2001/ICAAC2001/Poster/P_ABT773-942.pdf
DB06419,,Clinical Trial NCT00336505,https://clinicaltrials.gov/ct2/show/results/NCT00336505
DB06421,,Link,http://www.prnewswire.co.uk/cgi/news/release?id=48518
DB06422,,Link,http://scripts.iucr.org/cgi-bin/paper?S1600536802017683
DB06441,,FDA Approved Drug Products: KENGREAL (cangrelor) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204958s002lbl.pdf
DB06448,,FDA Approved Drug Products: Zokinvy (lonafarnib) capsules,https://www.zokinvy.com/pdf/ZOKINVY_US_PRESCRIBING_INFORMATION.pdf
DB06448,,Eiger Bio: Lonafarnib license agreement,https://eigerbio.com/press_releases/eiger-announces-expanded-license-agreement-with-merck-for-investigational-candidate-lonafarnib-and-collaboration-with-the-progeria-research-foundation-prf/
DB06448,,FDA Press Announcement: FDA Approves First Treatment for Hutchinson-Gilford Progeria Syndrome and Some Progeroid Laminopathies,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies
DB06448,,Cayman Chemical: lonafarnib MSDS,https://www.caymanchem.com/msdss/11746m.pdf
DB06448,,EMA Approved Drug Products: Zokinvy (lonafarnib) capsules,https://www.eigerbio.com/wp-content/uploads/2022/07/Zokinvy-ema-combined-h-5271-en.pdf
DB06480,,FDA reports,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM623493.pdf
DB06480,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210166
DB06480,,Canadian Society of Intestinal Research,https://www.badgut.org/information-centre/a-z-digestive-topics/serious-toll-of-chronic-constipation-overlooked/
DB06480,,FDA Approved Drug Products: Motality (Prucalopride) Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210166s002lbl.pdf
DB06504,,Alzheimer’s Therapy: GABA Receptor Inverse Agonists,http://cnsdiseases.com/alzheimers-therapy-gaba-receptor-inverse-agonists
DB06544,,"Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors",https://aacrjournals.org/clincancerres/article/15/9/3177/74974/Phase-I-Study-of-MG98-an-Oligonucleotide-Antisense
DB06584,,NCI Drug Dictionary: MVA-MUC1-IL2 vaccine,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mva-muc1-il2-vaccine
DB06595,,Abmole Midostaurin MSDS,http://www.abmole.com/literature/midostaurin-msds.html
DB06595,,Alfa Aesar Midostaurin MSDS,https://www.alfa.com/en/content/msds/british/J62917.pdf
DB06595,,Cayman Midostaurin MSDS,https://www.chemblink.com/MSDS/MSDSFiles/120685-11-2Cayman.pdf
DB06595,,FDA Approved Drug Products: RYDAPT (midostaurin) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207997s008lbl.pdf
DB06602,,FDA approves Cinqair to treat severe asthma,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491980.htm
DB06603,,Link,http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm
DB06603,,Drugs of the Future - Panobinostat,https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1094476&p_IsPs=N
DB06605,,FDA Drug Approval Package: Apixaban,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155orig1s000toc.cfm
DB06606,,FDA Approved Drug Products: TZIELD (teplizumab-mzwv) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf
DB06606,,US Food & Drug Administration: FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes
DB06607,,EMA: Removab Withdrawal from Market,http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/human/000972/WC500231226.pdf
DB06608,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210795
DB06608,,"FDA Approved Drug Products: KRINTAFEL (tafenoquine) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf
DB06612,,FDA Approved Drug Products: Nucala (mepolizumab) for subcutaneous injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761122s008,125526s019lbl.pdf"
DB06612,,GlaxoSmithKline: NUCALA safety data sheet,https://www.obaid.info/pdf/MSDS/N/Nucala-Injection.pdf
DB06614,,FDA Approved Drug Products: RAPIVAB (peramivir) intravenous,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206426s007lbl.pdf
DB06616,,"FDA Approved Drug Products: BOSULIF® (bosutinib) tablets/capsules, for oral use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf
DB06616,,"FDA Approved Drug Products: BOSULIF (bosutinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203341s020lbl.pdf
DB06616,,Bosutinib Pfizer MSDS,https://pfe-pfizercom-prod.s3.amazonaws.com/products/material_safety_data/BOSULIF%28Bosutinib%29_FC_Tablets_22-Oct-2017.pdf
DB06616,,Bosutinib Thermofisher Scientific MSDS,https://www.fishersci.com/store/msds?partNumber=AC465650010&countryCode=US&language=en
DB06616,,FDA grants accelerated approval to bosutinib for treatment of newly-diagnosed PH+ CML,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-bosutinib-treatment-newly-diagnosed-ph-cml
DB06616,,FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-bosutinib-pediatric-patients-chronic-myelogenous-leukemia
DB06626,,DRUG NAME: Axitinib - BC Cancer,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Axitinib_monograph_1March2014.pdf
DB06636,,FDA Approved Drug Products: Cresemba (isavuconazonium sulfate),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207500s005,207501s004lbl.pdf"
DB06636,,"FDA Approved Drug Products: CRESEMBA® (isavuconazonium sulfate) capsules/injection, for oral/intravenous use",https://www.astellas.us/docs/cresemba.pdf
DB06636,,FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis,https://www.biospace.com/article/releases/fda-approves-expanded-use-of-cresemba-isavuconazonium-sulfate-in-children-with-invasive-aspergillosis-and-invasive-mucormycosis/?s=74
DB06637,,FDA Approved Drug Products: AMPYRA (dalfampridine) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022250s018lbl.pdf
DB06643,,"FDA Approved Drug Products: Prolia® (denosumab) Injection, for subcutaneous use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125320s216lbl.pdf
DB06643,,"FDA Approved Drug Products: Xgeva (denosumab) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125320s201lbl.pdf
DB06650,,"FDA Approved Drug Products: ARZERRA (ofatumumab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125326s062lbl.pdf
DB06650,,"Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)",https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-ofatumumab-novel-b-cell-therapy-patients-relapsing-forms-multiple-sclerosis-rms
DB06650,,Arzerra (ofatumumab) FDA Approval History - Drugs.com,https://www.drugs.com/history/arzerra.html
DB06650,,FDA Approved Drug Products: KESIMPTA (ofatumumab) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s070lbl.pdf
DB06650,,"FDA Approved Drug Products: KESIMPTA® (ofatumumab) injection, for subcutaneous use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125326s080lbl.pdf
DB06655,,FDA Drug Approval Package: Liraglutide,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm
DB06655,,FDA News Release: Liraglutide Indication,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-type-2-diabetes
DB06655,,FDA Approved Drug Products: Victoza (liraglutide) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022341s036lbl.pdf
DB06655,,FDA Approved Drug Products: Saxenda (liraglutide) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s012s013s014lbl.pdf
DB06655,,FDA Approved Drug Products: Xultophy (insulin degludec/liraglutide 100/3.6) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208583s014s015lbl.pdf
DB06674,,"FDA Approved Products: SIMPONI ARIA (golimumab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125433s030s031lbl.pdf
DB06674,,"FDA Approved Products: SIMPONI (golimumab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125289s146lbl.pdf
DB06681,,FDA Approved Drug Products: Nulojix (beltacept) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125288s075lbl.pdf
DB06684,,FDA Drug Approval Package: Vilazodone,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000TOC.cfm
DB06693,,Chemspider,http://www.chemspider.com/Chemical-Structure.58262.html
DB06693,,Pubchem,http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=49896293&viewopt=PubChem
DB06694,,DailyMed Label: Sinosil (xylometazoline) nasal spray,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b1f1890-044a-4bc2-bf87-648bdc479a13
DB06694,,Fagron: Xylometazoline Hydrochloride Safety Data Sheet,https://fagron.com/sites/default/files/document/msds_coa/1218-35-5_(GB).pdf
DB06694,,Cayman Chemical: Xylometazoline Hydrochloride Safety Data Sheet,https://www.caymanchem.com/msdss/27797m.pdf
DB06695,,FDA Drug Approval Package for Dabigatran Etexilate,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512orig1s000toc.cfm
DB06695,,FDA Approved Drug Products: PRADAXA (dabigatran) oral pellets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214358s000lbl.pdf
DB06695,,FDA Approved Drug Products: PRADAXA (dabigatran) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022512s041lbl.pdf
DB06695,,EMA Approved Drug Products: Dabigatran etexilate capsules for oral use,https://www.ema.europa.eu/en/documents/product-information/dabigatran-etexilate-accord-epar-product-information_en.pdf
DB06695,,FDA Approved Drug Products: Pradaxa (dabigatran etexilate) oral pellets (November 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214358s007lbl.pdf
DB06696,,Antimicrobial agents and Chemotherapy,http://aac.asm.org/cgi/content/full/44/7/1925
DB06698,,Product Monograph: SERC (betahistine hydrochloride) oral tablets,https://www.mylan.ca/-/media/mylanca/documents/english/product-pdf/pdfs-dec-2015/serc-pm-2016.01.08.pdf?la=en-ca
DB06698,,Medicines UK: Betahistine Dihydrochloride 16mg Tablets,https://www.medicines.org.uk/emc/product/4038/smpc#gref
DB06698,,NIH StatPearls: Meniere's disease,https://www.ncbi.nlm.nih.gov/books/NBK536955/
DB06698,,"Product monograph: SERC † (Betahistine dihydrochloride) 8 mg, 16 mg, and 24 mg oral tablets",https://pdf.hres.ca/dpd_pm/00000089.PDF
DB06699,,FDA Approved Drug Products: Firmagon (degarelix) powder for solution for subcutaneous injection (February 2020),https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022201s016lbl.pdf
DB06699,,Health Canada Approved Drug Products: Firmagon (degarelix) powder for solution for subcutaneous injection,https://pdf.hres.ca/dpd_pm/00034229.PDF
DB06699,,EMA Summary of Product Characteristics: Firmagon (degarelix) powder for solution for subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/firmagon-epar-product-information_en.pdf
DB06700,,FDA Drug Approval Package for Desvenlafaxine,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021992s000TOC.cfm
DB06700,,"FDA Approved Drug Products: DESVENLAFAXINE extended-release tablets, for oral use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204150s020lbl.pdf
DB06700,,The Absolute Bioavailability of Desvenlafaxine in Healthy Subjects,https://www.walshmedicalmedia.com/open-access/the-absolute-bioavailability-of-desvenlafaxine-in-healthy-subjects-jbb.1000105.pdf
DB06702,,FDA Approved Drug Products: TOVIAZ (fesoterodine fumarate) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022030s019lbl.pdf
DB06703,,FDA Approved Drug Products: Gadavist (gadobutrol) injection for intravenous administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201277s017lbl.pdf
DB06703,,"FDA Approved Drug Products: GADAVIST (gadobutrol) injection, for intravenous use (Feb 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/201277s023lbl.pdf
DB06704,,FDA Approved Drug Products: AdreView (Iobenguane I 123 Injection) for Intravenous Use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022290s005lbl.pdf
DB06704,,AZEDRA® (iobenguane I 131) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209607s000lbl.pdf
DB06705,,FDA Approved Drug Products: ABLAVAR (gadofosveset trisodium) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021711s004lbl.pdf
DB06709,,FDA Approved Drug Products: PROVOCHOLINE (methacholine chloride) inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019193s024lbl.pdf
DB06711,,Naphazoline Hydrochloride Solution/Drops,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eee62a16-5d68-4639-8aec-63189f3afe60&type=display
DB06711,,Toxnet: Naphazoline Hydrochloride,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2174
DB06711,,INVIMA Product Authorization: Osmocrom-N (sodium cromoglycate/naphazoline hydrochloride) ophthalmic drops,http://web.sivicos.gov.co/registros/pdf/15387366_2017013574.pdf
DB06711,,INVIMA Product Authorization: Ocunid (dexamethasone/naphazoline) ophthalmic solution,http://web.sivicos.gov.co/registros/pdf/1496858_2016031951.pdf
DB06711,,BASG Product Information: Coldistan (diphenhydramine hydrochloride/naphazoline hydrochloride) nasal drops,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=7506&type=DOTC_FACH_INFO
DB06711,,BASG Product Information: Coldistan (diphenhydramine hydrochloride/naphazoline hydrochloride) ophthalmic drops,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=17356&type=DOTC_FACH_INFO
DB06717,,"FDA Approved Drug Products: EMEND (fosaprepitant) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022023s019lbl.pdf
DB06719,,Link,http://www.sanofi.ca
DB06724,,Cruz Verde: Caprimida D (calcium citrate/vitamin D),https://www.cruzverde.com.co/caprimida-d-1500mg200ui-pague-30-lleve-60-tableta-recubierta/132484.html
DB06727,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB06736,,UK Medicines and Healthcare products Regulatory Agency: ACECLOFENAC 100MG TABLETS product information,http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2023359.pdf
DB06736,,DailyMed Label: Clanza CR (Aceclofenac) Oral Tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a023942-01e8-4849-aa3c-1a640ffc7fd3
DB06751,,Cayman Chemical: Drotaverine Safety Data Sheet,https://www.caymanchem.com/msdss/20944m.pdf
DB06751,,FDA Thailand: Spablock (Drotaverine) Oral Tablet,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022420044711C
DB06752,,The rise and fall of chemonucleolysis,http://eknygos.lsmuni.lt/springer/525/351-358.pdf
DB06752,,Worthington,http://www.worthington-biochem.com/pcyp/default.html
DB06752,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018663
DB06752,,Spine Health,https://www.spine-health.com/conditions/herniated-disc/whats-a-herniated-disc-pinched-nerve-bulging-disc
DB06755,,FDA Code of Federal Regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1245
DB06755,,FDA Code of Federal Regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=73.95
DB06755,,FDA Code of Federal Regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=73.1095
DB06755,,FDA Code of Federal Regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=73.2095
DB06755,,UCSD lecture,http://jwhitesell.ucsd.edu/documents/Beta_Carotene.pdf
DB06755,,AHFS,http://www.ahfsdruginformation.com/drug-information-fulltext-dif/
DB06755,,Meeting the vitamin A requirements,https://www.hindawi.com/journals/tswj/2016/7393620/
DB06756,,FDA Approved Drug Products: CYSTADANE (betaine anhydrous) for oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020576s014lbl.pdf
DB06756,,EMA Summary of Product Characteristics: Amversio (betaine anhydrous) oral powder,https://www.ema.europa.eu/en/documents/product-information/amversio-epar-product-information_en.pdf
DB06756,,EMA Scientific Discussion: Cystadane (betaine anhydrous) for oral solution,https://www.ema.europa.eu/en/documents/scientific-discussion/cystadane-epar-scientific-discussion_en.pdf
DB06757,,FDA Approved Drug Products: Manganese Chloride Intravenous Injection (December 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018962s030lbl.pdf
DB06757,,"FDA Approved Drug Products: MULTRYS (trace elements injection 4*), for intravenous use (June 2021)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209376s002lbl.pdf
DB06757,,Agency for Toxic Substances and Disease Registry: Toxicological Profile for Manganese,https://www.atsdr.cdc.gov/ToxProfiles/tp151-c3.pdf
DB06759,,EMA Label: Vitravene (fomivirsen sodium) Summary of Product Characteristics,https://ec.europa.eu/health/documents/community-register/1999/199907293331/anx_3331_en.pdf
DB06764,,DailyMed Label: VISINE ORIGINAL REDNESS RELIEF (tetrahydrozoline) ophthalmic solution/ drops,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3c41a58-fc93-4e6c-99be-0529edfb54a4
DB06764,,DailyMed Label: CAREONE ITCHY RELIEF (tetrahydrozoline and zinc sulfate) ophthalmic solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=997f16ff-2632-2e9d-e053-2995a90a6f51
DB06764,,"DailyMed Label: CLEAR EYES TRIPLE ACTION (polyvinyl alcohol, povidone, and tetrahydrozoline) ophthalmic solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1269a1a6-843d-4d08-bb3c-c1f3d2e7080d
DB06764,,"DailyMed Label: COLIRIO OCUSAN (tetrahydrozoline, polyethylene glycol 400, povidone, and dextran 70) ophthalmic solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f0dd0bd-9a35-4671-933a-f3f8e834ae65
DB06764,,DailyMed Label (archived): TYZINE (tetrahydrozoline) NASAL SOLUTION,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9bea4aec-219f-46a9-9af4-5baab2552073
DB06764,,Toronto Research Chemicals: Tetrahydrozoline Safety Data Sheet,https://www.trc-canada.com/prod-img/MSDS/T296100MSDS.pdf
DB06764,,Cayman Chemical: Tetrahydrozoline Safety Data Sheet,https://www.caymanchem.com/msdss/23004m.pdf
DB06767,,product info,https://pubchem.ncbi.nlm.nih.gov/compound/ammonium_chloride#section=Absorption-Distribution-and-Excretion
DB06767,,INVIMA Product Authorization: Pulbronc NF (noscapine/ammonium chloride/fenoterol hydrobromide) oral syrup,http://web.sivicos.gov.co/registros/pdf/1352977_2015039253.pdf
DB06769,,FDA Approved Drug Products: Bendamustine hydrochloride injection for intravenous use (April 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215033s003lbl.pdf
DB06771,,FDA Approved Drug Products: Besivance (besifloxacin) ophthalmic suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022308s013lbl.pdf
DB06772,,"FDA Approved Drug Products: JEVTANA (cabazitaxel) injection, for intravenous use (June 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf
DB06772,,Health Canada Approved Drug Products: CABAZITAXEL Intravenous Injection,https://pdf.hres.ca/dpd_pm/00069636.PDF
DB06772,,EMA Approved Drug Products: Jevtana (cabazitaxel) Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/jevtana-epar-product-information_en.pdf
DB06772,,Biosynth Carbosynth: Cabazitaxel MSDS,https://static.cymitquimica.com/products/3D/pdf/sds-FC19621.pdf
DB06774,,Oleoresin Capsicum Toxicology Evaluation and Hazard Review,http://prod.sandia.gov/techlib/access-control.cgi/1995/952129.pdf
DB06774,,FDA Approved Drug Proucts: QUTENZA® (capsaicin) topical system,https://www.qutenza.com/pdfs/Qutenza_Prescribing_Information.pdf
DB06774,,TITCK Product Information: Thermo Sulidin (Capsaicin and Nimesulide) Topical Gel,https://titck.gov.tr/storage/kubKtAttachments/1QT5UhfIHQzhX.pdf
DB06775,,Carbaglu,http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000461/human_med_000685.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true
DB06775,,FDA Approved Drug Products: CARBAGLU (carglumic acid) tablets for oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022562s013lbl.pdf
DB06778,,Cupric Sulfate,https://pubchem.ncbi.nlm.nih.gov/compound/Copper_II__sulfate_pentahydrate
DB06778,,Copper Sulfate,http://npic.orst.edu/factsheets/cuso4gen.html
DB06778,,Cupric Sulfate ToxNet,http://pmep.cce.cornell.edu/profiles/extoxnet/carbaryl-dicrotophos/copper-sulfate-ext.html
DB06778,,"Cupric Sulfate, Britannica Online",https://www.britannica.com/science/cupric-sulfate
DB06778,,Cupric Sulfate,http://www.mims.com/philippines/drug/info/copper%20sulfate?mtype=generic
DB06778,,Wilson Disease,https://www.niddk.nih.gov/health-information/liver-disease/wilson-disease
DB06778,,Complications and management of acute copper sulphate poisoning; a case discussion,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269987/
DB06778,,Using Copper to Improve the Well-Being of the Skin,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556990/
DB06778,,Veterinary Toxicology: Basic and Clinical Principals,https://books.google.ca/books?id=SB8wDwAAQBAJ&pg=PA426&lpg=PA426&dq=copper+sulfate+mechanism+of+action&source=bl&ots=Nlep4d-WrL&sig=eu1xNrHEagOkxMASrOKpWBpRR5Y&hl=fr&sa=X&ved=0ahUKEwj5u8Pj9ILaAhUKEHwKHZzHDMIQ6AEImAEwCQ#v=onepage&q=copper%20sulfate%20mechanism%20of%20action&f=false
DB06778,,Abnormal Copper Homeostasis: Mechanisms and Roles in Neurodegeneration,https://www.researchgate.net/publication/294424113_Abnormal_Copper_Homeostasis_Mechanisms_and_Roles_in_Neurodegeneration
DB06778,,Copper,https://www.canada.ca/en/health-canada/services/publications/healthy-living/guidelines-canadian-drinking-water-quality-guideline-technical-document-copper.html
DB06778,,Metallic Copper as an Antimicrobial Surface,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067274/
DB06778,,Bacterial Killing by Dry Metallic Copper Surfaces,http://aem.asm.org/content/77/3/794.full
DB06782,,FDA Approved Drug Products: BAL in Oil (dimercaprol) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/005939s007lbl.pdf
DB06783,,World Health Organization Model List of Essential Medicines (19th List),http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
DB06783,,FERRIC HEXACYANOFERRATE Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7127
DB06784,,Gallium-Mechanism article,http://jnm.snmjournals.org/content/21/3/282.full.pdf
DB06784,,Gallium citrate,http://www.nuclearonline.org/PI/Du%20Pont%20Ga-67%20Citrate%20doc.pdf
DB06784,,Drugs.com,https://www.drugs.com/pro/gallium-citrate-ga-67.html
DB06784,,FDA Approved Drug Products: Gallium Citrate Ga 67 Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017478s016lbl.pdf
DB06785,,EMA Approved Drug Products: Ganirelix Gedeon Richter (Ganirelix) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/ganirelix-gedeon-richter-epar-product-information_en.pdf
DB06785,,DailyMed Label: Ganirelix Acetate Subcutaneous Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fb74ff-993a-49fe-8943-e029372b863e
DB06785,,Organon: Ganirelix MSDS,https://www.organon.com/docs/product/safety-data-sheets/Ganirelix%20Formulation_HH_NZ_6N.pdf
DB06785,,FDA Drug Approval Package: Antagon (Ganirelix Acetate),https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21057_Antagon.cfm#:~:text=Approval%20Date%3A%207%2F29%2F1999
DB06787,,WHOCC-ATC: Hexocyclium,https://www.whocc.no/atc_ddd_index/?code=A03AB10&showdescription=yes
DB06788,,FDA Approved Drug Products: Supprelin LA (histrelin acetate) subcutaneous implant,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022058s017lbl.pdf
DB06788,,FDA Drug Shortages: Vantas 50 mg Implantation Kit,https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Histrelin+Acetate+Implant&st=d&tab=tabs-2
DB06788,,FDA Approved Drug Products: Vantas (histrelin acetate) subcutaneous implant,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021732s023lbl.pdf
DB06788,,Health Canada Approved Drug Products: Vantas (histrelin acetate) subdermal implant,https://pdf.hres.ca/dpd_pm/00013986.PDF
DB06789,,FDA News Release: FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena,https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena
DB06789,,"US Federal Register: Determination That DELALUTIN (hydroxyprogesterone caproate) Injection, 125 Milligrams/Milliliter and 250 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",https://www.federalregister.gov/documents/2010/06/25/2010-15416/determination-that-delalutin-hydroxyprogesterone-caproate-injection-125-milligramsmilliliter-and-250
DB06789,,TITCK Product Information: Proluton (hydroprogesterone caproate) for intramuscular injection,https://titck.gov.tr/storage/kubKtAttachments/df0b7d7574706.pdf
DB06791,,FDA Approved Drug Products: Somatuline Depot (lanreotide) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022074s024lbl.pdf
DB06792,,FDA Approved Drug Products: Fosrenol (lanthanum carbonate) chewable tablets/oral powder for oral use (December 2023),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021468s024,204734s006lbl.pdf"
DB06795,,FDA Approved Drug Products: SULFAMYLON (mafenide acetate) topical,https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/19832lbl.pdf
DB06795,,"US Food & Drug Administration: Withdrawal of Approval of a New Drug Application for SULFAMYLON (Mafenide Acetate, USP) Powder for 5% Topical Solution",https://public-inspection.federalregister.gov/2022-26057.pdf
DB06796,,European Medicines Agency (EMA): TESLASCAN Summary of Product Characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000137/WC500036336.pdf
DB06796,,European Medicines Agency (EMA): TESLASCAN Scientific Discussion,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000137/WC500036332.pdf
DB06802,,FDA Approved Drug Products: NEVANAC (nepafenac) suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021862s017lbl.pdf
DB06803,,"Federal Register: Withdrawal of Approval of 29 NADA's (July 3, 1996)",https://www.govinfo.gov/content/pkg/FR-1996-07-03/html/96-16887.htm
DB06809,,FDA Approved Drug Products: MOZOBIL (plerixafor) injection for subcutaneous use (August 2020),https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022311s022lbl.pdf
DB06809,,EMA Summary of Product Characteristics: Mozobil (plerixafor) injection solution for subcutaneous use (April 2014),https://www.ema.europa.eu/en/documents/product-information/mozobil-epar-product-information_en.pdf
DB06809,,FDA Pharmacology Review: Mozobil (plerixafor) injection (December 2008),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_pharmr.pdf
DB06809,,Toronto Research Chemicals: Plerixafor SDS,https://www.trc-canada.com/prod-img/MSDS/P580500MSDS.pdf
DB06809,,CHMP Assessment Report: Mozobil (plerixafor),https://www.ema.europa.eu/en/documents/assessment-report/mozobil-epar-public-assessment-report_en.pdf
DB06811,,Link,http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_113.pdf
DB06812,,The efficacy and risks of using povidone-iodine irrigation to prevent surgical site infection: an evidence-based review,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386220/
DB06812,,"Iodophore activity, CDC",https://www.cdc.gov/hicpac/Disinfection_Sterilization/8_0Iodophors.html
DB06813,,FDA Approved Drug Products: FOLOTYN (pralatrexate injection) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022468s014lbl.pdf
DB06813,,Health Canada Approved Drug Products: FOLOTYN (pralatrexate injection) injection,https://pdf.hres.ca/dpd_pm/00047981.PDF
DB06813,,Cayman Chemical: Pralatrexate MSDS,https://cdn.caymanchem.com/cdn/msds/23689m.pdf
DB06815,,Pyrithione zinc - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+4498
DB06815,,NPRA Product Information: Dezor Plus (zinc pyrithione/ketoconazole) topical shampoo,http://quest3plus.bpfk.gov.my/front-end/attachment/293/pharma/69168/V_48322_20201130_094218_D4.pdf
DB06816,,HSDB: Pyrvinium,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3178
DB06817,,FDA Approved Drug Products: ISENTRESS (raltegravir) oral suspension and tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022145s044,203045s017,205786s009lbl.pdf"
DB06819,,"FDA Approved Drug Products: BUPHENYL (sodium phenylbutyrate) Tablets or Powder, for oral administration","https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020572s016,020573s015lbl.pdf"
DB06819,,Health Canada Approved Drug Products: ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) Oral Powder for suspension,https://pdf.hres.ca/dpd_pm/00066255.PDF
DB06819,,EMA Assessment Report: Pheburane (sodium phenylbutyrate),https://www.ema.europa.eu/en/documents/assessment-report/pheburane-epar-public-assessment-report_en.pdf
DB06819,,FDA Approved Drug Products: RELYVRIO (sodium phenylbutyrate and taurursodiol) for oral suspension,https://www.amylyx.com/document/RELYVRIO-US-Prescribing-Information.pdf
DB06820,,FDA Approved Drug Products: Exelderm (sulconazole nitrate) cream 1.0% tor topical use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/18737slr003_exelderm_lbl.pdf
DB06820,,FDA Approved Drug Products: Exelderm (sulconazole nitrate) solution 1.0% for topical use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018738s009lbl.pdf
DB06824,,"FDA Approved Drug Products: CUVRIOR (trientine tetrahydrochloride) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215760s000lbl.pdf
DB06824,,CDH Chemicals: Triethylenetetramine MSDS,https://www.cdhfinechemical.com/images/product/msds/37_1605852200_TriethyleneTetramine-CASNO-112-24-3-MSDS.pdf
DB06826,,article,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958522/
DB06826,,Monogragh,http://www.rxlist.com/rescula-drug/clinical-pharmacology.htm
DB07565,,FDA Approved Drug Products: Chloramphenicol Sodium Succinate Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/050155s039lbl.pdf
DB07565,,DailyMed: Chloramphenicol Succinate Powder for Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aed29594-211d-49ef-813f-131975a8d0e3
DB08604,,ON THE FATE OF TRICLOSAN IN HUMANS,http://diss.kib.ki.se/2009/978-91-7409-510-4/thesis.pdf
DB08804,,FDA Approved Drug Products: Deca-Durabolin (Nandrolone Decanoate) Injection (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013132
DB08804,,DPD Approved Drugs: Durabolin,https://pdf.hres.ca/dpd_pm/00007111.PDF
DB08804,,Jurox: Reepair Injection MSDS,https://www.jurox.com.au/wp-content/uploads/Reepair-Injection.pdf
DB08804,,Spain Patent: ES246402A1,https://patents.google.com/patent/ES246402A1/en
DB08806,,Product Insert,http://home.intekom.com/pharm/hmr/roxit.html
DB08814,,MIMS,http://www.mims.com/malaysia/drug/info/triflusal?mtype=generic
DB08815,,FDA Approved Drug Products: Latuda (lurasidone hydrochloride) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200603s035lbl.pdf
DB08816,,"FDA Approved Drug Products: BRILINTA (ticagrelor) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022433s032lbl.pdf
DB08816,,EMA Summary of Product Characteristics: Brilique Ticagrelor Oral Tablet,https://www.ema.europa.eu/en/documents/product-information/brilique-epar-product-information_en.pdf
DB08818,,NIH StatPearls: Hyaluronic acid,https://www.ncbi.nlm.nih.gov/books/NBK482440/
DB08818,,DailyMed: HALUCORT gel dressing with hyaluronic acid,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29ee67f8-0663-4403-a7c5-67e98731ee89
DB08818,,NIH DailyMed: Hyaluronic acid injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a75e2bb2-f89a-53f4-e053-2a95a90a93c7
DB08818,,DailyMed: PRO PH (hyaluronic acid gel) for injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4152de40-e1cb-653d-e054-00144ff88e88
DB08818,,DailyMed: Vista advanced dry eye capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b32851d7-07b0-09c4-e053-2a95a90afcf4
DB08818,,DailyMed: Hyaluronic acid gel,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a6b8e3-49f8-2ac7-e054-00144ff88e88
DB08818,,FDA Approved Drug Products: SYNOJOYNT (sodium hyaluronate) intra-articular injection,https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160057C.pdf
DB08818,,Fischer Scientific MSDS: Sodium hyaluronate,https://www.fishersci.com/store/msds?partNumber=AC251770010&productDescription=SODIUM+HYALURONATE+94%25+1GRS&vendorId=VN00032119&countryCode=US&language=en
DB08819,,FDA Approved Drug Products: ZIOPTAN (tafluprost) ophthalmic,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202514s003s004lbl.pdf
DB08820,,"FDA Approval Update May 17, 2017",https://www.drugs.com/newdrugs/fda-expands-approved-kalydeco-additional-mutations-cystic-fibrosis-4534.html?utm_source=ddc&utm_medium=email&utm_campaign=Today%27s+news+summary+-+May+18%2C+2017&utm_content=FDA+Expands+Approved+Use+of+Kalydeco+to+Treat+Additional+Mutations+of+Cystic+Fibrosis
DB08820,,"FDA Approved Drug Products: SYMDEKO (tezacaftor/ivacaftor) tablets; (ivacaftor) tablets, for oral use (December 2020)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210491s007lbl.pdf
DB08820,,"Cystic Fibrosis, Canada",https://www.cysticfibrosis.ca/our-programs/advocacy/access-to-medicines/kalydeco
DB08820,,"FDA Approved Drug Products: ORKAMBI (lumacaftor/ivacaftor) granules or tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s010lbl.pdf
DB08820,,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf
DB08820,,"FDA Approved Drug Products: Kalydeco (ivacaftor) tablets or granules, for oral use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203188s034,207925s013lbl.pdf"
DB08820,,Health Canada Product Monograph: KALYDECO (ivacaftor) Oral Tablets or Granules,https://pdf.hres.ca/dpd_pm/00065151.PDF
DB08820,,"FDA Approved Drug Products: ORKAMBI (lumacaftor and ivacaftor) tablets or granules, for oral use (September 2022)",https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf
DB08820,,Health Canada Approved Drug Producs: ORKAMBI (Lumacaftor / Ivacaftor) tablets for oral use,https://pi.vrtx.com/files/Canadapm_orkambi_en.pdf
DB08820,,"Dailymed: TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor kit) tablets, for oral use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f354423a-85c2-41c3-a9db-0f3aee135d8d
DB08820,,"FDA Approved Drug Products: SYMDEKO™ (tezacaftor/ivacaftor) tablets; (ivacaftor) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf
DB08820,,"FDA Approved Drug Products: TRIKAFTA® (elexacaftor, tezacaftor, and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use May 2023",https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf
DB08820,,"FDA Approved Drug Products: KALYDECO (ivacaftor) tablets or granules, for oral use (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203188s038lbl.pdf
DB08820,,Health Canada Product Monograph: KALYDECO (ivacaftor) Oral Tablets or Granules (Dec 2023),https://pi.vrtx.com/files/Canadapm_kalydeco_en.pdf
DB08822,,FDA Approved Drug Products: Edarbi (azilsartan medoxomil) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200796s006lbl.pdf
DB08822,,"FDA Approved Drug Products: EDARBYCLOR (azilsartan medoxomil and chlorthalidone) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202331lbl.pdf
DB08822,,"FDA Approved Drug Products: Edarbi (azilsartan medoxomil) tablets, for oral use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/200796s013lbl.pdf
DB08823,,FDA Approved Drug Products: Natroba (spinosad) topical suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022408Orig1s010lbl.pdf
DB08824,,Link,http://md.gehealthcare.com/files/pdfs/msds/datscan.pdf
DB08826,,FDA Approved Drug Products: Ferriprox (deferiprone) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021825s010lbl.pdf
DB08827,,FDA Approved Drug Products: Juxtapid (lomitapide) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203858s019lbl.pdf
DB08828,,FDA Approved Drug Products: ERIVEDGE (vismodegib) capsules for oral use (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203388s017lbl.pdf
DB08828,,MedChemExpress: Vismodegib SDS,https://file.medchemexpress.com/batch_PDF/HY-10440/Vismodegib-SDS-MedChemExpress.pdf
DB08834,,AIFA: Tauro (Tauroursodeoxycholic Acid) Oral Capsules,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_026772_FI.pdf&retry=0&sys=m0b1l3
DB08834,,Health Canada Approved Drug Products: ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) Oral Powder for suspension,https://pdf.hres.ca/dpd_pm/00066255.PDF
DB08834,,FDA Approved Drug Products: RELYVRIO (sodium phenylbutyrate and taurursodiol) for oral suspension,https://www.amylyx.com/document/RELYVRIO-US-Prescribing-Information.pdf
DB08836,,Clearance of Temocapril and Enalapril during Haemodialysis Treatment,http://link.springer.com/article/10.2165%2F00044011-199509040-00008
DB08860,,FDA Approved Drug Products: Livalo (pitavastatin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022363s017lbl.pdf
DB08860,,FDA Approved Drug Products: Zypitamag (pitavastatin magnesium) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208379s003lbl.pdf
DB08860,,"FDA Approved Drug Products: NIKITATM (pitavastatin) tablets, for oral use (November 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209875s003lbl.pdf
DB08862,,cholecystokinin,http://www.vivo.colostate.edu/hbooks/pathphys/endocrine/gi/cck.html
DB08862,,Cholecystokinin metabolism in man and dogs,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1344019/
DB08862,,Cholecystokinin,https://www.drugs.com/mmx/cck.html
DB08862,,Cholecystokinin- a review,https://www.sciencedirect.com/topics/chemistry/cholecystokinin
DB08862,,Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839260/
DB08862,,"Cholecystokinin receptors in brain: Effects of obesity, drug treatment, and lesions Author links open overlay panel",https://www.sciencedirect.com/science/article/abs/pii/0196978181900516
DB08862,,"SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI",https://link.springer.com/article/10.1007/s00213-002-1214-z
DB08862,,Physiology of CCK,https://www.uptodate.com/contents/physiology-of-cholecystokinin
DB08862,,"Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon.",https://www.ncbi.nlm.nih.gov/pubmed/12496267
DB08862,,"Effect of Exogenous Cholecystokinin (CCK)-8 on Food Intake and Plasma CCK, Leptin, and Insulin Concentrations in Older and Young Adults: Evidence for Increased CCK Activity as a Cause of the Anorexia of Aging",https://watermark.silverchair.com/jcem5830.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAaowggGmBgkqhkiG9w0BBwagggGXMIIBkwIBADCCAYwGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM8C4jETgsbOcKN1RJAgEQgIIBXby2TDMTqLoxgQ6ubmlN4HjHutX56ZK5YSit8uXY_SxCH-FeJHHRd96DO6Xelfs_AWHgOkwYiSjyYiuJ6R5G75IuAh7TqXiqfShWHfHPGcr6jbX8N95S0Q25p6CTV_9-3_c8L1bA6AmtrsINgJbKbocjEZYJz0Dw51NqiUsO8g8f8Junna_pmyfUuz8j4wEmV7mywP_MWfvtH85E-gZ1XvGsQ7CiBLVtSW2g_4VGxNQgySqQqOqwvwdBXWNGFaIdAEDcvTqNslGyKbBNDf9OG_vZdli5fQXImHAhuyg1MGK4DKqzXh1FLuaRnRpOILyQrw5Wdw9pmiH_t6LxvC4RDlG5gi_fhjlAbLBZSLFxxefkX9NV8s9_sjKTpGFpVRDLooh6_luWVvHcFmS8OyEbaj-Jy8E0d_n_JndMakMvJT1ijVQpi4RbOrA6zCGeAvlPoDhBVT5IfTTQ61uJSsQ
DB08862,,Comparison of Gallbladder Function Obtained with Regular CCK-8 and Pharmacy-Compounded CCK-8,http://jnm.snmjournals.org/content/44/4/499.full
DB08862,,Bioactivity of synthetic human cholecystokinin (CCK)-33 in vitro and in vivo,https://link.springer.com/article/10.1007%2FBF02779509
DB08862,,Cholecystokinin Octapeptide,https://pubchem.ncbi.nlm.nih.gov/compound/16219094
DB08862,,"Cholecystokinin Octapeptide, [125I]-, Bolton-Hunter Labeled, 10µCi",http://www.perkinelmer.ca/en-ca/product/cholecystokinin-octapeptide-125i-bolt-nex203010uc
DB08862,,"Alfa Aesar™ Cholecystokinin, CCK Octapeptide (26-33)",https://www.fishersci.ca/shop/products/cholecystokinin-cck-octapeptide-26-33-2/p-5384644
DB08862,,Cholecystokinin-Pancreozymin Peptides Products,http://www.biosyn.com/catalog-peptides/cholecystokinin-pancreozymin-peptides.aspx
DB08862,,CCK Octapeptide sulfated,https://www.tocris.com/products/cck-octapeptide-sulfated_1166
DB08862,,Cholecystokinin Octapeptide,https://www.perkinelmer.com/Content/MSDSDatabase/MSDS_NEX203010UC_AU_EN.pdf
DB08864,,J&J News,https://www.jnj.com/media-center/press-releases/fda-approves-edurant-rilpivirine-for-use-in-treatment-naive-adults-with-hiv-1
DB08864,,FDA News and Events,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm586305.htm
DB08864,,Australian Government: Australian Public Assessment Report for Rilpivirine,https://www.tga.gov.au/sites/default/files/auspar-rilpivirine-120327.pdf
DB08864,,FDA Approved Drug Products: Edurant (rilpivirine) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202022s013lbl.pdf
DB08864,,FDA Approved Drug Products: Cabenuva (Cabotegravir and Rilpivirine) Intramuscular Extended-Release Suspension,https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF
DB08864,,"BioSpace News: ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment",https://www.biospace.com/article/releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment/?s=74
DB08864,,"FDA Approved Drug Products: JULUCA (dolutegravir and rilpivirine tablets), for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210192s013lbl.pdf
DB08864,,"FDA Approved Drug Products: EDURANT (rilpivirine) suspension or tablets, for oral use (March 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202022s020s022lbl.pdf
DB08865,,FDA Approved Drug Products: XALKORI (crizotinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf
DB08865,,FDA Clinical Pharmacology and Biopharmaceutics Review: XALKORI (crizotinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf
DB08865,,Health Canada Approved Drug Products: XALKORI (crizotinib) capsules for oral use,https://www.pfizer.ca/sites/default/files/202102/XALKORI_PM_EN_243841_03-Feb-2021.pdf
DB08867,,Electronic Medicines Compendium: ellaOne (ulipristal acetate) 30 mg Monograph,https://www.medicines.org.uk/emc/product/6657/smpc
DB08867,,FDA Approved Drug Products: ELLA (ulipristal acetate) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022474s011lbl.pdf
DB08868,,FDA Approved Products: Gilenya (fingolimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf
DB08868,,Clinicaltrials.gov: Fingolimod in COVID-19,https://clinicaltrials.gov/ct2/show/NCT04280588
DB08868,,Clinical trials on drug repositioning for COVID-19 treatment,https://www.paho.org/journal/sites/default/files/2020-03/40-20-249-Rosa-prelim.pdf?ua=1
DB08868,,European Medicines Agency Public Assessment Report: Gilenya (fingolimod),https://www.ema.europa.eu/en/documents/assessment-report/gilenya-epar-public-assessment-report_en.pdf
DB08868,,FDA Approved Drug Products: TASCENSO ODT (fingolimod) orally disintegrating tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214962s000lbl.pdf
DB08870,,FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601935.htm
DB08870,,Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma Read more: http://www.digitaljournal.com/pr/3703005#ixzz5AKAaxmbe,http://www.digitaljournal.com/pr/3703005
DB08870,,NCCN Flash UpdatesTM: NCCN Guidelines® and NCCN Compendium® Updated,https://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=472
DB08870,,EMA label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf
DB08870,,Cancer Care Ontario Formulary,https://www.cancercareontario.ca/sites/ccocancercare/files/brentuximab%20vedotin.pdf
DB08870,,"Merck Manuals, Progressive Multifocal Leukoencephalopathy","https://www.merckmanuals.com/en-ca/home/brain,-spinal-cord,-and-nerve-disorders/brain-infections/progressive-multifocal-leukoencephalopathy-pml"
DB08870,,Seattle genetics Brentuximab Vedotin,http://www.seattlegenetics.com/pipeline/brentuximab-vedotin
DB08870,,Brentuximab vedotin: clinical updates and practical guidance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762734/
DB08870,,FDA Approved Drug Products: Adcetris (brentuximab vedotin) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125388s100lbl.pdf
DB08873,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB08874,,"FDA Approved Drug Products: DIFICID (fidaxomicin) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213138lbl.pdf
DB08874,,"Santa Cruz Biotechnology, Inc.: Fidaxomicin Safety Data Sheet",http://datasheets.scbt.com/sds/wpna/en/sc-362739.pdf
DB08875,,FDA Approved Drug Products: Cometriq (cabozantinib) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203756s008lbl.pdf
DB08875,,FDA Approved Drug Products: Cabometyx (cabozantinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s012lbl.pdf
DB08875,,Health Canada Product Monograph: Cabometyx (cabozantinib) oral tablets,https://pdf.hres.ca/dpd_pm/00056366.PDF
DB08877,,"FDA Approved Drug Products: JAKAFI (ruxolitinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202192Orig1s019Rpllbl.pdf
DB08877,,"Santa Cruz Biotechnology, Inc.: Ruxolitinib Safety Data Sheet",https://datasheets.scbt.com/sds/aghs/en/sc-364729.pdf
DB08877,,LC Laboratories: Ruxolitinib Safety Data Sheet,https://lclabs.com/sdss/147
DB08877,,Drugs.com: Jakafi FDA Approval History,https://www.drugs.com/history/jakafi.html
DB08877,,Novartis: Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19,https://www.novartis.com/news/media-releases/novartis-provides-update-ruxcovid-study-ruxolitinib-hospitalized-patients-covid-19
DB08877,,BC Cancer - Ruxolitinib monograph,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Ruxolitinib_monograph.pdf
DB08877,,EMA Approved Drug Products: Jakavi (ruxolitinib) oral tablets,https://www.ema.europa.eu/en/documents/product-information/jakavi-epar-product-information_en.pdf
DB08877,,"FDA Approved Drug Products: OPZELURA (ruxolitinib) cream, for topical use",https://www.opzelura.com/prescribing-information.pdf
DB08877,,EMA Approved Drug Products: OPZELURA (ruxolitinib) Topical Cream,https://www.ema.europa.eu/en/documents/product-information/opzelura-epar-product-information_en.pdf
DB08879,,"FDA Approved Drug Products: BENLYSTA (belimumab) for injection, for intravenous or subcutaneous use (July 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761043s021lbl.pdf
DB08879,,EMA Approved Drug Products: Benlysta (belimumab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf
DB08879,,"FDA Approved Drug Products: BENLYSTA (belimumab) for injection, for intravenous/subcutaneous use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125370s082,761043s028lbl.pdf"
DB08880,,FDA Approved Drug Products: AUBAGIO (teriflunomide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202992s013s015lbl.pdf
DB08881,,Roche news,https://www.roche.com/media/store/releases/med-cor-2011-08-17.htm
DB08881,,FDA News and Events,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583931.htm
DB08881,,FDA Vemurafenib application,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000ClinPharmR.pdf
DB08882,,FDA Approved Drug Products: Linagliptin Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201280s018lbl.pdf
DB08882,,FDA Approved Drug Products: Trijardy XR (empagliflozin/linagliptin/metformin) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212614s000lbl.pdf
DB08882,,FDA Approved Drug Products: Linagliptin Oral Tablets (2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201280s025lbl.pdf
DB08883,,FDA Approved Drug Products: FYCOMPA (perampanel) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202834s016,208277s004lbl.pdf"
DB08884,,"FDA Approved Drug Products: EOVIST (gadoxetate disodium) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022090s024lbl.pdf
DB08885,,FDA Approved Drug Products: EYLEA (aflibercept) injection for intravitreal use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125387s075lbl.pdf
DB08885,,FDA Approved Drug Products: ZALTRAP (ziv-aflibercept) injection for intravenous use (June 2020),https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125418s047lbl.pdf
DB08885,,"FDA Approved Drug Products: EYLEA® HD (aflibercept) injection, for intravitreal use (August 2023)",https://www.regeneron.com/downloads/eyleahd_fpi.pdf
DB08885,,Aflibercept MSDS,https://s3-us-west-2.amazonaws.com/drugbank/msds/DB08885.pdf?1369433895
DB08885,,ZALTRAP® (ZIV-AFLIBERCEPT) APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER,https://investor.regeneron.com/news-releases/news-release-details/zaltrapr-ziv-aflibercept-approved-eu-patients-previously-treated
DB08885,,U.S. FDA APPROVES ZALTRAP® (ZIV-AFLIBERCEPT) AFTER PRIORITY REVIEW FOR PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER,https://newsroom.regeneron.com/news-releases/news-release-details/us-fda-approves-zaltrapr-ziv-aflibercept-after-priority-review
DB08885,,"EYLEA HD (AFLIBERCEPT) INJECTION 8 MG APPROVED BY FDA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (WAMD), DIABETIC MACULAR EDEMA (DME) AND DIABETIC RETINOPATHY (DR)","https://investor.regeneron.com/news-releases/news-release-details/eylea-hd-aflibercept-injection-8-mg-approved-fda-treatment-wet#:~:text=35%20PM%20EDT-,EYLEA%20HD%20(aflibercept)%20Injection%208%20mg%20Approved%20by%20FDA%20for,)%20and%20Diabetic%20Retinopathy%20(DR)&text=TARRYTOWN%2C%20N.Y.%20%2C%20Aug.,)%20%2D%2D%20Regeneron%20Pharmaceuticals%2C%20Inc."
DB08885,,AJMC Center for Biosimilars: European Commission Approves First Aflibercept Biosimilar,https://www.centerforbiosimilars.com/view/european-commission-approves-first-aflibercept-biosimilar
DB08886,,"FDA Approved Drug Products: ERWINAZE (asparaginase Erwinia chrysanthemi) for injection, intramuscular use",http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125359lbl.pdf
DB08886,,BC Cancer Asparaginase Monograph,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Asparaginase_monograph_1June2013_formatted.pdf
DB08886,,Pegylated l-asparaginase: Protein Sequence of Erwinia Asparaginase,https://patents.google.com/patent/EP2451486A1
DB08886,,FDA Press Announcements: FDA Approves Component of Treatment Regimen for Most Common Childhood Cancer,https://www.fda.gov/news-events/press-announcements/fda-approves-component-treatment-regimen-most-common-childhood-cancer
DB08886,,"FDA Approved Drug Products: RYLAZE (asparaginase erwinia chrysanthemi (recombinant)­ rywn) injection, for intramuscular use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761179s000lbl.pdf
DB08887,,FDA Approved Drug Products: Vascepa (icosapent ethyl) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s035lbl.pdf
DB08889,,"FDA Approved Drug Products: KYPROLIS (carfilzomib) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202714s033lbl.pdf
DB08889,,"FDA Approved Drug Products: KYPROLIS (carfilzomib) for injection, for intravenous use 2022",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202714s034lbl.pdf
DB08890,,FDA Approved Drug Products: LINZESS (linaclotide) Oral Capsules (April 2021),https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202811s017lbl.pdf
DB08890,,FDA Approved Drug Products: LINZESS (linaclotide) Oral Capsules (June 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202811s021lbl.pdf
DB08890,,EMA Approved Drug Products: CONSTELLA (Linaclotide) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/constella-epar-product-information_en.pdf
DB08890,,Health Canada Approved Drug Products: CONSTELLA (Linaclotide) Oral Capsules,https://pdf.hres.ca/dpd_pm/00066795.PDF
DB08893,,"FDA Approved Drug Products: MYRBETRIQ (mirabegron) extended-release tablets or granules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202611Orig1s017lbl.pdf
DB08893,,Health Canada Product Monograph: Myrbetriq (mirabegron) extended-release tablets,https://pdf.hres.ca/dpd_pm/00035298.PDF
DB08893,,EMA Summary of Product Characteristics: Betmiga (mirabegron) prolonged-release tablets,https://www.ema.europa.eu/en/documents/product-information/betmiga-epar-product-information_en.pdf
DB08895,,Link,http://www.accessdata.fda.gov/spl/data/34f69a09-8707-42ca-8cd1-33dabe698756/34f69a09-8707-42ca-8cd1-33dabe698756.xml
DB08895,,BusinessWire: U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis,https://www.businesswire.com/news/home/20200928005729/en/U.S.-FDA-Approves-Pfizer%E2%80%99s-XELJANZ%C2%AE-tofacitinib-for-the-Treatment-of-Active-Polyarticular-Course-Juvenile-Idiopathic-Arthritis
DB08895,,BioSpace: XELJANZ for the treatment of Ankylosing Spondylitis,https://www.biospace.com/article/releases/pfizer-s-xeljanz-tofacitinib-receives-marketing-authorization-in-the-european-union-for-the-treatment-of-active-ankylosing-spondylitis/?keywords=CHMP+approval
DB08895,,"FDA Approved Drug Products: Xeljanz (Tofacitinib) Oral Solution, Tablets, and Extended Release Tablets","https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203214s028,208246s013,213082s003lbl.pdf"
DB08896,,FDA Approved Drug Products: STIVARGA (regorafenib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf
DB08898,,"FDA Approved Drug Products: VORAXAZE (glucarpidase) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125327s064lbl.pdf
DB08898,,GlobeNewswire: SERB receives EU approval for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity,https://www.globenewswire.com/news-release/2022/01/14/2367290/0/en/SERB-receives-EU-approval-for-Voraxaze-glucarpidase-as-Rescue-Therapy-for-High-Dose-Methotrexate-Toxicity.html
DB08898,,Summary of Product Characteristics: Voraxaze (glucarpidase) intravenous injection,https://www.ema.europa.eu/en/documents/product-information/voraxaze-epar-product-information_en.pdf
DB08899,,FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use (January 2022),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203415s018,213674s005lbl.pdf"
DB08899,,FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use (September 2022),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203415s019,213674s006lbl.pdf"
DB08899,,Health Canada Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use (January 2022),https://www.astellas.com/ca/system/files/xtandi_pm_jan_24_2022-final_en.pdf
DB08899,,FDA Approved Drug Products: Xtandi (enzalutamide) capsules/tablets for oral use (August 2012),https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf
DB08899,,"FDA Approved Drug Products: TALZENNA (talazoparib) capsules, for oral use (June 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf
DB08899,,"FDA Approved Drug Products: XTANDI® (enzalutamide) capsules/tablet, for oral use (November 2023)",https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf
DB08899,,Health Canada Approved Drug Products: Xtandi (enzalutamide) Oral Capsules (January 2024),https://www.astellas.com/ca/system/files/pdf/xtandi_pm_05jan2024_en.pdf
DB08899,,EMA Approved Drug Products: TALZENNA (talazoparib) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf
DB08900,,FDA Approved Drug Products: Gattex (teduglutide) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203441s018lbl.pdf
DB08903,,"FDA Approved Drug Products: SIRTURO (bedaquiline) tablets, for oral use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204384s017lbl.pdf
DB08903,,"FDA Approved Drug Products: SIRTURO (bedaquiline) tablets, for oral use (May 2020)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204384s013lbl.pdf
DB08903,,"FDA Approved Drug Products: SIRTURO (bedaquiline) tablets, for oral us (June 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204384s019lbl.pdf
DB08904,,FDA news,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634671.htm
DB08904,,Pubmed books,https://www.ncbi.nlm.nih.gov/pubmed/30222277
DB08904,,Nature,https://www.nature.com/subjects/inflammatory-diseases
DB08904,,FDA Approved Drug Products: CIMZIA (certolizumab pegol) injection for subcutaneous use (December 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125160s305lbl.pdf
DB08906,,FDA Fluticasone Furoate Approval 2007,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022051_veramyst_toc.cfm
DB08906,,FDA Approved Drug Products: Breo Ellipta (fluticasone furoate/vilanterol) powder for inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204275s017lbl.pdf
DB08906,,FDA Approved Drug Products: Arnuity Ellipta (fluticasone furoate) powder for inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205625s007lbl.pdf
DB08906,,DailyMed: Flonase Sensimist (fluticasone furoate) nasal spray,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=893234b5-be82-4425-b850-2b884637b18e
DB08906,,"FDA Approved Drug Products: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) powder for inhalation",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209482s010s011lbl.pdf
DB08906,,"FDA Approved Drug Products: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) powder for inhalation (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209482s016lbl.pdf
DB08906,,FDA Approved Drug Products: Breo Ellipta (fluticasone furoate/vilanterol) powder for inhalation (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204275s022lbl.pdf
DB08906,,Fluticasone Furoate MSDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9GLAXC_BREO_ELLIPTA_100_25MCG_INH.pdf
DB08906,,Fluticasone furoate/vilanterol: Clinical Pharmacology and Biopharmaceutics review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204275Orig1s000ClinPharmR.pdf
DB08906,,FDA Approved Drug Products: VERAMYST (fluticasone furoate) nasal spray,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8eaee9bf-91c7-484b-b8b1-b8242198181f
DB08906,,Health Canada Approved Drug Proucts: BREO ELLIPTA (fluticasone furoate/vilantero) dry powder for oral inhalation,https://ca.gsk.com/media/6157/breo-ellipta.pdf
DB08906,,"FDA Approved Drug Products: ARNUITY ELLIPTA (fluticasone furoate inhalation powder), for oral corticosteroids (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205625s011lbl.pdf
DB08907,,"U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease",https://www.janssen.com/us-fda-approves-invokanar-canagliflozin-reduce-risk-heart-attack-stroke-or-cardiovascular-death
DB08907,,"Diabetes, Heart Disease, and Stroke: NIDDK",https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/heart-disease-stroke
DB08907,,FDA Approved Drug Products: Invokana (canagliflozin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204042s034lbl.pdf
DB08907,,"FDA Approved Products: INVOKAMET (canagliflozin and metformin hydrochloride tablets), for oral use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204353s039,205879s017lbl.pdf"
DB08907,,FDA Approved Drug Products: Invokana (canagliflozin) tablets for oral use (July 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204042s040lbl.pdf
DB08908,,FDA Approved Drug Products: TECFIDERA (dimethyl fumarate) delayed-release capsules for oral use (September 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204063s028s030lbl.pdf
DB08908,,EMA Assessment Report: Tecfidera (dimethyl fumarate) capsules for oral use,https://www.ema.europa.eu/en/documents/assessment-report/tecfidera-epar-public-assessment-report_en.pdf
DB08908,,Santa Cruz Biotechnology: Dimethyl fumarate SDS,https://datasheets.scbt.com/sds/aghs/en/sc-239774.pdf
DB08908,,EMA Summary of Product Characteristics: Tecfidera (dimethyl fumarate) gastro-resistant hard capsules for oral use,https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_en.pdf
DB08908,,"FDA Approved Drug Products: TECFIDERA (dimethyl fumarate) delayed-release capsules, for oral use (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204063s032lbl.pdf
DB08909,,FDA Approved Drug Products: RAVICTI (glycerol phenylbutyrate) oral liquid,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203284Orig1s012lbl.pdf
DB08910,,FDA Approved Drug Products: POMALYST (pomalidomide) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204026s028lbl.pdf
DB08911,,"FDA Approved Drug Products: MEKINIST (trametinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204114s021lbl.pdf
DB08911,,"FDA Approved Drug Products: MEKINIST (trametinib) tablets or solution, for oral use (March 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217513s000lbl.pdf
DB08911,,EMA Approved Drug Products: Mekinist (trametinib) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf
DB08911,,Health Canada Approved Drug Products: MEKINIST (Trametinib) Oral Tablets,https://pdf.hres.ca/dpd_pm/00066787.PDF
DB08911,,"FDA Approved Drug Products: MEKINIST (trametinib) tablets or solution, for oral use (June 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf
DB08912,,Dabrafenib,https://pubchem.ncbi.nlm.nih.gov/compound/Dabrafenib
DB08912,,"Drug Duo, Tafinlar and Mekinist, Approved for Aggressive Thyroid Cancer",https://www.drugs.com/news/duo-tafinlar-mekinist-approved-aggressive-thyroid-cancer-74098.html?utm_source=ddc&utm_medium=email&utm_campaign=Today%27s+news+summary+-+May+5%2C+2018&utm_content=Drug+Duo%2C+Tafinlar++and+Mekinist%2C+Approved+for+Aggressive+Thyroid+Cancer
DB08912,,FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564331.htm
DB08912,,Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma,https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-tafinlarr-mekinistr-adjuvant-treatment-braf-v600-mutant-melanoma
DB08912,,Dabrafenib,https://www.rcsb.org/ligand/P06
DB08912,,Cancer. gov Dabrafenib,https://www.cancer.gov/about-cancer/treatment/drugs/fda-dabrafenib
DB08912,,Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer,http://ascopubs.org/doi/abs/10.1200/JCO.2017.73.6785
DB08912,,"FDA Approved Drug Proucts: TAFINLAR® (dabrafenib) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s023lbl.pdf
DB08912,,Santa Cruz Biotech: Dabrafenib MSDS,https://datasheets.scbt.com/sds/aghs/en/sc-364477.pdf
DB08912,,GSK: Dabrafenib MSDS,https://www.obaid.info/pdf/MSDS/T/Tafinlar-Capsules-1.pdf
DB08912,,FDA Approved Drug Products: TAFINLAR (dabrafenib) Oral Capsules or Tablets for Oral Suspension (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217514s000lbl.pdf
DB08912,,FDA Approved Drug Products: TAFINLAR (dabrafenib) Oral Capsules or Tablets for Oral Suspension (June 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf
DB08916,,Electronic Medicines Compendium: Giotrif 30 mg film-coated tablets Monograph,https://www.medicines.org.uk/emc/product/7701/smpc
DB08916,,Boehringer Ingelheim: FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC,https://www.boehringer-ingelheim.us/press-release/fda-approves-new-indication-gilotrif-egfr-mutation-positive-nsclc
DB08917,,FDA Approved Drug Products: Injectafer (ferric carboxymaltose) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203565Orig1s016_CORRECTED_lbl.pdf
DB08917,,FDA Approved Drug Products: Injectafer (ferric carboxymaltose) for intravenous injection (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203565s020lbl.pdf
DB08918,,"FDA Approved Drug Products: FETZIMA (levomilnacipran) extended-release capsules, for oral use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204168s011lbl.pdf
DB08918,,Allergan: FETZIMA (Levomilnacipran) MSDS,https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/safety-data-sheets/FETZIMA-EN-AGHS-2018100295254.pdf
DB08918,,FDA Drug Approval Package: FETZIMA (levomilnacipran) Extended-Release Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204168Orig1s000TOC.cfm
DB08918,,European Medicines Agency decision: P/0128/2015,https://www.ema.europa.eu/en/documents/pip-decision/p/0128/2015-ema-decision-5-june-2015-refusal-product-specific-waiver-levomilnacipran-emea-001724-pip01-14_en.pdf
DB08930,,ViiV Healthcare News,https://www.viivhealthcare.com/media/press-releases/2013/august/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-for-the-treatment-of-hiv-1.aspx
DB08930,,FDA News and Events,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm586305.htm
DB08930,,"Johnson & Johnson News: Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection",https://www.jnj.com/media-center/press-releases/janssen-announces-us-fda-approval-of-first-and-only-complete-single-pill-two-drug-regimen-juluca-dolutegravir-and-rilpivirine-for-the-treatment-of-hiv-1-infection
DB08930,,"FDA Approved Drug Products: Triumeq/Triumeq PD (abacavir, dolutegravir, and lamivudine) for oral administration",https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG-IFU.PDF
DB08930,,"FDA Approved Drug Products: TIVICAY (dolutegravir) tablets, for oral use or oral suspension","https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204790s028,213983s002lbl.pdf"
DB08930,,"FDA Approved Drug Products: JULUCA (dolutegravir and rilpivirine tablets), for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210192s013lbl.pdf
DB08930,,"FDA Approved Drug Products: DOVATO (dolutegravir and lamivudine) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211994s011lbl.pdf
DB08930,,FDA Approved Drug Products: Dovato (dolutegravir and lamivudine) tablets for oral use (April 2024),https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Dovato/pdf/DOVATO-PI-PIL.PDF
DB08932,,FDA Approved Drug Products: OPSUMIT (macitentan) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204410s021lbl.pdf
DB08932,,DPD Approved Drug Products: Opsynvi (tadalafil/macitentan) combination tablets,https://pdf.hres.ca/dpd_pm/00063187.PDF
DB08932,,FDA Approved Drug Products: Opsynvi (macitentan and tadalafil) tablets for oral use,https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/OPSYNVI-pi.pdf
DB08933,,FDA Approved Drug Products: Luzu (luliconazole 1%) cream for topical use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204153s004s005lbl.pdf
DB08934,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB08934,,FDA Approved Drug Products: Epclusa (sofosbuvir and velpatasvir) tablets or pellets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208341s017lbl.pdf
DB08934,,FDA Approved Drug Products: Harvoni (Ledipasvir and Sofosbuvir) tablets or pellets for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205834s032,212477s003lbl.pdf"
DB08934,,"FDA Approved Drug Products: Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209195s003lbl.pdf
DB08934,,FDA Approved Drug Products: Sovaldi (sofosbuvir) tablets or pellets for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204671s017,212480s002lbl.pdf"
DB08935,,"FDA Approved Drug Products: GAZYVA (obinutuzumab) injection, for intravenous use (July 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s034lbl.pdf
DB08937,,Link,http://clinicaltrials.gov/ct2/show/NCT01607957
DB08942,,Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999,http://dij.sagepub.com/content/35/1/293.abstract
DB08943,,INVIMA Product Authorization: Micofentin (isoconazole/clindamycin) vaginal cream,http://web.sivicos.gov.co/registros/pdf/15556810_2018009411.pdf
DB08949,,SCIENTIFIC OPINION Inositol hexanicotinate,http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/949.pdf
DB08949,,"Vitamin and Mineral Safety 3rd Edition (2013) Council for Responsible Nutrition (CRN); Niacin: Nicotinic Acid, Nicotinamide, and Inositol Hexanicotinate",https://www.crnusa.org/sites/default/files/files/resources/13-CRNVMS3-NIACIN.pdf
DB08954,,Clinical Trial NCT04382924,https://clinicaltrials.gov/ct2/show/NCT04382924
DB08964,,CERVAGEM (Gemeprost) Product information,https://gp2u.com.au/static/pdf/C/CERVAGEM-PI.pdf
DB08995,,Xymogen product monograph: DIOVASC (Diosmin and hesperidin) oral capsules,http://xymogen.ca/media/15228/diovasc_can-drs-12_101314_ea.pdf
DB08995,,DailyMed label: VASCULERA (diosmiplex) oral tablets,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=563d3d34-a547-471e-aecd-f4a4a57cbf1d&type=pdf
DB08995,,ECHA Europa Registration Dossier: Diosmin,https://echa.europa.eu/registration-dossier/-/registered-dossier/21071/7/3/1
DB08995,,Summary of Product Characteristics: Diosmin,https://mri.cts-mrp.eu/human/downloads/IS_H_0212_001_FinalPI.pdf
DB08998,,Link,http://www.catalog.md/drugs/tinoran.html
DB09009,,FDA Approved Drug Products: SEPTOCAINE® (articaine hydrochloride and epinephrine injection),https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020971s042lbl.pdf
DB09014,,Link,http://chem.sis.nlm.nih.gov/chemidplus/rn/486-17-9
DB09019,,NPRA Product Information: Salmodil (salbutamol sulfate/bromhexine hydrochloride) oral syrup,http://quest3plus.bpfk.gov.my/front-end/attachment/624/pharma/213912/V_10533_20171009_002330_D4.pdf
DB09019,,NPRA Product Information: Rexom Unizet (diphenhydramine hydrochloride/bromhexine hydrochloride/ammonium chloride) oral syrup,http://quest3plus.bpfk.gov.my/front-end/attachment/703/pharma/513371/513371_20190710_085504_.pdf
DB09019,,AUSTRALIAN PRODUCT INFORMATION – BISOLVON® CHESTY (BROMHEXINE HYDROCHLORIDE) for oral use,https://apps.medicines.org.au/files/swpbiche.pdf
DB09019,,Fischer Scientific MSDS: Bromhexine hydrochloride,https://www.fishersci.com/store/msds?partNumber=AAJ6345122&productDescription=BROMHEXINE+HYDROCLRID+98++100G&vendorId=VN00024248&countryCode=US&language=en
DB09019,,"FDA Thailand: BIMED (bromhexine, brompheniramine, guaifenesin, phenylephrine) oral tablets",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022330011511C
DB09019,,BPOM: Dextromethorphan,http://pionas.pom.go.id/monografi/dekstrometorfan
DB09020,,US Patent: US2764590,https://patentimages.storage.googleapis.com/38/66/48/c3f7640b1acfb4/US2764590.pdf
DB09020,,DailyMed:Bet-R-Prep (Bisacodyl) Oral Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c222dc49-3081-4b4f-b1f3-8c60a86456dc
DB09020,,"FDA Pharmacology Review: HalfLytely (Polyethylene Glycol-3350, Sodium Chloride, Sodium Bicarbonate, Potassium Chloride) Oral Solution and Bisacodyl Oral Tablet",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021551s000_HalfLytely%20Tabs_pharmr.PDF
DB09026,,FDA Approved Products: Tekturna (Aliskiren) oral tablets and pellets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021985s039lbl.pdf
DB09026,,The Pharmaletter: Novartis and Speedel,https://www.thepharmaletter.com/article/novartis-and-speedel
DB09026,,"NIH StatPearls: Physiology, Renin Angiotensin System",https://www.ncbi.nlm.nih.gov/books/NBK470410/
DB09026,,FDA Approved Products: Tekamlo (amlodipine and aliskiren) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022545s014lbl.pdf
DB09026,,FDA Approved Products: Tekturna HCT (aliskiren and hydrochlorothiazide) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022107s023lbl.pdf
DB09026,,Product monograph: Rasilez HCT (Aliskiren fumarate and hydrochlorothiazide oral tablets),https://www.novartis.ca/sites/www.novartis.ca/files/rasilez%20hct_scrip_e.pdf
DB09026,,NIH StatPearls: Aliskiren,https://www.ncbi.nlm.nih.gov/books/NBK507868/
DB09027,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB09027,,FDA Approved Drug Products: Harvoni (Ledipasvir and Sofosbuvir) tablets or pellets for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205834s032,212477s003lbl.pdf"
DB09029,,FDA Approved Drug Products: Cosentyx (secukinumab) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125504_S050_S051lbl.pdf
DB09029,,EMA Approved Drug Products: Cosentyx (secukinumab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
DB09029,,"FDA Approved Drug Products: COSENTYX® (secukinumab) injection, for subcutaneous use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504Orig1s054s055s067lbl.pdf
DB09029,,"FDA Approved Drug Products: COSENTYX (secukinumab) injection, for subcutaneous or intravenous use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s073lbl.pdf
DB09029,,"FDA Approved Drug Products: COSENTYX® (secukinumab) injection, for subcutaneous or intravenous use (November 2023)",https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
DB09031,,FDA Approved Drug Products: IMPAVIDO (miltefosine) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204684s006lbl.pdf
DB09033,,"FDA Approved Drug Products: ENTYVIO (vedolizumab) for injection, for intravenous use",https://assets-dam.takeda.com/image/upload/v1682549460/legacy-dotcom/globalassets/Prescribing_information.pdf
DB09033,,Assessment report: Entyvio (International non-proprietary name vedolizumab),https://www.ema.europa.eu/en/documents/assessment-report/entyvio-epar-public-assessment-report_en.pdf
DB09033,,Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis,https://www.takeda.com/newsroom/newsreleases/2023/takeda-announces-fda-acceptance-of-bla-resubmission-for-investigational-subcutaneous-administration-of-entyvio-vedolizumab-for-maintenance-therapy-in-moderately-to-severely-active-ulcerative-colitis/
DB09033,,Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease,https://www.businesswire.com/news/home/20230912387756/en/Takeda-Announces-FDA-Acceptance-of-BLA-for-Subcutaneous-Administration-of-ENTYVIO%C2%AE-vedolizumab-for-Maintenance-Therapy-in-Moderately-to-Severely-Active-Crohn%E2%80%99s-Disease
DB09033,,"FDA Approved Drug Products: ENTYVIO (vedolizumab) for injection, for intravenous or subcutaneous use (April 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761133s005s006lbl.pdf
DB09034,,FDA Approved Drug Products: BELSOMRA (suvorexant) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204569s008lbl.pdf
DB09035,,FDA Approved Drug Products: Opdivo (nivolumab) for intravenous injection,https://packageinserts.bms.com/pi/pi_opdivo.pdf
DB09035,,BC Cancer Agency: Opdivo Monograph,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Nivolumab_monograph.pdf
DB09035,,Health Canada Product Monograph: Opdivo (nivolumab) for intravenous injection,https://pdf.hres.ca/dpd_pm/00063347.PDF
DB09035,,Health Canada Approved Drug Products: OPDIVO (nivolumab) injection for Intravenous Infusion (August 2022),https://www.bms.com/assets/bms/ca/documents/productmonograph/OPDIVO_EN_PM.pdf
DB09035,,"EMA Approved Drug Products: OPDIVO (Nivolumab) solution, for intravenous injection",https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf
DB09035,,FDA Approved Drug Products: Opdualag (nivolumab and relatlimab-rmbw) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf
DB09035,,"FDA Approved Drug Products: OPDIVO (nivolumab) injection, for intravenous use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554Orig1s121lbl.pdf
DB09035,,EMA EPAR: Opdualag (relatlimab/nivolumab),https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag
DB09035,,Health Canada Product Monograph: Opdualag (nivolumab and relatlimab) solution for intravenous injection,https://pdf.hres.ca/dpd_pm/00072494.PDF
DB09037,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=125514
DB09037,,FDA news,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm
DB09037,,FDA Approved Drug Products: Keytruda (pembrolizumab) solution for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf
DB09037,,Health Canada Approved Drug Products: KEYTRUDA (pembrolizumab) solution for intravenous infusion,https://www.merck.ca/en/wp-content/uploads/sites/20/2021/04/KEYTRUDA-PM_E.pdf
DB09037,,EMA Summary of Product Characteristics: Keytruda (pembrolizumab) concentrate for solution for infusion (December 2023),https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf
DB09037,,FDA Approved Drug Products: Keytruda (pembrolizumab) solution for intravenous injection (January 2024),https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
DB09037,,FDA Approved Drug Products: Keytruda (pembrolizumab) solution for intravenous administration (Oct 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s139lbl.pdf
DB09038,,FDA Approved Drug Products: Trijardy XR (empagliflozin/linagliptin/metformin) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212614s000lbl.pdf
DB09038,,FDA Summary Review: Empagliflozin,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000SumR.pdf
DB09038,,FDA Approved Drug Products: Glyxambi (empagliflozin/linagliptin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206073s021lbl.pdf
DB09038,,FDA Approved Drug Products: Synjardy (empagliflozin/metformin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206111s022lbl.pdf
DB09038,,FDA Approved Drug Products: Synjardy XR (empagliflozin/metformin) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208658s009lbl.pdf
DB09038,,FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s034lbl.pdf
DB09038,,Health Canada Product Monograph: Jardiance (empagliflozin) oral tablets,https://www.boehringer-ingelheim.ca/sites/ca/files/documents/jardiancepmen.pdf
DB09038,,CaymanChem: Empagliflozin MSDS,https://www.caymanchem.com/msdss/17375m.pdf
DB09038,,EMA Summary of Product Characteristics: Jardiance (Empagliflozin) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/jardiance-epar-product-information_en.pdf
DB09038,,BusinessWire News: Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction,https://www.businesswireindia.com/jardiance-empagliflozin-becomes-the-first-and-only-approved-treatment-in-europe-for-adults-with-symptomatic-chronic-heart-failure-regardless-of-ejection-fraction-77638.html
DB09038,,FDA Approved Drug Products: Synjardy (empagliflozin/metformin) oral tablets (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206111s033lbl.pdf
DB09038,,"FDA Approved Drug Products: JARDIANCE (empagliflozin) tablets, for oral use (September 2023)",https://content.boehringer-ingelheim.com/DAM/7d9c411c-ec33-4f82-886f-af1e011f35bb/jardiance-us-pi.pdf
DB09039,,FDA Approved Drug Products: Cerdelga (eliglustat) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205494s003lbl.pdf
DB09039,,EMA Assessment Report: Cerdelga (eliglustat) oral capsules,https://www.ema.europa.eu/en/documents/assessment-report/cerdelga-epar-public-assessment-report_en.pdf
DB09039,,EMA Summary of Product Characteristics: Cerdelga (eliglustat) oral capsules,https://www.ema.europa.eu/en/documents/product-information/cerdelga-epar-product-information_en.pdf
DB09039,,Health Canada Approved Drug Products: Cerdelga (eliglustat) oral capsules,https://pdf.hres.ca/dpd_pm/00048638.PDF
DB09040,,FDA Approved Drug Products: Jublia (efinaconazole) topical solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203567s010lbl.pdf
DB09041,,FDA Approved Drug Products: KERYDIN (tavaborole) topical,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf
DB09042,,FDA Approved Products: Sivextro (tedizolid phosphate) tablet and injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
DB09045,,FDA Approved Drug Products: Trulicity (dulaglutide) subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s051lbl.pdf
DB09045,,"AJMC: FDA Approves Dulaglutide for Adults With T2D, Regardless of CVD",https://www.ajmc.com/view/fda-approves-dulaglutide-for-adults-with-t2d-regardless-of-cvd
DB09045,,EMA Assessment Report: Trulicity (dulaglutide) solution for injection,https://www.ema.europa.eu/en/documents/assessment-report/trulicity-epar-public-assessment-report_en.pdf
DB09045,,Eli Lilly MSDS: Trulicity (dulaglutide),http://ehs.lilly.com/msds/Trulicity_US%20SDS.pdf
DB09046,,FDA Approved Drug Products: Myalept (metreleptin) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125390s024lbl.pdf
DB09046,,Health Canada Product Monograph: Myalepta (metreleptin) injection for subcutaneous administration,https://pdf.hres.ca/dpd_pm/00074266.PDF
DB09050,,Ceftolozane Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/53234134
DB09050,,Zerbaxa MedSafe NZ data sheet,https://medsafe.govt.nz/profs/Datasheet/z/zerbaxainj.pdf
DB09050,,FDA news,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia
DB09050,,"FDA Approved Drug Products: ZERBAXA (ceftolozane and tazobactam) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206829s011s012lbl.pdf
DB09052,,"FDA Approved Drug Products: BLINCYTO (blinatumomab) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125557s021lbl.pdf
DB09052,,"FDA Approved Drug Products: BLINCYTO (blinatumomab) for injection, for intravenous use (June 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125557s023s026lbl.pdf
DB09052,,BioSpace: FDA grants full approval for BLINCYTO (blinatumomab) to treat minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia,https://www.biospace.com/article/releases/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukemia/
DB09052,,"FDA Approved Drug Products: BLINCYTO® (blinatumomab) for injection, for intravenous use (Feb 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557s029lbl.pdf
DB09052,,"FDA Approved Drug Products: Blincyto (blinatumomab) for injection, for intravenous use (June 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf
DB09053,,FDA: Ibrutinib cGVHD approval,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm569710.htm
DB09053,,Canadian cancer society,http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/mantle-cell-lymphoma/?region=on
DB09053,,National Cancer Institute,https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq
DB09053,,American Cancer Society,https://www.cancer.org/cancer/waldenstrom-macroglobulinemia/about/what-is-wm.html
DB09053,,FDA Approved Drug Products: Imbruvica (ibrutinib) oral capsules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205552s033,210563s010lbl.pdf"
DB09053,,"FDA Approved Drug Products: IMBRUVICA (ibrutinib) capsules, tablets, or suspension, for oral use (August 2022)",https://www.imbruvica.com/files/prescribing-information.pdf?inline?inline
DB09053,,Janssen Biotech: IMBRUVICA for Previously Treated cGVHD in Children 1 Year and Older,https://www.imbruvica.com/cgvhd/imbruvica-for-childhood-cgvhd
DB09053,,EMA Approved Drug Products: Imbruvica (ibrutinib) Oral Capsules or Tablets,https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf
DB09053,,Health Canada Approved Drug Products: IMBRUVICA (ibrutinib) Oral Capsules or Tablets,https://pdf.hres.ca/dpd_pm/00070123.PDF
DB09053,,"BioSpace: AbbVie, J&J Pull Two Accelerated Approvals for Imbruvica",https://www.biospace.com/article/abbvie-j-and-j-pull-two-accelerated-approvals-for-imbruvica/?s=74
DB09059,,EMA: Tractocile Product Information,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000253/WC500040495.pdf
DB09061,,Health Canada Product Label,https://pdf.hres.ca/dpd_pm/00016162.PDF
DB09061,,New York Times: F.D.A. Panel Recommends Approval of Cannabis-Based Drug for Epilepsy (April 2018),https://www.nytimes.com/2018/04/19/health/epidiolex-fda-cannabis-marajuana.html
DB09061,,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol),https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-announces-positive-phase-3-pivotal-study-results-epidiolex
DB09061,,"FDA Briefing Document - Peripheral and Central Nervous System Drugs Advisory Committee Meeting (April 19, 2018)",https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM604736.pdf
DB09061,,FDA Approved Drug Products: EPIDIOLEX (cannabidiol) oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210365s012s013lbl.pdf
DB09066,,Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35–42 years with a body weight ≥50 kg: a randomized controlled trial,https://academic.oup.com/hropen/article/2017/3/hox023/4670555
DB09066,,EMA label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001106/WC500074787.pdf
DB09066,,Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation,https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.12939
DB09066,,Corifollitropin alfa approval,https://www.drugs.com/history/corifollitropin-alfa.html
DB09066,,"Australian APA report document, corifollitropin alfa",https://www.tga.gov.au/sites/default/files/auspar-elonva.pdf
DB09066,,"Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility.",https://www.jove.com/visualize/abstract/19337959/corifollitropin-alfa-long-acting-follicle-stimulating-hormone-agonist
DB09066,,Ovarian hyperstimulation syndrome,https://www.mayoclinic.org/diseases-conditions/ovarian-hyperstimulation-syndrome-ohss/symptoms-causes/syc-20354697
DB09066,,Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465305/
DB09066,,Gonadotrophins: The future,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296397/
DB09068,,FDA Approved Drug Products: Trintellix (vortioxetine) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204447s021s022lbl.pdf
DB09069,,Icelandic Medicines Agency: Trimetazidine Oral Modified Release Tablets (Summary of Product Characteristics),https://mri.cts-mrp.eu/Human/Product/Details/51961
DB09069,,EMA Assessment Report: Trimetazidine Containing Medicinal Products,https://www.ema.europa.eu/en/documents/referral/trimetazidine-article-31-referral-assessment-report_en.pdf
DB09069,,Cayman Chemical: Trimetazidine MSDS,https://www.caymanchem.com/msdss/18165m.pdf
DB09070,,Tibolone for Postmenopausal Women: Systematic Review of Randomized Trials,https://academic.oup.com/jcem/article/87/1/16/2846489
DB09070,,Tibolone Approval Status,https://www.drugs.com/history/tibolone.html
DB09070,,WHO DRUG INFORMATION,http://apps.who.int/medicinedocs/pdf/s5407e/s5407e.pdf
DB09070,,Livial,https://www.news-medical.net/drugs/Livial.aspx
DB09070,,Postmenopausal hormonal therapy: Current status,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830366/
DB09070,,LIVIAL- Drug sheet NZ,http://www.medsafe.govt.nz/profs/Datasheet/l/Livialtab.pdf
DB09070,,Tibolone Drug Monograph,http://www.druginfosys.com/drug.aspx?drugcode=1070&type=1
DB09070,,Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2603018/
DB09070,,The Effects of Tibolone in Older Postmenopausal Women,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684062/
DB09070,,Tibolone Metabolism in Human Liver Is Catalyzed by 3α/3β-Hydroxysteroid Dehydrogenase Activities of the Four Isoforms of the Aldo-Keto Reductase (AKR)1C Subfamily,https://doi.org/10.1359/jbmr.2001.16.9.1651
DB09070,,Tibolone: A Unique Version of Hormone Replacement Therapy,http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.919.2384&rep=rep1&type=pdf
DB09070,,Cardiovascular Effects of Tibolone: A Selective Tissue Estrogenic Activity Regulator,https://onlinelibrary.wiley.com/doi/full/10.1111/j.1527-3466.2007.00007.x
DB09070,,Drug and Liver prelims,http://www.pharmpress.com/files/docs/d_and_liver_sample.pdf
DB09071,,FDA Approved Drug Products: Hetlioz (tasimelteon) capsules/suspension for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205677Orig1s007lbl.pdf
DB09072,,"FDA Approved Drug Products: XYREM (sodium oxybate) oral solution, CIII (September 2020)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021196s032lbl.pdf
DB09072,,Toronto Research Chemicals: : Sodium Oxybate (4-Hydroxybutyric Acid Sodium Salt) MSDS,https://www.trc-canada.com/prod-img/MSDS/H833015MSDS.pdf
DB09072,,GlobeNewswire News Release: Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension,https://www.globenewswire.com/news-release/2022/07/19/2481626/0/en/Avadel-Pharmaceuticals-Announces-Tentative-Approval-of-LUMRYZ-sodium-oxybate-extended-release-oral-suspension.html
DB09072,,Health Canada Approved Drug Products: XYREM (sodium oxybate) oral solution,https://pdf.hres.ca/dpd_pm/00045919.PDF
DB09072,,EMA Approved Drug Products: XYREM (sodium oxybate) oral solution,https://www.ema.europa.eu/en/documents/product-information/xyrem-epar-product-information_en.pdf
DB09072,,"FDA Approved Drug Products: LUMRYZ (sodium oxybate) for extended-release oral suspension, CIII (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214755Orig1s000lbl.pdf
DB09073,,FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s002s003lbl.pdf
DB09073,,Pfizer history,https://www.pfizer.com/sites/default/files/news/Palbociclib_Timeline.pdf
DB09073,,Canadian cancer society,http://www.cancer.ca/en/cancer-information/cancer-type/breast/breast-cancer/?region=on
DB09073,,Canadian cancer society,http://www.cancer.ca/en/cancer-information/cancer-type/breast/breast-cancer/breast-cancer-in-men/?region=on
DB09073,,Clinical trials,https://clinicaltrials.gov/ct2/show/NCT02499146
DB09073,,FDA Approved Drug Products: Ibrance (palbociclib) capsules for oral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf
DB09074,,New Zealand Data Sheet: LYNPARZA (olaparib) Oral Capsules,https://medsafe.govt.nz/profs/Datasheet/l/lynparzacap.pdf
DB09074,,"FDA Approved Drug Products: LYNPARZA (olaparib) tablets, for oral use",https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/00997c3f-5912-486f-a7db-930b4639cd51/00997c3f-5912-486f-a7db-930b4639cd51_viewable_rendition__v.pdf
DB09074,,"FDA Approved Drug Products: LYNPARZA (olaparib) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206162s011lbl.pdf
DB09074,,Astrazeneca: Lynparza (Olaparib) MSDS,https://www.astrazeneca.com.au/content/dam/az-au/Material%20Safety%20Data/2018/MSDS_Lynparza%20tablets_SDS10922_10.18_v1.0.pdf
DB09074,,EMA Approved Drug Products: Lynparza (olaparib) Oral Tablets (March 2023),https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf
DB09074,,Health Canada Approved Drug Products: LYNPARZA (Olaparib) Oral Tablets,https://pdf.hres.ca/dpd_pm/00066912.PDF
DB09074,,"FDA Approved Drug Products: LYNPARZA (olaparib) tablets, for oral use (October 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s024lbl.pdf
DB09074,,"FDA Approved Drug Products: LYNPARZA (olaparib) tablets, for oral use (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf
DB09074,,"Health Canada Approved Drug Products: LYNPARZA (Olaparib) Tablets, for oral use (July 2023)",https://pdf.hres.ca/dpd_pm/00071549.PDF
DB09074,,"FDA Approved Drug Products: LYNPARZA (olaparib) tablets, for oral use (September 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf
DB09075,,FDA Approved Drug Products: Savaysa (edoxaban tosylate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206316s017lbl.pdf
DB09076,,FDA Approved Drug Products: INCRUSE ELLIPTA (umeclidinium inhalation powder) for oral inhalation use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205382s010lbl.pdf
DB09076,,Health Canada Approved Drug Proucts: INCRUSE ELLIPTA (umeclidinium dry powder) for oral inhalation,https://ca.gsk.com/media/6185/incruse_ellipta.pdf
DB09076,,FDA Approved Drug Products: ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) for oral inhalation use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203975s013lbl.pdf
DB09076,,"FDA Approved Drug Products: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) powder for inhalation (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209482s016lbl.pdf
DB09076,,CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW: Umeclidinium Bromide,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205382Orig1s000ClinPharmR.pdf
DB09076,,Health Canada Approved Drug Proucts: ANORO ELLIPTA (umeclidinium/vilanterol powder) for oral inhalation,https://pdf.hres.ca/dpd_pm/00069868.PDF
DB09076,,Health Canada Approved Drug Proucts: TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol powder) for oral inhalation,https://pdf.hres.ca/dpd_pm/00068965.PDF
DB09076,,GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD,https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-incruse-ellipta-umeclidinium-in-the-us-for-the-treatment-of-copd/
DB09076,,FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease,https://www.fiercepharma.com/regulatory/fda-approves-anoro-ellipta-to-treat-chronic-obstructive-pulmonary-disease
DB09076,,FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US,"https://www.gsk.com/en-gb/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/#:~:text=Trelegy%20Ellipta%20was%20approved%20in%20the%20US%20on%209%20September,for%20relief%20of%20acute%20bronchospasm."
DB09076,,"FDA Approved Drug Products: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) powder for inhalation (June 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209482s018lbl.pdf
DB09076,,"FDA Approved Drug Products: INCRUSE ELLIPTA (umeclidinium inhalation powder), for oral inhalation use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205382s013lbl.pdf
DB09078,,FDA Approved Drug Products: Lenvima (lenvatinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206947s021lbl.pdf
DB09079,,FDA Approved Drug Products: Ofev (nintedanib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205832s016lbl.pdf
DB09079,,EMA Summary of Product Characteristics: Vargatef (nintedanib) soft capsules for oral use,https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf
DB09079,,FDA New Indication Approval: Nintedanib,https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/205832Orig1s012ltr.pdf
DB09081,,EMA Product Label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003834/WC500193836.pdf
DB09081,,TITCK Product Information: Everon (idebenone/memantine hydrochloride) film-coated tablets,https://translate.google.com/translate?sl=auto&tl=en&u=https%3A%2F%2Ftitck.gov.tr%2Fstorage%2FkubKtAttachments%2F44611fdc53315.pdf
DB09082,,FDA Approved Drug Products: Breo Ellipta (fluticasone furoate/vilanterol) powder for inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204275s017lbl.pdf
DB09082,,"FDA Approved Drug Products: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) powder for inhalation (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209482s016lbl.pdf
DB09082,,FDA Approved Drug Products: ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) for oral inhalation use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203975s013lbl.pdf
DB09082,,FDA Approved Drug Products: Breo Ellipta (fluticasone furoate/vilanterol) powder for inhalation (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204275s022lbl.pdf
DB09082,,Health Canada Approved Drug Proucts: BREO ELLIPTA (fluticasone furoate/vilantero) dry powder for oral inhalation,https://ca.gsk.com/media/6157/breo-ellipta.pdf
DB09082,,FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US,https://www.gsk.com/en-gb/media/press-releases/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us/
DB09082,,FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease,https://www.fiercepharma.com/regulatory/fda-approves-anoro-ellipta-to-treat-chronic-obstructive-pulmonary-disease
DB09082,,FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US,"https://www.gsk.com/en-gb/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/#:~:text=Trelegy%20Ellipta%20was%20approved%20in%20the%20US%20on%209%20September,for%20relief%20of%20acute%20bronchospasm."
DB09083,,hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes,http://journals.sagepub.com/doi/abs/10.1177/2042098615595546
DB09083,,FDA Approved Drug Products: CORLANOR (ivabradine) oral,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206143s008,209964s002lbl.pdf"
DB09084,,Electronic Medicines Compedium Difflam (Benzydamine Hydrochloride) Spray Monograph,https://www.medicines.org.uk/emc/medicine/13#PRODUCTINFO
DB09084,,Electronic Medicines Compedium Benzydamine Hydrochloride 0.15% w/v Mouthwash Monograph,https://www.medicines.org.uk/emc/product/3347
DB09084,,Electronic Medicines Compedium Difflam (Benzydamine Hydrochloride) 3% Cream Monograph,https://www.medicines.org.uk/emc/product/825
DB09084,,Benzydamine - Tantum Verde,https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=6&ved=0ahUKEwiF3q-XvdPaAhVCWq0KHUz4BQYQFghdMAU&url=http%3A%2F%2Fwww.tantum-verde.de%2Fpflichtangaben.html%3Ffile%3Dfiles%2Fpflichtangaben_upload%2FTANTUM_VERDE_Benzydamin.pdf&usg=AOvVaw2r3MBiTXb2XWY8xYv3SfGs
DB09087,,FDA GRAS,https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260848.htm
DB09087,,Homepathic label,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e93e2938-5c91-4dff-8346-7faa154ed0cc
DB09087,,EWG's skin deep,https://www.ewg.org/skindeep/ingredient/705178/POTASSIUM_ALUM/#.WirqskriY2w
DB09087,,Cosmetics info,http://www.cosmeticsinfo.org/ingredient/potassium-alum-0
DB09087,,FDA OTC ingredients,https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135688.pdf
DB09087,,Encyclopaedia Britannica,https://www.britannica.com/science/astringent
DB09087,,What is alum?,https://www.thoughtco.com/what-is-alum-608508
DB09088,,The Wood Library-Museum: Stovaine Profile,https://www.woodlibrarymuseum.org/museum/item/504/stovaine
DB09089,,AA Pharma Inc.: TRIMEBUTINE product monograph,http://www.aapharma.ca/downloads/en/PIL/Trimebutine_PM.pdf
DB09090,,BGP Pharma ULC: DICETEL (Pinaverium Bromide) product monograph,http://www.mylan.ca/-/media/mylanca/documents/english/product%20pdf/pdfs%20dec%202015/dicetel-pm-2016.01.08.pdf
DB09091,,Chemotechnique diagnostics,https://www.chemotechnique.se/get_pdf.php?l=en&p=386
DB09091,,Clinical experience with tixocortol pivalate,http://downloads.hindawi.com/journals/cjgh/1988/819089.pdf
DB09092,,Exercise,https://www.exercise.com/supplements/xanthinol-nicotinate
DB09092,,Smart publications,http://www.smart-publications.com/books/full-text/smart-drugs-and-nutrients/smart-drugs-and-nutrients-sec-5/smart-drugs-and-nutrients-sec5-xanthinol
DB09092,,Xanthinol,https://www.google.ca/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&cad=rja&uact=8&ved=0ahUKEwjIrefY-4TYAhWjyoMKHQmXAwoQFghIMAY&url=http%3A%2F%2Fwww.drugfuture.com%2Fmt%2Fxantinol-nicotinate.pdf&usg=AOvVaw2hzzAzSkuCgM5yKwbKzqnC
DB09094,,product info,http://www.inchem.org/documents/pims/pharm/pim427.htm
DB09095,,FDA Submission,https://www.fda.gov/downloads/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/ucm370723.txt
DB09095,,Dokteronline,https://www.dokteronline.com/en/nerisone
DB09095,,J-stage papers,https://www.jstage.jst.go.jp/article/dmpk1986/7/5/7_5_591/_article
DB09095,,Diflucortolone monograph,https://www.google.ca/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&ved=0ahUKEwicvuWUtYfYAhWq34MKHd3kALMQFgg1MAI&url=https%3A%2F%2Fwww.old.health.gov.il%2Funits%2Fpharmacy%2Ftrufot%2Falonim%2FNeriderm_dr_1409827405542.pdf&usg=AOvVaw2ugd9AqSVOs5HlRGSO_I3r
DB09095,,Medicine.ie,http://www.medicines.ie/medicine/1993/SPC
DB09096,,BASG: Benzaknen Wash (Benzoyl Peroxide) Topical Suspension,https://portal.dimdi.de/amguifree/am/docoutput/additionalDocDownload.xhtml?dntObjId=781c2aa2-4ba5-6b17-e053-0b0c10ac9d93
DB09096,,Fisher Scientific: Benzoyl Peroxide MSDS,https://beta-static.fishersci.com/content/dam/fishersci/en_US/documents/programs/education/regulatory-documents/sds/chemicals/chemicals-b/S25672.pdf
DB09096,,FDA Approved Drug Products: Benzamycin (Benzoyl Peroxide and Erythromycin) Topical Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/050557s025lbl.pdf
DB09096,,FDA Approved Drug Products: Duac (Benzoyl Peroxide and Clindamycin) Topical Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050741s024lbl.pdf
DB09096,,DailyMed: 111 Medco (Benzoyl Peroxide) Topical Soap,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8590214e-e5a7-8934-e053-2a91aa0a248b
DB09096,,FDA Approved Drug Products: Epiduo (Benzoyl Peroxide and Adapalene) Topical Gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022320s004lbl.pdf
DB09096,,DailyMed Label: TWYNEO (tretinoin and benzoyl peroxide) topical cream,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27208dff-e376-4c18-b56e-0a260f685a39
DB09096,,"FDA Approved Drug Products: EPSOLAY (benzoyl peroxide) cream, for topical use",https://ml.globenewswire.com/Resource/Download/c90c6cab-73f1-4f49-a08a-83bbf291a415
DB09097,,DRUG NAME: Quinagolide - BC Cancer Agency,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Quinagolide_monograph_1June2013_formatted.pdf
DB09097,,NORPROLAC® (quinagolide) Product information,http://www.medicines.org.au/files/fppnorpt.pdf
DB09098,,Human Growth Hormone: Protropin,https://www.worldhealth.net/news/protropin/
DB09100,,Health Canada Approved Drug Products: Desiccated Thyroid Oral Tablets,https://pdf.hres.ca/dpd_pm/00034857.PDF
DB09101,,"FDA Approved Drug Products: Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203100s036lblet.pdf
DB09102,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB09102,,American Liver Foundation: Advances in Medications to Treat Hepatitis C,http://hepc.liverfoundation.org/treatment/the-basics-about-hepatitis-c-treatment/advances-in-medications/
DB09102,,"FDA Approved Drug Products: DAKLINZA (daclatasvir) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206843s008lbl.pdf
DB09102,,NPRA: Dasvir (Daclatasvir) Oral Tablet,https://quest3plus.bpfk.gov.my/front-end/attachment/39206/pharma/512289/512289_20190227_153944_.pdf
DB09103,,Health Canada,https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63758
DB09103,,Sobi,http://www.sobi.com/en/Healthcare-Professionals/Products-alphabetical-list/Stemgen/
DB09103,,Stemgen monograph,https://pdf.hres.ca/dpd_pm/00007290.PDF
DB09103,,Stemgen monograph,http://www.medicines.org.au/files/anpstemi.pdf
DB09104,,Drugs.com,https://www.drugs.com/ppa/magnesium-hydroxide.html
DB09104,,Glow,https://www.glowm.com/resources/glowm/cd/pages/drugs/m001.html
DB09104,,Medicines,https://www.medicines.org.uk/emc/medicine/17293
DB09104,,Drugs.com,https://www.drugs.com/mtm/milk-of-magnesia.html
DB09105,,FDA Approved Drug Products: Strensiq (Asfotase Alfa) Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125513s018lbl.pdf
DB09106,,MSDS,http://pss-polymer.com/fileadmin/custom_documents/MSDS_Hydroxyethyl_starch.pdf
DB09107,,Daily Med Micera Monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c6b7448-152f-435f-a672-7404b1bfe7eb
DB09107,,FDA Approved Drug Products:MIRCERA (methoxy polyethylene glycol-epoetin beta) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125164s089lbl.pdf
DB09108,,Nuwiq Product Monograph,http://www.octapharma.ca/fileadmin/user_upload/octapharma.ca/Product_Monographs/NUWIQ-PM.pdf
DB09108,,EMA Summary of Product Characteristics: Nuwiq (simoctocog alfa) Intraveous Injection,https://www.ema.europa.eu/en/documents/product-information/nuwiq-epar-product-information_en.pdf
DB09108,,FDA Approved Drug Products: NUWIQ [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Solution for Intravenous Injection,https://www.fda.gov/media/93485/download
DB09109,,FiercePharma,https://www.fiercepharma.com/pharma/novoeight%C2%AE-turoctocog-alfa-receives-approval-from-fda
DB09109,,EMA Reports,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002719/WC500157553.pdf
DB09109,,NovoNordisk,http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Zonovate_PM_English.pdf
DB09109,,EU Reports,http://ec.europa.eu/health/documents/community-register/2013/20131113127003/anx_127003_en.pdf
DB09109,,Australian report,https://www.tga.gov.au/sites/default/files/auspar-turoctocog-140507.pdf
DB09110,,DynaMed,http://www.dynamed.com/home/
DB09114,,Pharmaintelligence,https://pink.pharmaintelligence.informa.com/PS017845/BURROUGHS-WELLCOMEs-EXOSURF-IS-APPROVED
DB09114,,Access,http://www.syrianclinic.com/med/en/ProfDrugs/Print/ColfoscerilPalmitatepd.html
DB09114,,Curoservice,http://www.curoservice.com/parents_visitors/surfactant/surfactant_composition_action.php
DB09114,,Rob Holland,http://www.robholland.com/Nursing/Drug_Guide/data/monographframes/C111.html
DB09116,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB09116,,Encyclopedia,http://www.encyclopedia.com/education/encyclopedias-almanacs-transcripts-and-maps/calcium-carbimide
DB09118,,EMA Approved Drug Products: DIACOMIT (stiripentol) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/diacomit-epar-product-information_en.pdf
DB09118,,"FDA Approved Drug Products: DIACOMIT (stiripentol) suspension or capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206709s003;207223s003lbl.pdf
DB09118,,Cayman Chemical: Stiripentol MSDS,https://www.chemblink.com/MSDS/MSDSFiles/49763-96-4_Cayman.pdf
DB09118,,Health Canada Approved Drug Products: DIACOMIT (stiripentol) Oral Capsules or Powder for suspension,https://pdf.hres.ca/dpd_pm/00062850.PDF
DB09119,,FDA Approved Drug Products: Aptiom (eslicarbazepine acetate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022416s011lbl.pdf
DB09120,,Health Canada Product Monograph: Zuacta (zucapsaicin) topical cream,https://pdf.hres.ca/dpd_pm/00012269.PDF
DB09121,,NLM Toxnet Toxicology Data Network: Aurothioglucose,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7174
DB09121,,RXmed: Solganal (Aurothioglucose) Monograph,https://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/cps-_monographs/CPS-_(General_Monographs-_S)/SOLGANAL.html
DB09121,,ChemIDplus: Aurothioglucose [USP],https://chem.nlm.nih.gov/chemidplus/rn/12192-57-3
DB09121,,ScienceDirect: Aurothioglucose,https://www.sciencedirect.com/topics/neuroscience/aurothioglucose
DB09121,,Arthritis Society: Rheumatoid Arthritis,https://www.arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/rheumatoid-arthritis
DB09122,,"MS Society Document, Canada",https://mssociety.ca/about-ms/symptoms
DB09122,,FDA approves new oral drug to treat multiple sclerosis,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634469.htm
DB09122,,FDA Approved Drug Products: Plegridy (peginterferon beta-1a) injection for subcutaneous or intramuscular use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125499s025lbl.pdf
DB09122,,EMD Serono MSDS: Interferon beta 1a,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/MSDS_9SERO_REBIF_SYR_%2044MCG.pdf
DB09122,,Product monograph: Avonex (interferon beta-1a) injection,https://www.biogen.ca/content/dam/corporate/en_CA/pdfs/products/AVONEX/AVONEX-Product-Monograph-EN.pdf
DB09122,,EMA Assessment Report: Plegridy (peginterferon beta-1a) for injection,https://www.ema.europa.eu/en/documents/assessment-report/plegridy-epar-public-assessment-report_en.pdf
DB09123,,Bayer Inc: VISANNE (2mg dienogest tablets) Product Monograph,http://www.bayer.ca/static/documents/news/en/VISANNE-PM-EN-19JUN2015-182736.pdf
DB09123,,Bayer Inc: VISANNE (2mg dienogest tablets) Product Information,http://www.bayerresources.com.au/resources/uploads/pi/file10142.pdf
DB09123,,FDA Approved Drug Products: Natazia (estradiol valerate and dienogest) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022252s007lbl.pdf
DB09124,,Health Canada,https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=759
DB09125,,Monograph,https://www.drugs.com/pro/potassium-citrate.html
DB09125,,safety data sheet,http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf
DB09128,,FDA Approved Drug Products: Rexulti (brexpiprazole) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205422s007lbl.pdf
DB09128,,FDA Approved Drug Products: REXULTI (brexpiprazole) tablets for oral use (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205422s009lbl.pdf
DB09129,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/chromic_chloride
DB09129,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/10025-73-7
DB09129,,DAILYMED,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4d01ebb-a36e-44b7-028c-43c0ab2d13b4
DB09130,,Product Monograph: Copper IUD,http://omr.bayer.ca/omr/online/nova-tpi-en-17feb2015.pdf
DB09131,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/24014#section=Absorption-Distribution-and-Excretion
DB09131,,inChem,http://www.inchem.org/documents/ukpids/ukpids/ukpid53.htm
DB09132,,FDA Approved Drug Products: DOTAREM® (gadoterate meglumine) Injection for intravenous us,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204781s015lbl.pdf
DB09132,,GADOTERATE CLINICAL PHARMACOLOGY NDA REVIEW,https://www.fda.gov/files/drugs/published/204781-Gadoterate-Clinpharm-PREA.pdf
DB09132,,Gadoterate Clinical Pharmacology Review,https://www.fda.gov/media/108483/download
DB09133,,FDA Approved Drug Products: Conray (Iothalamate Meglumine Injection),https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/013295s070lbl.pdf
DB09134,,FDA Approved Products: OPTIRAY (ioversol) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019710s064lbl.pdf
DB09134,,FDA approval package: OPTIRAY (ioversol) injection,https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20923-optiray_lbl.pdf
DB09134,,Molecular Imaging and Contrast Agent Database (MICAD) [Internet]: Ioversol,https://www.ncbi.nlm.nih.gov/books/NBK26366/
DB09134,,Toronto Research Chemicals: Ioversol SDS,https://www.trc-canada.com/prod-img/MSDS/I737000MSDS.pdf
DB09136,,FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf
DB09136,,Drugs.com,https://www.drugs.com/pro/isosulfan-blue-injection.html
DB09139,,WHO,http://www.who.int/medicines/publications/pharmacopoeia/Radgenmono.pdf
DB09139,,IAEA,http://www-pub.iaea.org/MTCD/publications/PDF/trs466_web.pdf
DB09139,,Human health IAEA,https://humanhealth.iaea.org/HHW/Radiopharmacy/VirRad/Selection_of_Labelling_Kit/index.html
DB09139,,Doctissimo,http://www.doctissimo.fr/medicament-OSTEOCIS.htm
DB09139,,Pubmedhealth,https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024006/?report=details
DB09139,,SNMjournals,http://jnm.snmjournals.org/content/22/7/local/advertising.pdf
DB09139,,Tc-99m compounds,http://eknygos.lsmuni.lt/springer/439/173-337.pdf
DB09140,,British Thoracic Society: Guideline for emergency oxygen use in adult patients,https://www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/emergency-oxygen-use-in-adult-patients-guideline/emergency-oxygen-use-in-adult-patients-guideline/
DB09140,,Airgas SDS,https://www.airgas.com/msds/001043.pdf
DB09140,,Linde SDS,http://www.linde-gas.com/internet.global.lindegas.global/en/images/Compressed%20oxygen17_24367.pdf?v=1.0
DB09141,,Product info,"https://www.google.ca/url?sa=t&rct=j&q=&esrc=s&source=web&cd=13&cad=rja&uact=8&sqi=2&ved=0ahUKEwjE44WH68fSAhWj24MKHSKCCzwQFghTMAw&url=https%3A%2F%2Fwww.drugs.com%2Fmonograph%2Fprotamine-sulfate.html&usg=AFQjCNEZpum1VIHPgqSl9Z8J3a4w3RFkKQ&bvm=bv.149093890,d.amc"
DB09141,,product info,http://www.rxlist.com/protamine-drug/indications-dosage.htm
DB09141,,Dailymed: Protamine sulfate Monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1964129-33f4-4e4e-86e3-8e6a4e65bd83
DB09141,,Prosulf (protamine sulfate) 10 mg/ml Solution for Injection,https://www.medicines.org.uk/emc/product/8/smpc
DB09142,,FDA Approved Drug Products: KINEVAC (sincalide) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017697s033lbl.pdf
DB09142,,"FDA Approved Drug Products: KINEVAC (sincalide for injection), for intravenous use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017697s038lbl.pdf
DB09143,,FDA Approved Drug Products: ODOMZO (sonidegib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205266s006lbl.pdf
DB09146,,monograph,https://www.drugs.com/monograph/iron-sucrose.html
DB09146,,article,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805051/
DB09146,,FDA Approved Drug Products: Velphoro Sucroferric Oxyhydroxide Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205109s008lbl.pdf
DB09147,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/Iron_III__pyrophosphate#section=Pharmacology-and-Biochemistry
DB09147,,Nippon,https://www.nippon.com/en/currents/d00106/
DB09147,,KEGG,http://www.genome.jp/dbget-bin/www_bget?D04946
DB09147,,FDA Reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206317orig1s000medr.pdf
DB09147,,Sunactive,https://taiyogmbh.com/en/sunactive-en/
DB09149,,FDA Approved Drug Products: AMYVID (florbetapir F18) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202008s036lbl.pdf
DB09151,,FDA Approved Drug Products: VIZAMYL (flutemetamol F 18) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf
DB09152,,"DailyMed: Unapproved label for liquid nitrogen, refrigerated",https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8519f7b5-2fe2-42e9-8604-431a9ccfc420&type=display
DB09152,,FDA Compliance Program Guidance Manual: Compressed Medical Gases,https://www.fda.gov/media/75194/download
DB09152,,ATSDR: Medical Management Guidelines for Nitrogen Oxides,https://www.atsdr.cdc.gov/MMG/MMG.asp?id=394&tid=69
DB09153,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/7647-14-5
DB09153,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/sodium_chloride
DB09154,,FDA Monograph: Sodium Citrate Tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a60660b2-c5db-45a0-885f-de93e655380d
DB09154,,FDA Monograph: Sodium Citrate Liquid,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb0bade0-fc86-4bfa-90cc-f0d5f7b4d3a8
DB09154,,TOXNET: Trisodium Citrate,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5201
DB09154,,SMPDB: Citric Acid Cycle,http://smpdb.ca/view/SMP00057
DB09155,,FDA Compliance Program Guidance Manual: Compressed Medical Gases,https://www.fda.gov/media/75194/download
DB09155,,DailyMed: Helium gas,https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb33fc07-e122-4f66-aa43-b659ee150150
DB09155,,FDA Approved Products: Heliox (helium and oxygen) gases for inhalation,https://www.accessdata.fda.gov/spl/data/1366bd51-4f64-48d6-baa1-1fb402553331/1366bd51-4f64-48d6-baa1-1fb402553331.xml
DB09156,,"FDA Approved Drug Products: ULTRAVIST (iopromide) injection, for intra-arterial or intravenous use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020220s054,021425s036lbl.pdf"
DB09156,,NPRA: Ultravist (Iopromide) Intravascular Injection,https://quest3plus.bpfk.gov.my/front-end/attachment/9873/pharma/231612/V_62364_20220118_161946_D3.pdf
DB09156,,Health Canada Approved Drug Products: Ultravist (Iopromide) Intravascular Injection,https://pdf.hres.ca/dpd_pm/00054785.PDF
DB09156,,Health Canada Approved Drug Proucts: ULTRAVIST (Iopromide) injection for intravascular use (March 2022),https://pdf.hres.ca/dpd_pm/00065182.PDF
DB09156,,AIFA approved drug products: Ultravist (Iopromide) injectable solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000689_026965_RCP.pdf&retry=0&sys=m0b1l3
DB09157,,product leaflet,http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1464324364725.pdf
DB09157,,product info,https://www.cdc.gov/niosh/idlh/124389.html
DB09157,,FDA Compliance Program Guidance Manual: Compressed Medical Gases,https://www.fda.gov/media/75194/download
DB09158,,FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022278s003lbl.pdf
DB09160,,Technetium radiopharmaceutical chemistry,https://pdfs.semanticscholar.org/bfa5/c1913650a8a23b0359c3d9d2f5710a243a27.pdf
DB09160,,Monograph,http://www.nuclearcardiologyseminars.net/articles/Tetrofosmin.pdf
DB09164,,Dailymed Hepatolite product information (FDA Label),https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=32c493f8-c4fa-4564-911b-ca2e1146c754
DB09166,,US Drug Enforcement Administration: ETIZOLAM Drug information,https://www.deadiversion.usdoj.gov/drug_chem_info/etizolam.pdf
DB09166,,World Health Organization: Etizolam (INN) Pre-Review Report,https://erowid.org/pharms/etizolam/etizolam_article1_who_2016.pdf
DB09167,,Co-pharma Ltd. SUMMARY OF PRODUCT CHARACTERISTICS: Dosulepin hydrochloride tablets,http://www.co-pharma.co.uk/downloads/v2/Approved%20Dosulepin%20Tablets%2075mg%20SPC%20updated%20section%206.5-%2023.01.13.pdf
DB09167,,Alphapharm: DOTHEP (Dothiepin hydrochloride) Product information,http://www.medicines.org.au/files/afpdothe.pdf
DB09173,,World Health Organization: Butyrfentanyl Critical Review Report,https://www.who.int/medicines/access/controlled-substances/4.2_Butyrfentanyl_CritReview.pdf
DB09173,,DEA: Temporary Placement of Butyryl Fentanyl and Beta-Hydroxythiofentanyl Into Schedule I,https://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr0512_2.htm
DB09173,,Cayman Chemicals: Butyrylfentanyl MSDS,https://www.caymanchem.com/msdss/14728m.pdf
DB09183,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB09185,,"FDA Approved Drug Products: QELBREE (viloxazine extended-release capsules), for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s003lbl.pdf
DB09185,,CymitQuimica: Viloxazine Hydrochloride MSDS,https://static.cymitquimica.com/products/86/pdf/sds-MM3361.00.pdf
DB09194,,Patents,https://www.google.com/patents/US4132791
DB09194,,Patents,https://www.google.com/patents/US4931445
DB09195,,Molecules 2016,https://www.google.ca/url?sa=t&rct=j&q=&esrc=s&source=web&cd=10&cad=rja&uact=8&ved=0ahUKEwj6xNae0d_YAhUiY98KHejwBPcQFgheMAk&url=http%3A%2F%2Fwww.mdpi.com%2F1420-3049%2F21%2F1%2F75%2Fs1&usg=AOvVaw11fr7ZS00i-2hlOa7d5w8q
DB09204,,Clinical trials,https://clinicaltrials.gov/ct2/show/record/NCT02612298?view=results
DB09205,,FDA-orphan products,https://google2.fda.gov/search?q=cache:cqX7toRQhxQJ:www.fda.gov/downloads/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/ucm162066.xls+thymoxamine&client=FDAgov&proxystylesheet=FDAgov&output=xml_no_dtd&site=FDAgov&ie=UTF-8&access=p&oe=UTF-8
DB09205,,Opilon monograph,https://www.medicines.org.uk/emc/medicine/18553#PHARMACODYNAMIC_PROPS
DB09205,,Jstage,https://www.jstage.jst.go.jp/article/jsma1939/45/6/45_6_739/_pdf
DB09208,,FDA Approved Drug Products: KRYSTEXXA (pegloticase) injection for intravenous use,https://www.hzndocs.com/KRYSTEXXA-Prescribing-Information.pdf
DB09208,,EMA Summary of Product Characteristics: KRYSTEXXA (pegloticase) injection for intravenous use,https://www.ema.europa.eu/en/documents/product-information/krystexxa-epar-product-information_en.pdf
DB09209,,Australian government,https://www.tga.gov.au/otc-medicine-monograph-pholcodine#indications
DB09209,,United Nations Office on Drugs and Crime,https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1961-01-01_2_page004.html
DB09209,,WHO,http://apps.who.int/iris/bitstream/10665/39030/3/Codeine_1970_eng_part2.pdf
DB09210,,Nootropil tablets Drug Summary,http://www.e-lactancia.org/media/papers/Piracetam-DS-UCB2013.pdf
DB09210,,electronic Medicines Compendium (eMC): Nootripil Summary of Product Characteristics,https://www.medicines.org.uk/emc/medicine/27470
DB09212,,Loxoprofen,http://www.chemspider.com/Chemical-Structure.3828.html
DB09212,,MIMS LOXOPROFEN,https://www.mims.com/malaysia/drug/info/loxoprofen?mtype=generic
DB09212,,Mechanism of action of non steroidal anti-inflammatory drugs,https://www.intechopen.com/books/nonsteroidal-anti-inflammatory-drugs/mechanism-of-action-of-nonsteroidal-anti-inflammatory-drugs
DB09212,,Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036661/
DB09212,,"Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935154/
DB09212,,"Comparison of Pharmacokinetics between Loxoprofen and Its Derivative with Lower Ulcerogenic Activity, Fluoro-loxoprofen",https://www.sciencedirect.com/science/article/pii/S134743671530389
DB09212,,"Comparison of Pharmacokinetics between Loxoprofen and Its Derivative with Lower Ulcerogenic Activity, Fluoro-loxoprofen",https://pdfs.semanticscholar.org/6f52/9ebb1b417438f2ca462c82d4720b30606a48.pdf
DB09212,,"Aspirin, Non-Aspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and risk of ovarian cancer",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454462/
DB09212,,LOXOPROFEN,http://www.druginfosys.com/drug.aspx?drugcode=909&type=1
DB09212,,Loxoprofen Sodium,http://repository-tnmgrmu.ac.in/320/1/MAHESH%20KUMAR%20K.pdf
DB09212,,Roxonin,http://www.meppo.com/pdf/drugs/3019-ROXONIN-1440574468.pdf
DB09213,,INVIMA Summary of Product Characteristics: Suitrom Caf (dexibuprofen/caffeine) oral tablets,http://consultaregistro.invima.gov.co:8082//Consultas/GenerarPdf?filename=c:%5Cupload%5CDocumentos%5CPDF%5Cp_1121938.pdf
DB09214,,Dexketoprofen,https://www.drugs.com/international/dexketoprofen.html
DB09214,,Concise info Dexketoprofen,https://www.mims.com/philippines/drug/info/dexketoprofen?mtype=generic
DB09214,,DEXKETOPROFEN,http://www.chemspider.com/Chemical-Structure.580922.html
DB09214,,PRECLINICAL AND CLINCIAL DEVELOPMENT OF DEXOKETOPROFEN,https://link.springer.com/article/10.2165/00003495-199600525-00005
DB09214,,Dexktoprofen drug insert,https://www.hpra.ie/img/uploaded/swedocuments/2153796.PA0865_002_002.fd883daf-dafe-4bb7-81bd-84144c3a5808.000001ProductLeaflet25.150508.pdf
DB09214,,Dexketoprofen information,http://www.drugsupdate.com/generic/view/1132/Dexketoprofen
DB09214,,Analgesic properties of dexketoprofen trometamol,https://www.researchgate.net/profile/Jean_Sebastien_Walczak/publication/260947943_Analgesic_properties_of_dexketoprofen_trometamol/links/571a523008aee3ddc568f435/Analgesic-properties-of-dexketoprofen-trometamol.pdf
DB09215,,WHO: Droxicam,https://www.whocc.no/atc_ddd_index/?code=M01AC04&showdescription=yes
DB09216,,EMA,http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2016/04/human_orphan_001714.jsp&mid=WC0b01ac058001d12b
DB09216,,European Journal of Chemistry,https://www.degruyter.com/downloadpdf/j/chem.2013.11.issue-9/s11532-013-0284-6/s11532-013-0284-6.pdf
DB09216,,Clotam leaflet,https://www.medicines.org.uk/emc/files/pil.3748.pdf
DB09216,,EMA,http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500015620.pdf
DB09219,,FAMPH: Bisoxatin Summary of Product Characteristics,https://drive.google.com/open?id=0B2K5buBGjy5rejZjMGRTb0dDTEk
DB09220,,IKOREL (Nicorandil) Product Information,http://www.medicines.org.au/files/swpikore.pdf
DB09220,,UK Medicines and Healthcare products Regulatory Agency (MHRA): Nicorandil Tablets_Scientific Discussion,http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con105865.pdf
DB09221,,Promac,https://www.drugs.com/international/promac.html
DB09221,,NCI dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polaprezinc
DB09221,,Applicability of Zinc Complex of L-Carnosine for Medical Use,http://www.protein.bio.msu.ru/biokhimiya/contents/v65/full/65070961.html
DB09221,,Residence Time of Polaprezinc (Zinc L-Carnosine Complex) in the Rat Stomach and Adhesiveness to Ulcerous Sites,https://pdfs.semanticscholar.org/3b5d/be879f38fa7952fe6c6ff0c04dafe2cd3491.pdf
DB09221,,Revision of Precautions for Poplaprezinc,https://www.pmda.go.jp/files/000219558.pdf
DB09222,,"FDA Approved Drug Products: EVITHROM (Human Thrombin), for topical use",https://www.fda.gov/media/71754/download
DB09222,,"DailyMed Label: VISTASEAL (human fibrinogen, human thrombin) kit, for topical use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8708417-2f74-4dfa-b6f9-ef88f902e0fc
DB09222,,"FDA Approved Drug Products: FIBRYGA [fibrinogen (human)] Lyophilized Powder for Reconstitution, For Intravenous Use",https://www.fda.gov/media/105864/download
DB09222,,DailyMed Label: EVARREST (fibrinogen human and human thrombin) Fibrin Sealant Absorbable Patch for Topical Use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92371a00-4bbd-4815-86dd-bae1505d0c2f
DB09222,,DailyMed Label: TACHOSIL (thrombin human and fibrinogen)Fibrin Sealant Absorbable Patch for Topical Use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69e05cbe-615e-45af-ad7e-92e3650cafc8
DB09223,,Blonanserin Approval Announcement,http://www.ds-pharma.com/ir/news/2017/20170228-2.html
DB09223,,ChemIDPlus: Blonanserin,https://chem.nlm.nih.gov/chemidplus/rn/132810-10-7
DB09224,,Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease,https://clinicaltrials.gov/ct2/show/NCT00125138
DB09224,,"The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia",https://www.sciencedirect.com/science/article/pii/S0920996401003292
DB09224,,Melperone MSDS,http://www.chemicalbook.com/ChemicalProductProperty_US_CB81011889.aspx
DB09224,,Melperone in Treatment-Refractory Schizophrenia: A Case Series,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736899/
DB09224,,Melperone in Treatment-Refractory Schizophrenia: A Case Series,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736899/#bibr5-2045125311399800
DB09224,,Melperone,https://drugs.ncats.io/ginas/app/drug/a2ef4d17
DB09224,,Quantification of selected antidepressants and antipsychotics in clinical samples using chromatographic methods combined with mass spectrometry: A review (2006-2015),https://pdfs.semanticscholar.org/7af2/95cd553c0def02c99d390fab51c7b5be8ff7.pdf
DB09224,,Pharmacological data of the atypical neuroleptic compound melperone (Buronil),https://www.researchgate.net/publication/20583412_Pharmacological_data_of_the_atypical_neuroleptic_compound_melperone_Buronil
DB09224,,Development of orally disintegrating tablets comprising controlled-release multiparticulate beads,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497912/
DB09225,,FDA Submission,https://www.fda.gov/downloads/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/ucm370723.txt
DB09225,,FDA antipsychotics,https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/psychopharmacologicdrugsadvisorycommittee/ucm493998.pdf
DB09225,,EMA reports,http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/03/WC500203705.pdf
DB09225,,NIMH,https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml
DB09225,,Zotepine monograph,http://www.drugfuture.com/mt/zotepine.pdf
DB09227,,Vasexten (barnidipine hydrochloride modified release capsules) Summary of Product Characteristics,http://mri.cts-mrp.eu/download/NL_H_0199_002_FinalPI_2of3.pdf
DB09228,,FDA Approved Blood Products: Ruconest C1 Esterase Inhibitor Intravenous Injection,https://www.fda.gov/media/89212/download
DB09229,,Researchgate,https://www.researchgate.net/publication/229817671_Aranidipine_MPC-1304_a_New_Dihydropyridine_Calcium_Antagonist_A_Review_of_Its_Antihypertensive_Action
DB09230,,DRUG: Azelnidipine,http://www.genome.jp/dbget-bin/www_bget?D01145
DB09230,,"Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study",https://www.nature.com/articles/hr2009179
DB09230,,Azelnidipine MSDS,https://www.chemblink.com/MSDS/MSDSFiles/123524-52-7_Sigma-Aldrich.pdf
DB09230,,Clinical use of azelnidipine in the treatment of hypertension in Chinese patients,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348133/
DB09230,,Determination of azelnidipine by LC–ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers,http://www.ingentaconnect.com/content/govi/pharmaz/2008/00000063/00000008/art00003?crawler=true
DB09230,,Calcium Channel Blocker Poisoning,https://www.uptodate.com/contents/calcium-channel-blocker-poisoning
DB09231,,IJBCP,http://www.ijbcp.com/index.php/ijbcp/article/download/1891/1616
DB09231,,Springer,http://adisinsight.springer.com/drugs/800000001
DB09232,,Centapres monograph,http://www.centaurpharma.com/newwebsite/downloads/CENTAPRES.pdf
DB09232,,Hypertension Canada,https://hypertension.ca/hypertension-and-you/about-hypertension/what-is-high-blood-pressure/
DB09232,,Kerala medical journal,http://journals.publishmed.com/index.php/KMJ/article/viewFile/265/282
DB09232,,Lloyd healthcare,http://www.lloydhealthcare.org/cilidin-t.php
DB09232,,Medfacts,http://factmed.com/study-CILNIDIPINE%20(CILNIDIPINE)-causing-DRUG%20TOXICITY.php
DB09232,,ResearchGate article,https://www.researchgate.net/publication/315976376_POLYMERIC_NANOPARTICLES_FOR_IMPROVED_BIOAVAILABILITY_OF_CILNIDIPINE
DB09235,,"Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study☆",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053062/
DB09235,,"Pharmaceutical Substances, 5th Edition, 2009",https://books.google.ca/books?id=4lCGAwAAQBAJ&pg=PA461&lpg=PA461&dq=ld50+of+efonidipine&source=bl&ots=rHGBcAgr4N&sig=Qk2sWFcDEkFvEsPPwhNE9nmEkyU&hl=en&sa=X&ved=0ahUKEwjjq7rIu8TZAhVE1mMKHZbSC18Q6AEILjAB#v=snippet&q=ld50%20efonidipine&f=false
DB09235,,Pharmacokinetic Interaction between Warfarin and Efonidipine in Rats,https://pdfs.semanticscholar.org/058d/a3935a5736ea1244a3b6f2e1a6348c792146.pdf
DB09235,,"Clinical Efficacy of Efonidipine Hydrochloride, a T-type Calcium Channel Inhibitor, on Sympathetic Activities Examination Using Spectral Analysis of Heart Rate/Blood Pressure Variabilities and 123I-Metaiodobenzylguanidine Myocardial Scintigraphy",https://www.omicsonline.org/open-access/development-and-validation-of-liquid-chromatography-rphplcmethodology-for-estimation-of-efonidipine-hcl-ethanolate-efd-2153-2435-1000547.pdf
DB09235,,DORSET CARDIOLOGY WORKING GROUP GUIDELINE FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION,http://www.dorsetccg.nhs.uk/Downloads/aboutus/medicines-management/Other%20Guidelines/Calcium%20channel%20blockers%20for%20hypertension.pdf
DB09235,,"Relationship between Lipophilicities of 1,4-Dihydropyridine Derivatives and Pharmacokinetic Interaction Strengths with Grapefruit Juice",https://www.researchgate.net/publication/5674263_Relationship_between_Lipophilicities_of_14-Dihydropyridine_Derivatives_and_Pharmacokinetic_Interaction_Strengths_with_Grapefruit_Juice
DB09235,,Effect of an L- and T-Type Calcium Channel Blocker on 24-Hour Systolic Blood Pressure and Heart Rate in Hypertensive Patients,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341419/
DB09235,,Efonidipine,http://www.maria-online.com/health/article.php?lg=en&q=Efonidipine
DB09235,,Drug profile: Efonidipine,http://adisinsight.springer.com/drugs/800000179
DB09235,,"Studies on the Metabolic Fate of NZ-105. (I). Absorption, Distribution, Metabolism and Excretion after a Single Administration to Rats.",https://www.researchgate.net/publication/273669636_Studies_on_the_Metabolic_Fate_of_NZ-105_I_Absorption_Distribution_Metabolism_and_Excretion_after_a_Single_Administration_to_Rats
DB09235,,Efonidipine,https://www.revolvy.com/main/index.php?s=Efonidipine&sr=50
DB09235,,CHEMICAL IDENTIFICATION,http://www.drugfuture.com/toxic/q113-q507.html
DB09236,,Lacidipine Summary of Product Characteristics,http://mri.cts-mrp.eu/download/NL_H_2992_002_FinalSPC.pdf
DB09237,,FDA Approved Drug Products: Conjupri Levamlodipine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212895s000lbl.pdf
DB09237,,S-Amlodipine,https://pubchem.ncbi.nlm.nih.gov/compound/_S_-Amlodipine
DB09241,,product info,http://www.alzforum.org/therapeutics/rember-tm
DB09241,,Article,http://www.alzforum.org/papers/preventive-methylene-blue-treatment-preserves-cognition-mice-expressing-full-length-pro
DB09241,,article,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087269/#ref1
DB09241,,Drug info,https://www.drugs.com/monograph/methylene-blue.html
DB09241,,Monograph,https://monographs.iarc.fr/ENG/Monographs/vol108/mono108-06.pdf
DB09241,,msds,https://www.fishersci.com/shop/msdsproxy?productName=BP117100&productDescription=METHYLENE+BLUE+100G&catNo=BP117-100&vendorId=VN00033897&storeId=10652
DB09241,,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204630s011lbl.pdf
DB09242,,Electronic Medicines Compedium Physiotens (Moxonidine) Monograph,https://www.medicines.org.uk/emc/medicine/22286
DB09244,,Psychiatry: The State of the Art Volume 3 Pharmacopsychiatry,https://books.google.ca/books?id=IgraBwAAQBAJ&pg=PA209&lpg=PA209&dq=pirlindole+pharmacokinetics&source=bl&ots=lN64zZ3EEg&sig=UN0rzaFBQg_vqXbJHo2ls2BO2JA&hl=en&sa=X&ved=0ahUKEwj12av-kLjZAhVP0mMKHYXuCXYQ6AEIRzAE#v=onepage&q=pirlindole%20pharmacokinetics&f=false
DB09244,,Chemistry Dashboard- Pirlindole,https://comptox.epa.gov/dashboard/dsstoxdb/results?search=Pirlindole
DB09244,,Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome,https://www.researchgate.net/publication/51605654_Pirlindole_in_the_Treatment_of_Depression_and_Fibromyalgia_Syndrome
DB09244,,Hypertensive effect and cheese,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738414/
DB09244,,Monamine oxide inhibitors,http://www.inchem.org/documents/pims/pharm/pimg025.htm
DB09245,,"A reversible monoamine oxidase inhibitor, toloxatone: spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD)",https://www.sciencedirect.com/science/article/pii/0223523494900965
DB09245,,Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects,https://link.springer.com/article/10.1007/BF02246239
DB09245,,Tolaxatone,http://www.mims.com/india/drug/info/toloxatone?mtype=generic
DB09245,,Chemistry,https://comptox.epa.gov/dashboard/dsstoxdb/results?search=Toloxatone
DB09255,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c273512-84e2-2cea-b201-12345a6bd1fe
DB09255,,Drugs.com,https://www.drugs.com/monograph/dextran-40.html
DB09255,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/9004-54-0
DB09255,,WHO,http://apps.who.int/medicinedocs/en/d/Jh2962f/9.2.html
DB09255,,Tears naturale monograph,https://www.medicines.org.uk/emc/files/pil.843.pdf
DB09255,,Military trauma research,http://www.dtic.mil/dtic/tr/fulltext/u2/a217721.pdf
DB09256,,European Medicines Agency (EMA): TEYSUNO (tegafur/gimeracil/oteracil) Summary of Product Characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001242/WC500104415.pdf
DB09256,,UFT (uracil/tegafur) capsules_Product information,https://hemonc.org/docs/packageinsert/uraciltegafur.pdf
DB09257,,European Medicines Agency (EMA): TEYSUNO (tegafur/gimeracil/oteracil) Summary of Product Characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001242/WC500104415.pdf
DB09258,,Irish Medicines Board: Bemiparin,http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1388-001-003_27012012144048.pdf
DB09258,,Hibor-Bemiparin Sodium,http://www.meppo.com/pdf/drugs/875-HIBOR-1444208315.pdf
DB09258,,"Zibor 2,500 IU Solution for Injection",http://www.medicines.ie/printfriendlydocument.aspx?documentid=12319&companyid=38
DB09258,,Injectable drugs guide,https://books.google.ca/books?id=42TEmTJ0ewAC&pg=PA80&lpg=PA80&dq=bemiparin+pharmacokinetics&source=bl&ots=-7uU8qynV5&sig=Y7WH-fzi8PLB_YCA6T1_DjQOggc&hl=en&sa=X&ved=0ahUKEwi-oJem-cbZAhVI1WMKHQE8CII4ChDoAQhUMAk#v=onepage&q=bemiparin%20pharmacokinetics&f=false
DB09258,,Thrombosis Advisors- Factor Xa inhibitor,https://www.thrombosisadviser.com/factor-xa-inhibitors/
DB09258,,Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells,https://pdfs.semanticscholar.org/e190/2ca30f2548cfa7f02e2b815705137ace90e3.pdf
DB09258,,"Bemiparin, an effective and safe low molecular weight heparin: a review",https://www.jove.com/visualize/abstract/24657810/bemiparin-an-effective-and-safe-low-molecular-weight-heparin-a-review
DB09258,,Bemiparin sodium,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bemiparin-sodium
DB09259,,FDA orphan list,https://www.fda.gov/downloads/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/ucm162066.xls
DB09263,,FDA Approved Drug Products: Veltassa (patiromer) for oral suspension (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205739s037lbl.pdf
DB09263,,"Relypsa, Inc: Valtessa (patiromer) Safety Data Sheet (SDS)",https://www.obaid.info/pdf/MSDS/V/Veltassa.pdf
DB09265,,Adlyxin FDA Approval Announcement,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm
DB09265,,EMA CHMP Assessment Report: Lyxumia (lixisenatide),http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002445/WC500140449.pdf
DB09265,,FDA Approved Drug Products: Adlyxin (lixisenatide) injection for subcutaneous use (Sept 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208471s007lbl.pdf
DB09265,,FDA Approved Drug Products: Soliqua (insulin glargine and lixisenatide) injection for subcutaneous use (Sept 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208673s013lbl.pdf
DB09266,,FDA Approved Drug Products: Lymphoseek (technetium Tc 99m tilmanocept) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202207s012lbl.pdf
DB09267,,Electronic Medicines Compedium Proteos (strontium ranelate) Monograph,https://www.medicines.org.uk/emc/product/5598/smpc
DB09268,,"FDA Approved Drug Products: CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209589s014lbl.pdf
DB09269,,article,http://cancerres.aacrjournals.org/content/54/7/1690.short
DB09269,,MSDS,http://www.sciencelab.com/msds.php?msdsId=9927390
DB09269,,Sigma-Aldrich MSDS: Phenylacetic acid,https://www.sigmaaldrich.com/CA/en/sds/aldrich/p16621
DB09270,,FDA Reports,https://www.fda.gov/ohrms/dockets/dailys/02/May02/052902/02p-0244-cp00001-02-Exhibit_A-vol1.pdf
DB09270,,Pubmedhealth,https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032601/
DB09270,,Diet supplement label,https://biomedicine.com/public_downloads/BiomedSupplements/Co-Q10%20Supreme%20monograph.pdf
DB09270,,Coenzyme Q,http://fodsupport.org/pdf/Description_of_CoQ_10.pdf
DB09270,,Journal of Health Science,http://jhs.pharm.or.jp/data/55(4)/55_540.pdf
DB09272,,FDA Approved Drug Products: VIBERZI (eluxadoline) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206940s007lbl.pdf
DB09273,,Doxofix Product Information,https://www.unilab.com.ph/assets/product-info/doxofix.pdf
DB09273,,Cayman Chemical Doxofylline Product Information,https://www.caymanchem.com/pdfs/18746.pdf
DB09273,,Ansimar tablets Product Information,http://oep.com.ph/assets/upload/images/Ansimar_200_mg_tablet_with_new_licensor.pdf
DB09274,,CDC: Artesunate,https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html
DB09274,,Artesunate Product Information,https://extranet.who.int/prequal/sites/default/files/documents/MA051part4v2.pdf
DB09274,,FDA Approved Drug Products: Artesunate Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf
DB09275,,FDA Label,http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050786s012lbl.pdf
DB09276,,product info,http://products.sanofi.ca/en/myochrysine.pdf
DB09277,,Society of nuclear medicine and molecular imaging,http://snmmi.files.cms-plus.com/Choline%20chloride%20C-11%20(3).pdf
DB09278,,World Health Organization Model List of Essential Medicines (19th List),http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
DB09278,,World Health Organization Model Formulary2008,http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf
DB09280,,The Canadian Drug Expert Committee (CDEC): Lumacaftor/Ivacaftor Recommendation,https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0379_Kalydeco_Dec-23-14.pdf
DB09280,,"FDA Approved Drug Products: ORKAMBI (lumacaftor/ivacaftor) granules or tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s010lbl.pdf
DB09280,,"FDA Approved Drug Products: ORKAMBI (lumacaftor and ivacaftor) tablets or granules, for oral use (September 2022)",https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf
DB09280,,Health Canada Approved Drug Producs: ORKAMBI (Lumacaftor / Ivacaftor) tablets for oral use,https://pi.vrtx.com/files/Canadapm_orkambi_en.pdf
DB09281,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+589
DB09281,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+211
DB09281,,Sciencedirect,http://www.sciencedirect.com/science/article/pii/B9780080552323620896
DB09282,,Molsidomine,https://www.drugs.com/international/molsidomine.html
DB09282,,Update: Molsidomine,http://neurocirugia.com/2017/02/07/update-molsidomine/
DB09282,,EPA Chemistry Dashboard: Molsidomine,https://comptox.epa.gov/dashboard/dsstoxdb/results?search=Molsidomine
DB09282,,Molsidomine,http://www.druginfosys.com/drug.aspx?drugcode=492&type=1
DB09282,,Molsidomide: an overview,https://www.sciencedirect.com/topics/medicine-and-dentistry/molsidomine
DB09282,,Molsidomine,http://www.bertin-bioreagent.com/pr3010/molsidomine
DB09282,,Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans,http://europepmc.org/abstract/med/3838400
DB09282,,Molsidomine 2/4 mg tablets,https://pdfs.semanticscholar.org/3cb7/a1d396f6d523af253581daf8033e64a0cb3f.pdf
DB09282,,Clinical Pharmacology of Antianginal Drugs,https://books.google.ca/books?id=nuXrCAAAQBAJ&pg=PA366&lpg=PA366&dq=molsidomine+liver+metabolism&source=bl&ots=qBCXm0vm5D&sig=lxa3AYTHHhiqJe-_8X94eUCSW_0&hl=en&sa=X&ved=0ahUKEwiXzM7rz7fZAhUD5mMKHcS0AmMQ6AEIczAJ#v=onepage&q=esterase&f=false
DB09285,,Morniflumate induced urticaria and angioedema,https://dadospdf.com/download/morniflumate-induced-urticaria-angioedema-_5a4bbaccb7d7bcab67ea383c_pdf
DB09285,,A gastroprotective anti-inflammatory agent: theβ-morpholinoethyl ester of niflumic acid (morniflumate),https://www.researchgate.net/publication/16587181_A_gastroprotective_anti-inflammatory_agent_theb-morpholinoethyl_ester_of_niflumic_acid_morniflumate
DB09285,,Modulation of arachidonic acid metabolism by orally administered morniflumate in man,https://link.springer.com/article/10.1007/BF01986568
DB09285,,The pharmacokinetics and availability of niflumic acid in humans,https://www.researchgate.net/publication/16346020_The_pharmacokinetics_and_availability_of_niflumic_acid_in_humans
DB09285,,Niflumic acid,http://www.medchemexpress.com/niflumic-acid.html
DB09286,,Pipamperone,https://pubchem.ncbi.nlm.nih.gov/compound/Pipamperone#section=Pharmacology-and-Biochemistry
DB09286,,The Treatment of Autism with Pipamperone,https://www.sciencedirect.com/science/article/pii/S0924933816020319
DB09286,,Pipamperone,https://www.kenniscentrum-kjp.nl/en/professionals/Medication-14/Antipsychotics-6/Pimpamperone
DB09286,,Pipamperone: International drug information,http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?17/10/17580?source=HISTORY
DB09286,,Low dose pipamperone in treatment mood disorders,https://patents.google.com/patent/WO2010112529A1
DB09286,,Pipamperone dihydrochloride,https://www.trc-canada.com/product-detail/?P475200
DB09286,,The Pharmacological Role and Clinical Applications of Antipsychotics’ Active Metabolites: Paliperidone versus Risperidone,https://www.omicsonline.org/the-pharmacological-role-and-clinical-applications-of-antipsychotics-active-metabolites-paliperidone-versus-risperidone-2161-1459.1000117.pdf
DB09286,,Pipamerone,https://chem.nlm.nih.gov/chemidplus/rn/1893-33-0
DB09286,,Pipamperone and increased excercise/weight,https://databankws.lareb.nl/Downloads/Signals_2017_Pipamperone%20and%20increased%20appetite.pdf
DB09286,,Current antipsychotics,https://books.google.ca/books?id=RpVtM_WVw64C&pg=PA258&lpg=PA258&dq=PIPAMPERONE+metabolism&source=bl&ots=jl4_fNIg92&sig=bBV2ZA-BLObu-ukpCv7fXsTOfvg&hl=en&sa=X&ved=0ahUKEwjFrtHr6NXZAhXFz1QKHeNPBnoQ6AEIczAJ#v=onepage&q=PIPAMPERONE%20metabolism&f=false
DB09286,,Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders,https://www.researchgate.net/publication/6814909_Influence_of_the_antipsychotic_drug_pipamperone_on_the_expression_of_the_dopamine_D4_receptor
DB09286,,PP232—Acute toxicity profile of pipamperone in overdose: A consecutive case series,https://www.researchgate.net/publication/270941129_PP232-Acute_toxicity_profile_of_pipamperone_in_overdose_A_consecutive_case_series
DB09287,,"PLENVU (polyethylene glycol 3350, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) US FDA 2018 Label",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209381s000lbl.pdf
DB09287,,PegaLAX (polyethylene glycol 3350) 2017 Canadian Prescribing Information,https://aralez.com/wp-content/uploads/2018/03/PEGALAX-Prescribing-Information-22-MARCH-2017.pdf
DB09287,,NCBI StatPearls [Internet]: Bowel Preparation,https://www.ncbi.nlm.nih.gov/books/NBK535368/
DB09287,,"DailyMed Label: GAVILAX (Polyethylene glycol 3350) powder, for solution",https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=267de1ce-baa2-5a0b-e054-00144ff8d46c
DB09287,,Laxatives - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK537246/#_article-24120_s2_
DB09287,,Spectrum Chemical: POLYETHYLENE GLYCOL 3350 Safety Data Sheet,https://www.spectrumchemical.com/MSDS/PO125_AGHS.pdf
DB09288,,"Anaesthesia, pain and intensive care",http://www.apicareonline.com/review-article-intravenous-paracetamol-in-pediatrics-a-global-perspective/
DB09288,,New zealand perfalgan report,http://www.medsafe.govt.nz/profs/datasheet/p/Perfalganinf.pdf
DB09288,,Sociedade brasileira de quimica,http://www.scielo.br/pdf/jbchs/v27n6/0103-5053-jbchs-27-06-1121.pdf
DB09288,,Update in anaesthesia,http://e-safe-anaesthesia.org/e_library/03/Paracetamol_Update_2008.pdf
DB09288,,Monograph,https://www.tga.gov.au/sites/default/files/foi-305-1112-1.pdf
DB09289,,Tianeptine,https://www.tianeptine.com
DB09289,,Tianeptine,https://www.drugs.com/international/tianeptine.html
DB09289,,Tianeptine properties,http://datasheets.scbt.com/sds/aghs/en/sc-204345.pdf
DB09289,,The neurobiological properties of Tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902200/
DB09289,,Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method,https://link.springer.com/article/10.1007/s00210-017-1448-2
DB09289,,Effects of tianeptine on symptoms of fibromyalgia via BDNF signaling in a fibromyalgia animal model,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507774/
DB09289,,Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565824/
DB09289,,"Antidepressants: Past, Present and Future",https://books.google.ca/books?id=Ue3uCAAAQBAJ&pg=PA305&lpg=PA305&dq=metabolism+of+tianeptine&source=bl&ots=GQEZ5hNG5Z&sig=JyJ0MOjIFxArnFR3em7zXGo2Cbo&hl=en&sa=X&ved=0ahUKEwjRlvec_bzZAhUS22MKHTLMCqk4ChDoAQgoMAA#v=onepage&q=metabolism%20of%20tianeptine&f=false
DB09289,,TIANEPTINE DRUG INFORMATION,http://cdn.neiglobal.com/content/pg/live/tianeptine.pdf
DB09289,,Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine,https://academic.oup.com/jat/article-abstract/41/6/547/3852120?redirectedFrom=fulltext
DB09289,,Management of Respiratory Depression from Tianeptine Overdose with Naloxone,https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5344
DB09289,,"HMDB, Tianeptine Metabocard",http://www.hmdb.ca/metabolites/HMDB0042038
DB09289,,Targeting opioid receptor signalling in depression: do we need selective kappa opioid receptor antagonists?,http://www.neuronalsignaling.org/content/early/2018/04/17/NS20170145
DB09289,,"The kappa opioid receptor: from addiction to depression, and back",https://www.frontiersin.org/articles/10.3389/fpsyt.2014.00170/full
DB09291,,FDA Approved Drug Products: Varubi (rolapitant) tablets for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206500s008,208399s004lbl.pdf"
DB09292,,FDA Approved Drug Products: ENTRESTO (sacubitril and valsartan) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf
DB09295,,Talniflumate,https://www.sigmaaldrich.com/catalog/product/sigma/sml1710?lang=en&region=CA
DB09295,,Screening study for genetic polymorphisms af­fecting pharmacokinetics of talnifumate,http://www.tcpharm.org/Data/Journal/2/349.pdf
DB09295,,"Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man",https://link.springer.com/article/10.1007/BF02976244
DB09295,,Talniflumate (Genaera),https://www.researchgate.net/publication/8504535_Talniflumate_Genaera
DB09295,,Talniflunate,https://pubchem.ncbi.nlm.nih.gov/compound/Talniflumate
DB09295,,Chemistry Dashboard: Talniflumate,https://comptox.epa.gov/dashboard/dsstoxdb/results?formula=1&isotopes=1&search=C21H13F3N2O4
DB09295,,TALNIFLUMATE,https://drugs.ncats.io/ginas/app/substance/7c324c44
DB09295,,Talniflumate Increases Survival in a Cystic Fibrosis Mouse Model of Distal Intestinal Obstructive Syndrome,https://pdfs.semanticscholar.org/5e51/25821836a281b38e976a20886bbd74048908.pdf
DB09295,,TALNIFLUMATE,https://www.drugs.com/international/talniflumate.html
DB09295,,KWANG DONG TARIFUL TAB,http://eng.ekdp.com/product/items_view.asp?s=202
DB09295,,Talniflumate,http://www.drugfuture.com/chemdata/talniflumate.html
DB09296,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB09296,,Dailymed: Technivie,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85130606-e6a4-cf08-4bac-a460a30b0984
DB09297,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB09299,,Pubmed books,https://www.ncbi.nlm.nih.gov/books/NBK533928/
DB09299,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207561
DB09299,,FDA Approved Drug Products: Descovy (Emtricitabine and Tenofovir Alafenamide) Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208215s012lbl.pdf
DB09299,,"FDA Approved Drug Products: Bictegravir, Emtricitabine, and Tenofovir Alafenamide Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf
DB09299,,"FDA Approved Drug Products: Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207561s000lbl.pdf
DB09299,,"FDA Approved Drug Products: Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210455s000lbl.pdf
DB09299,,Health Canada Approved Drug Products: Tenofovir Alafenamide Oral Tablets,https://pdf.hres.ca/dpd_pm/00046979.PDF
DB09299,,European Medicines Agency Assessment Report: Tenofovir Alafenamide,https://www.ema.europa.eu/en/documents/assessment-report/vemlidy-epar-public-assessment-report_en.pdf
DB09299,,FDA Press Announcements: FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic,https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic
DB09299,,"FDA Approved Drug Products: VEMLIDY (tenofovir alafenamide) tablets, for oral use (October 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208464s014lbl.pdf
DB09299,,"EMA Approved Drug Products: Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) Oral Tablets",https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_en.pdf
DB09299,,"FDA Approved Drug Products: BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use (October 2021)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210251s014lbl.pdf
DB09299,,"FDA Approved Drug Products: BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use (February 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210251s018lbl.pdf
DB09300,,Duo-Pas Product Information,https://titomora.webcindario.com/productos/duopas_tabletas.htm
DB09301,,Chemical selection summary,https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/chondroitin_508.pdf
DB09301,,Arthritis foundation,https://www.arthritis.org/living-with-arthritis/treatments/natural/supplements-herbs/guide/chondroitin-sulfate.php
DB09301,,Metafishnet,http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png
DB09302,,FDA Approved Drug Products: Praluent (alirocumab) for subcutaneous injection (March 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125559s039lbl.pdf
DB09303,,FDA Approved Drug Products: Repatha (evolocumab) injection for subcutaneous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125522s029s031lbl.pdf
DB09311,,Monograph,http://www.robholland.com/Nursing/Drug_Guide/data/monographframes/C012.html
DB09311,,webmd,http://www.webmd.com/drugs/2/drug-6278/calcium-polycarbophil-oral/details
DB09313,,Loxaglic acid,https://pubchem.ncbi.nlm.nih.gov/compound/ioxaglic_acid#section=Top
DB09313,,"Ioxaglic acid, NZ MedSAFE Data sheet",http://www.medsafe.govt.nz/profs/datasheet/h/Hexabrix320inj.pdf
DB09313,,"FDA letter, Ioxaglic Acid",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
DB09313,,"HEXABRIX 320 (320 mg I/ml), solution for injection",https://www.old.health.gov.il/units/pharmacy/trufot/alonim/hexabrix_spc-_1460026610609.pdf
DB09313,,Are low osmolality contrast media less neprotoxic?,https://watermark.silverchair.com/11-6-930.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAaIwggGeBgkqhkiG9w0BBwagggGPMIIBiwIBADCCAYQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMwV4qlJ5SoXYTnm4nAgEQgIIBVf0gNR3GKaTsiazPlAUb40UrMgHGzcLxzK3HeR1RfzFpV5xfdDVAvE8oi9T_QWcAlmtHXVN5B9-F5PI1DS68buzsUItQsD9VCNs8OosJEOVY8jnLLRSvdkUduECUQ4ILNk3LgG1w8uGuyw8Fy1Ixk6FG-whN-1wKGQeIxdrZVsV7uxk34qs3lQoTgoV08sFTvlOVU0Jf9rN0aTDNo2pvRuS5Du3NrCwkZjdFzQhAgynFP5k1kK-ecxwZ4RWqOn3x695xkPdai2ivL_-erzmj6U8ruVZcCEgEMhHXBYIayG9jiWIpCZmtna069zETceXt8qCIs0IH3vypyOI-EfMfn6YX9ymsnN0K7LkhEJHrnPnEdJqqbm5dYfw8PmvzPa6yGOxmTtUPQc7CgZ2LAGw4ixA0tH1rUtE7AtDEuJgYXbNb1fE8uCGWEKST4J5GPSiJrRwzV3RA
DB09313,,"Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538464/
DB09313,,Imaging-related medications: a class overview,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014815/
DB09315,,FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017284s012lbl.pdf
DB09316,,Monograph,https://www.drugs.com/sfx/thallous-chloride-tl-201-side-effects.html
DB09320,,product info,https://www.drugs.com/pro/penicillin-g-procaine.html
DB09320,,World Health Organization Model Prescribing Information: Drugs Used in Skin Diseases,http://apps.who.int/medicinedocs/en/d/Jh2918e/23.2.html
DB09321,,Fisher Scientific: Zinc oxide MSDS,https://www.fishersci.ca/content/dam/fishersci/en_US/documents/programs/education/regulatory-documents/sds/chemicals/chemicals-z/S25641.pdf
DB09321,,product info,http://www.drugsupdate.com/generic/view/580/Zinc-Oxide
DB09322,,DRUGS.COM,https://www.drugs.com/pro/zinc-sulfate-injection.html
DB09322,,NCBI,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113371/
DB09322,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/7733-02-0
DB09322,,WebMD,http://www.webmd.com/drugs/2/drug-4086/zinc-sulfate-oral/details
DB09322,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/24424#section=Absorption-Distribution-and-Excretion
DB09322,,DAILYMED,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a03fe85-fdc9-4847-960f-1fc782d7d493
DB09324,,"FDA Approved Drug Products: XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf
DB09324,,"DailyMed Label: UNASYN (ampicillin sodium and sulbactam sodium) intravenous and intramuscular injection, powder, for solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=155c7ec0-5862-404f-b1d0-f278f8a8bbda
DB09324,,Pfizer: Unasyn (Ampicillin and Sulbactam) MSDS,https://cdn.pfizer.com/pfizercom/products/material_safety_data/230.pdf
DB09325,,"MSDS, sodium fluoride",http://www.inchem.org/documents/icsc/icsc/eics0951.htm
DB09325,,"Daily med: Sodium fluoride tablet, chewable",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c868e459-33b6-47e9-af4d-3d421d91772d
DB09325,,"Sodium fluoride F-18 injection, DailyMed",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96e61ba1-30ca-4844-b503-056afd247e69
DB09325,,Medline NIH: Fluoride overdose information,https://medlineplus.gov/ency/article/002650.htm
DB09325,,"MSDS, sodium fluoride, Fisher Scientific",https://fscimage.fishersci.com/msds/21230.htm
DB09325,,What happens to sodium fluoride in your body? DG Health and Consumer Protection,https://ec.europa.eu/health/scientific_committees/opinions_layman/fluoridation/en/l-3/2.htm
DB09325,,FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s002s003lbl.pdf
DB09325,,Fluoride therapy APPD,https://www.aapd.org/media/Policies_Guidelines/BP_FluorideTherapy.pdf
DB09325,,ADA guidelines on fluoride use,https://www.ada.org/en/member-center/oral-health-topics/fluoride-topical-and-systemic-supplements
DB09325,,"Sodium fluoride, science direct",https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/sodium-fluoride
DB09326,,article,http://www.uth.tmc.edu/pet/Assets/pdf/cad/20-jnm-1996.pdf
DB09326,,product info,http://interactive.snm.org/docs/PET_PROS/ammonia.pdf
DB09326,,article,https://www.ncbi.nlm.nih.gov/books/NBK23075/
DB09327,,UFT (uracil/tegafur) capsules_Product information,https://hemonc.org/docs/packageinsert/uraciltegafur.pdf
DB09327,,National Cancer Institute,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tegafur-uracil
DB09327,,FDA presentations,https://www.fda.gov/ohrms/dockets/ac/99/slides/3540s1c/sld004.htm
DB09328,,Efficacy Study of Vayarin in Children With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD),https://clinicaltrials.gov/ct2/show/NCT03115671
DB09328,,Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment (VAYA-fMRI),https://clinicaltrials.gov/ct2/show/NCT02473419
DB09328,,"mproved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study",https://globenewswire.com/news-release/2017/01/10/904861/0/en/Improved-Academic-Performance-and-Medication-Rebound-in-Patients-with-ADHD-Following-the-Use-of-Vayarin-a-Multi-Year-Real-World-Retrospective-Study.html
DB09328,,"Pharmacokinetics Basics- Absorption, Distribution, Metabolism and Excretion",https://www.ndrugs.com/?s=vayarin&t=actions
DB09328,,Vaya Direct,https://vayadirect.com
DB09328,,Vayarin product label,https://vayadirect.com/wp-content/uploads/2018/01/RIN_PI_PA-Final_new-slip.pdf
DB09328,,FDA label PS,https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm513828.pdf
DB09328,,"Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA",https://www.frontiersin.org/articles/10.3389/fnagi.2015.00052/
DB09328,,Drug Insert Vayarin,http://122.179.130.16/~vayarin/wp-content/uploads/2015/02/vayarin-60ct-outsert-ver-9.pdf
DB09329,,Adynovate Pro,http://www.adynovatepro.com/science/how-it-works/
DB09329,,Adynovate assessment report EMA,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004195/WC500243897.pdf
DB09329,,Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients,http://www.bloodjournal.org/content/bloodjournal/119/13/3031.full.pdf
DB09329,,Potential role of a new PEGylated recombinant factor VIII for hemophilia A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920230/
DB09329,,Potential role of a new PEGylated recombinant factor VIII for hemophilia A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387834/
DB09329,,PEGylation of a Factor VIII–Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291190/
DB09329,,"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551361/
DB09329,,"Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII",https://www.sciencedirect.com/science/article/pii/S004938481400156X
DB09329,,Antihemophilic Factor (Recombinant [Pegylated]),https://www.drugs.com/ppa/antihemophilic-factor-recombinant-pegylated.html
DB09329,,EMA label Adate,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000520/WC500022464.pdf
DB09329,,F8 gene coagulation factor VIII,https://ghr.nlm.nih.gov/gene/F8
DB09329,,Advate Product Monograph,https://www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdffiles/product%20information/advate-pm-en.pdf
DB09330,,FDA Approved Drug Products: TAGRISSO (osimertinib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208065s026lbl.pdf
DB09330,,"FDA Approved Drug Products: TAGRISSO (osimertinib) tablets, for oral use (February 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf
DB09331,,"FDA Approved Drug Products: DARZALEX (daratumumab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761036s035lbl.pdf
DB09331,,"FDA Approved Drug Products: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761145s012lbl.pdf
DB09332,,Kappadione patent,https://www.drugpatentwatch.com/p/tradename/KAPPADIONE
DB09332,,Endocrine Disrupters,https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/menadione
DB09332,,"Vitamin K, Systemic",https://www.drugs.com/mmx/menadiol-sodium-diphosphate.html
DB09332,,Menadiol Sodium,https://www.medicines.org.uk/emc/product/1349
DB09332,,Menadiol Sodium Pharmacology,https://www.ndrugs.com/?s=creatinine%20sulfate/esculoside/hesperidin%20methyl%20chalcone/menadiol%20sodium%20phosphate/tranexamic%20acid&t=actions#doctor_pharmacology
DB09332,,Foye's Principles of Medicinal Chemistry,https://books.google.ca/books?id=Sd6ot9ul-bUC&pg=PA870&lpg=PA870&dq=menadiol+phosphate+pharmacodynamics&source=bl&ots=TNPwJHhGOo&sig=Flj9-vlEjeVhbswimLW8Tt5WXJ0&hl=en&sa=X&ved=0ahUKEwiEyL7OrdvZAhUEzGMKHQuBBeU4ChDoAQgmMAA#v=onepage&q=menadiol%20phosphate%20pharmacodynamics&f=false
DB09332,,Drugs and haemostats,https://clinicalgate.com/drugs-and-haemostasis/
DB09332,,Menadiol,http://www.drugfuture.com/chemdata/menadiol.html
DB09332,,"Menadiol diphosphate, a new substrate for non-specific alkaline phosphatase in histochemistry and immunohistochemistry",https://www.semanticscholar.org/paper/Menadiol-diphosphate%2C-a-new-substrate-for-non-spec-Dikow-Gossrau/0bffb6a475339a3879f5cf99e15af5c355640e68
DB09332,,Vitamin K metabolism,http://smpdb.ca/view/SMP00464
DB09332,,A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits,https://tmu.pure.elsevier.com/en/publications/a-pharmacokinetic-study-with-the-high-dose-anticancer-agent-menad
DB09332,,Chapter 10. Vitamin K,http://www.fao.org/docrep/004/y2809e/y2809e0g.htm
DB09332,,Menadione,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3354
DB09333,,FDA Submission,https://www.fda.gov/downloads/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/ucm370723.txt
DB09333,,Up to date,https://www.uptodate.com/contents/iodinated-radiocontrast-agents-in-the-treatment-of-hyperthyroidism
DB09333,,Radiologyinfo,https://www.radiologyinfo.org/en/info.cfm?pg=abdominrad
DB09333,,Endocrinology association,https://www.thyroid.org/hyperthyroidism/
DB09336,,Technetium radiopharmaceutical chemistry,https://pdfs.semanticscholar.org/bfa5/c1913650a8a23b0359c3d9d2f5710a243a27.pdf
DB09336,,Cancer,https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html
DB09336,,Pharmacopeia,http://www.pharmacopeia.cn/v29240/usp29nf24s0_m80698.html
DB09336,,Pharmacological science,https://www.pharmacologicalsciences.us/pharmaceutical-chemistry/monoclonal-antibody-radionuclide-test-kits.html
DB09336,,National Public library,http://www.nationalpubliclibrary.info/articles/eng/Technetium_(99mTc)_nofetumomab_merpentan
DB09336,,FDA CDER list,https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm164641.pdf
DB09336,,FDA Submission,https://www.fda.gov/downloads/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/ucm370723.txt
DB09338,,Mersalyl,https://pubchem.ncbi.nlm.nih.gov/compound/23690449#section=Pharmacology-and-Biochemistry
DB09338,,Mersalyl,http://www.mims.com/philippines/drug/info/mersalyl?mtype=generic
DB09338,,Mersalyl,https://en.oxforddictionaries.com/definition/mersalyl
DB09338,,Mercurial Diuretics Their Mechanism of Action and Application,https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/562756?redirect=true
DB09338,,MIMS: Mersalyl,https://www.mims.com/hongkong/drug/info/mersalyl?mtype=generic
DB09338,,Uncouplers and inhibitors,http://www.bmb.leeds.ac.uk/illingworth/oxphos/poisons.htm
DB09338,,On the inhibitory action of mersalyl on microsomal drug oxidation: A rigid organization of the electron transport chain,https://www.sciencedirect.com/science/article/pii/000398617190213X
DB09338,,Mersalyl acid,http://www.t3db.ca/toxins/T3D1362
DB09338,,Pharmacokinetics and Toxicology of Aluminum in the Brain,https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1068&context=ps_facpub
DB09338,,MERSALYL- AN ANTIVIRAL DIURETIC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC429309/
DB09338,,Salt and Water Balance,https://books.google.ca/books?id=T_cbBQAAQBAJ&pg=PA69&lpg=PA69&dq=mersalyl+blood+pressure&source=bl&ots=en5ogYEJet&sig=UJRLLTS-s6GAtlH4pL6hHQYGvPw&hl=en&sa=X&ved=0ahUKEwjI07_L4N3ZAhUD32MKHaGEBtgQ6AEITTAE#v=onepage&q=mersalyl%20blood%20pressure&f=false
DB09338,,Metabolic adaptation of renal carbohydrate metabolism. V.In vivo response of rat renal-tubule gluconeogenesis to different diuretics,https://link.springer.com/article/10.1007/BF00944073
DB09340,,Tyropanoic acid,https://pubchem.ncbi.nlm.nih.gov/compound/Tyropanoic_acid
DB09340,,Iopanoic Acid,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3345
DB09340,,Inhibition of Hepatic Binding of Thyroxine by Cholecystographic Agents,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC371433/
DB09340,,Tyropanoate sodium,https://www.medkoo.com/products/10768
DB09340,,Tyropanoate sodium,http://www.drugfuture.com/chemdata/tyropanoate-sodium.html
DB09340,,Foreign Compound Metabolism in Mammals,https://books.google.ca/books?id=raKIFKRdi0AC&pg=PA423&lpg=PA423&dq=tyropanoic+acid&source=bl&ots=qASeCBztrt&sig=Ux3ZzP6AIeG9EQyKiq90uLdTUh8&hl=en&sa=X&ved=0ahUKEwjMs9PgjuDZAhUE6mMKHY3qA404ChDoAQhBMAY#v=onepage&q=tyropanoic%20acid&f=false
DB09340,,Hormone resistance and other metabolic paradoxes,https://books.google.ca/books?id=KHQoBgAAQBAJ&pg=PT109&lpg=PT109&dq=tyropaque&source=bl&ots=DF-bIZuEq8&sig=rdB3GxcKY7SMBz4XBXhZwL7N84g&hl=en&sa=X&ved=0ahUKEwjA0vPIj-DZAhUEx2MKHcZGAcI4ChDoAQg1MAM#v=onepage&q=tyropaque&f=false
DB09340,,ORAL CHOLECYSTOGRAPHY WITH IOPANOIC ACID (TELEPAQUE),https://sites.jamanetwork.com/jnc8//?utm_campaign=JNC8&utm_medium=banner&utm_source=house&utm_content=High_BP_Site&utm_term=728x90%5bgoogle.com%5d
DB09340,,CHOLECYSTOGRAPHIC AGENT: A RE-EVALUATION OF ITS CLINICAL UTILITY,https://vdocuments.site/prolonged-treatment-of-hyperthyroidism-with-sodium-tyropanoate-an-oral-cholecystographic.html
DB09340,,Diagnostic process using sodium tyropanoate,https://patents.google.com/patent/US4002731
DB09340,,Drug dosing in renal insufficiency,https://books.google.ca/books?id=OavnCAAAQBAJ&pg=PA603&lpg=PA603&dq=tyropanoate+sodium+drug+information&source=bl&ots=lgdOlC83fh&sig=hX_ooOrR9qAoQvhVK-AMyJiP4ts&hl=en&sa=X&ved=0ahUKEwi80sKBouDZAhUT2WMKHRnDA3E4ChDoAQg4MAQ#v=onepage&q=tyropanoate%20sodium%20drug%20information&f=false
DB09341,,Baxter Health GLUCOSE INTRAVENOUS INFUSION BP Product information,http://www.baxterhealthcare.com.au/downloads/healthcare_professionals/cmi_pi/glucose%20IVI_pi.pdf
DB09341,,Glucose injection (Viaflex bag) Product information,http://www.medsafe.govt.nz/profs/Datasheet/g/glucoseinjviaflex.pdf
DB09342,,PROPOXYCAINE,https://pubchem.ncbi.nlm.nih.gov/compound/Propoxycaine
DB09342,,New local anesthetic solutions containing propoxycaine,https://www.sciencedirect.com/sdfe/pdf/download/eid/1-s2.0-S0002817755110042/first-page-pdf
DB09342,,Handbook of Dental Anesthesia- Ebook,https://books.google.ca/books?id=3MfsAwAAQBAJ&pg=PA57&lpg=PA57&dq=dental+anesthetic+propoxycaine&source=bl&ots=83RGmRB2vJ&sig=EQcChwt3P5m2LM5yto8r8a5C-GI&hl=en&sa=X&ved=0ahUKEwjVt6-D1t_ZAhUB_2MKHaM4A6cQ6AEITTAD#v=onepage&q=dental%20anesthetic%20propoxycaine&f=false
DB09342,,Essentials of local anesthetic pharmacology,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1693664/
DB09342,,Propoxycaine Hydrochloride,http://www.pharmacopeia.cn/v29240/usp29nf24s0_m70480.html
DB09343,,EMA.europa,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003897/WC500206246.pdf
DB09343,,EMA.europa,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003897/WC500206248.pdf
DB09343,,Australia TGA: Trifluridine/Tipiracil Clinical Evaluation Report,https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiLzPvsxO7sAhUkHDQIHRYjAeIQFjABegQIARAC&url=https://www.tga.gov.au/sites/default/files/auspar-trifluridine-tipiracil-180612-cer.docx&usg=AOvVaw2f87nqWrVsmBblLUeTqlyq
DB09343,,"FDA Approved Drug Products: LONSURF (trifluridine and tipiracil) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf
DB09343,,"FDA Approved Drug Products: LONSURF (trifluridine and tipiracil) tablets, for oral use (August 2023)",https://taihocorp-media-release.s3.us-west-2.amazonaws.com/documents/prescribing-information.pdf
DB09343,,"EMA Product Information: LONSURF (trifluridine and tipiracil) tablets, for oral use",https://www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_en.pdf
DB09344,,DCP monograph,https://mri.cts-mrp.eu/Human/Downloads/DE_H_3724_001_FinalPI_1of3.pdf
DB09345,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/Pramocaine#section=Substances-by-Category
DB09346,,Metrizoic Acid,https://pubchem.ncbi.nlm.nih.gov/compound/Metrizoic_acid
DB09346,,Metrizoic Acid,https://www.sciencedirect.com/topics/immunology-and-microbiology/metrizoic-acid
DB09347,,Acetrizoic acid,https://www.scbt.com/scbt/product/acetrizoic-acid-85-36-9
DB09347,,FDA Records,https://www.fda.gov/downloads/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/ucm370722.xls
DB09347,,Cilag,http://www.cilag.ch/de/index.html
DB09347,,ChemSrc,https://www.chemsrc.com/en/cas/85-36-9_701814.html
DB09347,,Radiographic constrat agents,https://www.ranzcr.com/documents/593-notes-on-radiographic-contrast-rad-part-i-exam-ait/file
DB09347,,Water soluble contrast media,https://pdfs.semanticscholar.org/a628/88f1f574e2d105aa9bd7b7c3a9f91b29b938.pdf
DB09348,,EPA report,https://www.epa.gov/sites/production/files/2016-09/documents/beta-propiolactone.pdf
DB09348,,Himedialabs,http://himedialabs.com/TD/TC223.pdf
DB09348,,Monograph propiolactone,https://monographs.iarc.fr/ENG/Monographs/vol71/mono71-51.pdf
DB09348,,Science alert,https://scialert.net/fulltext/?doi=jbs.2013.521.527
DB09350,,article,http://npic.orst.edu/factsheets/archive/pbotech.pdf
DB09352,,product info,https://www.drugs.com/cdi/hydroxyamphetamine-tropicamide.html
DB09352,,American Academy of Ophthalmology - Horner syndrome Article,https://www.aao.org/bcscsnippetdetail.aspx?id=0f6d09c9-8bee-4003-8652-0c4e062295a6
DB09352,,product info,http://reference.medscape.com/drug/paremyd-hydroxyamphetamine-tropicamide-999448
DB09353,,MSDS,http://pmep.cce.cornell.edu/profiles/extoxnet/pyrethrins-ziram/sulfur-ext.html
DB09357,,DRUGS.COM,https://www.drugs.com/pro/dexpanthenol.html
DB09357,,Webmd,http://www.webmd.com/drugs/2/drug-75143/dexpanthenol-topical/details
DB09357,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/4678#section=Pharmacology-and-Biochemistry
DB09357,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/81-13-0
DB09357,,BASG Product Information: Dolobene (DMSO/heparin sodium/dexpanthenol) topical gel,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-21937&type=DOTC_FACH_INFO
DB09363,,Rauwolfia in the Treatment of Hypertension,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566472/
DB09363,,Rauwolfia,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e4edf7-dca9-4d8b-8f04-da6fc202d40e
DB09363,,Rauwolfia serpentina,https://www.drugs.com/mmx/rauwolfia-serpentina.html
DB09363,,Human kidney proximal tubule cells are vulnerable to the effects of Rauwolfia serpentina.,http://europepmc.org/abstract/med/26838987
DB09363,,Hyserpin/rauwolfia,https://www.drugpatentwatch.com/p/NDA/010581
DB09363,,Reserpine,https://medlineplus.gov/druginfo/meds/a601107.html
DB09363,,Review of Rauwolfia,https://www.sciencedirect.com/topics/medicine-and-dentistry/rauvolfia-serpentina
DB09363,,"Prospecting for Novel Plant-Derived Molecules of Rauvolfia serpentina as Inhibitors of Aldose Reductase, a Potent Drug Target for Diabetes and Its Complications",http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061327
DB09363,,Rauwolfia Serpentina in the Treatment of High Blood Pressure A Review of the Literature,http://circ.ahajournals.org/content/12/2/220
DB09363,,"Reserpine, Pub chem",https://pubchem.ncbi.nlm.nih.gov/compound/reserpine
DB09363,,Sympatholytic therapy in primary hypertension: a user friendly role for the future,https://www.nature.com/articles/1001356.pdf?origin=publication_detail
DB09363,,Reserpine,http://flipper.diff.org/app/items/3998
DB09363,,"Reserpine, Drugs.com",https://www.drugs.com/pro/reserpine.html
DB09363,,Differential Network Analysis Reveals Evolutionary Complexity in Secondary Metabolism of Rauvolfia serpentina over Catharanthus roseus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988974/
DB09363,,Reserpine,http://www.inchem.org/documents/pims/pharm/reserpn.htm#SectionTitle:6.3%20%20Biological%20half-life%20by%20route%20of%20exposure
DB09363,,MSDS,http://www.waters.com/webassets/cms/support/docs/700001673.pdf
DB09363,,Severe depression caused by reserpine,https://www.semanticscholar.org/paper/Severe-depression-caused-by-reserpine./3e0338937c0882d799d2374efac9aa93c0515995
DB09363,,Reserpine-induced Reduction in Norepinephrine Transporter Function Requires Catecholamine Storage Vesicles,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859979/
DB09372,,article,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1928430/pdf/canmedaj01105-0011.pdf
DB09372,,Book,https://books.google.ca/books?id=Ca3QAQAAQBAJ&pg=PA67&lpg=PA67&dq=tannic+acid+pharmacokinetics&source=bl&ots=Qc-poT_GSL&sig=QX2QfNbK4iFUDzd27L7_t8zf1YY&hl=ar&sa=X&ved=0ahUKEwil_MyY3IPSAhXD1IMKHemcD6AQ6AEIbDAJ#v=onepage&q=tannic%20acid%20pharmacokinetics&f=false
DB09372,,database,http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=217&AspxAutoDetectCookieSupport=1
DB09374,,DRUGS.COM,https://www.drugs.com/pro/indocyanine-green.html
DB09374,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/3599-32-4
DB09374,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/indocyanine_green
DB09376,,ChemIDPlus: Lapyrium Chloride,https://chem.nlm.nih.gov/chemidplus/rn/6272-74-8
DB09379,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012828
DB09379,,US Army Annual progress report,http://www.dtic.mil/dtic/tr/fulltext/u2/a021858.pdf
DB09381,,MSDS,http://www.pfizer.com/sites/default/files/products/material_safety_data/MENEST(esterified_estrogen)tablets_30-Jan-2017pdf.pdf
DB09381,,product info,https://www.drugs.com/ingredient/esterified-estrogens.html
DB09381,,product info,http://www.webmd.com/drugs/2/drug-6028/esterified-estrogens-oral/details
DB09381,,article,http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf
DB09389,,"FDA Approved Drug Products: Opill (Norgestrel) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017031s041lbl.pdf
DB09394,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/phosphoric_acid#section=Top
DB09394,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/7664-38-2
DB09394,,inChem,http://www.inchem.org/documents/ukpids/ukpids/ukpid73.htm
DB09395,,rxlist,http://www.rxlist.com/sodium-acetate-drug/indications-dosage.htm
DB09395,,monograph,http://www.medsafe.govt.nz/Profs/datasheet/d/dblsodiumacetatesol.pdf
DB09398,,article,http://www.fda.gov/downloads/drugs/developmentapprovalprocess/manufacturing/ucm257994.pdf
DB09398,,drug label,https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=43688
DB09398,,article,http://www-pub.iaea.org/MTCD/Publications/PDF/TE-1782_web.pdf
DB09398,,article,https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jat/31/8/10.1093/jat/31.8.526/2/31-8-526.pdf?Expires=1486832749&Signature=gYf2KeNoTFpEpHy47hbt2SYABrAEBn0WI6sSBPjBiYq0kJ0FQgtHC80j17QdOaKnplUbk2ATGEeyxIlsStlQyyvA-Zh9qrMJCy6EGfFx02RHJ0swLeZ8Yht2ES0LQBjPD9j3PWH-WEteQC29M94tIng9ps~k9yzkvoSVyM4VRhre8SxPeGiqotS6uaTiqqh1uS7npqKE6Npo6hjTAgRcakyCkPQVTf8jqyJWVXd-9suXIb5ZwKPVIyfE22KmGkB3zkPYOMTaaE8IrkaZ0aNpi1k8D8BSorprJR5mYKh~2fV85QsZUNJNLWDOzA98EZHoks4GeXbJPdA3vKIjj4mzug__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q
DB09401,,FDA Approved Products: Bidil (isosorbide dinitrate and hydralazine hydrochloride) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020727lbl.pdf
DB09401,,FDA Approved Drug Products: Monoket (isosorbide mononitrate) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdf
DB09401,,Product monograph: PRO-ISMN-60 (Isosorbide-5-mononitrate ) extended release tablets,https://pdf.hres.ca/dpd_pm/00043683.PDF
DB09401,,DailyMed: ISMOTIC (isosorbide) oral solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f305b18b-8506-4414-87a1-10aa3b76a691&audience=professional
DB09407,,DRUGS.COM,https://www.drugs.com/mtm/magnesium-chloride.html
DB09407,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/magnesium_chloride#section=Pharmacology-and-Biochemistry
DB09407,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+657
DB09407,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/7791-18-6
DB09409,,Santa Cruz Biotechnology,https://www.scbt.com/scbt/product/magnesium-acetate-tetrahydrate-molecular-biology-grade-16674-78-5
DB09409,,"PLASMA-LYTE 56 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in VIAFLEX Plastic Container: Drug Label",https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=162726
DB09409,,Magnesium Absorption in Humans,http://e-collection.library.ethz.ch/eserv/eth:26387/eth-26387-02.pdf
DB09409,,TOXNET Magnesium compounds,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7065
DB09413,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/516951#section=Bionecessity
DB09413,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/7778-77-0
DB09413,,DAILYMED,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b01eac95-dbe3-4b21-a922-187e0fc8ad23
DB09413,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5046
DB09414,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/24450#section=Bionecessity
DB09414,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+935
DB09414,,MSDS,http://www.sciencelab.com/msds.php?msdsId=9924689
DB09418,,POTASSIUM PERCHLORATE - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1222
DB09418,,FDA is Revoking Food Additive Approval for the Use of Perchlorate in Sealing Gaskets for Food Containers Because its Use Has Been Abandoned,https://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm555609.htm
DB09418,,Perchlorate Toxicity and Risk Assessment,https://pdfs.semanticscholar.org/7974/fd30f936f33aecc961c24986018cd7e3f1b2.pdf
DB09418,,Toxicological Profile For Perchlorates,https://www.atsdr.cdc.gov/toxprofiles/tp162-c3.pdf
DB09419,,Sugar Alcohols (Polyols) and Polydextrose Used as Sweeteners in Foods - Food Safety - Health Canada,https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/sugar-substitutes/sugar-alcohols-polyols-polydextrose-used-sweeteners-foods-food-safety.html
DB09419,,U.S. Food & Drug Administration: High-Intensity Sweeteners,https://www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397716.htm
DB09419,,MedlinePlus: D-xylose absorption,https://medlineplus.gov/ency/article/003606.htm
DB09422,,SMOFLIPID (lipid injectable emulsion) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207648lbl.pdf
DB09422,,NUTRILIPID® (lipid injectable emulsion) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019531s002lbl.pdf
DB09422,,CLINOLEIC 20% (Lipid Emulsion for Intravenous Nutrition) FDA Label,http://www.baxter.ca/en_CA/assets/downloads/monographs/ClinOleic_PM_30Jul2014_EN.pdf
DB09422,,INTRALIPID (soybean oil emulsion) Dailymed drug label information,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b007eb60-e18e-4dbc-bf8d-1a3cf434a722
DB09422,,FDA Approved Drug Products: Clinolipid (lipid injectable emulsion) for intravenous infusion,https://baxterpi.com/pi-pdf/Clinolipid+PI.pdf
DB09429,,DailyMed: Jeanatope (iodinated I-125 albumin) for injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b6f6a5e-f456-4db9-a3da-44d870ee6547
DB09430,,DailyMed: Megatope (iodinated I-131 albumin) for injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62ca4278-8cc9-46b7-8f3c-303ce6a9c155
DB09436,,"FDA Approved Drug Products: NEPHROSCAN (kit for the preparation of technetium Tc 99m succimer injection), for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214993s000lbl.pdf
DB09436,,PR Newswire: Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan™ (Kit for the Preparation of Technetium Tc 99m Succimer Injection),https://www.prnewswire.com/news-releases/theragnostics-announces-us-fda-approval-for-its-radiodiagnostic-imaging-drug-nephroscan-kit-for-the-preparation-of-technetium-tc-99m-succimer-injection-301488281.html
DB09446,,SAFFLOWER OIL - National Library of Medicine HSDB Database - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5153
DB09449,,FDA Guide: Sodium Phosphate Tablet,https://www.fda.gov/downloads/drugs/drugsafety/ucm134684.pdf
DB09449,,ChemIDPlus: Sodium Phosphate,https://chem.nlm.nih.gov/chemidplus/rn/7558-80-7
DB09456,,Beef Insulin Discontinuation Notice,https://www.iddt.org/wp-content/uploads/2017/07/Hypurin-Bovine-Discontinuation-Patient-announcement.pdf?x15779
DB09459,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/444305#section=Pharmacology-and-Biochemistry
DB09459,,Sigma-Aldrich MSDS: L-(+)-tartaric acid,https://www.geneseo.edu/sites/default/files/users/247/L-(%2B)-Tartaric%20acid.pdf
DB09460,,Glowm,https://www.glowm.com/resources/glowm/cd/pages/drugs/s014.html
DB09460,,Drugs.com,https://www.drugs.com/pro/sodium-bicarbonate.html
DB09460,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/497-19-8
DB09460,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/sodium_carbonate
DB09462,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+492
DB09462,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/56-81-5
DB09462,,DAILYMED,https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=GLYCERIN
DB09472,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/sodium_sulfate#section=Top
DB09472,,DRUGS.COM,https://www.drugs.com/drp/sodium-sulfate.html
DB09472,,DAILYMED,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ca2803e-a4d6-4e57-a910-13237c93a4ce
DB09472,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/7757-82-6
DB09472,,inChem,http://www.inchem.org/documents/sids/sids/7757826.pdf
DB09479,,CardioGen-82: Rubidium Rb 82 Generator,http://www.nuclearonline.org/PI/Cardiogen.pdf
DB09479,,Daily med,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee95aa18-9f2f-40eb-9b4c-583bea6f36bf
DB09481,,CDC NIOSH: MgCO3,https://www.cdc.gov/niosh/npg/npgd0373.html
DB09481,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+211
DB09484,,Safety Data Sheet,http://www.sigmaaldrich.com/MSDS/MSDS/DisplayMSDSPage.do?country=PL&language=EN-generic&productNumber=344443&brand=ALDRICH&PageToGoToURL=http%3A%2F%2Fwww.sigmaaldrich.com%2Fcatalog%2Fproduct%2Faldrich%2F344443%3Flang%3Dpl
DB09484,,Drug information,https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c40be43e-3da9-441b-8cde-82a471b94012
DB09490,,FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/in111med042403LB.pdf
DB09494,,1-HEXADECANOL - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2643
DB09494,,Synthetic Fatty Alcohols - FDA,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=172.864&SearchTerm=stearyl%20alcohol
DB09494,,FDA OTC ingredients,https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135688.pdf
DB09495,,MSDS,https://toxnet.nlm.nih.gov/cgi-bin
DB09495,,article,http://www.thedermreview.com/avobenzone/
DB09495,,product info,https://www.drugs.com/mmx/avobenzone-octyl-methoxycinnamate-octyl-salicylate-and-oxybenzone.html
DB09496,,The Dermatology Review: Octinoxate,http://www.thedermreview.com/octinoxate/
DB09499,,Medsafe New Zealand Approved Drug Products: DBL sodium thiosulfate solution for injection,http://www.medsafe.govt.nz/profs/Datasheet/d/DBL-SodiumThiosulfateinj.pdf
DB09499,,FDA Approved Drug Products: NITHIODOTE (sodium nitrite and sodium thiosulfate) injection for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/201444s026lbl.pdf
DB09499,,FDA Approved Drug Products: PEDMARK (sodium thiosulfate) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212937s000lbl.pdf
DB09499,,EMA Approved Drug Products: Pedmarqsi (sodium thiosulfate) injection for intravenous injection,https://www.ema.europa.eu/en/documents/product-information/pedmarqsi-epar-product-information_en.pdf
DB09502,,FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021870lbl.pdf
DB09511,,MSDS,http://www.sciencelab.com/msds.php?msdsId=9927617
DB09511,,product info,https://www.drugcenter.com/drugs/talcum-powder/
DB09512,,"FDA Approved Drug Products: Imodium Multi-Symptom Relief (Loperamide HCl, Simethicone) Oral Tablet",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021140Orig1s026lbl.pdf
DB09512,,"Health Canada Approved Drug Products: Imodium Complete (Loperamide HCl, Simethicone) Oral Chewable Tablets",https://pdf.hres.ca/dpd_pm/00037553.PDF
DB09516,,TOXNET: 4-methoxyphenol,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+4258
DB09516,,Drugs.com: Mequinol and Tretinoin (Topical),https://www.drugs.com/mmx/mequinol-and-tretinoin.html#citec50007323
DB09516,,PucChem: Mequinol Fb,https://pubchem.ncbi.nlm.nih.gov/compound/4-Methoxyphenol#section=Synonyms
DB09516,,ECHA: Mequinol,https://echa.europa.eu/registration-dossier/-/registered-dossier/16005/7/2/2
DB09517,,SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE MONOGRAPH,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc374c01-f3ed-4920-920b-b19f20fd20a9
DB09517,,"FDA Approved Drug Products: FERRLECIT (sodium ferric gluconate complex in sucrose), injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020955s020lbl.pdf
DB09532,,21-256 Synthetic Human Secretin Pharmacology Review - FDA,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-256_Synthetic%20Human%20Secretin_Pharmr.pdf
DB09535,,Drug Information,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97628e66-1550-43b9-ba1c-c2202049e8f5
DB09535,,Skin care research,http://www.smartskincare.com/skinprotection/sunblocks/sunblock_octocylene.html
DB09536,,Drugs.com,https://www.drugs.com/inactive/titanium-dioxide-70.html
DB09536,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/13463-67-7
DB09536,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/26042#section=Biological-Half-Life
DB09537,,FDA label,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021586Orig1s005lbl.pdf
DB09537,,MSDS,http://www.mercedesmedical.com/customer/MEMESA/specpages/THR-8630.pdf
DB09537,,article,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2812878/
DB09539,,Omega-3-acid ethyl esters 90 (K85EE),https://products.basf.com/en/K85EE-Omega-3-acid-ethyl-esters.html
DB09539,,Australian Public Assessment Report for Omega-3-acid ethyl esters 90,https://www.tga.gov.au/sites/default/files/auspar-omacor.pdf
DB09539,,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000PharmR.pdf
DB09543,,FDA SALONPAS® Pain Relief Patch Clinical Review,https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM453825.pdf
DB09543,,Norwegian Food Safety Authority: Methyl salicylate risk review,https://www.mattilsynet.no/kosmetikk/stoffer_i_kosmetikk/risk_profile_methyl_salicylate.9877/binary/Risk%20Profile%20Methyl%20Salicylate
DB09552,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/11102#section=Drug-Labels-for-Ingredients
DB09552,,CORTISPORIN-TC Otic Suspension (Monarch) with Neomycin and Hydrocortisone,https://www.drugs.com/drp/thonzonium-bromide.html
DB09555,,Dexchlorpheniramine monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1950f4d6-7fc2-44cd-9f7d-1359315353fc
DB09563,,"FDA Approved Drug Products: Choline C 11 Injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203155s000lbl.pdf
DB09564,,FDA Approved Drug Products: Tresiba (insulin degludec) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203314s015s016lbl.pdf
DB09564,,FDA Approved Drug Products: Tresiba (insulin degludec) for subcutaneous injection 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203314s018s020lbl.pdf
DB09564,,"FDA Approved Drug Products: XULTOPHY® 100/3.6 (insulin degludec and liraglutide) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208583s018s019lbl.pdf
DB09564,,"EMA Approved Drug Proucts: RYZODEG® 70/30 (insulin degludec and insulin aspart injection), for 7 subcutaneous use",https://www.ema.europa.eu/en/documents/product-information/ryzodeg-epar-product-information_en.pdf
DB09564,,Health Canada Approved Drug Proucts: Tresiba (insulin degludec) for subcutaneous injection,https://pdf.hres.ca/dpd_pm/00062216.PDF
DB09564,,Clinical Pharmacology Review: Tresiba,https://www.fda.gov/media/102778/download
DB09567,,ChemIDPlus: Olive Oil,https://chem.nlm.nih.gov/chemidplus/unii/6UYK2W1W1E
DB09567,,FDA Approved Drug Products: Clinolipid (lipid injectable emulsion) for intravenous infusion,https://baxterpi.com/pi-pdf/Clinolipid+PI.pdf
DB09568,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=205060
DB09568,,Epanova,http://www.epanovahcp.com/
DB09568,,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000CrossR.pdf
DB09568,,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000PharmR.pdf
DB09570,,"FDA Approved Drug Products: NINLARO (ixazomib) capsules, for oral use (July 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208462s017lbl.pdf
DB09570,,Health Canada Approved Drug Products: NINLARO (Ixazomib) Oral Capsules,https://pdf.hres.ca/dpd_pm/00074469.PDF
DB09570,,EMA Approved Drug Products: NINLARO (Ixazomib) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf
DB10061,,"FDA Approved Drug Products: MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] solution for injection, for intramuscular use",https://www.fda.gov/media/78514/download
DB10062,,DailyMed: Imovax rabies vaccine,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba8d4e72-f452-4859-ae6f-3644b4b0a78c
DB10076,,Dailymed Label: ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8143d01c-4911-40db-95b2-47f3ebea2a7d
DB10276,,Rotateq FDA Label,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf3b24e-85fd-43ee-b657-2ee4df312ec3
DB10276,,CDC: About Rotavirus,https://www.cdc.gov/rotavirus/about/index.html
DB10315,,"DailyMed: Proquad (measles, mumps, rubella, and varicella live vaccine) lyophilized powder for injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73eae9fc-507b-4c9c-883d-63eb2e3cc6f6
DB10315,,"FDA Approved Drug Products: PRIORIX (Measles, Mumps, and Rubella Vaccine, Live), suspension for subcutaneous injection",https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Priorix/pdf/PRIORIX.PDF
DB10316,,"DailyMed: Proquad (measles, mumps, rubella, and varicella live vaccine) lyophilized powder for injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73eae9fc-507b-4c9c-883d-63eb2e3cc6f6
DB10316,,"FDA Approved Drug Products: PRIORIX (Measles, Mumps, and Rubella Vaccine, Live), suspension for subcutaneous injection",https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Priorix/pdf/PRIORIX.PDF
DB10317,,"TITCK Product Information: R-VAC (rubella vaccine, live, attenuated) for subcutaneous injection",https://translate.google.com/translate?sl=auto&tl=en&u=https%3A%2F%2Ftitck.gov.tr%2Fstorage%2FArchive%2F2019%2FkubKtAttachments%2Fk%C3%BCb.pdf_7510c7ab-d67d-4e2d-8426-db8773172bbf.pdf
DB10317,,"DailyMed: Proquad (measles, mumps, rubella, and varicella live vaccine) lyophilized powder for injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73eae9fc-507b-4c9c-883d-63eb2e3cc6f6
DB10317,,"FDA Approved Drug Products: PRIORIX (Measles, Mumps, and Rubella Vaccine, Live), suspension for subcutaneous injection",https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Priorix/pdf/PRIORIX.PDF
DB10318,,CDC - Clinical Overview of Shingles (Herpes Zoster),https://www.cdc.gov/shingles/hcp/clinical-overview.html
DB10318,,CDC - What Everyone Should Know about Shingles Vaccine,https://www.cdc.gov/vaccines/vpd/shingles/public/index.html
DB10318,,CDC - About Chickenpox,https://www.cdc.gov/chickenpox/about/index.html
DB10366,,"FDA Approved Drug Products: ORALAIR 6 (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use",https://www.fda.gov/media/87935/download
DB10379,,"FDA Approved Drug Products: ORALAIR 6 (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use",https://www.fda.gov/media/87935/download
DB10385,,DailyMed Label: RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70216cba-11b5-40fd-8656-9f27b24f7b60
DB10385,,"DailyMed Label: SHORT RAGWEED (ambrosia artemisiifolia) injection for cutaneous, subcutaneous, or intradermal use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1482f8a2-c2c0-45a1-8e90-b427227f0b28
DB10389,,"FDA Approved Drug Products: ORALAIR 6 (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use",https://www.fda.gov/media/87935/download
DB10394,,"FDA Approved Drug Products: ORALAIR 6 (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use",https://www.fda.gov/media/87935/download
DB10400,,Drug information,http://ballaratallergyclinic.com.au/public_documents/Sublingual%20Immunotherapy%20for%20House%20Dust%20Mite/(2016)%20ACTAIR%20HOUSE%20DUST%20MITE%20TABLET%20PI.pdf
DB10400,,FDA Approved Drug Products: ODACTRA House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract Tablet for Sublingual Use,https://www.fda.gov/media/103380/download
DB10401,,FDA label,https://www.fda.gov/downloads/biologicsbloodvaccines/allergenics/ucm544382.pdf
DB10401,,Drug information,http://ballaratallergyclinic.com.au/public_documents/Sublingual%20Immunotherapy%20for%20House%20Dust%20Mite/(2016)%20ACTAIR%20HOUSE%20DUST%20MITE%20TABLET%20PI.pdf
DB10401,,FDA Approved Drug Products: ODACTRA House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract Tablet for Sublingual Use,https://www.fda.gov/media/103380/download
DB10404,,"FDA Approved Drug Products: ORALAIR 6 (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use",https://www.fda.gov/media/87935/download
DB10583,,TITCK Product Information: Tetadif (purified diphtheria/tetanus toxoid) for injection,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/yayntetadifkub_5da4194b-0308-424f-b08d-852560c84401.pdf
DB10770,,"FDA document,: SUMMARY OF SAFETY AND EFFECTIVENESS DATA",https://www.accessdata.fda.gov/cdrh_docs/pdf/P000036b.pdf
DB10770,,"Apligraf document, FDA",https://www.accessdata.fda.gov/cdrh_docs/pdf/P950032c.pdf
DB10770,,Three-Dimensional Human Tissue Models That Incorporate Diabetic Foot Ulcer-Derived Fibroblasts Mimic In Vivo Features of Chronic Wounds,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410281/
DB10770,,Skin Substitutes for Treating Chronic Wounds [Internet],https://www.ncbi.nlm.nih.gov/books/NBK248357/
DB10770,,Human foreskin fibroblast produces interleukin-6 to support derivation and self-renewal of mouse embryonic stem cells,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580467/
DB10770,,IL6 interleukin 6 [ Homo sapiens (human) ],https://www.ncbi.nlm.nih.gov/gene/3569
DB10770,,IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism,https://www.sciencedirect.com/science/article/pii/S0022202X15601658
DB10770,,Fibronectin human foreskin fibroblasts,https://www.sigmaaldrich.com/catalog/product/sigma/f2518?lang=en&region=CA
DB10770,,"SUMMARY OF SAFETY AND EFFECTIVENESS DATA, Orcel",https://www.accessdata.fda.gov/cdrh_docs/pdf/P010016b.pdf
DB10770,,Immortalized human skin fibroblast feeder cells support growth and maintenance of both human embryonic and induced pluripotent stem cells,https://academic.oup.com/humrep/article/24/10/2567/774983
DB10770,,Pre-Clinical Demo Orcel,https://www.fda.gov/ohrms/dockets/ac/01/briefing/3771b1_01.pdf
DB10770,,SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED),https://www.accessdata.fda.gov/cdrh_docs/pdf/P900033S042b.pdf
DB10770,,Advancement of wound care from grafts to bioengineered smart skin substitutes,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299852/
DB10770,,Premarket Approval (PMA),https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p000036
DB10771,,Computational analysis of bovine alpha-1 collagen sequences,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563415/
DB10771,,Gintuit,https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM295525.pdf
DB10771,,"SUMMARY OF SAFETY AND EFFECTIVENESS DATA, Orcel",https://www.accessdata.fda.gov/cdrh_docs/pdf/P010016b.pdf
DB10771,,Advances in Skin Substitutes—Potential of Tissue Engineered Skin for Facilitating Anti-Fibrotic Healing,http://www.mdpi.com/2079-4983/6/3/547
DB10771,,Development and utilization of a bovine type I collagen microfibril model,https://www.ars.usda.gov/ARSUserFiles/80720525/1-s2.0-s0141813012004266-main.pdf
DB10771,,"CoMatryx wound dressing, FDA letters and documents",https://www.accessdata.fda.gov/cdrh_docs/pdf17/K171645.pdf
DB10771,,Bovine Collagen Type I,https://rockland-inc.com/store/Collagen-Proteins-001-001-103-O4L_22962.aspx
DB10771,,Type 1 Collagen,https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/type-i-collagen
DB10771,,Scielo,http://www.scielo.br/pdf/rbcp/v26n4/en_a28.pdf
DB10771,,A Bovine Collagen Type I-Based Biodegradable Matrix as a Carrier for Tissue-Engineered Urothelium,https://www.omicsonline.org/open-access/a-bovine-collagen-type-ibased-biodegradable-matrix-as-a-carrier-for-tissueengineered-urothelium-2157-7633-1000275.php?aid=50701
DB10771,,Collagen: A review on its sources and potential cosmetic applications,https://onlinelibrary.wiley.com/doi/pdf/10.1111/jocd.12450
DB10771,,"Bovine type 1 Collagen, Santa Cruz Biology",https://www.scbt.com/scbt/product/collagen-i-bovine
DB10771,,Updated Report and Scientific Opinion on the safety of hydrolysed proteins produced from bovine hides. Initially adopted by the Scientific Steering Committee at its meeting of 22-23 October 1998 and updated at its meeting of 25-26 May 2000,https://ec.europa.eu/food/sites/food/files/safety/docs/sci-com_ssc_out109_en.pdf
DB10771,,WHO Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies,http://www.who.int/bloodproducts/tse/WHO%20TSE%20Guidelines%20FINAL-22%20JuneupdatedNL.pdf
DB10771,,Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev.3),http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003700.pdf
DB10771,,Excellagen,http://www.empr.com/excellagen/drug/7834/
DB10772,,Pre-Clinical Demo Orcel,https://www.fda.gov/ohrms/dockets/ac/01/briefing/3771b1_01.pdf
DB10772,,"Apligraf document, FDA",https://www.accessdata.fda.gov/cdrh_docs/pdf/P950032c.pdf
DB10772,,Advances in Skin Substitutes—Potential of Tissue Engineered Skin for Facilitating Anti-Fibrotic Healing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598670/
DB10772,,Skin Substitutes: A Brief Review of Types and Clinical Applications,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269619/
DB10772,,Foreskin‐isolated keratinocytes provide successful extemporaneous autologous paediatric skin grafts,https://onlinelibrary.wiley.com/doi/full/10.1002/term.1690
DB10772,,Allogeneic cultured keratinocytes/fibroblasts in bovine collagen (Rx),https://reference.medscape.com/drug/formulary/gintuit-allogeneic-cultured-keratinocytes-fibroblasts-bovine-collagen-999735#3
DB10772,,The importance of both fibroblasts and keratinocytes in a bilayered living cellular construct used in wound healing,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211362/
DB10772,,Advancement of wound care from grafts to bioengineered smart skin substitutes,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299852/
DB10772,,Gintuit,https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM295525.pdf
DB10772,,Orcel,https://www.ndrugs.com/?s=orcel
DB10772,,Advances in keratinocyte delivery in burn wound care,https://www.sciencedirect.com/science/article/pii/S0169409X17300960
DB10772,,Apligraf,http://www.apligraf.com/professional/clinical_data/index.html
DB10772,,Molecular biology of keratinocyte differentiation.,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1567608/
DB10805,,World Health Organization - Yellow Fever Fact Sheet,http://www.who.int/mediacentre/factsheets/fs100/en/
DB10805,,World Health Organization - Yellow fever vaccination booster not needed,http://www.who.int/mediacentre/news/releases/2013/yellow_fever_20130517/en/
DB10805,,CDC - Yellow Fever Symptoms and Treatment,https://www.cdc.gov/yellowfever/symptoms/index.html
DB10805,,CDC - Yellow Fever Vaccine,https://www.cdc.gov/yellowfever/vaccine/index.html
DB10989,,MSDS,http://www.msds-gsk.com/Product.aspx?id=227
DB10989,,WHO website,http://www.who.int/ith/vaccines/hepatitisA/en/
DB10989,,product info,http://www.rxlist.com/havrix-drug/side-effects-interactions.htm
DB10989,,Havrix Monograph,http://healthsensetravelclinic.ca/wp-content/uploads/havrix.pdf
DB10989,,FDA approved vaccines: Havrix (Hepatitis A) intramuscular injection,https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert---HAVRIX.pdf
DB10989,,WHO: Vaccine immunology,https://www.who.int/immunization/documents/Elsevier_Vaccine_immunology.pdf
DB10989,,GSK: Twinrix adult MSDS,https://www.vaxserve.com/image.cfm?doc_id=15077&image_type=msds_sheet
DB10989,,NIH StatPearls: Hepatitis A Vaccine,https://www.ncbi.nlm.nih.gov/books/NBK554604/
DB10989,,Health Canada Product Monograph: Vivaxim (Combined Purified Vi Polysaccharide Typhoid and Inactivated Hepatitis A Vaccine) for intramuscular administration,https://pdf.hres.ca/dpd_pm/00032177.PDF
DB10997,,FDA Approved Drug Products: MACI (autologous cultured chondrocytes on porcine collagen membrane) Cellular sheet for autologous implantation,https://wayback.archive-it.org/7993/20180726060853/https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM533182.pdf
DB11003,,"FDA Approved Drug Products: CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) Suspension for Intramuscular Injection",https://www.emergentbiosolutions.com/wp-content/uploads/2023/07/Cyfendus-Prescribing-Information-and-Patient-Information.pdf
DB11003,,FDA Approved Drug Products: BIOTHRAX® (Anthrax Vaccine Adsorbed) Suspension for Intramuscular or Subcutaneous Injection,https://www.fda.gov/media/71954/download
DB11003,,"Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use",https://www.benzinga.com/pressreleases/23/07/g33313589/emergent-biosolutions-receives-u-s-fda-approval-of-cyfendus-anthrax-vaccine-adsorbed-adjuvanted-pr
DB11003,,Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-fda-approval-large-scale
DB11051,,FDA Approved Drug Products: LAVIV (azficel-T) Suspension for Intradermal Injection,https://www.fda.gov/media/80838/download
DB11054,,DailyMed Label: HEMACORD (human cord blood hematopoietic progenitor cell) Injectable Suspension for Intravenous Use,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd9a5180-1773-11e0-980a-0002a5d5c51b
DB11058,,FDA Monograph: Petrolatum,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9164696-3128-4712-9276-e1d3e69dfd1b
DB11059,,DailyMed: Refresh Tears (carboxymethylcellulose) lubricating eye drops,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b94f67c-d675-4e16-846a-3ca39b0405e0
DB11060,,"Polyvinyl alcohol, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/Ethenol
DB11060,,Polivinyl Alcohol Review,https://www.omicsonline.org/open-access/polyvinyl-alcohol-in-medicine-and-pharmacy-a-perspective-2329-6631.1000112.php?aid=21700
DB11060,,"Daily Med, Artificial Tears",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=736f9577-d8ff-45c7-8205-dfdb7193492f
DB11060,,HYPOTEARS - polyvinyl alcohol and polyehtylene glycol 400 solution/ drops,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c57d917-8114-03b5-0fa5-63dc420ae94d
DB11060,,"MIMS, Polyvinyl Alcohol",http://www.mims.com/india/drug/info/polyvinyl%20alcohol?type=full&mtype=generic
DB11060,,Pediatrics On Call: Polyvinyl Alcohol,https://www.pediatriconcall.com/drugs/polyvinyl-alcohol/1321
DB11060,,Express Chemist: Allergan Liquifilm Tears (polyvinyl alcohol) ocular lubricant,https://www.expresschemist.co.uk/allergan-liquifilm-tears-15-ml.html
DB11061,,DailyMed: Moisture Eyes Lubricant Eye Drops (povidone 2%),https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d6d830-bc0e-4838-bde9-90250f27e651&version=2
DB11061,,DailyMed: Murine Tears (polyvinyl alcohol/povidone) eye drops,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e81bb895-0743-460a-88a0-bf57ec729422
DB11061,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB11062,,product info,http://www.smartskincare.com/skinprotection/sunblocks/sunblock_octisalate.html
DB11062,,MSDS,https://www.whatsinproducts.com/files/brands_pdf/1368132770.pdf
DB11063,,Polysorbate 80,https://pubchem.ncbi.nlm.nih.gov/compound/5281955
DB11063,,Code of Federal Regulation,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=172.840
DB11063,,Common Ingredients in U.S. Licensed Vaccines,https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm187810.htm
DB11063,,NTP Toxicology and Carcinogenesis Studies of Polysorbate 80 (CAS No. 9005-65-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).,https://www.ncbi.nlm.nih.gov/pubmed/12616296
DB11063,,Polysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural study,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537525/
DB11063,,Food Emulsifier Polysorbate 80 Increases Intestinal Absorption of Di-(2-Ethylhexyl) Phthalate in Rats,https://academic.oup.com/toxsci/article/139/2/317/2511598
DB11063,,"Polysorbates, peroxides, protein aggregation, and immuno- genicity – a growing concern.",https://pdfs.semanticscholar.org/8b1b/e7f127f8a7ae1c71e62550f4e5a15639c91f.pdf
DB11063,,In uence of excipients on drug absorption via modulation of intestinal transporters activity,https://www.asiapharmaceutics.info/index.php/ajp/article/viewFile/435/394
DB11063,,Polysorbate 80,https://www.drugs.com/inactive/polysorbate-80-372.html
DB11063,,Overview of pharmaceutical excipients used in tablets and capsules,http://biologicpharma.com/wp-content/uploads/Overview-of-pharmaceutical-excipients-used-in-tablets-and-capsules.pdf
DB11063,,Effect of Polysorbate 80 Quality on Photostability of a Monoclonal Antibody,https://www.ncbi.nlm.nih.gov/pubmed/22362139
DB11063,,Evaluation reports of Polysorbates,http://www.fsc.go.jp/english/evaluationreports/foodadditive/polysorbate_report.pdf
DB11063,,DailyMed: Aviteras (Polysorbate 80.1%) drops,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbb0d312-c79a-4c89-acb1-b895b52c05d5
DB11064,,MSDS,http://www.sciencelab.com/msds.php?msdsId=9924271
DB11064,,product info,http://www.cosmeticsinfo.org/ingredient/homosalate-0
DB11065,,Creon monograph,http://www.rxabbvie.com/pdf/creon_PI.pdf
DB11065,,FDA approval,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022523_pancreaze_toc.cfm
DB11065,,Amylase product information,https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/a3176pis.pdf
DB11065,,FDA reports,https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM308286.pdf
DB11065,,CENTER FOR DRUG EVALUATION AND RESEARCH- 20755,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020725s000PharmR.pdf
DB11065,,EMA reports,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002070/WC500210680.pdf
DB11065,,INVIMA Product Authorization: Panzytrat (pancreatic lipase/amylase/protease) gastroresistant tablets,http://web.sivicos.gov.co/registros/pdf/15780247_2019024887.pdf
DB11065,,TITCK Product Information: Fermento (pancreatic lipase/amylase/protease with dimethicone) oral capsules,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK-K%C3%9CB-%20FERMENTO.pdf_cee0aae5-d6ad-455d-acf6-a11b523255cc.pdf
DB11066,,Creon monograph,http://www.rxabbvie.com/pdf/creon_PI.pdf
DB11066,,FDA approval,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022523_pancreaze_toc.cfm
DB11066,,VIVO pathophysiology,http://www.vivo.colostate.edu/hbooks/pathphys/digestion/pancreas/exocrine.html
DB11066,,EMBL-EBI,https://www.ebi.ac.uk/interpro/potm/2003_5/Page1.htm
DB11071,,Phenyl Salicylate,https://www.drugs.com/drp/phenyl-salicylate.html
DB11071,,Phenyl Salicylate,https://pubchem.ncbi.nlm.nih.gov/compound/Phenyl_salicylate
DB11071,,"Phenyl Salicylate, CHeBi",http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:34918
DB11071,,"HYOPHEN- methenamine, benzoic acid, phenyl salicylate, methylene blue, and hyoscyamine sulfate tablet",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c1f0f4c-e57b-4df5-9a58-41d39c3d8893
DB11071,,"Methenamine, benzoic acid, phenyl salicylate, methylene blue, and hyoscyamine sulfate",https://www.hyophen.com
DB11071,,"Phenyl Salicylate, Norway RISK PROFILE",https://www.mattilsynet.no/kosmetikk/stoffer_i_kosmetikk/risk_profile_phenyl_salicylate.9879/binary/Risk%20Profile%20Phenyl%20Salicylate
DB11071,,The pharmacokinetics of salicylate,https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2125.1980.tb01811.x
DB11071,,A toxicologic and dermatologic assessment of salicylates when used as fragrance ingredients,https://pdfs.semanticscholar.org/130a/43234f7a843e67be3f2b518effabc54c9d46.pdf
DB11071,,"Santa Cruz SDS sheet, Phenyl Salicylate",http://datasheets.scbt.com/sc-250695.pdf
DB11071,,Phenyl Salicylate SDS,http://www.esciencelabs.com/sites/default/files/msds_files/Salol.pdf
DB11071,,Phenyl salicylate (T3D4905),http://www.t3db.ca/toxins/T3D4905
DB11071,,"Absorption, Biotransformation, and Pharmacokinetics of Salicylsalicylic Acid in Humans",https://www.researchgate.net/publication/15889003_Absorption_Biotransformation_and_Pharmacokinetics_of_Salicylsalicylic_Acid_in_Humans
DB11071,,FDA Everything Added to Food Listing,https://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?filter=118-55-8&sortColumn=&rpt=eafusListing
DB11071,,Molecular Targets of Aspirin and Cancer Prevention,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090734/
DB11073,,The Role of Cetylpyridinium Chloride Mouthwash In The Treatment of Periodontitis.,http://www.ijpsi.org/Papers/Vol2(12)/H0212036037.pdf
DB11073,,Electronic Medicines Compendium: Cetylpyridinium chloride formulations,https://www.medicines.org.uk/emc/search?q=Cetylpyridinium+chloride
DB11073,,Electronic Medicines Compendium: Covonia Cold & Flu Formula Monograph,https://www.medicines.org.uk/emc/product/4826/smpc
DB11073,,IPCS INCHEM: Quaternary ammonium profile,http://www.inchem.org/documents/pims/chemical/pimg022.htm
DB11073,,Pubchem: Cetylpyridinium Chloride Profile,https://pubchem.ncbi.nlm.nih.gov/compound/cetylpyridinium_chloride#section=Top
DB11073,,Electronic Medicines Compendium: Lemsip Cough for Mucus Cough & Catarrh 100mg/2.5mg/5ml Oral Solution Monograph,https://www.medicines.org.uk/emc/product/7255/smpc
DB11073,,Electronic Medicines Database: Calgel Teething Gel Monograph,https://www.medicines.org.uk/emc/product/259/smpc
DB11073,,DailyMed: Advanced Guard (cetylpyridinium chloride) oral rinse,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0fc1add-c834-4de2-9ff7-142c43a8192c
DB11073,,Lloyd's Farmacia: Neo Formitrol (cetylpyridinium chloride) buccal tablets,https://www.lloydsfarmacia.it/neo-formitrol-1-mg-20-compresse-orosolubili-p-032250021.html
DB11074,,Dimethicone,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1808
DB11074,,Safety and efficacy of a 100 % dimethicone pediculocide in school-age children,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475297/
DB11074,,"Public Assessment Report, Dimethicone",http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2023415.pdf
DB11074,,CENTER FOR DRUG EVALUATION AND RESEARCH- 20755,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020725s000PharmR.pdf
DB11074,,Dimethicone,https://www.drugs.com/cdi/dimethicone-topical-products.html
DB11074,,"Moisturel, Daily Med monograph",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdbe0d25-f76b-4f5f-bfe6-8d6271eecfd1
DB11074,,Guidelines of care for the management of atopic dermatitis,https://www.aad.org/File%20Library/Main%20navigation/.../AD-part-2.pdf
DB11074,,"Product Monograph, NYDA",http://www.pedia-pharm.com/en/wp-content/uploads/sites/3/2014/03/NYDA-Product-Monograph-2012-09-11-EN.pdf
DB11074,,POLYDIMETHYLSILOXANE,http://www.maria-online.com/health/article.php?lg=en&q=Polydimethylsiloxane
DB11074,,Dimethicone,https://www.ewg.org/skindeep/ingredient/702011/DIMETHICONE/#.WrLbYrYZN-U
DB11074,,"DailyMed Label: DIMETHICONE, skin protectant cream",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96886b33-44d4-5a2a-e053-2a95a90a505e
DB11075,,BION TEARS,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e48d82f0-2f18-e514-4caa-e397d6713b99
DB11075,,Hypromellose,https://www.drugs.com/mmx/hypromellose.html
DB11075,,MIMS Hypromellose,http://www.mims.com/malaysia/drug/info/hypromellose?mtype=generic
DB11075,,SUMMARY OF PRODUCT CHARACTERISTICS,http://mri.cts-mrp.eu/download/DE_H_0534_001_FinalSPC.pdf
DB11075,,SUMMARY PRODUCT ASSESSMENT,http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2023972.pdf
DB11075,,Hydroxypropyl methyl cellulose,http://www.lookchem.com/Hydroxypropyl-methyl-cellulose/
DB11075,,DailyMed: Genteal Mild Eye Drops (hypromellose 0.2%),https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c4ea323-2407-4f9d-b44f-eebf127924ba
DB11077,,Polyethylene glyco,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5159
DB11077,,SIGMA-ALDRICH PEG 400,https://www.sigmaaldrich.com/catalog/search?term=PEG+400&interface=All&N=0&mode=partialmax&lang=en&region=CA&focus=product
DB11077,,Polyethylene glycol 400 (PEG400) affects the systemic exposure of oral drugs based on multiple mechanisms: taking berberine as an example,http://pubs.rsc.org/-/content/articlelanding/2017/ra/c6ra26284h#!divAbstract
DB11077,,Polyethylene glycol,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15bc06ec-f3dc-3180-ca1a-106769a770ea
DB11077,,Polyethylene Glycol,http://www.abcam.com/primary-antibodies/polyethylene-glycol-peg-faqs
DB11077,,Safety Evaluation of Polyethylene Glycol (PEG) Compounds for Cosmetic Use,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505343/
DB11077,,PEG-400,https://www.drugs.com/inactive/polyethylene-glycol-400-272.html
DB11077,,Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects,https://clinicaltrials.gov/ct2/show/NCT02260076
DB11077,,PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies,http://dmd.aspetjournals.org/content/dmd/35/1/9.full.pdf
DB11077,,The Absorption and Excretion of a Liquid Polyethylene Glycol,https://www.sciencedirect.com/science/article/pii/S0095955315319119
DB11077,,Polyethylene Glycol 400,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=POLYETHYLENE+GLYCOL+400&pagesize=100&page=2&vfile=
DB11077,,Systane Mechanism of Action,http://www.systane.dk/professional/media/pdf/SYS_Ultra_MOA.pdf
DB11077,,Ocular lubricants: what is the best choice?,http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782016001102055
DB11077,,Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex vivo and Distribution in vivo,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890729/
DB11077,,The different faces of poly(ethylene glycol),http://www.pnas.org/content/pnas/94/16/8378.full.pdf
DB11079,,Health Canada: Triethanolamine Salicylate (Trolamine) Label,https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/triethanolamine-salicylate-trolamine.html
DB11081,,"FDA CFR - Code of Federal Regulations Title 21, PART 350: ANTIPERSPIRANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE",https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=350&showFR=1
DB11081,,ALUMINUM CHLORIDE - National Library of Medicine HSDB ... - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+607
DB11081,,TITCK Product Information: Anti-Fosfat AL (aluminum chloride complex) oral capsule,https://titck.gov.tr/storage/kubKtAttachments/034849e584856.pdf
DB11082,,product info,https://www.drugs.com/cdi/coal-tar-ointment.html
DB11082,,Doctoralia: Soriderm (allantoin/coal tar) product information,https://www.doctoralia.co/medicamentos/soriderm
DB11085,,NIH Toxnet: Resorcinol Profile,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+722
DB11085,,Drugs.com: Resorcinol Profile,https://www.drugs.com/mmx/resorcinol.html
DB11085,,Resorcinol Peel as a Part of a Facial Rejuvenation Program,http://journals.sagepub.com/doi/pdf/10.1177/074880689701400109
DB11085,,INCHEM: Resorcinol Profile,http://www.inchem.org/documents/cicads/cicads/cicad71.htm#8.10
DB11085,,DailyMed Label: BENZOCAINE AND RESORCINOL cream,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e994ff-5a7f-4e69-8a93-552a132668a7
DB11089,,Docusate sodium/Senna: Drug Information,https://davisplus.fadavis.com/3976/meddeck/pdf/docusatesodiumsenna.pdf
DB11089,,Docusate sodium Drug Summary,http://www.pdr.net/drug-summary/Colace-Capsules-docusate-sodium-1023
DB11089,,Alberta Health Services Drugs and Therapeutics Background- Stool Softeners: WHY Are They Still Used?,https://www.albertahealthservices.ca/assets/info/hp/pharm/if-hp-pharm-docusate-delisting-backgrounder.pdf
DB11089,,World Health Organization List of Essential Medicines 2017,https://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf
DB11089,,DailyMed: Docusate/Sennosides oral tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87aed85e-efb1-229f-e053-2a95a90ab8cd
DB11090,,Potassium Nitrate,https://pubchem.ncbi.nlm.nih.gov/compound/potassium_nitrate#section=Top
DB11090,,Committee for Veterinary Medicinal Products: Potassium nitrate summary report (EMEA/MRL/232/97-FINAL),http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500015775.pdf
DB11090,,CHEBI:63043 - potassium nitrate,http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63043
DB11090,,POTASSIUM NITRATE,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1227
DB11090,,Mechanism of Action of a Desensitizing Fluoride Toothpaste Delivering Calcium and Phosphate Ingredients in the Treatment of Dental Hypersensitivity,https://www.aegisdentalnetwork.com/cced/2009/10/mechanism-of-action-of-a-desensitizing-fluoride-toothpaste-delivering-calcium-and-phosphate-ingredients-in-the-treatment-of-dental-hypersensitivity
DB11090,,EPA NITRATES DOCUMENT,https://www3.epa.gov/pesticides/chem_search/reg_actions/reregistration/fs_G-49_1-Sep-91.pdf
DB11090,,Nitrates,https://rais.ornl.gov/tox/profiles/nitrates_f_V1.html
DB11090,,Potassium Nitrate,https://www.drugs.com/drp/potassium-nitrate.html
DB11090,,NITRATE,http://www.inchem.org/documents/jecfa/jecmono/v35je14.htm
DB11090,,Guideline-Potassium Intake,https://www.ncbi.nlm.nih.gov/books/NBK132460/
DB11090,,Nitrates in the meat industry,http://www.mapleleaffoods.com/wp-content/themes/maplecorporate/pdf/food%20nutrition%20and%20the%20nitric%20oxide%20pathway%20(chapter%205).pdf
DB11090,,POTASSIUM CHLORIDE,http://www.inchem.org/documents/sids/sids/kchloride.pdf
DB11090,,"Reduction in Dental Hypersensitivity with Nano-Hydroxyapatite, Potassium Nitrate, Sodium Monoflurophosphate and Antioxidants",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378071/
DB11090,,Dietary nitrite and nitrate: a review of potential mechanisms of cardiovascular benefits,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489477/
DB11090,,DailyMed: Dr. Sheffield Sensitive Care (potassium nitrate 5%),https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=702a0dec-64cf-4834-8d80-f3d4f0c08a3a
DB11091,,HYDROGEN PEROXIDE - National Library of Medicine HSDB ... - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+547
DB11091,,Chemical Summary for Hydrogen Peroxide - SSWM,https://www.sswm.info/sites/default/files/reference_attachments/OAK%20RIDGE%20NATIONAL%20LABORATORY%201995%20Chemical%20Summary%20of%20Hydrogen%20Peroxide.pdf
DB11091,,FDA Approved Drug Products: Eskata Hydrogen Peroxide Topical Solution (Discontinued),https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209305s001lbl.pdf
DB11093,,HSDB: Calcium Compounds,https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+6931
DB11094,,Vitamin D Supplementation: An Update,https://www.uspharmacist.com/article/vitamin-d-supplementation-an-update
DB11094,,Sandoz: PediaVit D (vitamin D) oral solution,https://www.sandoz.ca/en/pediavit-dtm-vitamin-d-oral-solution-50ml50-doses-oral-solution
DB11095,,Monograph,https://www.drugs.com/ppa/desirudin.html
DB11095,,FDA label,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021271s006lbl.pdf
DB11096,,FDA,https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079686.pdf
DB11096,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB11096,,Dermapproved,http://dermapproved.com/active-ingredients/meradimate
DB11097,,Electronic Medicines Compendium: Fybogel Orange Monograph,https://www.medicines.org.uk/emc/product/1447
DB11097,,Sigma Aldrich: Psyllium Profile,https://www.sigmaaldrich.com/life-science/nutrition-research/learning-center/plant-profiler/plantago-ovata.html
DB11097,,"European Medicines Agency: Community Herbal Monograph on Plantago afar L. et. Plantago indica L., semen",http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2009/12/WC500018447.pdf
DB11097,,DailyMed: Metamucil (psylllium husk) fiber therapy,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d030b0-df97-4dd6-88ba-e9fe863c95ea
DB11098,,FDA Code of Federal Regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=331&showFR=1
DB11098,,Potassium Bicarbonate Handbook,http://www.armandproducts.com/content/pdfs/PotBiVs6.PDF
DB11098,,Efferk monograph,http://www.efferk.com/images/PIEffer-K25.pdf
DB11098,,TITCK Product Information: Gaviscon Advance oral suspension,https://titck.gov.tr/storage/kubKtAttachments/YEH7z8uHeFCVG.pdf
DB11100,,Toxnet Toxicology Data Network: Allantoin,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7490
DB11100,,TITCK Product Information: Noskar (allium cepa extract/allantoin/heparin sodium) topical gel,https://titck.gov.tr/storage/kubKtAttachments/2QlTzMQuwzXVz.pdf
DB11104,,FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203684s001lbl.pdf
DB11105,,DailyMed: Benzalkonium Chloride - antibacterial hand soap refill liquid Monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e00ec76-8600-1091-e054-00144ff88e88
DB11105,,NIH Toxnet Benzalkonium Chloride Compounds,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+234
DB11105,,The National Institute for Occupational Safety and Health (NIOSH) Benzalkonium Chloride Chemical Safety Card,https://www.cdc.gov/niosh/ipcsneng/neng1584.html
DB11105,,European Medicines Agency: Benzalkonium chloride used as an excipient,http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/10/WC500235907.pdf
DB11105,,Food and Drug Administration: Safety and Effecrtiveness for Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/UCM447035.pdf
DB11105,,Doctoralia: IntimaAzul (benzalkonium chloride) vaginal douche,https://www.doctoralia.co/medicamentos/intima-azul-ducha-vaginal
DB11105,,DailyMed: 0.13% Benzalkonium Chloride instant hand sanitizer,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9a6b624-d6d9-8373-e053-2a95a90a85e3
DB11107,,FDA CFR - Code of Federal Regulations Title 21 Sec. 184.1077 Potassium acid tartrate,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1077
DB11107,,Drugs.com: Phexxi Approval History,https://www.drugs.com/history/phexxi.html
DB11107,,"FDA Approved Drug Products: PHEXXI (lactic acid, citric acid, and potassium bitartrate) vaginal gel",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208352s000lbl.pdf
DB11110,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB11110,,FDA Inactive ingredient search,https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browsebyletter.page&letter=m
DB11110,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50314e6b-c2bf-4e6e-94e8-220044c959d9
DB11110,,Supplements manufacturer,https://www.nowfoods.com/supplements/magnesium-citrate-softgels
DB11112,,Code of federal regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10&SearchTerm=lanolin
DB11112,,NIH: Lanolin on the skin,https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0018933/
DB11112,,Lanolin Ointment,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=115af0c8-a6fa-4d8e-9b22-9912d7fbc9ba
DB11112,,Lanolin MeSH,https://www.ncbi.nlm.nih.gov/mesh?Db=mesh&Cmd=DetailsSearch&Term=%22Lanolin%22%5BMeSH+Terms%5D
DB11112,,Lanolin synthesis reference,https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/lanolin
DB11112,,"Lanolin, Drugs.com",https://www.drugs.com/mtm/lanolin-topical.html
DB11112,,NIH Toxnet Lanolin,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1817
DB11112,,"Final Report of the Safety Assessment for PEG-75 Lanolin, PEG-20 Lanolin, PEG-27 Lanolin, PEG-30 Lanolin, PEG-40 Lanolin, PEG-50 Lanolin, PEG-60 Lanolin, and PEG-85 Lanolin",http://journals.sagepub.com/doi/pdf/10.3109/10915818209021263
DB11112,,LipidBank Wax,http://lipidbank.jp/cgi-bin/detail.cgi?id=WWA2201
DB11112,,"Lanolin Monograph, Epocrates",https://online.epocrates.com/u/1ba5356/Lansinoh+HPA+Lanolin
DB11112,,"Lanolin, Web MD",https://www.webmd.com/drugs/2/drug-77393/lanolin-hydrophilic-cream-topical/details
DB11112,,Contact allergy to lanolin: temporal changes in prevalence and association with atopic dermatitis,https://onlinelibrary.wiley.com/doi/abs/10.1111/cod.12872
DB11112,,An evaluation of the effect ov lanolin in healing nipple injuries,http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-21002008000100002
DB11112,,Alpha Keri Skincare Product Information,https://www.alphakeri.com.au/
DB11112,,TITCK Product Information: Duratears ophthalmic ointment,https://titck.gov.tr/storage/kubKtAttachments/cc1247e451229.pdf
DB11113,,DailyMed: Top Care Castor Oil,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8dce1a1f-e765-9c75-e053-2995a90abf9f
DB11114,,Safety Assessment of Eucalyptus globulus (Eucalyptus) - Derived Ingredients as Used in Cosmetics,https://www.cir-safety.org/sites/default/files/eucalyptus.pdf
DB11114,,Electronic Medicines Compendium: Eucalyptus Oil BP Monograph,https://www.medicines.org.uk/emc/product/4843
DB11114,,Sigma-Aldrich: Eucalyptus oil Profile,https://www.sigmaaldrich.com/life-science/nutrition-research/learning-center/plant-profiler/eucalyptus0.html
DB11115,,"ENSULIZOLE: material safety data sheet - Cymit Quimica, SL",http://www.cymitquimica.com/uploads/products/45/pdf/1530809-msds.pdf
DB11117,,ZINC COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6912
DB11117,,Arkema: Oleris® Undecylenic acid,https://www.arkema.com/en/products/product-finder/product-viewer/Oleris-Undecylenic-acid/
DB11117,,DailyMed: Undecylenic Acid topical antifungal liquid,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b6a8f23-bc1b-4cc3-be84-b91ad0f5e60e
DB11118,,Ammonia - National Library of Medicine HSDB Database - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+162
DB11119,,SODIUM IODIDE - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+750
DB11119,,"Dailymed - IODOPEN SODIUM IODIDE- sodium iodide injection, solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a601734d-e6f4-414e-8a13-f4c0c391b30b
DB11120,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+204
DB11120,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/8006-64-2
DB11121,,US EPA Reregistration Eligibility Decision (RED): Chloroxylenol,https://archive.epa.gov/pesticides/reregistration/web/pdf/3045.pdf
DB11121,,Exponent FDA Consumer Antispetics Rule: FDA Request for Data on Safety and Efficacy of Chloroxylenol,http://www.cleaninginstitute.org/assets/1/Page/American%20Cleaning%20Institute%20Comments%20on%20chloroxylenolProposed%20FDA%20Amendment%20of%20TFM1.pdf
DB11121,,Electronic Medicines Compendium: Dettol (Chloroxylenol) Antiseptic Cream Monograph,https://www.medicines.org.uk/emc/product/5621
DB11121,,NLM Toxnet: Chloroxylenol,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7427
DB11121,,Electronic Medicines Compendium: Dettol (chloroxylenol) Liquid Monograph,https://www.medicines.org.uk/emc/product/5633
DB11123,,SODIUM HYPOCHLORITE - National Library of Medicine Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+748
DB11124,,DailyMed: Asthmanefrin (racepinephrine) solution,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=80480838-832c-4fdd-9f8e-f6f877ae3549&type=display
DB11125,,BENZETHONIUM CHLORIDE - National Library of Medicine HSDB Database,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+567
DB11126,,DRUGS.COM,https://www.drugs.com/pro/calcium-gluconate-injection.html
DB11126,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/calcium_gluconate#section=Therapeutic-Uses
DB11126,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/299-28-5
DB11126,,DRUGS.COM,https://www.drugs.com/mmx/calcium-gluceptate-and-calcium-gluconate.html
DB11126,,TITCK Product Information: Calciles (calcium gluconate/calcium levulinate) solution for injection,https://titck.gov.tr/storage/kubKtAttachments/xlTDn7I69772T.pdf
DB11127,,Selenious Acid PubChem,https://pubchem.ncbi.nlm.nih.gov/compound/selenious_acid#section=Top
DB11127,,Selenium (As selenious acid),https://www.drugs.com/ppa/selenium-as-selenious-acid.html
DB11127,,Selenium overview,https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/selenous-acid
DB11127,,"EPA Label, Selenious Acid",https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0097_summary.pdf
DB11127,,High-dose selenium for critically ill patients with systemic inflammation: Pharmacokinetics and pharmacodynamics of selenious acid: A pilot study,http://www.nutritionjrnl.com/article/S0899-9007(09)00297-4/pdf
DB11127,,"Selenium, URMC Rochester encyclopedia",https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=19&contentid=selenium
DB11127,,"Absorption, distribution, and retention of inhaled selenious acid and selenium metal aerosols in Beagle dogs",https://www.sciencedirect.com/science/article/pii/0041008X83903162
DB11127,,"Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase",https://doi.org/10.1093/carcin/20.9.1657
DB11127,,Distribution of Selenium in Plasma of French Women: Relation to Age and Selenium Status,http://clinchem.aaccjnls.org/content/46/5/731
DB11127,,Interaction between SNPs in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2800981/
DB11127,,Selenium in the prevention of atherosclerosis and its underlying mechanisms,http://pubs.rsc.org/en/content/articlelanding/2017/mt/c6mt00195e#!divAbstract
DB11127,,Selenium Injection,https://www.drugs.com/pro/selenium-injection.html
DB11127,,Selenious acid as a source of selenium added for nutritional purposes to food supplements,https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2009.1009
DB11127,,Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488827/
DB11127,,Application of Sodium Selenite in the Prevention and Treatment of Cancers,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755498/
DB11127,,Selenious Acid Injection,http://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/selenious_acid_injection-m74778.pdf
DB11127,,Selenium Overview,https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/hydrogen-selenide
DB11127,,Selenoprotein P,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763998/
DB11127,,FDA Approved Drug Products: Selenious Acid Injection for intravenous administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209379s000lbl.pdf
DB11127,,AIFA Product Information: Selesyn (sodium selenite pentahydrate) oral solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001562_037309_RCP.pdf&retry=0&sys=m0b1l3
DB11129,,electronic Medicines Compendium (eMC): Otex Ear Drops,https://www.medicines.org.uk/emc/product/299
DB11129,,CFR - Code of Federal Regulations Title 21: Sec. 310.534 Drug products containing active ingredients offered over-the-counter (OTC) for human use as oral wound healing agents.,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=310.534
DB11129,,DailyMed: Earwax Treatment Drops (carbamide peroxide) otic solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7006b786-ec05-44b1-b5b2-be07bc2219da
DB11130,,Chemical and engineering news,https://pubs.acs.org/cen/coverstory/83/8325/8325morphine.html
DB11130,,Encyclopedia,https://www.britannica.com/science/opium
DB11130,,WHO,http://www.who.int/substance_abuse/activities/opium_abuse_and_its_management.pdf
DB11130,,NZIC,https://nzic.org.nz/ChemProcesses/biotech/12C.pdf
DB11130,,FDA Reports,https://www.fda.gov/ohrms/dockets/ac/02/slides/3873S1_08_Katz.ppt
DB11130,,Health partners,https://www.healthpartners.com/ucm/groups/public/@hp/@public/@ime/@content/documents/documents/cntrb_031044.pdf
DB11131,,Oleoresin Capsicum Toxicology Evaluation and Hazard Review,http://prod.sandia.gov/techlib/access-control.cgi/1995/952129.pdf
DB11133,,National Institutes of Health (NIH) Office of Dietary Supplements: Omega-3 Fatty Acids Fact Sheet for Health Professionals,https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
DB11133,,Lovaza FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021654s034lbl.pdf
DB11134,,COPPER(II) OXIDE - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+266
DB11134,,European Food Safety Authority (EFSA): Copper(II) oxide as a source of copper added for nutritional purposes,https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2009.1089
DB11136,,"CHROMIUM, ELEMENTAL - National Library of Medicine HSDB ... - Toxnet - NIH",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+910
DB11136,,CHROMIUM COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6999
DB11136,,Chromium Toxicological Overview - Health Protection Agency - Gov.uk,https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/338694/Chromium_toxicological_overview.pdf
DB11136,,Dietary Supplement Fact Sheet: Chromium,https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/
DB11136,,Dailymed Label: DIVISTA - chromium picolinate capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c485cd-ee30-44f2-be63-bb98f8d1a907
DB11140,,Drugs.com Sodium Chromate CR 51 product label,https://www.drugs.com/pro/sodium-chromate-cr-51.html
DB11143,,TOXNET: Cresol,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+250
DB11143,,"CDC NIOSH: Cresol (o, m, p isomers)",https://www.cdc.gov/niosh/idlh/cresol.html
DB11143,,OCED SIDS UNEP Publications: M/P-Cresol Catgory,http://www.inchem.org/documents/sids/sids/m-p-cresols.pdf
DB11143,,"Interim Specific Ground Water Criterion: o, m, p-Cresol",http://www.state.nj.us/dep/dsr/gw-criteria-pql-public-comment/Cresols.pdf
DB11143,,International Programme On Chemical Safety (IPCS) INCHEM Environmental Health Criteria 168: Cresols,http://www.inchem.org/documents/ehc/ehc/ehc168.htm
DB11143,,IPCS INCHEM: o-cresol,http://www.inchem.org/documents/icsc/icsc/eics0030.htm
DB11143,,IPCS INCHEM: m-cresol,http://www.inchem.org/documents/icsc/icsc/eics0646.htm
DB11143,,IPCS INCHEM: p-cresol,http://www.inchem.org/documents/icsc/icsc/eics0031.htm
DB11145,,IARC Monographs Volume 13,http://monographs.iarc.fr/ENG/Monographs/vol1-42/mono13.pdf
DB11148,,Tesis,https://openaccess.leidenuniv.nl/bitstream/handle/1887/12865/Thesis.pdf?sequence=1
DB11148,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB11150,,Barium Sulfate PubChem,https://pubchem.ncbi.nlm.nih.gov/compound/barium_sulfate
DB11150,,"Barium Sulfate, Drugs.com",https://www.drugs.com/mmx/barium-sulfate.html
DB11150,,"NDA, Barium Sulfate",https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM489008.pdf
DB11150,,FDA Approved Drug Products: E-Z-CAT DRY (barium sulfate) for oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208036s002lbl.pdf
DB11151,,"Sodium Hydroxide, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/sodium_hydroxide
DB11151,,"FDA document, Sodium Hydroxide",https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1763
DB11151,,Sodium Hydroxide Solution,https://www.drugs.com/pro/sodium-hydroxide-solution.html
DB11151,,"EPA, Sodium Hydroxide",https://www3.epa.gov/pesticides/chem_search/reg_actions/reregistration/fs_PC-075603_1-Sep-92.pdf
DB11151,,"Chemical Safety Facts, Sodium Hydroxide",https://www.chemicalsafetyfacts.org/sodium-hydroxide/
DB11151,,SODIUM HYDROXIDE,https://www.nap.edu/read/690/chapter/14#88
DB11151,,Sodium Hydroxide,https://onlinelibrary.wiley.com/doi/pdf/10.1002/3527600418.mb131073e0012
DB11151,,Chlorine and sodium hydroxide,http://scifun.chem.wisc.edu/CHEMWEEK/ChlorineSodiumHydroxide2017.pdf
DB11153,,Evaluation of Topical Potassium Hydroxide Solution for Treatment of Plane Warts,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312655/
DB11153,,Potassium Hydroxide,https://pubchem.ncbi.nlm.nih.gov/compound/potassium_hydroxide
DB11153,,"FDA document, potassium hydroxide",https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1631&SearchTerm=potassium%20hydroxide
DB11153,,Potassium,http://www.druginfosys.com/drug.aspx?drugcode=1964&type=1
DB11153,,"NJ Gov Document, Potassium Hydroxide",http://nj.gov/health/eoh/rtkweb/documents/fs/1571.pdf
DB11153,,Comparison of 5% potassium hydroxide with 10% potassium hydroxide solution in treatment of molluscum contagiosum: A comparative study,http://applications.emro.who.int/imemrf/J_Pak_Assoc_Dermatol/J_Pak_Assoc_Dermatol_2014_24_4_337_341.pdf
DB11153,,Potassium Hydroxide Liquid,https://www.drugs.com/pro/potassium-hydroxide-liquid.html
DB11153,,Potassium hydroxide overview,https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/potassium-hydroxide
DB11153,,Overview of KOH,https://www.sciencedirect.com/topics/medicine-and-dentistry/koh-test
DB11153,,"NIH MeSH search, Potassium Hydroxide",https://www.ncbi.nlm.nih.gov/mesh/68002424
DB11153,,"ECHA information page, Potassium Hydroxide",https://echa.europa.eu/substance-information/-/substanceinfo/100.013.802
DB11153,,Potassium Hydroxide- Continental Chemical,http://continentalchemicalusa.com/oil-gas-exploration-production/potassium-hydroxide/
DB11153,,"InCHEM, Potassium Hydroxide",http://www.inchem.org/documents/sids/sids/potassiumhyd.pdf
DB11155,,FDA bans triclosan and triclocarban in consumer soaps,https://cen.acs.org/articles/94/web/2016/09/FDA-bans-triclosan-triclocarban-consumer.html
DB11155,,FDA issues final rule on safety and effectiveness of antibacterial soaps,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517478.htm
DB11155,,Triclorcarban ToxNet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5009
DB11155,,European Chemicals Agency - Triclorcarban,https://echa.europa.eu/substance-information/-/substanceinfo/100.002.659
DB11155,,Temporal Development of Gut Microbiota in Triclocarban Exposed Pregnant and Neonatal Rats,https://www.nature.com/articles/srep33430
DB11155,,Binding mechanism of triclocarban with human serum albumin: Effect on the conformation and activity of the model transport protein,https://www.sciencedirect.com/science/article/pii/S0167732217339946
DB11155,,Triclocarban and Triclosan Inhibit Human Aromatase via Different Mechanisms,https://www.hindawi.com/journals/bmri/2017/8284097/
DB11155,,Triclocarban,https://www.pharmacompass.com/chemistry-chemical-name/triclocarban
DB11155,,"Investigation of human exposure, metabolism and biological effects of the antibacterial triclocarban",https://pdfs.semanticscholar.org/76e2/4869adc7cd1ca73e43a94b547d7cb42509f8.pdf
DB11155,,"Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells",https://www.sciencedirect.com/science/article/pii/S0887233313000672
DB11155,,"Triclocarban, PuBMED",https://pubchem.ncbi.nlm.nih.gov/compound/Triclocarban
DB11156,,Pharmacokinetics of praziquantel and pyrantel pamoate combination following oral administration in cats,http://journals.sagepub.com/doi/abs/10.1177/1098612X17734065?journalCode=jfma
DB11156,,Pyrantel Pamoate PDR,http://m.pdr.net/drug-summary/Reese--39-s-Pinworm-Medicine-pyrantel-pamoate-2158
DB11156,,CDC for healthcare professionals,https://www.cdc.gov/parasites/pinworm/health_professionals/index.html
DB11156,,MSDS for pyrantel,http://www.sciencelab.com/msds.php?msdsId=9924756
DB11156,,Strongidpaste,https://www.horse.com/ContentFiles/Associated_Content/strongidpaste.pdf
DB11156,,Pyrantel Dosage,https://www.drugs.com/dosage/pyrantel.html
DB11156,,Pyrantel Pamoate,https://reference.medscape.com/drug/pin-rid-pin-x-pyrantel-pamoate-342667
DB11156,,"Pyrantel, Science Direct",https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/pyrantel
DB11156,,Pediatric Ascaris Medication,https://emedicine.medscape.com/article/996482-medication
DB11156,,Summary of product characteristics,http://mri.cts-mrp.eu/download/DE_V_0101_001_FinalSPC.pdf
DB11156,,Pyrantel Pamoate Monograph,https://www.drugs.com/monograph/pyrantel-pamoate.html
DB11156,,Pyrantel MeSH NIH,https://www.ncbi.nlm.nih.gov/mesh?Db=mesh&Cmd=DetailsSearch&Term=D02.886.778.634%5BAll+Fields%5D
DB11156,,Principles and Practice of Infectious Diseases,https://books.google.ca/books?id=BseNCgAAQBAJ&pg=PA525&lpg=PA525&dq=drug+target+for+pyrantel&source=bl&ots=0KHyn8g9MU&sig=UoubwY2uNKIu-jsFyOtQhIU2pwY&hl=fr&sa=X&ved=0ahUKEwi44OG3wo3aAhVPw2MKHacQAuo4ChDoAQhYMAg#v=onepage&q=pyrantel&f=false
DB11156,,Pharmacotherapeutics For Advanced Practice Nurse Prescribers,https://books.google.ca/books?id=2Q5hCgAAQBAJ&pg=PA787&lpg=PA787&dq=pyrantel+excreted+feces+50%25&source=bl&ots=m4H2pjGjOF&sig=9lq5pMb3YdzEmePL4lGyzk-8maI&hl=fr&sa=X&ved=0ahUKEwjZl52Zy43aAhUS2mMKHQUmA1UQ6AEISjAF#v=onepage&q=pyrantel%20excreted%20feces%2050%25&f=false
DB11156,,Delmar Nurse's Drug Handbook 2012 Edition,https://books.google.ca/books?id=bNNtCgAAQBAJ&pg=PA1469&lpg=PA1469&dq=pyrantel+absorption+1-3+h+peak&source=bl&ots=tSCNdeUZY5&sig=kR6IqlsjMSKn4df8SoSyAjibx8A&hl=fr&sa=X&ved=0ahUKEwiQpPrcy43aAhUFz2MKHX1tA1YQ6AEINjAD#v=onepage&q=pyrantel%20absorption%201-3%20h%20peak&f=false
DB11156,,MSD vet manual,https://www.msdvetmanual.com/pharmacology/anthelmintics/pharmacokinetics-of-anthelmintics
DB11156,,DailyMed: Pyrantel pamoate oral suspension,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=133b5e91-7f2f-4af8-8536-c5ecaaf56017
DB11156,,INVIMA Product Information: Vanpar (pirantel pamoate/oxantel pamoate) oral suspension,http://web.sivicos.gov.co/registros/pdf/1337571_2015033324.pdf
DB11157,,Anthralin,https://www.drugs.com/mmx/anthralin.html
DB11157,,"Zithranol, PDR",http://www.pdr.net/drug-summary/Zithranol-RR-anthralin-2822
DB11157,,Anthralin/dithranol in dermatology,https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-4632.2012.05611.x
DB11157,,"PubChem, Anthralin",https://pubchem.ncbi.nlm.nih.gov/compound/anthralin#section=Top
DB11157,,Zithranol-RR,http://www.empr.com/zithranol-rr/drug/3423/
DB11157,,American Academy of Dermatology Recommendations,https://www.aad.org/practicecenter/quality/clinical-guidelines/psoriasis/topical-therapy/recommendations-for-anthralin
DB11157,,NIH.gov Topical Therapies in psoriasis,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518573/
DB11157,,Prophase Definition,https://www.nature.com/scitable/definition/prophase-189
DB11158,,FDA regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1588
DB11158,,Dissolutiontech,http://www.dissolutiontech.com/DTresour/201511Articles/DT201511_A06.pdf
DB11158,,ScienceDirect,https://www.sciencedirect.com/science/article/pii/S0921042396803005
DB11160,,Prescribing Information: Tussionex Suspension and Tablets,http://products.sanofi.ca/en/tussionex.pdf
DB11160,,"DailyMed: Dologesic (Acetaminophen, Phenyltoloxamine citrate, and Ethanol) Oral Liquid",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=738e7767-42de-4076-acf2-9152484c2007
DB11160,,SMPDB: Phenyltoloxamine H1-Antihistamine Action,http://smpdb.ca/view/SMP58916
DB11164,,"DailyMed Label: Bicisate injection, powder, lyophilized, for solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e094cb1d-80fe-4277-b8f4-9817918f8c76
DB11164,,FDA approved drugs,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=020256
DB11164,,WHO,http://www.who.int/medicines/areas/quality_safety/quality_assurance/Technetium99mTc-bicisate-complex-injection-QAS17-736_21092017.pdf
DB11164,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=f9adbcd5-1ac1-42d8-b18a-a76c9204014c&type=pdf&name=f9adbcd5-1ac1-42d8-b18a-a76c9204014c
DB11164,,Heart and stroke foundation,http://www.heartandstroke.ca/stroke/what-is-stroke
DB11166,,ATryn monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed3eaf69-1cbd-4b01-a6fa-1fe02c90c3e1
DB11168,,European Food Safety Authority (EFSA): Opinion on Calcium L-threonate for use as a source of calcium in food supplements,https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2008.866
DB11171,,FDA Code of Federal Regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1307
DB11179,,FDA Approved Drug Products: Drax Exametazime (kit for the preparation of technetium Tc99m exametazime for leukocyte labeling) for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208870Orig1s000Lbl.pdf
DB11180,,Tetrofosmin monograph,https://www3.gehealthcare.com/~/media/documents/us-global/products/nuclear-imaging-agents_non-gatekeeper/clinical%20product%20info/myoview/gehealthcare_myoview-30ml-prescribing-information.pdf?Parent=%7B8676C68D-813E-43A2-BBB8-036FD061A97B%7D
DB11180,,FDA Approved Drug Products: Myoview (Kit for the preparation of technetium Tc99m tetrofosmin injection) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020372s028lbl.pdf
DB11185,,Sulsibenzone,https://pubchem.ncbi.nlm.nih.gov/compound/Sulisobenzone
DB11185,,SULISOBENZONE,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7422
DB11185,,SULISOBENZONE,https://www.ewg.org/skindeep/ingredient/706390/SULISOBENZONE/#.WuyKoi8ZP-Y
DB11185,,"Sulisobezone, U.S. Pharmacopoeia Monograph",http://www.pharmacopeia.cn/v29240/usp29nf24s0_m80090.html
DB11185,,FDA - CFR - Code of Federal Regulations Title 21: PART 352 -- SUNSCREEN DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE [STAYED INDEFINITELY],https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=352.50
DB11185,,ECHA Sulisobenzone toxicity study,https://echa.europa.eu/registration-dossier/-/registered-dossier/10063/7/3/4
DB11185,,"Sulisobenzone, Daily Med Search",https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=SULISOBENZONE
DB11185,,Benzophenone,https://pubchem.ncbi.nlm.nih.gov/compound/benzophenone
DB11185,,"Benzophenone, science direct",https://www.sciencedirect.com/topics/neuroscience/benzophenone
DB11185,,DermNet NZ: Benzophenone Allergy,https://www.dermnetnz.org/topics/allergy-to-benzophenone/
DB11186,,Sanofi: Sedotussin (pentoxyverine citrate) oral solution product information,https://www.apotheke.de/pdf/beipackzettel/02517204/Beipackzettel+Sedotussin+Hustenstiller+30mg%2Fml-30-ml.pdf
DB11186,,AIFA Product Information: Pentossiverina Sanofi (pentoxyverine citrate) oral solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008055_043933_RCP.pdf&retry=0&sys=m0b1l3
DB11186,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB11191,,Cobamamide Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/24892716
DB11191,,Cobamamide Overview,https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/cobamamide
DB11191,,Vitamin B12,https://www.whocc.no/atc_ddd_index/?code=B03BA04&showdescription=yes
DB11191,,Cobamamide,http://www.ebi.ac.uk/chebi/fr/searchId.do;1E0D9C58D62CF2B18E447193C800A132?printerFriendlyView=true&locale=null&chebiId=18408&viewTermLineage=null&structureView=&
DB11191,,Science Labs MSDS Cobamamide,http://www.sciencelab.com/msds.php?msdsId=9923527
DB11191,,Neuroenhancement with Vitamin B12—Underestimated Neurological Significance,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875920/
DB11191,,Treatment of vitamin B12 deficiency–Methylcobalamine? Cyancobalamine? Hydroxocobalamin?—clearing the confusion,https://www.nature.com/articles/ejcn2014165
DB11191,,Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency,https://onlinelibrary.wiley.com/doi/pdf/10.1002/mnfr.201500019
DB11191,,"Cobamamide, Drugs.com",https://www.drugs.com/international/cobamamide.html
DB11200,,ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY,https://www.ewg.org/skindeep/ingredient/716585/ALUMINUM_ZIRCONIUM_OCTACHLOROHYDREX_GLY/#
DB11200,,Aluminum zirconium pentachlorohydrex Gly,https://pubchem.ncbi.nlm.nih.gov/compound/72941670#section=Top
DB11200,,Product Assessment Against Criteria: Antiperspirants,https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/industry-professionals/product-assessment-against-criteria-antiperspirants.html
DB11200,,LABEL: SECRET COOL WATERLILY CLEAR- aluminum zirconium octachlorohydrex gly gel,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40529ae4-72f0-1f97-e054-00144ff8d46c
DB11200,,SECRET ACTIVE COOL INVISIBLE- aluminum zirconium tetrachlorohydrex gly stick,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51c9ade0-cb14-4d56-e054-00144ff8d46c
DB11200,,"Household Product Database, NIH",https://hpd.nlm.nih.gov/cgi-bin/household/brands?tbl=brands&id=4002183
DB11200,,"FDA CFR - Code of Federal Regulations Title 21, PART 350: ANTIPERSPIRANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE",https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=350&showFR=1
DB11200,,Health Canada Document : Chemical Substance - Aluminum zirconium octachlorohydrex glycine,http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredReq.do?id=13702&lang=eng
DB11200,,"Breast Cancer Organization, UK",https://www.breastcanceruk.org.uk/science-and-research/background-briefings/aluminium-salts/
DB11201,,"Menthyl Salicylate, EWG",https://www.ewg.org/skindeep/ingredient/720582/MENTHYL_SALICYLATE/#.Wv9EhC_Mz-Y
DB11201,,Menthyl Salicylate,https://www.webmd.com/drugs/2/drug-18536/methyl-salicylate-menthol-topical/details
DB11201,,Salicylate toxicity,https://www.uptodate.com/contents/salicylate-aspirin-poisoning-in-adults
DB11201,,"Best Practice BMJ, Salicylate poisoning",http://bestpractice.bmj.com/topics/en-us/1129
DB11201,,"Salicylate poisoning, patient info",https://patient.info/doctor/salicylate-poisoning
DB11201,,Medicine.net: menthol and methylsalicylate,https://www.medicinenet.com/methyl_salicylate_and_menthol-topical/article.htm
DB11202,,The Clorox Company: Ingredients Inside Clorox Disinfecting Wipes,https://www.thecloroxcompany.com/en-us/what-were-made-of/ingredients-inside/clorox/clorox-disinfecting-wipes1-citrus-blend-44600017273/
DB11202,,IPCS INCHEM: Quaternary ammonium profile,http://www.inchem.org/documents/pims/chemical/pimg022.htm
DB11221,,Pharmacokinetic and Toxicological Characterization of Repellent DEET and Sunscreen Oxybenzone (2011) - by DJ Fediuk,https://mspace.lib.umanitoba.ca/bitstream/handle/1993/8112/fediuk_daryl.pdf?sequence=1
DB11221,,BENZOPHENONE - National Library of Medicine HSDB Database - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6809
DB11226,,Hallstar: SolaStay S1 Product Profile,https://www.hallstar.com/product/solastay-s1/
DB11228,,HMDB,http://www.hmdb.ca/metabolites/HMDB29925
DB11228,,FDA,https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260473.htm
DB11228,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1198
DB11228,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/9004-67-5
DB11228,,Webmd,http://www.webmd.com/drugs/2/drug-6391/methylcellulose-laxative-oral/details
DB11234,,FDA Packaging label: Shrimp-derived chitosan,https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm337459.pdf
DB11237,,BASG Product Information: Phlogenzym (bromelain/trypsin/rutoside) film-coated tablets for oral use,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-22763&type=DOTC_FACH_INFO
DB11239,,Aluminum sulfate PubChem,https://pubchem.ncbi.nlm.nih.gov/compound/3080712
DB11239,,Aluminium sulphate exposure increases oxidative stress and suppresses brain development in Ross broiler chicks,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560745/
DB11239,,Aluminum Sulfate,https://www.drugs.com/ingredient/aluminum-sulfate.html
DB11239,,"Aluminum Sulfate, Brittanica online",https://www.britannica.com/science/aluminum-sulfate
DB11239,,Aluminum Sulfate Excipient,https://www.drugs.com/inactive/aluminum-sulfate-596.html
DB11239,,Aluminum in Drinking Water,http://apps.who.int/iris/bitstream/handle/10665/75362/WHO_SDE_WSH_03.04_53_eng.pdf;jsessionid=D408B68ACD76B131D7F51835F1F1DD38?sequence=1
DB11239,,HIS STYPTIC PENCIL- aluminum sulfate stick,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c679f9-b082-4a3b-9d26-661300e95271&audience=consumer#
DB11239,,EMA document,http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500010018.pdf
DB11239,,"ToxNet, Aluminum sulfate",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5067
DB11239,,"InChem, Aluminum Sulfate",http://www.inchem.org/documents/ukpids/ukpids/ukpid34.htm
DB11239,,PRIORITY SUBSTANCES LIST ASSESSMENT REPORT,https://www.ec.gc.ca/lcpe-cepa/documents/substances/sa-as/assessment_rpt-eng.pdf
DB11239,,Aluminium Toxicokinetics: An Updated MiniReview,https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.2001.880401.x
DB11239,,Aluminum Sulfate Overview,https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/aluminium-sulfate
DB11239,,"Hazardous Materials Sheet, NJ",http://www.nj.gov/health/eoh/rtkweb/documents/fs/0068.pdf
DB11239,,Formulation and evaluation of potash alum as deodorant lotion and after shaving astringent as cream and gel,https://www.banglajol.info/index.php/ICPJ/article/viewFile/17512/12288
DB11239,,Use of Underarm Cosmetic Products in Relation to Risk of Breast Cancer: A Case-Control Study,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514401/
DB11239,,ASSURED- aluminum sulfate powder,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad067b04-ff57-44ab-a6cb-f524f8294989&audience=consumer
DB11239,,Antiperspirants/Deodorants and Breast Cancer,https://www.cancer.gov/about-cancer/causes-prevention/risk/myths/antiperspirants-fact-sheet
DB11239,,Underarm antiperspirants/deodorants and breast cancer,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797685/
DB11239,,BREAST CANCER AND DEODORANTS/ ANTIPERSPIRANTS: A SYSTEMATIC REVIEW,https://pdfs.semanticscholar.org/2877/4ce8ef9459eac3d0fb8ef8db755aa75dc492.pdf
DB11239,,Influence of Lifestyle Factors on Breast Cancer Risk,https://www.karger.com/Article/Abstract/369571
DB11242,,FDA GRAS Substances: Gelatin,https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm261307.htm
DB11242,,GELATIN—ITS USEFULNESS AND TOXICITY,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2135456/
DB11242,,"Federal code of regulations, Gelatin",https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=189.5
DB11242,,Gelatin-based hydrogels for biomedical applications,https://www.cambridge.org/core/journals/mrs-communications/article/gelatinbased-hydrogels-for-biomedical-applications/C1DA8426E188AEBDBC412B64B7D87BFD
DB11242,,Daily consumption of the collagen supplement Pure Gold Collagen® reduces visible signs of aging,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206255/
DB11242,,"Gelatin Supplements, Medline plus",https://medlineplus.gov/druginfo/natural/1051.html
DB11242,,"MIMS, gelatin",http://www.mims.com/philippines/drug/info/gelatin?mtype=generic
DB11242,,Volume expander,https://www.sciencedirect.com/topics/neuroscience/volume-expander
DB11242,,Plasma Expanders in Practice,http://shoof.co.nz/docs/InFocus_May12.pdf
DB11242,,Intravenous volume replacement: which fluid and why?,http://adc.bmj.com/content/archdischild/67/5/649.full.pdf
DB11242,,Benefits and risks of using gelatin solution as a plasma expander for perioperative and critically ill patients: A meta-analysis,https://www.researchgate.net/publication/221813335_Benefits_and_risks_of_using_gelatin_solution_as_a_plasma_expander_for_perioperative_and_critically_ill_patients_A_meta-analysis
DB11242,,Religious constraints on prescribing medication,https://onlinelibrary.wiley.com/doi/pdf/10.1002/psb.1524
DB11242,,FUNCTIONAL AND BIOACTIVE PROPERTIES OF COLLAGEN AND GELATIN FROM ALTERNATIVE SOURCES: A REVIEW,https://pdfs.semanticscholar.org/f004/71261cc9f93aeda9d5049ec3c7351cd32754.pdf
DB11242,,"Gelatin, Lab Grade",https://beta-static.fishersci.com/content/dam/fishersci/en_US/documents/programs/education/regulatory-documents/sds/chemicals/chemicals-g/S25335.pdf
DB11242,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB11248,,Zinc Gluconate,https://pubchem.ncbi.nlm.nih.gov/compound/452949
DB11248,,NCBI,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113371/
DB11248,,Code of federal regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=182.8988
DB11248,,Zinc Absorption by Young Adults from Supplemental Zinc Citrate Is Comparable with That from Zinc Gluconate and Higher than from Zinc Oxide,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901420/
DB11248,,Zinc Gluconate Toxicity,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1054
DB11248,,"Zinc Gluconate, Anhydrous",http://www.t3db.ca/system/msds/attachments/000/000/802/original/T3D0729.pdf?1413587577
DB11248,,"Zinc gluconate, Drugs.com",https://www.drugs.com/ppa/zinc-gluconate.html
DB11248,,Zinc Medline Plus,https://medlineplus.gov/druginfo/natural/982.html
DB11248,,Drug Info SYS Zinc Gluconate,http://www.druginfosys.com/drug.aspx?drugcode=2238&type=1
DB11248,,"Absorption and metabolism of oral zinc gluconate in humans in fasting state, during, and after a meal",https://link.springer.com/article/10.1007/BF02784604
DB11248,,ReductioninDurationofCommon ColdsbyZincGluconate Lozengesina Double-BlindStudy,"https://www.colorado.edu/intphys/Class/IPHY3700_Greene/TIPS/zinc/Eby,_GA-Yes.pdf"
DB11248,,Zinc Toxicity in Humans,https://pdfs.semanticscholar.org/a9e2/8321ae506e646f32ce59d87b7589851aa7e4.pdf
DB11248,,The pharmacokinetics of zinc from zinc gluconate: a comparison with zinc oxide in healthy men,https://www.researchgate.net/publication/7397767_The_pharmacokinetics_of_zinc_from_zinc_gluconate_a_comparison_with_zinc_oxide_in_healthy_men
DB11251,,FDA Code of Federal Regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=182.3890
DB11251,,National Institute for Health,https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/#h5
DB11251,,Researchgate,https://www.researchgate.net/publication/244357310_Antioxidant_activities_of_tocopherols
DB11254,,DailyMed: S.T.37-hexylresorcinol solution monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d7acca2-aa8a-5272-e813-faab039cc798
DB11254,,Electronic Medicines Compendium: Strepsils (hexylresorcinol) Extra Triple Action Blackcurrant Lozenges Monograph,https://www.medicines.org.uk/emc/product/5601/smpc
DB11254,,Hexylresorcinol: Providing Skin Benefits by Modulating Multiple Molecular Targets,https://www.researchgate.net/publication/283776287_Hexylresorcinol_Providing_Skin_Benefits_by_Modulating_Multiple_Molecular_Targets
DB11254,,NIH Toxnet: Hexylresorcinol Profile,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+566
DB11254,,IPCS INCHEM 4-Hexylresorcinol Profile,http://www.inchem.org/documents/jecfa/jecmono/v35je04.htm
DB11256,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=174005
DB11256,,FDA Center for Drug Evaluation and Research: Summary Review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022532Orig1s000SumR.pdf
DB11256,,Cayman Chemicals Safety Data Sheet,https://www.caymanchem.com/msdss/21616m.pdf
DB11256,,Dailymed L-Methyl-MC-NAC Tablets,https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=177531
DB11265,,"EMA Assessment Report: Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma for oral use",https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-curcuma-xanthorrhiza-roxb-c-xanthorrhiza-d-dietrich-rhizoma_en.pdf
DB11269,,EMA Scientific Committee on Consumer Products (SCCP): OPINION ON Diethylamino hydroxybenzoyl hexyl benzoate,https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_130.pdf
DB11271,,DSM Presents Latest Data on Parsol,https://www.happi.com/contents/view_breaking-news/2010-11-01/dsm-presents-latest-data-on-parsol-slx/
DB11271,,"IJPDerma: International Journal of Parenteral and Dermatology - Sunscreen Actives, An Overview",http://www.ijpderma.com/assets/resources/documents/20170817T0823516353.pdf
DB11271,,Cosmetics Info: Polysilicone-15,http://www.cosmeticsinfo.org/ingredient/polysilicone-15
DB11271,,Ross Organic: Sunscreen Photostability 101,http://www.rossorg.com/sunscreen-photostability-101
DB11271,,Health Canada Approved ingredients list,https://www.canada.ca/en/public-health/services/antibiotic-antimicrobial-resistance/animals/veterinary-antimicrobial-sales-reporting/list-a.html
DB11274,,DIMDI Drug Product Information: Almirid-Cripar (dihydro-alpha-ergocryptine) oral tablets,https://portal.dimdi.de/amispb/doc/2017/02/09/2127755/Of88129d1aae24fe79d74a32e5898dc22.pdf
DB11278,,DL-Methylphedrine Hydrochloride,https://pubchem.ncbi.nlm.nih.gov/compound/13666
DB11278,,"Methylphedrine, DL, Drugs.com",https://www.drugs.com/international/methylephedrine-dl.html
DB11278,,"NIH Toxnet, DL Methylphedrine",https://chem.nlm.nih.gov/chemidplus/rn/18760-80-0
DB11278,,Methylphedrine concentrations in drug ad urine specimens,https://watermark.silverchair.com/22-4-310.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAZ8wggGbBgkqhkiG9w0BBwagggGMMIIBiAIBADCCAYEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMHvBl58PCAh5IVtqRAgEQgIIBUsAFre-k9JzoXFCVGmsHsnRKuW46Ad4sCK1dN9GGaobEaRK1DdpCEw3ZyiJ6Dm0dKrzcPU4c_Y6DnDZD-q7xudRPzrz6NlHoCsflEneNYFg25Lu-tHZ81seowX9n9P66nzU-K_aayGvYnod7uC2_PscJmSNh5YyxY34u6tW1PMTXbUTR9pqstD7gAmJPvD5nO5Uk8D1Q0VGAxzbz7jmqutL8rwpIek2RfhAjRXI-NF_Ru1nE8d-4kGBxfVh5ucWeop_SnbR3NSYWZHRwzDacJPE-MyqMLKkimR1zWPvr_1EJ2iHy2XlAEmhYy04mUr2QGRg-bXBzgw4zA3snuEsgfU03frQAsZgQ-l_EkotnzYf-IpbZy_KdQBTbhIT7AgYRuN8JN3KFWpR9sneEdSeAase_zhUf11bz9NwJlh0hQ3gyE1JspVje0vndhPPL1cqR6RI_
DB11278,,Genome. JP DL-methylphedrine,http://www.genome.jp/dbget-bin/www_bget?dr:D02109
DB11278,,"Daily Med, Pancold S",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52726d93-b3ba-432f-96f6-d03bf9f7b840
DB11278,,Chlorphenamine/Dihydrocodeine/Guaifenesin/Methylephedrine/dl Uses More: https://www.ndrugs.com/?s=chlorphenamine/dihydrocodeine/guaifenesin/methylephedrine/dl More: https://www.ndrugs.com/?s=chlorphenamine/dihydrocodeine/guaifenesin/methylephedrine/dl,https://www.ndrugs.com/?s=chlorphenamine/dihydrocodeine/guaifenesin/methylephedrine/dl
DB11278,,Tossamin Plus,https://www.sdrugs.com/?c=drug&s=tossamin%20plus&ingredient=codeine%20phosphate%20hemihydrate/diphenhydramine%20hydrochloride/methylephedrine%20hydrochloride/noscapine
DB11278,,"Methylphedrine, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/N-Methylephedrine#section=Pharmacology-and-Biochemistry
DB11278,,Family Practice Notebook: Sympathomimetics,https://fpnotebook.com/Pharm/Alternative/Ephdrn.htm
DB11282,,United States Environmental Protection Agency: DEET Profile,https://www.epa.gov/insect-repellents/deet
DB11282,,IPCS INCHEM: DEET Profile,http://www.inchem.org/documents/pims/chemical/deet.htm#SectionTitle:5.1%20Oral
DB11282,,"In Vitro Human Metabolism and Interactions of Repellent N,N-Diethyl-m-Toluamide",https://www.researchgate.net/figure/Primary-in-vitro-metabolites-of-DEET_fig1_11507717
DB11282,,National Pesticide Information Centre: DEET Technical Fact Sheet,http://npic.orst.edu/factsheets/archive/DEETtech.html
DB11282,,"""Mosquito odorant receptor for DEET and methyl jasmonate."" Proceedings of the National Academy of Sciences.",http://www.pnas.org/content/111/46/16592
DB11282,,NIH Toxnet: Diethyltoluamide Profile,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1582
DB11294,,Spherusol Monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77108624-4771-4886-a3e2-b2625c444d1b
DB11300,,EMEA European Medicines Agency Withdrawal Assessment Report for Recothrom (thrombin alpha),http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/001063/WC500076372.pdf
DB11304,,Phenoxyethanol,https://pubchem.ncbi.nlm.nih.gov/compound/2-phenoxyethanol
DB11304,,Phenoxyethanol - Brumer,https://brumer.com/products/phenoxyethanol
DB11304,,Phenoxyethanol: A Globally-Approved Preservative,https://knowledge.ulprospector.com/2532/pcc-phenoxyethanol-globally-approved-preservative/
DB11304,,Health Canada: Phenoxyethanol,http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredReq.do?id=4720&lang=eng
DB11304,,Opinion on Phenoxyethanol - EU Law and Publications,https://publications.europa.eu/en/publication-detail/-/publication/1c728aea-ffde-11e6-8a35-01aa75ed71a1/language-en
DB11304,,pharmacokinetic model of 2-phenoxyethanol and its metabolite phenoxyacetic acid in rats and humans to address toxicokinetic uncertainty in risk assessment,https://www.semanticscholar.org/paper/Development-of-a-physiologically-based-model-of-and-Troutman-Rick/f89ee428f803f27ec66490cc1c4cc3e2a42a01bf
DB11304,,"Simultaneous determination of phenoxyethanol and its major metabolite, phenoxyacetic acid, in rat biological matrices by LC–MS/MS with polarity switching: Application to ADME studies",https://www.sciencedirect.com/science/article/pii/S003991401530031X
DB11305,,"Final Report on the Safety Assessment of Quaternium-18, Quaternium-18 Hectorite, and Quaternium-18 Bentonite",http://journals.sagepub.com/doi/pdf/10.3109/10915818209013148
DB11311,,"FDA Approved Drug Products: BALFAXAR (prothrombin complex concentrate, human-lans) lyophilized powder for solution, for intravenous use (July 2023)",https://www.fda.gov/media/170477/download
DB11312,,FDA Approved Drug Products: Ceprotin (protein C concentration [human]) powder for solution,https://www.fda.gov/media/75033/download
DB11312,,"FDA Approved Drug Products: KCENTRA (Prothrombin Complex Concentrate (Human)) For Intravenous Use, Lyophilized Powder for Reconstitution",https://www.fda.gov/media/85512/download
DB11312,,"FDA Approved Drug Products: BALFAXAR (prothrombin complex concentrate, human-lans) lyophilized powder for solution, for intravenous use (July 2023)",https://www.fda.gov/media/170477/download
DB11321,,"USDA: Full Report (All Nutrients): 04589, Fish oil, cod liver",https://ndb.nal.usda.gov/ndb/foods/show?n1=%7BQv%3D1%7D&fg=&fgcd=&man=&lfacet=&count=&max=25&sort=c&qlookup=&offset=0&format=Full&new=&rptfrm=nl&ndbno=04589&nutrient1=621&nutrient2=629&nutrient3=851&subset=0&totCount=5674&measureby=g
DB11321,,NIH NCCIH Clinical Digest for Health Professionals: Omega-3 Fatty Acids - What the Science Says,https://nccih.nih.gov/health/providers/digest/omega3s-science
DB11323,,"Glycol Salicylate, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/2-Hydroxyethyl_salicylate
DB11323,,Skin Irritation and Pharmacokinetics of Glycol Salicylate Transdermal Patches in Sprague–Dawley Rats,http://abstracts.aaps.org/Verify/AAPS2016/PosterSubmissions/10T1000.pdf
DB11323,,Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies,https://pdfs.semanticscholar.org/c16b/e26a1373f9560453c96473e178b105297c6d.pdf
DB11323,,FAMILY CARE THERA FLEX- menthol glycol salicylate nonivamide tocopherol acetate patch,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9753542-1b08-4dcc-a0f5-299384b44227
DB11323,,SALONPAS,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=724bc4d3-0bc1-4275-a23b-4bbc62fbc0d2
DB11323,,"Salicylates, PubMED",https://emedicine.medscape.com/article/1009987-overview
DB11323,,Aspirin and Other Salicylate Poisoning,https://www.merckmanuals.com/en-ca/professional/injuries-poisoning/poisoning/aspirin-and-other-salicylate-poisoning
DB11323,,Glycol Salicylate,https://www.tabletwise.com/medicine/glycol-salicylate
DB11323,,Glycol Salicylate,http://www.worldofchemicals.com/chemicals/chemical-properties/glycol-salicylate.html
DB11323,,Counter-Irritant,https://www.sciencedirect.com/topics/neuroscience/counterirritant
DB11323,,Counterirritants,http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=counter
DB11323,,Clinical Pharmacokinetics of the Salicylates,https://link.springer.com/article/10.2165/00003088-198510020-00004
DB11324,,Nonivamine,https://pubchem.ncbi.nlm.nih.gov/compound/N-Vanillylnonanamide
DB11324,,Nonivamide/Nicoboxil Ointment in Acute Low Back Pain,https://clinicaltrials.gov/ct2/show/NCT01708915
DB11324,,Capsaicin and nonivamide similarly modulate outcome measures of mitochondrial energy metabolism in HepG2 and 3T3-L1 cells,http://pubs.rsc.org/en/content/articlelanding/2018/fo/c7fo01626c/unauth#!divAbstract
DB11324,,"Nonivamide, a capsaicin analog, increases dopamine and serotonin release in SH‐SY5Y cells via a TRPV1‐independent pathway",https://onlinelibrary.wiley.com/doi/pdf/10.1002/mnfr.201200846
DB11326,,BORIC ACID - National Library of Medicine HSDB Database- Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1432
DB11326,,Boric Acid - National Toxicology Program - NIH,https://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr324.pdf
DB11327,,Dipyrithione,https://www.drugs.com/international/dipyrithione.html
DB11327,,Dipyrithione,https://drugs.ncats.io/ginas/app/substance/9L87N86R9A
DB11327,,PPBD: dipyrithione (Ref: OSY-20),https://sitem.herts.ac.uk/aeru/ppdb/en/Reports/2764.htm
DB11327,,Dipyrithione inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in macrophages and protects against endotoxic shock in mice,https://www.sciencedirect.com/science/article/pii/S0014579308003347
DB11327,,Feix-Sulfur Liquid,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a00ab0c-eb56-4463-9897-90e521b80db5
DB11327,,Dandruff,https://www.mayoclinic.org/diseases-conditions/dandruff/diagnosis-treatment/drc-20353854
DB11327,,Fungicide,https://www.britannica.com/science/fungicide
DB11328,,"SOTRADECOL- tetradecyl hydrogen sulfate (ester) injection, solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1756c28-dcd2-4b49-be62-07ca20682018
DB11328,,"Sotradecol, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/23665772
DB11328,,Sodium tetradecyl sulfate,https://www.sciencedirect.com/topics/neuroscience/sodium-tetradecyl-sulfate
DB11328,,Sodium Tetradecyl Sulfate,https://www.drugs.com/monograph/sodium-tetradecyl-sulfate.html
DB11328,,PDR Sotradecol,http://www.pdr.net/drug-summary/Sotradecol-sodium-tetradecyl-sulfate-878
DB11328,,Evaluation of sodium tetradecyl sulfate and polidocanol as sclerosants for leg telangiectasia based on histological evaluation with clinical correlation,http://journals.sagepub.com/doi/abs/10.1177/0268355516673768
DB11328,,Anaphylactoid Reaction After the Use of Sodium Tetradecyl Sulfate: A Case Report,http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.848.8389&rep=rep1&type=pdf
DB11328,,Drug Approval Package,https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/005970-S22_Sotradecol_toc.cfm
DB11328,,NZ Drug Safe Fibrovein,http://www.medsafe.govt.nz/profs/Datasheet/f/Fibroveininj.pdf
DB11328,,Intralesional 3% Sodium Tetradecyl Sulfate for Treatment of Cutaneous Kaposi's Sarcoma,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276773/
DB11328,,Sodium tetradecyl sulfate actions,https://www.ndrugs.com/?s=sodium%20tetradecyl%20sulfate&t=actions
DB11328,,Sotradecol,http://www.angiodynamics.com/uploads/pdf/120711-044819_Sotradecol%20Dilution%20Chart.pdf
DB11332,,"Sinapultide, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/Sinapultide
DB11332,,"Sinapultide, Pharmacodia",http://en.pharmacodia.com/web/drug/1_14364.html
DB11332,,Sinapultide,http://www.drugfuture.com/chemdata/sinapultide.html
DB11332,,Surfactant respiratory therapy using Surfaxin/sinapultide,http://journals.sagepub.com/doi/pdf/10.1177/1753465808097113
DB11332,,Sinapultide - Windtree Therapeutics,https://adisinsight.springer.com/drugs/800008549
DB11332,,EMA Withdrawal Public Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500069610.pdf
DB11332,,FDA label for Surfaxin,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021746s000lbl.pdf
DB11332,,"KL4 Surfactant, WindTree",http://www.windtreetx.com/kl4-surfactant-technology2/
DB11338,,Drug Infosys: Clove Oil,http://www.druginfosys.com/drug.aspx?drugcode=1272&type=1
DB11338,,"Medicines UK Document, Clove Oil",https://www.medicines.org.uk/emc/product/4817/smpc
DB11338,,Eugenol Overview,https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/eugenol
DB11341,,Ichthyol official website,http://www.ichthyol.com/ichthammol_1.html
DB11345,,CAMPHOR - National Library of Medicine HSDB Database,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+37
DB11348,,HSDB: Calcium Phosphate,http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+879
DB11358,,FDA new dietary ingredients,https://www.fda.gov/Food/DietarySupplements/NewDietaryIngredientsNotificationProcess/ucm109764.htm
DB11358,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB11358,,EMA,http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2012/04/WC500124922.pdf
DB11359,,Monograph,https://pubchem.ncbi.nlm.nih.gov/compound/guaiacol#section=Pharmacology-and-Biochemistry
DB11361,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB11361,,FDA EAFUS,https://www.accessdata.fda.gov/scripts/fcn/fcndetailnavigation.cfm?rpt=eafuslisting&id=212
DB11361,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a001d2e-f076-4bfc-a61c-c8f8d8044fea
DB11361,,EMA Records,http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/herbal/medicines/herbal_med_000030.jsp&mid=WC0b01ac058001fa1d
DB11361,,Vishpha,http://www.vishpha.ua/en/drugs/catalogue/vishpha/ointments/balsamic-liniment-wishnevsky/
DB11361,,EMA Public Assessment,http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2010/01/WC500069013.pdf
DB11361,,Liniment balsamic,https://vision1cycling.com/zdorove/116563-liniment-balzamicheskiy-po-vishnevskomu-za-i-protiv.html
DB11362,,FDA Approved Drug Products: UPTRAVI (selexipag) tablets and injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214275s000lbl.pdf
DB11363,,FDA Approved Drug Products: Alecensa (alectinib) capsules for oral use (April 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf
DB11364,,AIFA: Pidotimod Summary of Product Characteristics,https://drive.google.com/open?id=0B2K5buBGjy5rSHQ2dTFlVk5LazQ
DB11364,,Vademecum: Broncotimod (pidotimod) for oral use,http://co.mivademecum.com/medicamento-broncotimod-id-46335
DB11365,,Senokot Tablet Product Information,https://www.medicines.org.uk/emc/medicine/6883
DB11387,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB11431,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210867
DB11431,,Pnswire,https://www.prnewswire.com/news-releases/us-fda-approves-moxidectin-for-the-treatment-of-river-blindness-300666114.html
DB11431,,Luxembourg Institute of Health,https://www.lih.lu/blog/our-news-1/post/a-new-treatment-against-river-blindness-lih-contributed-to-clinical-trials-for-moxidectin-194
DB11431,,FDA Approved Drug Products: Moxidectin for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210867s001lbl.pdf
DB11477,,"CDC: Notes from the Field: Xylazine, a Veterinary Tranquilizer, Identified as an Emerging Novel Substance in Drug Overdose Deaths — Connecticut, 2019–2020",https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a5.htm
DB11477,,Canadian Centre on Substance Use and Addiction: Xylazine Drug Alert,https://www.ccsa.ca/sites/default/files/2022-07/CCSA-CCENDU-Drug-Alert-Xylazine-2022-en.pdf
DB11482,,FDA Poisonous Plant Database,https://www.accessdata.fda.gov/scripts/plantox/detail.cfm?id=26974
DB11482,,FDA Inactive ingredient search,https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browsebyletter.page&letter=b
DB11482,,Food Additives & Ingredients,https://www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm091048.htm
DB11482,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB11512,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB11516,,"WHO: Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments",https://p2infohouse.org/ref/32/31846.pdf
DB11561,,EMC Summary of Product Characteristics: Medijel (lidocaine hydrochloride/aminoacridine hydrochloride) oral gel,https://www.medicines.org.uk/emc/product/6610/smpc
DB11563,,Sebelipase alfa FDA Approval,http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476013.htm
DB11563,,FDA Approved Drug Products: Kanuma (sebelipase alfa) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125561s013lbl.pdf
DB11563,,EMA Summary of Product Characteristics: Kanuma (sebelipase alfa) concentrate for solution for intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/kanuma-epar-product-information_en.pdf
DB11569,,FDA Approved Drug Products: TALTZ (ixekizumab) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s019lbl.pdf
DB11570,,PADIMATE O - National Library of Medicine HSDB Database,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7169
DB11570,,FDA - CFR - Code of Federal Regulations Title 21: PART 352 -- SUNSCREEN DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE [STAYED INDEFINITELY],https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=352.50
DB11571,,EMEA European Medicines Agency Withdrawal Assessment Report for Recothrom (thrombin alpha),http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/001063/WC500076372.pdf
DB11571,,"DailyMed Label: VISTASEAL (human fibrinogen, human thrombin) kit, for topical use",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8708417-2f74-4dfa-b6f9-ef88f902e0fc
DB11571,,"FDA Approved Drug Products: EVITHROM (Human Thrombin), for topical use",https://www.fda.gov/media/71754/download
DB11572,,EMEA European Medicines Agency Withdrawal Assessment Report for Recothrom (thrombin alpha),http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/001063/WC500076372.pdf
DB11573,,DailyMed: Amerfresh Roll-on Antiperspirant,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30835d44-6b3d-49ef-8bfc-c7a6c1573d06
DB11574,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB11574,,Zepatier FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf
DB11575,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB11575,,"FDA Approved Drug Products: ZEPATIER (elbasvir and grazoprevir) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208261s007lbl.pdf
DB11577,,Indigo Carmine Daily Med,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6f0dfc8-63b1-4bc1-96eb-3cd0c3d5d4c2
DB11577,,FDA Approved Drug Products: BLUDIGO (indigotindisulfonate sodium) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216264s000lbl.pdf
DB11577,,Alphachem: Indigo carmine SDS,https://alphachem.ca//upload/SDS-Products%20-%20H%20-%20K/1523-Indigo%20Carmine%20SDS.pdf
DB11577,,European Food Safety Authority: Scientific Opinion on the re-evaluation of Indigo Carmine (E 132) as a food additive,http://www.cibr.es/ka/apps/cibr/docs/indigo-julio-2014.pdf
DB11580,,"FDA Approved Drug Products: ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use",https://alexion.com/Documents/Ultomiris_USPI.pdf
DB11580,,EMA Summary of Product Characteristics: Ultomiris (ravulizumab) intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf
DB11580,,European Medicines Agency Medicines: Ultomiris (ravulizumab),https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris
DB11580,,ClinicalTrials.gov: Ravulizumab and COVID-19 (NCT04570397),https://clinicaltrials.gov/ct2/show/NCT04570397
DB11580,,"FDA Approved Drug Products: ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous or subcutaneous use (March 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761108s026s031lbl.pdf
DB11581,,"Venetoclax, Safety Sheet",https://lclabs.com/products/v-3579-venetoclax-free-base/sds
DB11581,,FDA Approved Drug Products: Venclexta (venetoclax) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208573s023lbl.pdf
DB11582,,European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection,http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001967.jsp&mid=WC0b01ac058004d5c1
DB11582,,Thiocolchicine EMA label,http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Thiocolchicoside-containing_medicines/WC500155449.pdf
DB11582,,Thiocolchicine Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/Thiocolchicine
DB11582,,Thiocolchicine,http://www.abcam.com/thiocolchicine-ab144374.html
DB11582,,THIOCOLCHICOSIDE AS MUSCLE RELAXANT: A REVIEW,https://www.ijpbs.com/ijpbsadmin/upload/ijpbs_50c8471a463c9.pdf
DB11582,,"To compare the efficacy and safety of fixed dose combination of thiocolchicoside and aceclofenac versus chlorzoxazone, aceclofenac and paracetamol in patients with acute lower backache associated with muscle spasm",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137632/
DB11582,,"The effect of topical thiocolchicoside in preventing and reducing the increase of muscle tone, stiffness, and soreness: A real-life study on top-level road cyclists during stage competition",https://journals.lww.com/md-journal/Fulltext/2017/07280/The_effect_of_topical_thiocolchicoside_in.63.aspx
DB11582,,Neurotransmitters as food supplements: the effects of GABA on brain and behavior,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594160/
DB11582,,GABA AND GLYCINE receptor modulators,https://www.sigmaaldrich.com/life-science/cell-biology/cell-biology-products.html?TablePage=18433831
DB11582,,"hiocolchicoside, 99% (HPLC)",https://aksci.com/item_detail.php?cat=W0078
DB11582,,"Review of the toxicology, pharmacodynamics and pharmacokinetics of thiocolchicoside, a GABA-agonist muscle relaxant with anti-inflammatory and analgesic actions",https://www.researchgate.net/publication/291818675_Review_of_the_toxicology_pharmacodynamics_and_pharmacokinetics_of_thiocolchicoside_a_GABA-agonist_muscle_relaxant_with_anti-inflammatory_and_analgesic_actions
DB11582,,MyHealthBox: Tiocolfen (thiocolchicide/ibuprofen) oral tablets,https://myhealthbox.eu/en/view/2803552/9c3f47234de919aec68cd1cab9ae10e1/leaflet
DB11582,,TITCK Product Information: Adeleks (thiocolchicoside) oral tablets,https://titck.gov.tr/storage/kubKtAttachments/7696cf1b43062.pdf
DB11582,,TITCK Product Information: Adeleks (thiocolchicoside) solution for intramuscular injection,https://titck.gov.tr/storage/kubKtAttachments/ec63367033582.pdf
DB11582,,TITCK Product Information: Fixoline (thiocolchicoside) topical cream,https://titck.gov.tr/storage/kubKtAttachments/22df3d5258364.pdf
DB11582,,Ilac Prospektusu: Tyoflex (thiocolchicoside) topical ointment,https://kt.ilacprospektusu.com/ilac/14733-tyoflex-merhem-yuzde-0-25-kt
DB11583,,FDA history,https://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm207938.xls
DB11583,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB11583,,Netdoctor: Bonjela treatment for mouth ulcers,http://www.netdoctor.co.uk/medicines/mouth-and-teeth/a7835/bonjela/
DB11583,,Current issues in Pharmacy and medical sciences,https://content.sciendo.com/view/journals/cipms/28/2/article-p77.xml
DB11583,,Quaternary ammonium compounds,http://www.inchem.org/documents/pims/chemical/pimg022.htm#PartTitle:6.%20%20KINETICS
DB11583,,FDA Thailand Product Information: Bonjela (choline salicylate/cetalkonium chloride) oral gel,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022290009611C
DB11584,,Pripradrol PubChem,https://pubchem.ncbi.nlm.nih.gov/compound/Pipradrol_hydrochloride
DB11584,,Use of Pripradrol in Obstetrics and Gynecology,http://www.nejm.org/doi/full/10.1056/NEJM195603152541103
DB11584,,"ToxNet, Pripradrol",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+8016
DB11584,,Norepinephrine-dopamine reuptake inhibitor,https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/norepinephrine-dopamine-reuptake-inhibitor
DB11584,,Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP),https://www.tandfonline.com/doi/abs/10.3109/15563650.2012.716158?src=recsys&journalCode=ictx20
DB11584,,NIH Inxight Drugs: Pipradrol,https://drugs.ncats.io/ginas/app/substance/S6I030E0DA
DB11584,,Psychiatric uses of Meratran,https://www.cambridge.org/core/journals/journal-of-mental-science/article/psychiatric-uses-of-meratran/3E82BB0C7B9BAF79D98065ECD971ECCB
DB11584,,Pipradrol and derivatives,https://www.researchgate.net/publication/279946278_Pipradrol_and_Pipradrol_Derivatives
DB11584,,Conditioned Place Preference,https://www.ncbi.nlm.nih.gov/books/NBK5229/
DB11585,,Dermascope: The State of Sunscreen Innovation in 2015,https://www.dermascope.com/scope-this/the-state-of-sunscreen-innovation-in-2015
DB11585,,Skin Therapy Letter: Update on Sunscreens,http://www.skintherapyletter.com/sunscreen/advances-update/
DB11585,,Current Trends in Photoprotection - A New Generation of Oral Photoprotectors,https://www.researchgate.net/profile/Angeles_Juarranz/publication/228352216_Current_Trends_in_Photoprotection-A_New_Generation_of_Oral_Photoprotectors/links/542be3990cf277d58e8a4f3f/Current-Trends-in-Photoprotection-A-New-Generation-of-Oral-Photoprotectors.pdf
DB11585,,PhaMix: Mexoryl SX/XL Sunscreens,https://phamix.com/2016/02/mexoryl-sxxl-sunscreens/
DB11585,,Government of Canada: What is ultraviolet radiation?,https://www.canada.ca/en/health-canada/services/sun-safety/what-is-ultraviolet-radiation.html?wbdisable=true
DB11585,,"Chemical & Engineering News: After More Than A Decade, FDA Still Won't Allow New Sunscreens",https://cen.acs.org/articles/93/i20/Decade-FDA-Still-Wont-Allow.html
DB11586,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB11586,,Health Canada Approved Drug Products: Sunvepra (asunaprevir) capsule,https://pdf.hres.ca/dpd_pm/00037935.PDF
DB11586,,WHO,http://www.who.int/mediacentre/factsheets/fs164/en/
DB11586,,HepatitisCentral,http://www.hepatitiscentral.com/hepatitis-c/
DB11586,,Australian Therapeutic Goods Administration: Australian Public Assessment Report for asunaprevir,https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf
DB11587,,https://pubchem.ncbi.nlm.nih.gov/compound/etafedrine,https://pubchem.ncbi.nlm.nih.gov/compound/etafedrine
DB11587,,"SA Drug label, Nethaprin",http://home.intekom.com/pharm/adcock/neth-exp.html
DB11587,,Etafedrine,https://www.revolvy.com/main/index.php?s=Etafedrine&item_type=topic
DB11587,,Ephedrine,https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0000654/
DB11587,,Ephedrine,http://www.inchem.org/documents/pims/pharm/pim209.htm
DB11587,,Dalmacol,http://sante.canoe.ca/drug/getdrug/dalmacol
DB11588,,CARBON MONOXIDE,https://www.rcsb.org/ligand/CMO
DB11588,,Therapeutic Applications of Carbon Monoxide,https://www.hindawi.com/journals/omcl/2013/360815/
DB11588,,FDA Federal Code of Regulation Document,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=173.350
DB11588,,Diverse Pharmacological Effects of Carbon Monoxide-Releasing Molecules,https://www.cell.com/biophysj/pdf/S0006-3495(17)33911-5.pdf
DB11588,,"Carbon Monoxide: Endogenous Production, Physiological Functions, and Pharmacological Applications",http://pharmrev.aspetjournals.org/content/57/4/585
DB11588,,Regulatory Status of Carbon Monoxide for Meat Packaging,http://www.meatscience.org/docs/default-source/publications-resources/rmc/2006/regulatory-status-of-carbon-monoxide-for-meat-packaging(4).pdf?sfvrsn=27cbbb3_2
DB11588,,FDA Is Urged to Ban Carbon-Monoxide-Treated Meat,http://www.washingtonpost.com/wp-dyn/content/article/2006/02/19/AR2006021901101.html
DB11588,,"NZ document, carbon monoxide in fish",https://www.mpi.govt.nz/dmsdocument/3357-carbon-monoxide-in-fish
DB11588,,Subscribe to our FREE newsletter Subscribe FDA asked to rescind use of carbon monoxide for meats,https://www.foodnavigator-usa.com/Article/2005/11/17/FDA-asked-to-rescind-use-of-carbon-monoxide-for-meats
DB11588,,Modified Atmosphere Packaging (MAP): Microbial Control and Quality,http://articles.extension.org/pages/27345/modified-atmosphere-packaging-map:-microbial-control-and-quality
DB11588,,Afrox Carbon Monoxide MSDS,http://www.afrox.co.za/internet.global.corp.zaf/en/images/Carbon%20Monoxide.doc266_27628.pdf?v=3.0
DB11588,,Myoglobin Chemistry and Meat Color,https://edisciplinas.usp.br/pluginfile.php/3363743/mod_resource/content/1/Paper%20de%20Cor%281%29.pdf
DB11588,,"WHO document, toxokinetics of CO",http://www.who.int/ipcs/publications/ehc/ehc_213_part_3.pdf
DB11588,,Pharmacokinetics and Mechanisms of Action of Carbon Monoxide,https://pdfs.semanticscholar.org/3899/ed954407ca7e2026269f5835634a5c850983.pdf
DB11588,,"METMYOGLOBIN REDUCTION IN BEEF SYSTEMS AS AFFECTED BY AEROBIC, ANAEROBIC AND CARBON MONOXIDE‐CONTAINING ENVIRONMENTS",https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2621.1978.tb07415.x
DB11588,,The binding of carbon monoxide to hemoglobin,http://www.jbc.org/content/243/11/2918.full.pdf
DB11588,,CDC toxicological Profile for Carbon Monoxide,https://www.atsdr.cdc.gov/ToxProfiles/tp201-c2.pdf
DB11588,,Carbon Monoxide Toxicity,https://emedicine.medscape.com/article/819987-overview?pa=Al6yOkIWUQx%2F9ocd8skTnBHDLsu9%2BeTnm4RWozCic5hzkZduVENL%2Bq3t4qQdyBJITux0glhnKYlQwHrKqLk34k3B6KLODm2MpyHuPkYf%2Bs0%3D
DB11588,,Diffusing capacity for carbon monoxide,https://www.uptodate.com/contents/diffusing-capacity-for-carbon-monoxide
DB11588,,"Merck Manuals, Diffusing Lung Capacity",https://www.merckmanuals.com/en-ca/professional/pulmonary-disorders/tests-of-pulmonary-function-pft/measurement-of-gas-exchange
DB11588,,Praxair website,http://www.praxair.com/gases/buy-carbon-monoxide-gas
DB11589,,"Neon, Elemental - National Library of Medicine HSDB Database - Toxnet",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7916
DB11589,,FDA Code of Federal Regulations (CFR) Title 21 Sec. 868.1670 Neon gas analyzer,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=868.1670
DB11590,,Thimerosal and Vaccines,https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228
DB11590,,"Thimerosal, Pubchem",https://pubchem.ncbi.nlm.nih.gov/compound/thimerosal
DB11590,,Questions about Vaccines,https://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm070430.htm
DB11590,,54-64-8(Thimerosal) Product Description,https://www.chemicalbook.com/ChemicalProductProperty_US_CB4227430.aspx
DB11590,,Thimerosal-Containing Vaccines and Autism: A Review of Recent Epidemiologic Studies,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018252/
DB11590,,Toxic Effects of Mercury on the Cardiovascular and Central Nervous Systems,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395437/
DB11590,,Thimerosal [54-64-8],https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/thimerosal_508.pdf
DB11590,,Toxicokinetics of Mercury after Long-Term Repeated Exposure to Thimerosal-Containing Vaccine,https://watermark.silverchair.com/kfr009.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAakwggGlBgkqhkiG9w0BBwagggGWMIIBkgIBADCCAYsGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMW0bWnQIT2cgCI9grAgEQgIIBXConbxAIybSm8nt9sq3XLD6FXwk5iR6JvWmt0TZ_eNo1i23x9WAeA27ZgFUJjbtsNrf_SPnPqljOSDTHviFNpDedT1VXht8CrynwJnGIxKgYSgTlvvLMTp529pd4W1rfpurel-Dtb0SEV2z7S5DC8sgbttUwVZldRaQX-BnhUB80qyNopJumFasQtCI2fv1mVs8_jcnECqFbIHY-QMKCcsSB9VYf1hNwnF0sNqPWBVjl-bP8Za1Wjq01NGA9qQUhdZ92c5jGmyFRBhZdbxmOC-9VzwcefYnWxb3C-5DbmOgg7dy3E9o-7JKuOqJWR4Earir-bepLCUqER5TQwzJ-P3XMEWqkuZeVDC7E5mfneV-uVSk7pFVKxLYfkDxma_e-s0xwm2G0DKCPUG2gAMaOcxTaRM2ybi3dOf-X_Hks3ZhQbocEy3ngvPbkmNmnDGzHK67asKvJr9LN27wFdQ
DB11590,,https://www.researchgate.net/publication/51732698_Administration_of_Thimerosal_to_Infant_Rats_Increases_Overflow_of_Glutamate_and_Aspartate_in_the_Prefrontal_Cortex_Protective_Role_of_Dehydroepiandrosterone_Sulfate,https://www.researchgate.net/publication/51732698_Administration_of_Thimerosal_to_Infant_Rats_Increases_Overflow_of_Glutamate_and_Aspartate_in_the_Prefrontal_Cortex_Protective_Role_of_Dehydroepiandrosterone_Sulfate
DB11590,,"Thimerosal, an overview",https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/thiomersal
DB11590,,Thimerosal in Flu Vaccine,https://www.cdc.gov/flu/protect/vaccine/thimerosal.htm
DB11590,,Thimerosal and Animal Brains: New Data for Assessing Human Ethylmercury Risk,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1280369/
DB11590,,"Thimerosal: Clinical, epidemiologic and biochemical studies",https://www.sciencedirect.com/science/article/pii/S0009898115001023
DB11590,,The Thimerosal Controversy,https://vtechworks.lib.vt.edu/bitstream/handle/10919/80308/media_aimee-2.pdf?sequence=1&isAllowed=y
DB11590,,A systematic study of the disposition and metabolism of mercury species in mice after exposure to low levels of thimerosal (ethylmercury),https://www.sciencedirect.com/science/article/pii/S0013935114002400
DB11590,,Toxicity of ethylmercury (and Thimerosal): a comparison with methylmercury,https://www.ncbi.nlm.nih.gov/pubmed/23401210
DB11590,,Mercury,http://enhs.umn.edu/current/5103_spring2003/mercury/mercdose.html
DB11590,,The toxicology of Mercury,https://watermark.silverchair.com/labmed33-0614.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAbQwggGwBgkqhkiG9w0BBwagggGhMIIBnQIBADCCAZYGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMsxyoo6ayNnavpRMYAgEQgIIBZwQ2AC4ARl-zeCYCa2MQcJAd1AkmoMK8ptLgKM9mBUBwirzWPTlFbE5wj9NMdzL8CS0Op19jzNhFCesfDlJPBce-OLrUnmUvT42HIhVtRptl68FzRpK7wHWZXsLO70kIvFnxhtV5GVf_O-S0OcIjX3BNjBOoPj7o5F-QuMhIILw5_Om7TXxyCLkS3IRTug9kahcrc6g3Hwo4pprHSocAK5z8-gGhBVbzJGtMtuGpbfuJ0j-5p2FmSA36w1E5vv1hEhdLB6OMvCBS_9YbHU2STapL0l4x2lZSzvGY3OfNu7JiM_5vFiIHaUa1MaHRGy2ymEe2ibQ1NCi31tGvnqPix2tumsBqVIMcaHyERB1fhZC4pQ-KXqj8ZGo_atoMGlHQKYJRvJMAXWTEjaPpUTaEm8vBJHKp2hSazSTt_mUSsSQisOKZKw2x88VbK6Bzy4GRcZiLOuiAEIuXQ0JigH9gE0m3hcdl4tcU
DB11590,,The Toxicology of Mercury,https://www.hindawi.com/journals/jt/2012/373678/
DB11590,,Sigma Aldrich Thimerosal,https://www.sigmaaldrich.com/catalog/product/aldrich/e35257?lang=en&region=CA
DB11590,,Identification and distribution of mercury species in rat tissues following administration of Thimerosal or methylmercury,https://www.researchgate.net/publication/43131971_Identification_and_distribution_of_mercury_species_in_rat_tissues_following_administration_of_Thimerosal_or_methylmercury
DB11590,,Molecular Interactions with Mercury in the Kidney,http://pharmrev.aspetjournals.org/content/52/1/113
DB11590,,Material Safety Data Sheet Thimerosal MSDS,http://www.sciencelab.com/msds.php?msdsId=9925236
DB11590,,World Health Organization: Thiomersal vaccines,https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/thiomersal-and-vaccines/thiomersal-vaccines
DB11591,,Health Canada Approved Drug Products: Blexten (Bilastine) Tablets,https://pdf.hres.ca/dpd_pm/00048706.PDF
DB11595,,FDA Approved Drug Products: Atezolizumab Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s014lbl.pdf
DB11595,,Roche News Release: Tecentriq as adjuvant treatment for NSCLC,https://www.roche.com/media/releases/med-cor-2021-10-15b.htm
DB11595,,European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer,https://www.globenewswire.com/news-release/2022/06/09/2459297/0/en/European-Commission-approves-Roche-s-Tecentriq-as-adjuvant-treatment-for-a-subset-of-people-with-early-stage-non-small-cell-lung-cancer.html
DB11595,,BioSpace: Roche Withdraws Tecentriq for Bladder Cancer Indication,https://www.biospace.com/article/genentech-withdraws-tecentric-for-bladder-cancer-indication/
DB11595,,"FDA Approved Drug Products: TECENTRIQ (atezolizumab) injection, for intravenous use (December 2022_2)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf
DB11595,,FDA Approved Drug Products: Tecentriq (atezolizumab) injection for intravenous use (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761034s049s051lbl.pdf
DB11596,,product info,http://www.rxlist.com/levoleucovorin-drug/clinical-pharmacology.htm
DB11596,,product info,http://davisplus.fadavis.com/3976/meddeck/pdf/levoleucovorincalcium.pdf
DB11597,,Rhophylac Summary of Basis for Approval,https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM119475.pdf
DB11597,,WinRho Product information,https://www.fda.gov/downloads/ApprovedProducts/UCM198717.pdf
DB11597,,RhoGam (Rho(D) Immune Globulin intramuscular injection) product information,http://www.ctint.org/inserts/RhoGam_insert.pdf
DB11598,,FDA label,https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM134045.pdf
DB11601,,Tubersol (Tuberculin Purified Protein Derivative) product information,https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm114924.pdf
DB11601,,World Health Organization Model List of Essential Medicines (19th List),http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
DB11602,,Cellosize product information,http://www.dow.com/assets/attachments/industry/building_construction/Cellosize_brochure.pdf
DB11603,,FDA Approved Drug Products: KEDRAB [Rabies Immune Globulin (Human)] solution for wound infiltration and intramuscular injection,https://www.fda.gov/media/106795/download
DB11605,,Myrrh Monograph Natural Medicines Database,"https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=570"
DB11606,,"FDA Approves Baxter's OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A",https://www.baxter.com/news-media/newsroom/press-releases/2014/10_24_14_obizur.page
DB11606,,Obizur Product Information,http://www.guildlink.com.au/gc/ws/zi/pi.cfm?product=zipobizu10317
DB11607,,"FDA Approved Drug Products: Eloctate (Antihemophilic Factor (Recombinant), Fc Fusion Protein) powder for intravenous injection",https://www.fda.gov/media/88746/download
DB11608,,"FDA Approved Drug Products: ALPROLIX [coagulation factor IX (recombinant), Fc fusion protein], lyophilized powder for solution, for intravenous injection",https://www.fda.gov/media/88119/download
DB11610,,KEGG: Oxilofrine,http://www.genome.jp/dbget-bin/www_bget?dr:D08314
DB11611,,FDA Clinical Pharmacology and Biopharmaceutics Review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf
DB11611,,FDA Approved Drug Products: Xiidra (lifitegrast) ophthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208073s002lbl.pdf
DB11613,,Epclusa FDA Approval Announcement,http://www.gilead.com/news/press-releases/2016/6/us-food-and-drug-administration-approves-gileads-epclusa-sofosbuvirvelpatasvir-for-the-treatment-of-all-genotypes-of-chronic-hepatitis-c
DB11613,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB11613,,FDA Approved Drug Products: Epclusa (sofosbuvir and velpatasvir) tablets or pellets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208341s017lbl.pdf
DB11619,,Gestrinone,http://www.druginfosys.com/drug.aspx?drugcode=1462&type=1
DB11619,,Gestrinone Pub Chef,https://pubchem.ncbi.nlm.nih.gov/compound/Gestrinone
DB11619,,Therapeutic effects of mifepristone combined with Gestrinone on patients with endometriosis,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103146/
DB11619,,Australian Gestrinone Prescriber Article,https://www.nps.org.au/australian-prescriber/articles/gestrinone
DB11619,,Gestrinone MIMS label,http://www.mims.com/india/drug/info/gestrinone?type=full&mtype=generic
DB11619,,"Approved Product Information, Dimetriose",https://gp2u.com.au/static/pdf/D/DIMETRIOSE-PI.pdf
DB11619,,Evolution of medical treatment for endometriosis: back to the roots?,https://watermark.silverchair.com/dmm015.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAaYwggGiBgkqhkiG9w0BBwagggGTMIIBjwIBADCCAYgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMmPqRMgd4-VnwfGbaAgEQgIIBWX72sDg7T9ge-XkZKPa1N7eDeq6yvLyeWRH625GyAVqNequbpH8nYdPB4DLzZlXv0VQqGkoPC0x7h1ly1RxX3lU-vexntnel51tijAuPa55BX4yqYKMFMQabKNlH0ytKlk1DH_A0XMtpnoKjWgIyBRD5V0GRSxZZ6FfwxkCUYUt1h2QrStHmXb9UP2onsSAYlNcb6Yxak0UR-lxTx86JuVssRYShkoCyFAyi_isHS2Zg_vIwlKSMuDEvONVs511cV2yucUhl4KrFeQmeF4FmpEPXt1PAaWJcqgjgEGIKnoYgYF8CjxuL-ueLPirVjHjVqg2WxhiaiqPVQkuOESyzLsx8srBBYfeurKC0iL3hGLoBzoozzJRRnX3rfeQcoYK7LzGt2g1Ugyf4RZ9ziBgW8OoWn21MzobRr5chXOi48fUI-D00WmkZMEnvufxPqmFeBCG3YvTvX0QUhQ
DB11619,,Gestrinone,https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1868702
DB11620,,AIFA Product Information: Nerixia (neridronic acid) for intravenous injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000972_035268_FI.pdf&retry=0&sys=m0b1l3
DB11621,,DRUGS.COM,https://www.drugs.com/monograph/varicella-zoster-immune-globulin.html
DB11621,,Virizig,http://varizig.com/capage/_uploads/documents/VariZIG_approved_PM_Jan_2008_English.pdf
DB11626,,EMA: Tasonermin Scientific Discussion,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000206/WC500052375.pdf
DB11626,,EMA Summary of Product Characteristics: Beromun (tasonermin) powder for solution for infusion,https://www.ema.europa.eu/en/documents/product-information/beromun-epar-product-information_en.pdf
DB11627,,Engerix-B Monograph,http://ca.gsk.com/media/590068/engerix-b.pdf
DB11627,,FDA Approved Products: Recombivax HB (hepatitis B) vaccine,https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/package-insert-recombivax-hb.pdf
DB11630,,EMA: Temoporfin Scientific Discussion,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000318/WC500024394.pdf
DB11632,,Opicapone:once-daily adjunctive therapy for Parkinson’s disease,https://onlinelibrary.wiley.com/doi/pdf/10.1002/psb.1543
DB11632,,Clinical pharmacology review of opicapone for the treatment of Parkinson's disease,https://www.futuremedicine.com/doi/10.2217/nmt-2016-0022
DB11632,,EMA assessment report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002790/WC500209538.pdf
DB11632,,Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853535/
DB11632,,Summary of Product Characteristics: Ongentys (opicapone) oral capsules,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002790/WC500209536.pdf
DB11632,,"Pharmacological Profile of Opicapone, a Third Generation Nitrocatechol COMT Inhibitor, in the Rat",https://www.fasebj.org/doi/abs/10.1096/fasebj.29.1_supplement.771.15
DB11632,,"FDA Approved Drug Products: ONGENTYS (opicapone) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf
DB11633,,"EMA Label: Cresemba, Isavuconazole - European Medicines Agency - Europa EU",http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002734/WC500196128.pdf
DB11634,,EMA Summary of Product Characteristics: BindRen (colestilan) for oral use,https://www.ema.europa.eu/en/documents/product-information/bindren-epar-product-information_en.pdf
DB11635,,EMA Summary Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000920/WC500047919.pdf
DB11635,,Cholestasis,https://www.merckmanuals.com/en-ca/home/liver-and-gallbladder-disorders/manifestations-of-liver-disease/cholestasis
DB11635,,"Emedicine, Cholestasis",https://emedicine.medscape.com/article/927624-overview
DB11635,,"Tocophersolan, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/Tocophersolan
DB11635,,Parmentier document,http://www.parmentier.de/gpfneu/english/tpgs.php
DB11635,,Dosage and formulation issues: oral vitamin E therapy in children,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805799/
DB11635,,"Scottish Medicines Document, Tocofersolan",https://www.scottishmedicines.org.uk/files/advice/tocofersolan_Vedrop_FINAL_APRIL_2011_for_website.pdf
DB11635,,"MSDS, Santa Cruz",http://datasheets.scbt.com/sds/aghs/en/sc-474339.pdf
DB11635,,Vitamin E Regulatory Mechanisms,https://www.annualreviews.org/doi/abs/10.1146/annurev.nutr.27.061406.093819
DB11635,,α-TOCOPHEROL β-OXIDATION LOCALIZED TO RAT LIVER MITOCHONDRIA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818260/
DB11635,,EMA Summary of Product Characteristics: Vedrop (tocofersolan) oral solution,https://www.ema.europa.eu/en/documents/product-information/vedrop-epar-product-information_en.pdf
DB11637,,"Deltyba, INN-Delamanid - European Medicines Agency - Europa EU",http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002552/WC500166232.pdf
DB11638,,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf
DB11638,,WHO: Guidelines for the Treatment of Malaria 3rd Edition,http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1&ua=1
DB11638,,EMA Summary of Product Characteristics: Eurartesim (piperaquine tetraphosphate/artenimol) oral tablets,https://www.ema.europa.eu/en/documents/product-information/eurartesim-epar-product-information_en.pdf
DB11639,,EMA Label: InductOs Summary of Product Characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000408/WC500032317.pdf
DB11640,,Harvard Law Blog: Jacobus and Catalyst Continue to Race for Approval of LEMS Drug,http://blogs.harvard.edu/billofhealth/2016/02/22/jacobus-and-catalyst-approval/
DB11640,,US FDA,https://www.drugs.com/newdrugs/fda-approves-firdapse-amifampridine-lambert-eaton-myasthenic-syndrome-4875.html
DB11640,,"FDA NEWS RELEASE: FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder",https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder
DB11640,,FDA Approved Drug Products: RUZURGI (amifampridine) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf
DB11640,,FDA Approved Drug Products: FIRDAPSE (amifampridine) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208078s007lbl.pdf
DB11640,,FDA Approved Drug Products: FIRDAPSE (amifampridine) tablets 2022,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208078s008lbl.pdf
DB11640,,EMA Public Assessment Report: Zenas (INN-amifampridine),https://www.ema.europa.eu/en/documents/assessment-report/firdapse-epar-public-assessment-report_en.pdf
DB11641,,EMA: Vinflunine Public Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000983/WC500039919.pdf
DB11641,,EMA Label (SUMMARY OF PRODUCT CHARACTERISTICS): Javlor,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000983/WC500039604.pdf
DB11642,,"FDA Approved Drug Products: WAKIX (pitolisant) tablets, for oral use (August 2019)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0211150s000lbl.pdf
DB11642,,Harmony Biosciences: Wakix (pitolisant) Safety data sheet,https://www.harmonybiosciences.com/static/Safety-Data-Sheet.808d8a4b.pdf
DB11642,,FDA Center for Drug Evaluation and Research: Pitolisant Non-clinical Review(s),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000PharmR.pdf
DB11642,,FDA Approved Drug Products: WAKIX (pitolisant) tablets for oral use (December 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211150s003lbl.pdf
DB11642,,EMA Approved Drug Products: Wakix (pitolisant) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/wakix-epar-product-information_en.pdf
DB11642,,"FDA Approved Drug Products: WAKIX (pitolisant) tablets, for oral use (June 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211150s005s006lbl.pdf
DB11644,,Tafamadis SmPC EMA,https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf
DB11644,,FDA Approved Drug Products: Vyndaqel Tafamidis Meglumine Oral Capsules,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211996s000,212161s000lbl.pdf"
DB11652,,FDA approved products: Tukysa (tucatinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf
DB11652,,"FDA News Release: FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer",https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-drug-under-international-collaboration-treatment-option-patients-her2
DB11652,,"FDA Approved Drug Products: TUKYSA (tucatinib) tablets, for oral use (January 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf
DB11653,,FDA Approved Drug Products: Bremelanotide Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
DB11656,,BPOM Drug Information: Rebamipide for oral use,http://pionas.pom.go.id/monografi/rebamipid
DB11675,,Allen Pharma: Digesal (mosapride citrate) oral tablets,https://allenpharma.com.co/producto/digesal/
DB11676,,Coronavirus treatment: Vaccines/drugs in the pipeline for Covid-19,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
DB11676,,BioCryst Initiates Phase 1 Clinical Trial of Galidesivir,http://ir.biocryst.com/news-releases/news-release-details/biocryst-initiates-phase-1-clinical-trial-galidesivir
DB11676,,Galidesivir - BioCryst,https://www.biocryst.com/our-program/galidesivir/
DB11677,,FDA Approved Drug Products: Dojolvi Triheptanoin Oral Liquid,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213687s000lbl.pdf
DB11678,,EMA Summary of Product Characteristics: Trecondi (treosulfan) powder for solution for infusion,https://www.ema.europa.eu/en/documents/product-information/trecondi-epar-product-information_en.pdf
DB11679,,"FDA Approved Drug Products: FRUZAQLA™ (fruquintinib) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf
DB11679,,FDA approves fruquintinib in refractory metastatic colorectal cancer,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancer
DB11682,,GSK: GSK reports outcome from US FDA Advisory Committee meeting on daprodustat for anaemia of CKD,https://www.gsk.com/en-gb/media/press-releases/gsk-reports-outcome-from-us-fda-advisory-committee-meeting-on-daprodustat-for-anaemia-of-ckd/
DB11682,,"FDA Approved Drug Products: JESDUVROQ (daprodustat) tablets, for oral use",https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Jesduvroq/pdf/JESDUVROQ-PI-MG.PDF
DB11682,,FDA News Release: FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-anemia-caused-chronic-kidney-disease-adults-dialysis
DB11689,,FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf
DB11689,,NIH National Cancer Institute: Clinical Trials Using Selumetinib,https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/selumetinib
DB11689,,Health Canada Approved Drug Products: KOSELUGO (Selumetinib) Oral Capsules,https://pdf.hres.ca/dpd_pm/00067226.PDF
DB11689,,"FDA: FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas",https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas
DB11691,,FDA Approved Drug Products: Symproic (naldemidine tosylate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208854s002lbl.pdf
DB11693,,Aurinia Pharmaceuticals Press Release: FDA Approves Aurinia Pharmaceuticals Lupkynis,https://ir.auriniapharma.com/press-releases/detail/210/fda-approves-aurinia-pharmaceuticals-lupkynis
DB11693,,"FDA Approved Products: LUPKYNIS (voclosporin) capsules, for oral use",https://d1io3yog0oux5.cloudfront.net/auriniapharma/files/pages/lupkynis-prescribing-information/FPI-0011+Approved+USPI++MG.pdf
DB11693,,Toronto Research Chemicals MSDS: Voclosporin,https://www.trc-canada.com/prod-img/MSDS/V678502MSDS.pdf
DB11693,,EMA Assessment Report: Luveniq (voclosporin) oral capsules,https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-luveniq_en.pdf
DB11693,,Aurinia Pharmaceuticals press release: Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil,https://ir.auriniapharma.com/press-releases/detail/160
DB11693,,EMA CHMP Positive Opinion: Lupkynis (voclosporin),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/lupkynis
DB11696,,EMC Summary of Product Characteristics: Hidrasec (racecadotril) granules for oral suspension,https://www.medicines.org.uk/emc/product/5065/pil
DB11697,,FDA Approved Drug Products: Vonjo (pacritinib) capsules for oral use,https://www.ctibiopharma.com/wp-content/uploads/2022/03/VONJO_PI_02-2022.pdf
DB11697,,National Organization for Rare Disorders: Primary Myelofibrosis,https://rarediseases.org/rare-diseases/primary-myelofibrosis/
DB11697,,BioSpace News: CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia,https://www.biospace.com/article/releases/cti-biopharma-announces-fda-accelerated-approval-of-vonjo-pacritinib-for-the-treatment-of-adult-patients-with-myelofibrosis-and-thrombocytopenia/?s=74
DB11699,,product info,https://pubchem.ncbi.nlm.nih.gov/compound/TROPISETRON_HCl#section=Pharmacology-and-Biochemistry
DB11699,,Monograph,http://www.medsafe.govt.nz/profs/Datasheet/t/tropisetronaftinj.pdf
DB11699,,MSDS,http://www.abcam.com/ps/Products/120/ab120156/Msds/ab120156_CLP1_EN.pdf
DB11699,,Article,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014558/
DB11699,,TITCK Product Information: Navoban (tropisetron) for oral use,https://titck.gov.tr/storage/kubKtAttachments/837de00e16262.pdf
DB11699,,TITCK Product Information: Navoban (tropisetron) for intravenous injection,https://titck.gov.tr/storage/kubKtAttachments/09ec041772023.pdf
DB11700,,FDA: Approval Letter for Imcivree (Setmelanotide),https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/213793Orig1s000ltr.pdf
DB11700,,FDA Press Announcements: FDA approves first treatment for weight management for people with certain rare genetic conditions,https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions
DB11700,,EMA Public Summary of Opinion on Orphan Designation: Setmelanotide,https://www.ema.europa.eu/en/documents/orphan-review/eu/3/18/2101-public-summary-opinion-orphan-designation-setmelanotide-treatment-leptin-receptor-deficiency_en.pdf
DB11700,,FDA Approved Drug Products: Imcivree (Setmelanotide) Subcutaneous Injection,https://www.rhythmtx.com/IMCIVREE/prescribing-information.pdf
DB11700,,"FDA Approved Drug Products: IMCIVREE (setmelanotide) injection, for subcutaneous use (June 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213793s001lbl.pdf
DB11700,,EMA Summary of Product Characteristics: Imcivree (setmelanotide) solution for injection,https://www.ema.europa.eu/en/documents/product-information/imcivree-epar-product-information_en.pdf
DB11700,,Health Canada Approved Drug Products: IMCIVREE (setmelanotide) Subcutaneous Injection,https://rhythmtx.ca/wp-content/uploads/2023/05/IMCIVREE-Product-Monograph-EN.pdf
DB11703,,Lymphoma Research Foundation's Getting the Facts: Mantle Cell Lymphoma - Relapsed/Refractory,https://lymphoma.org/wp-content/uploads/2018/04/MCL-Relapsed_Refractory.pdf
DB11703,,Astra Zeneca Press Release: US FDA Approves Astrazeneca's Calquence for Adult Patients with Previously-Treated Mantle Cell Lymphoma,https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html#!
DB11703,,FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf
DB11703,,FDA Approved Drug Products: Calquence (acalabrutinib) tablets for oral use,https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e2a005a7-65a0-4388-a671-dc887815a938/e2a005a7-65a0-4388-a671-dc887815a938_viewable_rendition__v.pdf
DB11703,,Bloomberg: CALQUENCE (acalabrutinib) tablet formulation approved in the US across current indications,https://www.bloomberg.com/press-releases/2022-08-05/calquence-acalabrutinib-tablet-formulation-approved-in-the-us-across-current-indications
DB11705,,EMC Summary of Product Characteristics: Iomeron (iomeprol) solution for injection,https://www.medicines.org.uk/emc/product/3894/smpc
DB11712,,Cystic fibrosis news,https://cysticfibrosisnewstoday.com/tezacaftor-vx-661-for-cystic-fibrosis
DB11712,,Vertex news,http://investors.vrtx.com/releasedetail.cfm?releaseid=1047092
DB11712,,Vertex news,https://www.vrtx.com/story/fda-approves-symdeko
DB11712,,Vertex news,http://investors.vrtx.com/releasedetail.cfm?releaseid=1038173
DB11712,,"FDA Approved Drug Products: SYMDEKO (tezacaftor/ivacaftor) tablets; (ivacaftor) tablets, for oral use (December 2020)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210491s007lbl.pdf
DB11712,,FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s002s003lbl.pdf
DB11712,,NIH Medline Tezacaftor/Ivacaftor,https://medlineplus.gov/druginfo/meds/a618022.html
DB11712,,"Pharmacology review, FDA",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210491Orig1s000PharmR.pdf
DB11712,,"Monograph, Tezacaftor/Ivacaftor",https://pdf.hres.ca/dpd_pm/00046145.PDF
DB11712,,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf
DB11712,,"FDA Approved Drug Products: TRIKAFTA® (elexacaftor, tezacaftor, and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use May 2023",https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf
DB11712,,"FDA Approved Drug Products: SYMDEKO™ (tezacaftor/ivacaftor) tablets; (ivacaftor) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf
DB11714,,"FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761069s028lbl.pdf
DB11714,,FDA.gov Resources for Information: FDA approves durvalumab for extensive-stage small cell lung cancer,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer
DB11714,,European Medicines Agency: IMFINZI (durvalumab) Summary of Product Characteristics,https://www.ema.europa.eu/en/documents/product-information/imfizi-epar-product-information_en.pdf
DB11714,,"FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use (September 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s035lbl.pdf
DB11714,,"FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use (October 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s036lbl.pdf
DB11714,,"FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use (November 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf
DB11714,,EMA Approved Drug Products: IMJUDO (tremelimumab) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf
DB11714,,"FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use (August 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf
DB11714,,"FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use (December 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s049lbl.pdf
DB11718,,"BRAF B-Raf proto-oncogene, serine/threonine kinase [ Homo sapiens (human) ]",https://www.ncbi.nlm.nih.gov/gene/673
DB11718,,Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma,http://clincancerres.aacrjournals.org/content/early/2017/08/21/1078-0432.CCR-16-2923
DB11718,,FDA Approved Drug Products: Braftovi (encorafenib) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf
DB11718,,"FDA Approved Drug Products: BRAFTOVI® (encorafenib) capsules, for oral use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf
DB11730,,"PDF Article- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer",http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609709
DB11730,,FDA approval,https://novartis.gcs-web.com/LEE011-US-FDA-Approval
DB11730,,FDA Approved Drug Products: Kisqali (ribociclib) tablets for oral use (September 2024),https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf
DB11732,,FDA Approved Drugs: Reyvow (lasmiditan) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211280s007lbl.pdf
DB11732,,AChemBlock: Lasmiditan hemisuccinate MSDS,https://www.achemblock.com/AC_SDS.php?Catalog=S72361
DB11732,,FDA News Release: Lasmiditan Approval,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine
DB11732,,Migraine Pregnancy Registry,https://migrainepregnancyregistry.com/
DB11732,,EMA Approved Drug Products: Rayvow (lasmiditan) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/rayvow-epar-product-information_en.pdf
DB11732,,EMA Medicines Overview: Rayvow (lasmiditan),https://www.ema.europa.eu/en/medicines/human/EPAR/rayvow
DB11735,,Electronic Medicines Compendium: Duphalac (lactulose) monograph,https://www.medicines.org.uk/emc/product/5525/smpc
DB11735,,ScienceDirect: Galactose Profile,https://www.sciencedirect.com/topics/medicine-and-dentistry/galactose
DB11737,,Icotonib approval,https://newdrugapprovals.org/2014/12/09/icotinib/
DB11737,,Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771396/
DB11738,,TITCK Product Information: Hyperium (rilmenidine) oral tablets,https://titck.gov.tr/storage/kubKtAttachments/QrQRUCYrk0FM1.pdf
DB11739,,FDA Thailand Product Information: Vocinti (vonoprazan fumarate) oral tablets,http://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/1163/59617143799c78416f40a1fd7d1442e5-a1.pdf
DB11739,,"FDA Approved Drug Products: VOQUEZNA TRIPLE PAK (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets), co-packaged for oral use and VOQUEZNA DUAL PAK (vonoprazan tablets; amoxicillin capsules) co-packaged for oral use",http://www.phathompharma.com/wp-content/uploads/VOQUEZNA-TRIPLE-PAK-and-VOQUEZNA-DUAL-PAK-FDA-Final-Label-3.pdf
DB11739,,"FDA Approved Drug Products: VOQUEZNA (vonoprazan) tablets, for oral use (November 2023)",https://www.phathompharma.com/wp-content/uploads/VOQUEZNA-tablets-Prescriber-Information.pdf
DB11739,,"FDA Approved Drug Products: VOQUEZNA (vonoprazan) tablets, for oral use (July 2024)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215151s006,218710s000lbl.pdf"
DB11742,,Apotheke.de: Ebastine Aristo orodispersible tablets,https://www.apotheke.de/ebastin-aristo-20-mg-schmelztabletten-20stk-pzn-10114153
DB11748,,Worwag Pharma: Milgamma Protekt (benfotiamine) film-coated tablets,https://www.woerwagpharma.de/fileadmin/media/de/produkte/gebrauchsinformationen/woerwagpharma-milgamma_protekt-GI_2019.pdf
DB11751,,FDA Approved Drug Products: Vocabria (Cabotegravir) Oral Tablets,https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Vocabria/pdf/VOCABRIA-PI-PIL.PDF
DB11751,,FDA Approved Drug Products: Cabenuva (Cabotegravir and Rilpivirine) Intramuscular Extended-Release Suspension,https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF
DB11751,,"FDA News Release: FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV",https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv
DB11751,,Cayman Chemical: Cabotegravir MSDS,https://www.caymanchem.com/msdss/27215m.pdf
DB11751,,FDA Approved Drug Products: Apretude (cabotegravir) extended-release suspension for intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf
DB11751,,"BioSpace News: ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment",https://www.biospace.com/article/releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment/?s=74
DB11751,,"FDA Approved Drug Products: APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215499s004lbl.pdf
DB11753,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/indeX.cfm?event=overview.process&ApplNo=210910
DB11753,,EMA approvals,https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001754-pip01-15
DB11753,,FDA news,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626121.htm
DB11753,,Bentham Science,http://www.eurekaselect.com/110777/article
DB11753,,"FDA Approved Drug Products: AEMCOLO (rifamycin) delayed-release tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf
DB11757,,FDA News Release: Istradefylline Approval,https://www.fda.gov/news-events/press-announcements/fda-approves-new-add-drug-treat-episodes-adults-parkinsons-disease
DB11757,,Cayman Chemicals: Istradefylline MSDS,https://www.caymanchem.com/msdss/22958m.pdf
DB11757,,Pharmaceuticals and Medical Devices Agency Japan: Report on Istradefylline,https://www.pmda.go.jp/files/000153870.pdf
DB11757,,FDA Approved Drug Products: Istradefylline Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf
DB11760,,"FDA Approved Drug Products: TALZENNA (talazoparib) capsules, for oral use (June 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf
DB11760,,Pfizer Press Release: European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer,https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer
DB11760,,Health Canada Approved Drug Products: TALZENNA (Talazoparib) Oral Capsules,https://pdf.hres.ca/dpd_pm/00064613.PDF
DB11760,,EMA Approved Drug Products: TALZENNA (talazoparib) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf
DB11761,,FDA Approved Drug Products: Isbrela (tenapanor) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211801s004lbl.pdf
DB11761,,"FDA Approved Drug Products: XPHOZAH (tenapanor) tablets, for oral use",https://ardelyx.com/XPHOZAH-Prescribing-Information.pdf
DB11763,,"FDA Approved Drug Products: OJJAARA (momelotinib) tablets, for oral use (September 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf
DB11763,,GSK: Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia,https://www.gsk.com/en-gb/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/
DB11767,,"EMA Assessment Report: Kevzara, INN-sarilumab",http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004254/WC500230070.pdf
DB11767,,FDA Approved Drug Products: KEVZARA (sarilumab) injection for subcutaneous use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf
DB11767,,FDA Approved Drug Products: KEVZARA (sarilumab) injection for subcutaneous use (June 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761037s015lbl.pdf
DB11771,,"FDA Approved Drug Products: IMJUDO (tremelimumab-actl) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289lbl.pdf
DB11771,,Pfizer: Tremelimumab MSDS,https://www.msdsdigital.com/system/files/PZ00158.pdf
DB11771,,"FDA Approved Drug Products: IMJUDO (tremelimumab-actl) injection, for intravenous use (November 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf
DB11771,,EMA Summary of Opinion: Imjudo (tremelimumab),https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-imjudo_en.pdf
DB11771,,EMA Approved Drug Products: IMJUDO (tremelimumab) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf
DB11776,,"FDA Approved Drug Products: SILIQ (brodalumab) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf
DB11783,,BPOM Drug Information: Imidapril monograph,http://pionas.pom.go.id/monografi/imidapril
DB11783,,TITCK Product Information: Tanatril (imidapril hydrochloride) oral tablets,https://titck.gov.tr/storage/kubKtAttachments/6596d1bb96048.pdf
DB11791,,FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf
DB11791,,FDA Approvals and Databases: FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer
DB11791,,CaymanChem: Capmatinib MSDS,https://www.caymanchem.com/msdss/20056m.pdf
DB11791,,Health Canada Approved Drug Products: TABRECTA (Capmatinib) Oral Tablets,https://pdf.hres.ca/dpd_pm/00066041.PDF
DB11791,,Cision PR Newswire: Health Canada approves (Pr)Tabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations,https://www.newswire.ca/news-releases/health-canada-approves-pr-tabrecta-r-targeted-cancer-therapy-for-locally-advanced-unresectable-or-metastatic-non-small-cell-lung-cancer-nsclc-harbouring-mesenchymal-epithelial-transition-met-exon-14-skipping-alterations-828642776.html
DB11793,,"FDA Approved Drug Products: ZEJULA (niraparib) capsules, for oral use (September 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208447s026lbl.pdf
DB11793,,EMA Approved Drug Products: Zejula (niraparib) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/zejula-epar-product-information_en.pdf
DB11793,,Health Canada Approved Drug Products: ZEJULA (niraparib) Oral Capsules or Tablets,https://ca.gsk.com/media/6229/zejula_pm_en.pdf
DB11793,,Health Canada Approved Drug Proucts: AKEEGA (Niraparib and abiraterone acetate) tablets for oral use,https://pdf.hres.ca/dpd_pm/00071216.PDF
DB11793,,"FDA Approved Drug Products: AKEEGA (niraparib and abiraterone acetate) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf
DB11796,,FDA Approved Drug Products: Rukobia (fostemsavir) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf
DB11796,,NIH AIDSinfo: Fostemsavir,https://aidsinfo.nih.gov/drugs/508/fostemsavir/0/professional
DB11796,,ViiV Healthcare: ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir),https://viivhealthcare.com/en-gb/media/press-releases/2020/july/viiv-healthcare-announces-us-fda-approval-for-rukobia/
DB11799,,"Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults",https://www.researchgate.net/publication/313581562_Antiviral_Activity_Safety_and_Pharmacokinetics_of_Bictegravir_as_10-Day_Monotherapy_in_HIV-1-Infected_Adults
DB11799,,BICTEGRAVIR,https://aidsinfo.nih.gov/drugs/print/570/bictegravir/0/1/professional
DB11799,,FDA APPROVES BIKTARVY,https://www.drugs.com/newdrugs/fda-approves-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-hiv-1-infection-4691.html
DB11799,,BICTEGRAVIR SODIUM,https://pubchem.ncbi.nlm.nih.gov/compound/122197537
DB11799,,"FDA Approved Drug Products: BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use (October 2021)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210251s014lbl.pdf
DB11799,,"FDA Approved Drug Products: BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use (October 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210251s015lbl.pdf
DB11799,,"EMA Approved Drug Products: Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) Oral Tablets",https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_en.pdf
DB11799,,"FDA Approved Drug Products: BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use (February 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210251s018lbl.pdf
DB11800,,EMC Summary of Product Characteristics: Fotivda (tivozanib hydrochloride monohydrate) oral capsules,https://www.medicines.org.uk/emc/product/8996/smpc
DB11800,,"FDA Approved Drug Products: FOTIVDA (tivozanib) capsules, for oral use",https://www.aveooncology.com/fotivdapi.pdf
DB11800,,Cancer.org: Key Statistics About Kidney Cancer,https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html
DB11800,,Cayman Chem safety data sheet: Tivozanib hydrate,https://www.caymanchem.com/msdss/18493m.pdf
DB11800,,EMA Assessment Report: Fotivda (tivozanib) oral capsules,https://www.ema.europa.eu/en/documents/assessment-report/fotivda-epar-public-assessment-report_en.pdf
DB11800,,AVEO Oncology: Tivozanib hydrochloride pharmacokinetic/pharmacodynamic analysis of blood pressure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma,https://investor.aveooncology.com/static-files/e87a94b0-a1f0-4d13-83f2-4790f62343f8
DB11817,,FDA: Emergency Use Authorization for Baricitinib in Combination with Remdesivir for COVID-19,https://www.fda.gov/media/143822/download
DB11817,,"FDA Approved Drug Products: OLUMIANT (baricitinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s006lbl.pdf
DB11817,,Cayman Chemical: Baricitinib MSDS,https://cdn.caymanchem.com/cdn/msds/16707m.pdf
DB11817,,EMA Approved Drug Products: Olumiant (baricitinib) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf
DB11817,,"FDA Approved Drug Products: OLUMIANT (baricitinib) tablets, for oral use 2022",https://pi.lilly.com/us/olumiant-uspi.pdf?s=pi
DB11820,,FDA Approved Products: Lampit (nifurtimox) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213464s000lbl.pdf
DB11820,,CDC: Chagas disease,https://www.cdc.gov/parasites/chagas/gen_info/detailed.html
DB11820,,Bioworld: Bayer’s Lampit approved by FDA for treating Chagas disease,https://www.bioworld.com/articles/496602-bayers-lampit-approved-by-fda-for-treating-chagas-disease
DB11820,,Clinicaltrials.gov: History of Changes for Study: NCT02625974 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease (CHICO),https://www.clinicaltrials.gov/ct2/history/NCT02625974?V_15=View
DB11820,,"Clinicaltrials.gov, Results: Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease (CHICO)",https://clinicaltrials.gov/ct2/show/results/NCT02625974
DB11820,,Cayman Chem MSDS: Nifurtimox,https://www.caymanchem.com/msdss/21784m.pdf
DB11820,,FDA Approved Drug Products: LAMPIT (nifurtimox) tablets for oral use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213464s004lbl.pdf
DB11823,,FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632761.htm
DB11823,,WHO International fact sheet,https://www.who.int/en/news-room/fact-sheets/detail/depression
DB11823,,FDA Approved Drug Products: Spravato (esketamine) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf
DB11827,,Pfizer: FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and Fixed-Dose Combination STEGLUJAN™ (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes,https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_sglt2_inhibitor_steglatro_ertugliflozin_and_fixed_dose_combination_steglujan_ertugliflozin_and_sitagliptin_for_adults_with_type_2_diabetes
DB11827,,FDA Approved Drug Products: Segluromet (ertugliflozin and metformin hydrochloride) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209806s006lbl.pdf
DB11827,,FDA Approved Drug Products: Steglujan (ertugliflozin and sitagliptin) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209805s008lbl.pdf
DB11827,,ClinicalTrials.gov: A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020),https://clinicaltrials.gov/ct2/show/results/NCT02411929?sect=Xgf0156#outcome10
DB11827,,"FDA Approved Drug Products: STEGLATRO (ertugliflozin) tablets, for oral use (September 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209803s007lbl.pdf
DB11827,,MSD: Ertugliflozin MSDS,https://www.msd.com/docs/product/safety-data-sheets/hh-sds/Ertugliflozin%20Formulation_HH_ZA_6N.pdf
DB11827,,EMA Approved Drug Products: STEGLATRO (ertugliflozin) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/steglatro-epar-product-information_en.pdf
DB11837,,FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf
DB11837,,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf
DB11837,,EMA Assessment Report: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/assessment-report/isturisa-epar-public-assessment-report_en.pdf
DB11837,,FDA News Release: Osilodrostat Approval,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-cushings-disease
DB11850,,FDA Approved Drug Products: Briumvi (ublituximab-xiiy) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf
DB11850,,TG Therapeutics Press Release: TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy),https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-fda-approval-briumvitm-ublituximab
DB11850,,"EMA Approved Drug Products: Briumvi (Ublituximab) injection, for intravenous use",https://www.ema.europa.eu/en/documents/product-information/briumvi-epar-product-information_en.pdf
DB11850,,TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults,https://www.globenewswire.com/news-release/2023/06/01/2680448/8790/en/TG-Therapeutics-Announces-European-Commission-Approval-for-BRIUMVI-ublituximab-xiiy-for-the-Treatment-of-Relapsing-Forms-of-Multiple-Sclerosis-in-Adults.html
DB11853,,FDA Approved Drug Products: Orgovyx (relugolix) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf
DB11853,,FDA News Release: FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-hormone-therapy-treating-advanced-prostate-cancer
DB11853,,GeekyMedics: How the Gonadal Axis Works,https://geekymedics.com/how-the-gonadal-axis-works/
DB11853,,"FDA Approved Drug Products: MYFEMBREE (relugolix, estradiol, and norethindrone acetate) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214846s000lbl.pdf
DB11853,,EMA Approved Drug Products: Orgovyx (relugolix) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/orgovyx-epar-product-information_en.pdf
DB11853,,GlobeNewswire News Release: Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer,https://www.globenewswire.com/en/news-release/2022/04/29/2432998/0/en/Myovant-Sciences-Announces-European-Commission-Approval-for-ORGOVYX-relugolix-for-the-Treatment-of-Advanced-Hormone-Sensitive-Prostate-Cancer.html
DB11855,,FDA approvals,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210598
DB11855,,FDA news,https://www.drugs.com/newdrugs/fda-approves-yupelri-revefenacin-chronic-obstructive-pulmonary-copd-4861.html
DB11855,,Respirology paper,https://onlinelibrary.wiley.com/doi/full/10.1111/resp.12660
DB11855,,Theravance Biopharma Report Filing,http://files.shareholder.com/downloads/AMDA-2C8P6P/0x0xS1104659-14-65070/1583107/filing.pdf
DB11855,,ATS Journals paper,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A3033
DB11855,,"FDA Approved Drug Products: YUPELRI (revefenacin) inhalation solution, for oral inhalation use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210598s003lbl.pdf
DB11859,,Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus: Press Release,https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-reports-top-line-results-phase-3-status-trial
DB11866,,Romosozumab FDA Approval Announcement,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635653.htm
DB11866,,"FDA Meeting Of The Bone, Reproductive and Urologic Drugs Advisory Committee For Rosozumab",https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM629776.pdf
DB11866,,"FDA Approved Drug Products: EVENITY (romosozumab-aqqg) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf
DB11876,,ilacaBak: Glutaviven (l-alanyl-l-glutamine) intravenous solution,https://www.ilacabak.com/glutaviven-20g-100-ml-iv-infuzyon-icin-konsantre-cozelti-iceren-flakon-24610/kisa-urun-bilgisi
DB11876,,AIFA Product Information: Dipeptiven (L-Alanyl-L-glutamine) concentrate for solution for infusion,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000724_032188_RCP.pdf&retry=0&sys=m0b1l3
DB11886,,"FDA Approved Drug Products: TRUSELTIQ (infigratinib) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf
DB11886,,FDA Drug Approvals and Databases: FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma
DB11892,,AIFA Product Information: Keraflox (prulifloxacin) oral film-coated tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002454_035680_RCP.pdf&retry=0&sys=m0b1l3
DB11901,,FDA Press Announcements: FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596768.htm
DB11901,,"FDA Approved Drug Products: ERLEADA® (apalutamide) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210951s011lbl.pdf
DB11901,,"EMA Approved Drug Products: ERLEADA® (apalutamide) tablets, for oral use",https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf
DB11914,,EMA Approved Drug Products: Ebglyss (Lebrikizumab) solution for subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/ebglyss-epar-product-information_en.pdf
DB11914,,Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis,https://www.businesswire.com/news/home/20231116347732/en/Almirall-Receives-European-Commission-Approval-of-EBGLYSS%C2%AE-lebrikizumab-for-Moderate-to-Severe-Atopic-Dermatitis
DB11914,,"FDA Approved Drug Products: EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761306Orig1s000correctedlbl.pdf
DB11914,,Eli Lilly and Company News Release: FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis,https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and
DB11915,,FDA Approved Drug Products: Ingrezza (valbenazine) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209241s016lbl.pdf
DB11915,,"FDA Approved Drug Products: INGREZZA® (valbenazine) capsules, for oral use (August 2023)",https://www.neurocrine.com/assets/2023/08/INGREZZA-Full-Prescribing-Information_PI_Approved.pdf
DB11915,,Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease,https://www.biospace.com/article/releases/neurocrine-biosciences-announces-fda-approval-of-ingrezza-valbenazine-capsules-for-the-treatment-of-chorea-associated-with-huntington-s-disease/?s=74
DB11921,,FDA approval information,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208684
DB11921,,Duchenne Muscular Dystrophy organization page,https://www.mda.org/disease/duchenne-muscular-dystrophy
DB11921,,"Calcort 6mg tablets, Medicines UK",https://www.medicines.org.uk/emc/product/6287/smpc
DB11921,,FDA Approved Drug Products: Emflaza (deflazacort) tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf"
DB11928,,FDA Approved Drug Products: Voxzogo (vosoritide) injection for subcutaneous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf
DB11928,,EMA Summary of Product Characteristics: Voxzogo (vosoritide) for subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/voxzogo-epar-product-information_en.pdf
DB11928,,FDA News Release: FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism
DB11928,,EMA European Public Assessment Report: Voxzogo (vosoritide),https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo
DB11928,,"FDA approved drug product: VOXZOGO (vosoritide) for injection, for subcutaneous use (October 2023)",https://d18j09vv8nr0vt.cloudfront.net/6f836309-d95f-42af-b717-2efa058ad82d/20f567d5-88c0-4950-a72d-88e93126df84/20f567d5-88c0-4950-a72d-88e93126df84_source__v.pdf
DB11932,,FDA Approved Drug Products: Xeglyze (Abametapir) topical lotion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf
DB11932,,BioVision: Abametapir SDS,https://www.biovision.com/documentation/sds/9665_SDS.pdf
DB11932,,"BusinessWire: Dr. Reddy's Laboratories received approval of XEGLYZE™ (abametapir) lotion, 0.74%, in the U.S.",https://www.businesswire.com/news/home/20200727005324/en/Dr.-Reddys-Laboratories-received-approval-XEGLYZE%E2%84%A2-abametapir
DB11936,,FDA Approved Products: Nexletol (bempedoic acid) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf
DB11936,,Bempedoic acid: A novel agent (Esperion),https://www.esperion.com/science/bempedoic-acid/
DB11936,,FDA Approved Products: Nexlizet (bempedoic acid and ezetimibe) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211617s000lbl.pdf
DB11936,,NIH StatPearls: Cholesterol levels,https://www.ncbi.nlm.nih.gov/books/NBK542294/
DB11936,,Biovision: Bempedoic acid MSDS,https://www.biovision.com/documentation/sds/B1913_SDS.pdf
DB11936,,The Role of Lipids and Lipoproteins in Atherosclerosis,https://www.ncbi.nlm.nih.gov/books/NBK343489/
DB11936,,Global News Wire: Esperion-Announces FDA Approval of NEXLETOL bempedoic acid Tablet an Oral Once Daily Non Statin LDL Cholesterol Lowering Medicine,https://www.globenewswire.com/news-release/2020/02/21/1988825/0/en/Esperion-Announces-FDA-Approval-of-NEXLETOL-bempedoic-acid-Tablet-an-Oral-Once-Daily-Non-Statin-LDL-Cholesterol-Lowering-Medicine.html
DB11936,,FDA Approved Drug Products: Nexletol (bempedoic acid) tablets for oral use (March 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211616s012s013lbl.pdf
DB11936,,FDA Approved Drug Products: Nexlizet (bempedoic acid and ezetimibe) tablets for oral use (March 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211617s016s017lbl.pdf
DB11938,,FDA Approved Drug Products: Korsuva (difelikefalin) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf
DB11938,,GlobeNewswire: Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients,https://www.globenewswire.com/news-release/2021/08/23/2285085/0/en/Cara-Therapeutics-and-Vifor-Pharma-announce-U-S-FDA-approval-of-KORSUVA-difelikefalin-injection-for-the-treatment-of-moderate-to-severe-pruritus-in-hemodialysis-patients.html
DB11938,,EMA Approved Drug Products: Kapruvia (Difelikefalin) Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/kapruvia-epar-product-information_en.pdf
DB11938,,BioSpace News: Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients,https://www.biospace.com/article/releases/kapruvia-approved-by-european-commission-for-the-treatment-of-moderate-to-severe-pruritus-in-hemodialysis-patients/?keywords=European+Commission+Approval
DB11942,,Xpovio FDA Announcement,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma
DB11942,,Cancer.ca: Multiple Myeloma,http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/multiple-myeloma/?region=bc
DB11942,,BC Cancer Agency: Treatment of Multiple Myeloma,http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-guidelines/lymphoma-chronic-leukemia-myeloma/multiple-myeloma#Treatment-of-Myeloma
DB11942,,Clinical Trials: BOSTON Trial,https://clinicaltrials.gov/ct2/show/NCT03110562
DB11942,,ChemSpider: Selinexor,http://www.chemspider.com/Chemical-Structure.32701989.html
DB11942,,FDA Approved Drug Products: XPOVIO (selinexor) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212306s005lbl.pdf
DB11942,,Health Canada Approved Drug Products: XPOVIO (selinexor) oral tablets,https://pdf.hres.ca/dpd_pm/00066090.PDF
DB11945,,"FDA Approved Drug Products: BAVENCIO (avelumab) injection, for intravenous use (November 2020)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s005lbl.pdf
DB11945,,"FDA Approved Drug Products: BAVENCIO (avelumab) injection, for intravenous use (September 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761049s015lbl.pdf
DB11945,,EMA Approved Drug Products: Bavencio (avelumab) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/bavencio-epar-product-information_en.pdf
DB11945,,"Health Canada Approved Drug Products: BAVENCIO (Avelumab) injection, for intravenous infusion",https://pdf.hres.ca/dpd_pm/00066988.PDF
DB11950,,FDA Thailand Product Information: Tenelia (teneligliptin) oral tablets,http://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/1163/2f4b9cbb0657cbd755ecd3d5f00d6b99-a1.pdf
DB11951,,FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
DB11951,,Carbosynth: Lemborexant MSDS,https://www.carbosynth.com/80257AD2003D1CDB/0/2DE532CE6709B35280258260002ED773/$file/MSDS+-+FL103847+-+SDS117181.pdf
DB11952,,FDA news,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm
DB11952,,Canadian Cancer Society,http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-lymphocytic-cll/chronic-lymphocytic-leukemia/?region=on
DB11952,,Cancer.gov,https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma
DB11952,,Canadian Cancer Society,http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/follicular-lymphoma/?region=on
DB11952,,FDA Approved Drug Products: Copiktra (duvelisib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211155s005lbl.pdf
DB11952,,"FDA Approved Drug Products: COPIKTRA (duvelisib), capsules for oral use (July 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211155s007lbl.pdf
DB11963,,FDA approval,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211288
DB11963,,FDA news,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621967.htm
DB11967,,Cancer.gov link,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/binimetinib
DB11967,,FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm
DB11967,,"FDA Approved Drug Products: MEKTOVI® (binimetinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf
DB11976,,FDA Approved Drug Products: Saphnelo (Anifrolumab-fnia) Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf
DB11976,,"FDA Approved Drug Products: SAPHNELO (anifrolumab-fnia) injection, for intravenous use (Dec 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761123s003lbl.pdf
DB11978,,FDA news,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626494.htm
DB11978,,NIH,https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
DB11978,,FDA Approved Drug Products: Daurismo (glasdegib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf
DB11978,,FDA Approved Drug Products: Daurismo (glasdegib) oral tablets (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210656s005lbl.pdf
DB11978,,EMA Assessment Report: Daurismo International non-proprietary name glasdegib,https://www.ema.europa.eu/en/documents/assessment-report/daurismo-epar-public-assessment-report_en.pdf
DB11986,,FDA Approved Drug Productsl: Rozlytrek (entrectinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf
DB11986,,Cayman Chemical: Entrectinib MSDS,https://www.caymanchem.com/msdss/19476m.pdf
DB11986,,FDA Announcement: Entrectinib Approval,https://www.fda.gov/news-events/press-announcements/fda-approves-third-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor
DB11986,,BioSpace: FoundationOne®Liquid CDx Receives FDA Approval as a Companion Diagnostic for Rozlytrek® (entrectinib),https://www.biospace.com/article/releases/foundationone-liquid-cdx-receives-fda-approval-as-a-companion-diagnostic-for-rozlytrek-entrectinib-/?s=74
DB11988,,FDA Press Announcements: FDA approves new drug to treat multiple sclerosis,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.htm
DB11988,,FDA Approved Drug Products: OCREVUS (ocrelizumab) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761053s029s030lbl.pdf
DB11988,,"FDA Approved Drug Products: OCREVUS® (ocrelizumab) injection, for intravenous use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761053s034lbl.pdf
DB11989,,FDA: Benznidazole Announcement,https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm573942.htm
DB11989,,FDA Approved Drug Products: Benznidazole tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209570s002lbl.pdf
DB11994,,WHO Diacerein: Restricted Use,http://www.who.int/medicines/publications/druginformation/DI_28-2_SafetyEfficacy.pdf
DB11994,,BASG Product Information: Verboril (diacerein) oral capsules,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-24325&type=DOTC_FACH_INFO
DB11995,,Avotrombopag,http://www.bloodjournal.org/content/123/25/3887?sso-checked=true
DB11995,,FDA Ok's avatrombopag,https://seekingalpha.com/news/3358283-fda-oks-dova-pharmas-avatrombopag
DB11995,,Avatrombopag,https://pubchem.ncbi.nlm.nih.gov/compound/avatrombopag
DB11995,,FDA approves avatrombopag for thrombocytopenia in adults with chronic liver disease,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm608323.htm
DB11995,,"Avatrombopag, a Novel Thrombopoietin Receptor Agonist, Increases Platelet Counts without Increasing Platelet Activation in Patients with Thrombocytopenia Due to Chronic Liver Disease",http://www.bloodjournal.org/content/130/Suppl_1/290
DB11995,,"Avotrombopag maleate approval, FDA",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210238
DB11995,,NCI Drug Dictionary: Avotrombopag maleate,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793425
DB11995,,Drugs.com: Avotrombopag,https://www.drugs.com/history/doptelet.html
DB11995,,NEJM Journal Watch: FDA Approval of Avatrombopag,https://www.jwatch.org/na46878/2018/06/01/fda-approval-avatrombopag
DB11995,,Avatrombopag Gains FDA Approval for Patients with Chronic Liver Disease,https://www.specialtypharmacytimes.com/news/avatrombopag-gains-fda-approval-for-patients-with-chronic-liver-disease
DB11995,,FDA Approved Drug Products: Doptelet (avatrombopag) tablets for oral use (June 2021),https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210238s006lbl.pdf
DB11995,,Health Canada Product Monograph: Doptelet (avatrombopag maleate) tablets for oral use,https://pdf.hres.ca/dpd_pm/00073257.PDF
DB11997,,RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for COVID-19,https://www.newswire.ca/news-releases/revimmune-announces-phase-ii-trial-of-the-t-cell-growth-factor-cyt107-for-covid-19-819548521.html
DB12001,,FDA approves new treatment for certain advanced or metastatic breast cancers,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm578071.htm
DB12001,,FDA Approved Drug Products: Verzenio (abemaciclib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s008lbl.pdf
DB12005,,"FDA Approved Drug Products: OGSIVEOTM (nirogacestat) tablets, for oral use",https://springworkstx.com/wp-content/uploads/2023/11/OGSIVEO-US-Prescribing-Information-11.27.23.pdf
DB12005,,SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors,https://www.biospace.com/article/releases/springworks-therapeutics-announces-fda-approval-of-ogsiveo-nirogacestat-as-the-first-and-only-treatment-for-adults-with-desmoid-tumors/
DB12007,,INVIMA Product Registration: Trifoliom (red clover extract 40%) capsules for oral use,http://web.sivicos.gov.co/registros/pdf/15437753_2017022791.pdf
DB12010,,Fostamatinib FDA Approval,https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm604956.htm
DB12015,,"FDA Approved Drug Products: PIQRAY (alpelisib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf
DB12015,,"FDA Approved Drug Products: VIJOICE (alpelisib) tablets, for oral use",https://www.novartis.us/sites/www.novartis.us/files/vijoice.pdf
DB12015,,Cayman Chemical: Alpelisib MSDS,https://cdn.caymanchem.com/cdn/msds/16986m.pdf
DB12015,,"FDA Approved Drug Products: PIQRAY (alpelisib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212526s006lbl.pdf
DB12016,,FDA Approved Drug Products: Ponvory (Ponesimod) Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf
DB12020,,FDA approves the first drug with an indication for treatment of smallpox,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.htm
DB12020,,FDA approves first smallpox indicated treatment,https://www.genengnews.com/gen-news-highlights/fda-approves-first-smallpox-indicated-treatment-sigas-tpoxx/81256026
DB12020,,BioSpace News: SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®,https://www.biospace.com/article/releases/siga-announces-health-canada-regulatory-approval-of-oral-tpoxx-/?keywords=health+canada+approval
DB12020,,Summary of Product Characteristics: Tecovirimat (tecovirimat) oral capsules,https://www.ema.europa.eu/en/documents/product-information/tecovirimat-siga-epar-product-information_en.pdf
DB12020,,GlobeNewsWire News Release: SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat,"https://www.globenewswire.com/news-release/2022/01/10/2363875/9738/en/SIGA-Technologies-Receives-Approval-from-the-European-Medicines-Agency-for-Tecovirimat.html#:~:text=(SIGA)%20(NASDAQ%3A%20SIGA,U.S.%20Food%20and%20Drug%20Administration"
DB12020,,"FDA Approved Drug Products: TPOXX (tecovirimat) capsules, for oral use or injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214518s000lbl.pdf
DB12020,,"FDA ADVISORY COMMITTEE BRIEFING DOCUMENT: Tecovirimat for the Treatment of Smallpox Disease (May 1, 2018)",https://www.fda.gov/media/112808/download
DB12023,,Newswire,https://www.prnewswire.com/news-releases/fasenra-benralizumab-receives-us-fda-approval-for-severe-eosinophilic-asthma-300556129.html
DB12023,,Astra Zeneca news,https://www.astrazeneca.com/media-centre/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html
DB12023,,FDA Approved Drug Products: Fasenra (benralizumab) for subcutaneous injection (April 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761070Orig1s020correctedlbl.pdf
DB12026,,"American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.",http://hcvguidelines.org/full-report-view
DB12026,,FDA News Release: FDA approves Vosevi for Hepatitis C,https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm567467.htm
DB12026,,"FDA Approved Drug Products: Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) tablets for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209195s003lbl.pdf
DB12035,,FDA Approval of Seysara (sarecycline) by Almirall Press Release,https://www.drugs.com/newdrugs/fda-approves-seysara-sarecycline-moderate-severe-acne-4835.html
DB12035,,"Acquisition of Allergan US Medical Dermatology Department by Almirall, S.A. Press Release",https://www.almirall.com/en/media/press-releases/media-detail-new?title=transformational-transaction-almirall-to-acquire-us-medical-dermatology-portfolio-from-allergan&articleId=3261397
DB12070,,FDA Approved Drugs: Letermovir,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=209939
DB12070,,FDA Approved Drug Products: Prevymis (letermovir) for oral or intravenous administration (June 2023),https://www.merck.com/product/usa/pi_circulars/p/prevymis/prevymis_pi.pdf
DB12095,,FDA Review- Telotristat,http://www.lexpharma.com/media-center/news/525-fda-extends-pdufa-date-for-telotristat-etiprate-for-the-treatment-of-carcinoid-syndrome
DB12095,,"FDA Approved Drug Products: XERMELO® (telotristat ethyl) tablets, for oral use 2022",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208794s004lbl.pdf
DB12095,,FDA Approved Drug Products: Xermelo (telotristat ethyl) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208794s001lbl.pdf
DB12095,,CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208794Orig1s000ClinPharmR.pdf
DB12095,,Assessment Report: Xermelo (International non-proprietary name telotristat ethyl),https://www.ema.europa.eu/en/documents/assessment-report/xermelo-epar-public-assessment-report_en.pdf
DB12095,,Carcinoid Syndrome,https://www.ncbi.nlm.nih.gov/books/NBK448096/
DB12118,,"FDA Approved Drug Products: WINREVAIR (sotatercept-csrk) for injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf
DB12118,,"BioSpace: FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)",https://www.biospace.com/article/releases/fda-approves-merck-s-winrevair-sotatercept-csrk-a-first-in-class-treatment-for-adults-with-pulmonary-arterial-hypertension-pah-who-group-1-/?s=74
DB12118,,EMA Approved Drug Products: WINREVAIR (sotatercept) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/winrevair-epar-product-information_en.pdf
DB12118,,"Merck: Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III",https://www.merck.com/news/merck-receives-european-commission-approval-for-winrevair-sotatercept-in-combination-with-other-pulmonary-arterial-hypertension-pah-therapies-for-the-treatment-of-pah-in-adult-patients-w/
DB12127,,AIFA Product Information: Unasyn (sultamicillin) for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000040_026360_RCP.pdf&retry=0&sys=m0b1l3
DB12130,,Drugs.com: FDA Approves Lorbrena,https://www.drugs.com/newdrugs/fda-approves-lorbrena-lorlatinib-previously-treated-alk-positive-metastatic-non-small-cell-lung-4856.html
DB12130,,FDA Approved Drug Products: Lorbrena (lorlatinib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf
DB12130,,EMA Summary of Product Characteristics: Lorviqua (lorlatinib) film-coated tablets for oral use,https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf
DB12131,,FDA Thailand Product Information: Cavinton (vinpocetine) for oral use,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022380010111C
DB12141,,FDA news,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm627072.htm
DB12141,,NIH,https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
DB12141,,American Society of Clinical Oncology,http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.7026
DB12141,,Clinical trials,https://clinicaltrials.gov/ct2/show/NCT02181660
DB12141,,Clinical trials,https://clinicaltrials.gov/ct2/show/NCT02456883
DB12147,,FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm635910.htm
DB12147,,First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval,https://www.pharmacytimes.com/news/first-targeted-therapy-for-metastatic-bladder-cancer-receives-fda-approval
DB12147,,"FDA Approved Drug Products: BALVERSA® (erdafitinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212018s005lbl.pdf
DB12147,,"Health Canada Approved Drug Proucts: BALVERSA (Erdafitinib) tablets, for oral use",https://pdf.hres.ca/dpd_pm/00060515.PDF
DB12147,,"FDA Approved Drug Products: BALVERSA® (erdafitinib) tablets, for oral use (Jan 2024)",https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/BALVERSA-pi.pdf
DB12148,,FDA Thailand Product Information: Glakay (menatetrenone) oral capsules,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1012420001211C
DB12151,,FDA Approved Drug Products: Tembexa (brincidofovir) for oral administration,https://www.chimerix.com/wp-content/uploads/2021/06/TEMBEXA-USPI-and-PPI-04June2021.pdf
DB12151,,FDA News Release: FDA approves drug to treat smallpox,https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-treat-smallpox
DB12151,,FDA MCM Regulatory Science: Animal Rule Information,https://www.fda.gov/emergency-preparedness-and-response/mcm-regulatory-science/animal-rule-information
DB12153,,AIFA Product Information: Difosfocin (citicoline) solution for injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004183_024121_FI.pdf&retry=0&sys=m0b1l3
DB12153,,INVIMA Product Information: Complegel NF (citicoline) coated tablets,http://web.sivicos.gov.co/registros/pdf/1331041_2015029729.pdf
DB12159,,FDA Approved Drug Products: Dupixent (dupilumab) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761055s031lbl.pdf
DB12159,,EMA Approved Drug Products: Dupixent (dupilumab) subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf
DB12159,,Dupixent® (dupilumab) Approved for Severe Asthma by European Commission - Regeneron,https://newsroom.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-severe-asthma-european-commission
DB12159,,FDA approves first treatment for chronic rhinosinusitis with nasal polyps,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-rhinosinusitis-nasal-polyps
DB12159,,European Medicines Agency: Dupixent (dupilumab) Public Assessment Report,https://www.ema.europa.eu/en/documents/assessment-report/dupixent-epar-public-assessment-report_en.pdf
DB12159,,Australian Public Assessment Report for Dupilumab - TGA,https://www.tga.gov.au/sites/default/files/auspar-dupilumab-180612.pdf
DB12159,,Health Canada Approved Drug Products: DUPIXENT (dupilumab) subcutaneous injection,https://pdf.hres.ca/dpd_pm/00065186.PDF
DB12159,,FDA Approved Drug Products: Dupixent (dupilumab) for subcutaneous injection (May 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s040lbl.pdf
DB12159,,"FDA Approved Drug Products: DUPIXENT (dupilumab) injection, for subcutaneous use (June 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s042lbl.pdf
DB12159,,"FDA Approved Drug Products: DUPIXENT (dupilumab) injection, for subcutaneous use (September 2022)",https://www.regeneron.com/downloads/dupixent_fpi.pdf
DB12159,,"FDA approved drug product: DUPIXENT® (dupilumab) injection, for subcutaneous use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s055lbl.pdf
DB12159,,"FDA Approved Drug Products: DUPIXENT® (dupilumab) injection, for subcutaneous use (Feb 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s057lbl.pdf
DB12161,,FDA Approved Drug Products: Austedo (deutetrabenazine) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208082s009lbl.pdf
DB12169,,EMA Summary of Product Characteristics: Adtralza (tralokinumab) for subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf
DB12169,,Health Canada Product Monograph: Adtralza (tralokinumab) for subcutaneous injection,https://pdf.hres.ca/dpd_pm/00063207.PDF
DB12169,,EMA European Public Assessment Report: Adtralza (tralokinumab),https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza
DB12169,,FDA Approved Drug Products: Adbry (tralokinumab-ldrm) for subcutaneous injection,https://www.leo-pharma.us/Files/Billeder/US%20Website%20Product%20PIs/AdbryPI.pdf
DB12169,,"FDA Approved Drug Products: ADBRY® (tralokinumab-ldrm) injection, for subcutaneous use (December 2023)",https://mc-df05ef79-e68e-4c65-8ea2-953494-cdn-endpoint.azureedge.net/-/media/corporatecommunications/us/therapeutic-expertise/our-product/adbrypi.pdf?rev=c8185030b1ef4650b12b41c9a40557f9
DB12173,,NCATS Drugs: Diphencyprone,https://drugs.ncats.io/substance/I7G14NW5EC
DB12184,,"FDA Approved Drug Products: EXXUA (gepirone) extended-release tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021164s000lbl.pdf
DB12184,,Gepirone US Patent Application Publication,https://patentimages.storage.googleapis.com/98/fb/27/2504cd09ad620c/US20060099267A1.pdf
DB12184,,"Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults",https://www.biospace.com/article/releases/fabre-kramer-pharmaceuticals-announces-fda-approval-of-exxua-the-first-and-only-oral-selective-5ht1a-receptor-agonist-for-the-treatment-of-major-depressive-disorder-in-adults/?s=74
DB12208,,Assos Pharma: Monofer (iron III isomaltose 1000) solution for intravenous injection,https://www.assospharma.com/pdf/Monofer1000mg-10ml-KUB.pdf
DB12212,,BASG Product Information: Rapibloc (landiolol hydrochloride) for infusion,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=137584&type=DOTC_FACH_INFO
DB12214,,FDA Thailand Product Information: Lusefi (luseogliflozin) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1012600000211C
DB12214,,NPRA Product Information: Lusefi (luseogliflozin) oral tablets,https://quest3plus.bpfk.gov.my/front-end/attachment/293/pharma/80274/V_42016_20200421_110331_D3.pdf
DB12218,,"FDA Approved Drug Products: TRUQAP™ (capivasertib) tablets, for oral use (November 2023)",https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/841065f2-fcba-4795-b92a-3afc2ba47325/841065f2-fcba-4795-b92a-3afc2ba47325_viewable_rendition__v.pdf
DB12218,,Truqap Plus Fulvestrant Approved for HR-Positive Advanced Breast Cancer,https://www.empr.com/home/news/truqap-plus-fulvestrant-approved-for-hr-positive-advanced-breast-cancer/
DB12221,,AIFA Product Information: Luvion (canrenone) for oral/intravenous administration,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003582_024273_FI.pdf&retry=0&sys=m0b1l3
DB12235,,FDA Approved Drug Products: NEXTSTELLIS (drospirenone and estetrol) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf
DB12235,,"Joint press release, Mayne Pharma and Mithra: MAYNE PHARMA AND MITHRA ANNOUNCE FDA APPROVAL OF NEW ORAL CONTRACEPTIVE NEXTSTELLIS",https://www.maynepharma.com/media/2506/fda-approval-of-novel-oral-contraceptive-nextstellis.pdf
DB12235,,Mithra Women's Health: E4 Paves the Road Towards a Revolutionary Era of Environmental Friendly Medicines,https://www.globenewswire.com/news-release/2020/01/10/1968775/0/en/E4-Paves-the-Road-Towards-a-Revolutionary-Era-of-Environmental-Friendly-Medicines.html
DB12235,,Cayman Chem MSDS: Estetrol hydrate,https://www.caymanchem.com/msdss/18232m.pdf
DB12235,,Product monograph: Nexstellis (estetrol and drospirenone) oral tablets,http://searchlightpharma.com/app/uploads/2021/03/Nextstellis-product-monograph-en-05mar21.pdf
DB12235,,Newswire: Mithra and Searchlight Pharma Announce Nextstellis® Approval in Canada,https://www.newswire.ca/news-releases/mithra-and-searchlight-pharma-announce-nextstellis-r-approval-in-canada-838812919.html
DB12236,,FDA Approved Drug Products: BRENZAVVY (bexagliflozin) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s000lbl.pdf
DB12240,,"FDA Approved Drug Products: POLIVY (polatuzumab vedotin-piiq) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121Orig1s003lbl.pdf
DB12240,,Health Canada Approved Drug Products: POLIVY (polatuzumab vedotin) Intravenous Injection,https://pdf.hres.ca/dpd_pm/00068214.PDF
DB12240,,"FDA Approved Drug Products: POLIVY (polatuzumab vedotin-piiq) for injection, for intravenous use (April 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761121s008lbl.pdf
DB12243,,FDA Approved Drug Products: RADICAVA (edaravone) intravenous injection and RADICAVA ORS (edaravone) oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215446s000lbl.pdf
DB12243,,Health Canada Approved Drug Products: RADICAVA (edaravone) oral suspension,https://pdf.hres.ca/dpd_pm/00068094.PDF
DB12243,,Cayman Chemical: Edaravone MSDS,https://cdn.caymanchem.com/cdn/msds/13320m.pdf
DB12243,,CymitQuimica: Edaravone MSDS,https://static.cymitquimica.com/products/04/pdf/sds-C13105000.pdf
DB12243,,EMA: Radicava; Withdrawal of the marketing authorisation application,"https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/radicava#:~:text=On%2024%20May%202019%2C%20Mitsubishi,amyotrophic%20lateral%20sclerosis%20(ALS)."
DB12243,,EMA Withdrawal assessment report: Radicava,https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-radicava_en.pdf
DB12243,,The Pharma Letter: Mitsubishi Tanabe pulls Radicava MAA for ALS in the Europe,https://www.thepharmaletter.com/article/mitsubishi-tanabe-pulls-radicava-maa-for-als-in-the-europe
DB12243,,Newswire: MITSUBISHI TANABE PHARMA CANADA ANNOUNCES CANADIAN AUTHORIZATION OF RADICAVA® (EDARAVONE) ORAL SUSPENSION FOR THE TREATMENT OF PATIENTS WITH ALS,https://www.newswire.ca/news-releases/mitsubishi-tanabe-pharma-canada-announces-canadian-authorization-of-radicava-r-edaravone-oral-suspension-for-the-treatment-of-patients-with-als-855308448.html
DB12245,,FDA Approves EGATEN (Triclabendazole) for Fascioliasis in Patients 6 Years of Age or Older,http://app.info.fda.gov/e/es?s=2027422842&e=186249&elqTrackId=78D8A052C380BCBFF284D754BEBE9730&elq=696bbb7220e749c480a24a2944222376&elqaid=6800&elqat=1
DB12245,,"Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease",https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-egaten-treatment-fascioliasis-neglected-tropical-disease
DB12245,,FDA Approved Drug Products: EGATEN (triclabendazole) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
DB12248,,TITCK Product Information: Tulair (tulobuterol hydrochloride) oral syrup,https://titck.gov.tr/storage/kubKtAttachments/7629b20984916.pdf
DB12255,,Akebia Therapeutics Press Release: Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis,https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-announces-top-line-results-its-pro2tect
DB12255,,EMA Summary of Product Characteristics: Vafseo (vadadustat) film-coated tablets for oral use,https://www.ema.europa.eu/en/documents/product-information/vafseo-epar-product-information_en.pdf
DB12255,,PR NewsWire: Akebia Receives European Commission Approval for Vafseo (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis,https://www.prnewswire.com/news-releases/akebia-receives-european-commission-approval-for-vafseo-vadadustat-for-the-treatment-of-symptomatic-anaemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis-301807286.html
DB12255,,EMA Assessment Report: Vafseo (vadadustat) film-coated tablets for oral use,https://www.ema.europa.eu/en/documents/assessment-report/vafseo-epar-public-assessment-report_en.pdf
DB12255,,"FDA Approved Drug Products: VAFSEO (vadadustat) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215192s000lbl.pdf
DB12255,,Pharmaceutical Technology: Akebia’s Vafseo gains FDA approval for anaemia due to CKD,https://www.pharmaceutical-technology.com/news/akebia-vafseo-fda-approval-ckd/
DB12265,,FDA Approved Drug Products: Fexinidazole tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214429s001lbl.pdf
DB12265,,Sigma-Aldrich: Fexinidazole SDS,https://www.sigmaaldrich.com/CA/en/sds/sigma/sml2524
DB12267,,FDA News and Events,https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555841.htm
DB12267,,FDA Reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf
DB12274,,FDA Approved Drug Products: Aduhelm (Aducanumab-avwa) Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf
DB12274,,FDA News Release: FDA Grants Accelerated Approval for Alzheimer’s Drug,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
DB12274,,FDA Approved Drug Products: ADUHELM (aducanumab-avwa) injection for intravenous use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761178s007lbl.pdf
DB12274,,"AJMC: Biogen Abandons Aducanumab, Pivots Focus to Lecanemab for Alzheimer Disease",https://www.ajmc.com/view/biogen-abandons-aducanumab-pivots-focus-to-lecanemab-for-alzheimer-disease
DB12277,,DailyMed: HBA Antibacterial Liquid (polihexanide) topical spray,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cc9a531-4e8e-453c-80c8-c71b1bc8dff6
DB12278,,Mictoryl monograph,https://www.duchesnay.com/files/pdf/mictoryl-monograph.pdf
DB12278,,CDR CLINICAL REVIEW REPORT FOR MICTORYL,https://www.cadth.ca/sites/default/files/cdr/clinical/SR0504_Mictoryl_CL%20Report.pdf
DB12278,,The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130959/
DB12278,,Propiverine hydrochloride,https://www.sigmaaldrich.com/catalog/product/sigma/sml0602?lang=en&region=CA
DB12278,,Propiverine Hydrochloride PubChem,https://pubchem.ncbi.nlm.nih.gov/compound/propiverine_hydrochloride
DB12278,,Public assessment report,http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con143796.pdf
DB12278,,Pharmacokinetic Studies on Propiverine Hydrochloride,https://www.jstage.jst.go.jp/article/dmpk1986/10/2/10_2_205/_article
DB12278,,Mictonorm,https://www.ioni.pom.go.id/sites/default/files/obat_baru/Mictonorm.pdf
DB12278,,The muscarinic receptor antagonist propiverine exhibits α1-adrenoceptor antagonism in human prostate and porcine trigonum,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062771/
DB12278,,"Mayo Clinic, Overactive Bladder",https://www.mayoclinic.org/diseases-conditions/overactive-bladder/symptoms-causes/syc-20355715
DB12278,,Maximizing the Treatment of Overactive Bladder in the Elderly,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2312344/
DB12278,,Muscarinic receptor antagonists for overactive bladder,https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1464-410X.2007.07205.x
DB12278,,Propiverine overview,https://www.sciencedirect.com/topics/neuroscience/propiverine
DB12278,,The N-Oxide Metabolite Contributes to Bladder Selectivity Resulting from Oral Propiverine: Muscarinic Receptor Binding and Pharmacokinetics,http://dmd.aspetjournals.org/content/38/8/1314
DB12281,,FDA Approved Drug Products: Reblozyl (luspatercept-aamt) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761136s006lbl.pdf
DB12281,,"FDA Approved Drug Products: REBLOZYL (luspatercept-aamt) for injection, for subcutaneous use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761136s009lbl.pdf
DB12293,,INVIMA Product Authorization: Katamox (nefopam hydrochloride) injectable solution,http://web.sivicos.gov.co/registros/pdf/15953059_2020023804.pdf
DB12301,,Merck Pifeltro FDA Approval Press Release,https://www.drugs.com/newdrugs/fda-approves-merck-s-pifeltro-doravirine-hiv-1-appropriate-patients-4815.html
DB12301,,FDA Approved Drug Products: Pifeltro (doravirine) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210806s003lbl.pdf
DB12319,,FDA Thailand Product Information: Benarone (benzbromarone) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022480021911C
DB12319,,FDA Thailand Product Information: Allomaron (allopurinol/benzbromarone) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022430004611C
DB12328,,"NIH ClinicalTrials.gov: First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699",https://clinicaltrials.gov/ct2/show/NCT03426995
DB12328,,NLM Toxnet: Catharidine,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2181
DB12328,,TITCK Product Information: Canthacur (cantharidin) topical solution,https://titck.gov.tr/storage/kubKtAttachments/d9351be186958.pdf
DB12328,,Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum,https://www.biospace.com/article/releases/verrica-pharmaceuticals-announces-fda-approval-of-ycanth-cantharidin-topical-solution-as-the-first-fda-approved-treatment-of-pediatric-and-adult-patients-with-molluscum-contagiosum/?s=74
DB12328,,FDA Approved Drug Product: YCANTHTM (cantharidin) topical solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212905s000lbl.pdf
DB12328,,Health Canada Approved Drug Proucts: CANTHARONE (Cantharidin) and CANTHARONE PLUS (Cantharidin + salicylic acid + podophyllin) topical solution,http://www.dormer.com/cantharone/pdf/canthbroch.pdf
DB12329,,Xerava Approval History,https://www.drugs.com/history/xerava.html
DB12329,,FDA Approved Drug Products: XERAVA (eravacycline) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf
DB12332,,"FDA Approved Drug Products: RUBRACA (rucaparib) tablets, for oral use (June 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s011lbl.pdf
DB12332,,EMA Approved Drug Products: Rubraca (rucaparib) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/rubraca-epar-product-information_en.pdf
DB12332,,"FDA Approved Drug Products: RUBRACA (rucaparib) tablets, for oral use (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf
DB12371,,FDA approves new oral drug to treat multiple sclerosis,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634469.htm
DB12371,,"MS Society Document, Canada",https://mssociety.ca/about-ms/symptoms
DB12371,,Health Canada Product Monograph: Mayzent (siponimod) oral tablets,https://pdf.hres.ca/dpd_pm/00055111.PDF
DB12374,,Summary of Product Characteristics: Lamzede (velmanase alfa) solution for intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/lamzede-epar-product-information_en.pdf
DB12374,,European Medicines Agency: Lamzede (velmanase alfa),https://www.ema.europa.eu/en/medicines/human/EPAR/lamzede
DB12374,,"FDA Approved Drug Products: LAMZEDE (velmanase alfa-tycv) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761278s000lbl.pdf
DB12377,,"FDA Approved Drug Products: Recarbrio (imipenem, cilastatin, and relebactam) for intravenous injection",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212819s002lbl.pdf
DB12390,,"FDA Approved Drug Products: LIVDELZI (seladelpar) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf
DB12390,,"Fierce Pharma: With FDA approval of Livdelzi, Gilead launches an inflammatory drug for the first time",https://www.fiercepharma.com/pharma/fda-approval-livdelzi-gilead-launches-inflammatory-drug-first-time
DB12401,,AIFA Product Information: Impromen (bromperidol) for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000045_026017_RCP.pdf&retry=0&sys=m0b1l3
DB12404,,FDA Approved Drug Products: Byfavo (remimazolam) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf
DB12404,,Cosmo Pharmaceuticals: Cosmo Pharmaceuticals Announces US FDA Approval of BYFAVO (remimazolam injection),https://www.cosmopharma.com/news-and-media/press-releases-and-company-news/2020/200702
DB12404,,FDA Approved Drug Products: Byfavo (remimazolam) for intravenous injection [Updated 01/2023],https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212295s003lbl.pdf
DB12407,,TITCK Product Information: Xenetix (iobitridol) solution for injection,https://titck.gov.tr/storage/kubKtAttachments/e8ca475e29932.pdf
DB12412,,FDA Thailand Product Information: Zemiglo (gemigliptin) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1012590008411C
DB12418,,Dulcaryl (saccharin) effervescent tablets (User Guide),http://www.bilimilac.com/tr/dosyalar/urun-portfoyu/urunler/1_73535287_dulcaryl-effervesan-tablet.pdf
DB12447,,TITCK Product Information: Nadixa (nadifloxacin) topical cream,https://titck.gov.tr/storage/kubKtAttachments/7a23f68565258.pdf
DB12457,,BiopharmaDive: 5 FDA Approval Decisions to Watch in the 1st Quarter,https://www.biopharmadive.com/news/5-fda-approval-decisions-to-watch-first-quarter/569687/
DB12457,,FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s006lbl.pdf
DB12457,,Biohaven Pharmaceuticals Press Release: Nurtec ODT FDA Approval,https://www.biohavenpharma.com/investors/news-events/press-releases/02-27-2020
DB12457,,CaymanChem: Rimegepant MSDS,https://www.caymanchem.com/msdss/26338m.pdf
DB12457,,"PR Newswire: FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine",https://www.prnewswire.com/news-releases/fda-approves-qulipta-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-the-preventive-treatment-of-migraine-301387297.html
DB12457,,Pfizer: Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biohavens-vydurar-rimegepant-granted-first-ever
DB12466,,Nature Biotechnology: Coronavirus puts drug repurposing on the fast track,https://www.nature.com/articles/d41587-020-00003-1
DB12466,,Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report,https://www.pmda.go.jp/files/000210319.pdf
DB12466,,World Health Organization: Influenza (Avian and other zoonotic),https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic)
DB12471,,FDA Approved Drug Products: Brexafemme (Ibrexafungerp) Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214900s000lbl.pdf
DB12471,,FDA Approved Drug Products: BREXAFEMME (Ibrexafungerp) Oral Tablets (November 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214900s002lbl.pdf
DB12472,,AIFA Product Information: Salvituss (levodropropizine) for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000211_027661_RCP.pdf&retry=0&sys=m0b1l3
DB12473,,FDA Approved Drug Products: Defencath (taurolidine and heparin) catheter lock solution for central venous catheter instillation use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214520s000lbl.pdf
DB12473,,CorMedix: About DefenCath,https://cormedix.com/about-defencath/
DB12473,,FDA News & Events for Human Drugs: FDA approves new drug under special pathway for patients receiving hemodialysis,https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-under-special-pathway-patients-receiving-hemodialysis
DB12473,,Cayman Chemical: Taurolidine MSDS,https://cdn.caymanchem.com/cdn/msds/15374m.pdf
DB12474,,FDA Thailand Product Information: Dailyton (lynestrenol) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022500023911C
DB12474,,TITCK Product Information: Orgametril (lynestrenol) oral tablets,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK-UYGUN-K%C3%9CB-%20ORGAMETR%C4%B0L.pdf_1568e10e-ad8a-400b-8668-dcc1292baa11.pdf
DB12478,,FDA Thailand Product Information: Trivastal (piribedil) extended-release tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022410014111C
DB12478,,TITCK Product Information: Trivatal (piribedil) extended-release tablets,https://titck.gov.tr/storage/kubKtAttachments/i2A8iNJSstu5W.pdf
DB12483,,FDA Press Announcements: FDA approves new treatment for adults with relapsed follicular lymphoma,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576129.htm
DB12483,,"FDA Approved Drug Products: ALIQOPA (copanlisib) for injection, for intravenous use (September 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209936s012lbl.pdf
DB12483,,EMA: Aliqopa (copanlisib) withdrawal assessment report,https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-aliqopa_en.pdf
DB12487,,AIFA Product Information: Colpotrophine (promestriene) for vaginal use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004828_026613_RCP.pdf&retry=0&sys=m0b1l3
DB12489,,FDA Approved Drug Products: ELAHERE (mirvetuximab soravtansine-gynx) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf
DB12489,,OncLive: FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer,https://www2.onclive.com/view/fda-approves-mirvetuximab-soravtansine-gynx-for-fr-platinum-resistant-ovarian-cancer
DB12489,,FDA Approved Drug Products: Elahere (mirvetuximab soravtansine-gynx) for intravenous injection,https://elahere.com/pdf/prescribing-information.pdf
DB12489,,BioSpace: U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients,https://www.biospace.com/article/releases/u-s-food-and-drug-administration-fda-grants-full-approval-for-elahere-mirvetuximab-soravtansine-gynx-for-certain-ovarian-cancer-patients/?s=74
DB12492,,BASG Product Information: Piritramid-hameln (piritramide) solution for injection,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-30412&type=DOTC_FACH_INFO
DB12498,,FDA approves treatment for two rare types of non-Hodgkin lymphoma,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm
DB12498,,Sezary Syndrome,https://ghr.nlm.nih.gov/condition/sezary-syndrome
DB12498,,POTELIGEO,https://www.drugs.com/history/poteligeo.html
DB12498,,Mogamulizumab NCI,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mogamulizumab
DB12498,,FDA Approved Drug Products: Poteligeo (mogamulizumab-kpkc) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761051s015lbl.pdf
DB12498,,Health Canada Product Monograph: Poteligeo (mogamulizumab) for intravenous injection,https://pdf.hres.ca/dpd_pm/00066376.PDF
DB12499,,Drugs.com: FDA Approves Winlevi,https://www.drugs.com/newdrugs/fda-approves-winlevi-clascoterone-cream-acne-5332.html
DB12499,,"FDA Approved Drug Products: WINLEVI (clascoterone) cream, for topical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf
DB12499,,Health Canada Approved Drug Products: WINLEVI (clascoterone) cream for topical use (June 2023),https://pdf.hres.ca/dpd_pm/00071308.PDF
DB12500,,FDA Approved Drug Products: Fedratinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf
DB12500,,FDA Approved Drug Products: INREBIC (fedratinib) capsules for oral use (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212327s005lbl.pdf
DB12513,,FDA Approved Drug Products: SKYCLARYS (omaveloxolone) capsules for oral use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf
DB12513,,EMA Approved Drug Products: Skyclarys (omaveloxolone) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/skyclarys-epar-product-information_en.pdf
DB12523,,EMC Package Leaflet: Mizollen (mizolastine) modified-release tablets,https://www.medicines.org.uk/emc/files/pil.363.pdf
DB12523,,EMC Summary of Product Characteristics: Mizollen (mizolastine) modified-release tablets for oral use,https://www.medicines.org.uk/emc/product/363
DB12530,,FDA Approved Drug Products: Uplizna (inebilizumab-cdon) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf
DB12530,,Health Canada Approved Drug Proucts: UPLIZNA (Inebilizumab) injection for intravenenous use,https://pdf.hres.ca/dpd_pm/00073831.PDF
DB12530,,Health Canada Approves UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD),https://www.newswire.ca/news-releases/health-canada-approves-uplizna-r-inebilizumab-for-injection-for-the-treatment-of-neuromyelitis-optica-spectrum-disorders-nmosd--885268847.html
DB12532,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB12532,,EMA Herbal substances,http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500163679
DB12543,,FDA Approved Drug Products: LYBALVI (olanzapine and samidorphan) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf
DB12543,,DEA Proposal: Removal of Samidorphan from Controlled Substance Schedule,https://www.federalregister.gov/documents/2020/12/10/2020-26812/schedules-of-controlled-substances-removal-of-samidorphan-from-control
DB12543,,DEA: Removal of Samidorphan from Schedule II,https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiqmKmXhIbxAhWsVN8KHZBtBUEQFjAGegQICBAD&url=https%3A%2F%2Fdownloads.regulations.gov%2FDEA-2021-0004-0002%2Fcontent.pdf&usg=AOvVaw2aNlpWgIFEK5omz3QmKuJ0
DB12545,,FDA Thailand Product Information: Ibustrin (indobufen) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022410028911C
DB12545,,AIFA Product Information: Ibustrin (indobufen) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000040_025308_RCP.pdf&retry=0&sys=m0b1l3
DB12548,,FDA Approved Drug Products: FILSPARI (sparsentan) tablets for oral use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf
DB12548,,EMJ: The Dual Role of Endothelin-1 and Angiotensin II in Disease Progression of Focal Segmental Glomerulosclerosis and IgA Nephropathy (Symposium Review),https://emj.emg-health.com/wp-content/uploads/sites/2/2022/06/The-Dual-Role-of-Endothelin-1-and-Angiotensin-II-in-Disease-Progression-of-Focal-Segmental-Glomerulosclerosis-and-IgA-Nephropathy.pdf
DB12548,,"Globe News Wire: Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy",https://www.globenewswire.com/news-release/2023/02/17/2610963/0/en/Travere-Therapeutics-Announces-FDA-Accelerated-Approval-of-FILSPARITM-sparsentan-the-First-and-Only-Non-immunosuppressive-Therapy-for-the-Reduction-of-Proteinuria-in-IgA-Nephropath.html
DB12548,,FDA Approved Drug Products: Filspari (sparsentan) tablets for oral use (September 2024),https://travere.com/wp-content/uploads/2024/09/FILSPARI-USPI-and-Med-Guide-09_2024.pdf
DB12548,,"Travere Therapeutics News Release: Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy",https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-full-fda-approval-filsparir
DB12548,,EMA Approved Drug Products: Filspari (sparsentan) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/filspari-epar-product-information_en.pdf
DB12548,,Travere Therapeutics: Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy,https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-and-csl-vifor-announce-european-commission
DB12592,,Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia,https://www.biospace.com/article/releases/enzychem-lifesciences-announces-fda-acceptance-of-phase-2-study-of-ec-18-in-preventing-acute-respiratory-distress-syndrome-ards-due-to-covid-19-pneumonia/
DB12597,,FDA Approved Drug Products: Scemblix (asciminib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig2lbl.pdf
DB12597,,FDA News Release: FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia
DB12597,,NIH National Cancer Institute: BCR-ABL fusion gene,https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bcr-abl-fusion-gene
DB12597,,EMA Summary of Product Characteristics: Scemblix (asciminib) film-coated tablets for oral use,https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf
DB12597,,FDA Approved Drug Products: Scemblix (asciminib) tablets for oral use (June 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215358s003lbl.pdf
DB12598,,FDA Executive Summary,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM543963.pdf
DB12612,,Celgene: Press releases archive,https://ir.celgene.com/press-releases-archive/default.aspx
DB12612,,AJMC: FDA approves Zeposia (Ozanimod) for patients with RMS,https://www.ajmc.com/newsroom/fda-approves-zeposia-ozanimod-for-patients-with-rms
DB12612,,FDA Approved Drug Products: Zeposia (ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209899s003lbl.pdf
DB12612,,BioSpace News Release: Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis,https://www.biospace.com/article/releases/bristol-myers-squibb-receives-european-commission-approval-of-zeposia-ozanimod-for-use-in-adults-with-moderately-to-severely-active-ulcerative-colitis/?keywords=European+Commission+Approval+
DB12612,,Summary of Product Characteristics: Zeposia (ozanimod) oral capsules,https://www.ema.europa.eu/en/documents/product-information/zeposia-epar-product-information_en.pdf
DB12612,,Health Canada Approved Drug Products: ZEPOSIA (ozanimod) Oral Capsules,https://www.bms.com/assets/bms/ca/documents/productmonograph/ZEPOSIA_EN_PM.pdf
DB12624,,BASG Product Information: Octenidine oral lozenge,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=138394&type=DOTC_FACH_INFO
DB12624,,TITCK Product Information: Oseptin (octenidine dihydrochloride) oral solution,https://titck.gov.tr/storage/kubKtAttachments/3wzw13a2rMBGb.pdf
DB12624,,TITCK Product Information: Octenisept (octenidine/phenoxyethanol) topical solution,https://titck.gov.tr/storage/kubKtAttachments/xEjmMujMoZOuM.pdf
DB12645,,FDA Approved Drug Products: Duvyzat (givinostat) suspension for oral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217865Orig1s000lbl.pdf
DB12645,,FDA Press Announcement: FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy,https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy
DB12656,,AIFA Product Information: GHRH Ferring (somatorelin acetate) powder for solution for injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007051_027548_RCP.pdf&retry=0&sys=m0b1l3
DB12661,,BASG Product Information: Urapidil prolonged-release capsules,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=139406&type=DOTC_FACH_INFO
DB12661,,AIFA Product Information: Ebrantil (urapidil hydrochloride) solution for intravenous infusion,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000348_026563_RCP.pdf&retry=0&sys=m0b1l3
DB12667,,TITCK Product Information: Promid (protionamide) coated tablets for oral use,https://titck.gov.tr/storage/kubKtAttachments/0dDjFYSnopaze.pdf
DB12668,,NIH: Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection (NCT04374032),https://clinicaltrials.gov/ct2/show/NCT04374032
DB12668,,Bosna Lijek: Enkorten Metenkefalin and Tridecactide Injection,http://www.bosnalijek.com/products-L2e?c=ign&ign=metenkefalin%20%2B%20tridecactide
DB12668,,Bosna Lijek: Enkorten Summary of Product Characteristics,http://bosnalijek.ba/enkorten-liofilizat-za-otopinu-za-injekciju-6-bocica-liofilizata---6-ampula-otopine-za-rastvaranje-5-mg---1-mg-
DB12674,,FDA Approved Drug Products: Zepzelca (lurbinectedin) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213702s004lbl.pdf
DB12674,,FDA Drug Approvals and Databases: FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
DB12688,,FDA news,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620448.htm
DB12688,,Patent WO20141002243A2,https://patents.google.com/patent/WO2014100443A2/en
DB12688,,AstraZeneca news,https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-03042018.html
DB12698,,FDA label Trogarzo,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf
DB12698,,Trogarzo Approved to Treat Multidrug Resistant HIV-1 Infection,https://www.empr.com/news/trogarzo-ibalizumab-antiretroviral-multi-drug-resistant-hiv-1-infection/article/749090/
DB12698,,Ibalizumab,https://aidsinfo.nih.gov/drugs/511/ibalizumab/0/professional
DB12698,,"Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630626/
DB12698,,Ibalizumab,https://aidsinfo.nih.gov/drugs/511/ibalizumab/0/patient
DB12698,,"Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711820/
DB12698,,Monotherapy With Anti-CD4 Monoclonal Antibody Cuts Viral Load 10-Fold in 7 Days,http://www.natap.org/2016/IDSA/IDSA_10.htm
DB12698,,"FDA Approved Drug Products: TROGARZO (ibalizumab-uiyk) injection, for intravenous use (October 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761065s013lbl.pdf
DB12698,,"Globe Newswire: Theratechnologies’ Trogarzo Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population",https://www.globenewswire.com/news-release/2022/10/03/2527271/0/en/Theratechnologies-Trogarzo-Approved-by-FDA-for-30-Second-Intravenous-IV-Push-Simplifying-HIV-Treatment-for-Heavily-Treatment-Experienced-Population.html
DB12708,,AIFA Product Information: Nalador (sulprostone) powder for solution for infusion,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000022_025998_RCP.pdf&retry=0&sys=m0b1l3
DB12710,,DIMDI Drug Product Information: Perazin-neuraxpharm (perazine) film-coated tablets,https://portal.dimdi.de/amispb/doc/2016/12/14/0625763/O438cd3368d50494097f0ff818cb178b1.pdf
DB12713,,EMA Summary of Product Characteristics: Zynquista (sotagliflozin) film-coated tablets for oral use,https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf
DB12713,,FDA Endocrinologic And Metabolic Drugs Advisory Committee: Sotagliflozin for the Treatment of Type 1 Diabetes,https://www.fda.gov/media/121285/download
DB12713,,EMA European Public Assessment Report: Zynquista (sotagliflozin),https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista
DB12713,,"US Federal Register: Proposal To Refuse To Approve a New Drug Application for Sotagliflozin Oral Tablets, 200 Milligrams and 400 Milligrams; Opportunity for a Hearing",https://public-inspection.federalregister.gov/2021-04342.pdf
DB12713,,"FDA Approved Drug Products: INPEFA (sotagliflozin) tablets, for oral use (May 2023)",https://www.lexpharma.com/inpefa-US-PI.pdf
DB12713,,EMA Public Statement: Zynquista Withdrawal of the marketing authorisation in the European Union,https://www.ema.europa.eu/en/documents/public-statement/public-statement-zynquista-withdrawal-marketing-authorisation-european-union_en.pdf
DB12742,,Product Announcement,http://www.emaxhealth.com/95/13668.html
DB12764,,RedHill Biopharma: Opaganib - COVID-19,https://www.redhillbio.com/opaganibcovid19
DB12764,,"Opaganib (Yeliva®, ABC294640)",https://www.redhillbio.com/yeliva
DB12768,,TITCK Product Information: Calgevax-BCG (BCG for immunotherapy) powder for intravesical injection,https://titck.gov.tr/storage/kubKtAttachments/6faHTwLCwcRsU.pdf
DB12768,,"TITCK Product Information: SII-BCG (BCG vaccine, live, attenuated) powder for suspension for intradermal injection",https://titck.gov.tr/storage/kubKtAttachments/6250706d10210.pdf
DB12783,,Electronic Medicines Compendium: Madopar (levodopa/benserazide hydrochloride) 200mg/50mg Hard Capsules Monograph,https://www.medicines.org.uk/emc/product/6926/smpc
DB12808,,FDA Approved Drugs: Aklief®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
DB12825,,Xenleta FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf"
DB12825,,FDA Approved Drug Products: XENLETA (lefamulin) tablets and injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211672s002,211673s002lbl.pdf"
DB12831,,AIFA Product Information: Gabexate mesylate powder for solution for infusion,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000823_041445_RCP.pdf&retry=0&sys=m0b1l3
DB12834,,INVIMA Product Information: Bioprox (itraconazole/secnidazole) oral tablets,http://web.sivicos.gov.co/registros/pdf/15714090_2019002657.pdf
DB12834,,FDA Approved Drug Products: Solosec (secnidazole) oral granules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209363Orig1s014s016lbl.pdf
DB12835,,EMA Approved Drug Products: Xenpozyme (olipudase alfa) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/xenpozyme-epar-product-information_en.pdf
DB12835,,GlobeNewswire News Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD,https://www.globenewswire.com/news-release/2022/06/28/2469974/0/en/Press-Release-Xenpozyme-olipudase-alfa-approved-by-European-Commission-as-first-and-only-treatment-for-ASMD.html
DB12835,,"FDA Approved Drug Products: XENPOZYME (olipudase alfa-rpcp) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761261s000lbl.pdf
DB12835,,"FDA NEWS RELEASE: FDA Approves First Treatment for Acid Sphingomyelinase Deficiency, a Rare Genetic Disease",https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-acid-sphingomyelinase-deficiency-rare-genetic-disease
DB12835,,"FDA Approved Drug Products: XENPOZYME® (olipudase alfa-rpcp) for injection, for intravenous use (Dec 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761261s002lbl.pdf
DB12836,,WHO,https://www.who.int/medicines/services/inn/stembook/en/
DB12839,,"FDA Press Announcements: FDA approves a new treatment for PKU, a rare and serious genetic disease",https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608835.htm
DB12839,,FDA Approved Drug Products: PALYNZIQ (pegvaliase-pqpz) injection for subcutaneous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761079s010lbl.pdf
DB12839,,Health Canada Approved Drug Products: PALYNZIQ (pegvaliase-pqpz) injection for subcutaneous use,https://pdf.hres.ca/dpd_pm/00065238.PDF
DB12846,,DIMDI Product Information: Aarane-N (reproterol hydrochloride/sodium cromoglycate) suspension for inhalation,https://portal.dimdi.de/amispb/doc/2014/04/29/2103159/OBFM9845B1E201CF5A9D.pdf
DB12846,,National Center for Advancing Translational Science: Reproterol,https://drugs.ncats.io/drug/11941YC6RN
DB12865,,FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208325Orig1s000Lbledt.pdf
DB12867,,DIMDI Product Information: Benperidol-neuraxpharm (benperidol) solution for injection,https://portal.dimdi.de/amispb/doc//2015/06/02/0198841/Oc97c8f243724422084b6d6532e3210e6.pdf
DB12867,,DIMDI Product Information: Glianimon (benperidol) for oral use,https://portal.dimdi.de/amispb/doc//2014/12/16/2127353/O847ddb7ecb6343b88793379385ee2781.pdf
DB12872,,EMA Approved Drug Products: Veyvondi (vonicog alfa) Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/veyvondi-epar-product-information_en.pdf
DB12874,,"FDA Approved Drug Products: VANFLYTA® (quizartinib) tablets, for oral use",https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Vanflyta&inline=true
DB12874,,EMA Assessment Report: quizartinib,https://www.ema.europa.eu/en/documents/assessment-report/vanflyta-epar-refusal-public-assessment-report_en.pdf
DB12874,,VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML,https://www.biospace.com/article/releases/vanflyta-first-flt3-inhibitor-approved-in-the-u-s-specifically-for-patients-with-newly-diagnosed-flt3-itd-positive-aml/
DB12874,,EMA Approved Drug Products: VANFLYTA (quizartinib) tablets for oral use,https://www.ema.europa.eu/en/documents/product-information/vanflyta-epar-product-information_en.pdf
DB12877,,AIFA Product Information: Tinset (oxatomide) for oral and topical use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000045_025293_RCP.pdf&retry=0&sys=m0b1l3
DB12887,,FDA Approved Drug Products: Tazverik (tazemetostat) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf
DB12893,,FDA Approved Drug Products: Trodelvy (sacituzumab govitecan-hziy) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf
DB12893,,BioSpace News Release: Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line,https://www.biospace.com/article/releases/trodelvy-sacituzumab-govitecan-granted-european-commission-marketing-authorization-for-treatment-of-metastatic-triple-negative-breast-cancer-in-second-line/?keywords=European+Commission+Approval+
DB12893,,FDA Approved Drug Products: Trodelvy (sacituzumab govitecan-hziy) for intravenous injection (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf
DB12893,,"Health Canada Approved Drug Proucts: TRODELVY (sacituzumab govitecan) lyophilized powder for solution for injection, for intravenous use",https://pdf.hres.ca/dpd_pm/00071772.PDF
DB12893,,HEALTH CANADA APPROVES TRODELVY® (SACITUZUMAB GOVITECAN) IN PRE-TREATED HR+/HER2- METASTATIC BREAST CANCER,https://www.newswire.ca/news-releases/health-canada-approves-trodelvy-r-sacituzumab-govitecan-in-pre-treated-hr-her2-metastatic-breast-cancer-863545609.html
DB12893,,EMA Approved Drug Products: Trodelvy (sacituzumab govitecan) for intravenous injection,https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf
DB12914,,"FDA Approved Drug Products: REZDIFFRA (resmetirom) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf
DB12914,,FDA: FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
DB12917,,EMA Summary of Product Characteristics: Bimzelx (bimekizumab) solution for subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf
DB12917,,EMA European Public Assessment Report: Bimzelx (bimekizumab),https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx
DB12917,,"FDA Approved Drug Products: BIMZELX (bimekizumab-bkzx) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761151s000lbl.pdf
DB12917,,PR Newswire: BIMZELX Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis,https://www.prnewswire.com/news-releases/bimzelx-approved-by-the-us-fda-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis-301960454.html
DB12917,,Health Canada Approved Drug Products: BIMZELX (bimekizumab) Subcutaneous Injection,https://pdf.hres.ca/dpd_pm/00074908.PDF
DB12917,,FDA Approved Drug Products: Bimzelx (bimekizumab-bkzx) solution for subcutaneous injection (September 2024),https://www.ucb-usa.com/bimzelx-prescribing-information.pdf
DB12924,,"FDA Approved Drug Products: XEPITM (ozenoxacin) cream, for topical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208945lbl.pdf
DB12930,,DIMDI Drug Product Information: Opipramol AbZ film-coated tablets,https://portal.dimdi.de/amispb/doc//2015/04/24/2158012/O976ecd332c5445f0b7f3e80f7bf34d72.pdf
DB12941,,"FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
DB12941,,Darolutamide MSDS,https://www.selleckchem.com/msds/MSDS_S7559.pdf
DB12941,,FDA approves darolutamide,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer
DB12941,,Darolutamide patent,https://patents.google.com/patent/WO2019032840A1/en
DB12941,,"FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use (August 2022)",https://labeling.bayerhealthcare.com/html/products/pi/Nubeqa_PI.pdf
DB12942,,FDA Approved Drug Products: Pizensy (lactitol) oral solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211281s000lbl.pdf
DB12942,,MOLBASE: Lactitol monohydrate MSDS,http://www.molbase.com/en/msds_81025-04-9-moldata-1532600.html
DB12944,,AIFA Product Information: Spasmex (phloroglucinol or phloroglucinol/trimethoxybenzene),https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008057_020851_RCP.pdf&retry=0&sys=m0b1l3
DB12958,,DIMDI Drug Product Information: Dominal (prothipendyl hydrochloride) for oral use,https://portal.dimdi.de/amispb/doc/2018/06/13/0373669/O3ccc873802704b559946ce965f1903b7.pdf
DB12965,,"SILVER, ELEMENTAL - National Library of Medicine HSDB Database - Toxnet",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5034
DB12978,,FDA Approved Drug Products: Turaliotm (pexidartinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf
DB12978,,"TURALIO (PEXIDARTINIB) CAPSULES - Daiichi Sankyo, Inc. - FDA Oncologic Drugs Advisory Committee Briefing Document",https://www.fda.gov/media/124893/download
DB12978,,FDA approves first therapy for rare joint tumor - FDA News Release,https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-joint-tumor
DB12978,,FDA Approved Drug Products: Turaliotm (pexidartinib) capsules (October 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211810s009lbl.pdf
DB13001,,SehatQ: Nonflamin (tinoridine hydrochloride) for oral use,https://www.sehatq.com/obat/nonflamin-kapsul-50-mg
DB13007,,FDA Approved Drug Products: Padcev (enfortumab vedotin-ejfv) for IV injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf
DB13007,,EMA Approved Drug Products: Padcev (enfortumab vedotin) intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/padcev-epar-product-information_en.pdf
DB13007,,Businesswise News: European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer,https://www.businesswire.com/news/home/20220410005042/en/European-Commission-Approves-PADCEV%E2%84%A2-enfortumab-vedotin-for-Locally-Advanced-or-Metastatic-Urothelial-Cancer
DB13007,,FDA Approved Drug Products: Padcev (enfortumab vedotin-ejfv) for IV injection (December 2023),https://astellas.us/docs/PADCEV_label.pdf
DB13007,,Pfizer Press Release: PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer,https://www.pfizer.com/news/press-release/press-release-detail/padcevr-enfortumab-vedotin-ejfv-keytrudar-pembrolizumab
DB13025,,AIFA Product Information: Sereprile (tiapride hydrochloride) solution for injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008055_023402_RCP.pdf&retry=0&sys=m0b1l3
DB13026,,TITCK Product Information: Bitazol (ornidazole) solution for infusion,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/Bitazol500mg3mlnfzyonlukzeltikb_481951d5-d12f-4d69-a540-667d9d2312d3.pdf
DB13026,,TITCK Product Information: Bitazol (ornidazole) film-coated tablets,https://titck.gov.tr/storage/kubKtAttachments/a4cdaefd86205.pdf
DB13026,,TITCK Product Information: Bitazol (ornidazole) vaginal tablets,https://titck.gov.tr/storage/kubKtAttachments/0b22a86856420.pdf
DB13026,,TITCK Product Information: Ornisasin (ornidazole/ciprofloxacin hydrochloride) film-coated tablets,https://titck.gov.tr/storage/kubKtAttachments/MpAcRhvRgxCzS.pdf
DB13028,,FDA Thailand Product Information: Omegacin (biapenem) for intravenous infusion,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1012560008111C
DB13042,,Vademecum: Spasmopriv Plus (fenoverine) oral capsules,"https://www.vademecum.es/equivalencia-lista-spasmopriv+plus+capsule,+hard+200+mg-colombia-a03ax05-co_1"
DB13055,,FDA Approved Drug Products: Vivjoa (oteseconazole) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf
DB13055,,FDA Letter of Approval: Vivjoa (oteseconazole) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215888Orig1s000ltr.pdf
DB13084,,FDA Thailand Product Information: Encephabol (pyritinol dihydrochloride) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022340027811C
DB13089,,TITCK Product Information: Anzibel (chlorhexidine/benzocaine/enoxolone) for oral use,https://titck.gov.tr/storage/kubKtAttachments/r3x3n8ExVr7G0.pdf
DB13091,,FDA Thailand Product Information: Maiorad (tiropramide hydrochloride) film-coated tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022480030111C
DB13091,,AIFA: Alfospas (Tiropramide) Oral Capsule,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_006137_024605_FI.pdf&retry=0&sys=m0b1l3
DB13092,,Meclocycline Phase II Trial: Oral Mucositis,https://clinicaltrials.gov/ct2/show/NCT00385515
DB13092,,Torrino Medica: Mecloderm (meclocycline) vaginal ovules,https://www.torrinomedica.it/schede-farmaci/mecloderm_35mg_ovuli/
DB13092,,Torrino Medica: Mecloderm (meclocycline) topical cream,https://www.torrinomedica.it/schede-farmaci/mecloderm_crema/
DB13114,,DIMDI Drug Product Information: Amioxid-Neuraxpharm (amitriptylinoxide) oral tablets,https://portal.dimdi.de/amispb/doc/2019/03/08/2115845/O3d7b326530f54873b9906ed7319c6845.pdf
DB13125,,FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm615348.htm
DB13131,,FDA Thailand Product Information: Sumidin (serrapeptase) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022280272211C
DB13131,,NPRA: Serrata (Serrapeptase) Oral Tablet,https://quest3plus.bpfk.gov.my/front-end/attachment/627/pharma/76009/V_34031_20190827_170339_D4.pdf
DB13133,,FDA Approved Drug Products: WILATE [von Willebrand Factor/Coagulation Factor VIII Complex (Human)] Lyophilized Powder for Solution for Intravenous Injection,https://www.fda.gov/media/77812/download
DB13133,,"FDA Approved Drug Products: VONVENDI [von Willebrand factor (recombinant)] lyophilized powder for solution, for intravenous injection",https://www.shirecontent.com/PI/PDFs/VONVENDI_USA_ENG.pdf
DB13139,,Sciencedirect,http://www.sciencedirect.com/science/article/pii/B978032301840150013X
DB13140,,"FDA Approved Drug Products: ZINPLAVA (bezlotoxumab) injection, for intravenous use (October 2016)",http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf
DB13140,,"FDA Approved Drug Products: ZINPLAVA (bezlotoxumab) injection, for intravenous use (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761046s012lbl.pdf
DB13140,,Merck: Bezlotoxumab MSDS,https://www.merck.com/docs/product/safety-data-sheets/hh-sds/Bezlotoxumab%20Formulation_HH_US_EN.pdf
DB13140,,EMA Approved Drug Products: ZINPLAVA (bezlotoxumab) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/zinplava-epar-product-information_en.pdf
DB13141,,AIFA Product Information: Ambromucil (ambroxol acefyllinate) for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000550_028061_RCP.pdf&retry=0&sys=m0b1l3
DB13142,,Drug Information,http://davisplus.fadavis.com/3976/meddeck/pdf/calciumglubionate.pdf
DB13142,,TITCK Product Information: Calcium glubionate solution for injection,https://titck.gov.tr/storage/kubKtAttachments/b83f4dd599758.pdf
DB13144,,Medsafe,http://www.medsafe.govt.nz/profs/Datasheet/g/Granocyteinj.htm
DB13144,,ChemIDPlus,https://chem.nlm.nih.gov/chemidplus/rn/135968-09-1
DB13144,,AIFA Product Information: Myelostim (lenograstim) powder for injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000068_029059_RCP.pdf&retry=0&sys=m0b1l3
DB13146,,FDA News and Events,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503920.htm
DB13146,,Axumin,http://www.axumin.com/pdf/formulary_information/Dosing_Admin_03%20FINAL.pdf
DB13146,,Axumin,http://www.axumin.com/pdf/formulary_information/Clinical_Summary_FINAL.pdf
DB13146,,FDA Reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208054Orig1s000PharmR.pdf
DB13146,,FDA Approved Drug Products: AXUMIN (fluciclovine F 18) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208054s034lbl.pdf
DB13147,,Creon monograph,http://www.rxabbvie.com/pdf/creon_PI.pdf
DB13147,,FDA approval,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022523_pancreaze_toc.cfm
DB13148,,FDA Approved Drug Products: COAGADEX (Coagulation Factor X (Human)) Lyophilized Powder for Solution for Intravenous Injection,https://www.fda.gov/media/94797/download
DB13148,,"FDA Approved Drug Products: KCENTRA (Prothrombin Complex Concentrate (Human)) For Intravenous Use, Lyophilized Powder for Reconstitution",https://www.fda.gov/media/85512/download
DB13148,,"FDA Approved Drug Products: BALFAXAR (prothrombin complex concentrate, human-lans) lyophilized powder for solution, for intravenous use (July 2023)",https://www.fda.gov/media/170477/download
DB13149,,"FDA Approved Drug Products: BALFAXAR (prothrombin complex concentrate, human-lans) lyophilized powder for solution, for intravenous use (July 2023)",https://www.fda.gov/media/170477/download
DB13150,,KCENTRA monograph,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eee1afb8-324c-42e4-8bf0-f0c9da5e6d42
DB13150,,"FDA Approved Drug Products: BALFAXAR (prothrombin complex concentrate, human-lans) lyophilized powder for solution, for intravenous use (July 2023)",https://www.fda.gov/media/170477/download
DB13152,,NCBI,https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Term=2158
DB13152,,"FDA Approved Drug Products: BALFAXAR (prothrombin complex concentrate, human-lans) lyophilized powder for solution, for intravenous use (July 2023)",https://www.fda.gov/media/170477/download
DB13153,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/_-_-alpha-Bisabolol
DB13153,,NCBI,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958188/
DB13153,,BASG Product Information: Sensicutan (bisabolol/heparin sodium) topical ointment,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-24304&type=DOTC_FACH_INFO
DB13154,,Sciencelab,http://www.sciencelab.com/msds.php?msdsId=9923432
DB13154,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/4684#section=Absorption-Distribution-and-Excretion
DB13154,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/2-chlorophenol#section=Mechanism-of-Action
DB13154,,TOXNET,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1414
DB13154,,ChemSpider,http://www.chemspider.com/Chemical-Structure.13875219.html
DB13154,,Septodont: Cresophene (dexamethasone/thymol/parachlorophenol) solution for dental use,https://www.septodont.co.uk/sites/default/files/Cresophene%20Patient%20information%20leaflet%20S%2005%2006%20007%2011%2000.pdf
DB13154,,FDA Thailand Product Information: Cresophene (dexamethasone/thymol/parachlorophenol) solution for dental use,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022310008711C
DB13154,,ThermoFisher Scientific: 4-Chlorophenol safety data sheet,https://www.fishersci.com/store/msds?partNumber=AC181000051&productDescription=4-CHLOROPHENOL+99%2B%25+5KG&vendorId=VN00032119&countryCode=US&language=en
DB13155,,HMDB,http://www.hmdb.ca/metabolites/HMDB30820
DB13155,,Indena,http://cn.indena.com/pdf/cn/esculoside.pdf
DB13155,,Toxnet,https://chem.nlm.nih.gov/chemidplus/rn/531-75-9
DB13155,,Health Canada Product Monograph: Proctosedyl (hydrocortisone/framycetin/cinchocaine/aesculin) for rectal administration,https://pdf.hres.ca/dpd_pm/00046842.PDF
DB13156,,ChemIDplus,https://chem.nlm.nih.gov/chemidplus/rn/36703-88-5
DB13156,,Pubchem,https://pubchem.ncbi.nlm.nih.gov/compound/inosine
DB13157,,US Patent 3211614,https://patentimages.storage.googleapis.com/ac/fe/8b/4510bbea246636/US3211614.pdf
DB13158,,Medsafe,http://www.medsafe.govt.nz/profs/Datasheet/e/Eumovatecrm.pdf
DB13158,,ChemIdplus,https://chem.nlm.nih.gov/chemidplus/rn/25122-57-0
DB13161,,CENTER FOR DRUG EVALUATION AND RESEARCH,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209531Orig1s000ClinPharmR.pdf
DB13161,,FDA Approved Drug Products: Spinraza (nusinersen) for intrathecal injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209531s010lbl.pdf
DB13164,,Hanmi Pharmaceutical Olmutinib Phase I Poster,http://www.hanmi.co.kr/hanmi/img/rnd/2013_WCLC_(HM61713).pdf
DB13165,,NPRA Product Information: Glanatec (ripasudil hydrochloride) ophthalmic solution,http://quest3plus.bpfk.gov.my/front-end/attachment/66/pharma/519766/519766_20200624_084100_.pdf
DB13166,,AIFA Product Information: Bifril (zofenopril calcium) film-coated tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000081_034408_RCP.pdf&retry=0&sys=m0b1l3
DB13170,,Drug Information,https://www.drugs.com/history/trulance.html
DB13170,,Medscape,http://reference.medscape.com/drug/trulance-pecanatide-1000108#10
DB13170,,FDA label,http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208745lbl.pdf
DB13170,,FDA Approved Drug Products: TRULANCE (plecanatide) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208745s011lbl.pdf
DB13173,,"FDA Approved Drug Products: BRINEURA (cerliponase alfa) injection, for intraventricular use (July 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761052s014lbl.pdf
DB13173,,EMA Approved Drug Products: Brineura (cerliponase alfa) Intracerebroventricular Infusion,https://www.ema.europa.eu/en/documents/product-information/brineura-epar-product-information_en.pdf
DB13173,,Health Canada Approved Drug Products: BRINEURA (cerliponase alfa) Intracerebroventricular Infusion (June 2020),https://pdf.hres.ca/dpd_pm/00056616.PDF
DB13173,,FDA News Release: FDA approves first treatment for a form of Batten disease,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-form-batten-disease
DB13175,,Human Metabolome Database: Rheinanthrone,http://www.hmdb.ca/metabolites/HMDB39449
DB13178,,Examine,https://examine.com/supplements/inositol/
DB13178,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13178,,FDA code of federal regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1370
DB13183,,INVIMA Product Authorization: Ehida (technetium Tc-99m etifenin) for intravenous injection,http://web.sivicos.gov.co/registros/pdf/15547891_2018007763.pdf
DB13190,,Likuid Pharmalab Indonesia: Rivanol (ethacridine lactate) product information,https://www.likuid.co.id/rivanol-medika/
DB13192,,CSL Behring,http://labeling.cslbehring.com/PI/US/Monoclate-P/EN/Monoclate-P-Prescribing-Information.pdf
DB13192,,Hemofil M,http://www.baxaltahematology.com/hcp/assets/files/Hemofil-M-EU-PI.pdf
DB13192,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d9c17023-cbff-4d95-8f44-ef842d59d938#CP
DB13192,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f77d685-e382-b2e7-2414-0d3a3448688a
DB13193,,TITCK Product Information: Agnucaston (fructus agni casti) film-coated tablet,https://titck.gov.tr/storage/kubKtAttachments/b4b02ebf15733.pdf
DB13194,,AIFA Product Information: Bisolhelix (Hedera helix extract) oral syrup,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008055_044141_RCP.pdf&retry=0&sys=m0b1l3
DB13198,,"Nutritional Interventions for Gastroesophageal Reflux, Irritable Bowel Syndrome, and Hypochlorhydria: A Case Report",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991651/
DB13198,,"Pepsin, Sigma Aaldrich",https://www.sigmaaldrich.com/catalog/product/roche/10108057001?lang=en&region=CA&gclid=EAIaIQobChMIt7vDocfE2gIVBqvsCh2qXQ-hEAMYASAAEgJSkPD_BwE
DB13198,,Effect of Pepsin on the Absorption of Food Vitamin B12 and Iron,https://academic.oup.com/ajcn/article-abstract/20/6/636/4787901?redirectedFrom=PDF
DB13198,,Pepsin,https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/pepsin
DB13198,,Pepsin: science.gov topics,https://www.science.gov/topicpages/p/pepsin+a
DB13198,,Pancreatic Enzyme Replacement Therapy During Pancreatic Insufficiency,http://journals.sagepub.com/doi/abs/10.1177/0884533614527773
DB13198,,Pepsin,https://www.britannica.com/science/pepsin
DB13198,,Gastritis,https://www.niddk.nih.gov/health-information/digestive-diseases/gastritis
DB13198,,Zypan,https://cdn.vortala.com/childsites/uploads/1819/files/zypan8475.pdf
DB13198,,PDB-pepsin,http://pdb101.rcsb.org/motm/12
DB13198,,NIH Dictionary- Pepsin,https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pepsin
DB13198,,"Code of Federal Regulations, Pepsin",https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1595
DB13198,,Pepsin Drug Monograph,http://www.druginfosys.com/drug.aspx?drugcode=1341&type=1
DB13198,,"Pepsin, Drugs.com",https://www.drugs.com/international/pepsin.html
DB13198,,Determining the Safety of Enzymes Used in Food Processing,http://jfoodprotection.org/doi/pdf/10.4315/0362-028X-46.5.453?code=fopr-site
DB13198,,"PEPSIN, SIGMA AALDRICH",https://www.sigmaaldrich.com/life-science/metabolomics/enzyme-explorer/analytical-enzymes/pepsin.html
DB13198,,Digestion of Nucleic Acids Starts in the Stomach,https://www.nature.com/articles/srep11936
DB13200,,European Medicines Agency (EMA) Summary of Product Characteristics: Lonquex (lipegfilgrastim),http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf
DB13200,,Australian Public Assessment Report for Lipefilgrastim (rbe),https://www.tga.gov.au/sites/default/files/auspar-lipegfilgrastimrbe-160223.pdf
DB13200,,Therapeutic Goods Administration (TGA) product Information: Lonquex,https://www.tga.gov.au/sites/default/files/auspar-lipegfilgrastim-rbe-160223-pi.pdf
DB13203,,AIFA Product Information: Bamifix (bamifylline hydrochloride) oral tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000546_026021_RCP.pdf&retry=0&sys=m0b1l3
DB13205,,INVIMA Product Authorization Renewal: Teclozan oral tablets (INVIMA 2016M-003080-R2),http://web.sivicos.gov.co/registros/pdf/1454593_2016019446.pdf
DB13207,,AIFA Package Leaflet: BIOARGININA (arginine glutamate) intravenous injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000529_017432_RCP.pdf&retry=0&sys=m0b1l3
DB13209,,BISMUTH SUBNITRATE - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1608
DB13210,,FDA - CFR - Code of Federal Regulations Title 21,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=173.325
DB13213,,NIH - Inxight Drugs - Butaperazine Maleate,https://drugs.ncats.io/drug/22VUW43J2H#general
DB13216,,NIH - Inxight: Drugs,https://drugs.ncats.io/drug/K5X4XBR694
DB13216,,New Zealand - Medicines Amendment Regulations 2009,http://www.legislation.govt.nz/regulation/public/2009/0212/latest/whole.html
DB13216,,Taiwan FDA - News,https://www.fda.gov.tw/EN/newsContent.aspx?id=7705
DB13216,,TITCK Product Information: Fenko (oxolamine citrate) oral citrate,https://titck.gov.tr/storage/kubKtAttachments/jyG9tgEJkfTlT.pdf
DB13218,,FDA - Alpha Hydroxy Acids,https://www.fda.gov/cosmetics/productsingredients/ingredients/ucm107940.htm
DB13219,,"WHO Pharmaceuticals Newsletter 1999, No. 09&12 (1999; 30 pages)",http://apps.who.int/medicinedocs/en/d/Js2266e/1.6.html#Js2266e.1.6
DB13220,,Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia (ACCESS),https://clinicaltrials.gov/ct2/show/NCT03524651?intr=FERROUS+ASPARTATE&rank=1
DB13222,,Pharmaceuticals: Restrictions in Use and Availability -2001,http://apps.who.int/medicinedocs/en/d/Js2203e/2.58.html#Js2203e.2.58
DB13227,,TITCK Product Information: Procto-Glyvenol (tribenoside/lidocaine hydrochloride) rectal cream,https://titck.gov.tr/storage/kubKtAttachments/3RJAokjgtzcdW.pdf
DB13227,,TITCK Product Information: Procto-Glyvenol (tribenoside/lidocaine hydrochloride) rectal suppositories,https://titck.gov.tr/storage/kubKtAttachments/4whoFrIPHz849.pdf
DB13228,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB13231,,FDA CFR - Code of Federal Regulations Title 21: Sec. 184.1207 Calcium lactate,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1207&SearchTerm=calcium%20lactate
DB13231,,FDA Thailand Product Information: Calion (calcium lactate) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022290175111C
DB13231,,NPRA: Pri-Calcium (Calcium Lactate) Oral Tablets,https://quest3plus.bpfk.gov.my/front-end/attachment/341/pharma/231400/V_43546_20200617_112847_D4.pdf
DB13235,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13235,,FDA Poisonous Plant Database,https://www.accessdata.fda.gov/scripts/plantox/detail.cfm?id=24999
DB13235,,Manufacturer,https://www.belinka-perkemija.com/sodium-perborate/
DB13235,,DailyMed Label: AMOSAN (Sodium perborate monohydrate) oral wound cleanser,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be57ca56-834f-4170-a407-f193484d8b0a
DB13235,,EPA,https://www.epa.gov/pesticides
DB13237,,AIFA Package Leaflet: GRAMPLUS (clofoctol) rectal suppository,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000546_025703_RCP.pdf&retry=0&sys=m0b1l3
DB13238,,FDA Thailand Product Information: Rionfluimucil (tuaminoheptane sulfate/acetylcysteine) nasal spray,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1062410002511C
DB13238,,"AIFA: Rinofluimucil (Acetylcysteine, Tuaminoheptane) Nasal Spray",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007158_021993_FI.pdf&retry=0&sys=m0b1l3
DB13245,,"Re-evaluation Decision RVD2018-38, Thiram and Its Associated End-use Products",https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/pesticides-pest-management/decisions-updates/reevaluation-decision/2018/thiram.html
DB13247,,FDA orphan list,https://www.fda.gov/downloads/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/ucm162066.xls
DB13247,,Inxight: Drugs - PRAMIRACETAM,https://drugs.ncats.io/substances?q=root_relationships_relatedSubstance_refPname:%22%5Epramiracetam$%22
DB13248,,"FDA Thailand: Dichlorrhea (Furazolidone, Metronidazole, and Phthalylsulfathiazole) Oral Tablet",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022280119111C
DB13249,,FDA Ingredients,https://www.fda.gov/Cosmetics/ProductsIngredients/Ingredients/ucm293184.htm
DB13249,,FDA code of federal regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=182.2437
DB13249,,Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5823
DB13253,,WHO Pharmaceuticals: Restrictions in Use and Availability (2001; 40 pages) View the PDF document,http://apps.who.int/medicinedocs/en/d/Js2203e/2.50.html
DB13256,,AIFA Product Information: Entumin (clothiapine) for oral or parenteral administration,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003634_021553_RCP.pdf&retry=0&sys=m0b1l3
DB13257,,FERROUS SULFATE - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+465
DB13257,,Iron poisoning,https://www.merckmanuals.com/en-ca/professional/injuries-poisoning/poisoning/iron-poisoning
DB13257,,Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336293/
DB13257,,"Ferrous sulfate, Daily Med",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c0fb0c2-8c64-4dd6-adfe-74b1bf8f39c3
DB13257,,"Ferrous sulfate, epocrates",https://online.epocrates.com/u/107327/ferrous+sulfate/Pharmacology
DB13257,,Ferrous sulfate DavisPlus,https://davisplus.fadavis.com/3976/meddeck/pdf/ferroussulfate.pdf
DB13257,,"Ferrous Sulfate Tablet, Delayed Release (Enteric Coated)",https://www.webmd.com/drugs/2/drug-4127/ferrous-sulfate-oral/details
DB13257,,Antianemia Drugs,http://tmedweb.tulane.edu/pharmwiki/doku.php/antianemia_drugs
DB13257,,Dailymed: Ferrous sulfate tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38104333-f334-4d97-8657-94a00942faf2
DB13257,,The Science Company: Ferrous sulfate MSDS,https://www.sciencecompany.com/msds/Ferrous_Sulfate_MSDS.pdf
DB13257,,ODS Health Professional Fact Sheet: Iron,https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/
DB13257,,Medicines UK: Ferrous sulfate 200mg oral tablets,https://www.medicines.org.uk/emc/product/3130/smpc
DB13257,,"NIH Statpearls: Biochemistry, Iron Absorption",https://www.ncbi.nlm.nih.gov/books/NBK448204/
DB13258,,Pfizer Brazil Kitnos,https://www.pfizer.com.br/noticias/Comunicado-Kitnos
DB13259,,FDA Thailand Product Information: Ethyl chloride topical spray,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022280116811C
DB13260,,AIFA Product Information: Lisozima Spa (lysozyme hydrochloride) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000246_004446_RCP.pdf&retry=0&sys=m0b1l3
DB13261,,FDA Thailand Product Information: Gracevit (sitafloxacin hydrate) film-coated tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1B1062540000711C
DB13264,,Health Canada Approved ingredients list,https://www.canada.ca/en/public-health/services/antibiotic-antimicrobial-resistance/animals/veterinary-antimicrobial-sales-reporting/list-a.html
DB13264,,Categorizing Antimicrobials on List A Government of Canada,https://www.canada.ca/en/health-canada/services/drugs-health-products/veterinary-drugs/antimicrobial-resistance/categorization-antimicrobial-drugs-based-importance-human-medicine.html
DB13268,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13268,,National Cancer Institute,https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C61621
DB13268,,NIH,https://drugs.ncats.io/ginas/app/substance/e7e0485f
DB13268,,NHS,https://www.sps.nhs.uk/wp-content/uploads/2015/06/QA17.7_Can_actarsol_be_used_to_treat_proctitis-Final.docx
DB13268,,NIH,https://meshb.nlm.nih.gov/record/ui?name=Protozoan%20Infections
DB13269,,FDA Inactive ingredient search,https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browsebyletter.page&letter=d
DB13269,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13270,,Institute of Microbial Chemistry - Japan - History,http://www.bikaken.or.jp/english/aboutus/history.html
DB13271,,DailyMed: Cheong Ro Hwan sugar-coated tablets,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cf3460b-9de9-ba1c-e053-2a91aa0a9bbb
DB13273,,Inxight: Drugs - Sultopride,https://drugs.ncats.io/drug/AA0G3TW31W
DB13279,,Springer AdisInsight Drug Profile Carbocromen,https://adisinsight.springer.com/drugs/800000219
DB13281,,AIFA Product Information: NexoBrid (bromelain-enriched proteolytic enzymes) for topical use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004011_042539_RCP.pdf&retry=0&sys=m0b1l3
DB13284,,Kegg Drug - Meticrane,https://www.genome.jp/dbget-bin/www_bget?D01605
DB13286,,WHO - Consolidated list of products whoes consumption has been banned or withdrawn,http://apps.who.int/medicinedocs/documents/s16780e/s16780e.pdf
DB13287,,Kegg Japanese Pharmacopoeia,https://www.genome.jp/kegg-bin/get_htext?br08311+D01636
DB13287,,AIFA Product Information: Macroral (miocamycin) for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000550_025320_RCP.pdf&retry=0&sys=m0b1l3
DB13288,,Viru-Merz Information,http://www.sukl.eu/modules/medication/detail.php?code=0070445&tab=info
DB13290,,AIFA Package Leaflet: ELMEX (Olaflur) dental gel,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002723_026487_RCP.pdf&retry=0&sys=m0b1l3
DB13293,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13293,,FDA code of federal regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.308
DB13293,,FDA federal register,http://cdn.loc.gov/service/ll/fedreg/fr040/fr040056/fr040056.pdf#page=115
DB13293,,FDA Poisonous Plant Database,https://www.accessdata.fda.gov/scripts/plantox/detail.cfm?id=10095
DB13295,,TITCK Product Information: Neucurium (atracurium besylate) solution for injection,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/NEUCUR%C4%B0UM%2025%20mg2.5%20mL%20%C4%B0.V.%20inf%C3%BCzyon%20ve%20enjeksiyon%20i%C3%A7in%20%C3%A7%C3%B6zelti%20i%C3%A7eren%20ampul%20-K%C3%9CB.pdf_50f980bc-506d-4118-b2df-3333f88e7de2.pdf
DB13309,,DIMDI Drug Product Information: Tussafug (benproperine phosphate) coated tablets,https://portal.dimdi.de/amispb/doc/2013/10/21/2100791/OBFMAE0B87EE01CECC62.pdf
DB13312,,AIFA Product Information: Delaket (delapril hydrochloride) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000546_027696_RCP.pdf&retry=0&sys=m0b1l3
DB13312,,AIFA Product Information: Delapride (delapril/indapamide) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007206_028969_RCP.pdf&retry=0&sys=m0b1l3
DB13312,,AIFA Product Information: Fragor (delapril hydrochloride/manidipine hydrochloride) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000546_035255_RCP.pdf&retry=0&sys=m0b1l3
DB13313,,AIFA Product Information: Sirio (melevodopa/carbidopa) effervescent tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000546_035625_RCP.pdf&retry=0&sys=m0b1l3
DB13315,,FDA Thailand Product Information: Mucoflex (sobrerol) oral syrup,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022400015311C
DB13315,,AIFA Package Leaflet: SOPULMIN (Sobrerol) intramuscular injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008057_025533_RCP.pdf&retry=0&sys=m0b1l3
DB13316,,AIFA Package Leaflet: TRAZYL (Ibopamine) ophthalmic solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_005121_032900_RCP.pdf&retry=0&sys=m0b1l3
DB13322,,DIMDI Drug Product Information: Talidat (hydrotalcite) chewable tablets,https://portal.dimdi.de/amispb/doc/2017/12/25/2139094/Offc12a7f5d4b4ecdad1a419617c1d47a.pdf
DB13326,,FDA Thailand Product Information: Flavinol (euflavine/thymol) for topical use,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022280104211C
DB13327,,AIFA Package Leaflet: PLACTIDIL (picotamide) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_025627_RCP.pdf&retry=0&sys=m0b1l3
DB13335,,AFIA: Domar (Pinazepam) Oral Capsule,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_023191_FI.pdf&retry=0&sys=m0b1l3
DB13345,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf973160-d467-4192-a432-04c8c2140369
DB13345,,ANVISA,https://www.smerp.com.br/anvisa/?ac=prodDetail&anvisaId=108970015
DB13346,,FDA Thailand: Mastu-S (bufexamac/bismuth subgallate/titanium dioxide/lidocaine hydrochloride) for rectal administration,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022420001311C
DB13353,,AIFA Product Information: Dividol (viminol) oral capsules,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007158_022222_RCP.pdf&retry=0&sys=m0b1l3
DB13354,,TITCK Product Information: Gamaflex (phenprobamate) oral tablet,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/43a6e109-72ae-4595-8dc5-96ca14509a80.pdf
DB13354,,TITCK Product Information: Kuiflex (phenprobamate/acetaminophen) oral tablets,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/yaynkuiflexkub_533aeb26-4e9f-486c-ac3f-fbc506cd6285.pdf
DB13359,,TITCK Product Information: Tromcardin (potassium aspartate/magnesium aspartate) solution for injection,https://titck.gov.tr/storage/kubKtAttachments/0877a5ee98600.pdf
DB13365,,AIFA Package Leaflet: CALCIUM SANDOZ (calcium and calcium lactate gluconate) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001392_005259_RCP.pdf&retry=0&sys=m0b1l3
DB13373,,FDA Thailand Product Information: Flavinol (euflavine/thymol) for topical use,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022280104211C
DB13373,,NPRA Product Information: PRIME'S acriflavine topical cream,https://quest3plus.bpfk.gov.my/front-end/attachment/341/pharma/204570/V_12678_20171207_021906_D4.pdf
DB13384,,FDA Thailand Product Information: Anxiset (melitracen/flupentixol) film-coated tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022570000311C
DB13385,,"FDA Thailand: NALINE (dihydroergocornine, dihydroergocristine, dihydroergocryptine) oral tablets",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022280040011C
DB13387,,AIFA Product Information: Normosang (human hemin) concentrate for solution for infusion,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001110_034543_RCP.pdf&retry=0&sys=m0b1l3
DB13392,,FDA Thailand Product Information: Mercurochrome (merbromin) topical solution,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022390084711C
DB13397,,AIFA Product Information: Libexin Mucolitico (prenoxdiazine/carbocysteine) oral suspension,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_023483_RCP.pdf&retry=0&sys=m0b1l3
DB13401,,AIFA Product Information: Lanitop (methyldigoxin) oral tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003978_022643_RCP.pdf&retry=0&sys=m0b1l3
DB13414,,TITCK Product Information: Draxol (feniramidol hydrochloride) film-coated tablets,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK-ONAYLI%20K%C3%9CB-DRAXOL.pdf_935c0808-6aa5-4c22-853f-b95c9f4dd0b4.pdf
DB13414,,TITCK Product Information: Phebdol (feniramidol hydrochloride) solution for intramuscular injection,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK%20UYGUN%20K%C3%9CB%20PHEBDOL%20800%20MG.pdf_60c6e620-1382-4c29-8238-b51694c3f57c.pdf
DB13415,,"AIFA: Cardiazol-Paracodina (Dihydrocodeine, Pentetrazole) Oral Solution",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_021473_FI.pdf&retry=0&sys=m0b1l3
DB13416,,NPRA Product Information: Sulbrimo (sulbutiamine) oral capsules,http://quest3plus.bpfk.gov.my/front-end/attachment/34978/pharma/78720/78720_20180117_172259_.pdf
DB13417,,TITCK Product Information: Morfozid (morfozinamide hydrochloride) oral tablets,https://titck.gov.tr/storage/kubKtAttachments/YJVJFsnW0BjpZ.pdf
DB13421,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13421,,National Cancer Institute,https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C87662
DB13421,,WHO,http://www.who.int/mediacentre/factsheets/fs400/en/
DB13431,,FDA Thailand Product Information: Milid (proglumide) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022400010611C
DB13434,,TITCK Product Information: Jinomed (fenticonazole nitrate) vaginal cream,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/jinomed%20krem-k%C3%BCb.pdf_f94246dc-9d64-423d-875b-75f00f570049.pdf
DB13434,,TITCK Product Information: Jinomed (fenticonazole nitrate) vaginal ovule,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/jinomed-k%C3%BCb.pdf_dd6c3433-8299-4cbb-9dc8-b38c639f04fb.pdf
DB13437,,DIMDI Drug Product Information: Rudotel (medazepam) oral tablets,https://portal.dimdi.de/amispb/doc/2019/10/04/3000637/O0d7acc8988af46a1aacc4b80ebbc8e16.pdf
DB13437,,FDA Thailand Product Information: Tranko-Buskas (hyoscine-N-butyl bromide/medazepam) oral dragee,https://titck.gov.tr/storage/kubKtAttachments/c333647737657.pdf
DB13444,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13445,,AIFA Product Information: Nepituss (nepinalone hydrochloride) for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000040_028620_RCP.pdf&retry=0&sys=m0b1l3
DB13456,,Health Canada Approved ingredients list,https://www.canada.ca/en/public-health/services/antibiotic-antimicrobial-resistance/animals/veterinary-antimicrobial-sales-reporting/list-a.html
DB13456,,FDA Thailand Product Information: Miotin (midecamycin) for oral use,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1B1022320000111C
DB13470,,AIFA Product Information: Modivid (cefodizime) powder for solution for injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008055_027951_RCP.pdf&retry=0&sys=m0b1l3
DB13483,,INVIMA Product Authorization Renewal: Stan Ka (etamsylate) oral tablets,http://web.sivicos.gov.co/registros/pdf/15880380_2020001739.pdf
DB13487,,National Cancer Institute - Iodine 131-6-beta-iodomethyl-19-norcholesterol,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/iodine-i-131-6-beta-iodomethyl-19-norcholesterol?redirect=true
DB13489,,DIMDI Drug Product Information: Soventol (bamipine) topical gel,https://portal.dimdi.de/amispb/doc/2017/09/15/0899503/Oe46c4fbb8cde4fe09604bbbf8b2e1f38.pdf
DB13490,,TITCK Product Information: Venosmil (hidrosmin) oral capsules,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/Venosmil%20-%20onayl%C4%B1%20k%C3%BCb.pdf_19c54a3e-23a4-4b3d-a7e4-de93d3cfa04b.pdf
DB13490,,NIH National Center for Advancing Translational Sciences - Hidrosmin,https://drugs.ncats.io/substance/4I5K8199OQ
DB13492,,DailyMed: Albothyl (policresulen) oral solution,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=847dca04-cfe6-19be-e053-2991aa0a04df
DB13497,,TITCK Product Information: Epimol (valethamate bromide) solution for injection,https://titck.gov.tr/storage/kubKtAttachments/2567e01f47367.pdf
DB13497,,National Center for Advancing Translational Sciences: Valethamate,https://drugs.ncats.io/substance/D64S64QVX7
DB13500,,TITCK Product Information: Motigen (otilonium bromide) film-coated tablets for oral use,https://titck.gov.tr/storage/kubKtAttachments/fa26fe5657349.pdf
DB13500,,TITCK Product Information: Pinix (otilonium bromide/simethicone) film-coated tablets for oral use,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/4697aa9e-258b-4cb2-bbb1-b914d019084b.pdf
DB13501,,Pre-Clinical Assessment of the Potential Intrinsic Hepatotoxicity of Candidate Drugs,https://www.intechopen.com/books/new-insights-into-toxicity-and-drug-testing/pre-clinical-assessment-of-the-potential-intrinsic-hepatotoxicity-of-candidate-drugs
DB13501,,eFarma.com: Bendazac Cream Product Page,https://www.efarma.com/versus-crema-50-gr-3.html
DB13501,,Iwaki Seiyaku Co.Ltd.: Bendazac Ointment 3% Discontinued Product Page,https://www.iwakiseiyaku.co.jp/en_medical/index.php/item?id=124
DB13501,,Pharmacompass: Bendazac Profile,https://www.pharmacompass.com/chemistry-chemical-name/bendazac
DB13503,,"Arnold Vosloo, J., Beims, H., Allsopp, M.H. et al. Tolerance of honey bee adults and larvae toward tyrothricin peptides derived from Brevibacillus parabrevis Apidologie (2017) 48: 833. https://doi.org/10.1007/s13592-017-0528-0",https://link.springer.com/article/10.1007/s13592-017-0528-0
DB13503,,National Research Foundation Institutional Repository: Characterization of natural antimicrobial peptides adsorbed to different matrices,http://ir.nrf.ac.za/handle/10907/406
DB13503,,Production and characterisation of analogues of the antimicrobial tyrocidine peptides with modified aromatic amino acid residues.,https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwii6LGp4czcAhWJJDQIHe6GCgoQFjAAegQIABAC&url=https%3A%2F%2Fscholar.sun.ac.za%2Fbitstream%2Fhandle%2F10019.1%2F103710%2Fberge_production_2018.pdf%3Fsequence%3D1%26isAllowed%3Dy&usg=AOvVaw00U0OObBdDGaJuIhtV_CRJ
DB13503,,Electronic Medicines Compendium: Tyrozets (benzocaine and tyrothricin) lozenges Monograph,https://www.medicines.org.uk/emc/product/372/smpc
DB13511,,SehatQ: Clast (clebopride maleate) oral tablets,https://www.sehatq.com/obat/clast-tablet-05-mg
DB13511,,AIFA Product Information: Motilex (clebopride maleate) for oral or parenteral administration,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000729_026362_RCP.pdf&retry=0&sys=m0b1l3
DB13511,,National Center for Advancing Translational Sciences: Clebopride,https://drugs.ncats.io/drug/I0A84520Y9
DB13514,,TITCK Product Information: Oftalar (pranoprofen) ophthalmic drops,https://titck.gov.tr/storage/kubKtAttachments/0ac7003176911.pdf
DB13515,,Centre for Addiction and Mental Health (CAMH) - Methadone,https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/methadone
DB13518,,FDA CFR - Code of Federal Regulations Title 21 Sec. 184.1011 Alginic acid,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1011
DB13518,,ALGINIC ACID - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2967
DB13518,,TITCK Product Information: Gaviscon Double Action (sodium alginate/sodium bicarbonate/calcium carbonate) chewable tablets,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK%20GAVISCON%20DOUBLE%20ACTION%20%C3%87TB%20UYGUN%20K%C3%9CB.pdf_ffe96b40-2786-49cc-9241-01f22ec7f799.pdf
DB13518,,INVIMA Product Authorization: Gastrofast Advance (sodium alginate/magaldrate/simeticone/sodium bicarbonate) for oral use,http://web.sivicos.gov.co/registros/pdf/15864375_2019051825.pdf
DB13524,,TITCK Product Information: Minamol Plus (acetaminophen/caffeine/propyphenazone) oral tablets,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/yay%C4%B1n%20minamol%20kub.pdf_a4d6e4a2-1756-49f1-b6f1-63fc7b40efac.pdf
DB13527,,AIFA Product Information: Proxil (proglumetacin) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000020_024116_RCP.pdf&retry=0&sys=m0b1l3
DB13528,,FDA Thailand Product Information: Belara (chlormadinone acetate/ethinyl estradiol) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1012510003011C
DB13528,,"INVIMA: Ladee (Chlormadinone, Ethinylestradiol) Oral Tablet",http://web.sivicos.gov.co/registros/pdf/1411606_2016005762.pdf
DB13529,,TITCK Product Information: Doxium (calcium dobesilate) oral capsules,https://titck.gov.tr/storage/kubKtAttachments/a2963eb314618.pdf
DB13565,,AIFA: Biacol Med (Benzoxonium) Topical Solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003337_032186_FI.pdf&retry=0&sys=m0b1l3
DB13569,,"BASG: Tracutil (Chromic Chloride, Cupric Chloride, Ferrous Chloride, Manganese, Potassium Iodide, Selenious Acid, Sodium Fluoride, Sodium Molybdate, Zinc Chloride) Intravenous Injection",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-23992&type=DOTC_FACH_INFO
DB13574,,"NPRA: Ginkor Fort (Ginkgo biloba, Heptaminol, Troxerutin) Oral Capsule",https://quest3plus.bpfk.gov.my/front-end/attachment/710/pharma/232314/V_50414_20210118_162123_D4.pdf
DB13581,,AIFA: Rilaten (Rociverine) Oral Tablet and Intravenous and Intramuscular Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000608_023598_FI.pdf&retry=0&sys=m0b1l3
DB13586,,FDA Thailand Product Information: Anapromine (methanedione/cyproheptadine hydrochloride) oral capsules,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022290016011C
DB13586,,Code of Federal Regulations Title 21 Sec. 1300.01: Definitions relating to controlled substances.,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1300.01
DB13587,,TITCK Product Information: Proviron (mesterolone) oral tablets,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/TTCKONAYLIKBPROVRON_3b2dc887-4101-49b7-950d-ff8e20157c4f.pdf
DB13588,,DIMDI Drug Product Information: Naftilong (naftidrofuryl oxalate) extended-release capsules,https://portal.dimdi.de/amispb/doc//2015/03/16/2123852/Ocfcee892955649639c2a1f7be3b9410d.pdf
DB13588,,EMC Summary of Product Characteristics: Naftidrofuryl oral capsules,https://www.medicines.org.uk/emc/product/5813/smpc
DB13588,,AIFA: Praxilene (Naftidrofuryl) Tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000045_022584_FI.pdf&retry=0&sys=m0b1l3
DB13595,,ScienceDirect: Aluminosilicate Profile,https://www.sciencedirect.com/topics/earth-and-planetary-sciences/aluminosilicate
DB13609,,Nature Biotechnology: Coronavirus puts drug repurposing on the fast track,https://www.nature.com/articles/d41587-020-00003-1
DB13612,,BASG: Iromin (Carbaspirin Calcium) Oral Tablet,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=6200&type=DOTC_FACH_INFO
DB13615,,"EMA Summary of product characteristics: Mepact, INN-mifamurtide",http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000802/WC500026565.pdf
DB13619,,DIMDI Drug Product Information: Sormodren (bornaprine hydrochloride) oral tablets,https://portal.dimdi.de/amispb/doc/2019/06/21/0899348/Obb748d5bf93c4a2d8c317e09651983af.pdf
DB13620,,"Potassium Gluconate, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/potassium_gluconate
DB13620,,POTASSIPOWDER- potassium gluconate powder,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66853766-f3a2-42ef-91e2-033a31caf0e7
DB13620,,NIH Potassium Fact Sheet for Health Professionals,https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/
DB13620,,"NIH Toxnet, Potassium",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3165
DB13620,,Everything Added to Food in the United States (EAFUS) Print Share E-mail,https://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?filter=&sortColumn=36%28%25%3AH%2152ED0%21AP%2C%2C1M%2F5Q9Q%2CF%40++%0D%0A&rpt=eafuslisting&displayAll=false&page=40
DB13620,,Potassium Supplements (Systemic),https://www.drugs.com/mmx/potassium-gluconate-and-potassium-chloride.html
DB13620,,POTASSIUM GLUCONATE,http://chemicalland21.com/lifescience/foco/POTASSIUM%20GLUCONATE.htm
DB13620,,DRUG: Potassium gluconate,http://www.genome.jp/dbget-bin/www_bget?D01298
DB13620,,Overview: Potassium Gluconate,https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/potassium-gluconate
DB13620,,"Potassium Supplement, Oral Route, Mayo Clinic",https://www.mayoclinic.org/drugs-supplements/potassium-supplement-oral-route-parenteral-route/proper-use/drg-20070753
DB13620,,Regulation of Potassium Homeostasis,http://cjasn.asnjournals.org/content/early/2014/04/30/CJN.08580813.full.html
DB13620,,INVIMA Product Authorization: Ion-K (potassium gluconate) oral solution,http://web.sivicos.gov.co/registros/pdf/15739192_2019011398.pdf
DB13622,,AIFA: Sehcat (Selenium 75Se Norcholesterol) Oral Capsule,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000908_039078_FI.pdf&retry=0&sys=m0b1l3
DB13624,,FDA Thailand Product Information: Asmeton-S (methoxyphenamine/noscapine/aminophylline/chlorpheniramine) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022270014811C
DB13626,,FDA Thailand: Amogin (Aluminum Glycinate) Oral Tablet,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022550012811C
DB13633,,AIFA Product Information: Tricandil (mepatricin) for vaginal use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000246_023083_RCP.pdf&retry=0&sys=m0b1l3
DB13633,,AIFA Product Information: Ipertrofan (mepartricin) gastro-resistant oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000246_025412_RCP.pdf&retry=0&sys=m0b1l3
DB13642,,AIFA Product Information: Lyseen (pridinol) for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001136_011987_RCP.pdf&retry=0&sys=m0b1l3
DB13654,,FDA Thailand Product Information: Dehecta (dioctahedral smectite) oral solution,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022530017511C
DB13654,,AIFA: Diosmectal (Montmorillonite) Oral Powder for Suspension,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003153_028852_FI.pdf&retry=0&sys=m0b1l3
DB13655,,FDA Thailand Product Information: Corazol (nikethamide) oral drops,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022270082011C
DB13656,,TITCK Product Information: Ebernet (eberconazole nitrate) topical cream,https://titck.gov.tr/storage/kubKtAttachments/224c943c29399.pdf
DB13670,,INVIMA Product Information: Vanpar (pirantel pamoate/oxantel pamoate) oral suspension,http://web.sivicos.gov.co/registros/pdf/1337571_2015033324.pdf
DB13673,,AIFA Package Leaflet: VISUCLOBEN ANTIBIOTICO (bekanamycin and clobetasone) ophthalmic suspension,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000902_026585_RCP.pdf&retry=0&sys=m0b1l3
DB13679,,INVIMA Product Authorization: Coricidin (acetaminophen/dexchlorpheniramine maleate) oral pediatric drops,http://web.sivicos.gov.co/registros/pdf/1307102_2015019541.pdf
DB13679,,AIFA Package Leaflet: POLARAMIN (Dexchlorpheniramine) for oral or topical use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000022_018554_RCP.pdf&retry=0&sys=m0b1l3
DB13680,,TITCK Product Information: Mediaven (naftazone) oral tablets,https://titck.gov.tr/storage/kubKtAttachments/f90af98047745.pdf
DB13682,,FDA Thailand: Romecef (Cefpirome) Powder,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1032590001411C
DB13689,,BASG Product Information: Curatoderm (tacalcitol) topical,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-21906&type=DOTC_FACH_INFO
DB13700,,TITCK Product Information: Protamine hydrochloride for intravenous administration,https://titck.gov.tr/storage/kubKtAttachments/FAuwn6JXGR0fT.pdf
DB13707,,"Sodium Tartrate, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/Sodium_tartrate
DB13707,,Sodium Tartrate Monograph,http://www.druginfosys.com/drug.aspx?drugcode=1355&type=1
DB13707,,"Sodium tartrate, chemspider",http://www.chemspider.com/Chemical-Structure.12786.html
DB13707,,"Sodium Tartrate Overiew, Science Direct",https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/sodium-tartrate
DB13707,,"List of Permitted Emulsifying, Gelling, Stabilizing or Thickening Agents (Lists of Permitted Food Additives)",https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/lists-permitted/4-emulsifying-gelling-stabilizing-thickening-agents.html
DB13707,,The pharmacology of sodium tartrate,https://jamanetwork.com/journals/jama/article-abstract/436979?redirect=true
DB13707,,Sodium tartrate,https://www.revolvy.com/main/index.php?s=Sodium%20tartrate
DB13707,,"Sodium Tartrate, FCC",https://www.ulprospector.com/en/na/Food/Detail/12002/392295/Sodium-Tartrate--FCC
DB13707,,Tartrates,http://www.harke.com/index.php?tx_hkcatalog_pi1%5Bproductid%5D=872&tx_hkcatalog_pi1%5Bcountry%5D=9999&tx_hkcatalog_pi1%5Blegal%5D=294
DB13710,,TITCK Product Information: Rimobolan (methenolone enanthate) solution for intramuscular injection,https://titck.gov.tr/storage/kubKtAttachments/67315d7217395.pdf
DB13717,,TITCK Product Information: Anti-Bit (phenothrin) topical shampoo,https://titck.gov.tr/storage/kubKtAttachments/fad476da29819.pdf
DB13721,,INVIMA Product Authorization: Pioxan (cypermethrin) topical emulsion,http://web.sivicos.gov.co/registros/pdf/1316814_2015022681.pdf
DB13724,,AIFA Product Information: Nifuratel Farmitalia for oral or vaginal use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000959_020513_RCP.pdf&retry=0&sys=m0b1l3
DB13724,,TITCK Product Information: Nifunis (nifuratel/nystatin) vaginal suppository,https://titck.gov.tr/storage/kubKtAttachments/z8j7tYGVTLPRW.pdf
DB13726,,FDA Thailand Product Information: Sulfayel (sulfaguanidine) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022370012211C
DB13728,,TITCK Product Information: Sicorten (halometasone) topical cream,https://titck.gov.tr/storage/kubKtAttachments/fwlbdi1JWPhWJ.pdf
DB13729,,Ono Pharmaceutical: Foipan Camostat Mesilate Oral Tablets,http://www.shijiebiaopin.net/upload/product/201272318373223.PDF
DB13731,,AIFA Product Information: Froben Dry Cough (butamirate citrate) for oral use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002322_035117_RCP.pdf&retry=0&sys=m0b1l3
DB13735,,AIFA Package Leaflet: CORYFIN SEDATIVO FLUIDIFICANTE (dextromethorphan and potassium guaiacolsulfonate) oral syrup,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000143_010519_RCP.pdf&retry=0&sys=m0b1l3
DB13746,,WHO SPECIFICATIONS AND EVALUATIONS FOR PUBLIC HEALTH PESTICIDES: Bioallethrin,http://www.who.int/whopes/quality/Bioallethrin_%20spec_eval_May2005.pdf?ua=1
DB13746,,HSDB: Allethrins,http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+1511
DB13749,,"PubChem, Sodium Gluconate",https://pubchem.ncbi.nlm.nih.gov/compound/Magnesium_gluconate
DB13749,,Magnesium Gluconate,https://www.webmd.com/drugs/2/drug-7946/magnesium-gluconate-oral/details
DB13749,,"NIH document, Magnesium",https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
DB13749,,"NIH Medlie, Magnesium Gluconate",https://medlineplus.gov/druginfo/meds/a601072.html
DB13749,,Mg products,http://www.globalrph.com/magnesium_supplements.htm
DB13749,,MIMS: Magnesium gluconate,http://www.mims.com/malaysia/drug/info/magnesium%20gluconate?mtype=generic
DB13749,,Mg Gluconate,https://www.drugs.com/ppa/magnesium-gluconate.html
DB13749,,Study of magnesium bioavailability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach,http://www.jle.com/download/mrh-267774-study_of_magnesium_bioavailability_from_ten_organic_and_inorganic_mg_salts_in_mg_depleted_rats_using_a_stable_isotope_approach--WuiPHn8AAQEAADOFX1sAAAAH-a.pdf
DB13749,,Fagron US: Magnesium gluconate dihydrate SDS,https://d84823jj91l2.cloudfront.net/documents/MSDS/59625-89-7_%28USA%29.pdf
DB13751,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13754,,TITCK Product Information: Dorsilon (acetaminophen/mephenoxalone) oral tablets,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/Dorsilon%20450%20mg-200%20mgTablet-k%C3%BCb.pdf_54064b65-2c50-41ce-b1cc-a3d4daf7f6ba.pdf
DB13759,,FDA Thailand: DONAGAN (fenpiverinium and pitofenone) tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022300039311C
DB13761,,WHO,http://apps.who.int/medicinedocs/index/assoc/h5775e/h5775e.pdf
DB13761,,Australian Complementary Medicines Evaluation,https://www.tga.gov.au/sites/default/files/cmec-minutes-47.pdf
DB13761,,Lacdigest monograph,https://compendium.ch/mpro/mnr/23598/html/fr?Platform=Desktop
DB13761,,AIFA: Lacdigest (Tilactase) Oral Tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_005016_035245_FI.pdf&retry=0&sys=m0b1l3
DB13762,,TITCK Product Information: RABBY-D (dexrabeprazole sodium) oral enteric coated tablet,https://pdf.ilacprospektusu.com/4433-rabby-d10-mg-enterik-kapli-tablet-kt.pdf
DB13771,,NPRA Product Information: FERROCYTE TABLET (ferric sodium citrate) oral tablets,https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/231441/V_35040_20190920_104239_D4.pdf
DB13772,,AIFA Product Information: MONOS (Rufloxacin hydrochloride) oral tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004037_028048_FI.pdf&retry=0&sys=m0b1l3
DB13773,,FDA Thailand: Gana Tab (Sulfamethoxypyridazine) Oral Tablet,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022270095311C
DB13783,,Rantudil label,http://www.meppo.com/pdf/drugs/2943-RANTUDIL-RETARD-1440583577.pdf
DB13783,,Emflex label,https://www.medicines.org.uk/emcmobile/PIL.26398.latest.pdf
DB13783,,Vademecum,http://mx.prvademecum.com/producto.php?producto=4873
DB13783,,DIMDI Product Information: acemetacin oral capsule,https://portal.dimdi.de/amispb/doc/2015/08/06/2133737/O5e4571e6c8da4b4b879b343f2371edf2.pdf
DB13785,,AIFA Package Leaflet: ACTIGRIP TOSSE SEDATIVO (dropropizine) oral syrup,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_006015_020875_RCP.pdf&retry=0&sys=m0b1l3
DB13787,,DIMDI Product Information: VALORON (naloxone and tilidine) oral,https://portal.dimdi.de/amispb/doc/2017/10/02/2140043/O04a75bf0fefa4f6c994c78eca2bf3456.pdf
DB13800,,Preparing process and application of calcium lévulinate,https://patents.google.com/patent/CN1304923A/en?oq=B.+Q.+Xue%2c+S.+Q.+Wang%2c+China+Patent+1304923%2c+2001.
DB13800,,Energy densification of levulinic acid by thermal deoxygenation,http://pubs.rsc.org/en/content/articlepdf/2010/gc/c005067a
DB13800,,Advances in the Catalytic Production of Valuable Levulinic Acid Derivatives,https://www.researchgate.net/profile/Shubin_Wu/publication/259293799_1230_ftp/links/0deec52ad14e084236000000.pdf
DB13800,,National Institutes of Health: Calcium Fact Sheet,https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/#h3
DB13800,,Dietary Reference Intakes for Calcium and Vitamin D,https://www.ncbi.nlm.nih.gov/books/NBK56060/
DB13803,,DIMDI Product Information: NEOTRI (xipamide and triamterene) oral tablet,https://portal.dimdi.de/amispb/doc/2020/02/12/2102405/O66b139db861e4b8da0f781a5e0cd53d1.pdf
DB13808,,FDA Thailand Product Information: MYDOLIN (mebhydrolin) capsule,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022580029511C
DB13813,,Iodoform MSDS Thermofisher,https://www.fishersci.com/store/msds?partNumber=AC149125000&productDescription=IODOFORM+99%2B%25+500GR&vendorId=VN00032119&countryCode=US&language=en
DB13823,,AIFA Product Information: Urotractin (pipemidic acid) oral capsule,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_023869_FI.pdf&retry=0&sys=m0b1l3
DB13835,,BASG Product Information: Spasmium (caroverine) injection,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=14027&type=DOTC_FACH_INFO
DB13843,,DIMDI Product Information: Syntestan (cloprednol) tablet,https://portal.dimdi.de/amispb/doc/2017/09/01/2100986/O640c322c5ec74a4291f1a1d6914fac38.pdf
DB13844,,TITCK Product Information: PİPTALİN (pipenzolate) oral tablet,https://pdf.ilacprospektusu.com/471-piptalin-5-mg-tablet-kt.pdf
DB13848,,FDA Approved Drug Products: Fluorodopa F18 injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200655s000lbl.pdf
DB13853,,NIH National Cancer Institute Dictionary of Cancer Terms: Anetholtrithione,https://www.cancer.gov/publications/dictionaries/cancer-terms/def/anetholtrithione
DB13853,,"The Medicine Shoppe Pharmacy: Sialor, 25MG, Tablet (anethole trithione) Monograph",https://www.medicineshoppe.ca/en/article/sialor
DB13853,,Anethole trithione liposome and its prepn,https://patents.google.com/patent/CN1771938A/en
DB13855,,INVIMA: Acta 15 (21 and 22 July 2015),https://www.invima.gov.co/documents/20143/1266653/Acta+No.+15+de+2015+SEMPB+PRIMERA+PARTE.pdf/dd97fdc1-06cf-566a-9261-b5be637b0f5c?t=1561669377000
DB13862,,DIMDI Product Information: BIOMAGNESIN (magnesium citrate and magnesium phosphate ) oral lozenge,https://portal.dimdi.de/amispb/doc//2015/07/14/2106672/Oe9bce479717a42289d5966695167cc78.pdf
DB13863,,AIFA Product Information: FDP FISIOPHARMA (fosfructose) injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000871_033631_FI.pdf&retry=0&sys=m0b1l3
DB13867,,FDA Approved Drug Products December 1990,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process&rptName=2&reportSelectMonth=12&reportSelectYear=1990&nav
DB13867,,FDA Fluticasone Furoate Approval 2007,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022051_veramyst_toc.cfm
DB13872,,MRHA: Lormetazepam Summary of Product Characteristics,https://drive.google.com/open?id=0B2K5buBGjy5rLTZfTUhIR1RsTms
DB13872,,ChemIDPlus: Lormetazepam,https://chem.nlm.nih.gov/chemidplus/rn/848-75-9
DB13872,,BASG: Sedalor (Lormetazepam) Intravenous Injection,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=135508&type=DOTC_FACH_INFO
DB13873,,DailyMed Trilipix (fenofibric acid) delayed release capsule monogram,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbf3e782-d163-49c8-0e81-4eeabef48190
DB13873,,"FDA Approved Drug Products: FIBRICOR (fenofibric acid) Tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022418s010lbl.pdf
DB13874,,"FDA Approved Drug Products: IDHIFA® (enasidenib) tablets, for oral use (Feb 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf
DB13878,,FDA Press Announcements: FDA approves Mavyret for Hepatitis C,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm
DB13878,,"FDA Approved Drug Products: MAVYRET (glecaprevir and pibrentasvir) tablets or pellets, for oral use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215110s000,209394s013lbl.pdf"
DB13878,,"Health Canada Approved Drug Products: MAVYRET (glecaprevir and pibrentasvir) tablets and granules, for oral use",https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/MAVIRET_PM_EN.pdf
DB13879,,FDA Press Announcements: FDA approves Mavyret for Hepatitis C,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm
DB13879,,"FDA Approved Drug Products: MAVYRET (glecaprevir and pibrentasvir) tablets or pellets, for oral use","https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215110s000,209394s013lbl.pdf"
DB13879,,"Health Canada Approved Drug Products: MAVYRET (glecaprevir and pibrentasvir) tablets and granules, for oral use",https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/MAVIRET_PM_EN.pdf
DB13881,,FDA Press Announcements: FDA approval brings first gene therapy to the United States,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm
DB13881,,FDA Approved Drug Products: Kymriah (tisagenlecleucel) suspension for intravenous infusion,https://www.novartis.us/sites/www.novartis.us/files/kymriah.pdf
DB13883,,"Dailymed: North American Coral Snake Antivenin (Equine) - coral snake (microbus fulvous) immune globulin antivenin (equine) injection, powder, for solution Label",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d0f94b4-82ca-37c7-edb0-4f0702cf6c8d
DB13884,,Health Canada monograph,https://pdf.hres.ca/dpd_pm/00039026.PDF
DB13884,,EMA Product report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003955/WC500207380.pdf
DB13884,,PMDA report on the deliberation,https://www.pmda.go.jp/files/000221483.pdf
DB13886,,Cytomegalovirus Immune Globulin (Intravenous-Human),https://www.drugs.com/cdi/cytomegalovirus-immune-globulin-intravenous-human.html
DB13886,,Cytomegalovirus Immune globulin,http://m.pdr.net/drug-summary/Cytogam-cytomegalovirus-immune-globulin-intravenous--human--836
DB13886,,Roche Document,http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/package_inserts/CMV%20IgG-04784596190-EN-CAN.pdf
DB13886,,Cytomegalovirus infection in immunosuppressed patients after kidney transplantation,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990428/
DB13886,,"Up to date, cytomegalovirus",https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-treatment-of-cytomegalovirus-infection-in-immunocompetent-adults
DB13886,,Monograph for Cytogam,https://www.drugs.com/monograph/cytogam.html
DB13891,,Mojave Rattlesnake Envenomation,https://emedicine.medscape.com/article/771586-overview
DB13891,,Crotalidae Polyvalent Immune Fab,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+8114
DB13891,,Crofab.com,https://www.crofab.com
DB13891,,Drugs.com Crotalidae polyvalent immune fab,https://www.drugs.com/monograph/crotalidae-polyvalent-immune-fab-ovine.html
DB13891,,Mayo clinic: Antivenin (crotalidae),https://www.mayoclinic.org/drugs-supplements/antivenin-crotalidae-polyvalent-immune-fab-intravenous-route/description/drg-20061997
DB13891,,Safety and Efficacy of Crotalidae Polyvalent Immune Fab in Pediatric Crotaline Envenomations,https://onlinelibrary.wiley.com/doi/pdf/10.1197/j.aem.2006.10.095
DB13891,,Review of Agkistrodon-Piscivorus,https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/agkistrodon-piscivorus
DB13892,,Delayed antivenom treatment for a patient after envenomation by Crotalus atrox,https://www.sciencedirect.com/science/article/pii/S0196064400701119
DB13892,,CROFAB.COM,https://www.crofab.com/Treatment-With-CroFab/What-is-CroFab
DB13892,,"Epocrates online, Crofab",https://online.epocrates.com/u/1073686/CroFab/Pharmacology
DB13892,,"Drugs.com, Crofab",https://www.drugs.com/monograph/crofab.html
DB13893,,"Crotalidae Antivenin, Drugs.com",https://www.drugs.com/drp/antivenin-crotalidae-polyvalent.html
DB13893,,"Drugs.com, Crofab",https://www.drugs.com/monograph/crofab.html
DB13893,,Eastern Diamondback Rattlesnake (Crotalus adamanteus) - Venomous,https://srelherp.uga.edu/snakes/croada.htm
DB13893,,"PDR, Crofab",http://m.pdr.net/drug-summary/CroFab-crotalidae-polyvalent-immune-fab--ovine--2650
DB13893,,Crotalus adamanteus,https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/crotalus-adamanteus
DB13893,,Uniprot PDE3,http://www.uniprot.org/uniprot/J3SEZ3
DB13893,,Amino Acid Sequence of Phospholipase AZ-a! from the Venom of Crotalus adamanteus,http://www.jbc.org/content/252/14/4913.full.pdf
DB13893,,Review of Agkistrodon-Piscivorus,https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/agkistrodon-piscivorus
DB13894,,Agkistrodon piscivorus &mdash; Details Cottonmouth,http://eol.org/pages/452959/hierarchy_entries/41232140/details
DB13894,,Review of Agkistrodon-Piscivorus,https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/agkistrodon-piscivorus
DB13894,,Crofab website,https://www.crofab.com/Envenomation/Venom-effects
DB13894,,Agkistrodon,https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/agkistrodon
DB13894,,Agkistrodon piscivorus,http://www.iucnredlist.org/details/64298/0
DB13896,,EMA: Imylgic (talimogene laherparepvec) prescribing information,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002771/WC500201079.pdf
DB13896,,Electronic Medicines Compendium: Imlygic (talimogene laherparepvec) monograph,https://www.medicines.org.uk/emc/product/5117
DB13896,,European Medicines Agency: Imlygic (talimogene laherparepvec),http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002771/human_med_001941.jsp&mid=WC0b01ac058001d124
DB13897,,"FDA Approved Drug Products: BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Sterile Solution for Injection",https://www.fda.gov/media/85514/download?attachment
DB13898,,"FDA Approved Drug Products: BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Sterile Solution for Injection",https://www.fda.gov/media/85514/download?attachment
DB13899,,"FDA Approved Drug Products: BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Sterile Solution for Injection",https://www.fda.gov/media/85514/download?attachment
DB13900,,"FDA Approved Drug Products: BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Sterile Solution for Injection",https://www.fda.gov/media/85514/download?attachment
DB13901,,"FDA Approved Drug Products: BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Sterile Solution for Injection",https://www.fda.gov/media/85514/download?attachment
DB13902,,"FDA Approved Drug Products: BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Sterile Solution for Injection",https://www.fda.gov/media/85514/download?attachment
DB13903,,"FDA Approved Drug Products: BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Sterile Solution for Injection",https://www.fda.gov/media/85514/download?attachment
DB13905,,Antidote Relieves Scorpion Stings,https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm266515.htm
DB13905,,Anascorp,https://www.drugs.com/history/anascorp.html
DB13905,,Scorpion antivenin approved,http://www.ajhp.org/content/68/18/1668.1?sso-checked=true
DB13905,,FDA Approves First-Ever Antivenom for Scorpion Stings,https://www.medscape.com/viewarticle/747536
DB13905,,Efficacy and safety of scorpion antivenom plus prazosin compared with prazosin alone for venomous scorpion (Mesobuthus tamulus) sting: randomised open label clinical trial,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016167/
DB13905,,Management of scorpion envenoming: a systematic review and meta-analysis of controlled clinical trials,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385045/
DB13905,,Emerging options for the management of scorpion stings,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401053/
DB13905,,Hypersensitivity reaction to scorpion antivenom,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252954/
DB13905,,"Adverse reactions to snake antivenom, and their prevention and treatment",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767202/
DB13905,,Centruroides (Scorpion) Immune F(ab′)2 (Equine),https://www.drugs.com/monograph/centruroides-scorpion-immune-f-ab-8242-2-equine.html
DB13905,,PDR drug reference,http://www.pdr.net/drug-summary/Anascorp-centruroides--scorpion--immune-F-ab--39--2--equine--1483
DB13905,,Utah poison control,https://poisoncontrol.utah.edu/newsletters/pdfs/toxicology-today-archive/Vol14_Iss3.pdf
DB13908,,Amylmetacresol,https://pubchem.ncbi.nlm.nih.gov/compound/Amylmetacresol
DB13908,,"Amylmetacresol, MIMS",https://www.mims.com/malaysia/drug/info/amylmetacresol?mtype=generic
DB13908,,"Bioxer Pharma, Amylmetacresol",http://www.bioxerapharma.com/product-details/amylmetacresol.php
DB13908,,"Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat",https://www.dovepress.com/amylmetacresol24-dichlorobenzyl-alcohol-hexylresorcinol-or-carrageenan-peer-reviewed-article-IJGM
DB13908,,Neo agin,https://www.neoangin.eu/neo-angin.html
DB13908,,A Note on the Toxicity of Amyl-meta-cresol,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2048249/?page=5
DB13908,,Review Article: Sprays and lozenges for sore throats,http://safpj.co.za/index.php/safpj/article/viewFile/2632/4120
DB13909,,Devrom Internal Deodorant (200 mg bismuth sabgallate),https://devrom.com
DB13909,,Drugs.com: Bismuth Subgallate Monograph,https://www.drugs.com/ppa/bismuth-subgallate.html
DB13909,,"COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS: BISMUTH SUBNITRATE, BISMUTH SUBCARBONATE, BISMUTH SUBGALLATE, BISMUTH SUBSALICYLATE",http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500010981.pdf
DB13909,,Pepto-Bismol: Why does Pepto-Bismol sometimes darken the tongue/stool and how long does it last?,https://www.pepto-bismol.com/en-us/faq/black-stool-black-tongue
DB13909,,ScienceDirect: Bismuth subgallate,https://www.sciencedirect.com/topics/neuroscience/bismuth-subgallate
DB13909,,TITCK Product Information: Kortos (bismuth subgallate/benzocaine/benzalkonium chloride/hydrocortisone acetate) rectal cream,https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/Ek1-Kortos-Krem-KUB_temiz.pdf_8edcd038-ab49-41cc-b595-eeec3c811934.pdf
DB13914,,Shire Pharmaceuticals - Newsroom Announcement,https://www.shire.com/newsroom/2016/july/7zve23
DB13915,,FDA Approved Drug Products: YESCARTA (axicabtagene ciloleucel) suspension for intravenous infusion (December 2023),https://www.fda.gov/media/108377/download
DB13915,,EMA Approved Drug Products: Yescarta (axicabtagene ciloleucel) intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/yescarta-epar-product-information_en.pdf
DB13919,,FDA Approved Drug Products: Atacand (candesartan cilexetil) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020838s041lbl.pdf
DB13923,,Roche news,https://www.roche.com/dam/jcr:cab28a4e-d5ba-4e19-a4b3-52eaa123147b/en/inv-update-2017-08-24-e.pdf
DB13923,,Bussiness wire,http://www.businesswire.com/news/home/20171116006052/en/FDA-Approves-Genentech%E2%80%99s-HEMLIBRA-emicizumab-kxwh-Hemophilia-Inhibitors
DB13923,,Roche study,https://www.roche.com/dam/jcr:ac88b7d7-1f5e-4c0d-be31-e293740f9469/en/haven-1-haven-2-presentation.pdf
DB13923,,Genentech professionals information,https://www.gene.com/medical-professionals/medicines/hemlibra
DB13923,,FDA news,https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm622564.htm
DB13923,,FDA news,https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm585650.htm
DB13924,,New phase 3 data on shingles vaccine Shingrix presented at CDC Advisory Meeting.,https://www.ptcommunity.com/news/20170622/new-phase-3-data-shingles-vaccine-shingrix-presented-cdc-advisory-meeting
DB13924,,CDC - Clinical Overview of Shingles (Herpes Zoster),https://www.cdc.gov/shingles/hcp/clinical-overview.html
DB13924,,CDC - What Everyone Should Know about Shingles Vaccine,https://www.cdc.gov/vaccines/vpd/shingles/public/index.html
DB13924,,"FDA Approved Drug Products: SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), suspension for intramuscular injection",https://www.fda.gov/media/108597/download
DB13925,,FDA News and Events,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504524.htm
DB13926,,Dompe Farmaceutici SpA Cenegermin FDA Approval Press Release,https://www.drugs.com/newdrugs/fda-approves-oxervate-cenegermin-neurotrophic-keratitis-4807.html
DB13926,,FDA Approved Drug Products: OXERVATE (cenegermin-bkbj) solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761094s001lbl.pdf
DB13926,,"FDA Approved Drug Products: OXERVATE® (cenegermin-bkbj) ophthalmic solution, for topical ophthalmic use (Dec 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761094s012s013lbl.pdf
DB13926,,"EMA Approved Drug Products: OXERVATE (cenegermin) solution, for opthalmic use",https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/502/original/WC500232105.pdf?1537141900
DB13926,,EMA Cenegermin Assessment Report,https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/503/original/WC500232107.pdf?1537141944
DB13928,,FDA Briefing Document: Semaglutide subcutaneous once-weekly,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM580461.pdf
DB13928,,FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM580460.pdf
DB13928,,"FDA Approved Drug Products: RYBELSUS (semaglutide) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213051s006lbl.pdf
DB13928,,"FDA Approved Drug Products: OZEMPIC (semaglutide) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
DB13928,,EMA Approved Drug Products: Ozempic (semaglutide) subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
DB13928,,DailyMed: Rybelsus (semaglutide) oral tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
DB13928,,"FDA Approved Drug Products: WEGOVY (semaglutide) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
DB13928,,"FDA Press Announcements: FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014",https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
DB13928,,Novo Nordisk New Release: Health Canada approves Wegovy™ for the treatment of adults with obesity,https://www.newswire.ca/news-releases/health-canada-approves-wegovy-tm-for-the-treatment-of-adults-with-obesity-829324682.html
DB13928,,EMA Approved Drug Products: Wegovy (semaglutide) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
DB13928,,"FDA Approved Drug Products: WEGOVY (semaglutide) injection, for subcutaneous use (December 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215256s005lbl.pdf
DB13928,,US Food & Drug Administration: Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss,https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
DB13928,,"FDA Approved Drug Proucts: WEGOVY (semaglutide) injection, for subcutaneous use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
DB13928,,"FDA Approved Drug Products: WEGOVY (semaglutide) injection, for subcutaneous use (March 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
DB13931,,FDA Dermatologic and Ophthalmic Drugs Advisory Committee Meeting Briefing Document on Rhopressa (netarsudil ophthalmic solution) 0.02%,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM579731.pdf
DB13931,,"FDA Approved Drug Products: RHOPRESSA® (netarsudil ophthalmic solution) 0.02%, for topical ophthalmic use",https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13931.pdf?1513787533
DB13932,,"FDA Vaccines, Blood and Biologics",https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm589507.htm
DB13932,,FDA News and Events,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm
DB13933,,Globe Newswire News Release: Novo Nordisk receives US FDA approval of REBINYN® (nonacog beta pegol; N9-GP),https://globenewswire.com/news-release/2017/05/31/1004785/0/en/Novo-Nordisk-receives-US-FDA-approval-of-REBINYN-nonacog-beta-pegol-N9-GP.html
DB13933,,"FDA Blood Products Advisory Committee: Coagulation Factor IX (Recombinant), GlycoPEGylated N9-GP (nonacog beta pegol)_Meeting Briefing Document (April 4, 2017)",https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM549858.pdf
DB13933,,"FDA Blood Products Advisory Committee: BLA 125611_FDA Briefing Document (April 4, 2017)",https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM549857.pdf
DB13933,,"EMA Assessment Report: Refixia, INN-nonacog beta pegol",http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004178/WC500232819.pdf
DB13933,,"DailyMed Label: REBINYN [Coagulation Factor IX (Recombinant), GlycoPEGylated] lyophilized powder for solution for intravenous injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ea37235-35fd-410d-b8c4-40ba15fe1294
DB13933,,Health Canada Product Monograph: REBINYN (nonacog beta pegol) Intravenous injection,https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/rebinyn-product-monograph.pdf
DB13933,,Summary of Product Characteristics: Refixia (nonacog beta pegol) intravenous injection,https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf
DB13933,,"Health Canada Approved Drug Products: REBINYN (nonacog beta pegol) Lyophilized powder for solution, intravenous (October 2022)",https://pdf.hres.ca/dpd_pm/00067850.PDF
DB13941,,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf
DB13943,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=3996
DB13943,,Pfizer monograph,https://www.pfizer.ca/sites/g/files/g10028126/f/201601/DepoTestosterone_PM_189981_15Jan2016_E.pdf
DB13943,,Pfizer monograph,http://www.bayerresources.com.au/resources/uploads/pi/file9425.pdf
DB13944,,Pfizer monograph,https://www.pfizer.ca/sites/g/files/g10028126/f/201601/DepoTestosterone_PM_189981_15Jan2016_E.pdf
DB13944,,Pfizer monograph,http://www.bayerresources.com.au/resources/uploads/pi/file9425.pdf
DB13944,,Drugs.com: FDA Approves Xyosted (testosterone enanthate) Press Release,https://www.drugs.com/newdrugs/fda-approves-xyosted-testosterone-enanthate-testosterone-replacement-therapy-adult-males-4834.html
DB13944,,FDA Approved Drug Products: Delatestryl Testosterone Enanthate Injection (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009165
DB13946,,"FDA Approved Drug Products: AVEED (testosterone undecanoate) injection, for intramuscular use CIII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022219s015lbl.pdf
DB13946,,"FDA Approved Drug Products: JATENZO (testosterone undecanoate) capsules, for oral use CIII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206089s000lbl.pdf
DB13946,,"FDA Approved Drug Products: TLANDO (testosterone undecanoate) capsules, for oral use, CIII",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208088s000lbl.pdf
DB13946,,Drug Product Monograph: pms-TESTOSTERONE (testosterone undecanoate) Oral Capsules,https://pdf.hres.ca/dpd_pm/00034424.PDF
DB13948,,Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice,https://www.frontiersin.org/articles/10.3389/fphar.2018.00017/abstract
DB13949,,Iron,http://lpi.oregonstate.edu/mic/minerals/iron
DB13949,,InChem: Iron,http://www.inchem.org/documents/jecfa/jecmono/v18je18.htm
DB13949,,TITCK: Ferimax (Ferric Cation) Oral Drops,https://titck.gov.tr/storage/kubKtAttachments/1e37383814413.pdf
DB13953,,INVIMA Summary of Product Characteristics: Menodin (estradiol benzoate) solution for injection,http://consultaregistro.invima.gov.co:8082//Consultas/GenerarPdf?filename=c:%5Cupload%5CDocumentos%5CPDF%5Cp_37974.pdf
DB13953,,FDA Thailand: PHENOKINON-F (Estradiol benzoate and progesterone) injection,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022280021211C
DB13955,,Ivademecum: SYNOVULAR (algestone acetophenide and estradiol dienanthate) injection,https://co.ivademecum.com/medicamento-synovular-suave-lafrancol-cod-1661106D23C568D2
DB13956,,FDA Thailand Product Information: Progynova (estradiol valerate) oral tablets,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022500010511C
DB13956,,FDA Approved Drug Products: Natazia (estradiol valerate and dienogest) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022252s007lbl.pdf
DB13959,,"FDA Approved Drug Products: SMOFLIPID (lipid injectable emulsion), for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207648s005lbl.pdf
DB13959,,Australian Government Therapeutic Goods Administration: Australian Public Assessment Report for SMOFlipid,https://www.tga.gov.au/sites/default/files/auspar-smoflipid.pdf
DB13960,,BRONOPOL - National Library of Medicine HSDB Database,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7195
DB13960,,Health Canada Cosmetic Ingredient Hotlist of Prohibited and/or Restricted Ingredients,https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/cosmetic-ingredient-hotlist-prohibited-restricted-ingredients/hotlist.html#b1
DB13960,,Health Canada Drug and Health Products Chemical Substance: Bronopol Profile,http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredReq.do?id=846&lang=eng
DB13961,,National Institutes of Health (NIH) Office of Dietary Supplements: Omega-3 Fatty Acids Fact Sheet for Health Professionals,https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
DB13961,,Electronic Medicines Compendium: Omacor (omega-3-acid ethyl esters 90) Monograph,https://www.medicines.org.uk/emc/product/1706/smpc
DB13961,,NIH National Centre for Complementary and Integrative Health: Omega-3 Supplements - In Depth,https://nccih.nih.gov/health/omega3/introduction.htm#hed6
DB13964,,FDA Inactive ingredient search,https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browsebyletter.page&letter=p
DB13964,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13964,,Oilatum,https://www.amazon.com/Oilatum-Cleansing-Bar-Unscented-3-5-Ounce/dp/B002QV6P7S
DB13964,,OLEIC ACID - National Library of Medicine HSDB Database - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1240
DB13964,,Natural Medicines,http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=483
DB13966,,Cosmetic Ingredient Review: Amended Safety Assessment of Alkyl Esters as Used in Cosmetics,https://www.cir-safety.org/sites/default/files/alkyle122012tent_faa_final%20for%20posting.pdf
DB13966,,Canadian Paediatric Society: Head Lice Infestations - A clinical update,https://www.cps.ca/en/documents/position/head-lice
DB13966,,Resultz: Why Resultz is the Best Choice For Your Patients,https://resultz.ca/why-resultz-is-the-best-choice-for-your-patients/
DB13966,,ECHA Registration Dossier: Isopropyl Myristate,https://echa.europa.eu/registration-dossier/-/registered-dossier/16077/7/2/3
DB13966,,NIH Toxnet: Isopropyl Myristate,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+626
DB13966,,Journal of the American College of Toxicology: Final Report on the Safety Assessment of Myristyl Myristate and Isopropyl Myristate,http://www.beauty-review.nl/wp-content/uploads/2014/05/Final-report-on-the-safety-assessment-of-myristyl-myristate-and-isopropyl-myristate.pdf
DB13967,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB13967,,Canadian Cancer Society,http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/tests-and-procedures/sentinel-lymph-node-biopsy-slnb/?region=on
DB13967,,Patent blue V monograph,http://www.pharmaline.co.il/images/newsletterregistration/neopharm/promedico/16112012/patentbluedr.pdf
DB13967,,European Food Safety Authority,https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2013.2818
DB13968,,FDA code of federal regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=640&showFR=1&subpartNode=21:7.0.1.1.7.9
DB13968,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=679bbaf2-b082-5948-8400-ece5340eabc1
DB13968,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=998415d8-9bbe-e5b8-c3b0-3ba0344faacb
DB13968,,Octapharma,http://www.octapharma.co.uk/fileadmin/user_upload/Octapharma_UK_New/OPL1402E.pdf
DB13968,,Octapharma monograph,http://www.octapharma.ca/fileadmin/user_upload/octapharma.ca/20120502_PM_950_Octaplasma.pdf
DB13973,,Health Canada Product Monograph: Prochymal (Remestemcel-L) Intravenous Injection,https://pdf.hres.ca/dpd_pm/00024994.PDF
DB13974,,AIFA Package Leaflet: TRACTANA (Passiflora incarnata flower) oral tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004818_047839_RCP.pdf&retry=0&sys=m0b1l3
DB13975,,Efficacy of black cohosh (Cimicifuga racemosa L.) in treating early symptoms of menopause: a randomized clinical trial,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029542/
DB13975,,Black Cohosh: Insights into its Mechanism(s) of Action,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046019/
DB13975,,Black Cohosh,https://ods.od.nih.gov/factsheets/BlackCohosh-HealthProfessional/
DB13975,,"Treatment of Vasomotor Symptoms of Menopause with Black Cohosh, Multibotanicals, Soy, Hormone Therapy, or Placebo",https://pdfs.semanticscholar.org/6d21/97a9078c86882f35caf132eacd893849077b.pdf
DB13975,,Black Cohosh,https://www.aafp.org/afp/2003/0701/p114.html
DB13975,,Triterpene Biosynthesis in Plants,https://www.annualreviews.org/doi/abs/10.1146/annurev-arplant-050312-120229
DB13975,,Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1142198/
DB13975,,Cytochrome P450 enzyme mediated herbal drug interactions (Part 2),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464477/
DB13975,,BASG: Mensifem (Black Cohosh) Oral Tablet,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=135879&type=DOTC_GEBR_INFO
DB13979,,EMA Assessment Report For Scintimun (International Nonproprietary Name: besilesomab),http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001045/WC500075575.pdf
DB13979,,Making bone inflammation/infection simpler to detect: Scintimun 1mg Monograph,http://www.isotopia.co.il/wp-content/uploads/2013/06/Scintimun_monograph_GB_march-2011.pdf
DB13979,,"Granulocyte-binding antibody constructs, their preparation and use: US Grant US5645817A (Monoclonal antibody amino acid sequence)",https://patents.google.com/patent/US5645817A/en
DB13979,,European Medicines Agency: Scintimun (besilesomab) Product Information (2022),https://www.ema.europa.eu/en/documents/product-information/scintimun-epar-product-information_en.pdf
DB13981,,EMC Summary of Product Characteristics: Zoely (nomegestrol acetate/estradiol) oral tablets,https://www.medicines.org.uk/emc/product/3038
DB13981,,AIFA Product Information: Lutenyl (nomegestrol acetate) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004828_028199_FI.pdf&retry=0&sys=m0b1l3
DB13985,,FDA Press Announcements: FDA approves new treatment for certain digestive tract cancers,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm
DB13985,,FDA Approved Drug Products: LUTATHERA (lutetium Lu 177 dotatate) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208700s019s023lbl.pdf
DB13987,,Natural Medicines Comprehensive Database: Strontium Monograph,http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=1077
DB13987,,Colgate: How Long Should You Brush Your Teeth For?,https://www.colgate.com/en-us/oral-health/basics/brushing-and-flossing/how-long-should-you-brush-your-teeth-for-0113
DB13987,,Pennsylvania Department of Health: Strontium,http://www.health.pa.gov/My%20Health/Environmental%20Health/Environmental%20Fact%20Sheets/Pages/Strontium.aspx#.Wwh-ULYZPOQ
DB13987,,PubChem: Strontium Chloride,https://pubchem.ncbi.nlm.nih.gov/compound/strontium_chloride#section=Metabolism-Metabolites
DB13987,,INVIMA: Acta 13 (28 April 1999),https://www.invima.gov.co/documents/20143/1266729/ceracta13-99.pdf/2374ae0a-e2cc-b312-5bf3-ad465212e677?t=1562121693906
DB13994,,AstraZeneca: AZD7325 Profile,https://openinnovation.astrazeneca.com/azd7325.html
DB13995,,KEGG,http://www.genome.jp/dbget-bin/www_bget?D04946
DB13995,,Nippon,https://www.nippon.com/en/currents/d00106/
DB13995,,FDA Reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206317orig1s000medr.pdf
DB13997,,FDA NEWS RELEASE: FDA Approves New Drug to Treat Influenza,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624226.htm
DB13997,,"FDA Approved Drug Products: XOFLUZA (baloxavir marboxil) tablets or suspension, for oral use (August 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214410Orig2s000lbl.pdf
DB13997,,Genentech: XOFLUZA (Baloxavir Marboxil) MSDS,https://www.gene.com/download/pdf/XOFLUZATablets40mgSAPSDS2.pdf
DB13997,,EMA Approved Drug Products: Xofluza (baloxavir marboxil) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/xofluza-epar-product-information_en.pdf
DB13999,,Have we forgotten the lessons of the tainted blood scandal? - The Globe and Mail,https://www.theglobeandmail.com/opinion/have-we-forgotten-the-lessons-of-the-tainted-blood-scandal/article37097051/
DB13999,,DailyMed Label: XYNTHA SOLOFUSE (antihemophilic factor [recombinant]) for intravenous injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25ea1c3c-14a2-ef11-302e-012bd683924f
DB13999,,Summary of Product Characteristics: ReFacto AF (moroctocog alfa) Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/refacto-af-epar-product-information_en.pdf
DB13999,,Health Canada Product Monograph: Xyntha [Antihemophilic Factor (Recombinant)] For Intravenous Injection,https://pdf.hres.ca/dpd_pm/00034847.PDF
DB14001,,Linus Pauling Institute Micronutrient Information Center: Vitamin E,http://lpi.oregonstate.edu/infocenter/vitamins/vitaminE/
DB14001,,Natural Medicine Journal: Alpha Tocopherol Succinate in Cancer Care,https://www.naturalmedicinejournal.com/journal/2011-06/alpha-tocopheryl-succinate-cancer-care
DB14001,,National Institute for Health,https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/#h5
DB14001,,Cosmetic Ingredient Review: Safety Assessment of Tocopherols and Tocotrienols as Used in Cosmetics,http://www.cir-safety.org/sites/default/files/tocopherols.pdf
DB14001,,Journal of Clinical & Experimental Cardiology: Pharmacokinetics and Bioavailability of Annatto δ-tocotrienol in Healthy Fed Subjects,https://www.omicsonline.org/open-access/pharmacokinetics-and-bioavailability-of-annatto-tocotrienol-in-healthy-fed-subjects-2155-9880-1000411.php?aid=64658
DB14002,,Linus Pauling Institute Micronutrient Information Center: Vitamin E,http://lpi.oregonstate.edu/infocenter/vitamins/vitaminE/
DB14002,,National Institute for Health,https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/#h5
DB14002,,Cosmetic Ingredient Review: Safety Assessment of Tocopherols and Tocotrienols as Used in Cosmetics,http://www.cir-safety.org/sites/default/files/tocopherols.pdf
DB14002,,Journal of Clinical & Experimental Cardiology: Pharmacokinetics and Bioavailability of Annatto δ-tocotrienol in Healthy Fed Subjects,https://www.omicsonline.org/open-access/pharmacokinetics-and-bioavailability-of-annatto-tocotrienol-in-healthy-fed-subjects-2155-9880-1000411.php?aid=64658
DB14003,,National Institute for Health,https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/#h5
DB14003,,Cosmetic Ingredient Review: Safety Assessment of Tocopherols and Tocotrienols as Used in Cosmetics,http://www.cir-safety.org/sites/default/files/tocopherols.pdf
DB14003,,Journal of Clinical & Experimental Cardiology: Pharmacokinetics and Bioavailability of Annatto δ-tocotrienol in Healthy Fed Subjects,https://www.omicsonline.org/open-access/pharmacokinetics-and-bioavailability-of-annatto-tocotrienol-in-healthy-fed-subjects-2155-9880-1000411.php?aid=64658
DB14004,,FDA Approves ILUMYA (tildrakizumab-asmn) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy,http://s2027422842.t.en25.com/e/es?s=2027422842&e=66767&elqTrackId=78D8A052C380BCBFF284D754BEBE9730&elq=096ab38d576c4c76b4f65be4cded361f&elqaid=2935&elqat=1
DB14004,,Ilumya,https://www.psoriasis.org/content/ilumya-tildrakizumab-asmn
DB14004,,The safety and side effects of monoclonal antibodies,http://theory.bio.uu.nl/immbio/pdf/TherapeuticReview2010.pdf
DB14004,,"The effect of tildrakizumab, a high-affinity, selective anti-IL23p19 monoclonal antibody (mAb), on cytochrome P450 (CYP) metabolism",http://www.jaad.org/article/S0190-9622(17)31465-2/fulltext
DB14004,,Tildrakizumab for treating psoriasis,https://www.tandfonline.com/doi/abs/10.1080/14712598.2017.1304537?scroll=top&needAccess=true&journalCode=iebt20
DB14004,,Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value,https://icer-review.org/wp-content/uploads/2017/11/ICER_Draft_Psoriasis_CU_Scope_120417.pdf
DB14004,,FDA Approved Drug Products: Ilumya (tildrakizumab-asmn) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf
DB14005,,FDA Code of Federal Regulations,https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10&SearchTerm=dimethicone
DB14005,,FDA Reports,https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm291010.pdf
DB14005,,Dow corning monograph,http://www.healthcare-plus.com.tw/big5/pdf/05-01.pdf
DB14005,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91c8fa1-9036-4c80-9b15-65100a3a7be3
DB14005,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ae82d2b7-eb86-4bbe-825c-f7d7cd7610ad&type=display
DB14005,,"Public Assessment Report, Dimethicone",http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2023415.pdf
DB14005,,"Public Assesment report, Silicone",http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2033274.pdf
DB14006,,PubChem: Choline Salicylate,https://pubchem.ncbi.nlm.nih.gov/compound/Arthropan#section=Top
DB14006,,Topical choline salicylates implicated in Reye’s syndrome,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427076/
DB14006,,Characterization of new eye drops with choline salicylate and assessment of their irritancy by in vitro short time exposure tests.,https://www.ncbi.nlm.nih.gov/pubmed/27134543
DB14006,,Drugs.com: Choline C 11,https://www.drugs.com/international/choline-salicylate.html
DB14006,,Choline Salicylate; Magnesium Salicylate oral tablet,https://www.pillpack.com/medication/choline-salicylate-magnesium-salicylate-oral-tablet
DB14006,,"Mayo Clinic Health Information: Salicylate (Oral Route, Rectal Route)",https://www.mayoclinic.org/drugs-supplements/salicylate-oral-route-rectal-route/precautions/drg-20070551
DB14006,,MIMS: Choline Salicylate,http://www.mims.com/malaysia/drug/info/choline%20salicylate?mtype=generic
DB14006,,Drugsupdate.com: Choline Salicylate,http://www.drugsupdate.com/generic/view/880/Choline-Salicylate
DB14006,,Oral salicylate gels: not for use in those younger than age 16 years,https://www.gov.uk/drug-safety-update/oral-salicylate-gels-not-for-use-in-those-younger-than-age-16-years
DB14006,,Summary of Product Characteristics: Bonjela oral mucosal gel,https://www.medicines.ie/medicines/bonjela-oromucosal-gel-31456/spc
DB14006,,Netdoctor: Bonjela treatment for mouth ulcers,http://www.netdoctor.co.uk/medicines/mouth-and-teeth/a7835/bonjela/
DB14006,,"Efficacy, Disposition and Pharmacodynamics of Aspirin, Acetaminophen and Choline Salicylate in Young Febrile Children","https://journals.lww.com/drug-monitoring/Abstract/1982/06000/Efficacy,_Disposition_and_Pharmacodynamics_of.3.aspx"
DB14006,,EMC Summary of Product Characteristics: Bonjela (Choline salicylate and cetalkonium chloride) oral gel,https://www.medicines.org.uk/emc/product/624
DB14007,,FDA Inactive ingredient search,https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browsebyletter.page&letter=p
DB14007,,FDA guidelines,https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071320.pdf
DB14007,,FDA orphan list,https://www.fda.gov/downloads/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/ucm162066.xls
DB14012,,"FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia",https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm604810.htm
DB14012,,Crysvita Drug Label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004275/WC500245537.pdf
DB14012,,Burosumab for a rare bone disease,http://www.who.int/medicines/publications/druginformation/issues/WHO_DI_32-1.pdf
DB14012,,DRUG: Burosumab,http://www.genome.jp/dbget-bin/www_bget?dr:D10913
DB14012,,NHS document,https://www.sps.nhs.uk/medicines/burosumab/
DB14012,,Burosumab for XLH,http://www.ultragenyx.com/pipeline/krn23-xlh/
DB14015,,"TITCK Product Information: Hepatamine (Admetionine, Adenine, Ascorbic Acid, Aspartame, Biotin, Calcifediol, Cysteine, Lysine, Methionine, NADH, Phosphoric Acid, Sodium Bisulfite. Thiamine, Tryptophan, Tyrosine, Valine, Vitamin A) Intravenous Solution",https://titck.gov.tr/storage/kubKtAttachments/fd459bac99974.pdf
DB14017,,H3 Biomedicine Granted Orphan Drug Designation of H3B-8800 for Treatment of Acute Myelogenous Leukemia and Chronic Myelomonocytic Leukemia,https://www.h3biomedicine.com/2017/08/14/h3-biomedicine-granted-orphan-drug-designation-of-h3b-8800-for-treatment-of-acute-myelogenous-leukemia-and-chronic-myelomonocytic-leukemia/
DB14018,,FDA Submission,https://www.fda.gov/downloads/drugs/developmentapprovalprocess/formssubmissionrequirements/drugmasterfilesdmfs/ucm370723.txt
DB14018,,Health Canada,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
DB14018,,FDA history,https://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm207938.xls
DB14018,,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37dfece3-d570-4ab2-ba95-af6eb1f3acd4
DB14018,,CNKI,http://en.cnki.com.cn/Article_en/CJFDTotal-ZGYZ201004009.htm
DB14018,,Annexpublishers,http://www.annexpublishers.co/articles/JBS/3101-Bioanalytical-Method-for-Pamabrom-Determined-As-8-Bromotheophylline-and-its-Application-to-a-Pharmacokinetic-Study.pdf
DB14019,,Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States,https://www.helsinn.com/news-and-events/helsinn-group-announces-the-fda-approval-of-the-iv-formulation-of-akynzeo-fosnetupitant-palonosetron-in-the-united-states/
DB14019,,"Safety Data Sheet, Netupitant",http://www.dcchemicals.com/product_show-Netupitant.html
DB14019,,Akynzeo.com,https://www.akynzeo.com/hcp/moa
DB14019,,"Antiemetic, Neurokinin-1 Receptor Blockers",https://www.ncbi.nlm.nih.gov/books/NBK470394/
DB14019,,"Netupitant, PubChem",https://pubchem.ncbi.nlm.nih.gov/compound/Netupitant#section=Top
DB14028,,AIFA: Madar (Nordazepam) Oral Tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_022714_FI.pdf&retry=0&sys=m0b1l3
DB14033,,Acetyl Sulfisoxazole,https://pubchem.ncbi.nlm.nih.gov/compound/Sulfisoxazole_acetyl
DB14033,,ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7
DB14033,,Sulfisoxazole,http://www.druginfosys.com/drug.aspx?drugcode=1506&type=1
DB14033,,Sulfadiazine or Sulfisoxazole,http://apps.who.int/medicinedocs/en/d/Js2252e/6.4.html
DB14033,,Sulfisoxazole,http://www.nextbio.com/b/search/details/Sulfisoxazole?type=compound
DB14033,,Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing,https://www.researchgate.net/publication/16079120_Comparison_of_the_disposition_of_total_and_unbound_sulfisoxazole_after_single_and_multiple_dosing
DB14033,,Gantrisin,http://www.druglib.com/druginfo/gantrisin/indications_dosage/
DB14033,,Gantrisin Description,https://www.drugs.com/pro/gantrisin.html
DB14033,,"Sulfisoxazole, ToxNET",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+797
DB14033,,Sulfisoxazole,https://drugs.ncats.io/ginas/app/substance/7c27a988
DB14039,,"Press Release: Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention",https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention
DB14039,,"FDA Approved Drug Products: AIMOVIG (erenumab-aooe) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761077s001lbl.pdf
DB14040,,EconoTimes Business Article: Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine,https://www.econotimes.com/Alder-BioPharmaceuticals-New-Data-Demonstrated-Eptinezumab-Increased-Migraine-Free-Intervals-Up-to-325-days-and-Improved-Quality-of-Life-Outcomes-in-Patients-with-Episodic-Migraine-1273647
DB14040,,FDA Approved Drug Products: Vyepti (eptinezumab-jjmr) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf
DB14041,,JAMA Network: Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine,https://jamanetwork.com/journals/jama/article-abstract/2681193?redirect=true
DB14041,,FDA Approved Drug Products: Ajovy (fremanezumab-vfrm) subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761089s002lbl.pdf
DB14041,,FDA Drug Approval Package: Ajovy (fremanezumab-vfrm),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761089Orig1s000TOC.cfm
DB14042,,FDA Approved Drug Products: EMGALITY (galcanezumab-gnlm) injection for subcutaneous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761063s006lbl.pdf
DB14048,,AstraZeneca: ZS-9 (sodium zirconium cyclosilicate) Phase III long-term safety and efficacy data presented at ASN Kidney Week 2017,https://www.astrazeneca.com/media-centre/medical-releases/zs-9-sodium-zirconium-cyclosilicate-phase-iii-long-term-safety-and-efficacy-data-presented-at-asn-kidney-week-201702112017.html
DB14048,,AstraZeneca: Lokelma approved in the US for the treatment of adults with hyperkalaemia,https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html
DB14048,,FDA Approved Drug Products: Lokelma (sodium zirconium cyclosilicate) for oral suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207078s000lbl.pdf
DB14050,,GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006,https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-announces-preliminary-results-phase-2a-study-its-pipeline-compound
DB14050,,GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy,https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-commences-phase-1-clinical-trial-gwp42006-potential-treatment
DB14050,,Public summary of opinion on orphan designation: Cannabidivarin for treatment of fragile X syndrome,http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2018/04/WC500247223.pdf
DB14050,,Public summary of opinion on orphan designation: Cannabidivarin for the treatment of Rett syndrome,http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2018/01/WC500241010.pdf
DB14058,,Basifungin,https://adisinsight.springer.com/drugs/800004447
DB14058,,AUR1- Uniprot,http://www.uniprot.org/uniprot/O13332
DB14059,,Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor,http://jpet.aspetjournals.org/content/323/3/778
DB14059,,SC-236,https://www.caymanchem.com/product/10004219
DB14059,,Enhancement of Tumor Response to -Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme,https://www.researchgate.net/publication/31132809_Enhancement_of_Tumor_Response_to_-Radiation_by_an_Inhibitor_of_Cyclooxygenase-2_Enzyme
DB14059,,Overview of selective COX-2 inhibitors,https://www.uptodate.com/contents/overview-of-selective-cox-2-inhibitors
DB14074,,"Gervais, J. A.; Wegner, P.; Luukinen, B.; Buhl, K.; Stone, D. 2009. Picaridin Technical Fact Sheet; National Pesticide Information Center, Oregon State University Extension Services.",http://npic.orst.edu/factsheets/archive/Picaridintech.html
DB14074,,DailyMed - SG PLUS REPELLENT AROMA MIST- icaridin liquid,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=495548e6-1734-44eb-8d40-23283d7377d2
DB14074,,PICARIDIN - National Library of Medicine HSDB Database - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+7374
DB14078,,DailyMed: Kit for the Preparation of Technetium Tc 99m Medronate for Injection,https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=703d347c-e240-408a-b69d-9713e958a201&type=display
DB14078,,FDA Approved Products: DRAXIMAGE® MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate Injection),https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018035s032lbl.pdf
DB14082,,DailyMed Label: KIT FOR THE PREPARATION OF TECHNETIUM TC99M MERTIATIDE,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ad62039-f848-4f3d-b489-2524e6b6b86e
DB14091,,DIMDI Product Information: SICCAPOS (carbomer 980) eye gel,https://portal.dimdi.de/amispb/doc/2015/07/20/2136060/O91191a83bf574e379339981d24820612.pdf
DB14106,,FDA Approved Drug Products: Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019785s022lbl.pdf
DB14113,,DailyMed: Antivenin (latrodectus mactans) kit,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=600e54ad-af13-462f-8a2d-2c3f7d91a8cd
DB14114,,FDA Approved Drug Products: ANAVIP [crotalidae immune F(ab’)2 (equine)] Lyophilized Powder for Solution for Injection For Intravenous Use Only,https://www.fda.gov/media/92139/download
DB14115,,"FDA Approved Drug Products: BabyBIG (botulism immune globulin, human) lyophilized powder for reconstitution for intravenous injection",https://www.fda.gov/media/150406/download
DB14115,,Infant Botulism Treatment and Prevention Program: Frequently Asked Questions,https://www.infantbotulism.org/general/faq.php
DB14115,,Centers for Disease Control and Prevention: Infant Botulism,https://www.cdc.gov/botulism/infant-botulism.html
DB14115,,California Department of Public Health: Infant Botulism Treatment and Prevention Program,https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/InfantBotulism.aspx
DB14115,,Infant Botulism Treatment and Prevention Program: What is BabyBIG?,https://www.infantbotulism.org/general/babybig.php
DB14126,,Pubmed books,https://www.ncbi.nlm.nih.gov/books/NBK533928/
DB14126,,"FDA Approved Drug Products: Bictegravir, Emtricitabine, and Tenofovir Alafenamide Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf
DB14126,,"FDA Approved Drug Products: VIREAD (tenofovir disoproxil fumarate), for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022577lbl.pdf
DB14126,,INVIMA: Emtricitabine and Tenofovir Oral Tablet,http://web.sivicos.gov.co/registros/pdf/1391639_2015050662.pdf
DB14146,,Nektar Therapeutics: Loxicodegol FDA Application Press Release,http://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-submission-new-drug-application-us
DB14151,,TITCK: Megadyn Pronatal (Multivitamin) Oral Tablet,https://titck.gov.tr/storage/kubKtAttachments/acddbRyk8dpR9h.pdf
DB14159,,"FDA Approved Drug Products: Technescan HDP (Kit for the Preparation of Technetium Tc 99m Oxidronate), for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018321s022lbl.pdf
DB14163,,"FDA Approved Drug Products: ORALAIR 6 (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use",https://www.fda.gov/media/87935/download
DB14183,,"Geraniol — A review of a commercially important fragrance material; Chen and Viljoen, 2010.",https://www.sciencedirect.com/science/article/pii/S0254629910001559
DB14185,,FDA Approved Drug Products: ARISTADA (aripiprazole lauroxil) injectable,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207533s017,209830s005lbl.pdf"
DB14222,,TITCK Product Information: Biober-Zn (Bacterial Culture and Zinc Sulfate) Oral Suspension,https://titck.gov.tr/storage/kubKtAttachments/v5T4SXFeoRnrM.pdf
DB14230,,DailyMed: Draximage (technetium tc99m albumin aggregated injection) contrast kit,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbefaa05-1dc0-3ae7-7264-ce1eddf0da2b
DB14233,,"TITCK Product Information: OMEGAVEN (DL-alpha-tocopherol, doconexent, egg phospholipids, glycerin, and icosapent) injection",https://titck.gov.tr/storage/kubKtAttachments/ec8c8ef126731.pdf
DB14349,,"NPRA: Evelle (Ascorbic acid, Bilberry, Biotin, Equisetum arvense top, Marine collagen, soluble, Maritime pine extract, Selenium, Tomato, Vitamin E, Zinc) Oral Tablet",https://quest3plus.bpfk.gov.my/front-end/attachment/112189/pharma/207874/F8(1).pdf
DB14407,,"TITCK Product Information: VAXİGRİP (influenza A X-275 (H1N1), influenza A IVR-186 (H3N2), influenza B BX-69A, and influenza B) injection",https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/02341604-933f-4082-84a3-73922099fd5d.pdf
DB14422,,"TITCK Product Information: VAXİGRİP (influenza A X-275 (H1N1), influenza A IVR-186 (H3N2), influenza B BX-69A, and influenza B) injection",https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/02341604-933f-4082-84a3-73922099fd5d.pdf
DB14443,,"FDA Approved Drug Products: Vaxchora (cholera vaccine, live, oral) oral suspension",https://www.fda.gov/media/128415/download
DB14443,,"EMA Summary of Product Characteristics: Vaxchora (Cholera vaccine, recombinant, live) powder for oral suspension",https://www.ema.europa.eu/en/documents/product-information/vaxchora-epar-product-information_en.pdf
DB14443,,"European Medicines Agency Medicines: Vaxchora (cholera vaccine, oral, live)",https://www.ema.europa.eu/en/medicines/human/EPAR/vaxchora#product-information-section
DB14473,,FDA Approved Drug Products: Alphanate (antihemophilic factor/von Willebrand factor complex) powder for intravenous injection,https://www.fda.gov/media/71753/download
DB14481,,HSDB: Calcium Phosphate,http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+879
DB14487,,Zinc and its importance for human health: An integrative review,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724376/
DB14487,,The Essential Toxin: Impact of Zinc on Human Health,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872358/
DB14487,,Dietary factors affecting Zinc bioavailability,http://journals.sagepub.com/doi/pdf/10.1177/156482650102200204
DB14487,,Zinc,https://www.mayoclinic.org/drugs-supplements-zinc/art-20366112
DB14487,,"Zinc Transporters, Mechanisms of Action and Therapeutic Utility: Implications for Type 2 Diabetes Mellitus",https://www.hindawi.com/journals/jnme/2012/173712/
DB14487,,"Zinc, future mono/adjunctive therapy for depression: Mechanisms of antidepressant action",https://www.sciencedirect.com/science/article/abs/pii/S1734114015000274
DB14487,,MeSH Zinc,https://www.ncbi.nlm.nih.gov/mesh?Db=mesh&Cmd=DetailsSearch&Term=%22Zinc%22%5BMeSH+Terms%5D
DB14487,,Agency for Toxic Substances and Disease Registry: Toxicological Profile for Zinc,https://www.atsdr.cdc.gov/toxprofiles/tp60-c3.pdf
DB14487,,ZINC COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6912
DB14487,,"Pharmacokinetics, tissue distribution, and excretion of zinc oxide nanoparticles",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394467/
DB14487,,Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia,https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.2830310203
DB14487,,Zinc Therapy in Dermatology: A review,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120804/
DB14487,,Treatment of Wilson’s Disease with Zinc. I. Oral Zinc Therapy Regimens,https://pdfs.semanticscholar.org/896f/03dae9396d9463c552aff6e9ab78dcd44f06.pdf
DB14487,,Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394849/
DB14487,,Zinc Supplementation in treating diarrhea in children,http://www.cochrane.org/CD005436/INFECTN_oral-zinc-supplementation-treating-diarrhoea-children
DB14487,,Zinc homeostasis in humans,https://academic.oup.com/jn/article/130/5/1360S/4686372
DB14487,,"ZINC: Uses, Side Effects, Interactions and Warnings - WebMD",https://www.webmd.com/vitamins.../ingredientmono-982-zinc.aspx?...982...zinc
DB14487,,Zinc Toxicity in Humans,https://pdfs.semanticscholar.org/a9e2/8321ae506e646f32ce59d87b7589851aa7e4.pdf
DB14487,,Chapter 16. Zinc,http://www.fao.org/docrep/004/y2809e/y2809e0m.htm
DB14487,,Zinc metabolism,http://flipper.diff.org/app/pathways/3503
DB14487,,"Copper and Zinc, Biological Role and Significance of Copper/Zinc Imbalance",https://www.omicsonline.org/copper-and-zinc-biological-role-and-significance-of-copper-zincimbalance-2161-0495.S3-001.php?aid=3055
DB14487,,The emerging role of zinc transporters,https://www.nature.com/articles/sigtrans201729
DB14488,,TITCK Product Information: Ferrozinc-G (ferrous gluconate/zinc gluconate) oral syrup,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/yaynferrozingurup_11735257-3a09-4c06-9a2a-e6a794557bbf.pdf
DB14489,,DIMDI Product Information: FERRLECIT 2 (iron succinate) tablet,https://portal.dimdi.de/amispb/doc/2014/03/04/2100295/OBFM204DC75201CF2C49.pdf
DB14500,,NIH Potassium Fact Sheet for Health Professionals,https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/
DB14500,,Potassium chloride FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206814lbl.pdf
DB14500,,Potassium chloride in dextrose and sodium chloride FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/18008s073,18037s073,18629s046,19308s030lbl.pdf"
DB14500,,Potassium citrate PDR,https://www.pdr.net/drug-summary/Urocit-K-potassium-citrate-414.583
DB14500,,Potassium acetate drug summary,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8123cce8-42e3-49e4-a488-3bb836ecccd0
DB14500,,"Highly concentrated potassium preparation, FDA label",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019904s014lbl.pdf
DB14500,,K-tab extended release FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018279s034lbl.pdf
DB14501,,DIMDI Product Information: FERRO SANOL (ferrous glycine sulfate) oral tablet,https://portal.dimdi.de/amispb/doc/2018/12/04/0160442/Ocdb0d89486244a7a8aed2b4f08371eec.pdf
DB14502,,FDA Guide: Sodium Phosphate Tablet,https://www.fda.gov/downloads/drugs/drugsafety/ucm134684.pdf
DB14502,,ChemIDPlus: Sodium Phosphate,https://chem.nlm.nih.gov/chemidplus/rn/7558-80-7
DB14503,,FDA Guide: Sodium Phosphate Tablet,https://www.fda.gov/downloads/drugs/drugsafety/ucm134684.pdf
DB14503,,ChemIDPlus: Sodium Phosphate,https://chem.nlm.nih.gov/chemidplus/rn/7558-80-7
DB14505,,BORIC ACID - National Library of Medicine HSDB Database- Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1432
DB14505,,Boric Acid - National Toxicology Program - NIH,https://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr324.pdf
DB14505,,Fisher Scientific: Sodium Borate MSDS,https://beta-static.fishersci.ca/content/dam/fishersci/en_US/documents/programs/education/regulatory-documents/sds/chemicals/chemicals-s/S25537.pdf
DB14507,,ILO: Lithium,http://www.ilo.org/dyn/icsc/showcard.display?p_card_id=0710
DB14509,,ILO: Lithium,http://www.ilo.org/dyn/icsc/showcard.display?p_card_id=0710
DB14509,,"Bipolar Disorders and Lithium: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Indications of Lithium: Review of Articles",http://austinpublishinggroup.com/psychiatry-behavioral-sciences/fulltext/ajpbs-v3-id1053.php
DB14509,,New Zealand Drug Data Sheet: Lithium Carbonate,https://medsafe.govt.nz/Profs/datasheet/l/Lithiumcarbonatecap.pdf
DB14509,,FDA Approved Drug Products: Lithium carbonate capsules/tablets/solution for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/017812s034,018421s033,018558s028lbl.pdf"
DB14510,,AIFA Package Leaflet: TARDYFER (ferrous cation) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000030_041219_RCP.pdf&retry=0&sys=m0b1l3
DB14512,,FDA Approved Drug Products: Asmanex Mometasone Furoate Inhalation Powder,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021067s026,s028lbl.pdf"
DB14512,,FDA Approved Drug Products: Nasonex (mometasone furoate) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf
DB14512,,FDA Approved Drug Products: Elocon Mometasone Furoate Lotion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019796s029lbl.pdf
DB14512,,FDA Approved Drug Products: Sinuva Mometasone Furoate Sinus Implant,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209310s001lbl.pdf
DB14512,,FDA Approved Drug Products: Elocon Mometasone Furoate Ointment,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019543s028lbl.pdf
DB14512,,FDA Approved Drug Products: Ryaltris (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211746s000lbl.pdf
DB14512,,FDA Approved Drug Products: Nasonex 24h Allergy (mometasone furoate) nasal spray (OTC),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215712Orig1s000lbl.pdf
DB14512,,Health Canada Approved Drug Proucts: Ryaltris (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray,https://pdf.hres.ca/dpd_pm/00067564.PDF
DB14512,,FDA Approved Drug Products: SINUVA (mometasone furoate)sinus implant Jan 2023,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209310s006lbl.pdf
DB14513,,Citroma Magnesium Citrate DailyMed label,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a58a14bf-3e49-4216-a8c8-cee53a620c80
DB14513,,"Magnesium Sulfate Injection, USP 50%",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019316s024lbl.pdf
DB14513,,"NIH document, Magnesium",https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
DB14514,,DIMDI: Magnesium Diasporal (Magnesium Levulinate) Oral Granule,https://portal.dimdi.de/amguifree/am/docoutput/additionalDocDownload.xhtml?dntObjId=3381ebcc-f57f-10ad-e053-0b0c10ac04b9
DB14517,,Vinmec International General Hospital: Phosphalugel - What you need to know,https://www.vinmec.com/eng/article/phosphalugel-phosphalugel-what-you-need-to-know-en
DB14520,,FDA Approved Drug Products: Auryxia (ferric citrate) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205874s013lbl.pdf
DB14520,,Spectrum Chemical: Ferric Citrate MSDS,https://www.spectrumchemical.com/MSDS/F3120.pdf
DB14526,,"CHROMIUM, ELEMENTAL - National Library of Medicine HSDB ... - Toxnet - NIH",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+910
DB14526,,CHROMIUM COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6999
DB14526,,Chromium Toxicological Overview - Health Protection Agency - Gov.uk,https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/338694/Chromium_toxicological_overview.pdf
DB14526,,Dietary Supplement Fact Sheet: Chromium,https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/
DB14526,,Dailymed Label: DIVISTA - chromium picolinate capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c485cd-ee30-44f2-be63-bb98f8d1a907
DB14527,,"CHROMIUM, ELEMENTAL - National Library of Medicine HSDB ... - Toxnet - NIH",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+910
DB14527,,CHROMIUM COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6999
DB14527,,Chromium Toxicological Overview - Health Protection Agency - Gov.uk,https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/338694/Chromium_toxicological_overview.pdf
DB14527,,Dietary Supplement Fact Sheet: Chromium,https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/
DB14527,,Dailymed Label: DIVISTA - chromium picolinate capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c485cd-ee30-44f2-be63-bb98f8d1a907
DB14528,,"CHROMIUM, ELEMENTAL - National Library of Medicine HSDB ... - Toxnet - NIH",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+910
DB14528,,CHROMIUM COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6999
DB14528,,Chromium Toxicological Overview - Health Protection Agency - Gov.uk,https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/338694/Chromium_toxicological_overview.pdf
DB14528,,Dietary Supplement Fact Sheet: Chromium,https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/
DB14528,,Dailymed Label: DIVISTA - chromium picolinate capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c485cd-ee30-44f2-be63-bb98f8d1a907
DB14529,,"CHROMIUM, ELEMENTAL - National Library of Medicine HSDB ... - Toxnet - NIH",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+910
DB14529,,CHROMIUM COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6999
DB14529,,Chromium Toxicological Overview - Health Protection Agency - Gov.uk,https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/338694/Chromium_toxicological_overview.pdf
DB14529,,Dietary Supplement Fact Sheet: Chromium,https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/
DB14529,,Dailymed Label: DIVISTA - chromium picolinate capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c485cd-ee30-44f2-be63-bb98f8d1a907
DB14530,,"CHROMIUM, ELEMENTAL - National Library of Medicine HSDB ... - Toxnet - NIH",https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+910
DB14530,,CHROMIUM COMPOUNDS - National Library of Medicine HSDB ... - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6999
DB14530,,Chromium Toxicological Overview - Health Protection Agency - Gov.uk,https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/338694/Chromium_toxicological_overview.pdf
DB14530,,Dietary Supplement Fact Sheet: Chromium,https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/
DB14530,,Dailymed Label: DIVISTA - chromium picolinate capsule,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06c485cd-ee30-44f2-be63-bb98f8d1a907
DB14533,,Fisher Scientific: Zinc Chloride MSDS,https://fscimage.fishersci.com/msds/25350.htm
DB14533,,Medsafe New Zealand Approved Drug Products: Zinc Chloride Solution for Injection,https://www.medsafe.govt.nz/profs/Datasheet/d/dblzincchlorideinj.pdf
DB14533,,Dailymed: Zinc Chloride Injection,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a1914a0-e195-4233-c1be-bc2075580eb8
DB14542,,AIFA Package Leaflet: IDROCORTISONE BRUNO FARMACEUTICI (Hydrocortisone) oral tablets,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000794_045566_RCP.pdf&retry=0&sys=m0b1l3
DB14548,,FDA Approved Drug Products: Zinc Sulfate Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209377s000lbl.pdf
DB14550,,FDA Approved Drug Products: Gallium Citrate Ga 67 Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017478s016lbl.pdf
DB14559,,"TITCK Product Information: VAXİGRİP (influenza A X-275 (H1N1), influenza A IVR-186 (H3N2), influenza B BX-69A, and influenza B) injection",https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/02341604-933f-4082-84a3-73922099fd5d.pdf
DB14560,,"TITCK Product Information: VAXİGRİP (influenza A X-275 (H1N1), influenza A IVR-186 (H3N2), influenza B BX-69A, and influenza B) injection",https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/02341604-933f-4082-84a3-73922099fd5d.pdf
DB14562,,"DailyMed Label: ANDEXXA- andexanet alfa injection, powder, lyophilized, for solution",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae7f0c50-ff2d-49e5-8e10-4efa861556e6
DB14562,,andexanet alfa | Ligand page | IUPHAR/BPS Guide to Pharmacology,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=7576
DB14568,,"FDA Approved Drug Products: TIBSOVO (ivosidenib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf
DB14568,,CHMP Summary of Positive Opinion: Tibsovo (ivosidenib),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/tibsovo
DB14568,,CHMP Summary of Positive Opinion: Tidhesco (ivosidenib),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/tidhesco
DB14568,,EMA Approved Drug Products: Tibsovo (ivosidenib) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf
DB14568,,PR Newswire: Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma,https://www.prnewswire.com/news-releases/servier-receives-european-commission-approval-of-tibsovo-ivosidenib-tablets-in-idh1-mutated-acute-myeloid-leukemia-and-idh1-mutated-cholangiocarcinoma-301820895.html
DB14568,,"FDA Approved Drug Products: TIBSOVO® (ivosidenib tablets), for oral use (October 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf
DB14569,,FDA Approved Products: Sivextro (tedizolid phosphate) tablet and injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf
DB14574,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB14575,,FDA Approved Drug Products: Aptiom (eslicarbazepine acetate) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022416s011lbl.pdf
DB14575,,AIFA: ZEBINIX (eslicarbazepine) oral tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003535_039910_FI.pdf&retry=0&sys=m0b1l3
DB14577,,"TITCK: Polifleks Laktatli Ringer (Sodium Chloride, Sodium Lactate, Potassium Chloride, and Calcium Chloride) Intravenous Infusion",https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/TİTCK%20POLİFLEKS%20LAKTATLI%20RİNGER%20UYGUN%20KT.pdf_3570a3ba-228e-4265-bf70-abb632416637.pdf
DB14580,,"FDA Approved Drug Products: LEQEMBI (lecanemab-irmb) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf
DB14580,,FDA News Release: FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
DB14580,,FDA News Release: FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval,https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval
DB14580,,"FDA Approved Drug Products: LEQEMBI (lecanemab-irmb) injection, for intravenous use (July 2023)",https://www.leqembi.com/-/media/Files/Leqembi/Prescribing-Information.pdf?hash=986ec373-a218-4b34-a1d7-74adf1bb08ee
DB14582,,FDA Announcement: Patisiran,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616518.htm
DB14582,,FDA Approved Drug Products: ONPATTRO (patisiran) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210922s009lbl.pdf
DB14583,,FDA Approves Annovera (segesterone acetate and ethinyl estradiol) Vaginal Contraceptive System - Drugs.com,https://www.drugs.com/newdrugs/fda-approves-annovera-segesterone-acetate-ethinyl-estradiol-vaginal-contraceptive-4796.html
DB14585,,DailyMed: Mucilin (plantago ovata) oral powder,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f909228e-f265-48b0-9fe5-b1c37dc4bbc4
DB14587,,"NPRA: SKYCellflu Trivalent (Influenza A virus A/Michigan/45/2015 X-275, Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186, Influenza B virus B/Maryland/15/2016) Intramuscular Injection",https://quest3plus.bpfk.gov.my/front-end/attachment/51806/pharma/521217/V_45760_20200825_111709_D3.pdf
DB14591,,"NPRA: SKYCellflu Trivalent (Influenza A virus A/Michigan/45/2015 X-275, Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186, Influenza B virus B/Maryland/15/2016) Intramuscular Injection",https://quest3plus.bpfk.gov.my/front-end/attachment/51806/pharma/521217/V_45760_20200825_111709_D3.pdf
DB00873,,Health Canada Approved Drug Products: Lotemax (Loteprednol) Ophthalmic Ointment,https://pdf.hres.ca/dpd_pm/00024518.PDF
DB14597,,FDA news,https://www.fda.gov/Drugs/DrugSafety/ucm618261.htm
DB14597,,Globalnews,https://globenewswire.com/news-release/2018/08/27/1557233/0/en/Shire-Announces-FDA-Approval-of-TAKHZYRO-lanadelumab-flyo-a-First-of-its-Kind-mAb-Preventive-Treatment-for-Hereditary-Angioedema.html
DB14597,,NIH,https://drugs.ncats.io/substance/2372V1TKXK
DB14597,,FDA Approved Drug Products: TAKHZYRO (lanadelumab-flyo) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s001lbl.pdf
DB14597,,"FDA Approved Drug Products: TAKHZYRO® (lanadelumab-flyo) injection, for subcutaneous use (February 2023)",https://www.shirecontent.com/PI/PDFs/TAKHZYRO_USA_ENG.pdf
DB14597,,EMA Summary of Product Characteristics: Takhzyro (lanadelumab) solution for subcutaneous administration,https://www.ema.europa.eu/en/documents/product-information/takhzyro-epar-product-information_en.pdf
DB14597,,EMA EPAR: Takhzyro (lanadelumab),https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro
DB14597,,Health Canada Approved Drug Products: Takhzyro (lanadelumab) solution for subcutaneous injection,https://pdf.hres.ca/dpd_pm/00047437.PDF
DB14598,,FDA Approved Drug Products: Edetate Calcium Disodium Intravenous or Intramuscular Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008922s016lbl.pdf
DB14600,,Dailymed: Endrate Edetate Disodium Anhydrous Intravenous Injection (Discontinued),https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=290c3e9c-c0c6-440a-1a9c-46e3e2b07a77
DB14600,,Medsafe New Zealand Approved Drug Products: Edetate Disodium Injection,https://www.medsafe.govt.nz/Profs/Datasheet/e/EdetateDisodiumUSPinj.pdf
DB14627,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB14631,,FDA Approved Drug Products: Pediapred Prednisolons Sodium Phosphate Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019157s021lbl.pdf
DB14631,,FDA Approved Drug Products: Orapred Prednisolone Sodium Phosphate Orally Disintegrating Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf
DB14631,,FDA Approved Drug Products: Inflamase Prednisolone Sodium Phosphate Ophthalmic Drops (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=080751
DB14633,,BASG Product Information: Prednisolut (prednisolone hemisuccinate) injection,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=135061&type=DOTC_FACH_INFO
DB14634,,DIMDI Product Information: DECODERM (fluprednidene acetate) topical,https://portal.dimdi.de/amispb/doc/2017/07/16/0109837/Odb46a65f4b9446509d16c991385beae3.pdf
DB14635,,"EMA Assessment Report: Curcuma xanthorrhiza Roxb. (C. xanthorrhiza D. Dietrich)., rhizoma for oral use",https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-curcuma-xanthorrhiza-roxb-c-xanthorrhiza-d-dietrich-rhizoma_en.pdf
DB14641,,Trimesta,http://www.syntheticbiologics.com/trimesta
DB14641,,Merck Safety Data Sheet: Estriol Formulation (Veterinary),https://www.merck.com/docs/product/safety-data-sheets/ah-sds/Estriol%20Formulation%20(Veterinary)_AH_CA_EN.pdf
DB14643,,AIFA Package Leaflet: ADVANTAN (Methylprednisolone aceponate) for cutaneous use,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000819_028159_RCP.pdf&retry=0&sys=m0b1l3
DB14644,,FDA Approved Drug Products: Solu-Medrol (methylprednisolone sodium succinate) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011856s133lbl.pdf
DB14649,,RECOVERY trial news release: dexamethasone,https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf
DB14649,,FDA Approved Drug Products: Decadron Dexamethasone Oral Tablet (Discontinued),https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011664
DB14649,,Chemocare: dexamethasone acetate,http://chemocare.com/chemotherapy/drug-info/dexamethasone-acetate.aspx
DB14649,,FDA Approved Drug Products: Dexamethasone Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/40572s002lbledt.pdf
DB14669,,FDA Approved Drug Products: Celestone Soluspan (betamethasone sodium phosphate and betamethasone acetate) injectable suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/014602s062lbl.pdf
DB14669,,British Pharmacopoeia: Betamethasone Sodium Phosphate MSDS,https://www.pharmacopoeia.com/Catalogue/Preview?uri=%2Fcontent%2Ffile%2Fproducts%2Fhealthandsafety%2FCat_041_GB.pdf
DB14678,,NPRA Product Information: NORISTERAT (norethindrone enanthate) intramuscular injection,https://quest3plus.bpfk.gov.my/front-end/attachment/9873/pharma/210287/V_17409_20180426_081720_D3.pdf
DB14684,,Monograph,http://www.robholland.com/Nursing/Drug_Guide/data/monographframes/C012.html
DB14684,,webmd,http://www.webmd.com/drugs/2/drug-6278/calcium-polycarbophil-oral/details
DB14697,,AIFA: Influvac S (Trivalent flu vaccine) Intramuscular Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004157_028851_RCP.pdf&retry=0&sys=m0b1l3
DB14700,,Pharmatimes: Bayer files long-acting haemophilia therapy in the US,http://www.pharmatimes.com/news/bayer_files_long-acting_haemophilia_therapy_in_the_us_1209901
DB14700,,A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII),https://clinicaltrials.gov/ct2/show/NCT01580293
DB14700,,EMA: Damoctagog Alfa,http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2011/03/human_orphan_000897.jsp&mid=WC0b01ac058001d12b
DB14707,,Drugs.com: FDA Approves Libtayo,https://www.drugs.com/newdrugs/fda-approves-libtayo-cemiplimab-rwlc-advanced-cutaneous-squamous-cell-carcinoma-4827.html
DB14707,,FDA Approved Drug Products: Libtayo (cemiplimab-rwlc) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf
DB14707,,EMA Pending EC decision: Libtayo (cemiplimab),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/libtayo-0
DB14707,,EMA Approved Drug Products: LIBTAYO (cemiplimab) intravenous injection,https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf
DB14707,,"FDA Approved Drug Products: LIBTAYO (cemiplimab-rwlc) injection, for intravenous use (November 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf
DB14708,,AIFA Product Information: STERIDROLO (chloramine) powder,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000549_032049_FI.pdf&retry=0&sys=m0b1l3
DB14711,,"FDA Approved Drug Products: ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) for percutaneous administration",https://www.fda.gov/media/75792/download
DB14711,,"FDA Approved Drug Products: ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) for suspension for percutaneous administration (August 2024)",https://www.emergentbiosolutions.com/wp-content/uploads/2024/08/ACAM2000-United-States-Prescribing-Information-USPI.pdf
DB14711,,CDC Vaccine Administration: Smallpox,https://www.cdc.gov/smallpox/clinicians/vaccination-administration2.html
DB14711,,"BioSpace: Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions",https://www.biospace.com/fda/emergent-biosolutions-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-u-s-fda-approval-for-mpox-indication-public-health-mpox-outbreak-continues-across-africa-other-regions
DB14712,,Rare DR,https://www.raredr.com/news/fda-approves-elapegademase-treatment-adascid-in-pediatric-adult-patients
DB14712,,Globe News Wire,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html
DB14712,,NIH,https://ghr.nlm.nih.gov/condition/adenosine-deaminase-deficiency#genes
DB14712,,FDA Approved Drug Products: Revcovi (elapegademase-lvlr) for intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761092s000lbl.pdf
DB14713,,FDA Approved Drug Products: TEGSEDI (inotersen) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211172s008lbl.pdf
DB14713,,"FDA Approved Drug Products: TEGSEDI (inotersen) injection, for subcutaneous use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211172s014lbl.pdf
DB14721,,NCI Drug Dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-1454
DB14722,,ChemieTek ADU-S100 Entry,http://www.chemietek.com/adu-s100--miw815-details.aspx
DB14723,,Larotrectinib FDA Approval Press Release,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626710.htm
DB14723,,FDA Approved Drug Products: Vitrakvi (larotrectinib) capsules or solution for oral administration (November 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210861s010lbl.pdf
DB14723,,National Cancer Institute (NCI) Drug Dictionary: Larotrectinib sulfate,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/larotrectinib
DB14724,,FDA news,https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626263.htm
DB14724,,Clinical trials,https://clinicaltrials.gov/ct2/show/NCT01818492
DB14724,,NHS,http://www.io.nihr.ac.uk/wp-content/uploads/2018/02/8727-Emapalumab-for-primary-HLH-V1.0-FEB2018-NON-CONF.pdf
DB14724,,American Society of Hematology,http://www.hematology.org/Thehematologist/Mini-Review/8257.aspx
DB14725,,BPOM Product Information: Cefamandole nafate injection,http://pionas.pom.go.id/monografi/sefamandol
DB14730,,Asparlas Approval History,https://www.drugs.com/history/asparlas.html
DB14730,,NCI: Calaspargase Pegol,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/calaspargase-pegol
DB14730,,Blood Journal: Randomized Study of Pegaspargase (SS-PEG) and Calaspargase Pegol (SPC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001,http://www.bloodjournal.org/content/128/22/175?sso-checked=true
DB14731,,"FDA Approved Drug Products: ELZONRIS (tagraxofusp-erzs) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761116s005lbl.pdf
DB14731,,EMA Approved Drug Products: Elzonris (tagraxofusp) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/elzonris-epar-product-information_en.pdf
DB14732,,The Human Metabolome Database: Queuine Profile,http://www.hmdb.ca/metabolites/HMDB0001495
DB14733,,AIFA Product Information: MABELIO (ceftobiprole medocaril) injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004698_043060_FI.pdf&retry=0&sys=m0b1l3
DB14733,,FDA Approved Drug Products: Zevtera (ceftobiprole medocaril sodium) injection for intravenous use,https://www.basilea.com/fileadmin/basilea.com/redaktion/documents/ZEVTERA_US_prescribing_information.pdf?v=1712131286
DB14733,,FDA Press Announcement: FDA Approves New Antibiotic for Three Different Uses,https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses
DB14733,,EMA Refusal Assessment Report: Zeftera,https://www.ema.europa.eu/en/documents/assessment-report/zeftera-epar-public-assessment-report_en.pdf
DB14733,,Health Canada Product Monograph: Zevtera (ceftobiprole medocaril sodium) for intravenous injection,https://pdf.hres.ca/dpd_pm/00060684.PDF
DB14738,,American Society of Hematology Blood: Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials),http://www.bloodjournal.org/content/132/Suppl_1/1177?sso-checked=true&utm_source=TrendMD&utm_medium=cpc&utm_campaign=Blood_TrendMD_0
DB14738,,FiercePharma,https://www.fiercepharma.com/pharma/novoeight%C2%AE-turoctocog-alfa-receives-approval-from-fda
DB14738,,"FDA Approved Drug Products: ESPEROCT [antihemophilic factor (recombinant), glycopegylated-exei] lyophilized powder for solution, for intravenous use",https://www.fda.gov/media/120351/download
DB14740,,FDA Approved Drug Products: Vitrase Hyaluronidase Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021640s025lbl.pdf
DB14740,,FDA News Release: FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional,https://www.fda.gov/news-events/press-announcements/fda-approves-breast-cancer-treatment-can-be-administered-home-health-care-professional
DB14740,,"FDA Approved Drug Products: Hylenex (hyaluronidase, human, recombinant) injection for administration via multiple routes",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021859s031lbl.pdf
DB00781,,SteriMax Inc: Polymyxin B for Injection USP Monograph,http://sterimaxinc.com/wp-content/uploads/2016/03/1.3.1-SteriMax-English-PM-February-8-201612.pdf
DB14751,,FDA Drug Approval Package for Mecaserim Rinfabate,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021884_s000_IplexTOC.cfm
DB14753,,Link,http://newdruginformation.com/Hydroxystilbamidine_Isethionate.htm
DB14754,,FDA Approved Drug Products: Sunosi Solriamfetol Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s001lbl.pdf
DB14761,,NIH: Clinical Trial NCT04252664,https://clinicaltrials.gov/ct2/show/NCT04252664
DB14761,,NIH: Clinical Trial NCT04257656,https://clinicaltrials.gov/ct2/show/NCT04257656
DB14761,,FDA: Emergency Use Authorization For Remdesivir,https://www.fda.gov/media/137564/download
DB14761,,FDA: Emergency Use Authorization Information,https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
DB14761,,FDA: Fact Sheet For Health Care Providers EUA of Remdesivir,https://www.fda.gov/media/137566/download
DB14761,,FDA Press Announcement: FDA Approves Remdesivir for COVID-19,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
DB14761,,"FDA Approved Drug Products: VEKLURY (remdesivir) injection, for intravenous use",https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf
DB14761,,FDA: Emergency Use Authorization for Baricitinib in Combination with Remdesivir for COVID-19,https://www.fda.gov/media/143822/download
DB14761,,Gilead Press Releases: European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression,https://www.gilead.com/news-and-press/press-room/press-releases/2021/12/european-commission-expands-indication-for-veklury-remdesivir-for-the-treatment-of-adults-not-on-supplemental-oxygen-and-considered-high-risk-for-co
DB14761,,European Medicines Agency Medicines: Veklury (remdesivir),https://www.ema.europa.eu/en/medicines/human/EPAR/veklury
DB14761,,"EMA Summary of Product Characteristics: Veklury (remdesivir) solution, for intravenous infusion",https://www.ema.europa.eu/en/documents/product-information/veklury-epar-product-information_en.pdf
DB14761,,"FDA Approved Drug Products: VEKLURY (remdesivir) injection, for intravenous use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s019lbl.pdf
DB14761,,"FDA Approved Drug Products: VEKLURY (remdesivir) injection, for intravenous use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s024lbl.pdf
DB14762,,European Medicines Agency Summaries Opinion: Skyrizi,https://www.ema.europa.eu/en/medicines/human/summaries-opinion/skyrizi-0
DB14762,,FDA Approved Drug Products: Skyrizi (risankizumab-rzaa) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761105s018lbl.pdf
DB14762,,Abbvie: Skyrizi (Risankizumab-rzaa) MSDS,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_ABBVIE_SKYRIZI_PEN_150MG_ML.PDF
DB14762,,Health Canada Approved Drug Products: SKYRIZI (risankizumab) subcutaneous injection,https://pdf.hres.ca/dpd_pm/00067871.PDF
DB14762,,EMA Approved Drug Products: Skyrizi (Risankizumab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf
DB14762,,"FDA Approved Drug Products: SKYRIZI (risankizumab-rzaa) injection, for subcutaneous or intravenous use (June 2024)","https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761105s029,761262s007lbl.pdf"
DB14766,,"FDA Approved Drug Products: VELSIPITY™ (etrasimod) tablets, for oral use",https://labeling.pfizer.com/ShowLabeling.aspx?id=19776
DB14766,,"FDA Approves Pfizer’s Ulcerative Colitis Drug, $6.7B Arena Buy Pays Off",https://www.biospace.com/article/fda-approves-pfizer-s-ulcerative-colitis-drug-6-7b-arena-buy-pays-off/?s=74
DB14766,,EMA Approved Drug Products: Velsipity (etrasimod) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/velsipity-epar-product-information_en.pdf
DB14766,,Pfizer: European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-velsipityr-patients
DB14782,,"FDA Approved Drug Products: QALSODY (tofersen) injection, for intrathecal use",https://www.biogencdn.com/us/pdfs/qalsody-prescribing-information.pdf
DB14782,,FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS,https://www.prnewswire.com/news-releases/fda-approves-qalsody-tofersen-as-the-first-treatment-targeting-a-genetic-cause-of-als-301807576.html
DB14783,,Vumerity FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf
DB14783,,Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis,https://www.prnewswire.com/news-releases/biogen-and-alkermes-announce-fda-approval-of-vumerity-diroximel-fumarate-for-multiple-sclerosis-300947775.html
DB14783,,FDA Clears More Tolerable Diroximel Fumarate (Vumerity) for MS,https://www.medscape.com/viewarticle/920574
DB14783,,Drugs.com: FDA approves Vumerity,https://www.drugs.com/newdrugs/fda-approves-vumerity-diroximel-fumarate-multiple-sclerosis-5096.html
DB14783,,"FDA Approved Drug Products: TECFIDERA (dimethyl fumarate) delayed-release capsules, for oral use",https://www.tecfidera.com/content/dam/commercial/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf
DB14783,,EMA Summary of Opinion: Vumerity (diroximel fumarate),https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vumerity_en.pdf
DB14783,,"FDA Approved Drug Products: VUMERITY (diroximel fumarate) delayed-release capsules, for oral use (February 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s009lbl.pdf
DB14805,,FDA Approved Drug Products: Pylarify (piflufolastat F 18) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf
DB14805,,American Cancer Society: Tests to Diagnose and Stage Prostate Cancer,https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html
DB14805,,OncLive: FDA Approves Piflufolastat F18 PSMA PET Imaging Agent for Prostate Cancer,https://www.onclive.com/view/fda-approves-piflufolastat-f-18-psma-pet-imaging-agent-for-prostate-cancer
DB14805,,EMA Approved Drug Products: Pylclari (piflufolastat F 18) injection for intravenous use,https://www.ema.europa.eu/en/documents/product-information/pylclari-epar-product-information_en.pdf
DB14805,,"Curium Receives Marketing Authorization in the EU for PYLCLARI(TM), an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer",https://www.investorsobserver.com/news/qm-pr/5308990892227351
DB14811,,FDA Approved Drug Products: Sarclisa (isatuximab-irfc) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761113s003lbl.pdf
DB14811,,FDA News Release: Isatuximab Approval,https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-patients-previously-treated-multiple-myeloma
DB14811,,"FDA Approved Drug Products: SARCLISA® (isatuximab-irfc) injection, for intravenous use (Nov 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761113s009lbl.pdf
DB14840,,FDA Approved Drug Products: Qinlock (ripretinib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213973s003lbl.pdf
DB14840,,FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-fourth-line-treatment-advanced-gastrointestinal-stromal-tumors
DB14840,,GIST Support International: Switch Pocket Kinase Inhibitors,https://www.gistsupport.org/ask-the-professional/switch-pocket-kinase-inhibitors/
DB14840,,Deciphera phase 1 study results,https://www.deciphera.com/wp-content/uploads/2018/10/ESMO-2018-George-et-al.-for-submission-to-ESMO-final.pdf
DB14840,,Deciphera phase 3 study results,https://www.deciphera.com/wp-content/uploads/2019/11/CTOS-2019-INVICTUS-Oral-Presentation-FINAL_Nov-15.pdf
DB14845,,EMA Summary of Product Characteristics: Jyseleca (filgotinib) film-coated tablets for oral use,https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf
DB14845,,EMA Summary of opinion (post authorisation): Jyseleca (filgotinib),https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jyseleca-ii-01_en.pdf
DB14845,,GlobeNewswire: Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis,https://www.globenewswire.com/news-release/2021/11/15/2334506/0/en/Jyseleca-filgotinib-approved-in-the-European-Union-for-the-treatment-of-ulcerative-colitis.html
DB14851,,FDA Approved Drug Products: Opdualag (nivolumab and relatlimab-rmbw) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf
DB14851,,"BioSpace: U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma",https://www.biospace.com/article/releases/u-s-food-and-drug-administration-approves-first-lag-3-blocking-antibody-combination-opdualag-nivolumab-and-relatlimab-rmbw-as-treatment-for-patients-with-unresectable-or-metastatic-melanoma/?s=74
DB14851,,NIH National Cancer Institute: Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma,https://www.cancer.gov/news-events/cancer-currents-blog/2021/melanoma-nivolumab-relatlimab-immunotherapy
DB14851,,EMA EPAR: Opdualag (relatlimab/nivolumab),https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag
DB14851,,Health Canada Product Monograph: Opdualag (nivolumab and relatlimab) solution for intravenous injection,https://pdf.hres.ca/dpd_pm/00072494.PDF
DB14851,,EMA Summary of Product Characteristics: Opdualag (nivolumab/relatlimab) solution for intravenous injection,https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf
DB14864,,FDA Approved Drug Products: BEOVU (brolucizumab) intravitreal injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761125s004lbl.pdf
DB14864,,Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration,https://clinicaltrials.gov/ct2/show/results/NCT02507388
DB14879,,ChemSpider: Cefiderocol,http://www.chemspider.com/Chemical-Structure.52084902.html?rid=8fe73583-cb45-43bd-9b2f-128a26660d6e&page_num=0
DB14879,,FDA Press Release Cefiderocol,https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts
DB14881,,FDA Approved Drug Products: Olinvyk (oliceridine) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210730s000lbl.pdf
DB14881,,FDA Briefing Document: Oliceridine,https://www.fda.gov/media/121233/download
DB14881,,"FDA Approved Drug Products: OLINVYK (oliceridine) injection, for intravenous use, CII (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210730s002lbl.pdf
DB14895,,"FDA Approved Drug Products: GEMTESA (vibegron) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213006s000lbl.pdf
DB14895,,Drugs.com: FDA Approves Gemtesa,https://www.drugs.com/newdrugs/fda-approves-gemtesa-vibegron-patients-overactive-bladder-oab-5415.html
DB14901,,"Novartis: Novartis receives EU approval for Leqvio (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year",https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-leqvio-inclisiran-first-class-sirna-lower-cholesterol-two-doses-year
DB14901,,"Summary of Product Characteristics: Leqvio (inclisiran), solution for subcutaneous injection",https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_en.pdf
DB14901,,"Novartis News: FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year",https://www.novartis.com/news/media-releases/fda-approves-novartis-leqvio-inclisiran-first-class-sirna-lower-cholesterol-and-keep-it-low-two-doses-year
DB14901,,"FDA Approved Drug Products: LEQVIO (inclisiran) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf
DB14901,,"FDA Approved Drug Products: LEQVIO (inclisiran) injection, for subcutaneous use (July 2023)",https://www.novartis.com/sites/novartis_us/files/leqvio.pdf
DB14909,,FDA Approved Drug Products: Rytelo (imetelstat) injection for intravenous use,https://pi.geron.com/products/US/pi/rytelo_pi.pdf
DB14909,,"Geron Corporation Press Release: Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia",https://ir.geron.com/investors/press-releases/press-release-details/2024/Geron-Announces-FDA-Approval-of-RYTELO-imetelstat-a-First-in-Class-Telomerase-Inhibitor-for-the-Treatment-of-Adult-Patients-with-Lower-Risk-MDS-with-Transfusion-Dependent-Anemia/default.aspx
DB14910,,CHMP Summary of Positive Opinion: Omvoh (mirikizumab),https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-omvoh_en.pdf
DB14910,,"FiercePharma: FDA rejects Eli Lilly's ulcerative colitis prospect mirikizumab, citing manufacturing shortfalls",https://www.fiercepharma.com/manufacturing/manufacturing-shortfall-trips-eli-lillys-ibd-biologic-fda-rejection
DB14910,,"Eli Lilly and Company: Lilly’s mirikizumab met primary endpoint and key secondary endpoints in Phase 2 study, including reductions of gastrointestinal lesions",https://www.lilly.ca/en-CA/news/press-releases/19.05.22-mirikizumab-data-digestive-disease-week
DB14910,,UniProt: Interleukin-23 subunit alpha (Q9NPF7),https://www.uniprot.org/uniprotkb/Q9NPF7/entry
DB14910,,FDA Approved Drug Products: Omvoh (mirikizumab-mrkz) injection for intravenous or subcutaneous administration,https://pi.lilly.com/us/omvoh-uspi.pdf?s=pi
DB14910,,"Eli Lilly and Company: FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis",https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class
DB14910,,EMA Summary of Product Characteristics: Omvoh (mirikizumab) concentrate for solution for infusion,https://www.ema.europa.eu/en/documents/product-information/omvoh-epar-product-information_en.pdf
DB14910,,Health Canada Product Monograph: Omvoh (mirikizumab) solution for subcutaneous or intravenous administration,https://pdf.hres.ca/dpd_pm/00071771.PDF
DB14914,,FDA Approved Drug Products: Tauvid (flortaucipir F-18) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf
DB14919,,"FDA Approved Drug Products: RYSTIGGO® (rozanolixizumab-noli) injection, for subcutaneous use",https://www.ucb-usa.com/RYSTIGGO-prescribing-information.pdf
DB14919,,UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis,https://www.biospace.com/article/releases/ucb-announces-u-s-fda-approval-of-rystiggo-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis/
DB14919,,EMA Approved Drug Products: Rystiggo (rozanolixizumab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/rystiggo-epar-product-information_en.pdf
DB14921,,FDA Approved Drug Proucts: CAMZYOS (mavacamten) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf
DB14921,,Health Canada Approved Drug Products: CAMZYOS (mavacamten) Oral Capsules,https://pdf.hres.ca/dpd_pm/00068186.PDF
DB14921,,"EMA Approved Drug Products: CAMZYOS (Mavacamten) capsules, for oral use",https://www.ema.europa.eu/en/documents/product-information/camzyos-epar-product-information_en.pdf
DB14921,,EC approves BMS’ Camzyos for hypertrophic cardiomyopathy,https://www.pharmaceutical-technology.com/news/ec-approves-bms-camzyos/
DB14922,,EMA Approved Drug Products: Tevimbra (tislelizumab) concentrate for solution for intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf
DB14922,,Anti-PD-1 antibody gains EU approval for oesophageal cancer,https://www.europeanpharmaceuticalreview.com/news/187017/anti-pd-1-antibody-gains-eu-approval-for-oesophageal-cancer/
DB14922,,"FDA Approved Drug Products: TEVIMBRA (tislelizumab-jsgr) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761232Orig1s000lbl.pdf
DB14922,,OncLive: FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy,https://www.onclive.com/view/fda-approves-tislelizumab-for-advanced-or-metastatic-escc-after-chemotherapy
DB14924,,FDA Approved Drug Products: LITFULO (ritlecitinib) capsules for oral use (June 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
DB14924,,Business Wire: FDA Approves Pfizer’s LITFULO (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata,https://www.businesswire.com/news/home/20230623087591/en/
DB14924,,EMA Approved Drug Products: Litfulo (ritlecitinib) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/litfulo-epar-product-information_en.pdf
DB14924,,Pfizer: European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata,"https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-litfulotm-adolescents#:~:text=The%20marketing%20authorization%20for%20LITFULO,(CHMP)%20in%20July%202023."
DB14924,,Health Canada Approved Drug Proucts: LITFULO (Ritlecitinib) capsule for oral use (Dec 2023),https://pdf.hres.ca/dpd_pm/00073579.PDF
DB14939,,FDA Approved Drug Products: Aphexda (motixafortide) for subcutaneous injection,https://www.aphexda.com/files/prescribing-information.pdf
DB14939,,National Cancer Institute: Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma,https://www.cancer.gov/news-events/cancer-currents-blog/2023/motixafortide-multiple-myeloma-stem-cell-transplant
DB14939,,FiercePharma: BioLineRx's Aphexda scores FDA nod to help myeloma patients undergo stem cell transplants,https://www.fiercepharma.com/pharma/israels-biolinerx-scores-fda-nod-multiple-myeloma-stem-cell-transplant-drug-aphexda
DB14960,,Pfizer: HEALTH CANADA APPROVES NGENLA (SOMATROGON) INJECTION FOR PEDIATRIC GROWTH HORMONE DEFICIENCY,https://www.pfizer.ca/health-canada-approves-ngenla-somatrogon-injection-pediatric-growth-hormone-deficiency
DB14960,,OPKO: About Somatrogon,https://www.opko.com/what-we-do/our-research/somatrogon
DB14960,,Health Canada Approved Drug Products: NGENLA (Somatrogon) subcutaneous injection,https://pdf.hres.ca/dpd_pm/00063339.PDF
DB14960,,FDA Approved Drug Products: NGENLA (somatrogon-ghla) injection for subcutaneous use (June 2023),https://labeling.pfizer.com/ShowLabeling.aspx?id=19642
DB14960,,"BioSpace: FDA Approves Pfizer’s NGENLA, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency",https://www.biospace.com/article/releases/fda-approves-pfizer-s-ngenla-a-long-acting-once-weekly-treatment-for-pediatric-growth-hormone-deficiency/?s=74
DB14962,,"FDA Approved Drug Products: Enhertu (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s024lbl.pdf
DB14962,,FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available
DB14962,,Health Canada Approved Drug Products: Enhertu (trastuzumab deruxtecan) powder for concentrate for intravenous infusion,https://pdf.hres.ca/dpd_pm/00069043.PDF
DB14962,,EMA Approved Drug Products: Enhertu (Trastuzumab deruxtecan) Powder for concentrate for solution for infusion.,https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf
DB14962,,"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use (April 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf
DB14967,,FDA Approved Drug Products: MARGENZA (margetuximab) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf
DB14973,,"FDA Approved Drug Products: CIBINQO (abrocitinib) tablets, for oral use",https://cdn.pfizer.com/pfizercom/USPI_Med_Guide_CIBINQO_Abrocitinib_tablet.pdf
DB14973,,Summary of Product Characteristics: Cibinqo (abrocitinib) oral tablets,https://www.ema.europa.eu/en/documents/product-information/cibinqo-epar-product-information_en.pdf
DB14973,,Pfizer News: U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults
DB14973,,Pfizer News: European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-cibinqor-abrocitinib
DB14973,,"Health Canada Approved Drug Products: CIBINQO (abrocitinib) tablets, for oral use",https://pdf.hres.ca/dpd_pm/00066473.PDF
DB14973,,"FDA Approved Drug Products: CIBINQO™ (abrocitinib) tablets, for oral use (February 2023)",https://labeling.pfizer.com/ShowLabeling.aspx?id=16652
DB14975,,"FDA Approved Drug Products: Oxbryta (voxelotor) tablets, for oral use or oral suspension",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213137s006lbl.pdf
DB14975,,FDA approves novel treatment to target abnormality in sickle cell disease,https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-target-abnormality-sickle-cell-disease
DB14975,,FDA approves Global Blood Therapeutics sickle cell disease drug,https://www.reuters.com/article/us-global-blood-theraprutics-fda/fda-approves-global-blood-therapeutics-sickle-cell-disease-drug-idUSKBN1XZ2E5
DB14975,,"Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects",https://ashpublications.org/blood/article/128/22/2487/98674/Absorption-Metabolism-and-Excretion-of-GBT440-a
DB14975,,EMA Approved Drug Products: Oxbryta (voxelotor) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/oxbryta-epar-product-information_en.pdf
DB14975,,GlobeNewswire News Release: European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older,https://www.globenewswire.com/news-release/2022/02/16/2386014/37049/en/European-Commission-Approves-Oxbryta-voxelotor-for-the-Treatment-of-Hemolytic-Anemia-in-Patients-with-Sickle-Cell-Disease-Age-12-Years-and-Older.html
DB14984,,FDA Approved Drug Products: AMONDYS 45 (casimersen) injection,https://www.amondys45.com/Amondys45_(casimersen)_Prescribing_Information.pdf
DB14984,,FDA Approved Drug Products: AMONDYS 45 (casimersen) injection (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213026s005lbl.pdf
DB14989,,FDA: FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-umbralisib-marginal-zone-lymphoma-and-follicular-lymphoma
DB14989,,"FDA Approved Drug Products: UKONIQ (umbralisib) tablets, for oral use",https://www.tgtherapeutics.com/prescribing-information/uspi-ukon.pdf
DB14989,,Selleck MSDS: Umbralisib,https://www.selleck.cn/msds/MSDS_S8194.pdf
DB14989,,HMDB MSDS: Umbralisib,https://hmdb.ca/system/metabolites/msds/000/001/063/original/S-Adenosylmethionine_MSDS.pdf?1368651702
DB14989,,FDA Drug Safety and Availability: FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns,https://www.fda.gov/drugs/drug-safety-and-availability/fda-approval-lymphoma-medicine-ukoniq-umbralisib-withdrawn-due-safety-concerns
DB14992,,EMA Summary of Product Characteristics: Elfabrio (pegunigalsidase alfa) solution for infusion (May 2023),https://www.ema.europa.eu/en/documents/product-information/elfabrio-epar-product-information_en.pdf
DB14992,,LABIOTECH: Fabry disease treatment gets EU marketing authorization,https://www.labiotech.eu/trends-news/fabry-disease-treatment-eu-marketing-authorization/
DB14992,,FDA Approved Drug Products: ELFABRIO (pegunigalsidase alfa-iwxj) injection for intravenous use (May 2023),https://resources.chiesiusa.com/Elfabrio/ELFABRIO_PI.pdf
DB14992,,BioSpace: Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease,https://www.biospace.com/article/releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-fda-approval-of-elfabrio-pegunigalsidase-alfa-iwxj-for-the-treatment-of-fabry-disease/?s=74
DB14996,,FDA Approved Drug Products: Enjaymo (sutimlimab-jome) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf
DB14996,,National Organization for Rare Disorders: Cold Agglutinin Disease,https://rarediseases.org/rare-diseases/cold-agglutinin-disease/
DB14996,,EMA Approved Drug Products: Enjaymo (Sutimlimab) Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/enjaymo-epar-product-information_en.pdf
DB14996,,Sanofi: Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease,"https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-17-17-50-00-2558583#:~:text=November%2017%2C%202022-,Press%20Release%3A%20European%20Commission%20approves%20Enjaymo%20%C2%AE%20(sutimlimab)%20for,patients%20with%20cold%20agglutinin%20disease&text=Paris%2C%20November%2017%2C%202022."
DB14996,,"FDA Approved Drug Products: ENJAYMO (sutimlimab-jome) injection, for intravenous use (January 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761164s003lbl.pdf
DB14999,,World Health Organization: Landscape analysis of therapeutics as of February 17 2020,https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1
DB14999,,FDA approved products: Extravia (interferon beta-1b) subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125290s067lbl.pdf
DB14999,,Nature Biotechnology: Coronavirus puts drug repurposing on the fast track,https://www.nature.com/articles/d41587-020-00003-1
DB14999,,Product monograph: Avonex pen (interferon beta 1a),https://www.wellrx.com/avonex%20pen/monographs/
DB14999,,FDA approved products: Betaseron (interferon beta 1b) subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103471s5193lbl.pdf
DB14999,,EMD Serono MSDS: Interferon beta 1a,https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/MSDS_9SERO_REBIF_SYR_%2044MCG.pdf
DB14999,,ThPDB: Interferon beta1a,http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1049
DB14999,,"DailyMed Label: AVONEX (interferon beta-1a) injection, for intramuscular injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d70a39cc-de15-4c12-a1ec-8063b69ea0e1
DB15001,,FDA Approved Drug Products: Rolvedon (eflapegrastim-xnst) for subcutaneous injection,https://www.rolvedon.com/pdf/rolvedon-prescribing-information.pdf
DB15001,,NIH Inxight: Eflapegrastim,https://drugs.ncats.io/drug/UT99UG9QJX
DB15001,,Cancer Network: FDA Approves Eflapegrastim Injection to Decrease Febrile Neutropenia–Related Infection in Non–Myeloid Malignancies,https://www.cancernetwork.com/view/fda-approves-eflapegrastim-injection-to-decrease-febrile-neutropenia-related-infection-in-non-myeloid-malignancies
DB15005,,FDA Approved Drug Products: Viltepso (vitolarsen) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212154s000lbl.pdf
DB15011,,FDA Approved Drug Products: TAVNEOS (avacopan) oral capsules,https://www.chemocentryx.com/wp-content/uploads/2021/10/FINAL-PI-and-Med-Guide-7-Oct-21.pdf
DB15011,,BioSpace News: ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis,https://www.biospace.com/article/releases/chemocentryx-announces-eu-approval-of-tavneos-avacopan-for-the-treatment-of-anca-associated-vasculitis/?keywords=European+Commission+Approval
DB15011,,Summary of Product Characteristics: Tavneos (avacopan) oral capsules,https://www.ema.europa.eu/en/documents/product-information/tavneos-epar-product-information_en.pdf
DB15011,,Cision PR Newswire: Otsuka Canada Pharmaceutical Inc. announces Health Canada approval of TAVNEOS® (avacopan) for ANCA-Associated Vasculitis,https://www.newswire.ca/news-releases/otsuka-canada-pharmaceutical-inc-announces-health-canada-approval-of-tavneos-r-avacopan-for-anca-associated-vasculitis-849824802.html
DB15031,,"FDA Approved Drug Products: QUVIVIQ (daridorexant) tablets, for oral use",https://www.idorsia.us/documents/us/label/Quviviq_PI.pdf
DB15031,,Idorsia News: Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia,https://www.idorsia.com/media/news-details?newsId=2665386
DB15031,,EMA Approved Drug Products: Quviviq (daridorexant) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/quviviq-epar-product-information_en.pdf
DB15031,,GlobeNewswire News Release: Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder,https://kommunikasjon.ntb.no/pressemelding/europes-first-dual-orexin-receptor-antagonist-quviviq-daridorexant-granted-approval-to-improve-both-nighttime-symptoms-and-daytime-functioning-in-adults-with-chronic-insomnia-disorder?publisherId=4954260&releaseId=17932369
DB15031,,Health Canada Approved Drug Products: QUVIVIQ (Daridorexant) Oral Tablets,https://pdf.hres.ca/dpd_pm/00070459.PDF
DB15035,,FDA Approved Drug Products: Brukinsa (zanubrutinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213217s005lbl.pdf
DB15035,,FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma
DB15035,,Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know,https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/clinical-trial-endpoints-in-cancer-research-four-terms-you-should-know-09242018.html
DB15035,,"FDA.gov: FDA approvals of Brukinsa (zanubrutinib), for adult patients with relapsed or refractory marginal zone lymphoma, and Exkivity (mobocertinib) for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations",https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approvals-brukinsa-zanubrutinib-adult-patients-relapsed-or-refractory-marginal-zone-lymphoma-and
DB15035,,FDA.gov: FDA approves zanubrutinib for Waldenström’s macroglobulinemia,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia
DB15035,,Businesswire: BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia,https://www.businesswire.com/news/home/20211123006162/en/BeiGene-Announces-Approval-of-BRUKINSA-zanubrutinib-in-the-European-Union-for-Treatment-of-Adults-with-Waldenstr%C3%B6m%E2%80%99s-Macroglobulinemia
DB15035,,Health Canada Product Monograph: BRUKINSA (zanubrutinib) Oral Capsules,https://pdf.hres.ca/dpd_pm/00064798.PDF
DB15035,,EMA Summary of Opinion: Brukinsa (zanubrutinib),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/brukinsa-1
DB15035,,"FDA Approved Drug Products: BRUKINSA (zanubrutinib) capsules, for oral use (January 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213217s007lbl.pdf
DB15035,,Health Canada Product Monograph: BRUKINSA (zanubrutinib) Oral Capsules (May 2023),https://pdf.hres.ca/dpd_pm/00070886.PDF
DB15035,,"FDA Approved Drug Products: BRUKINSA® (zanubrutinib) capsules, for oral use (Jan 2024)",https://www.beigene.com/PDF/BRUKINSAUSPI.pdf
DB15035,,Health Canada Approved Drug Proucts: BRUKINSA (zanubrutinib) capsules for oral use (Feb 2024),https://pdf.hres.ca/dpd_pm/00074465.PDF
DB15035,,EMA Approved Drug Products: BRUKINSA (zanubrutinib) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/brukinsa-epar-product-information_en.pdf
DB15035,,"FDA Approved Drug Products: BRUKINSA (zanubrutinib) capsules, for oral use (March 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213217s011lbl.pdf
DB15043,,FDA Approved Drug Products: Loqtorzi (toripalimab-tpzi) for intravenous injection,https://loqtorzihcp.com/pdf/prescribing-information.pdf
DB15043,,US Food & Drug Administration: FDA approves toripalimab-tpzi for nasopharyngeal carcinoma,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-toripalimab-tpzi-nasopharyngeal-carcinoma
DB15044,,FDA Approved Drug Products: Monjuvi (tafasitamab-cxix) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf
DB15044,,Morphosys Proprietary Portfolio: Tafasitamab (MOR208),https://www.morphosys.com/pipeline/proprietary-portfolio/tafasitamab-mor208
DB15044,,FDA Drug Approvals: FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma
DB15059,,American Journal of Managed Care: FDA Approves Idorsia's Tryvio for Resistant Hypertension,https://www.ajmc.com/view/fda-approves-idorsia-s-tryvio-for-resistant-hypertension
DB15059,,FDA Approved Drug Products: Tryvio (aprocitentan) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf
DB15066,,FDA Approved Drug Products: Givlaari subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf
DB15067,,EMA Summary of Product Characteristics: Waylivra Volanesorsen Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/waylivra-epar-product-information_en.pdf
DB15071,,"FDA Approved Drug Products: OMLONTI (omidenepag isopropyl) ophthalmic solution 0.002%, for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf
DB15071,,FDA Thailand Product Information: EYBELIS (omidenepag isopropyl) ophthalmic solution 0.002%,https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f637364499863668969&type=2&cid=35029
DB15090,,FDA Approved Drug Products: TEZSPIRE (tezepelumab-ekko) injection,https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/tezspire/tezspire_pi_hcp_english.ashx
DB15090,,EMA Approved Drug Products: Tezspire (tezepelumab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.pdf
DB15090,,FDA Approved Drug Products: TEZSPIRE (tezepelumab-ekko) injection Feb 2023,https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e306dc06-d580-4457-b15f-9f28545ad63a/e306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf
DB15091,,"FDA Approved Drug Products: RINVOQ (upadacitinib) extended-release tablets, for oral use",https://www.rxabbvie.com/pdf/rinvoq_pi.pdf
DB15091,,AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis,https://news.abbvie.com/news/press-releases/abbvie-receives-european-commission-approval-rinvoq-upadacitinib-for-treatment-adults-with-moderate-to-severe-active-rheumatoid-arthritis.htm
DB15091,,FDA: Upadacitinib Summary Review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000SumR.pdf
DB15091,,EZSolution: Upadacitinib MSDS,https://www.biovision.com/documentation/sds/B2486_SDS.pdf
DB15091,,FDA: Upadacitinib Clinical Pharmacology and Biopharmaceutics Review(s),https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf
DB15091,,EMA Product Information: RINVOQ (upadacitinib) extended-release tablets,https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf
DB15091,,Health Canada Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets for oral use (October 2023),https://pdf.hres.ca/dpd_pm/00073108.PDF
DB15091,,"FDA Approved Drug Products: RINVOQ (upadacitinib) extended-release tablets, for oral use (April 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211675s012lbl.pdf
DB15091,,"FDA Approved Drug Products: RINVOQ (upadacitinib) extended-release tablets, for oral use (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211675s015lbl.pdf
DB15093,,Novo Nordisk: Sogroya FDA Label,https://www.novo-pi.com/sogroya.pdf
DB15093,,FDA Approved Drug Products: Sogroya Somapacitan Subcutaneous Injection,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156
DB15097,,EMA Summary of Product Characteristics: Lyfnua (gefapixant citrate) film-coated tablets for oral administration,https://www.ema.europa.eu/en/documents/product-information/lyfnua-epar-product-information_en.pdf
DB15097,,EMA CHMP Assessment Report: Lyfnua (gefapixant),https://www.ema.europa.eu/en/documents/assessment-report/lyfnua-epar-public-assessment-report_en.pdf
DB15097,,Merck News Release: Merck Receives Positive European Union CHMP Opinion for Gefapixant,https://www.merck.com/news/merck-receives-positive-european-union-chmp-opinion-for-gefapixant/
DB15100,,Argenx Drug Pipeline: Cusatuzumab,https://www.argenx.com/pipeline/cusatuzumab
DB15102,,"FDA Approved Drug Products: PEMAZYRE (pemigatinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf
DB15102,,FDA Resources for Information | Approved Drugs: FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion
DB15102,,"FDA Approved Drug Products: PEMAZYRE (pemigatinib) tablets, for oral use (August 2022)",https://www.pemazyre.com/pdf/prescribing-information.pdf
DB15107,,AIFA: Efdege (Fluodeoxyglucose) Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002648_036751_RCP.pdf&retry=0&sys=m0b1l3
DB15114,,FDA Approved Drug Products: Agamree (vamorolone) suspension for oral administration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215239s000lbl.pdf
DB15114,,American Journal of Managed Care: FDA Approves Vamorolone to Treat Duchenne Muscular Dystrophy,https://www.ajmc.com/view/fda-approves-vamorolone-to-treat-duchenne-muscular-dystrophy
DB15114,,EMA Summary of Product Characteristics: Agamree (vamorolone) suspension for oral administration,https://www.ema.europa.eu/en/documents/product-information/agamree-epar-product-information_en.pdf
DB15114,,EMA EPAR: Agamree (vamorolone),https://www.ema.europa.eu/en/medicines/human/EPAR/agamree
DB15118,,FDA Approved Drug Products: Vyloy (zolbetuximab-clzb) injection for intravenous use (October 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf
DB15119,,EMA Approved Products: Besremi (ropeginterferon alfa-2b ) solution for injection,https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf
DB15119,,FDA Approved Drug Products: BESREMi (ropeginterferon alfa-2b-njft) injection,https://us.pharmaessentia.com/wp-content/uploads/2021/11/BESREMi-USPI-November-2021-1.pdf
DB15133,,FDA Approved Drug Products: Tepmetko (tepotinib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf
DB15133,,CaymanChem: Tepotinib MSDS,https://www.caymanchem.com/msdss/18492m.pdf
DB15133,,PR Newswire: FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations,https://www.prnewswire.com/news-releases/fda-approves-tepmetko-as-the-first-and-only-once-daily-oral-met-inhibitor-for-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-301221542.html
DB15133,,European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations,https://www.businesswire.com/news/home/20220218005153/en/European-Commission-Approves-TEPMETKO%C2%AE-tepotinib-for-Patients-with-Advanced-NSCLC-with-METex14-Skipping-Alterations
DB15133,,FDA Approved Drug Products: TEPMETKO (tepotinib) tablets for oral use (March 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214096s001s002lbl.pdf
DB15149,,"FDA Approved Drug Products: LYTGOBI (futibatinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf
DB15149,,EMA Approved Drug Products: LYTGOBI (futibatinib) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf
DB15149,,PR Newswire: European Commission Grants Conditional Marketing Authorization for Taiho's LYTGOBI® Tablets for the Treatment of Adults With Cholangiocarcinoma,https://www.prnewswire.com/news-releases/european-commission-grants-conditional-marketing-authorization-for-taihos-lytgobi-tablets-for-the-treatment-of-adults-with-cholangiocarcinoma-301869543.html
DB15164,,"FDA Approved Drug Products: Adzynma (ADAMTS13, recombinant-krhn) lyophilized powder for intravenous injection",https://www.fda.gov/media/173756/download
DB15164,,FDA Press Announcement: FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-inherited-blood-clotting-disorder
DB15165,,FDA Approved Drug Products: IZERVAY™ (avacincaptad pegol) intravitreal solution,https://ivericbio.com/wp-content/uploads/IZERVAY-avacincaptad-pegol-intravitreal-solution-PI_Final_8.4.23.pdf
DB15165,,"Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy",https://www.prnewswire.com/news-releases/iveric-bio-receives-us-fda-approval-for-izervay-avacincaptad-pegol-intravitreal-solution-a-new-treatment-for-geographic-atrophy-301894042.html
DB15171,,"FDA Approved Drug Products: MOUNJARO (tirzepatide) Injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
DB15171,,"Eli Lilly and Company Investors News Release: FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes",https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and
DB15171,,EMA Approved Drug Products: Mounjaro (tirzepatide) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
DB15171,,Pharmaceutical Technology: European Commission’s approval of Mounjaro provides hope within obesity space,https://www.pharmaceutical-technology.com/comment/european-commission-mounjaro/
DB15171,,"FDA Approved Drug Products: ZEPBOUND™ (tirzepatide) Injection, for subcutaneous use (November 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
DB15171,,FDA Approves New Medication for Chronic Weight Management,https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
DB15218,,"FDA Approved Drug Products: VEOPOZ™ (pozelimab-bbfg) injection, for intravenous or subcutaneous use",https://www.regeneron.com/downloads/veopoz_fpi.pdf
DB15218,,VEOPOZ™ (POZELIMAB-BBFG) RECEIVES FDA APPROVAL AS THE FIRST TREATMENT FOR CHILDREN AND ADULTS WITH CHAPLE DISEASE,https://investor.regeneron.com/news-releases/news-release-details/veopoztm-pozelimab-bbfg-receives-fda-approval-first-treatment
DB15218,,Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease,https://www.biospace.com/article/releases/veopoz-pozelimab-bbfg-receives-fda-approval-as-the-first-treatment-for-children-and-adults-with-chaple-disease/
DB15226,,"FDA Approved Drug Products: ZEGALOGUE (dasiglucagon) injection, for subcutaneous use (March 2021)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf
DB15226,,FDA Center for Drug Evaluation and Research: Summary Review for Dasiglucagon,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000SumR.pdf
DB15226,,"GlobeNewsWire: Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes",https://www.globenewswire.com/news-release/2021/03/22/2197267/0/en/Zealand-Pharma-Announces-FDA-Approval-of-Zegalogue-dasiglucagon-injection-for-the-Treatment-of-Severe-Hypoglycemia-in-People-with-Diabetes.html
DB15233,,EMA Approved Drug Products: AYVAKYT (avapritinib) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf
DB15233,,"FDA Approved Drug Products: AYVAKIT (avapritinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf
DB15233,,"FDA Approved Drug Products: AYVAKIT (avapritinib) tablets, for oral use (March 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s012lbl.pdf
DB15233,,"FDA Approved Drug Products: AYVAKIT (avapritinib) tablets, for oral use (May 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf
DB15248,,EMA Public Assessment Report: Hepcludex (bulevirtide) powder for injectable solution,https://www.ema.europa.eu/en/documents/assessment-report/hepcludex-epar-public-assessment-report_en.pdf
DB15248,,"PRN Newswire: MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (bulevirtide), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infections",http://www.prnewswire.com/news-releases/myr-pharmaceuticals-receives-positive-chmp-opinion-for-hepcludex-bulevirtide-the-first-in-class-entry-inhibitor-for-the-treatment-of-chronic-hepatitis-d-infections-301067823.html
DB15248,,"Fierce Biotech: Gilead snaps ups German virology biotech MYR, nabbing a European-approved hepatitis D therapy",https://www.fiercebiotech.com/biotech/gilead-snaps-ups-german-virology-biotech-myr-nabbing-a-european-approved-hepatitis-d
DB15248,,"MYR Pharmaceuticals: MYR Pharmaceuticals Receives Positive CHMP Opinion For HEPCLUDEX® (Bulevirtide), The First-In-Class Entry Inhibitor For The Treatment Of Chronic Hepatitis D Infections",https://www.myr-pharma.com/myr-pharmaceuticals-receives-positive-chmp-opinion-hepcludex-bulevirtide
DB15248,,NIH StatPearls: Hepatitis D,https://www.ncbi.nlm.nih.gov/books/NBK470436/
DB15248,,Clinicaltrial.gov: Phase 2b Study of Bulevirtide (With Peginterferon Alfa-2a) in Patients With CHD,https://clinicaltrials.gov/ct2/show/NCT03852433
DB15248,,MYR pharma: company page,https://www.myr-pharma.com
DB15248,,AP News: Gilead Sciences to Acquire MYR GmbH,https://apnews.com/press-release/pr-newswire/business-products-and-services-ownership-changes-drug-approvals-western-europe-eccbb8f8ed38a6efd228973231716884
DB15248,,EMA Summary of Product Characteristics: Bulevirtide,https://www.ema.europa.eu/en/documents/product-information/hepcludex-epar-product-information_en.pdf
DB15252,,"FDA Approved Drug Products: NEMLUVIO (nemolizumab-ilto) for injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761390s000lbl.pdf
DB15252,,"Fierce Pharma: Itching for leadership in 'therapeutic dermatology,' Galderma wins FDA nod for Nemluvio to treat prurigo nodularis",https://www.fiercepharma.com/pharma/itching-leadership-therapeutic-dermatology-galderma-wins-fda-nod-nemluvio-treat-prurigo
DB15258,,EMA Summary of Product Characteristics - Idefirix (imlifidase) powder for concentrate for solution for infusion,https://www.ema.europa.eu/en/documents/product-information/idefirix-epar-product-information_en.pdf
DB15258,,EMA Assessment Report - Idefirix (imlifidase),https://www.ema.europa.eu/en/documents/assessment-report/idefirix-epar-public-assessment-report_en.pdf
DB15263,,AIFA: Thyrogen (Thyrotropin) Intramuscular Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000767_034716_RCP.pdf&retry=0&sys=m0b1l3
DB15266,,"FDA Approved Drug Products: OJEMDA (tovorafenib) suspension and tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218033s000lbl.pdf
DB15266,,FDA: FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric
DB15270,,FDA Approved Drug Products: Vyvgart (efgartigimod alfa-fcab) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761195s000lbl.pdf
DB15270,,FDA News Release: FDA Approves New Treatment for Myasthenia Gravis,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis
DB15270,,Argenx: Efgartigimod Proposed Mechanism of Action,https://www.argenx.com/pipeline/efgartigimod/mechanism-of-action-Efgartigimod
DB15270,,EMA Approved Drug Products: Vyvgart (efgartigimod alfa) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/vyvgart-epar-product-information_en.pdf
DB15270,,argenx News: argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis,https://www.argenx.com/news/argenx-announces-european-commission-approval-vyvgarttm-efgartigimod-alfa-fcab-treatment
DB15270,,FDA Approved Drug Products: VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use (August 2024),https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf
DB15270,,Globe News Wire: argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis,https://www.globenewswire.com/news-release/2023/6/20/2691658/0/en/argenx-Announces-U-S-Food-and-Drug-Administration-Approval-of-VYVGART-Hytrulo-efgartigimod-alfa-and-hyaluronidase-qvfc-Injection-for-Subcutaneous-Use-in-Generalized-Myasthenia-Grav.html
DB15270,,FDA Approved Drug Products: Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous administration (December 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761304s002lbl.pdf
DB15270,,FDA Approved Drug Products: Vyvgart (efgartigimod alfa-fcab) injection for intravenous administration (December 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761195s003lbl.pdf
DB15271,,FDA Approved Drug Products: Adakveo Crizanlizumab-TMCA Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf
DB15271,,BioSpace: EU Pulls Authorization of Novartis’ Sickle Cell Disease Drug,https://www.biospace.com/article/eu-pulls-authorization-of-novartis-sickle-cell-disease-drug-adakveo/
DB15275,,FDA Approved Drug Products: Itovebi (inavolisib) tablets for oral use (October 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s001lbl.pdf
DB15275,,"FDA News Release: FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer",https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive
DB15283,,"FDA Approved Drug Products: KIMMTRAK (tebentafusp-tebn) injection, for intravenous use",https://ir.immunocore.com/static-files/4e58e85c-de58-4b36-8076-f14cf1cbe206
DB15283,,BioSpace News: Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma,https://www.biospace.com/article/releases/immunocore-announces-fda-approval-of-kimmtrak-tebentafusp-tebn-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma/?s=74
DB15283,,NIH NCATS Inxight Drugs: TEBENTAFUSP,https://drugs.ncats.io/substance/N658GY6L3E
DB15283,,EMA Summary of Product Characteristics: Kimmtrak (tebentafusp) concentrate for intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/kimmtrak-epar-product-information_en.pdf
DB15300,,AIFA Product Information: IDROCHINIDINA LIRCA (hydroquinidine hydrochloride) oral tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_005494_FI.pdf&retry=0&sys=m0b1l3
DB15303,,FDA Approved Drug Products: VABYSMO (faricimab-svoa) injection,https://www.gene.com/download/pdf/vabysmo_prescribing.pdf
DB15303,,Health Canada Product Monograph: Vabysmo (faricimab) solution for intravitreal injection,https://pdf.hres.ca/dpd_pm/00066073.PDF
DB15303,,EMA CHMP Positive Opinion: Vabysmo (faricimab),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/vabysmo
DB15303,,EMA Approved Drug Products: Vabysmo (faricimab) solution of intravitreal injection,https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf
DB15305,,BiopharmaDive: 5 FDA Approval Decisions to Watch in the 2nd Quarter,https://www.biopharmadive.com/news/5-fda-approval-decisions-to-watch-2nd-quarter/575058/
DB15305,,BusinessWire: FDA Approves Genentech’s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older,https://www.businesswire.com/news/home/20200807005410/en/FDA-Approves-Genentech%E2%80%99s-Evrysdi-risdiplam-Treatment-Spinal
DB15305,,FDA Approved Drug Products: Evrysdi (risdiplam) powder for oral solution,https://www.gene.com/download/pdf/evrysdi_prescribing.pdf
DB15305,,CaymanChem: Risdiplam MSDS,https://www.caymanchem.com/msdss/29028m.pdf
DB15305,,BiopharmaDive: First oral drug for spinal muscular atrophy approved by FDA,https://www.biopharmadive.com/news/roche-ptc-risdiplam-approval-spinal-muscular-atrophy/583167/
DB15305,,FDA Approved Drug Products: EVRYSDI (risdiplam) Powder for oral solution (May 2022),https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213535s003s005lbl.pdf
DB15323,,FDA Thailand Product Information: ZAFATEK (trelagliptin) oral tablet,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1012611500111C
DB15327,,Sorrento Therapeutics: Abivertinib,https://sorrentotherapeutics.com/research/immuno-oncology/abivertinib/
DB15327,,Sorrento Therapeutics: Abivertinib COVID-19 Trial,https://sorrentotherapeutics.com/research/covid-19/abivertinib-covid-19-trial/
DB15327,,NCT04440007: Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19 (SOC),https://clinicaltrials.gov/ct2/show/NCT04440007
DB15327,,Targeted Oncology: FDA Clears Phase 2 Study of Abivertinib in Hospitalized Patients With COVID-19,https://www.targetedonc.com/view/fda-clears-phase-2-study-of-abivertinib-in-hospitalized-patients-with-covid-19
DB15328,,FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf
DB15328,,FDA News Release: Ubrogepant approval,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine
DB15328,,Health Canada Approved Drug Products: UBRELVY (Ubrogepant) oral tablets,https://pdf.hres.ca/dpd_pm/00068130.PDF
DB15328,,FDA Approved Drug Products: Ubrelvy (ubrogepant) tablets for oral use (February 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211765s007lbl.pdf
DB15354,,FDA Approved Drug Products: Evkeeza (evinacumab-dgnb) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf
DB15354,,PR Newswire: FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol,https://www.prnewswire.com/news-releases/fda-approves-first-in-class-evkeeza-evinacumab-dgnb-for-patients-with-ultra-rare-inherited-form-of-high-cholesterol-301227183.html
DB15354,,"EVKEEZA® (evinacumab-dgnb) injection, for intravenous use (March 2023)",https://www.regeneron.com/downloads/evkeeza_pi.pdf
DB15354,,Health Canada Approved Drug Proucts: EVKEEZA (evinacumab) injection for intravenous use,https://pdf.hres.ca/dpd_pm/00072602.PDF
DB15354,,Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH),"https://www.biospace.com/article/releases/ultragenyx-launches-evkeeza-evinacumab-for-injection-in-canada-for-the-treatment-of-homozygous-familial-hypercholesterolemia-hofh-/#:~:text=Evkeeza%20is%20approved%20by%20Health,homozygous%20familial%20hypercholesterolemia%20(HoFH)."
DB15354,,EMA Approved Drug Products: Evkeeza (evinacumab) injection for intravenous use,https://www.ema.europa.eu/en/documents/product-information/evkeeza-epar-product-information_en.pdf
DB15354,,Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH),https://www.globenewswire.com/news-release/2023/12/18/2797775/20739/en/Ultragenyx-Receives-European-Commission-Decision-for-Evkeeza-evinacumab-Expanded-Indication-in-Children-Aged-5-Years-and-Older-with-Homozygous-Familial-Hypercholesterolemia-HoFH.html
DB15357,,FDA Approved Drug Products: Cobenfy (xanomeline tartrate/trospium chloride) capsules for oral use (September 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216158s000lbl.pdf
DB15357,,FDA News Release: FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia
DB15395,,"FDA Approved Drug Products: ELREXFIO (elranatamab-bcmm) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf
DB15395,,FDA: FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma
DB15395,,EMA Approved Drug Products: LREXFIO (elranatamab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/elrexfio-epar-product-information_en.pdf
DB15395,,Pfizer: European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-elrexfior-relapsed-and
DB15401,,FDA Approved Drug Products: Voydeya (danicopan) tablets for oral use,https://alexion.com/Documents/voydeya_uspi
DB15401,,AstraZeneca Press Release: Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH,https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-us.html
DB15401,,MSD Manual: Complement System,https://www.msdmanuals.com/professional/immunology-allergic-disorders/biology-of-the-immune-system/complement-system
DB15401,,AstraZeneca Press Release: Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy,https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy.html
DB15401,,National Organization for Rare Disorders (NORD): Paroxysmal Nocturnal Hemoglobinuria,https://rarediseases.org/rare-diseases/paroxysmal-nocturnal-hemoglobinuria/
DB15413,,"FDA Approved Drug Products: CYTALUX (pafolacianine) injection, for intravenous use",https://cytalux.com/wp-content/uploads/2021/11/CYTALUX-Prescribing-Information.pdf
DB15433,,Reuters: Sarepta drug protects lab monkeys from Ebola,https://www.reuters.com/article/health-ebola-sarepta-idINKBN0LE1ZO20150210
DB15434,,European Medicines Agency (EMA) Summary of Product Characteristics: Lunsumio (mosunetuzumab) solution for intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf
DB15434,,Globe News Wire: European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma,https://www.globenewswire.com/news-release/2022/06/08/2458330/0/en/European-Commission-approves-Roche-s-first-in-class-bispecific-antibody-Lunsumio-for-people-with-relapsed-or-refractory-follicular-lymphoma.html
DB15434,,FDA Approved Drug Products: LUNSUMIO (mosunetuzumab-axgb) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf
DB15442,,FDA News Release: FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy
DB15442,,FDA Approved Drug Products: Cosela (Trilaciclib) Intravenous Injection,https://www.g1therapeutics.com/cosela/pi/
DB15444,,FDA News Release: Trikafta Approval,https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis
DB15444,,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf
DB15444,,"FDA Approved Drug Products: TRIKAFTA® (elexacaftor, tezacaftor, and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use May 2023",https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf
DB15456,,FDA Approved Drug Products: Verquvo (vericiguat) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf
DB15456,,BusinessWire: Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat),https://www.businesswire.com/news/home/20210120005289/en/Merck-Announces-U.S.-FDA-Approval-of-VERQUVO%C2%AE-vericiguat
DB15456,,Adempas (Riociguat) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204819s000lbl.pdf
DB15463,,FDA Approved Drug Products: Welireg (belzutifan) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf
DB15463,,FDA News Release: FDA approves belzutifan for cancers associated with von Hippel-Lindau disease,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease
DB15463,,VHL Alliance: Belzutifan (Welireg; MK-6482; PT-2977) and VHL Disease,https://www.vhl.org/belzutifan-mk-6482-pt-2977-and-vhl-disease/
DB15463,,UT Southwestern Medical Center News Release: FDA approval of belzutifan culminates 25-year journey at UTSW from gene discovery to a first-in-class drug,https://www.utsouthwestern.edu/newsroom/articles/year-2021/fda-approval-belzutifan.html
DB15463,,"FDA Approved Drug Products: WELIREG® (belzutifan) tablets, for oral use (Dec 2023)",https://www.merck.com/product/usa/pi_circulars/w/welireg/welireg_pi.pdf
DB15465,,FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208653s002s003lbl.pdf
DB15465,,KemPharm: Apadaz approval announcement,http://investors.kempharm.com/news-releases/news-release-details/kempharm-announces-fda-approval-apadaztm-benzhydrocodone-and
DB15465,,FDA Approved Drug Products: Apadaz (benzhydrocodone/acetaminophen) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208653s005lbl.pdf
DB15465,,"FDA Approved Drug Products: APADAZ (benzhydrocodone and acetaminophen) tablets, for oral use, CII (December 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208653s008lbl.pdf
DB15471,,ZW25 Anti-HER2 x HER2 Bispecific Overview,https://www.zymeworks.com/our-pipeline/zw25
DB15471,,FDA Approved Drug Products: Ziihera (zanidatamab-hrii) injection for intravenous use (November 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761416s000lbl.pdf
DB15471,,FDA News Release: FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanidatamab-hrii-previously-treated-unresectable-or-metastatic-her2
DB15472,,ZW49 Anti-HER2 x HER2 ADC Overview,https://www.zymeworks.com/our-pipeline/zw49
DB15481,,"BASG: Sperti Preparation H (Fish Oil, Shark Liver Oil, Yeast) Rectal Suppository",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=12945&type=DOTC_FACH_INFO
DB15483,,"DailyMed Label: JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating) suspension for subcutaneous injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69fc3841-a461-4706-bdcb-1176c40bf486
DB15483,,"FDA Approved Drug Products: Jynneos (smallpox and monkeypox vaccine, live, non-replicating) for suspension for subcutaneous injection",https://www.fda.gov/media/131078/download
DB15483,,EMA Summary of Product Characteristics: Imvanex (Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)) for subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/imvanex-epar-product-information_en.pdf
DB15483,,Health Canada Product Monograph: IMVAMUNE (modified vaccinia ankara) injection,https://pdf.hres.ca/dpd_pm/00040089.PDF
DB15489,,INVIMA Product Information: SEDOXIL (mexazolam) oral tablet,http://web.sivicos.gov.co/registros/pdf/1526601_2016043509.pdf
DB15490,,"FDA Approved Drug Products: ZURZUVAETM (zuranolone) capsules, for oral use,",https://documents.sage-biogen.com/us/zurzuvae/pi.pdf
DB15490,,"FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder",https://investors.biogen.com/news-releases/news-release-details/fda-approves-zurzuvaetm-zuranolone-first-and-only-oral-treatment
DB15493,,Med Chem Express: Cambinol Product Data Sheet,https://file.medchemexpress.com/batch_PDF/HY-100732/Cambinol-DataSheet-MedChemExpress.pdf
DB15494,,FDA Approved Drug Products: Gallium Dotatoc GA 68,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf
DB15494,,EMA Assessment Report: SomaKit TOC,https://www.ema.europa.eu/en/documents/assessment-report/somakit-toc-epar-public-assessment-report_en.pdf
DB15498,,Cancer.gov Mps1 inhibitor BOS172722 definition,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/794872
DB15507,,"Health Canada Approved Drug Products: FLUCELVAX QUAD Influenza Vaccine, for intramuscular injection",https://pdf.hres.ca/dpd_pm/00065002.PDF
DB15514,,AIFA: Influvac S (Trivalent flu vaccine) Intramuscular Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004157_028851_RCP.pdf&retry=0&sys=m0b1l3
DB15515,,AIFA: Influvac S (Trivalent flu vaccine) Intramuscular Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004157_028851_RCP.pdf&retry=0&sys=m0b1l3
DB15517,,AIFA: Flucelvax Tetra (Quadrivalent Flu Vaccine) Intramuscular Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004980_047475_FI.pdf&retry=0&sys=m0b1l3
DB15518,,AIFA: Flucelvax Tetra (Quadrivalent Flu Vaccine) Intramuscular Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004980_047475_FI.pdf&retry=0&sys=m0b1l3
DB15528,,ZOLGENSMA® (onasemnogene abeparvovec-xioi) FDA Label,https://www.fda.gov/media/126109/download
DB15528,,SMN1 gene - Genetics Home Reference - NIH,https://ghr.nlm.nih.gov/gene/SMN1
DB15561,,EMA Summary of Product Characteristics: ROCTAVIAN (valoctocogene roxaparvovec) solution for infusion,https://www.ema.europa.eu/en/documents/product-information/roctavian-epar-product-information_en.pdf
DB15561,,BioMarin: Valoctocogene roxaparvovec is an investigational AAV5 gene therapy for the treatment of severe hemophilia A. It has been approved for conditional use in the European Union and is marketed as ROCTAVIAN (valoctocogene roxaparvovec),https://www.biomarin.com/our-treatments/pipeline/valoctocogene-roxaparvovec-for-severe-hemophilia-a/
DB15561,,FDA approved drug product: ROCTAVIAN (valoctocogene roxaparvovec-rvox) suspension for intravenous infusion,https://investors.biomarin.com/events-presentations?item=149
DB15566,,FDA Approved Drug Products: Prednisolone Acetate Oral Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022067s007lbl.pdf
DB15566,,FDA Approved Drug Products: Prednisolone Acetate Ophthalmic Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017100s045lbl.pdf
DB15566,,FDA Approved Drug Products: Prednisolone Acetate Ophthalmic Suspension 1%,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017011s050lbl.pdf
DB15566,,Greenstone LLC: Prednisolone Acetate Ophthalmic Suspension MSDS,https://www.greenstonellc.com/sites/default/files/pdfs/MSDS/PREDNISOLONE%20ACETATE%20OPHTHALMIC%20SUSPENSION%2C%20USP%201MSDS_0.pdf
DB15567,,"Patent: Epigenetic silencing of NMT2 (2018, Pacylex Pharmaceuticals, Inc.)",https://patents.google.com/patent/US20180208990A1/en?q=PCLX-001&oq=PCLX-001
DB15568,,Cancer Network: New Drug Application for Adagrasib Accepted by FDA for KRAS G12C+ NSCLC,https://www.cancernetwork.com/view/new-drug-application-for-adagrasib-accepted-by-fda-for-kras-g12c-nsclc
DB15568,,FDA Approved Drug Products: KRAZATI (adagrasib) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s001lbl.pdf
DB15568,,PR NewsWire: Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation,https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-us-fda-accelerated-approval-of-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc-with-a-krasg12c-mutation-301700902.html
DB15568,,"FDA Approved Drug Products: KRAZATI (adagrasib) tablets, for oral use (June 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216340s005lbl.pdf
DB15569,,FDA Approved Drug Products: Lumakras (Sotorasib) Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf
DB15569,,BioSpace News: European Commission Approves Lumykras® (Sotorasib) For Patients With KRAS G12C-mutated Advanced Non-Small Cell Lung Cancer,https://www.biospace.com/article/releases/european-commission-approves-lumykras-sotorasib-for-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer/?keywords=European+Commission+Approval
DB15570,,NCI Drug Dictionary - Definition of CCR4 inhibitor FLX475,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/796771
DB15572,,"BioPharma Dive: First look at CRISPR, Vertex gene-editing therapy hints at treatment potential",https://www.biopharmadive.com/news/crispr-vertex-gene-editing-data-sickle-cell-beta-thalassemia/567557/
DB15572,,FDA Approved Drug Products: Casgevy (exagamglogene autotemcel) suspension for intravenous infusion (January 2024),https://pi.vrtx.com/files/uspi_exagamglogene_autotemcel.pdf
DB15572,,FDA Press Announcements: FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease,https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
DB15572,,Vertex Pharmaceuticals News Release: Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia,https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-casgevytm-exagamglogene
DB15573,,"FDA Thailand: Rowatinex (Anethole, Borneol, Camphene, Eucalyptol, Fenchone, Alpha-Pinene, Beta-Pinene) Capsule",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022300012311C
DB15574,,"FDA Thailand: Rowatinex (Anethole, Borneol, Camphene, Eucalyptol, Fenchone, Alpha-Pinene, Beta-Pinene) Capsule",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022300012311C
DB15575,,Summary of Product Characteristics: TOOKAD (padeliporfin) intravenous injection,https://www.ema.europa.eu/en/documents/product-information/tookad-epar-product-information_en.pdf
DB15575,,European Medicines Agency: Tookad (padeliporfin),https://www.ema.europa.eu/en/medicines/human/EPAR/tookad#authorisation-details-section
DB15576,,"NPRA: Deep Heat Sports Pain Relief (Ethyl Salicylate, Glycol Salicylate, Methyl Nicotinate, and Methyl Salicylate) Topical Aerosol",http://quest3plus.bpfk.gov.my/front-end/attachment/229/pharma/500829/500829_20180404_090105_.pdf
DB15578,,DIMDI Product Information: TOVEDESO (desfesoterodine) oral tablet,https://portal.dimdi.de/amispb/doc/2017/12/24/2195770/O677e9539644244f489232211fbd99cc3.pdf
DB15593,,FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation
DB15593,,"FDA label, Golodirsen",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf
DB15593,,Muscular dystrophy UK Research: What is exon skipping and how does it work?,https://www.musculardystrophyuk.org/research/understanding-research/what-is-exon-skipping-and-how-does-it-work
DB15593,,MSDS: Golodirsen,https://www.novachemistry.com/index.php/Index/product_info/pid/334067
DB15593,,Eteplirsen FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf
DB15593,,FDA Approved Drug Products: VYONDYS 53 (golodirsen) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211970s002lbl.pdf
DB15594,,Brilliant Blue G Opthalmic solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209569s000lbl.pdf
DB15594,,"Brilliant Blue G MSDS, Cayman Chem",https://www.caymanchem.com/msdss/14320m.pdf
DB15595,,"FDA Approved Drug Products: ERVEBO (Ebola Zaire Vaccine, Live) Suspension for intramuscular injection",https://www.fda.gov/media/133748/download
DB15595,,"ERVEBO, INN-Ebola Zaire Vaccine - Summary of Product Characteristics - EMA",https://www.ema.europa.eu/en/documents/product-information/ervebo-epar-product-information_en.pdf
DB15595,,How the new Ebola vaccine was made in Canada - CBC News,https://www.cbc.ca/news/health/second-opinion-ebola-vaccine-1.4672807
DB15595,,2014-2016 Ebola Outbreak in West Africa | History | Ebola (Ebola Virus Disease) | CDC,https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html
DB15595,,"FDA Approved Drug Products: ERVEBO® (Ebola Zaire Vaccine, Live) Suspension for intramuscular injection (August 2023)",https://www.merck.com/product/usa/pi_circulars/e/ervebo/ervebo_pi.pdf
DB15598,,FDA Approved Drug Products: Accrufer Ferric Maltol Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212320Orig1s000lbl.pdf
DB15598,,EMA Summary of Product Characteristics: Feraccru,https://www.ema.europa.eu/en/documents/product-information/feraccru-epar-product-information_en.pdf
DB15598,,Crystalline Ferric Maltol Patent,https://patentimages.storage.googleapis.com/5f/36/38/437858f5844c0c/WO2016066555A1.pdf
DB15601,,EPA Insight: NNZ-2591 patent granted in Europe to 2034 for neurodevelopmental disorders,https://www.epa-insight.com/post/nnz-2591-patent-granted-in-europe-to-2034-for-neurodevelopmental-disorders
DB15601,,"BusinessWire: FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes",https://www.businesswire.com/news/home/20191017005361/en
DB15601,,Neuren Pharmaceuticals: Product Development,http://www.neurenpharma.com/irm/content/the-science-behind-neuren-s-products1.aspx?RID=304&RedirectCount=1
DB15617,,FDA Approved Products: MONOFERRIC (ferric derisomaltose) for injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208171s000lbl.pdf
DB15617,,EMPR: Monoferric injection approved for iron deficiency anemia,https://www.empr.com/home/news/monoferric-injection-approved-for-iron-deficiency-anemia/
DB15617,,Auspar: Monofer (ferric derisomaltose),https://www.tga.gov.au/sites/default/files/auspar-ferric_derisomaltose-181105-pi.pdf
DB15617,,EMC: Monofer 100mg/ml solution for injection/infusion,https://www.medicines.org.uk/emc/medicine/23669
DB15617,,Canadian Monograph: Venofer (iron sucrose),https://pdf.hres.ca/dpd_pm/00018889.PDF
DB15617,,"FDA Approved Drug Products: MONOFERRIC (ferric derisomaltose) injection, for intravenous use (August 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208171s003lbl.pdf
DB15621,,"NPRA: Influvac (Influenza A virus A/Brisbane/02/2018 IVR-190, Influenza A virus A/South Australia/34/2019 IVR-197, Influenza B virus B/Phuket/3073/2013, Influenza B virus B/Washington/02/2019) Intramuscular Injection",https://quest3plus.bpfk.gov.my/front-end/attachment/511/pharma/518537/V_40250_20200221_115008_D3.pdf
DB15622,,RT Question More: China tests Russian anti-viral drug which might treat coronavirus as Moscow warns of possible 'mass outbreak',https://www.rt.com/russia/480037-china-tests-russian-drug-coronavirus/
DB15622,,Triazavirin,http://www.triazavirin.ru
DB15623,,NIH AIDSinfo: TMC-310911 Pharmacology,https://aidsinfo.nih.gov/drugs/549/tmc-310911/0/professional
DB15623,,Nature Biotechnology: Coronavirus puts drug repurposing on the fast track,https://www.nature.com/articles/d41587-020-00003-1
DB15626,,"FDA Approved Drug Products: SPEVIGO (spesolimab-sbzo) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf
DB15626,,EMA Summary of Opinion: Spevigo (spesolimab),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/spevigo
DB15626,,European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares,https://pipelinereview.com/index.php/2022121482291/Antibodies/European-Commission-approves-SPEVIGO-spesolimab-for-generalized-pustular-psoriasis-flares.html
DB15626,,"EMA Approved Drug Products: Spevigo (spesolimab) concentrate, for intravenous injection",https://www.ema.europa.eu/en/documents/product-information/spevigo-epar-product-information_en.pdf
DB15626,,"FDA Approved Drug Products: SPEVIGO (spesolimab-sbzo) injection, for subcutaneous or intravenous use (March 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761244s003lbl.pdf
DB15627,,FDA Approved Drug Products: Jemperli (dostarlimab-gxly) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf
DB15627,,FDA News Release: FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer
DB15627,,Statement on a Nonproprietary Name Adopted by the USAN Council: Dostarlimab,https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/dostarlimab.pdf
DB15627,,"FDA Approved Drug Products: JEMPERLI (dostarlimab-gxly) injection, for intravenous use (February 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s003s004lbl.pdf
DB15627,,BioSpace: US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer,https://www.biospace.com/article/releases/us-fda-grants-regular-approval-for-jemperli-for-the-treatment-of-patients-with-recurrent-or-advanced-mismatch-repair-deficient-endometrial-cancer/?s=74
DB15627,,"FDA Approved Drug Products: JEMPERLI (dostarlimab-gxly) injection, for intravenous use (July 2023)",https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Jemperli/pdf/JEMPERLI-PI-MG.PDF
DB15627,,Health Canada Approved Drug Products: JEMPERLI (dostarlimab) Intravenous Solution for Infusion,https://ca.gsk.com/media/6620/jemperli_pm.pdf
DB15627,,EMA Approved Drug Products: JEMPERLI (dostarlimab) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf
DB15627,,"FDA Approved Drug Products: JEMPERLI (dostarlimab-gxly) injection, for intravenous use (August 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s009lbl.pdf
DB15628,,ElsaLys Biotech: What is inolimomab (LEUKOTAC®)?,https://www.elsalysbiotech.com/inolimomab/what-inolimomab-leukotacr
DB15636,,"FDA Approved Drug Products: ZILBRYSQ (zilucoplan) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216834s000lbl.pdf
DB15636,,PR Newswire: UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis,https://www.prnewswire.com/news-releases/ucb-announces-us-fda-approval-of-zilbrysq-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis-301959745.html
DB15636,,EMA Approved Drug Products: Zilbrysq (zilucoplan) solution for injection,https://www.ema.europa.eu/en/documents/product-information/zilbrysq-epar-product-information_en.pdf
DB15636,,UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis,https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-European-Commission-approval-of-ZILBRYSQRV-zilucoplan-for-the-treatment-of-adults-with-generalized-Myasthenia-Gravis
DB15641,,DROLOXIFENE: Inxight Drugs,https://drugs.ncats.io/drug/0M67U6Z98F
DB15654,,Pharmaceutical Business Review: Moderna's mRNA-1273 vaccine,https://www.pharmaceutical-business-review.com/news/moderna-mrna-1273-coronavirus-trial/
DB15654,,Clinical Trials: Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection,https://clinicaltrials.gov/ct2/show/NCT04283461
DB15654,,FDA EUA Drug Products: Moderna COVID-19 Vaccine,https://www.fda.gov/media/144637/download
DB15654,,FDA Press Announcements: FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine,https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid
DB15654,,Health Canada: Regulatory Decision Summary - Moderna COVID-19 Vaccine,https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00736
DB15654,,Health Canada Statement: Health Canada authorizes the use of the Moderna Spikevax COVID-19 vaccine as a booster shot,https://www.canada.ca/en/health-canada/news/2021/11/health-canada-authorizes-the-use-of-the-moderna-spikevax-covid-19-vaccine-as-a-booster-shot.html
DB15654,,FDA COVID-19 Vaccines: Moderna COVID-19 Vaccine,https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
DB15654,,FDA News Release: FDA Expands Eligibility for COVID-19 Vaccine Boosters,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters
DB15654,,"Summary of Product Characteristics: Spikevax (COVID-19 mRNA Vaccine, nucleoside modified) Intramuscular Injection",https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf
DB15654,,Health Canada Product Monograph: Spikevax (elasomeran mRNA vaccine) for intramuscular injection,https://covid-vaccine.canada.ca/info/pdf/covid-19-vaccine-moderna-pm-en.pdf
DB15654,,EMA COVID-19 Vaccine Safety Update: Spikevax (Dec 9/21),https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-spikevax-previously-covid-19-vaccine-moderna-9-december-2021_en.pdf
DB15654,,"FDA Approved Drug Products: Spikevax (COVID-19 Vaccine, mRNA) suspension for injection for intramuscular use (August 2024)",https://www.fda.gov/media/155675/download
DB15654,,FDA News Release: Coronavirus (COVID-19) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-key-action-approving-second-covid-19-vaccine
DB15654,,"BioSpace News: Going it Alone, FDA Authorizes Second Booster for Adults 50 Plus",https://www.biospace.com/article/fda-authorizes-4th-shot-of-pfizer-biontech-and-moderna-covid-19-vaccines-/?s=74
DB15654,,Health Canada Product Monograph: SPIKEVAX™ Bivalent (Elasomeran / davesomeran mRNA vaccine) for intramuscular injection,https://pdf.hres.ca/dpd_pm/00067971.PDF
DB15654,,Moderna COVID-19 Vaccines,https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines#Spikevax
DB15654,,Health Canada Product Monograph: Spikevax Bivalent (Original / BA.1 Omicron) dispersion for intramuscular injection,https://pdf.hres.ca/dpd_pm/00069607.PDF
DB15654,,FDA NEWS RELEASE: Coronavirus (COVID-19) Update; FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children
DB15654,,EMA EPAR: Spikevax (Moderna COVID-19 vaccine),https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax
DB15654,,"Health Canada Product Monograph: Spikevax (COVID-19 mRNA vaccine, Omicron KP.2 variant) dispersion for intramuscular injection (September 2024)",https://pdf.hres.ca/dpd_pm/00077065.PDF
DB15655,,Chinese Clinical Trial Register: A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector),http://www.chictr.org.cn/showprojen.aspx?proj=51154
DB15655,,Antibody Society: COVID-19 Archives,https://www.antibodysociety.org/covid-19/
DB15656,,Clinical Trials: A Study of a Candidate COVID-19 Vaccine (COV001),https://www.clinicaltrials.gov/ct2/show/NCT04324606
DB15656,,TrialSite News: University of Oxford Commences Clinical Trial for Vaccine Candidate (ChAdOx1 nCoV-19) Targeting COVID-19,https://www.trialsitenews.com/university-of-oxford-commences-clinical-trial-for-vaccine-candidate-chadox1-ncov-19-targeting-covid-19-2/
DB15656,,Health Canada Product Monograph: AstraZeneca COVID-19 Vaccine,https://www.azcovid-19.com/content/dam/azcovid/pdf/canada/ca-pm-azd1222-en.pdf
DB15656,,TrialSite News: University of Oxford Selects AstraZeneca as its Commercial Partner for its SARS-CoV-2 Vaccine ChAdOx1 nCoV-19,https://trialsitenews.com/university-of-oxford-selects-astrazeneca-as-its-commercial-partner-for-its-sars-cov-2-vaccine-chadox1-ncov-19/
DB15656,,AstraZeneca: Medical Information Site for COVID-19 Vaccine AstraZeneca,https://www.azcovid-19.com/
DB15656,,UK Reg 174: AstraZeneca COVID-19 Vaccine Information for UK Healthcare Professionals,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963838/AZD1222_Information_for_Healthcare_Professionals_-_22-02-2021.pdf
DB15656,,EMA PRAC Committee: COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets Share,https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
DB15656,,EMA Summary of Product Characteristics: AstraZeneca COVID-19 Vaccine for intramuscular injection,https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-epar-product-information_en.pdf
DB15656,,Health Canada Public Advisory: Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines,https://recalls-rappels.canada.ca/en/alert-recall/health-canada-updating-labels-janssen-and-vaxzevria-astrazeneca-covid-19-vaccines
DB15656,,EMA COVID-19 Vaccine Safety Update: Vaxzevria (Dec 9/21),https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-9-december-2021_en.pdf
DB15661,,DC Chemicals: EIDD-2081 MSDS,http://www.dcchemicals.com/usr/uploads/gene/2020326/MSDS_12096_DC27035_2349386-89-4.pdf
DB15661,,"GOV.UK: First oral antiviral for COVID-19 Lagevrio (molnupiravir), approved by MHRA",https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra
DB15661,,Electronic Medicines Compendium: Lagevrio (Molnupiravir) 200mg Oral Capsules Summary of Product Characteristics,https://www.medicines.org.uk/emc/product/13044
DB15661,,Merck News Release: Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19,https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-receives-u-s-fda-emergency-use-authorization-for-the-treatment-of-high-risk-adults-with-mild-to-moderate-covid-19/
DB15665,,Sunovion Pharmaceuticals,https://www.sunovion.ca
DB15669,,"FDA Approved Drug Products: VEOZAHTM (fezolinetant) tablets, for oral use",https://www.astellas.com/us/system/files/veozah_uspi.pdf
DB15669,,EMA Summary of Product Characteristics: Veoza (fezolinetant) film-coated tablets for oral administration,https://www.ema.europa.eu/en/documents/product-information/veoza-epar-product-information_en.pdf
DB15669,,Astellas Newsroom: Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause,https://newsroom.astellas.us/2023-12-10-Astellas-VEOZA-TM-fezolinetant-Approved-by-European-Commission-for-Treatment-of-Vasomotor-Symptoms-Associated-with-Menopause
DB15673,,EMA Approved Drug Products: Sunlenca (lenacapavir) Subcutaneous Injection or Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/sunlenca-epar-product-information_en.pdf
DB15673,,"Gilead Press Releases: Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option",https://www.gilead.com/news-and-press/press-room/press-releases/2022/8/gilead-announces-first-global-regulatory-approval-of-sunlenca-lenacapavir-the-only-twiceyearly-hiv-treatment-option
DB15673,,"FDA Approved Drug Products: SUNLENCA (lenacapavir) tablets, for oral use or injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf
DB15673,,"Gilead: Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV",https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv
DB15679,,NPRA Product Information: Xyloproct (Aluminum subacetate / Hydrocortisone acetate / Lidocaine / Zinc oxide) rectal ointment/suppository,https://quest3plus.bpfk.gov.my/front-end/attachment/54379/pharma/210194/V_21921_20181005_024414_D3.pdf
DB15680,,"DailyMed Label: PENBRAYA (Meningococcal Groups A, B, C, W, and Y Vaccine), suspension for intramuscular injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd5652b6-5ae4-437e-a456-47deaf500794
DB15681,,"DailyMed Label: PENBRAYA (Meningococcal Groups A, B, C, W, and Y Vaccine), suspension for intramuscular injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd5652b6-5ae4-437e-a456-47deaf500794
DB15682,,"DailyMed Label: PENBRAYA (Meningococcal Groups A, B, C, W, and Y Vaccine), suspension for intramuscular injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd5652b6-5ae4-437e-a456-47deaf500794
DB15683,,"DailyMed Label: PENBRAYA (Meningococcal Groups A, B, C, W, and Y Vaccine), suspension for intramuscular injection",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd5652b6-5ae4-437e-a456-47deaf500794
DB15685,,FDA Approved Drug Products: Retevmo (selpercatinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf
DB15685,,EMA Approved Drug Products: Retsevmo (selpercatinib) Oral Capsules,https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf
DB15685,,"FDA Approved Drug Products: RETEVMO (selpercatinib) capsules, for oral use (June 2024)",https://pi.lilly.com/us/retevmo-uspi.pdf
DB15686,,FDA: Fact Sheet For Health Care Providers EUA of Remdesivir,https://www.fda.gov/media/137566/download
DB15686,,European Patent Specification: 1'-substituted carba-nucleoside analogs for antiviral treatment,https://patentimages.storage.googleapis.com/4b/84/70/16d3c8634171ba/EP2937350B1.pdf
DB15687,,NIH: Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection (NCT04374032),https://clinicaltrials.gov/ct2/show/NCT04374032
DB15687,,Bosna Lijek: Enkorten Metenkefalin and Tridecactide Injection,http://www.bosnalijek.com/products-L2e?c=ign&ign=metenkefalin%20%2B%20tridecactide
DB15688,,FDA Approved Drug Products: ZAVZPRET (zavegepant) nasal spray (March 2023),https://labeling.pfizer.com/ShowLabeling.aspx?id=19471
DB15688,,BioSpace: Pfizer’s Biohaven Bet Pays Off Again as Migraine Nasal Spray Wins Approval,https://www.biospace.com/article/pfizer-s-biohaven-bet-pays-off-again-as-migraine-nasal-spray-wins-approval/?s=74
DB15690,,FDA Approved Drug Products: Cerianna (fluoroestradiol F 18) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf
DB15690,,"Applied Radiology News Release: PETNET, Zionexa Announce FDA Approval of Cerianna (Fluoroestradiol F 18)",https://www.appliedradiology.com/articles/petnet-zionexa-announce-fda-approval-of-cerianna-fluoroestradiol-f-18
DB15691,,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",https://clinicaltrials.gov/ct2/show/NCT04426695?term=REGN10933&draw=2&rank=2
DB15691,,Regeneron: Regeneron begins first clinical trials of antibody-antiviral cocktail REGN-COV-2 for the treatment and prevention of COVID-19,https://investor.regeneron.com/news-releases/news-release-details/regeneron-begins-first-clinical-trials-anti-viral-antibody
DB15692,,FDA recommendations for investigational COVID-19 convalescent plasma,https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma
DB15693,,INO-4800 Phase I clinical trial NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410
DB15693,,INOVIO Press release phase 1/2 clinical trial,http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-and-IVI-Partner-with-Seoul-National-University-Hospital-to-Start-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19-DNA-Vaccine-INO-4800-in-South-Korea/default.aspx
DB15694,,FDA Approved Drug Products: INQOVI (decitabine and cedazuridine) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212576s000lbl.pdf
DB15695,,Gen Eng News: BNT162 vaccine candidates,https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/
DB15695,,BioNTech BNT162 Update,https://investors.biontech.de/static-files/398d9bd8-e2cb-49ca-9d6d-7dfd01c66b8a
DB15695,,Mulligan et al. BNT162b1 medRxiv pre-print,https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1
DB15695,,Clinical Trial NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728
DB15695,,Clinical Trial NCT04380701,https://clinicaltrials.gov/ct2/show/NCT04380701
DB15695,,FDA fast track designation: BNT162b1 and BNT162b2,https://www.cnbc.com/2020/07/13/pfizer-biontechs-coronavirus-vaccines-get-fdas-fast-track-status.html
DB15696,,Gen Eng News: BNT162 vaccine candidates,https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/
DB15696,,BioNTech BNT162 Update,https://investors.biontech.de/static-files/398d9bd8-e2cb-49ca-9d6d-7dfd01c66b8a
DB15696,,Clinical Trial NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728
DB15696,,Clinical Trial NCT04380701,https://clinicaltrials.gov/ct2/show/NCT04380701
DB15696,,FDA fast track designation: BNT162b1 and BNT162b2,https://www.cnbc.com/2020/07/13/pfizer-biontechs-coronavirus-vaccines-get-fdas-fast-track-status.html
DB15696,,"Health Canada Approved Drug Products: COMIRNATY (COVID-19 Vaccine, mRNA) Suspension for Intramuscular Injection",https://pdf.hres.ca/dpd_pm/00067032.PDF
DB15696,,MHRA Interim Product Monograph: BNT162b2 SARS-CoV-2 Vaccine,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/941452/Information_for_healthcare_professionals.pdf
DB15696,,FDA News Release: FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine,https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19
DB15696,,"Pfizer: Fact Sheet for Healthcare Providers Administering Vaccine, Pfizer-BioNtech COVID-19 vaccine",https://www.cvdvaccine-us.com/images/pdf/fact-sheet-for-hcp-administering-vaccine-vaccination-providers-full-eua-prescribing-information.pdf
DB15696,,"Pfizer: Fact Sheet for Recipients and Caregivers, Pfizer BioNTech COVID-19 vaccine",https://www.cvdvaccine-us.com/images/pdf/fact-sheet-for-recipients-and-caregivers.pdf
DB15696,,"FDA Emergency Use Authorization: Full EUA Prescribing information, Pfizer-BioNTech COVID-19 vaccine",https://www.cvdvaccine-us.com/dosing-and-administration
DB15696,,FDA Press Announcements: FDA Approves First COVID-19 Vaccine,https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine?utm_medium=email&utm_source=govdelivery
DB15696,,FDA Approved Drug Products: Comirnaty (COVID-19 mRNA vaccine) Intramuscular Injection,https://www.fda.gov/media/151707/download
DB15696,,FDA News Release: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age,https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age
DB15696,,Health Canada: Regulatory Decision Summary for COMIRNATY,https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detail.html?linkID=RDS00878
DB15696,,FDA News Release: FDA Expands Eligibility for COVID-19 Vaccine Boosters,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters
DB15696,,"Summary of Product Characteristics: Comirnaty (COVID-19 mRNA Vaccine, nucleoside modified) Intramuscular Injection",https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf
DB15696,,GlobeNewswire: Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older,https://www.globenewswire.com/news-release/2021/12/09/2349543/0/en/Pfizer-and-BioNTech-Receive-U-S-FDA-Emergency-Use-Authorization-of-COVID-19-Vaccine-Booster-for-Individuals-16-Years-and-Older.html
DB15696,,Health Canada: Pfizer-BioNTech Comirnaty COVID-19 vaccine,https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/pfizer-biontech.html
DB15696,,EMA COVID-19 Vaccine Safety Update: Comirnaty (Dec 9/21),https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-9-december-2021_en.pdf
DB15696,,"BioSpace News: Going it Alone, FDA Authorizes Second Booster for Adults 50 Plus",https://www.biospace.com/article/fda-authorizes-4th-shot-of-pfizer-biontech-and-moderna-covid-19-vaccines-/?s=74
DB15696,,FDA NEWS RELEASE: Coronavirus (COVID-19) Update; FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children
DB15696,,"Health Canada Approved Drug Products: COMIRNATY (COVID-19 Vaccine, mRNA) Suspension for Intramuscular Injection 2022",https://pdf.hres.ca/dpd_pm/00067155.PDF
DB15696,,FDA Emergency Use Authorization: Pfizer-BioNTech COVID-19 Vaccine (Original & Omicron BA.4/BA.5 strain) suspension for intramuscular injection,https://www.fda.gov/media/161327/download
DB15696,,"Health Canada Approved Drug Products: COMIRNATY Original & Omicron BA.4/BA.5 [COVID-19 mRNA vaccine, Bivalent (Original and Omicron BA.4/BA.5)] Suspension for Intramuscular Injection",https://covid-vaccine.canada.ca/info/pdf/comirnaty-original-omicron-ba4ba5-pm-en.pdf
DB15697,,Gen Eng News: BNT162 vaccine candidates,https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/
DB15697,,BioNTech BNT162 Update,https://investors.biontech.de/static-files/398d9bd8-e2cb-49ca-9d6d-7dfd01c66b8a
DB15697,,Clinical Trial NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728
DB15697,,Clinical Trial NCT04380701,https://clinicaltrials.gov/ct2/show/NCT04380701
DB15698,,Gen Eng News: BNT162 vaccine candidates,https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/
DB15698,,BioNTech BNT162 Update,https://investors.biontech.de/static-files/398d9bd8-e2cb-49ca-9d6d-7dfd01c66b8a
DB15698,,Clinical Trial NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728
DB15698,,Clinical Trial NCT04380701,https://clinicaltrials.gov/ct2/show/NCT04380701
DB15699,,FDA Approved Drug Products: Tecartus (brexucabtagene autoleucel) suspension,https://www.fda.gov/media/140409/download
DB15709,,"Health Canada Approved Drug Products: FLUCELVAX QUAD Influenza Vaccine, for intramuscular injection",https://pdf.hres.ca/dpd_pm/00065002.PDF
DB15718,,Eli Lilly: Initial LY-CoV555 statement,https://investor.lilly.com/news-releases/news-release-details/lilly-begins-worlds-first-study-potential-covid-19-antibody
DB15718,,Eli Lilly: LY-CoV555 phase three statement,https://investor.lilly.com/news-releases/news-release-details/lilly-initiates-phase-3-trial-ly-cov555-prevention-covid-19-long
DB15718,,NIH: LYCoV555 phase three statement,https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-test-antibody-treatment-hospitalized-covid-19-patients?utm_source=dlvr.it&utm_medium=twitter
DB15718,,FDA Emergency Use Authorization Letter: Bamlanivimab,https://www.fda.gov/media/143602/download
DB15718,,FDA Emergency Use Authorization Fact Sheet: Bamlanivimab,https://www.fda.gov/media/143603/download
DB15718,,"FDA Press Announcements: FDA Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-Exposure Prevention of COVID-19 to Younger Pediatric Patients, Including Newborns",https://www.fda.gov/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19
DB15718,,"Emergency Use Authorization (EUA) Letter of Authorization (January 24, 2022): Bamlanivimab and Etesevimab",https://www.fda.gov/media/145801/download
DB15718,,FDA: Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab and Etesevimab,https://www.fda.gov/media/145802/download
DB15719,,FDA Approved Drug Products: Blenrep Belantamab Mafodotin-blmf Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761158s006lbl.pdf
DB15719,,GSK: GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation,https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/
DB15720,,BASG Product Information: Zinkorotat-Pos (zinc orotate) tablet,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-22564&type=DOTC_FACH_INFO
DB15721,,TheScientist: Natural Killer Cell Therapies Catch Up to CAR T,https://www.the-scientist.com/bio-business/natural-killer-cell-therapies-catch-up-to-car-t-67332
DB15722,,Lifespan: CELULARITY INC. – CYNK-001,https://www.lifespan.io/road-maps/the-covid-19-roadmap/celularity-inc-cynk-001
DB15722,,Oncology Nursing News: Novel Cancer Agent To Be Investigated for Coronavirus Treatment,https://www.oncnursingnews.com/web-exclusives/novel-cancer-agent-to-be-investigated-for-coronavirus-treatment
DB15725,,TheScientist: Natural Killer Cell Therapies Catch Up to CAR T,https://www.the-scientist.com/bio-business/natural-killer-cell-therapies-catch-up-to-car-t-67332
DB15727,,TheScientist: Natural Killer Cell Therapies Catch Up to CAR T,https://www.the-scientist.com/bio-business/natural-killer-cell-therapies-catch-up-to-car-t-67332
DB15731,,Technologies,https://orbsentherapeutics.com/our-technologies/
DB15732,,Fate Therapeutics: FT516,https://fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft516/
DB15732,,Intrado GlobeNewswire: Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood,https://www.globenewswire.com/news-release/2020/01/13/1969545/0/en/Fate-Therapeutics-Announces-Expansion-of-FT516-Clinical-Investigation-and-Publication-of-Preclinical-Data-in-the-Journal-Blood.html
DB15732,,"American Association for Cancer Research (AACR) Publications: Abstract 3191: FT516, an off-the-shelf engineered NK cell therapeutic product for universal anti-tumor targeting strategy in combination with monoclonal antibodies",https://cancerres.aacrjournals.org/content/79/13_Supplement/3191
DB15736,,NCBI MedGen: Recombinant Human Angiotensin Converting Enzyme 2 APN01,https://www.ncbi.nlm.nih.gov/medgen/416051
DB15736,,Phase 2 Clinical Trial of APN01 for Treatment of COVID-19 Inititated,https://www.technologynetworks.com/drug-discovery/news/phase-2-clinical-trial-of-apn01-for-treatment-of-covid-19-inititated-332897
DB15739,,News Release,https://www.globenewswire.com/news-release/2018/12/18/1668688/0/en/Cynata-Completes-Clinical-Study-Report-for-Phase-1-Trial-of-CYP-001-in-GvHD.html;https://www.fujifilm.com/news/n190917.html
DB15740,,Company Article,https://www.jacionline.org/article/S0091-6749(17)32287-X/fulltext
DB15741,,NCBI MedGen: Recombinant Human Angiotensin Converting Enzyme 2 APN01,https://www.ncbi.nlm.nih.gov/medgen/416051
DB15742,,MultiStem,https://www.athersys.com/multistem-therapy/overview/default.aspx
DB15742,,Mechanisms of Action,https://www.athersys.com/multistem-therapy/mechanisms-of-action/default.aspx
DB15747,,Labome: Rabbit Antibody,https://www.labome.com/method/Rabbit-Antibody.html
DB15751,,Contract Pharma: 4D Pharma Begins Phase II COVID-19 Study,https://www.contractpharma.com/contents/view_breaking-news/2020-04-20/4d-pharma-begins-phase-ii-covid-19-study/
DB15751,,4D Pharma: Poster presentation on MRx-4DP0004,https://www.4dpharmaplc.com/download_file/force/216/311
DB15751,,TITCK Product Information: Biober-Zn (Bacterial Culture and Zinc Sulfate) Oral Suspension,https://titck.gov.tr/storage/kubKtAttachments/v5T4SXFeoRnrM.pdf
DB15752,,National Cancer Institute Drug Dictionary: recombinant super-compound interferon,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-super-compound-interferon
DB15752,,Google Patents: Recombinant super-compound interferon,https://patents.google.com/patent/US20100061961A1/en
DB15760,,INVIMA Product Information: TUGAL (prenatal multivitamin) oral capsule,http://web.sivicos.gov.co/registros/pdf/15529414_2018000965.pdf
DB15761,,Trifamox IBL Duo Product Information,https://translate.googleusercontent.com/translate_c?depth=1&hl=en&prev=search&pto=aue&rurl=translate.google.com&sl=es&sp=nmt4&u=https://www.bago.com.ar/vademecum/prospectos/trifamox_ibl_duo_comp_recubiertos.pdf&usg=ALkJrhhOZkbdeWGZxmMz37uFaucC_hz-lw
DB15762,,FDA Approved Drug Products: Enspryng (satralizumab-mwge) for subcutaneous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf
DB15762,,Health Canada Product Monograph: Enspryng (satralizumab) for subcutaneous injection,https://pdf.hres.ca/dpd_pm/00056524.PDF
DB15762,,Creative BioLabs: Satralizumab Data Sheet,https://www.creativebiolabs.net/pdf/TAB-032ML.pdf
DB15762,,"FDA News Release: FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord",https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-disease-affecting-optic-nerves-spinal-cord
DB15764,,TITCK Product Information: THERMOFLEX (benzyl nicotinate and etofenamate) topical cream,https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/Thermoflex%20101%20Krem%20-k%C3%BCb.pdf_68ef7b4c-4dea-43ea-a60f-af68b9225334.pdf
DB15766,,"FDA Approved Drug Products: ZYNYZ (retifanlimab-dlwr) injection, for intravenous use (March 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334s000lbl.pdf
DB15766,,EMA Withdrawal Assessment Report: Zynyz (retifanlimab),https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zynyz_en.pdf
DB15766,,US Food & Drug Administration: FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel
DB15766,,EMA: Withdrawal of application for the marketing authorisation of Zynyz (retifanlimab),https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-zynyz_en.pdf
DB15774,,AIFA Product Information: EDEVEXIN (beta-Escin) injection and tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000555_031219_FI.pdf&retry=0&sys=m0b1l3
DB15775,,Ivademecum: SYNOVULAR (algestone acetophenide and estradiol dienanthate) injection,https://co.ivademecum.com/medicamento-synovular-suave-lafrancol-cod-1661106D23C568D2
DB15777,,INVIMA Product Information: SCHERIPROCT (fluocortolone pivalate and lidocaine HCl) topical cream,http://web.sivicos.gov.co/registros/pdf/15354216_2016052484.pdf
DB15780,,TITCK Product Information: NEPHROMAG (mertiatide) intravenous injection kit,https://titck.gov.tr/storage/kubKtAttachments/e94FvjfcEhmyW.pdf
DB15781,,INVIMA Product Information: CIMAVAX (Hu-rhEGF-rP64k/Mont) intramuscular emulsion,http://www.med-informatica.net/STAR/AntologiaFarmacoterapeutica/RACOTUMOMAB_CimavaxEGF_RS_1396759_2016006539.pdf
DB15784,,TITCK Product Information: Luxnid (carmoterol hydrochloride/ciclesonide) powder for inhalation,https://titck.gov.tr/storage/kubKtAttachments/29c1ef1244305.pdf
DB15784,,TITCK Product Information: ROPITAL (carmoterol and tiotropium) powder for inhalation,https://titck.gov.tr/storage/kubKtAttachments/e598120864749.pdf
DB15785,,BASG: Algesal (Myrtecaine and Salicylic Acid) Topical Cream,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-21187&type=DOTC_FACH_INFO
DB15786,,"NPRA: Evelle (Ascorbic acid, Bilberry, Biotin, Equisetum arvense top, Marine collagen, soluble, Maritime pine extract, Selenium, Tomato, Vitamin E, Zinc) Oral Tablet",https://quest3plus.bpfk.gov.my/front-end/attachment/112189/pharma/207874/F8(1).pdf
DB15787,,Biopharma dive: AstraZeneca's coronavirus antibody drug cocktail begins human tests as rivals slip,https://www.biopharmadive.com/news/astrazeneca-covid-19-antibody-phase-1-trial/584071/
DB15787,,"Clinicaltrials.gov: Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults",https://clinicaltrials.gov/ct2/show/NCT04507256
DB15790,,"TITCK Product Information: AVMIGRAN (acetaminophen, caffeine, ergotamine tartrate, and mecloxamine citrate) tablet",https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK%20Onayl%C4%B1%20K%C3%9CB%20AVM%C4%B0GRAN.pdf_c1608b0b-ec6d-4500-95f1-2f916f04a67f.pdf
DB15793,,AIFA approved drug products: Oftalmil (Naphazoline / Zinc phenolsulfonate) ophthalmic solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000237_013108_RCP.pdf&retry=0&sys=m0b1l3
DB15794,,Malaysia NPRA: Solcoseryl eye gel,https://quest3plus.bpfk.gov.my/front-end/attachment/7292/pharma/234474/V_28407_20190418_165119_D4.pdf
DB15800,,VA-MENGOC-BC Information,https://www.finlay.edu.cu/en/vaccine/va-mengoc-bc-vaccine-antimeningococica-bc/
DB15804,,Nature Article on Covid-19 Vaccines,https://www.nature.com/articles/d41573-020-00073-5
DB15805,,Clover Biopharma Page,http://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=61
DB15806,,Sinovac Announcement,https://www.businesswire.com/news/home/20200506005601/en/Sinovac-Announces-Animal-Study-Results-Vaccine-COVID-19
DB15806,,Vaccine in Rheus Monkeys,https://www.sciencemag.org/news/2020/04/covid-19-vaccine-protects-monkeys-new-coronavirus-chinese-biotech-reports
DB15808,,News Report on Vaccine,https://www.caribbean-council.org/clinical-trials-underway-on-vaccine-to-boost-immunity-to-covid-19/
DB15809,,News Article on CIGB,https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1
DB15810,,Novavax Pipeline Page,https://novavax.com/our-pipeline
DB15810,,Novavex News Release,https://ir.novavax.com/news-releases/news-release-details/novavax-identifies-coronavirus-vaccine-candidate-accelerates
DB15810,,EMA Product Information: Nuvaxovid (recombinant SARS-CoV-2 spike protein and Matrix-M adjuvant) injection,https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_en.pdf
DB15810,,Health Canada News: Health Canada authorizes Novavax's Nuvaxovid COVID-19 vaccine,https://www.canada.ca/en/health-canada/news/2022/02/health-canada-authorizes-novavaxs-nuvaxovid-covid-19-vaccine.html
DB15810,,"Health Canada Product Monograph: NUVAXOVID [COVID-19 Vaccine (Recombinant protein, Adjuvanted)] intramuscular injection",https://covid-vaccine.canada.ca/info/pdf/nuvaxovid-pm-en.pdf
DB15810,,"FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted",https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted
DB15810,,"FDA Emergency Use Authorization: Novavax (covid-19 vaccine, adjuvanted) for intramuscular injection",https://www.fda.gov/media/159897/download
DB15810,,"Health Canada Approved Drug Products: NUVAXOVID COVID-19 Vaccine (Recombinant protein, Adjuvanted) Suspension for intramuscular injection",https://pdf.hres.ca/dpd_pm/00068588.PDF
DB15810,,Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID,https://www.biospace.com/article/releases/novavax-s-nuvaxovid-receives-full-marketing-authorization-in-the-eu-for-the-prevention-of-covid/?keywords=European+Commission+Approval
DB15810,,BioSpace: Novavax's Updated COVID-19 Vaccine Now Approved in the EU,https://www.biospace.com/article/releases/novavax-s-updated-covid-19-vaccine-now-approved-in-the-eu/?keywords=European+Commission+Approval
DB15810,,"Health Canada Approved Drug Products: Nuvaxovid XBB.1.5 (COVID-19 Vaccine, recombinant, adjuvanted) suspension for intramuscular injection",https://pdf.hres.ca/dpd_pm/00073582.PDF
DB15810,,"Health Canada Product Monograph: Nuvaxovid (COVID-19 vaccine, recombinant, adjuvanted) suspension for intramuscular injection (September 2024)",https://pdf.hres.ca/dpd_pm/00077115.PDF
DB15810,,"FDA Vaccines, Blood, & Biologics: Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) Authorized For Individuals 12 Years of Age and Older",https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19-vaccine-adjuvanted
DB15813,,Nature Article on Covid-19 Vaccines,https://www.nature.com/articles/d41573-020-00073-5
DB15815,,"AIFA Package Leaflet: CONFETTI LASSATIVI GIULIANI C.M. (Boldo leaf extract, frangula purshiana bark, sennoside) oral tablets",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000051_011899_RCP.pdf&retry=0&sys=m0b1l3
DB15819,,AIFA Product Information: K FLEBO (potassium aspartate) solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002278_019311_FI.pdf&retry=0&sys=m0b1l3
DB15821,,AIFA: Ultralan (Fluocortolone) Topical Cream,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004974_020910_FI.pdf&retry=0&sys=m0b1l3
DB15821,,"TITCK Product Information: ULTRAPROCT (cinchocaine, fluocortolone pivalate, and fluocortolone caproate) rectal",https://titck.gov.tr/storage/Archive/2020/kubKtAttachments/yaynlanacakkbultraproctmerhem_5b07909b-8192-4564-8754-e752ff441072.pdf
DB15822,,FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf
DB15822,,Pralsetinib product sheet,https://file.medchemexpress.com/batch_PDF/HY-112301/Pralsetinib-DataSheet-MedChemExpress.pdf
DB15822,,Roche News Release: Gavreto for the treatment of NSCLC,https://www.globenewswire.com/news-release/2021/11/19/2338282/0/en/European-Commission-approves-Roche-s-Gavreto-pralsetinib-for-the-treatment-of-adults-with-RET-fusion-positive-advanced-non-small-cell-lung-cancer.html
DB15822,,"FDA Approved Drug Products: GAVRETO (pralsetinib) capsules, for oral use (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s011lbl.pdf
DB15822,,"FDA Approved Drug Products: GAVRETO (pralsetinib) capsules, for oral use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf
DB15824,,TITCK Product Information: GRANULOFER (ferrimannitol ovalbumin) oral powder,https://titck.gov.tr/storage/kubKtAttachments/a1d5577671922.pdf
DB15825,,TITCK Product Information: KOMPENSAN (Dihydroxyaluminum sodium carbonate) oral tablet,https://titck.gov.tr/storage/kubKtAttachments/26f4105b26668.pdf
DB15826,,AIFA Product Information: VENORUTON (oxerutins),https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001561_017076_FI.pdf&retry=0&sys=m0b1l3
DB15830,,AIFA: Ruscoroid (Ruscogenin / Tetracaine) cutaneous cream,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003337_025825_FI.pdf&retry=0&sys=m0b1l3
DB15832,,"AIFA Package Leaflet: ALFA KAPPA (ketoisoleucine, ketoleucine, ketophenylalanine, ketovaline, hydroxy-methionine, L-Lysine, threonine, histidine, tyrosine) oral tablets",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002829_026363_RCP.pdf&retry=0&sys=m0b1l3
DB15835,,TITCK: Prenacid (Desonide Sodium Phosphate) Ophthalmic Drops,https://titck.gov.tr/storage/Archive/2021/kubKtAttachments/PrenacidKT_2061d2ea-949a-4157-adf9-e6808e7ae9d7.pdf
DB15836,,"TITCK Product Information: KATALJİN BUHARLAŞAN MERHEM (camphor, cedar leaf oil, coconut oil, eucalyptol, levomenthol, timolol, turpentine) topical ointment",https://titck.gov.tr/storage/kubKtAttachments/1ad5942938556.pdf
DB15840,,NPRA Product Information: Pinetarsol (pine tar) topical,https://quest3plus.bpfk.gov.my/front-end/attachment/36439/pharma/230718/V_10484_20170928_040717_D4.pdf
DB15842,,"TITCK Product Information: NEOFLEKS IZOPLEN-M (D-glucose monohydrate, dipotassium phosphate, potassium chloride, sodium acetate, sodium chloride, sodium metabisulfite) injection",https://pdf.ilacprospektusu.com/7704-neofleks-izoplen-m-yuzde-5-dekstrozlu-dengeli-elektrolit-iceren-infuzyon-icin-cozelti-kub.pdf
DB15844,,CureVac & Covid-19,https://www.curevac.com/en/covid-19/
DB15844,,Smart Patients,https://www.smartpatients.com/trials/NCT04449276
DB15844,,Regulatory News,https://www.curevac.com/en/2020/06/17/curevac-receives-regulatory-approval-from-german-and-belgian-authorities-to-initiate-phase-1-clinical-trial-of-its-sars-cov-2-vaccine-candidate/
DB15846,,Information on Covax-19,https://www.firstwordpharma.com/node/1731601?tsid=17
DB15846,,Vaxine announcement,https://www.genengnews.com/covid-19-candidates/vaxine-and-medytox-covax-19/
DB15847,,Vaccine News,https://www.biorxiv.org/content/10.1101/2020.09.09.285445v1.full
DB15847,,Deadline News Article,https://www.bioworld.com/articles/496390-indian-deadline-for-covid-19-vaccine-raises-doubts
DB15848,,Info on Gam Covid Vac,https://www.bioworld.com/keywords/23867-gam-covid-vac-lyo
DB15849,,UQ Covid Vaccine Info,https://www.precisionvaccinations.com/vaccines/uq-covid-19-vaccine
DB15849,,UQ Covid Preclinical data,https://www.pharmaceutical-technology.com/news/uq-covid-vaccine-preclinical-data/
DB15849,,Phase 1,https://www.technologynetworks.com/biopharma/news/phase-1-clinical-trial-of-university-of-queensland-covid-19-vaccine-begins-337387
DB15850,,News Story,http://www.ohri.ca/newsroom/story/view/1256?l=en
DB15850,,News for IMM101,https://www.cancer.ca/en/about-us/for-media/media-releases/national/2020/cctg-covid-trial/?region=on
DB15852,,Medicago,https://www.medicago.com/en/pipeline/
DB15852,,Collaboration News,https://www.medicago.com/en/newsroom/dynavax-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-vaccine-candidate/
DB15852,,Medicago Vaccine,https://www.evaluate.com/vantage/articles/news/snippets/glaxo-signs-medicago-its-third-covid-19-vaccine
DB15852,,Announced Clinical Trial,https://www.pmlive.com/pharma_news/medicago_doses_first_patients_with_plant-derived_covid-19_vaccine_1344898
DB15853,,Trial Announced,http://biotech-spain.com/en/articles/archivel-s-ruti-vaccine-begins-clinical-trial-to-increase-the-immunity-of-healthcare-professionals-exposed-to-covid-19/
DB15853,,News for Covid-19,https://www.web24.news/u/2020/09/the-spanish-ruti-vaccine-for-tuberculosis-will-be-tested-to-prevent-covid-19.html
DB15854,,News Announcement,https://www.globenewswire.com/news-release/2020/07/23/2066551/0/en/Dynavax-and-Medigen-Announce-Collaboration-to-Develop-a-Novel-Adjuvanted-COVID-19-Vaccine-Candidate.html
DB15855,,Phase 1 Announcement,https://news.cgtn.com/news/2020-06-29/China-s-first-COVID-19-mRNA-vaccine-starts-phase-I-clinical-trial-RILRptOyLS/index.html
DB15855,,mRNA vaccine approved for clinical trials,https://news.cgtn.com/news/2020-06-26/China-s-first-COVID-19-mRNA-vaccine-approved-for-clinical-trials-RDTXX0jVJK/index.html
DB15856,,AnGes News,https://www.anges.co.jp/pdf_news/public/IGiJ94QWoV9U7EIYJybHY6SNv3BxVXRN.pdf
DB15856,,Nature Article on Covid-19 Vaccines,https://media.nature.com/original/magazine-assets/d41573-020-00151-8/18354090
DB15857,,Precision Vaccine,https://www.precisionvaccinations.com/vaccines/ad26cov2-s-vaccine
DB15857,,Johnson & Johnson Announcement,https://www.newswire.ca/news-releases/johnson-amp-johnson-announces-agreement-with-u-s-government-for-100-million-doses-of-investigational-covid-19-vaccine-814210456.html
DB15857,,Health Canada Product Monograph: Janssen COVID-19 Vaccine,https://covid-vaccine.canada.ca/info/pdf/janssen-covid-19-vaccine-pm-en.pdf
DB15857,,Health Canada Public Advisory: Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines,https://recalls-rappels.canada.ca/en/alert-recall/health-canada-updating-labels-janssen-and-vaxzevria-astrazeneca-covid-19-vaccines
DB15857,,EMA COVID-19 Vaccine Safety Update: Janssen COVID-19 Vaccine (Dec 9/21),https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-9-december-2021_en.pdf
DB15857,,FDA: Janssen COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers,https://www.fda.gov/media/146304/download
DB15858,,KBP Testing Vaccine in Animals,https://www.owensborotimes.com/news/2020/04/kbp-begins-testing-covid-19-vaccine-candidate-on-animals/
DB15859,,Open Forum Infectious Diseases on NasoVAX,https://academic.oup.com/ofid/article/5/suppl_1/S68/5206100
DB15859,,AltImmune NasoVAX,https://altimmune.com/nasovax/
DB15859,,News on NasoVAX,https://www.globenewswire.com/news-release/2019/03/19/1756852/0/en/Altimmune-Announces-Positive-Results-from-NasoVAX-Extension-Study.html
DB15860,,AIFA Product Information: TAMARINE (cassia fistula fruit and senna leaf) oral,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000040_021528_FI.pdf&retry=0&sys=m0b1l3
DB15861,,AIFA Product Information: KADIUR (Buthiazide and Potassium canrenoate) tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003582_025166_FI.pdf&retry=0&sys=m0b1l3
DB15864,,WHO Oral Polio Vaccine,https://www.who.int/biologicals/areas/vaccines/polio/opv/en/
DB15865,,National Cancer Institute: IgM-enriched Immunoglobulins (CUI CL563000),https://ncim.nci.nih.gov/ncimbrowser/ajax?action=addtocart&code=CL563000
DB15866,,CISION PR Newswire: Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells,https://www.prnewswire.com/news-releases/johns-hopkins-reports-promising-clinical-data-in-covid-19-ards-treated-with-cellenkos-cord-blood-t-regulatory-cells-301088812.html
DB15867,,U.S. National Library of Medicine Clinical Trials: Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 (SENTAD-COVID),https://clinicaltrials.gov/ct2/show/NCT04473170
DB15870,,Probionase Therapies: PROBIORINSE™ NASAL AND SINUS IRRIGATION SOLUTION WITH PROBIOTICS,https://probiorinse.com/products/probiorinse-probiotic-safest-nasal-irrigation
DB15871,,"National Center for Biotechnology Information: Embryology, Amniotic Fluid",https://www.ncbi.nlm.nih.gov/books/NBK541089/
DB15871,,"University of Utah Health: AMNIOTIC FLUID COULD REDUCE ACUTE SYMPTOMS, LONG-TERM RISKS OF COVID-19",https://uofuhealth.utah.edu/newsroom/news/2020/07/covid-amniotic-fluid.php
DB15872,,AIFA Product Information: ESTO (L-alpha-Glycerophosphorylethanolamine) tablet and solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000219_028062_FI.pdf&retry=0&sys=m0b1l3
DB15873,,FDA Approved Drug Products: Detectnet (copper Cu 64 dotatate injection) for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf
DB15873,,RadiologyInfo.org: Positron Emission Tomography - Computed Tomography (PET/CT),"https://www.radiologyinfo.org/en/info.cfm?pg=pet#:~:text=Positron%20emission%20tomography%20(PET)%20uses,before%20other%20imaging%20tests%20can."
DB15874,,EMA Summary of Product Characteristics: Replagal Agalsidase Alfa Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/replagal-epar-product-information_en.pdf
DB15874,,EMA: Replagal Authorization Details,https://www.ema.europa.eu/en/medicines/human/EPAR/replagal#authorisation-details-section
DB15875,,AIFA Product Information: Spasmex (phloroglucinol or phloroglucinol/trimethoxybenzene),https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008057_020851_RCP.pdf&retry=0&sys=m0b1l3
DB15877,,AIFA Product Information: FLUIMUCIL GOLA (cetyltrimethylammonium naproxenate) oral,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007158_032328_FI.pdf&retry=0&sys=m0b1l3
DB15879,,AIFA Product Information: EMAGEL (polygeline) injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004906_020310_FI.pdf&retry=0&sys=m0b1l3
DB15880,,AIFA Product Information: MISTRAL (dermatan sulfate) injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003582_029006_RCP.pdf&retry=0&sys=m0b1l3
DB15882,,AIFA Product Information: PENSULVIT SIFI (sulfamethylthiazole and tetracycline) ophthalmic ointment,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001024_002177_FI.pdf&retry=0&sys=m0b1l3
DB15883,,"AIFA Product Information: SINARTROL (piroxicam cinnamate) tablet, suppository, and cream",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000246_026396_FI.pdf&retry=0&sys=m0b1l3
DB15885,,BASG Product Information: LiMAxetin (methacetin methoxy-C-13) injection,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=138125&type=DOTC_FACH_INFO
DB15886,,"BASG: Hädensa (Carvasept, Ichthammol, and Levomenthol) Topical Ointment",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=2465&type=DOTC_FACH_INFO
DB15887,,BASG Product Information: Fluorochol ((18F)Fluorocholine) injection,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=438039&type=DOTC_FACH_INFO
DB15888,,"AIFA Product Information: SPASMODIL (pipethanate ethobromide) tablet, injection, and suppository",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000299_028580_FI.pdf&retry=0&sys=m0b1l3
DB15889,,"AIFA: Tamarine (Cassia Fistula, Senna) Oral Gel",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001136_021528_RCP.pdf&retry=0&sys=m0b1l3
DB15890,,U.S. National Library of Medicine Clinical Trials: RAPA-501-Allo Off-the-Shelf Therapy of COVID-19,https://clinicaltrials.gov/ct2/show/NCT04482699
DB15891,,Genexine Vaccine News,https://www.genengnews.com/covid-19-candidates/genexine-gx-19/
DB15892,,Phase II Information,https://www.indiatvnews.com/business/news-zycov-d-coronavirus-vaccine-zydus-cadila-phase-ii-clinical-trials-covid-19-vaccine-august-6-639700
DB15892,,Pipeline Review for Zycov-D,https://pipelinereview.com/index.php/2020080575496/Vaccines/Zydus-Cadila-Announces-Completion-of-Dosing-in-Phase-I-Clinical-Trial-of-ZyCoV-D.html
DB15895,,Xenothera Innovative Therapy,https://www.business-solutions-atlantic-france.com/news/xav-19-the-biotech-xenothera-is-working-on-an-innovative-therapy-against-coronavirus/
DB15895,,News on XAV-19,https://www.endcoronadisease.com/xav-19-a-new-treatment-route-for-covid-19-patients/
DB15895,,LFB Announcement,https://www.groupe-lfb.com/en/news/lfb-signs-agreement-with-xenothera-to-manufacture-first-clinical-batch-of-candidate-xav-19-for-the-treatment-of-coronavirus/
DB15897,,Lilly Investors: Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs,https://investor.lilly.com/news-releases/news-release-details/lilly-provides-comprehensive-update-progress-sars-cov-2
DB15897,,Junshi Biosciences: Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of JS016,http://junshipharma.com/en/News.html
DB15897,,"FDA Press Announcements: FDA Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-Exposure Prevention of COVID-19 to Younger Pediatric Patients, Including Newborns",https://www.fda.gov/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19
DB15897,,"Emergency Use Authorization (EUA) Letter of Authorization (January 24, 2022): Bamlanivimab and Etesevimab",https://www.fda.gov/media/145801/download
DB15897,,FDA: Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab and Etesevimab,https://www.fda.gov/media/145802/download
DB15898,,"FDA Approved Drug Products: INMAZEB (atoltivimab, maftivimab, and odesivimab-ebgn) injection",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf
DB15899,,"FDA Approved Drug Products: INMAZEB (atoltivimab, maftivimab, and odesivimab-ebgn) injection",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf
DB15900,,"FDA Approved Drug Products: INMAZEB (atoltivimab, maftivimab, and odesivimab-ebgn) injection",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf
DB15903,,"AIFA: Belara (Chlormadinone Acetate, Ethinylestradiol) Oral Tablet",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003130_036875_RCP.pdf&retry=0&sys=m0b1l3
DB15903,,Code of Federal Regulations 216.24: Drug products withdrawn or removed from the market for reasons of safety or effectiveness.,https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
DB15903,,FDA Federal Register: List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,https://www.govinfo.gov/content/pkg/FR-1998-10-08/html/98-26923.htm
DB15906,,"BASG: iCOmas (Acetylene, Carbon Monoxide, Methane) Inhalation Gas",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=138377&type=DOTC_FACH_INFO
DB15907,,"AIFA: Edeven CM (Escin, Diethylamine Salicylate) Topical Gel",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000555_037028_RCP.pdf&retry=0&sys=m0b1l3
DB15908,,"NPRA: Actal Plus (Alexitol Sodium, Magnesium Hydroxide, Simethicone) Oral Tablet",https://quest3plus.bpfk.gov.my/front-end/attachment/7292/pharma/68090/V_9229_20170821_093217_D4.pdf
DB15912,,FDA Thailand: DAKIN S 0.5% (calcium hypochlorite) solution,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022340062111C
DB15912,,"NPRA: Infecco Eusol Solution A and B Antiseptic (Calcium Hypochlorite, Acetic Acid) Topical Solution",https://quest3plus.bpfk.gov.my/front-end/attachment/517/pharma/512122/V_37495_20200129_105452_D4.pdf
DB15916,,"FDA Thailand: Rowatinex (Anethole, Borneol, Camphene, Eucalyptol, Fenchone, Alpha-Pinene, Beta-Pinene) Capsule",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022300012311C
DB15917,,"FDA Thailand: Rowatinex (Anethole, Borneol, Camphene, Eucalyptol, Fenchone, Alpha-Pinene, Beta-Pinene) Capsule",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022300012311C
DB15918,,"FDA Thailand: Rowatinex (Anethole, Borneol, Camphene, Eucalyptol, Fenchone, Alpha-Pinene, Beta-Pinene) Capsule",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022300012311C
DB15919,,FDA Thailand: DIQUAS (diquafosol) ophthalmic solution / drops,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1012580006011C
DB15920,,"FDA Thailand: Rowachol (Borneol, Camphene, Eucalyptol, Levomenthol, Menthone, Alpha-Pinene, and Beta-Pinene) Oral Capsule",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022290033411C
DB15921,,NPRA: Hijuven (Tocopheryl Nicotinate) Oral Capsule,https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/231793/V_35195_20191008_102916_D4.pdf
DB15922,,"NPRA: Tiger Balm Soft (Cajuput Oil, Camphor, Menthol, Clove Oil) Topical Ointment",https://quest3plus.bpfk.gov.my/front-end/attachment/990/pharma/206570/V_21218_20180828_041116_D4.pdf
DB15926,,"FDA Thailand: AMMONIUM CARBONATE AND GLYCYRRHIZA MIXTURE, oral solution",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022550005811C
DB15930,,FDA Thailand: HAFIF (carbaryl) shampoo,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022621511711C
DB15935,,FDA News Release: FDA Approves First Drug to Treat Rare Metabolic Disorder,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder
DB15935,,Alylam Pharmaceuticals: Lumasiran Clinical Development Program,https://www.alnylam.com/wp-content/uploads/pdfs/Lumasiran-ILLUMINATE-Fact-Sheet.pdf
DB15935,,EMA Summary of Product Characteristics: Oxlumo (Lumasiran) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/oxlumo-epar-product-information_en.pdf
DB15935,,EMA Assessment Report: Oxlumo (Lumasiran) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/assessment-report/oxlumo-epar-public-assessment-report_en.pdf
DB15935,,"FDA Approved Drug Products: OXLUMO (lumasiran) injection, for subcutaneous use (October 2022)",https://www.alnylam.com/sites/default/files/pdfs/OXLUMO-Prescribing-Information.pdf
DB15940,,FDA Letter: EUA for Regeneron's casirivimab and imdevimab,https://www.fda.gov/media/143891/download
DB15940,,FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
DB15940,,FDA Fact Sheet: Regeneron EUA HCP Fact Sheet,https://www.fda.gov/media/145611/download
DB15940,,Regeneron: Casirivimab and imdevimab,https://www.regeneron.com/casirivimab-imdevimab
DB15940,,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",https://clinicaltrials.gov/ct2/show/NCT04426695?term=REGN10933&draw=2&rank=2
DB15940,,EMA COVID-19 News: EMA recommends authorisation of two monoclonal antibody medicines,https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines
DB15940,,EMA Summary of Product Characteristics: RONAPREVE (casirivimab and imdevimab) intravenous or subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/ronapreve-epar-product-information_en.pdf
DB15941,,Regeneron: Casirivimab and imdevimab,https://www.regeneron.com/casirivimab-imdevimab
DB15941,,FDA Letter: EUA for Regeneron's casirivimab and imdevimab,https://www.fda.gov/media/143891/download
DB15941,,FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
DB15941,,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",https://clinicaltrials.gov/ct2/show/NCT04426695?term=REGN10933&draw=2&rank=2
DB15941,,EMA Summary of Product Characteristics: RONAPREVE (casirivimab and imdevimab) intravenous or subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/ronapreve-epar-product-information_en.pdf
DB15941,,EMA COVID-19 News: EMA recommends authorisation of two monoclonal antibody medicines,https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines
DB15941,,FDA Fact Sheet: Regeneron EUA HCP Fact Sheet,https://www.fda.gov/media/145611/download
DB15945,,AIFA: Clarvisan PVA (Pirenoxine) Ophthalmic Solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000526_023912_FI.pdf&retry=0&sys=m0b1l3
DB15946,,PIROCTONE: Inxight Drugs,https://drugs.ncats.io/drug/R49EFA73Q7
DB15947,,"FDA Thailand: Genalgan (Fenpiverinium, Pitofenone) Oral Tablet",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022580009711C
DB15955,,FDA Thailand: SELBEX (teprenone) oral capsule,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1022330024211C
DB15956,,"AIFA: Calyptol (Eucalyptol, Terpineol) Inhalant",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008055_005583_FI.pdf&retry=0&sys=m0b1l3
DB15958,,"BASG: Arca-Be (Cyanocobalamin, Pyridoxine, Thiamine) Oral Tablet",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-21190&type=DOTC_FACH_INFO
DB15963,,"FDA Thailand: Lipochol (Ascorbic Acid, Cyanocobalamin, Inositol, Nicotinamide, Orotic Acid, Pantothenic Acid, Pyridoxine HCl, Racemethionine, Riboflavin, Thiamine Mononitrate, Thioctamide) Oral Tablet",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022480005511C
DB15965,,FDA Approved Drug Products: Danyelza (naxitamab-gqgk) for intravenous infusion,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf
DB15965,,FDA Approved Drug Products: Unituxin (dinutuximab) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125516s025lbl.pdf
DB15965,,FDA Drug Approvals and Databases: FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow
DB15966,,Health Canada Approved Drug Products: Flumist (Influenza virus type B) Nasal Spray,https://pdf.hres.ca/dpd_pm/00025175.PDF
DB15968,,NPRA: Coliopan (Butropium) Oral Tablet,https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/210295/V_36481_20191101_110605_D4.pdf
DB15969,,AIFA: Adona (Carbazochrome Sulfonic Acid) Oral Tablet and Powder for Solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000143_012943_FI.pdf&retry=0&sys=m0b1l3
DB15975,,"BASG: Rokiprim (Sulfametrol, Trimethoprim) Intravenous Injection",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=16591&type=DOTC_FACH_INFO
DB15980,,AIFA: Dromos (Levocarnitine Propionate) Intravenous Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004375_028776_FI.pdf&retry=0&sys=m0b1l3
DB15982,,Drugs.com: FDA Approves Orladeyo,https://www.drugs.com/newdrugs/fda-approves-orladeyo-berotralstat-first-oral-once-daily-therapy-prevent-attacks-hereditary-5399.html
DB15982,,"FDA Approved Drug Products: ORLADEYO (berotralstat) capsules, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf
DB15982,,"GlobeNewswire News Release: BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks",https://www.globenewswire.com/news-release/2022/06/06/2456568/29446/en/BioCryst-Announces-Health-Canada-has-Authorized-ORLADEYO-berotralstat-the-Only-Oral-Treatment-for-the-Prevention-of-Hereditary-Angioedema-Attacks.html
DB15982,,EMA Approved Drug Products: Orladeyo (berotralstat) oral capsules,https://www.ema.europa.eu/en/documents/product-information/orladeyo-epar-product-information_en.pdf
DB15982,,Health Canada Approved Drug Products: ORLADEYO (Berotralstat) oral capsules,https://pdf.hres.ca/dpd_pm/00066149.PDF
DB15983,,"AIFA: Coryin (Menglytate, Sodium Ascorbate) Transmucosal Tablet",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000143_012377_FI.pdf&retry=0&sys=m0b1l3
DB15984,,"AIFA: Trofodermin (Clostebol Acetate, Neomycin Sulfate) Topical Cream",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000143_020942_FI.pdf&retry=0&sys=m0b1l3
DB15985,,AIFA: Gamibetal (Gamma-amino-beta-hydroxybutyric Acid) Oral Tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000143_018866_FI.pdf&retry=0&sys=m0b1l3
DB15988,,"BASG: Coldargan (Ephedrine levulinate, Silver proteinate) Nasal, Oral Solution",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=11378&type=DOTC_FACH_INFO
DB15990,,BASG: Glavamin (Amino Acids) Intravenous Solution,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-21374&type=DOTC_FACH_INFO
DB15991,,BASG: Glavamin (Amino Acids) Intravenous Solution,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-21374&type=DOTC_FACH_INFO
DB15993,,BASG: Sangenor (Arginine Aspartate) Oral Solution,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-14654&type=DOTC_FACH_INFO
DB15994,,"BASG: iCOmas (Acetylene, Carbon Monoxide, Methane) Inhalation Gas",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=138377&type=DOTC_FACH_INFO
DB15998,,"BASG: Trommcardin (Magnesium Aspartate, Potassium Hydrogen DL-Aspartate) Oral Tablet",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=15016&type=DOTC_FACH_INFO
DB15998,,"BASG: Trommcardin (Magnesium Aspartate, Potassium Hydrogen DL-Aspartate) Intravenous Injection",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=16187&type=DOTC_FACH_INFO
DB15999,,BASG: Scheriproct (Prednisolone Caproate) Topical Ointment,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=10260&type=DOTC_FACH_INFO
DB15999,,BASG: Scheriproct (Prednisolone Caproate) Rectal Suppository,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=10261&type=DOTC_FACH_INFO
DB16000,,"BASG: Rheumesser 3 ml - Ampullen (Cyanocobalamin, Dexamethason, Kebuzone, Lidocaine, Salicylamide O-acetic acid) Intramuscular Injection",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=17397&type=DOTC_FACH_INFO
DB16001,,"FDA Thailand: Test - Comp 250 (Testosterone Decanoate, Testosterone Isocaproate, Testosterone Phenylpropionate, Testosterone Propionate) Injection",https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022610001111C
DB16002,,"FDA Thailand: Test - Comp 250 (Testosterone Decanoate, Testosterone Isocaproate, Testosterone Phenylpropionate, Testosterone Propionate) Injection",https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022610001111C
DB16003,,"FDA Thailand: Test - Comp 250 (Testosterone Decanoate, Testosterone Isocaproate, Testosterone Phenylpropionate, Testosterone Propionate) Injection",https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022610001111C
DB16004,,BASG: Teceos - Trockenstechampullen (Butedronic Acid) Intravenous Powder for Solution,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=4-00026&type=DOTC_FACH_INFO
DB16005,,"FDA Thailand: Ezon-T (Tolnaftate, Triacetin) Topical Ointment",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022280097311C
DB16005,,"FDA Thailand: Ezon-T (Tolnaftate, Triacetin) Topical Solution",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022280100011C
DB16007,,Summary of Product Characteristics: ADYNOVI (rurioctocog alfa pegol) intravenous injection,https://www.ema.europa.eu/en/documents/product-information/adynovi-epar-product-information_en.pdf
DB16007,,European Medicines Agency Medicines: Adynovi (rurioctocog alfa pegol),https://www.ema.europa.eu/en/medicines/human/EPAR/adynovi
DB16007,,"European Medicines Agency Assessment Report: ADYNOVI, INN (rurioctocog alfa pegol)",https://www.ema.europa.eu/en/documents/assessment-report/adynovi-epar-public-assessment-report_en.pdf
DB16019,,"FDA Approved Drug Products: Gallium Ga 68 PSMA-11 Injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212643s000lbl.pdf
DB16019,,FDA Press Announcements: FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer,https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer
DB16019,,FDA Approved Drug Products: Illuccix ((kit for the preparation of gallium Ga 68 gozetotide) for intravenous injection,https://static1.squarespace.com/static/61b38a4425299d61d409b695/t/61c391a85e61766415c28145/1640206783403/illuccix-prescribing-information.pdf
DB16019,,EMA Summary of Opinion: Locametz (gozetotide),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/locametz
DB16019,,EMA Approved Drug Products: Locametz (gozetotide) Intravenous Injection,https://www.ema.europa.eu/en/documents/product-information/locametz-epar-product-information_en.pdf
DB16019,,EMA Medicines: Locametz,https://www.ema.europa.eu/en/medicines/human/EPAR/locametz
DB16019,,"FDA Approved Drug Products: JILLUCCIX ® (kit for the preparation of gallium Ga 68 gozetotide injection), for intravenous use (March 2023)",https://illuccix.com/wp-content/uploads/2023/03/illuccix-prescribing-information.pdf
DB16019,,"Health Canada Approved Drug Proucts: ILLUCCIXTM Powder for Solution, 25 microgram PSMA-11 per vial Kit for the preparation of gallium (68Ga) PSMA-11 for intravenous injection",https://pdf.hres.ca/dpd_pm/00067755.PDF
DB16020,,"AFIA: Proctolyn (Fluocinolone Acetonide, Ketocain) Rectal Cream and Suppository",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000107_021925_FI.pdf&retry=0&sys=m0b1l3
DB16021,,AIFA Product Information: LEVOSULPIRIDE FERRER (levosulpiride) oral,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002179_045300_RCP.pdf&retry=0&sys=m0b1l3
DB16022,,"AIFA Product Information: NTR (benzalkonium, phenylephrine, and thenyldiamine) spray and solution",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007046_027077_RCP.pdf&retry=0&sys=m0b1l3
DB16023,,"AIFA Package Leaflet: NEO CROMATON BICOMPLESSO (vitamin B complex mixture) powder, for oral solution",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000542_023864_RCP.pdf&retry=0&sys=m0b1l3
DB16024,,FDA Thailand: Diagnogreen (Indocyanine Green) Injection,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1092560000411C
DB16098,,FDA Approved Drug Products: Qulipta (atogepant) tablets for oral use,https://www.rxabbvie.com/pdf/qulipta_pi.pdf
DB16098,,"PR Newswire: FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine",https://www.prnewswire.com/news-releases/fda-approves-qulipta-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-the-preventive-treatment-of-migraine-301387297.html
DB16098,,Cision Newswire: QULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults,https://www.newswire.ca/news-releases/qulipta-tm-now-approved-by-health-canada-for-the-preventive-treatment-of-episodic-migraine-in-adults-856500946.html
DB16098,,Health Canada Product Monograph: Qulipta (atogepant) tablets for oral use,https://pdf.hres.ca/dpd_pm/00068864.PDF
DB16098,,"FDA Approved Drug Products: QULIPTA (atogepant) tablets, for oral use (April 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215206s004lbl.pdf
DB16098,,"EMA Approved Drug Products: AQULIPTA (atogepant) tablets, for oral use",https://www.ema.europa.eu/en/documents/product-information/aquipta-epar-product-information_en.pdf
DB16098,,AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults,https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-aquipta-atogepant-for-the-preventive-treatment-of-migraine-in-adults-301903027.html
DB16099,,"FDA Approved Drug Products: NEXVIAZYME (avalglucosidase alfa-ngpt) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761194s000lbl.pdf
DB16099,,FDA Press Announcements: FDA Approves New Treatment for Pompe Disease,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pompe-disease
DB16099,,KEGG DRUG: Avalglucosidase alfa,https://www.genome.jp/entry/D11744
DB16099,,Newswire.ca: Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for patients with late-onset Pompe disease (acid α-glucosidase deficiency),https://www.newswire.ca/news-releases/nexviazyme-tm-avalglucosidase-alfa-for-injection-is-now-approved-in-canada-for-patients-with-late-onset-pompe-disease-acid-a-glucosidase-deficiency--892569271.html
DB16099,,Health Canada Approved Drug Products: NEXVIAZYME (avalglucosidase alfa) for intravenous injection,https://pdf.hres.ca/dpd_pm/00063565.PDF
DB16099,,EMA Approved Drug Products: Nexviadyme (avalglucosidase alfa) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/nexviadyme-epar-product-information_en.pdf
DB16128,,"FDA Approved Drug Products: PIASKY (crovalimab-akkz) injection, for intravenous or subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761388s000lbl.pdf
DB16128,,OncLive: FDA Approves Crovalimab for Paroxysmal Nocturnal Hemoglobinuria,https://www.onclive.com/view/fda-approves-crovalimab-for-paroxysmal-nocturnal-hemoglobinuria
DB16133,,EMA Approved Drug Products: Anzupgo (delgocitinib) Topical Cream,https://www.ema.europa.eu/en/documents/product-information/anzupgo-epar-product-information_en.pdf
DB16133,,Business Wire: European Commission Approves LEO Pharma’s Anzupgo® (delgocitinib) Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE),https://www.businesswire.com/news/home/20240923751725/en/European-Commission-Approves-LEO-Pharma%E2%80%99s-Anzupgo%C2%AE-delgocitinib-Cream-for-Adults-with-Moderate-to-Severe-Chronic-Hand-Eczema-CHE
DB16157,,"FDA Approved Drug Products: OHTUVAYRE (ensifentrine) inhalation suspension, for oral inhalation use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217389s000lbl.pdf
DB16157,,Verona Pharma: Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine),https://www.veronapharma.com/news/verona-pharma-announces-us-fda-approval-of-ohtuvayre-ensifentrine/
DB16159,,NPRA: Locoa (Esflurbiprofen) Transdermal Patch,https://quest3plus.bpfk.gov.my/front-end/attachment/293/pharma/521411/V_48409_20201110_134931_D4.pdf
DB16165,,FDA Approved Drug Products: Kerendia (Finerenone) Oral Tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf
DB16165,,EMA Approved Drug Products: Kerendia (finerenone) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_en.pdf
DB16165,,European Medicines Agency Medicines: Kerendia (finerenone),https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia
DB16183,,"AIFA: Tonogen (Cyanocobalamin, Hematoporphyrin Dihydrochloride) Oral Powder for Solution",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002301_021229_FI.pdf&retry=0&sys=m0b1l3
DB16199,,"FDA Approved Drug Products: WAINUA™ (eplontersen) injection, for subcutaneous use",https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/d9f47b27-50ff-4cc5-807e-3f69664872e2/d9f47b27-50ff-4cc5-807e-3f69664872e2_viewable_rendition__v.pdf
DB16199,,WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis,https://www.biospace.com/article/releases/wainua-eplontersen-granted-regulatory-approval-in-the-u-s-for-the-treatment-of-adults-with-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis/?s=74
DB16200,,"FDA Approved Drug Products: FABHALTA® (iptacopan) capsules, for oral use",https://www.novartis.com/us-en/sites/novartis_us/files/fabhalta.pdf
DB16200,,Novartis Wins FDA Approval for Oral Monotherapy for Rare Blood Disorder,https://www.biospace.com/article/novartis-wins-first-fda-approval-for-oral-monotherapy-for-rare-blood-disorder-/
DB16216,,"FDA Approved Drug Products: LAZCLUZE (lazertinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf
DB16216,,FDA: FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer
DB16217,,"FDA Approved Drug Products: JOENJA (leniolisib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217759s000lbl.pdf
DB16217,,FDA News: FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome,https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-activated-phosphoinositide-3-kinase-delta-syndrome
DB16220,,FDA Approved Drug Products: Skytrofa (Lonapegsomatropin-tcgd) Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177lbl.pdf
DB16220,,Clinical Trials: NCT02781727,https://clinicaltrials.gov/ct2/show/NCT02781727
DB16220,,"FDA Approved Drug Products: Norditropin (somatropin) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021148s049lbl.pdf
DB16220,,"StatPearls: Physiology, Growth Hormone",https://www.ncbi.nlm.nih.gov/books/NBK482141/
DB16220,,BioSpace News: Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone DeficiencyTransCon hGH,https://www.biospace.com/article/releases/ascendis-pharma-a-s-receives-european-approval-for-transcon-hgh-for-pediatric-growth-hormone-deficiencytranscon-hgh-/?keywords=European+Commission+Approval
DB16220,,Summary of Product Characteristics: Lonapegsomatropin subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/lonapegsomatropin-ascendis-pharma-epar-product-information_en.pdf
DB16222,,FDA Approved Drug Products: Zylonta (loncastuximab tesirine-lpyl) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf
DB16222,,FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma,https://www.fda.gov/drugs/fda-grants-accelerated-approval-loncastuximab-tesirine-lpyl-large-b-cell-lymphoma
DB16222,,Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2),https://clinicaltrials.gov/ct2/show/NCT03589469
DB16222,,ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma,https://www.benzinga.com/pressreleases/22/12/b30155957/adc-therapeutics-and-sobi-announce-european-commission-approval-of-zynlonta-loncastuximab-tesirine
DB16222,,EMA Approved Drug Products: Zynlonta (loncastuximab tesirine) powder for concentrate,https://www.ema.europa.eu/en/documents/product-information/zynlonta-epar-product-information_en.pdf
DB16226,,FDA Approved Drug Products: Livmarli (Marilixibat) Oral Solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214662s000lbl.pdf
DB16226,,EMA Summary of Opinion: Livmarli (maralixibat chloride),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/livmarli
DB16226,,EMA Approved Drug Products: Livmarli (maralixibat) Oral Solution,https://www.ema.europa.eu/en/documents/product-information/livmarli-epar-product-information_en.pdf
DB16226,,Business Wire: Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older,https://www.businesswire.com/news/home/20221213005467/en/
DB16226,,Health Canada Approved Drug Products: LIVMARLI (Maralixibat) Oral Solution,https://files.mirumpharma.com/livmarli/livmarli-product-monograph-en.pdf
DB16226,,FDA Approved Drug Products: LIVMARLI® (maralixibat) oral solution (September 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214662s004lbl.pdf
DB16226,,FDA Approved Drug Products LIVMARLI (maralixibat) oral solution (March 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214662s005s008lbl.pdf
DB16236,,"FDA Approved Drug Products: PYRUKYND (mitapivat) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf
DB16236,,GlobeNewsWire: Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency,https://www.globenewswire.com/news-release/2022/02/17/2387542/0/en/Agios-Announces-FDA-Approval-of-PYRUKYND-mitapivat-as-First-Disease-Modifying-Therapy-for-Hemolytic-Anemia-in-Adults-with-Pyruvate-Kinase-Deficiency.html
DB16258,,EMA Summary of Product Characteristics: Beyfortus (nirsevimab) solution for injection,https://www.ema.europa.eu/en/documents/product-information/beyfortus-epar-product-information_en.pdf
DB16258,,Health Canada Approved Drug Products: BEYFORTUS (nirsevimab) Intramuscular Injection,https://pdf.hres.ca/dpd_pm/00070439.PDF
DB16258,,"FDA Approved Drug Products: BEYFORTUS (nirsevimab-alip) injection, for intramuscular use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf
DB16258,,Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease,https://www.globenewswire.com/news-release/2023/07/17/2705911/0/en/Press-Release-FDA-approves-Beyfortus-nirsevimab-alip-to-protect-infants-against-RSV-disease.html
DB16261,,FDA Approved Drug Products: Bylvay (Odevixibat) Oral Capsule,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215498s000lbl.pdf
DB16261,,Clinical Trials: NCT03082937,https://clinicaltrials.gov/ct2/show/record/NCT03082937
DB16261,,"Globe Newswire: Albireo Announces FDA Approval of Bylvay (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)",https://www.globenewswire.com/news-release/2021/07/20/2266030/0/en/Albireo-Announces-FDA-Approval-of-Bylvay-odevixibat-the-First-Drug-Treatment-for-Patients-With-Progressive-Familial-Intrahepatic-Cholestasis-PFIC.html
DB16261,,FDA Approved Drug Products: Bylvay (Odevixibat) Oral Capsule (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215498s004lbl.pdf
DB16261,,FDA Approved Drug Products: Bylvay (Odevixibat) Oral Capsule (June 2023),https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/9/2023/06/13165353/Bylvay-USPI-06-2023.pdf
DB16261,,Health Canada Approved Drug Proucts: BYLVAY (Odevixibat) capsule for oral use,https://pdf.hres.ca/dpd_pm/00073106.PDF
DB16261,,Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC),https://www.prnewswire.com/apac/news-releases/ipsen-and-medison-pharma-announce-health-canada-approval-of-bylvay-odevixibat-for-the-treatment-of-pruritus-due-to-progressive-familial-intrahepatic-cholestasis-pfic-301986027.html
DB16264,,BioSpace: Lysogene Becomes Latest Company to Fail with AAVs in CNS Disorders (Updated),https://www.biospace.com/article/lysogene-becomes-latest-company-to-fail-to-make-aavs-work-for-cns-disorders/
DB16267,,FDA Approved Drug Products: REZLIDHIA (olutasidenib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf
DB16267,,US Food & Drug Administration: FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olutasidenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-idh1-mutation
DB16310,,FDA Approved Drug Products: REZZAYO (rezafungin) injection for intravenous use (March 2023),https://rezzayo.com/pdfs/REZZAYO%20(rezafungin%20for%20injection)%20Package%20Insert.pdf
DB16310,,Globe News Wire: Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis,https://www.globenewswire.com/news-release/2023/03/22/2632765/0/en/Cidara-Therapeutics-and-Melinta-Therapeutics-Announce-FDA-Approval-of-REZZAYO-rezafungin-for-injection-for-the-Treatment-of-Candidemia-and-Invasive-Candidiasis.html
DB16335,,FDA Approved Drug Products: Orlynvah (sulopenem etzadroxil and probenecid) tablets for oral use (October 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213972s000lbl.pdf
DB16335,,FDA News Release: FDA approves new treatment for uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibiotic treatment options,https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no
DB16353,,Aerpio Pharmaceuticals: Razuprotafib (AKB-9778) Diabetic Nephropathy,https://aerpio.com/pipeline/razuprotafib-akb-9778-diabetic-nephropathy/
DB16353,,Aerpio Pharmaceuticals: Razuprotafib COVID-19/ARDS,https://aerpio.com/pipeline/razuprotafib-covid-19-ards/
DB16354,,GlobeNewswire: Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin,https://www.globenewswire.com/news-release/2020/05/29/2040873/0/en/Galera-Therapeutics-Announces-Avasopasem-Manganese-Improved-Markers-of-Chronic-Kidney-Disease-in-Patients-Receiving-Cisplatin.html
DB16354,,Galera Therapeutics: AVASOPASEM (GC4419),https://www.galeratx.com/our-pipeline/gc4419/
DB16355,,GSK: Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19,https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-global-expansion-to-phase-3-of-comet-ice-study-evaluating-vir-7831-for-the-treatment-of-covid-19/
DB16355,,FDA Emergency Use Authorization Letter: Sotrovimab,https://www.fda.gov/media/149532/download
DB16355,,FDA: Sotrovimab fact sheet for healthcare providers,https://www.fda.gov/media/149534/download
DB16355,,GlaxoSmithKline: GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients,https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-us-fda/
DB16355,,Clinicaltrials.gov: VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE),https://clinicaltrials.gov/ct2/show/NCT04545060
DB16355,,BioSpace: Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19,https://www.biospace.com/article/releases/xevudy-sotrovimab-granted-marketing-authorization-by-the-european-commission-for-the-early-treatment-of-covid-19/?keywords=CHMP+approval
DB16355,,EMA Summary of Product Characteristics: Xevudy (sotrovimab) concentrate for solution for infusion,https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-information_en.pdf
DB16355,,FDA Drug Safety and Availability: FDA updates Sotrovimab emergency use authorization,"https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization#:~:text=%5B2%2F25%2F2022%5D,not%20susceptible%20to%20this%20treatment."
DB16356,,Science: Can a nose-full of chicken antibodies ward off coronavirus infections?,https://www.sciencemag.org/news/2020/11/can-nose-full-chicken-antibodies-ward-coronavirus-infections%20
DB16357,,ClinicalTrials.gov: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),https://clinicaltrials.gov/ct2/show/NCT04551898
DB16358,,ClinicalTrials.gov: A Clinical Study to Evaluate MW33 Injection,https://clinicaltrials.gov/ct2/show/NCT04533048
DB16359,,"ScienceDirect: 164: CSL324, a humanised anti G-CSFR antibody, can inhibit neutrophil migration while not impaction on neutrophil number or effector functions",https://www.sciencedirect.com/science/article/abs/pii/S1043466614003810
DB16360,,ClinicalTrials.gov: IInpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),https://clinicaltrials.gov/ct2/show/NCT04546581
DB16360,,European Pharmaceutical Review: Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients,https://www.europeanpharmaceuticalreview.com/news/129967/trial-testing-anti-coronavirus-hivig-plus-remdesivir-in-covid-19-patients/
DB16361,,Cartesian Therapeutics: Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19,https://www.cartesiantherapeutics.com/cartesian-therapeutics-initiates-clinical-trial-of-first-rna-engineered-cell-therapy-for-acute-respiratory-distress-syndrome-and-covid-19/
DB16361,,Cartesian Therapeutics: Descartes-30 in ARDS,https://www.cartesiantherapeutics.com/descartes-30-ards/
DB16362,,AIFA Product Information: ARGENTO PROTEINATO ZETA (silver proteinate) nasal,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_006685_031304_RCP.pdf&retry=0&sys=m0b1l3
DB16363,,CellPraxis: PlasmaCord®,http://cellpraxis.com/plasmacord/
DB16366,,Evive Biotech: F-652,https://www.evivebiotech.com/pipeline/pipeline-f-652/
DB16366,,BioSpectrum: Evive Biotech unveiled as the new corporate brand for Generon Biomed,https://www.biospectrumasia.com/news/48/16180/evive-biotech-unveiled-as-the-new-corporate-brand-for-generon-biomed.html
DB16367,,Caladrius Biosciences: CLBS119,https://www.caladrius.com/product-candidates/clbs119-for-repair-of-covid-19-induced-lung-damage/
DB16368,,ClinicalTrials.gov: Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19,https://clinicaltrials.gov/ct2/show/NCT04514302
DB16369,,Novavax: Novavax addresses urgent global public health needs with innovative technology,https://www.novavax.com/our-unique-technology
DB16371,,Health Canada Product Monograph: Columvi (glofitamab) concentrate for solution for intravenous infusion,https://pdf.hres.ca/dpd_pm/00070059.PDF
DB16371,,Canadian Cancer Society: Diffuse large B-cell lymphoma,https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/what-is-non-hodgkin-lymphoma/diffuse-large-b-cell-lymphoma
DB16371,,BioSpace: COLUMVI® (Glofitamab for Injection) Receives Health Canada Authorization with Conditions for Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma,https://www.biospace.com/article/releases/columvi-and-174-glofitamab-for-injection-receives-health-canada-authorization-with-conditions-for-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/?keywords=health+canada
DB16371,,"Globe News Wire: FDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma",https://www.globenewswire.com/news-release/2023/06/16/2689505/0/en/FDA-approves-Roche-s-Columvi-the-first-and-only-bispecific-antibody-with-a-fixed-duration-treatment-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html
DB16371,,FDA Approved Drug Products: COLUMVI (glofitamab-gxbm) injection for intravenous use (June 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf
DB16371,,"EMA Approved Drug Products: Columvi (glofitamab) injection, for intravenous use",https://www.ema.europa.eu/en/documents/product-information/columvi-epar-product-information_en.pdf
DB16371,,European Commission approves Roche's fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma,https://www.benzinga.com/pressreleases/23/07/tr33177629/european-commission-approves-roches-fixed-duration-columvi-glofitamab-for-people-with-relapsed-or
DB16385,,DailyMed: EBANGA (ansuvimab) injection,https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=9c008384-379d-48d3-b5a5-9809ed0f655c&type=pdf
DB16388,,FDA Approved Drug Products: Niktimvo (axatilimab-csfr) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761411s000lbl.pdf
DB16388,,BioSpace: Incyte Wins Second Graft-Versus-Host Disease FDA Approval,https://www.biospace.com/fda/incyte-wins-second-graft-versus-host-disease-fda-approval
DB16390,,FDA Approved Drug Products: Exkivity (mobocertinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf
DB16390,,FDA News Release: FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20
DB16391,,VIB7734 - Viela Bio,https://vielabio.com/products-pipeline/in-development/vib7734/
DB16393,,FDA EUA Fact Sheet: EVUSHELD (tixagevimab and cilgavimab) injection,https://www.fda.gov/media/154701/download
DB16393,,Astrazeneca Press Release: Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population,https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/evusheld-approved-in-the-eu-for-covid-19.html
DB16393,,"EMA Approved Drug Products: Evusheld (tixagevimab, cilgavimab) Intramuscular Injection",https://www.ema.europa.eu/en/documents/product-information/evusheld-epar-product-information_en.pdf
DB16393,,Health Canada Approved Drug Products: EVUSHELD (tixagevimab and cilgavimab) intramuscular injection,https://covid-vaccine.canada.ca/info/pdf/evusheld-pm-en.pdf
DB16393,,US Food & Drug Administration: FDA releases important information about risk of COVID-19 due to certain variants not neutralized by Evusheld,https://www.fda.gov/drugs/drug-safety-and-availability/fda-releases-important-information-about-risk-covid-19-due-certain-variants-not-neutralized-evusheld
DB16393,,Health Canada: EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance,https://recalls-rappels.canada.ca/en/alert-recall/evusheld-tixagevimab-and-cilgavimab-injection-risk-prophylaxis-or-treatment-failure
DB16394,,FDA EUA Fact Sheet: EVUSHELD (tixagevimab and cilgavimab) injection,https://www.fda.gov/media/154701/download
DB16394,,Astrazeneca Press Release: Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population,https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/evusheld-approved-in-the-eu-for-covid-19.html
DB16394,,"EMA Approved Drug Products: Evusheld (tixagevimab, cilgavimab) Intramuscular Injection",https://www.ema.europa.eu/en/documents/product-information/evusheld-epar-product-information_en.pdf
DB16394,,Health Canada Approved Drug Products: EVUSHELD (tixagevimab and cilgavimab) intramuscular injection,https://covid-vaccine.canada.ca/info/pdf/evusheld-pm-en.pdf
DB16394,,US Food & Drug Administration: FDA releases important information about risk of COVID-19 due to certain variants not neutralized by Evusheld,https://www.fda.gov/drugs/drug-safety-and-availability/fda-releases-important-information-about-risk-covid-19-due-certain-variants-not-neutralized-evusheld
DB16394,,Health Canada: EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance,https://recalls-rappels.canada.ca/en/alert-recall/evusheld-tixagevimab-and-cilgavimab-injection-risk-prophylaxis-or-treatment-failure
DB16395,,NeoImmuneTech: NT-I7 is a Unique T Cell Amplifier.,http://neoimmunetech.com/technology/page2020_ver3.html
DB16405,,EMA Summary of Product Characteristics: Regkirona (regdanvimab) concentrate for solution for intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/regkirona-epar-product-information_en.pdf
DB16405,,EMA COVID-19 News: EMA recommends authorisation of two monoclonal antibody medicines,https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines
DB16405,,EMA CHMP Assessment Report: Celltrion use of regdanvimab for the treatment of COVID-19,https://www.ema.europa.eu/en/documents/referral/regdanvimab-treatment-covid-19-celltrion-covid-19-article-53-procedure-assessment-report_en.pdf
DB16405,,Protein Data Bank: Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,https://www.rcsb.org/structure/7CM4
DB16406,,National Cancer Institute: Sumoylation inhibitor TAK-981,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795544
DB16406,,newdrugapprovals.org: TAK-981,https://newdrugapprovals.org/2019/04/12/tak-981/
DB16416,,"FDA EUA Drug Products: GOHIBIC (vilobelimab) injection, for intravenous use",https://www.fda.gov/media/166824/download
DB16416,,FDA: FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19,https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-gohibic-vilobelimab-injection-treatment-covid-19
DB16423,,"BMJ Journals: AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19",https://jitc.bmj.com/content/8/Suppl_3/A292
DB16424,,Enlivex: Allocetra™ Immune rebalancing,https://www.enlivex.com/allocetra/
DB16424,,"Enlivex: Pipeline: Lifesaving, immunomodulating cell therapies",https://www.enlivex.com/pipeline/
DB16427,,Sanofi: Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly,https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-11-07-00-00
DB16427,,Sanofi Press Release: Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission,https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-10-15-36-50-2553486
DB16427,,"EMA Summary of Product Characteristics: VidPrevtyn Beta (COVID-19 vaccine, recombinant, adjuvanted) for intramuscular injection",https://www.ema.europa.eu/en/documents/product-information/vidprevtyn-beta-epar-product-information_en.pdf
DB16427,,EMA Public Assessment Report: VidPrevtyn Beta,https://www.ema.europa.eu/en/documents/assessment-report/vidprevtyn-beta-epar-public-assessment-report_en.pdf
DB16428,,covidX: GRAd-COV2,https://www.covidx.eu/grad-cov2
DB16428,,REITHERA: REITHERA ANNOUNCES ITS GRAD-COV2 COVID-19 VACCINE CANDIDATE IS WELL TOLERATED AND INDUCES CLEAR IMMUNE RESPONSES IN HEALTHY SUBJECTS AGED 18-55 YEARS PHASE 1 TRIAL TO ADVANCE INTO ELDERLY SUBJECTS AGED 65-85 YEARS,https://www.reithera.com/2020/11/24/reithera-announces-its-grad-cov2-covid-19-vaccine-candidate-is-well-tolerated-and-induces-clear-immune-responses-in-healthy-subjects-aged-18-55-years-phase-1-trial-to-advance-into-elderly-subjects-age/
DB16429,,ClinicalTrials.gov: Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC),https://clinicaltrials.gov/ct2/show/NCT04546841
DB16430,,"Institut Pasteur: COVID-19: VACCINE AGAINST SARS-COV-2 INFECTION, USING THE MEASLES VECTOR",https://www.pasteur.fr/en/all-sars-cov-2-covid-19-institut-pasteur/research-projects/covid-19-vaccine-against-sars-cov-2-infection-using-measles-vector
DB16432,,"ClinicalTrials.gov: Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19",https://clinicaltrials.gov/ct2/show/NCT04569383
DB16432,,DZIF: MVA-SARS-2-S DZIF COVID-19 vaccine candidate,https://www.pei.de/SharedDocs/Downloads/EN/newsroom-en/dossiers/presentation-vaccine-idt-biologika-dzif.pdf?__blob=publicationFile&v=2
DB16433,,ClinicalTrials.gov: Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,https://clinicaltrials.gov/ct2/show/NCT04563702
DB16433,,bioRxiv: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection,https://www.biorxiv.org/content/10.1101/2020.09.04.283853v1.full.pdf
DB16434,,Stanford Medicine: IN01 vaccine,https://racetoacure.stanford.edu/development-leads/304
DB16435,,News Medical: The COVID-19 vaccine pipeline,https://www.news-medical.net/news/20201014/The-COVID-19-vaccine-pipeline.aspx
DB16436,,GeneOnline: Taiwanese Government Grants 16 Million to aid Adimmune’s COVID-19 Vaccine Trials,https://geneonline.news/en/2020/10/23/taiwanese-government-grants-16-million-to-aid-adimmunes-covid-19-vaccine-trials/
DB16436,,News Medical: The COVID-19 vaccine pipeline,https://www.news-medical.net/news/20201014/The-COVID-19-vaccine-pipeline.aspx
DB16437,,Genetic Engineering & Biotechnology News (GEN): Merck & Co. and IAVI – V590,https://www.genengnews.com/covid-19-candidates/merck-co-and-iavi/
DB16437,,MERCK: IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2,https://www.merck.com/news/iavi-and-merck-collaborate-to-develop-vaccine-against-sars-cov-2/
DB16437,,The Motley Fool: This Late-to-the-Party Coronavirus Vaccine Maker Could Be the Biggest Winner Over the Long Run,https://www.fool.com/investing/2020/10/02/this-late-to-the-party-coronavirus-vaccine-maker-c/
DB16438,,MERCK: Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur,https://www.merck.com/news/merck-to-acquire-themis/
DB16439,,Precision Vaccinations: VACCINE INFO EpiVacCorona Vaccine,https://www.precisionvaccinations.com/vaccines/epivaccorona-vaccine
DB16439,,The Pharma Letter: Russia’s EpiVacCorona vaccine post-registration trials started,https://www.thepharmaletter.com/article/russia-s-epivaccorona-vaccine-post-registration-trials-started
DB16441,,"The Astana Times: Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in",https://astanatimes.com/2020/12/kazakhstan-begins-vaccinating-3000-volunteers-with-self-made-qazcovid-in/
DB16441,,The Lancet: COVID-19 response in central Asia,https://www.thelancet.com/pdfs/journals/lanmic/PIIS2666-5247(20)30177-4.pdf
DB16441,,Economic Research Institute: QazCovid-in,http://economy.kz/en/Novosti_ekonomiki_Kazahstana/id=1588
DB16442,,"FIERCE Biotech: Pfizer, BioNTech 'quietly' usher a 5th COVID-19 jab into the clinic: analyst",https://www.fiercebiotech.com/biotech/pfizer-biontech-quietly-usher-a-5th-covid-19-jab-into-clinic-analyst
DB16442,,citybizlist: Pfizer's Latest Stealthy Move Could Help It Win the Coronavirus Vaccine Race,https://newyork.citybizlist.com/article/628052/pfizers-latest-stealthy-move-could-help-it-win-the-coronavirus-vaccine-race
DB16444,,News Medical: Novel “multitope” vaccine shows promise in the fight against COVID-19,https://www.news-medical.net/news/20201203/Novel-e2809cmultitopee2809d-vaccine-shows-promise-in-the-fight-against-COVID-19.aspx
DB16444,,bioRxiv: A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an Adeno Associated Virus Human Angiotensin-Converting Enzyme 2 (AAV hACE2) Mouse Model,https://www.biorxiv.org/content/10.1101/2020.11.30.399154v1
DB16444,,ExBulletin: The new “multi-tope” vaccine is promising in the fight against COVID-19,https://exbulletin.com/world/health/594320/
DB16445,,Bangkok Post: COVID-19 Spurs Thailand’s Rise as Global Medical Hub,https://www.bangkokpost.com/business/1993579/covid-19-spurs-thailands-rise-as-global-medical-hub
DB16445,,China Daily: Thai researcher pins vaccine hopes on cooperation,http://epaper.chinadaily.com.cn/a/202008/19/WS5f3c7375a3107831ec754645.html
DB16448,,External Link,https://biopharmadealmakers.nature.com/posts/54983-immunotherapy-drug-development-powered-by-deep-biology-insights
DB16448,,External Link,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cd24-extracellular-domain-igg1-fc-domain-recombinant-fusion-protein-cd24fc
DB16450,,External Link,https://www.cancertherapyadvisor.com/home/cancer-topics/general-oncology/forgotten-cancer-gene-therapy-revival-with-off-shelf-potential/
DB16450,,External Link,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/retrovector-encoding-mutant-anti-cyclin-g1
DB16451,,External Link,https://www.biorxiv.org/content/10.1101/2020.08.11.242834v2
DB16451,,Roche announcement.,https://cen.acs.org/pharmaceuticals/drug-development/Roche-partners-Atea-COVID-19/98/i43
DB16452,,External Link,https://www.novartis.com/our-science/novartis-global-pipeline?page=11
DB16453,,External Link,https://www.atyrpharma.com/programs/atyr1923/
DB16453,,External Link,https://sarcoidosisnews.com/2018/10/02/pulmonary-sarcoidosis-clinical-trial-test-atyr-pharmas-atyr1923/
DB16453,,External Link,https://www.globenewswire.com/news-release/2019/12/12/1959818/0/en/aTyr-Pharma-Announces-Positive-Interim-Safety-Results-from-Ongoing-Phase-1b-2a-Clinical-Trial-of-ATYR1923.html
DB16457,,External Link,https://www.biophytis.com/en/aging-sciences/sarcopenie/
DB16458,,External Link,https://www.genosciencepharma.com/2020/04/05/important-advances-in-novel-covid-19-antiviral-program/
DB16460,,External Link,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373584
DB16460,,Apellis Provides Update on APL-9 for Severe COVID-19,https://investors.apellis.com/news-releases/news-release-details/apellis-provides-update-apl-9-severe-covid-19
DB16461,,External Link,https://www.novartis.com/news/media-releases/novartis-adds-clinical-and-preclinical-anti-inflammatory-programs-portfolio-acquisition-ifm-tre
DB16461,,External Link,https://www.prnewswire.com/news-releases/ifm-therapeutics-announces-dosing-of-first-subjects-in-phase-1-healthy-volunteer-study-of-lead-nlrp3-antagonist-ifm-2427-300819851.html
DB16462,,External Link,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/797224
DB16462,,Information,https://www.medchemexpress.com/veru-111.html
DB16463,,External Link,https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-announces-first-subject-dosed-phase-1-study
DB16463,,External Link,https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-responds-covid-19-pandemic-advancing-td
DB16466,,External Link,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/800239
DB16469,,External Link,http://www.argenx.com/pipeline/argx-117
DB16469,,argenx: Empasiprubart,https://www.argenx.com/pipeline/empasiprubart
DB16471,,External Link,https://nortonhealthcare.com/news/coronavirus-treatment-covid-19-clinical-trials/
DB16472,,External Link,https://archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/162-arch-biopartners-announces-fda-acknowledgement-of-its-investigational-new-drug-application-for-metablok-lsalt-peptid
DB16472,,External Link,https://archbiopartners.com/index.php/our-science/our-key-platforms/metablok
DB16473,,External Link,https://www.astrazeneca.com/our-science/pipeline.html
DB16474,,External Link,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr-2-6-9-agonist-pul-042
DB16476,,External Link,https://patents.google.com/patent/CA3010020A1/en
DB16477,,External Link,https://clinicaltrials.gov/ct2/show/NCT04401475
DB16477,,External Link,https://www.edesabiotech.com/technology/
DB16479,,"FDA Approved Drug Products: ANKTIVA (nogapendekin alfa inbakicept-pmln) solution, for intravesical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761336s000lbl.pdf
DB16479,,FDA: FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer
DB16480,,External Link,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795388
DB16481,,External Link,https://www.chimerix.com/our-science/dstat/
DB16481,,External Link,https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.7001
DB16482,,External Link,https://www.globenewswire.com/news-release/2020/05/28/2040087/0/en/Cerecor-Announces-FDA-Clearance-of-IND-for-CERC-002-in-COVID-19-Induced-ARDS.html
DB16485,,External Link,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr-2-6-9-agonist-pul-042
DB16486,,External Link,https://evelobio.com/portfolio/
DB16486,,External Link,https://www.biospace.com/article/releases/evelo-biosciences-announces-edp1815-to-advance-into-phase-2-3-tactic-e-covid-19-trial/
DB16487,,External Link,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sti-1499-potent-anti-sars-cov-2-antibody-demonstrates-ability
DB16488,,External Link,https://www.corvuspharma.com/our-science/covid-19/
DB16488,,External Link,https://clinicaltrials.gov/ct2/show/NCT04441918
DB16491,,External Link,https://www.sabbiotherapeutics.com/2020/08/21/sab-biotherapeutics-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-sab-185-for-the-treatment-of-covid-19/
DB16492,,External Link,https://www.sanofigenzyme.com/en/products-research/research-pipeline
DB16492,,External Link,https://www.bloomberg.com/press-releases/2018-11-01/sanofi-sanofi-and-denali-therapeutics-to-develop-treatments-for-neurological-and-inflammatory-diseases
DB16492,,External Link,https://clinicaltrials.gov/ct2/show/NCT04469621
DB16493,,External Link,https://www.briibio.com/pipeline.php
DB16494,,External Link,https://www.briibio.com/pipeline.php
DB16496,,External Link,https://www.longdom.org/proceedings/op101-a-novel-therapy-for-treatment-of-childhood-cerebral-adrenoleukodystrophy-18784.html
DB16496,,External Link,https://www.businesswire.com/news/home/20200528005275/en/Ashvattha-Therapeutics-Subsidiary-Orpheris-Announces-FDA-Agreement
DB16497,,External Link,https://30.technology/covid-19/
DB16498,,External Link,https://phasebio.com/pipeline/pb1046/
DB16498,,External Link,https://treat-nmd.org/tact-review/vasomera-pb1046/
DB16499,,External Link,https://covdb.stanford.edu/compound-list/?target=Entry%20%28convalescent%20plasma%29
DB16500,,External Link,https://www.bioworld.com/articles/435758-singapores-tychan-kicks-off-speedy-phase-i-trial-for-covid-19-monoclonal-antibody
DB16500,,External Link,https://www.genengnews.com/covid-19-candidates/tychan-ty027/
DB16500,,External Link,https://www.biospectrumasia.com/news/26/16091/tychan-to-begin-ph-1-trials-for-mab-against-covid-19.html
DB16501,,External Link,https://www.emdgroup.com/en/news/m5049-treatment-covid-19-pneumonia.html
DB16502,,External Link,https://www.aclaristx.com/pipeline/
DB16502,,External Link,https://www.globenewswire.com/news-release/2020/06/17/2049394/0/en/Aclaris-Therapeutics-Supports-Investigator-Initiated-Clinical-Trial-of-ATI-450-for-Cytokine-Release-Syndrome-in-Hospitalized-Patients-with-COVID-19.html
DB16503,,External Link,https://clinicaltrials.gov/ct2/show/NCT04487574
DB16503,,External Link,https://adisinsight.springer.com/drugs/800051490
DB16505,,External Link,https://chineseantibody.org/covid-19-track/
DB16505,,External Link,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454247/
DB16507,,External Link,https://atossatherapeutics.com/product-pipeline/
DB16507,,External Link,https://www.oindpnews.com/2020/07/atossa-to-advance-at-301-nasal-spray-into-clinical-development-for-covid-19/
DB16509,,External Link,https://www.henlius.com/en/NewsDetails-2780-26.html
DB16509,,External Link,https://clinicaltrials.gov/ct2/show/NCT04561076
DB16511,,External Link,https://kancera.com/en/research/this-is-how-kand567-works/
DB16511,,Nature Article,https://www.nature.com/articles/d43747-020-01156-3
DB16512,,External Link,https://joseahbio.com/pipeline
DB16514,,External Link,https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2.full.pdf
DB16514,,c&en,https://cen.acs.org/pharmaceuticals/drug-discovery/Pfizers-novel-COVID-19-antiviral/98/web/2020/09
DB16514,,trial site news,https://trialsitenews.com/pfizer-takes-antiviral-drug-pf-07304814-into-phase-1-clinical-trial-targeting-covid-19/
DB16514,,Comparative Study,https://www.biorxiv.org/content/10.1101/2020.08.28.272880v1
DB16515,,External Link,https://pliantrx.com/pln-74809/
DB16515,,pulmonary fibrosis foundation,https://www.pulmonaryfibrosis.org/life-with-pf/clinical-trials/pipeline/drug/idiopathic-pulmonary-fibrosis/pln-74809
DB16515,,ERS journal,https://erj.ersjournals.com/content/54/suppl_63/PA1286
DB16515,,ERS-Integris IPF,https://erj.ersjournals.com/content/56/suppl_64/782
DB16515,,pulmonary firbrosis news,https://pulmonaryfibrosisnews.com/2020/03/06/pliant-therapeutics-raises-100m-develop-therapies-fibrotic-diseases-pln-74809/
DB16515,,biospace,https://www.biospace.com/article/releases/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2020-financial-results/
DB16516,,External Link,https://www.eurekalert.org/pub_releases/2019-03/tes-edr032019.php
DB16516,,Journal of the Endocrine Society,https://academic.oup.com/jes/article/3/Supplement_1/OR22-6/5483429
DB16516,,Endocrine.org,https://www.endocrine.org/news-and-advocacy/news-room/2019/endo-2019--experimental-drug-reverses-high-cholesterol
DB16516,,Cochrane Library Study,https://covid-19.cochrane.org/studies/crs-14730495
DB16517,,National Center for Advancing Translational Sciences: INFLUENZA A VIRUS A/BRISBANE/10/2010 (H1N1) WHOLE,https://drugs.ncats.io/substance/P5CHAO4ZF3
DB16518,,National Center for Advancing Translational Sciences: INFLUENZA A VIRUS A/SOUTH AUSTRALIA/55/2014 (H3N2) WHOLE,https://drugs.ncats.io/substance/HJY5L9V6CA
DB16519,,Organicell: Zofin,https://organicell.com/zofin-2/
DB16520,,ClinicalTrials.gov: Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP) (AP-TP-Bio),https://clinicaltrials.gov/ct2/show/NCT03348670
DB16521,,ClinicalTrials.gov: Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M),https://clinicaltrials.gov/ct2/show/NCT04512027
DB16521,,"medRxiv: Galectin antagonist use in mild cases of SARS-CoV-2 cases; pilot feasibility randomised, open label, controlled trial.",https://www.medrxiv.org/content/10.1101/2020.12.03.20238840v1.full.pdf
DB16524,,The Caribbean Council: Cuba begins clinical trials of a COVID-19 vaccine,https://www.caribbean-council.org/cuba-begins-clinical-trials-of-a-covid-19-vaccine/
DB16527,,"FDA Thailand: Sulcain (Ethyl piperidinoacetylaminobenzoate, Magaldrate) Oral Tablet",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022290116211C
DB16536,,EMA Summary of Product Characteristics: Filsuvez (birch bark extract) gel for cutaneous use,https://www.ema.europa.eu/en/documents/product-information/filsuvez-epar-product-information_en.pdf
DB16536,,EMA Summary of Product Characteristics: Episalvan (birch bark extract) gel for cutaneous use,https://www.ema.europa.eu/en/documents/product-information/episalvan-epar-product-information_en.pdf
DB16536,,EMA Assessment Report: Filsuvez (birch bark extract) gel for cutaneous use,https://www.ema.europa.eu/en/documents/assessment-report/filsuvez-epar-public-assessment-report_en.pdf
DB16536,,Globe News Wire: European Commission Approves Filsuvez for the treatment of Dystrophic and Junctional EB,https://www.globenewswire.com/news-release/2022/06/23/2467833/0/en/European-Commission-Approves-Filsuvez-for-the-treatment-of-Dystrophic-and-Junctional-EB.html
DB16536,,FDA Approved Drug Products: Filsuvez (birch triterpenes) topical gel,https://resources.chiesiusa.com/Filsuvez/FILSUVEZ_PI.pdf
DB16536,,Chiesi Global Rare Diseases News Release: Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa,https://chiesirarediseases.com/media/fda-approval-for-filsuvez-topical-gel
DB16537,,AIFA: Enterogermina (Bacillus clausii) Oral Suspension,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_008055_013046_FI.pdf&retry=0&sys=m0b1l3
DB16539,,BASG: Uro-Vaxom (E. coli) Oral Capsule,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-25631&type=DOTC_FACH_INFO
DB16539,,BASG: Symbioflor (E. coli) Oral Solution,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-23846&type=DOTC_FACH_INFO
DB16543,,BASG: Döderlein Med (Lactobacillus gasseri) Vaginal Capsule,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-23623&type=DOTC_FACH_INFO
DB16545,,"FDA Thailand: Blackmores Bio C (Ascorbic Acid, Calcium Ascorbate, Citrus bioflavonoids, Hesperidin, Malpighia emarginata, Rosa canina Fruit, Rutin, Sodium Ascorbate) Oral Tablet",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022400007011C
DB16548,,AIFA: Endolac (Streptococcus thermophilus) Oral Powder for Suspension,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007137_033968_FI.pdf&retry=0&sys=m0b1l3
DB16554,,"AIFA: Metadoxil (Metadoxine) Oral Solution, Oral Tablet, and Intramuscular and Intravenous Injection",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000522_025316_FI.pdf&retry=0&sys=m0b1l3
DB16556,,"FDA Thailand: Hemorhin (Docusate Sodium, Spermaceti) Oral Tablet",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022280091311C
DB16557,,PubMed Central (PMC): Passive Monoclonal and Polyclonal Antibody Therapies,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153350/
DB16557,,Aridis Pharmaceuticals: AR-301: Fully Human mAb Against Staphylococcus aureus,https://www.aridispharma.com/ar-301/
DB16558,,"FDA Thailand: Blackmores Bio C (Ascorbic Acid, Calcium Ascorbate, Citrus bioflavonoids, Hesperidin, Malpighia emarginata, Rosa canina Fruit, Rutin, Sodium Ascorbate) Oral Tablet",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1022400007011C
DB16560,,"FDA Thailand: Baby Cough Syrup (Ammonia, Ethyl Nitrate, Glycyrrhiza glabra, Tolu Balsam) Oral Syrup",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022260007711C
DB16561,,FDA Thailand: Vermetab (Tetramisole) Oral Tablet,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1022300001611C
DB16564,,NPRA: Hirudoid Cream (Mucopolysaccharide Polysulphate) Topical Cream,https://quest3plus.bpfk.gov.my/front-end/attachment/66/pharma/234579/V_7714_20170707_075235_D4.pdf
DB16566,,"FDA Thailand: Carminative Sahakarn (Camphor, Capsicum, Gneiana lutea Extract, Ginger) Solution",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022450000311C
DB16567,,"FDA Thailand: SM Oto (Fludrocortisone, Furaltadone, Lidocaine, Neomycin, Polymyxin B) Otic Liquid",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2A1022440003911C
DB16568,,AIFA: Gelofusine (Succinylated Gelatin) Intravenous Injection,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000718_036615_FI.pdf&retry=0&sys=m0b1l3
DB16569,,FDA Thailand: MALAYAN KRAIT ANTIVENIN (PURIFIED) (Bungarus candidus antivenom) Solution,http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1A1042540000111C
DB16573,,"FDA Thailand: Tetanus Immune Globulin, Equine Injection Solution",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1042600000211C
DB16574,,"FDA Thailand: Rabies Immune Globulin, Equine Injection Solution",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1042550002411C
DB16575,,"NPRA: Tiger Balm Back Pain Patch (Capsicum, Eucalyptus Oil, Levomenthol, Mentha arvensis Leaf Oil, Synthetic Camphor) Topical Patch",https://quest3plus.bpfk.gov.my/front-end/attachment/990/pharma/504960/504960_20180425_165821_.pdf
DB16577,,"FDA Thailand: Japanese Encephalitis Vaccine (Live, Attenuated) Injection",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR1C1012500010811C
DB16578,,"FDA Thailand: BIVALENT ORAL POLIOMYELITIS VACCINE (Live Attenuated Poliomyelitis virus type 1, type 3) Oral Suspension",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1042590000211C
DB16579,,"FDA Thailand: BIVALENT ORAL POLIOMYELITIS VACCINE (Live Attenuated Poliomyelitis virus type 1, type 3) Oral Suspension",http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1042590000211C
DB16580,,Bristol-Myers Squibb: Investor Series,https://s21.q4cdn.com/104148044/files/doc_presentations/2020/BMY-Investor-Series-Day1.pdf
DB16580,,MedKoo Biosciences: Afimetoran,https://www.medkoo.com/products/43474
DB16581,,Summary of Product Characteristics: Alofisel (darvadstrocel) suspension for injection,https://www.ema.europa.eu/en/documents/product-information/alofisel-epar-product-information_en.pdf
DB16581,,European Medicines Agency: Alofisel (darvadstrocel),https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel#product-information-section
DB16582,,FDA Press Announcements: FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma
DB16582,,FDA Approved Drug Products: Breyanzi (Lisocabtagene Maraleucel) Intravenous Infusion,https://www.fda.gov/media/145711/download
DB16582,,EMA Approved Drug Products: Breyanzi (lisocabtagene maraleucel) intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/breyanzi-epar-product-information_en.pdf
DB16582,,Bristol Myers Squibb News: Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma,https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-CAR-T-Cell-Therapy-Breyanzi-lisocabtagene-maraleucel-for-Certain-Forms-of-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspx
DB16582,,Health Canada Approved Drug Products: BREYANZI (lisocabtagene maraleucel) Intravenous Infusion,https://pdf.hres.ca/dpd_pm/00066444.PDF
DB16583,,"AIFA: Kaloba (Pelargonium sidoides root) Oral Tablet, Solution",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001292_038135_FI.pdf&retry=0&sys=m0b1l3
DB16584,,AIFA: Flaminase (Liprotamase Protease) Oral Tablet,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000045_026420_FI.pdf&retry=0&sys=m0b1l3
DB16585,,BASG: Uralyt U (Potassium Sodium Hydrogen Citrate) Oral Granules for Solution,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=13320&type=DOTC_FACH_INFO
DB16586,,AIFA: Pigenil (Pygeum africanum bark) Oral Capsule,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001569_023717_FI.pdf&retry=0&sys=m0b1l3
DB16587,,BASG: Poltechnet (Molybdate Mo-99) Generator,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=436188&type=DOTC_FACH_INFO
DB16599,,"BASG: Ambotonin (Cerebrolysin) Intramuscular, Intravenous Injection",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-21372&type=DOTC_FACH_INFO
DB16600,,"NPRA: Axe Brand Heat Oil (Cinnamon Leaf Oil, Cinnamon Oil, Citronella Oil, Methyl Salicylate, Turpentine Oil) Topical Oil",https://quest3plus.bpfk.gov.my/front-end/attachment/32661/pharma/205788/V_38681_20200106_122726_D4.pdf
DB16603,,BASG: Mutaflor Suspension (Escherichia coli strain Nissle 1917) Oral Suspension,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=2-00399&type=DOTC_FACH_INFO
DB16607,,"BASG: Lithiumchlorid LiDCO 0,15 mmol/ml Injektionslösung (Lithium Chloride) Intravenous Injection",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-25211&type=DOTC_FACH_INFO
DB16608,,BASG: Irenat - Tropfen (Sodium Perchlorate) Oral Solution,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=10510&type=DOTC_FACH_INFO
DB16609,,"NPRA: Pneumosil (S. pneumoniae capsular antigens type 1, 5, 6a, 6b, 7f, 9v, 14, 19a, 19f, 23f) Intramuscular Injection",https://quest3plus.bpfk.gov.my/front-end/attachment/5140/pharma/528698/1600651554.pdf
DB16611,,"BASG: FSME-Immun 0,5 ml Erwachsene Injektionssuspension in einer Fertigspritze (Tick-born encephalitis inactivated virus vaccine) Intramuscular Injection",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=2-00174&type=DOTC_FACH_INFO
DB16611,,FDA Approved Drug Products: TICOVAC (Tick-Borne Encephalitis vaccine) injection,https://www.fda.gov/media/151502/download
DB16611,,Pfizer Press Release: Acquisition of Baxter Vaccines,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_baxter_s_marketed_vaccines
DB16613,,"BASG: Sulmycin Implant - Schwamm (Equine Collagen, Gentamicin) Intralesional Implant Sponge",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-20152&type=DOTC_FACH_INFO
DB16614,,"AIFA: Proctosedyl (Amlintide, Benzalkonium, Benzocaine, Esculin, Hydrocortisone) Rectal Cream, Suppository, and Ointment",https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000022_013868_FI.pdf&retry=0&sys=m0b1l3
DB16617,,"BASG: Galle - Donau - Dragees (1-naphthaleneacetic Acid, 2-(p-Tolyl)ethyl Nicotinate) Oral Tablet",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=10202&type=DOTC_FACH_INFO
DB16618,,AIFA: NIAOULI ESSENZA NOVA ARGENTIA (Niaouli Oil) Nasal Solution,https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002745_030554_FI.pdf&retry=0&sys=m0b1l3
DB16619,,BASG: Magnesiocard i.v. - Ampullen (Magnesium Aspartate) Intravenous Injection,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-18609&type=DOTC_FACH_INFO
DB16621,,"BASG: Celsior Organkonservierungslösung (Calcium Chloride, Glutamic Acid, Glutathione, Histidine, Lactobionic Acid, Magnesium Chloride, Mannitol, Potassium Chloride, Sodium Hydroxide) Extracorporeal Solution",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-31077&type=DOTC_FACH_INFO
DB16622,,"BASG: elmex Zahngel (Dectaflur, Olaflur, Sodium Fluoride) Dental Gel",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=1-18093&type=DOTC_FACH_INFO
DB16623,,BASG: Fentrinol - Nasentropfen (Amidephrine) Nasal Drops,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=14022&type=DOTC_FACH_INFO
DB16624,,BASG: Thalliumchlorid (201Tl) Curium Injektionslösung (Thallous chloride Tl-201) Intravenous Injection,https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=4-00016&type=DOTC_FACH_INFO
DB16625,,"BASG: Gynodian Depot - Fertigspritze (Estradiol Valerate, Prasterone Enantate) Intramuscular Injection",https://aspregister.basg.gv.at/document/servlet?action=show&zulnr=15426&type=DOTC_FACH_INFO
DB16627,,FDA Approved Drug Products: Pepaxto (Melphalan Flufenamide) Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf
DB16627,,Cancer Network: FDA Has Requested a Partial Clinical Hold on All Trials With Melflufen in Following Study in R/R Myeloma,https://www.cancernetwork.com/view/treatment-options-for-patients-with-high-risk-ndmm
DB16627,,"BioSpace: Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D",https://www.biospace.com/article/releases/oncopeptides-withdraws-pepaxto-in-us-scale-down-organization-and-focus-on-r-and-amp-d/
DB16628,,FDA News Release: FDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-molybdenum-cofactor-deficiency-type
DB16628,,"OMIM: MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP A (# 252150)",https://www.omim.org/entry/252150
DB16628,,FDA Approved Drug Products: Nulibry (fosdenopterin) for intravenous injection,https://www.nulibry.com/pdfs/nulibry-prescribing-information.pdf
DB16628,,Health Canada: Sun safety tips for parents,https://www.canada.ca/en/health-canada/services/sun-safety/sun-safety-tips-parents.html
DB16628,,EMA CHMP Positive Opinion: Nulibry (fosdenopterin),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/nulibry
DB16628,,Globe Newswire: BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY (fosdenopterin) for the Treatment of MoCD Type A,https://www.globenewswire.com/news-release/2022/09/20/2519096/0/en/BridgeBio-Pharma-and-Sentynl-Therapeutics-Receive-Marketing-Authorization-in-the-EU-for-NULIBRY-fosdenopterin-for-the-Treatment-of-MoCD-Type-A.html
DB16628,,EMA Summary of Product Characteristics: NULIBRY (fosdenopterin) solution for injection,https://www.ema.europa.eu/en/documents/product-information/nulibry-epar-product-information_en.pdf
DB16629,,FDA Approved Drug Products: AZSTARYS (serdexmethylphenidate and dexmethylphenidate) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212994s000lbl.pdf
DB16629,,"KemPharm Poster: Braeckman, et al. (2018) American Professional Society for ADHD and Related Disorders",https://kempharm.com/wp-content/uploads/2018/01/Poster_KP415.109_Braeckman_FINAL.pdf
DB16629,,"KemPharm Poster: Braeckman, et al. (2019) American Professional Society for ADHD and Related Disorders",https://kempharm.com/wp-content/uploads/2019/01/APSARD-2019-KMPH-KP415-105-Ped-PK-Poster-2019_0118-FINAL.pdf
DB16629,,"KemPharm Poster: Braeckman, et al. poster 2 (2019) American Professional Society for ADHD and Related Disorders",https://kempharm.com/wp-content/uploads/2019/01/APSARD-2019-KMPH-KP415-110-Dose-Proportionality-Poster-2019_0118-FINAL.pdf
DB16641,,CStone Pharmaceuticals: CStone Pharmaceuticals Announced FDA Granted Breakthrough Therapy Designation to Anti-PD-L1 Antibody Sugemalimab for the Treatment of Adult Patients with R/R ENKTL,https://www.cstonepharma.com/en/html/news/2480.html
DB16641,,CStone Pharmaceuticals: Pipeline,https://www.cstonepharma.com/en/develop/p3.html
DB16647,,"FDA Approved Drug Products: KISUNLA (donanemab-azbt) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761248s000lbl.pdf
DB16647,,FDA News Release: FDA approves treatment for adults with Alzheimer’s disease,"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease#:~:text=The%20U.S.%20Food%20and%20Drug,the%20treatment%20of%20Alzheimer's%20disease."
DB16648,,Health Canada Product Monograph: Verity-BCG (Bacillus Calmette-Guérin Strain Russian BCG-I) for bladder instillation,https://pdf.hres.ca/dpd_pm/00061917.PDF
DB16648,,BioSpace: Bladder Cancer drug shortage resolved with health canada approval,https://www.biospace.com/article/releases/bladder-cancer-drug-shortage-resolved-with-health-canada-approval/
DB16650,,"FDA Approved Drug Products: SOTYKTU (deucravacitinib) tablets, for oral use",https://packageinserts.bms.com/pi/pi_sotyktu.pdf
DB16650,,Health Canada Approved Drug Products: SOTYKTU (deucravacitinib) Oral Tablets,https://pdf.hres.ca/dpd_pm/00068437.PDF
DB16650,,EMA Approved Drug Products: Sotyktu (deucravacitinib) Oral Tablets,https://www.ema.europa.eu/en/documents/product-information/sotyktu-epar-product-information_en.pdf
DB16650,,"Bristol Myers Squibb: Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis",https://news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Receives-European-Commission-Approval-of-Sotyktu-deucravacitinib-a-Once-Daily-Oral-Treatment-for-Adults-With-Moderate-to-Severe-Plaque-Psoriasis/default.aspx
DB16655,,EMA Approved Drug Products: TECVAYLI (teclistamab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf
DB16655,,Johnson & Johnson: Janssen Marks First Approval Worldwide for TECVAYLI® (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma,https://www.jnj.com/janssen-marks-first-approval-worldwide-for-tecvayli-teclistamab-with-ec-authorisation-of-first-in-class-bispecific-antibody-for-the-treatment-of-patients-with-multiple-myeloma
DB16655,,FDA: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma
DB16655,,"FDA Approved Drug Products: TECVAYLI (teclistamab-cqyv) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf
DB16662,,"FDA Approved Drug Products: ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] lyophilized powder for solution, for intravenous use (February 2023)",https://www.fda.gov/media/165594/download
DB16662,,"Globe News Wire: FDA approves once-weekly ALTUVIIIO, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection",https://www.globenewswire.com/news-release/2023/02/23/2614759/0/en/Press-Release-FDA-approves-once-weekly-ALTUVIIIO-a-new-class-of-factor-VIII-therapy-for-hemophilia-A-that-offers-significant-bleed-protection.html
DB16665,,FDA Approved Drug Products: Abecma (Idecabtagene Vicleucel) Intravenous Infusion,https://www.fda.gov/media/147055/download
DB16665,,FDA Approval Letter: Idecabtagene Vicleucel,https://www.fda.gov/media/147062/download
DB16665,,EMA Approved Drug Products: Abecma (idecabtagene vicleucel) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/abecma-epar-product-information_en.pdf
DB16665,,Health Canada Approved Drug Products: ABECMA (Idecabtagene vicleucel) Intravenous Injection,https://pdf.hres.ca/dpd_pm/00062535.PDF
DB16672,,FDA Approved Drug Products: EPKINLY (epcoritamab-bysp) injection for subcutaneous use (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf
DB16672,,PR NewsWire: EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),https://www.prnewswire.com/news-releases/epkinly-epcoritamab-bysp-approved-by-us-fda-as-the-first-and-only-bispecific-antibody-to-treat-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-301829783.html
DB16672,,EMA Summary of Product Characteristics: Tepkinly (epcoritamab) concentrate for solution for subcutaneous injection,https://www.ema.europa.eu/en/documents/product-information/tepkinly-epar-product-information_en.pdf
DB16672,,GlobeNewswire: Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL),https://www.globenewswire.com/news-release/2023/09/25/2748547/0/en/Genmab-Announces-European-Commission-Approval-of-TEPKINLY-epcoritamab-for-Adults-with-Relapsed-or-Refractory-R-R-Diffuse-Large-B-cell-Lymphoma-DLBCL.html
DB16672,,"FDA Approved Drug Products: EPKINLY (epcoritamab-bysp) injection, for subcutaneous use (June 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761324s003lbl.pdf
DB16678,,"FDA Approved Drug Products: TALVEY (talquetamab-tgvs) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf
DB16678,,FDA: FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma
DB16678,,Johnson & Johnson: Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma,https://www.jnj.com/janssen-receives-positive-chmp-opinions-for-novel-bispecific-antibodies-talvey-talquetamab-and-tecvayli-teclistamab-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma
DB16678,,EMA Summary of Opinion: Talvey (talquetamab),https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-talvey_en.pdf
DB16678,,EMA Approved Drug Products: Talvey (talquetamab) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/talvey-epar-product-information_en.pdf
DB16678,,"Johnson & Johnson: European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma",https://www.jnj.com/european-commission-approves-talvey-talquetamab-janssens-novel-bispecific-therapy-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma
DB16684,,OncLive: FDA Lifts Partial Clinical Hold on Odronextamab Studies in Follicular Lymphoma and DLBCL,https://www2.onclive.com/view/fda-lifts-partial-clinical-hold-on-odronextamab-studies-in-follicular-lymphoma-and-dlbcl
DB16684,,Regeneron: Regeneron Provides Update on Odronextamab Clinical Trials in B-cell NonHodgkin Lymphomas,https://investor.regeneron.com/static-files/690eeaf2-643e-44eb-9c3f-baad97eb9703
DB16688,,National Center for Advancing Translational Sciences (NCATS): REPROXALAP,https://drugs.ncats.io/substance/F0GIZ22IJH
DB16689,,European Medicines Agency (EMA): Zafiride,https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-zafiride_en.pdf%20
DB16691,,Clinical Trials: NCT04756531,https://clinicaltrials.gov/ct2/show/NCT04756531
DB16691,,Pfizer Press Release: PFIZER INITIATES PHASE 1 STUDY OF NOVEL ORAL ANTIVIRAL THERAPEUTIC AGENT AGAINST SARS-COV-2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral
DB16691,,FDA Emergency Use Authorization Fact Sheet: Paxlovid (nirmatrelvir and ritonavir) co-packaged for oral use,https://www.covid19oralrx.com/files/PP-PAX-USA-0007-EUA-Full-Prescribing-Info-HCP-Fact-Sheet-COVID-19-Oral-Antiviral-Combined.pdf
DB16691,,Health Canada Product Monograph: Paxlovid (nirmatrelvir and ritonavir) co-packaged for oral use,https://covid-vaccine.canada.ca/info/pdf/paxlovid-pm-en.pdf
DB16691,,Summary of Product Characteristics: Paxlovid (nirmatrelvir and ritonavir) oral tablets,https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf
DB16691,,EMA News: COVID-19: EMA recommends conditional marketing authorisation for Paxlovid,https://www.ema.europa.eu/en/news/covid-19-ema-recommends-conditional-marketing-authorisation-paxlovid
DB16691,,"FDA Approved Drug Products: PAXLOVID (nirmatrelvir and ritonavir) tablets, co-packaged for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf
DB16691,,FDA News Release: FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults
DB16693,,Health Canada Product Monograph: Awiqli (insulin icodec) solution for subcutaneous injection (March 2024),https://pdf.hres.ca/dpd_pm/00074917.PDF
DB16693,,EMA Summary of Product Characteristics: Awiqli (insulin icodec) solution for subcutaneous injection (March 2024),https://www.ema.europa.eu/en/documents/product-information/awiqli-epar-product-information_en.pdf
DB16693,,NIH Inxight Drugs: Insulin icodec,https://drugs.ncats.io/drug/P7YU3ED05N
DB16693,,"Fierce Pharma: Citing manufacturing issue, FDA rejects Novo Nordisk's once-weekly insulin",https://www.fiercepharma.com/pharma/fda-rejects-novo-nordisks-once-weekly-insulin-manufacturing-issues
DB16694,,FDA Approved Drug Products: Empaveli (Pegcetacoplan) Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215014s000lbl.pdf
DB16694,,Press Release: pegcetacoplan EMA approval,https://www.prnewswire.com/news-releases/aspaveli-pegcetacoplan-approved-in-eu-as-orphan-drug-for-treatment-of-pnh-301445216.html
DB16694,,Health Canada Approved Drug Products: EMPAVELI (pegcetacoplan) injection solution for subcutaneous infusion use,https://pdf.hres.ca/dpd_pm/00068658.PDF
DB16694,,FDA Approved Drug Products: SYFOVRE (pegcetacoplan) injection for intravitreal use (February 2023),https://pi.apellis.com/files/PI_SYFOVRE.pdf
DB16695,,FDA Approved Drug Products: Rybrevant (Amivantamab-vmjw) Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf
DB16695,,US Patent: US9593164B2,https://patentimages.storage.googleapis.com/41/64/24/577d7dd3d72d76/US9593164.pdf
DB16695,,"Health Canada Approved Drug Products: Rybrevant (amivantamab) injection, for intravenous infusion (March 2022)",https://pdf.hres.ca/dpd_pm/00065221.PDF
DB16695,,European Medicines Agency Medicines: Rybrevant (amivantamab),https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant
DB16695,,EMA Approved Drug Products: Rybrevant (amivantamab) intravenous injection,https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf
DB16695,,"FDA Approved Drug Products: RYBREVANT (amivantamab-vmjw) injection, for intravenous use (November 2022)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761210s002lbl.pdf
DB16695,,Health Canada Approved Drug Products: RYBREVANT (amivantamab) Intravenous Injection (June 2024),https://pdf.hres.ca/dpd_pm/00076138.PDF
DB16695,,"FDA Approved Drug Products: RYBREVANT (amivantamab-vmjw) injection, for intravenous use (August 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s005lbl.pdf
DB16698,,Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study,https://acrabstracts.org/abstract/efficacy-and-safety-of-neihulizumab-abgn-168h-in-patients-with-active-psoriatic-arthritis-24-week-results-from-a-phase-ii-open-label-study/
DB16699,,Alnylam: Vutrisiran Fact Sheet,https://www.alnylam.com/wp-content/uploads/pdfs/Vutrisiran-Fact-Sheet.pdf
DB16699,,FDA Approved Drug Products: AMVUTTRA (vutrisiran) injection for subcutaneous use,https://www.alnylam.com/sites/default/files/pdfs/amvuttra-us-prescribing-information.pdf
DB16699,,"Business Wire: Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults",https://www.businesswire.com/news/home/20220603005487/en/Alnylam-Announces-FDA-Approval-of-AMVUTTRA%E2%84%A2-vutrisiran-an-RNAi-Therapeutic-for-the-Treatment-of-the-Polyneuropathy-of-Hereditary-Transthyretin-Mediated-Amyloidosis-in-Adults
DB16699,,EMA Approved Drug Products:AMVUTTRA (vutrisiran) injection for subcutaneous use,https://www.ema.europa.eu/en/documents/product-information/amvuttra-epar-product-information_en.pdf
DB16701,,"FDA News Release: FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder",https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-plasminogen-deficiency-rare-genetic-disorder
DB16701,,"FDA Approved Drug Products: Ryplazim (plasminogen, human-tvmh) powder for reconsitution for intravenous injection",https://www.fda.gov/media/149806/download
DB16701,,National Organization for Rare Disorders: Congenital Plasminogen Deficiency,https://rarediseases.org/rare-diseases/congenital-plasminogen-deficiency/
DB16701,,Pathology Outlines: Anticoagulation / fibrinolytic pathway,https://www.pathologyoutlines.com/topic/coagulationantithrombinnormal.html
DB16702,,National Center for Advancing Translational Sciences - Famprofazone,https://drugs.ncats.io/drug/HN0NCX453C#general
DB16702,,World Anti-Doping Agency: Prohibited In-Competition,https://www.wada-ama.org/en/content/what-is-prohibited/prohibited-in-competition
DB16703,,FDA Approved Drug Products: Rezurock (belumosudil) tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214783s000lbl.pdf
DB16703,,FDA News Release: FDA approves belumosudil for chronic graft-versus-host disease,https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-belumosudil-chronic-graft-versus-host-disease
DB16703,,Kadmon: Belumosudil Mechanism of Action,https://kadmon.com/clinical-pipeline/kd025-in-cgvhd/about-kd025/
DB16703,,MedChemExpress: Belumosudil Safety Data Sheet,https://file.medchemexpress.com/batch_PDF/HY-15307/Belumosudil-SDS-MedChemExpress.pdf
DB16703,,Health Canada Approved Drug Proucts: RHOLISTIQ (Belumosudil) tablet for oral use,https://pdf.hres.ca/dpd_pm/00065146.PDF
DB16703,,Health Canada News Release: Health Canada approves belumosudil for chronic graft-versus-host disease,https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00595&lang=en
DB16704,,"FDA Approved Drug Products: XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf
DB16708,,EMA Summary of Opinion: Pombiliti (cipaglucosidase alfa),https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-pombiliti_en.pdf
DB16708,,EMA Approved Drug Products: Pombiliti (cipaglucosidase alfa) Intravenous Infusion,https://www.ema.europa.eu/en/documents/product-information/pombiliti-epar-product-information_en.pdf
DB16708,,"FDA Approved Drug Products: POMBILITI (cipaglucosidase alfa-atga) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761204s000lbl.pdf
DB16708,,Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease,https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-fda-approval-and-launch-new
DB16709,,FDA Approved Drug Products: Stratagraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen- dsat) for topical use,https://www.fda.gov/media/150129/download
DB16709,,FDA Press Announcement: FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns,https://www.fda.gov/news-events/press-announcements/fda-approves-stratagraft-treatment-adults-thermal-burns
DB16726,,"Health Canada Approved Drug Products: FLUCELVAX QUAD Influenza Vaccine, for intramuscular injection",https://pdf.hres.ca/dpd_pm/00065002.PDF
DB16727,,"Health Canada Approved Drug Products: FLUCELVAX QUAD Influenza Vaccine, for intramuscular injection",https://pdf.hres.ca/dpd_pm/00065002.PDF
DB16732,,"FDA Approved Drug Products: TIVDAK (tisotumab vedotin-tftv) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf
DB16732,,Drugs.com News: FDA Grants Accelerated Approval for Tivdak,https://www.drugs.com/newdrugs/fda-grants-accelerated-approval-tivdak-tisotumab-vedotin-tftv-previously-treated-recurrent-5663.html
DB16732,,"FDA Approved Drug Products: TIVDAK (tisotumab vedotin-tftv) for injection, for intravenous use (April 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761208s007lbl.pdf
DB16732,,FDA: FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer
DB16733,,Clinical Trial: NCT03688685,https://clinicaltrials.gov/ct2/show/NCT03688685
DB16736,,FDA Approved Drug Products: RETHYMIC (Allogeneic processed thymus tissue–agdc) For surgical implantation,https://www.fda.gov/media/152912/download
DB16736,,Drugs.com: FDA Approves Rethymic,https://www.drugs.com/newdrugs/fda-approves-rethymic-allogeneic-processed-thymus-tissue-agdc-one-time-regenerative-tissue-based-5684.html
DB16738,,FDA Approved Drug Products: Carvykti (ciltacabtagene autoleucel) suspension for intravenous infusion,https://www.fda.gov/media/156560/download
DB16738,,"Johnson & Johnson: U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma",https://www.jnj.com/u-s-fda-approves-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy-a-bcma-directed-car-t-immunotherapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma
DB16738,,National Organization for Rare Disorders: Multiple Myeloma,https://rarediseases.org/rare-diseases/multiple-myeloma/
DB16746,,EMA Summary of Product Characteristics: Skyvona (elivaldogene autotemcel) for intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/skysona-epar-product-information_en.pdf
DB16746,,European Medicines Agency: Skysona (elivaldogene autotemcel),https://www.ema.europa.eu/en/medicines/human/EPAR/skysona
DB16746,,FDA Approved Drug Products: SKYSONA (elivaldogene autotemcel) suspension for intravenous infusion,https://www.bluebirdbio.com/-/media/bluebirdbio/Corporate%20COM/Files/Skysona/SKYSONA_Prescribing_Information.pdf
DB16755,,FDA Emergency Use Authorization Fact Sheet: Bebtelovimab injection for intravenous administration,http://pi.lilly.com/eua/bebtelovimab-eua-factsheet-hcp.pdf
DB16755,,FDA News Release: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains
DB16755,,FDA News Release: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron
DB16755,,FDA Drug Safety and Availability: FDA Updates on Bebtelovimab,"https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-bebtelovimab#:~:text=%5BNovember%204%2C%202022%5D%20FDA,.1%20and%20BQ.1.1."
DB16755,,FDA Drug Safety and Availability: FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region,https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region
DB16756,,BioSpace: Reistone Announces Positive Results from a Phase II Study Evaluating SHR0302 Ointment for Patients with Mild-to-Moderate Atopic Dermatitis,https://www.biospace.com/article/releases/reistone-announces-positive-results-from-a-phase-ii-study-evaluating-shr0302-ointment-for-patients-with-mild-to-moderate-atopic-dermatitis/
DB16756,,"PR Newswire: Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis",https://www.prnewswire.com/news-releases/reistone-biopharma-announces-positive-topline-results-from-phase-2-clinical-trial-evaluating-shr0302-a-jak1-inhibitor-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301159478.html
DB16756,,NCT04481139: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis,https://clinicaltrials.gov/ct2/show/NCT04481139
DB16756,,NCT04333771: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis,https://clinicaltrials.gov/ct2/show/NCT04333771
DB16756,,NCT04957550: To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis,https://clinicaltrials.gov/ct2/show/NCT04957550
DB16756,,NCT04146207: SHR0302 and Steroid as First Line Therapy for Chronic GVHD,https://clinicaltrials.gov/ct2/show/NCT04146207
DB16756,,NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (MARBLE-23),https://clinicaltrials.gov/ct2/show/NCT04717310
DB16756,,NCT04774809: Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo,https://clinicaltrials.gov/ct2/show/NCT04774809
DB16756,,NCT05181137: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis,https://clinicaltrials.gov/ct2/show/NCT05181137
DB16756,,NCT04162899: A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis,https://clinicaltrials.gov/ct2/show/NCT04162899
DB16756,,NCT04346316: A Phase II Study in Patients With Alopecia Areata,https://clinicaltrials.gov/ct2/show/NCT04346316
DB16756,,NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis,https://clinicaltrials.gov/ct2/show/NCT04875169
DB16756,,NCT05136456: Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy,https://clinicaltrials.gov/ct2/show/NCT05136456
DB16757,,"Health Canada Product Monograph: Covifenz (plant-based virus-like particles, recombinant, adjuvanted) emulsion for intramuscular injection (February 2022)",https://medicago.com/app/uploads/2022/02/Covifenz-PM-en.pdf
DB16757,,"Health Canada Approved Drug Products: COVIFENZ COVID-19 Vaccine (plant-based virus-like particles [VLP], recombinant, adjuvanted) Intramuscular Injection (March 2023)",https://pdf.hres.ca/dpd_pm/00070331.PDF
DB16778,,"FDA Approved Drug Products: PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use",https://www.novartis.us/sites/www.novartis.us/files/pluvicto.pdf
DB16778,,"Novartis News: Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer",https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer
DB16778,,"EMA Assessment Report: EndolucinBeta, INN-Lutetium (177 Lu) chloride",https://www.ema.europa.eu/en/documents/assessment-report/endolucinbeta-epar-public-assessment-report_en.pdf
DB16778,,EMA Summary of Opinion: Pluvicto (lutetium Lu 177 vipivotide tetraxetan),https://www.ema.europa.eu/en/medicines/human/summaries-opinion/pluvicto
DB16778,,EMA Summary of Product Characteristics: Pluvicto (lutetium 177Lu vipivotide tetraxetan) solution for injection/infusion for intravenous use (December 2022),https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf
DB16780,,EMA Assessment Report: Upstaza (eladocagene exuparvovec) solution for infusion,https://www.ema.europa.eu/en/documents/product-information/upstaza-epar-product-information_en-0.pdf
DB16780,,PTC Therapeutics: Upstaza Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency,https://ir.ptcbio.com/news-releases/news-release-details/upstazatm-granted-marketing-authorization-european-commission
DB16780,,FDA Approved Drug Products: Kebilidi (eladocagene exuparvovec-tneq) suspension for intraputaminal infusion (November 2024),https://www.fda.gov/media/183530/download
DB16780,,FDA News Release: FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency,https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-aromatic-l-amino-acid-decarboxylase-deficiency
DB16783,,Pfizer: Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study
DB16783,,Health Canada Approved Drug Proucts: BEQVEZ (Fidanacogene elaparvovec) Concentrate for solution for intravenous infusion,https://pdf.hres.ca/dpd_pm/00073965.PDF
DB16783,,HEALTH CANADA APPROVES PFIZER CANADA'S GENE THERAPY IN HEMOPHILIA B,https://www.newswire.ca/news-releases/health-canada-approves-pfizer-canada-s-gene-therapy-in-hemophilia-b-841249479.html
DB16783,,"FDA Approved Drug Products: BEQVEZ (fidanacogene elaparvovec-dzkt) injection, for intravenous infusion",https://www.fda.gov/media/178140/download?attachment
DB16783,,"Business Wire: U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B",https://www.businesswire.com/news/home/20240425269649/en/U.S.-FDA-Approves-Pfizer%E2%80%99s-BEQVEZ%E2%84%A2-fidanacogene-elaparvovec-dzkt-a-One-Time-Gene-Therapy-for-Adults-with-Hemophilia-B
DB16788,,PR Newswire: Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B,https://www.prnewswire.com/news-releases/sangamo-announces-treatment-of-first-patient-in-phase-12-clinical-trial-of-in-vivo-genome-editing-therapy-for-hemophilia-b-300767281.html
DB16788,,National Hemophilia Foundation: Sangamo Announces First Patient Treated in Hemophilia B Gene Therapy Trial,https://www.hemophilia.org/news/sangamo-announces-first-patient-treated-in-hemophilia-b-gene-therapy-trial
DB16789,,PR Newswire: Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913,https://www.prnewswire.com/news-releases/sangamo-announces-interim-results-of-phase-12-champions-study-showing-preliminary-evidence-of-in-vivo-genome-editing-in-patients-with-mps-ii-treated-with-sb-913-300791656.html
DB16790,,Sangamo: Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I,https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-interim-results-phase-12-empowers-study
DB16791,,FDA Approved Drug Products: Hemgenix (etranacogene dezaparvovec-drlb) suspension for intravenous infusion,https://www.fda.gov/media/163467/download
DB16791,,FDA News Release: FDA Approves First Gene Therapy to Treat Adults with Hemophilia B,https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b
DB16791,,National Hemophilia Foundation: Hemophilia B,https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-b
DB16791,,National Organization for Rare Disorders (NORD): Hemophilia B,https://rarediseases.org/rare-diseases/hemophilia-b/
DB16791,,"CNN: FDA approves $3.5 million treatment for hemophilia, now the most expensive drug in the world",https://www.cnn.com/2022/11/23/health/hemophilia-drug-hemgenix
DB16791,,EMA Summary of Opinion: Hemgenix (etranacogene dezaparvovec),https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-hemgenix_en.pdf
DB16791,,"PR NewsWire: First Gene Therapy for Hemophilia B, CSL's HEMGENIX, Approved by the European Commission",https://www.prnewswire.com/news-releases/first-gene-therapy-for-hemophilia-b-csls-hemgenix-approved-by-the-european-commission-301751222.html
DB16791,,EMA Summary of Product Characteristics: HEMGENIX (etranacogene dezaparvovec) concentrate for solution for infusion,https://www.ema.europa.eu/en/documents/product-information/hemgenix-epar-product-information_en.pdf
DB16791,,Canadian Hemophilia Society (CHS) Contact: Health Canada approves Hemgenix gene therapy for hemophilia B,https://chscontact.ca/health-canada-approves-hemgenix-gene-therapy-for-hemophilia-b/
DB16791,,Health Canada Product Monograph: Hemgenix (etranacogene dezaparvovec) suspension for intravenous infusion,https://pdf.hres.ca/dpd_pm/00072954.PDF
DB16802,,"FDA Approved Drug Products: ELEVIDYS (delandistrogene moxeparvovec-rokl) suspension, for intravenous infusion",https://www.fda.gov/media/169679/download
DB16802,,"Business Wire: Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy",https://www.businesswire.com/news/home/20230622454844/en/
DB16816,,BioSpace: Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis,https://www.biospace.com/article/releases/lysogene-announces-fda-fast-track-designation-for-lys-gm101-gene-therapy-for-the-treatment-of-gm1-gangliosidosis/
DB16820,,Health Canada Product Monograph: Letybo (letibotulinumtoxinA) powder for solution for intramuscular injection,https://pdf.hres.ca/dpd_pm/00066317.PDF
DB16820,,BusinessWire: Croma Aesthetics Canada Ltd. Receives Canadian Market Authorization for Letybo (LetibotulinumtoxinA for Injection) for the Treatment of Glabellar Lines,https://www.businesswire.com/news/home/20220623005812/en/Croma-Aesthetics-Canada-Ltd.-Receives-Canadian-Market-Authorization-for-Letybo-LetibotulinumtoxinA-for-Injection-for-the-Treatment-of-Glabellar-Lines
DB16820,,Botox Medical: BOTOX Mechanism of Action,https://www.botoxmedical.com/FocalSpasticity/Efficacy/MechanismOfAction
DB16820,,BioSpace: Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines,https://www.biospace.com/article/releases/hugel-receives-fda-approval-in-the-united-states-of-letybo-letibotulinumtoxina-wlbg-for-injection-for-the-treatment-of-glabellar-lines/
DB16820,,FDA Approved Drug Products: Letybo (letibotulinumtoxinA-wlbg) for intramuscular injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761225s000lbl.pdf
DB16826,,"FDA Approved Drug Products: AUGTYRO™ (repotrectinib) capsules, for oral use (November 2023)",https://packageinserts.bms.com/pi/pi_augtyro.pdf
DB16826,,"U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)",https://news.bms.com/news/corporate-financial/2023/US-Food-and-Drug-Administration-Approves-Augtyro/default.aspx
DB16826,,FDA Approved Drug Products: Augtyro (repotrectinib) capsules for oral use (June 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf
DB16900,,FDA Approved Drug Products: ZYNTEGLO (betibeglogene autotemcel) suspension for intravenous infusion,https://www.bluebirdbio.com/-/media/bluebirdbio/CorporateCOM/Files/Zynteglo/ZYNTEGLO_prescribing_information.pdf
DB16900,,"Business Wire: bluebird bio Announces FDA Approval of ZYNTEGLO, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions",https://www.businesswire.com/news/home/20220817005667/en/bluebird-bio-Announces-FDA-Approval-of-ZYNTEGLO%C2%AE-the-First-Gene-Therapy-for-People-with-Beta-Thalassemia-Who-Require-Regular-Red-Blood-Cell-Transfusions
DB16956,,FDA Approved Drug Products: Aqneursa (levacetylleucine) for oral suspension (September 2024),https://intrabio.com/wp-content/aqneursa-prescribing-information.pdf
DB16956,,"FDA News Release: FDA Approves New Drug to Treat Niemann-Pick Disease, Type C",https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-niemann-pick-disease-type-c
DB16981,,Ultragenyx: ULTRAGENYX AND GENETX PROVIDE PROGRAM UPDATE ON GTX-102 FOR ANGELMAN SYNDROME INCLUDING PROMISING INTERIM DATA FROM PHASE 1/2 STUDY,https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-and-genetx-provide-program-update-gtx-102-angelman
DB17011,,Globe Newswire News Release: Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy,https://www.globenewswire.com/news-release/2023/06/26/2694388/0/en/Benitec-Biopharma-Receives-FDA-Clearance-of-the-IND-for-BB-301-for-the-Treatment-of-Oculopharyngeal-Muscular-Dystrophy.html
DB17019,,Imcyse: Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope IMCY-0141 for Multiple Sclerosis,https://www.imcyse.com/news-2/53-imcyse-announces-first-patient-dosed-in-adaptive-phase-1-2-clinical-trial-of-imotope%E2%84%A2-imcy-0141-for-multiple-sclerosis.html
DB17069,,"SciTechDaily: A New, More Effective Alzheimer’s Drug With No Inflammatory Side Effects",https://scitechdaily.com/a-new-more-effective-alzheimers-drug-with-no-inflammatory-side-effects/
DB17070,,Prevail Therapeutics: Pipeline,https://www.prevailtherapeutics.com/programs/
DB17072,,EMA: First therapy to treat transplant patients with post-transplant lymphoproliferative disease,https://www.ema.europa.eu/en/news/first-therapy-treat-transplant-patients-post-transplant-lymphoproliferative-disease
DB17072,,Atara Biotherapeutics: Tabelecleucel (tab‐cel) – Investigational PTLD T-cell immunotherapy,https://www.atarabio.com/pipeline/tabelecleucel/
DB17075,,Business Wire: Myrtelle Completes Dosing of 8 Patients with Canavan Disease in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA,https://www.businesswire.com/news/home/20221004005149/en/Myrtelle-Completes-Dosing-of-8-Patients-with-Canavan-Disease-in-Its-Phase-12-Clinical-Trial-of-the-Investigational-Gene-Therapy-rAAV-Olig001-ASPA
DB17075,,"Business Wire: Myrtelle Receives FDA Fast Track, Rare Pediatric Disease, and Orphan Drug Designations for its Proprietary Gene Therapy for the Treatment of Canavan Disease",https://www.businesswire.com/news/home/20220315005230/en/Myrtelle-Receives-FDA-Fast-Track-Rare-Pediatric-Disease-and-Orphan-Drug-Designations-for-its-Proprietary-Gene-Therapy-for-the-Treatment-of-Canavan-Disease
DB17080,,Kyowa Kirin: Kyowa Kirin Announces Positive Phase 2b Results for KW-6356 in Patients with Parkinson's Disease,https://www.kyowakirin.com/media_center/news_releases/2020/e20201021_01.html
DB17083,,EMA Summary of Product Characteristics: Yselty (linzagolix choline) film-coated tablets for oral administration,https://www.ema.europa.eu/en/documents/product-information/yselty-epar-product-information_en.pdf
DB17083,,CHMP Public Assessment Report: Linzagolix choline,https://www.ema.europa.eu/en/documents/assessment-report/yselty-epar-public-assessment-report_en.pdf
DB17084,,FDA Approved Drug Products: ELUCIREM (gadopiclenol) injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf
DB17084,,"FDA Approved Drug Products: ELUCIREMTM (gadopiclenol) injection, for intravenous use (Jan 2024)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216986s002lbl.pdf
DB17088,,Health Canada Product Monograph: Comirnaty Original & Omicron BA.4/BA.5 (tozinameran/famtozinameran) suspension for intramuscular injection,https://pdf.hres.ca/dpd_pm/00067598.PDF
DB17088,,FDA Emergency Use Authorization: Pfizer-BioNTech COVID-19 Vaccine (Original & Omicron BA.4/BA.5 strain) suspension for intramuscular injection,https://www.fda.gov/media/161327/download
DB17088,,CDC COVID-19: Variants of the Virus,https://www.cdc.gov/coronavirus/2019-ncov/variants/index.html
DB17088,,WHO: Tracking SARS-CoV-2 Variants,https://www.who.int/activities/tracking-SARS-CoV-2-variants
DB17088,,FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-updated-bivalent-covid-19-vaccines-children-down-6-months
DB17090,,Health Canada Product Monograph: Spikevax Bivalent (Original / BA.1 Omicron) dispersion for intramuscular injection,https://pdf.hres.ca/dpd_pm/00069607.PDF
DB17090,,WHO: Tracking SARS-CoV-2 Variants,https://www.who.int/activities/tracking-SARS-CoV-2-variants
DB17091,,Health Canada Product Monograph: SPIKEVAX™ Bivalent (Elasomeran / davesomeran mRNA vaccine) for intramuscular injection,https://pdf.hres.ca/dpd_pm/00067971.PDF
DB17091,,"FDA Approved Drug Products: MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)",https://www.fda.gov/media/161318/download
DB17091,,FDA EUA Drug Products: Moderna COVID-19 Vaccine,https://www.fda.gov/media/144637/download
DB17091,,"Summary of Product Characteristics: Spikevax (COVID-19 mRNA Vaccine, nucleoside modified) Intramuscular Injection",https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf
DB17091,,FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age,https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-updated-bivalent-covid-19-vaccines-children-down-6-months
DB17095,,Health Canada Product Monograph: Comirnaty Original & Omicron BA.1 (tozinameran/riltozinameran) suspension for intramuscular injection,https://pdf.hres.ca/dpd_pm/00067818.PDF
DB17095,,WHO: Tracking SARS-CoV-2 Variants,https://www.who.int/activities/tracking-SARS-CoV-2-variants
DB17095,,CDC COVID-19: Variants of the Virus,https://www.cdc.gov/coronavirus/2019-ncov/variants/index.html
DB17097,,"FDA Approved Drug Products: VORANIGO (vorasidenib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf
DB17097,,FDA: FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation
DB17107,,FDA Approved Drug Products: AMTAGVI (lifileucel) suspension for intravenous infusion,https://www.fda.gov/media/176417/download?attachment
DB17107,,FDA: FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma
DB17132,,FDA Approved Drug Products: OMISIRGE (omidubicel-onlv) suspension for infusion for intravenous use (April 2023),http://www.gamida-cell.com/wp-content/uploads/Omisirge-final-PI.pdf
DB17132,,US Food & Drug Administration: FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation,https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell
DB17162,,Antengene Biologics Limited: Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA,https://www.antengene.com/static/upload/sofa/20220919/5da0c0f70e8d5b29cdc320ffd7762115.pdf
DB17164,,PR NewsWire: ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma,https://www.prnewswire.com/news-releases/zielbio-receives-orphan-drug-designation-for-zb131-for-the-treatment-of-cholangiocarcinoma-301678075.html
DB17165,,"Kymera: Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma",https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-receives-fda-orphan-drug-designation-kt-0
DB17192,,OncLive: FDA Grants Orphan Drug Designation to WP1122 for Glioblastoma Multiforme,https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-wp1122-for-glioblastoma-multiforme
DB17207,,BioSpace: FDA Grants Orphan Drug Designation To OS2966 In The Treatment Of Ovarian Cancer,https://www.biospace.com/article/releases/fda-grants-orphan-drug-designation-to-os2966-in-the-treatment-of-ovarian-cancer-/
DB17215,,Singh Biotechnology: Singh Biotechnology Receives FDA Orphan Drug Designation for its Novel Single Domain Antibody for Treatment of Pancreatic Cancer,https://www.singhbiotechnology.com/pancreatic-cancer-orphan-drug-press-release.html
DB17215,,Singh Biotechnology: Singh Biotechnology Receives Second FDA Orphan Drug Designation for its Novel Single Domain Antibody for the Treatment of Osteosarcoma by Targeting Intracellular STAT3,https://www.singhbiotechnology.com/osteosarcoma.html
DB17256,,FDA Approved Drug Products: Imdelltra (tarlatamab-dlle) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf
DB17256,,"BioSpace: FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER",https://www.biospace.com/article/releases/fda-approves-imdelltra-tarlatamab-dlle-the-first-and-only-t-cell-engager-therapy-for-the-treatment-of-extensive-stage-small-cell-lung-cancer/?s=74
DB17262,,Immuno-oncology News: GALE-301,https://immuno-oncologynews.com/immuno-oncology-therapy-gale-301-is-designed-to-prevent-cancer-from-returning/
DB17262,,BioSpace: Galena Biopharma Receives Two Orphan Drug Designations For GALE-301 And GALE-301/GALE-302,https://www.biospace.com/article/releases/galena-biopharma-receives-two-orphan-drug-designations-for-gale-301-and-gale-301-gale-302-/
DB17275,,Sapience Therapeutics: Sapience Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ST-36 for the Treatment of Glioma,https://sapiencetherapeutics.com/sapience-therapeutics-receives-orphan-drug-designation-from-the-u-s-fda-for-st-36-for-the-treatment-of-glioma/
DB17288,,Globe Newswire News Release: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305,https://www.globenewswire.com/en/news-release/2016/01/08/800617/21160/en/Immune-Design-Receives-Orphan-Drug-Designation-From-the-U-S-FDA-for-Complementary-Components-of-CMB305.html
DB17292,,Globe Newswire News Release: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305,https://www.globenewswire.com/en/news-release/2016/01/08/800617/21160/en/Immune-Design-Receives-Orphan-Drug-Designation-From-the-U-S-FDA-for-Complementary-Components-of-CMB305.html
DB17338,,Fierce Biotech: miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for the Treatment of Polycythemia Vera,https://www.fiercebiotech.com/biotech/miragen-therapeutics-receives-orphan-drug-designation-for-mgn-4893-for-treatment-of
DB17367,,Clinicaltrials.gov: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer,https://clinicaltrials.gov/ct2/show/NCT03907852
DB17369,,Rigenerand SRL: Anti-Cancer Gene Therapies,https://rigenerand-biotech.com/drug-development/
DB17370,,Cancer.gov: autologous TBX-4000-treated peripheral blood mononuclear cells TBX-3400,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/autologous-tbx-4000-treated-peripheral-blood-mononuclear-cells-tbx-3400
DB17370,,BioSpace: Taiga Treats First Cancer Patient in TBX-3400-003 Clinical Trial in Israel,https://www.biospace.com/article/releases/taiga-treats-first-cancer-patient-in-tbx-3400-003-clinical-trial-in-israel/
DB17373,,ASH: Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes,https://ash.confex.com/ash/2020/webprogram/Paper140410.html
DB17381,,FDA Approved Drug Products: ADSTILADRIN (nadofaragene firadenovec-vncg) suspension for intravesical use,https://www.ferringusa.com/wp-content/uploads/sites/12/2022/12/ADSTILADRIN_pi.pdf
DB17381,,"Ferring Pharmaceuticals: Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer",https://www.ferring.com/ferring-receives-approval-from-u-s-fda-for-adstiladrin-for-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer/
DB17386,,FDA Approved Drug Products: XENOVIEW (xenon Xe 129 hyperpolarized) for oral inhalation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf
DB17386,,Globe News Wire: FDA Approves Polarean’s XENOVIEW (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation,https://www.globenewswire.com/news-release/2022/12/28/2580194/0/en/FDA-Approves-Polarean-s-XENOVIEW-xenon-Xe-129-hyperpolarized-for-use-with-MRI-for-the-Evaluation-of-Lung-Ventilation.html
DB17424,,National Cancer Institute: MVA-BN-brachyury-TRICOM vaccine,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mva-bn-brachyury-tricom-vaccine?redirect=true
DB17449,,FDA Approved Drug Products: NEXOBRID (anacaulase-bcdb) for topical gel,https://nexobrid-us.com/pdf/nexobrid-full-prescribing-information.pdf
DB17449,,EMA Summary of Product Characteristics: NexoBrid powder and gel,https://www.ema.europa.eu/en/documents/product-information/nexobrid-epar-product-information_en.pdf
DB17472,,FDA Approved Drug Products: JAYPIRCA (pirtobrutinib) tablets for oral use,https://pi.lilly.com/us/jaypirca-uspi.pdf?s=pi
DB17472,,"BioSpace: U.S. FDA Approves Jaypirca (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor",https://www.biospace.com/article/releases/u-s-fda-approves-jaypirca-pirtobrutinib-the-first-and-only-non-covalent-reversible-btk-inhibitor-for-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-after-at-least-two-lines-of-systemic-therapy-including-a-btk-inhibitor/?s=74
DB17477,,EMA: Graspa: Withdrawal of the marketing authorisation application,https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/graspa-0
DB17511,,F-Star Therapeutics: SB 11285,https://f-star.com/pipeline/sb-11285/
DB17512,,Cancer.gov: DNA vaccine VB10.16,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/dna-vaccine-vb1016
DB17538,,EMA Summary of Product Characteristics: Libmeldy (atidarsagene autotemcel) dispersion for intravenous infusion,https://www.ema.europa.eu/en/documents/product-information/libmeldy-epar-product-information_en.pdf
DB17538,,EMA EPAR: Libmeldy (atidarsagene autotemcel),https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy
DB17538,,FDA Approved Drug Products: Lenmeldy (atidarsagene autotemcel) suspension for intravenous infusion,https://www.orchard-tx.com/wp-content/uploads/2024/03/USPI_final_3-18-24.pdf
DB17538,,FDA Press Announcement: FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy,https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-children-metachromatic-leukodystrophy
DB17586,,AbbVie: Pipeline,https://www.abbvie.com/science/pipeline.html
DB17587,,NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations,https://clinicaltrials.gov/ct2/show/study/NCT05242822
DB17587,,Pharmaceutical Technology: Kinnate Biopharma’s CCA therapy KIN-3248 receives FDA Fast Track status,https://www.pharmaceutical-technology.com/news/kinnate-kin-3248-fda-fast-track/
DB17587,,"Kinnate Biopharma: Validated Oncogenic Drivers, An Important Source to Expand Targeted Therapy Access",https://www.thejournalofprecisionmedicine.com/wp-content/uploads/validated-oncogenic-drivers.pdf
DB17597,,"Globe Newswire News Release: Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema",https://www.globenewswire.com/news-release/2022/09/01/2508902/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2002-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Hereditary-Angioedema.html
DB17598,,Business Wire: LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate,https://www.businesswire.com/news/home/20200415005265/en/LEO-Pharma-Enters-License-Agreement-with-Oneness-Biotech-and-Microbio-Shanghai-for-FB825-a-Novel-Atopic-Dermatitis-and-Asthma-Drug-Candidate
DB17625,,Arrowhead Pharmaceuticals: Arrowhead Receives FDA Fast Track Designation for ARO-APOC3,https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-receives-fda-fast-track-designation-aro-apoc3
DB17626,,Arrowhead Pharmaceuticals: Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3,https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-orphan-drug-designation-aro-1
DB17628,,BioSpace: Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022,https://www.biospace.com/article/releases/denali-therapeutics-announces-new-interim-data-from-phase-1-2-study-of-dnl310-etv-ids-in-mps-ii-hunter-syndrome-at-ssiem-2022/
DB17632,,REGENXBIO: FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I),https://ir.regenxbio.com/news-releases/news-release-details/fda-grants-rare-pediatric-disease-designation-regenxbios-rgx-111
DB17635,,"FDA Approved Drug Products: RIVFLOZA (nedosiran) injection, for subcutaneous use",https://www.novo-pi.com/rivfloza.pdf
DB17635,,"FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition","https://www.prnewswire.com/news-releases/fda-approves-rivfloza-for-children-9-years-old-and-adults-living-with-primary-hyperoxaluria-type-1-ph1-a-rare-genetic-condition-301944564.html#:~:text=RivflozaTM%20(nedosiran)%20injection%2C,PH1)%20and%20relatively%20preserved%20kidney"
DB17637,,Sanfilippo News: Phoenix Nest Gains Rights to Potential Gene Therapy for Sanfilippo Syndrome Type C,https://sanfilipponews.com/news/phoenix-nest-gains-rights-develop-gene-therapy-sanfilippo-type-c/
DB17639,,REGENXBIO: REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia,https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-initiation-phase-iii-clinical-trial-rgx-501
DB17643,,The University of Alabama at Birmingham: Drug developed from UAB research sharply lowers cholesterol in animal tests,https://www.uab.edu/news/research/item/6366-drug-developed-from-uab-research-sharply-lowers-cholesterol-in-animal-tests
DB17643,,"Globe Newswire News Release: Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study",https://www.globenewswire.com/news-release/2016/12/19/898902/0/en/Capstone-Therapeutics-Announces-Profound-Rapid-LDL-Cholesterol-Reduction-in-AEM-28-14-Primate-Study.html
DB17645,,"Pharmaceutical Technology: As EGT-101 moves closer to clinical approval, what is the likelihood that the drug will be approved?",https://www.pharmaceutical-technology.com/data-analysis/egt-101-what-is-the-likelihood-that-drug-will-be-approved/
DB17646,,Pfizer: VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease,https://www.pfizer.com/news/press-release/press-release-detail/vtx-801-receives-us-fda-fast-track-designation-treatment
DB17647,,Business Wire: Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease,https://www.businesswire.com/news/home/20230206005252/en/Rocket-Pharmaceuticals-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-RP-A501-Gene-Therapy-for-Danon-Disease
DB17648,,PR Newswire: ESTEVE and UAB Expand Their Research to Two New Gene Therapies for Sanfilippo B Syndrome and Hunter Syndrome,https://www.prnewswire.com/news-releases/esteve-and-uab-expand-their-research-to-two-new-gene-therapies-for-sanfilippo-b-syndrome-and-hunter-syndrome-570100741.html
DB17649,,PR Newswire: ESTEVE and UAB Expand Their Research to Two New Gene Therapies for Sanfilippo B Syndrome and Hunter Syndrome,https://www.prnewswire.com/news-releases/esteve-and-uab-expand-their-research-to-two-new-gene-therapies-for-sanfilippo-b-syndrome-and-hunter-syndrome-570100741.html
DB17650,,Clinicaltrials.gov: Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease,https://clinicaltrials.gov/ct2/show/NCT04145037
DB17651,,"Clinicaltrials.gov: Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease",https://clinicaltrials.gov/ct2/show/NCT03454893
DB17651,,AVROBIO: AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease,https://investors.avrobio.com/news-releases/news-release-details/avrobio-provides-regulatory-update-investigational-avr-rd-01
DB17652,,Globe Newswire News Release: Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA,https://www.globenewswire.com/news-release/2022/12/12/2571716/0/en/Orchard-Therapeutics-Announces-Promising-Early-Neurocognitive-Outcomes-from-Ongoing-Proof-of-concept-Study-of-OTL-201-in-MPS-IIIA.html
DB17655,,Aro Biotherapeutics: Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease,https://www.arobiotx.com/aro-receives-fda-orphan-drug-designation-for-abx1100
DB17666,,Synlogic: Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update,https://investor.synlogictx.com/news-releases/news-release-details/synlogic-announces-synb1353-achieves-proof-mechanism-treatment
DB17667,,Business Wire: Synlogic Proprietary Synthetic Biotic Receives FDA Orphan Drug Designation,https://www.businesswire.com/news/home/20160829005243/en/Synlogic-Proprietary-Synthetic-Biotic-Receives-FDA-Orphan-Drug-Designation
DB17667,,Synlogic: Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia,https://investor.synlogictx.com/news-releases/news-release-details/synlogic-discontinues-development-synb1020-treat-hyperammonemia
DB17669,,Business Wire: Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927),https://www.businesswire.com/news/home/20191022006101/en/Moderna-Receives-FDA-Fast-Track-Designation-for-Propionic-Acidemia-Program-mRNA-3927
DB17696,,Pharmaceutical Technology: ASP-8731 by Mitobridge for Sickle Cell Disease: Likelihood of Approval,https://www.pharmaceutical-technology.com/data-insights/asp-8731-mitobridge-sickle-cell-disease-likelihood-of-approval/
DB17697,,BioSpace: Vaderis Forms to Tackle Vascular Malformations with Novartis Vet at the Helm,https://www.biospace.com/article/vaderis-forms-to-tackle-vascular-malformations-with-novartis-veteran-at-the-helm-/
DB17699,,BioSpace: Dimension Therapeutics Throws In The Towel On Hemophilia B Drug,https://www.biospace.com/article/releases/dimension-therapeutics-throws-in-the-towel-on-hemophilia-b-drug-/
DB17702,,Wong Pharmaceuticals: WP1301,http://www.worgpharma.com/index.php?c=category&id=82
DB17703,,The Pharma Letter: Avigen discontinues Coagulin-B,https://www.thepharmaletter.com/article/avigen-discontinues-coagulin-b
DB17708,,"Fierce Biotech: Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset",https://www.fiercebiotech.com/biotech/sanofi-hit-by-filing-delays-for-key-drugs-drops-early-sangamo-thalassemia-asset
DB17710,,Globe Newswire News Release: Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease,https://www.globenewswire.com/news-release/2021/03/05/2187883/0/en/Sigilon-Therapeutics-Receives-Orphan-Drug-Designation-for-SIG-007-for-the-Treatment-of-Fabry-Disease.html
DB17711,,Globe Newswire News Release: Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress,https://www.globenewswire.com/en/news-release/2022/12/12/2571819/0/en/Caribou-Biosciences-Reports-CB-010-ANTLER-Phase-1-Trial-Progress.html
DB17712,,PR Newswire: FDA Grants Orphan Status for ATX-F8-117 for the Treatment of Haemophilia A Patients in the US,https://www.prnewswire.com/news-releases/fda-grants-orphan-status-for-atx-f8-117-for-the-treatment-of-haemophilia-a-patients-in-the-us-506593851.html
DB17714,,Pharmaceutical Technology: Thalagen by San Rocco Therapeutics for Beta Thalassaemia: Likelihood of Approval,https://www.pharmaceutical-technology.com/data-insights/thalagen-san-rocco-therapeutics-beta-thalassaemia-likelihood-of-approval/
DB17715,,"Clinicaltrials.gov: A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male",https://clinicaltrials.gov/ct2/show/NCT02919800
DB17719,,GlobeNewswire: Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD,https://www.globenewswire.com/en/news-release/2023/03/06/2621127/0/en/Anti-Properdin-Antibody-NM3086-Demonstrates-Efficacy-in-a-Primate-Model-of-Wet-AMD-and-Dry-AMD.html
DB17725,,"FDA Approved Drug Products: HYMPAVZI (marstacimab-hncq) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761369s000lbl.pdf
DB17741,,PR Newswire: MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure,https://www.prnewswire.com/news-releases/mappbio-announces-contract-with-barda-for-mbp091-as-a-pan-marburg-medical-countermeasure-300864711.html
DB17743,,"FDA Approved Drug Products: REBYOTA (fecal microbiota, live - jslm) suspension for rectal use",https://www.fda.gov/media/163587/download
DB17743,,"FDA Approved Drug Products: VOWST (fecal microbiota spores, live-brpk) capsules for oral administration (April 2023)",https://www.serestherapeutics.com/our-products/VOWST_PI.pdf
DB17743,,US Food & Drug Administration: FDA Approves First Fecal Microbiota Product,https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product
DB17743,,"Business Wire: Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI",https://www.businesswire.com/news/home/20230426006066/en/Seres-Therapeutics-and-Nestl%C3%A9-Health-Science-Announce-FDA-Approval-of-VOWSTTM-fecal-microbiota-spores-live-brpk-for-Prevention-of-Recurrence-of-C.-difficile-Infection-in-Adults-Following-Antibacterial-Treatment-for-Recurrent-CDI
DB17762,,"FDA Approved Drug Products: AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) suspension for intramuscular injection",https://www.fda.gov/media/167805/download
DB17762,,FDA News Release: FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine,https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine
DB17762,,"Health Canada Approved Drug Proucts: AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) Lyophilized Powder and Suspension for intramuscular injection",https://ca.gsk.com/media/6988/arexvy.pdf
DB17762,,"GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults approved in Canada",https://ca.gsk.com/en-ca/media/press-releases/gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults-approved-in-canada/
DB17795,,"FDA Approved Drug Products: IXIARO (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) Suspension for Intramuscular Injection",https://www.fda.gov/media/75777/download
DB17817,,"PR Newswire: Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist",https://www.prnewswire.com/news-releases/biohaven-announces-initiation-of-clinical-development-for-bhv-5000-a-novel-low-trapping-nmda-antagonist-300584389.html
DB17823,,"FDA Approved Drug Products: MIEBO (perfluorohexyloctane ophthalmic solution), for topical ophthalmic use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216675s000lbl.pdf
DB17823,,"Ophthalmology Times: Bausch + Lomb, Novaliq announce FDA approval of perfluorohexyloctane ophthalmic solution for treatment of dry eye disease",https://www.ophthalmologytimes.com/view/bausch-lomb-novaliq-announce-fda-approval-of-perfluorohexyloctane-ophthalmic-solution-for-treatment-of-dry-eye-disease
DB17831,,FDA Approved Drug Products: VYJUVEK (beremagene geperpavec-svdt) biological suspension mixed with excipient gel for topical application,https://www.krystallabel.com/pdf/vyjuvek-us-pi.pdf
DB17831,,"BioSpace: Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa",https://www.biospace.com/article/releases/krystal-biotech-receives-fda-approval-for-the-first-ever-redosable-gene-therapy-vyjuvek-beremagene-geperpavec-svdt-for-the-treatment-of-dystrophic-epidermolysis-bullosa/
DB17836,,Neurology Live: FDA Pauses IND Submission for Duchenne Therapy ENTR-601-44,https://www.neurologylive.com/view/fda-pauses-ind-submission-for-duchenne-therapy-entr-601-44
DB17840,,Angitia: FDA Grants Rare Pediatric Disease Designation (RPDD) to Angitia's AGA2115 for the Treatment of Osteogenesis Imperfecta,https://www.angitiabio.com/news/item?id=37
DB17841,,Codexis: Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021,https://www.codexis.com/investors/news-events/press-releases/detail/313/codexis-presents-pre-clinical-data-highlighting-its
DB17841,,Codexis: Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria,https://www.codexis.com/investors/news-events/press-releases/detail/316/codexis-announces-fda-orphan-drug-and-rare-pediatric
DB17842,,Rett Syndrome News: Novartis Cancels Plans for Clinical Trials of Gene Therapy OAV201,https://rettsyndromenews.com/news/novartis-cancels-plans-clinical-trials-rett-syndrome-gene-therapy-oav201/
DB17844,,Ophthalmology Times: Nanoscope Therapeutics presents results from phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa,https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-presents-results-from-phase-2b-restore-trial-of-mco-010-for-treatment-of-retinitis-pigmentosa
DB17844,,Pharmaceutical Technology: Sonpiretigene isteparvovec by Nanoscope Therapeutics for Retinitis Pigmentosa (Retinitis): Likelihood of Approval,https://www.pharmaceutical-technology.com/data-insights/sonpiretigene-isteparvovec-nanoscope-therapeutics-retinitis-pigmentosa-retinitis-likelihood-of-approval/
DB17847,,"GenSight Biologics: GenSight Biologics Announces 1 Year Safety data and Efficacy signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa",https://www.gensight-biologics.com/2023/02/13/gensight-biologics-announces-1-year-safety-data-and-efficacy-signals-from-pioneer-phase-i-ii-clinical-trial-of-gs030-an-optogenetic-treatment-candidate-for-retinitis-pigmentosa/
DB17851,,FDA Approved Drug Products: POSLUMA (flotufolastat F-18) injection for intravenous use (May 2023),https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216023s000lbl.pdf
DB17851,,"BioSpace: U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer",https://www.biospace.com/article/releases/u-s-fda-approves-blue-earth-diagnostics-posluma-flotufolastat-f-18-injection-first-radiohybrid-psma-targeted-pet-imaging-agent-for-prostate-cancer/?s=74
DB17855,,BioSpace: Milo Biotechnology Release: First Duchenne Muscular Dystrophy Patient Treated In Follistatin Gene Therapy Trial,https://www.biospace.com/article/releases/milo-biotechnology-release-first-duchenne-muscular-dystrophy-patient-treated-in-follistatin-gene-therapy-trial-/
DB17855,,BioSpace: Milo Biotechnology's Follistatin Gene Therapy Increases Function In Becker Muscular Dystrophy Patients,https://www.biospace.com/article/releases/milo-biotechnology-s-follistatin-gene-therapy-increases-function-in-becker-muscular-dystrophy-patients-/
DB17855,,Pharmaceutical Technology: Milo Biotechnology receives orphan drug designation for AAV1-FS344 to treat inclusion body myositis,https://www.pharmaceutical-technology.com/uncategorized/newsmilo-biotechnology-receives-orphan-drug-designation-for-aav1-fs344-to-treat-inclusion-body-myositis-5025374/
DB17858,,"PR Newswire: Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa",https://www.prnewswire.com/news-releases/coave-therapeutics-and-thea-open-innovation-sign-exclusive-licensing-co-development-and-commercialization-agreement-for-europe-for-ctx-pde6b-a-novel-gene-therapy-candidate-in-retinitis-pigmentosa-301377909.html
DB17866,,"PR Newswire: SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis, at the European Cystic Fibrosis Conference",https://www.prnewswire.com/news-releases/splisense-presents-preclinical-data-for-spl23-aso-mrna-altering-drug-candidate-for-the-treatment-of-cystic-fibrosis-at-the-european-cystic-fibrosis-conference-301310187.html
DB17868,,ProQR: ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA,https://www.proqr.com/press-releases/proqrs-drug-candidate-qrx-411-for-usher-syndrome-receives-orphan-drug-designation
DB17869,,ProQR: ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa,https://www.proqr.com/press-releases/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant
DB17870,,Globe Newswire News Release: Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease,https://www.globenewswire.com/en/news-release/2022/09/20/2519092/0/en/Wave-Life-Sciences-Announces-Positive-Update-from-Phase-1b-2a-SELECT-HD-Trial-with-Initial-Results-Indicating-Allele-Selective-Target-Engagement-with-WVE-003-in-Huntington-s-Diseas.html
DB17878,,Castle Creek Biosciences Inc.: D-Fi Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB),https://castlecreekbio.com/pipeline/gene-therapy-dystrophic-epidermolysis-bullosa/
DB17928,,BioSpace: TissueTech Furthers Late-Phase Research of Biologic Candidate TTAX01 to Treat Advanced Wagner Grade 3-4 Diabetic Foot Ulcers,https://www.biospace.com/article/releases/tissuetech-furthers-late-phase-research-of-biologic-candidate-ttax01-to-treat-advanced-wagner-grade-3-4-diabetic-foot-ulcers/
DB17929,,"FDA Approved Drug Products: DAXXIFY (daxibotulinumtoxinA-lanm) for injection, for intramuscular use (August 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761127s002lbl.pdf
DB17929,,StatPearls: DaxibotulinumtoxinA-Ianm,https://www.ncbi.nlm.nih.gov/books/NBK594233/
DB17929,,"Fierce Pharma; With long-awaited FDA nod, Revance set to take on AbbVie's Botox with its longer-lasting Daxxify",https://www.fiercepharma.com/pharma/long-awaited-fda-nod-revance-set-take-abbvies-botox-its-longer-lasting-daxxify
DB17929,,Business Wire: U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia,https://www.businesswire.com/news/home/20230814502174/en/U.S.-FDA-Approves-First-Therapeutic-Indication-for-Revance%E2%80%99s-DAXXIFY%C2%AE-DaxibotulinumtoxinA-lanm-for-Injection-for-the-Treatment-of-Cervical-Dystonia
DB17934,,Pharmaceutical Technology: Debamestrocel by BrainStorm Cell Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval,https://www.pharmaceutical-technology.com/uncategorized/debamestrocel-brainstorm-cell-therapeutics-amyotrophic-lateral-sclerosis-likelihood-of-approval/
DB17937,,AlaMab Therapeutics: FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168 GRANTED RARE PEDIATRIC DISEASE DESIGNATION BY THE U.S. FDA,https://alamab.com/almb-0168-granted-rare-pediatric-disease-designation/
DB17942,,PR Newswire: FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease,https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-rgx-181-gene-therapy-for-the-treatment-of-cln2-form-of-batten-disease-300749729.html
DB17943,,ALS News Today: AveXis and Its Potential ALS Gene Therapy to Be Purchased by Novartis for $8.7B,https://alsnewstoday.com/news/avexis-and-als-therapy-avxs-301-to-be-acquired-novartis/
DB17944,,Lineage Cell Therapeutics: OPC1 for Spinal Cord Injury,https://lineagecell.com/products-pipeline/opc1/
DB17954,,PR Newswire: Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS,https://www.prnewswire.com/news-releases/seneca-biopharma-announces-results-of-meeting-with-fda-regarding-the-design-of-phase-3-trial-for-nsi-566-in-als-301037880.html
DB17956,,Parkinson's News Today: Potential Therapy FB-101 Well-tolerated in Healthy Volunteers,https://parkinsonsnewstoday.com/news/fb-101-well-tolerated-phase-1-parkinsons-clinical-trial/
DB17957,,BioSpace: Nutra Pharma Corp. Receives Patent for Novel Antiviral Treatment Using Modified Cobra Venom,https://www.biospace.com/article/releases/nutra-pharma-corp-receives-patent-for-novel-antiviral-treatment-using-modified-cobra-venom-/
DB17961,,FDA Approved Drug Products: LANTIDRA (donislecel-jujn) Allogeneic Pancreatic Islet Cellular Suspension for hepatic portal vein infusion,https://www.fda.gov/media/169920/download
DB17961,,FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes,https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes
DB17975,,PR Newswire: ViraCyte Completes Phase 1 Clinical Trial of Viralym-C,https://www.prnewswire.com/news-releases/viracyte-completes-phase-1-clinical-trial-of-viralym-c-300485215.html
DB17976,,ClinicalTrials.gov: Efficacy and Safety of Tocotrienols in CADASIL,https://classic.clinicaltrials.gov/ct2/show/NCT04658823
DB17992,,"FDA Approved Drug Products: XDEMVY (lotilaner) 0.25%, Ophthalmic Solution (July 2023)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217603s000lbl.pdf
DB17992,,Business Wire: FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis,https://www.globenewswire.com/news-release/2023/07/25/2710273/0/en/FDA-Approves-XDEMVY-lotilaner-ophthalmic-solution-0-25-for-the-treatment-of-Demodex-blepharitis.html
DB17992,,EMA Medicines Overview: Credelio,https://www.ema.europa.eu/en/documents/overview/credelio-epar-medicine-overview_en.pdf
DB18045,,FierceBiotech: Bayhill Therapeutics Announces the Successful Clearance of an IND for BHT-3034 for the Treatment of Myasthenia Gravis,https://www.fiercebiotech.com/biotech/bayhill-therapeutics-announces-successful-clearance-of-an-ind-for-bht-3034-for-treatment-of
DB18085,,GlobeNewswire: FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis,https://www.globenewswire.com/en/news-release/2023/05/15/2668400/0/en/FDA-Grants-SiSaf-s-Innovative-siRNA-Therapy-SIS-101-ADO-Orphan-Drug-Designation-and-Rare-Pediatric-Disease-Designation-for-the-Treatment-of-Autosomal-Dominant-Osteopetrosis.html
DB18086,,PRNewswire: DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A),https://www.prnewswire.com/news-releases/dtx-pharma-receives-fda-orphan-drug-designation-for-dtx-1252-for-the-treatment-of-charcot-marie-tooth-disease-type-1a-cmt1a-301844177.html
DB18094,,Ambulero: Pipeline,https://www.ambulero.com/pipeline
DB18116,,Peptilogics: Pipeline,https://peptilogics.com/pipeline/
DB18173,,Biosyngen News: Biosyngen’s Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer,https://www.biosyngen.com/index.php?m=home&c=View&a=index&aid=101
DB18227,,"FDA Approved Drug Products: Spikevax (COVID-19 Vaccine, mRNA) suspension for injection for intramuscular use (August 2024)",https://www.fda.gov/media/155675/download
DB18227,,"Health Canada Product Monograph: Spikevax XBB.1.5 (monovalent COVID-19 vaccine, andusomeran) dispersion for intramuscular injection",https://pdf.hres.ca/dpd_pm/00072370.PDF
DB18227,,EMA EPAR: Spikevax (Moderna COVID-19 vaccine),https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax
DB18316,,"BioSpace: CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA",https://www.biospace.com/article/releases/ctb001-bioheng-auto-car-t-product-received-orphan-drug-designation-odd-from-the-u-s-fda/
DB18332,,MipSalus: New proprietary drug (Phelimin),https://www.mipsalus.dk/new-proprietary-drug/
DB18333,,Guardian Therapeutics: R&D Pipeline,https://www.guardiantherapeutics.com/RD-pipeline.html
DB18334,,MegaPro Biomedical: MPB-1523 (IOP Injection),https://www.megaprobio.com/en/product_development_en/product_mpb1523-en_menu.html
DB18336,,Pharmaceutical Technology: TLY-012 by D&D Pharmatech for Systemic Sclerosis (Scleroderma): Likelihood of Approval,https://www.pharmaceutical-technology.com/data-insights/tly-012-d-d-pharmatech-systemic-sclerosis-scleroderma-likelihood-of-approval/
DB18362,,Eligo Bioscience: Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 (Prevention of Hemolytic Uremic Syndrome) with First-in-class CRISPR-based medicine,https://eligo.bio/eb003-odd-rdp-fda/
DB18363,,SMA News Today: FDA Grants Shift’s E1v1.11 Orphan Drug Status for SMA,https://smanewstoday.com/news/shifts-sma-treatment-e1v1-11-gets-orphan-drug-status/
DB18447,,PegBio Pipeline & Science: PB-722,http://www.pegbio.com/en/ProductInfo.aspx?Id=10063
DB18453,,Extend Biosciences: EXT608 for Hypoparathyroidism,https://extendbio.com/ext607-for-hypoparathyroidism/
DB18460,,Genexine Pipeline: GX-H9 (eftansomatropin alfa),http://www.genexine.com/en/pipeline/gx-h9
DB18515,,FDA Approved Drug Products: Revuforj (revumenib) tablets for oral use (November 2024),https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf
DB18515,,FDA News Release: FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation
DB18515,,Syndax Pharmaceuticals: Revumenib Physiologically Based Pharmacokinetic (PBPK) Model for Evaluation of Age Effect and CYP3A4-Mediated Drug–Drug Interaction (DDI) in Relapsed/Refractory Acute Leukemias,https://cms.syndax.com/wp-content/uploads/2024/08/Chapron_2024-ACoP_AUGMENT-101-Clin-Pharm-PBPK_Poster_Final.pdf
DB18515,,"Syndax Pharmaceuticals: Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation",https://ir.syndax.com/news-releases/news-release-details/syndax-announces-fda-approval-revuforjr-revumenib-first-and-only
DB18538,,Abionyx Pharma: CER-001,https://www.abionyx.com/en/our-assets/cer-001
DB18574,,Beactica Therapeutics: Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma,https://www.beactica.com/press/beactica-therapeutics-receives-fda-orphan-drug-designation-for-bea-17-for-the-treatment-of-glioblast
DB18592,,"FDA Approved Drug Products: TECELRA (afamitresgene autoleucel) suspension, for intravenous infusion",https://www.fda.gov/media/180565/download?attachment
DB18592,,FDA News Release: FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma,https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma
DB18628,,Transcode Therapeutics: TTX-MC138,https://www.transcodetherapeutics.com/uploads/1/7/4/2/17421591/transcode_ttxmc138_revised.pdf
DB18629,,Artiva Biotherapeutics: NK Cell Therapy Pipeline,https://www.artivabio.com/nk-cell-therapy-pipeline/
DB18649,,ProJenX: Our Science,https://projenx.com/our-science/
DB18658,,MBX Biosciences: Pipeline (MBX-2109),https://mbxbio.com/pipeline/#mbx-2109
DB18659,,Drug Development & Delivery: CELL THERAPY – PLX-R18: Cell Therapy for Treatment of Acute Radiation Syndrome & Bone Marrow Failure Diseases,https://drug-dev.com/cell-therapy-plx-r18-cell-therapy-for-treatment-of-acute-radiation-syndrome-bone-marrow-failure-diseases/
DB18660,,EMA Summary of Product Characteristics: Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) living tissue equivalent,https://www.ema.europa.eu/en/documents/product-information/holoclar-epar-product-information_en.pdf
DB18676,,"FDA Approved Drug Products: YORVIPATH (palopegteriparatide) injection, for subcutaneous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216490s000lbl.pdf
DB18676,,"FDA News Release: FDA approves new drug for hypoparathyroidism, a rare disorder",https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-hypoparathyroidism-rare-disorder
DB18676,,EMA Approved Drug Products: Yorvipath (palopegteriparatide) Subcutaneous Injection,https://www.ema.europa.eu/en/documents/product-information/yorvipath-epar-product-information_en.pdf
DB18680,,FDA Approved Drug Products: LYFGENIA® (lovotibeglogene autotemcel) suspension for intravenous infusion,https://www.bluebirdbio.com/-/media/bluebirdbio/Corporate%20COM/Files/Lyfgenia/LYFGENIA_Prescribing_Information.pdf
DB18680,,bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events,https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-lyfgeniatm-lovotibeglogene
DB18680,,FDA Press Announcements: FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease,https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
DB18701,,"FDA Approved Drug Products: Ixchiq (Chikungunya vaccine, live) solution for intramuscular injection",https://www.fda.gov/media/173758/download?attachment
DB18701,,FDA Press Announcement: FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus,https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus
DB18701,,Centers for Disease Control & Prevention (CDC): Chikungunya Virus,https://www.cdc.gov/chikungunya/index.html
DB18701,,Centers for Disease Control & Prevention (CDC): Areas at Risk for Chikungunya,https://www.cdc.gov/chikungunya/geo/index.html
DB18704,,"FDA Approved Drug Products: RYZNEUTA® (efbemalenograstim alfa-vuxw) injection, for subcutaneous use I",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761134s000lbl.pdf
DB18704,,Evive Biotech and Acrotech Biopharma Announce FDA Approval of Ryzneuta® (Efbemalenograstim alfa Injection) for Chemotherapy-Induced Neutropenia (CIN),https://www.evivebiotech.com/en/newsd/index?id=56
DB18705,,EMA Summary of Product Characteristics: Bimervax (SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains) for intramuscular injection,https://www.ema.europa.eu/en/documents/product-information/bimervax-epar-product-information_en.pdf
DB18705,,EMA EPAR: Bimervax,https://www.ema.europa.eu/en/medicines/human/EPAR/bimervax
DB18710,,Anti-SEZ6 Antibody-drug Conjugate ABBV-706 (Code C198215),https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C198215
DB18710,,AbbVie: Pipeline ABBV-706,https://www.abbvie.com/science/pipeline.html#abbv-706
DB18712,,FDA Approved Drug Products: ZELSUVMI (berdazimer) topical gel,https://zelsuvmi.com/wp-content/uploads/2024/01/ZELSUVMI-Berdazimer-Topical-Gel-10.3.-Prescribing-Information-and-Instructions-for-Use.pdf
DB18712,,U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum,https://www.biospace.com/article/releases/u-s-food-and-drug-administration-approves-zelsuvmi-as-a-first-in-class-medication-for-the-treatment-of-molluscum-contagiosum/?s=74
DB18713,,FDA Approved Drug Products: ABRYSVO (Respiratory Syncytial Virus Vaccine) solution for intramuscular injection (August 2023),https://www.fda.gov/media/168889/download
DB18713,,FDA Press Announcement: FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants,https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants
DB18713,,"EMA EPAR: Abrysvo (Respiratory syncytial virus vaccine, bivalent, recombinant)",https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo
DB18713,,Health Canada Approved Drug Products: Abrysvo (Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine) for intramuscular injection,https://pdf.hres.ca/dpd_pm/00073900.PDF
DB18714,,FDA Approved Drug Products: ABRYSVO (Respiratory Syncytial Virus Vaccine) solution for intramuscular injection (August 2023),https://www.fda.gov/media/168889/download
DB18714,,FDA Press Announcement: FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants,https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants
DB18714,,Health Canada Approved Drug Products: Abrysvo (Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine) for intramuscular injection,https://pdf.hres.ca/dpd_pm/00073900.PDF
DB18714,,"EMA EPAR: Abrysvo (Respiratory syncytial virus vaccine, bivalent, recombinant)",https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo
DB18716,,"FDA Approved Drug Products: EXBLIFEP (cefepime and enmetazobactam) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216165s000lbl.pdf
DB18716,,Contemporary OB/GYN: FDA approves enmetazobactam for treatment of cUTIs,https://www.contemporaryobgyn.net/view/fda-grants-new-drug-approval-to-enmetazobactam-against-cutis
DB18720,,FDA Letter of Emergency Use Authorization: Pemgarda (pemivibart),https://www.fda.gov/media/177068/download
DB18720,,"FDA Emergency Use Approved Drug Products: PEMGARDA (pemivibart) injection, for intravenous use",https://www.fda.gov/media/177067/download
DB18720,,Invivyd Press Release: Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19,https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-fda-authorization-emergency-use-pemgardatm
DB18731,,FDA Approved Drug Products: Lumisight (pegulicianine) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214511s000lbl.pdf
DB18731,,FDA News & Events for Human Drugs: FDA approves imaging drug to assist in detection of cancerous tissue following lumpectomy,https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-imaging-drug-assist-detection-cancerous-tissue-following-lumpectomy
DB18736,,NIH Inxight Drugs: Celastrol,https://drugs.ncats.io/drug/L8GG98663L
DB18740,,"FDA Approved Drug Products: ANKTIVA (nogapendekin alfa inbakicept-pmln) solution, for intravesical use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761336s000lbl.pdf
DB18740,,FDA: FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer
DB18773,,"FDA Approved Drug Products: FLYRCADO (flurpiridaz F 18) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215168s000lbl.pdf
DB18829,,AMIDEBIO: AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon,https://www.amidebio.com/2020/04/22/amidebio-granted-orphan-drug-designation-by-fda-for-novel-solution-stable-glucagon/
DB18830,,ReCode Therapeutics: New Treatment Possibilities in Primary Ciliary Dyskinesia,https://recodetx.com/pcd/
DB18831,,GenixCure: Pipeline,http://www.genix-cure.com/company/pipeline.php?PHPSESSID=587727f82eff0ec4b318daf2ff127263
DB18832,,InSilico Medicine: TEAD,https://insilico.com/pipeline_target_tead
DB18832,,InSilico Medicine: Insilico Medicine announces potential best-in-class pan-TEAD inhibitor candidate ISM6331 targeting advanced solid tumors,https://www.eurekalert.org/news-releases/991924
DB18847,,"FDA Approved Drug Products: LEQSELVI (deuruxolitinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217900Orig1s000correctedlbl.pdf
DB18847,,AJMC: FDA Approves Deuruxolitinib for Alopecia Areata,https://www.ajmc.com/view/fda-approves-deuruxolitinib-for-alopecia-areata
DB19244,,Alentis Therapeutics: Lixudebart for organ fibrosis,https://alentis.ch/lixudebart-ale-f02-for-organ-fibrosis/
DB19298,,Mabwell: Pipeline,https://www.mabwell.com/en/rd.html
DB19298,,Mabwell: Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND,https://mabwell.com/en/news_info/id-109.html
DB19325,,Dermatology Times: FDA Approves Sofpironium (Sofdra) as First and Only Chemical Entity for Primary Axillary Hyperhidrosis,https://www.dermatologytimes.com/view/fda-approves-sofpironium-sofdra-as-first-and-only-chemical-entity-for-primary-axillary-hyperhidrosis
DB19325,,FDA Approved Drug Products: Sofdra (sofpironium bromide) topical gel,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217347s000lbl.pdf
DB19325,,2021 Fall Clinical Dermatology Conference: Investigating Treatment of Primary Axillary Hyperhidrosis With a Topical Retrometabolic Anticholinergic Drug,https://dermsquared.com/skin/article/view/1425/pdf
DB19353,,FDA Approved Drug Products: Zunveyl (benzgalantamine) delayed-release tablets for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218549s000lbl.pdf
DB19353,,Fierce Pharma: Alpha Cognition's delayed-release Alzheimer's drug Zunveyl passes muster with FDA,https://www.fiercepharma.com/pharma/alpha-cognition-passes-commercial-threshold-fda-nod-delayed-release-alzheimers-drug
DB19353,,Alpha Cognition: Corporate Presentation Oct 2024,https://www.alphacognition.com/_resources/presentations/corporate-presentation.pdf?v=0.818
DB19414,,"FDA Approved Drug Products: Spikevax (COVID-19 Vaccine, mRNA) suspension for injection for intramuscular use (August 2024)",https://www.fda.gov/media/155675/download
DB19415,,FDA Approved Drug Products: Comirnaty (COVID-19 mRNA vaccine) Intramuscular Injection,https://www.fda.gov/media/151707/download
